<SEC-DOCUMENT>0000939767-21-000076.txt : 20210805
<SEC-HEADER>0000939767-21-000076.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161925
ACCESSION NUMBER:		0000939767-21-000076
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		77
CONFORMED PERIOD OF REPORT:	20210702
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			EXELIXIS, INC.
		CENTRAL INDEX KEY:			0000939767
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				043257395
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30235
		FILM NUMBER:		211148490

	BUSINESS ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502
		BUSINESS PHONE:		6508377000

	MAIL ADDRESS:	
		STREET 1:		1851 HARBOR BAY PARKWAY
		CITY:			ALAMEDA
		STATE:			CA
		ZIP:			94502

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS INC
		DATE OF NAME CHANGE:	20000207

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EXELIXIS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20000106
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>exel-20210702.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" ?><!--XBRL Document Created with Wdesk from Workiva--><!--Copyright 2021 Workiva--><!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8,d:164d1fcc16004d86847619b30cbdc0ba--><html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:exel="http://www.exelixis.com/20210702" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:dei="http://xbrl.sec.gov/dei/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>exel-20210702</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:AmendmentFlag" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y18yLTEtMS0xLTA_8627af2e-2f76-4845-b803-d45ab592a72e">false</ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:DocumentFiscalYearFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y180LTEtMS0xLTA_83586d31-097d-424e-ac94-2c3fbe7d1d72">2021</ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:DocumentFiscalPeriodFocus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y181LTEtMS0xLTA_d3fc636a-b4c5-4c0f-8961-b202f2d408eb">Q2</ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityCentralIndexKey" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y182LTEtMS0xLTA_e256dc68-33e4-4149-a574-c704a71a5ed2">0000939767</ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt:datemonthdayen" name="dei:CurrentFiscalYearEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y183LTEtMS0xLTA_ed049941-2f89-4b12-bc35-281918995c86">December 31</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="exel-20210702.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:context id="i57cc8f2d4f634e00aa1fbe4e770ca58b_I20210726"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:context id="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7d18f1537d8b43a38ece66de91e63886_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:context id="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9259a9d7933146308c821508a3ddee27_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia21d371856cc48a68b4309847396fa80_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic35c76885c08464e8536056814cc87b0_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i18f71f314ed04df18bb6962c37407e37_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8d1d3b56237f4f60b09904a6c28afefa_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7f72b97be95433eb01da77344b924b4_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9055e59c6448472b8afad20e904571c0_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic2d314200efc414286c58e02a72592ae_I20210402"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-04-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i44dd4e95f4af402e9f077cd335eb7007_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i53be24f47fe943889e3a6dda67c33519_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i506073af88c340ebb62b33816c074aaf_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idaaa8f6eb6fe4306b163861f98903231_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i693dc4f870124e0b9ddd7456d2a2738c_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i748018c371b647b38103dedba2c84de1_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic45af8276000456da83f9b42424d83fd_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iccf0f3d464b14f8689aace6957954839_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i0f53374fa9494a2bbfec8a0dac4cec86_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if4476ab3366d4b4aa330a4b0fa517edf_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i946cc6b151944fdc8ee643e1575173c6_I20200403"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib54c97a496384e2f8bf53ca6af61aaca_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36169ffce5154dfabab0771e977ca089_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i664240e571634cfbaf15ac1e52615971_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i493e0445ef74439faa8e33e8d3bd99fc_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56aa11bddb1f4538a589748b0433902b_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i35af602dfdfc44a7b9bc433d59cbc821_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-07-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i081256c453a249839e8537f1c0153e9f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a0940ae62e5401b9c203c706d89df2f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i058b3f9310334495bbc354761bd6647b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if0687bdba44c461687736aa0a7fa9b21_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ief41d78e50cb4a93a62920da7cecefef_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifa16a9d12d014d909104f7045186de11_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i84739d5f149041178c34597093926bd6_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5556cef549ed44c18c579369e37ccdf2_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3025b4065aaf4cdba68bd29f0237a548_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if13daa675eb9480989a9cdb6f2a297e6_I20200103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-01-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i80c8d20e80cc4ad7bca1dc91ecf75437_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i081971405e1741eeb1fc749632c1c0aa_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i616ab7befeac4dd19930969171845d06_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="product"><xbrli:measure>exel:product</xbrli:measure></xbrli:unit><xbrli:context id="i0788ba9b7348408294dc259c3a82acb4_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibb1fe7255a2442e295f20f47559b739d_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="segment"><xbrli:measure>exel:segment</xbrli:measure></xbrli:unit><xbrli:context id="i947f11dce7724c8a92d7f9d767d30430_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibab3c993c7644d7a946dcb256efda5b9_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib167b52f75e74c39838cc0b9a5bafec1_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic4d233c682dd4c8e86078cfa757643ba_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id8f066b777054049b67a402360c6a782_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i88bdab6e93514c5ca7163e90e6740f46_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id31ef9d0f4694bdf8921fc58940a8cd7_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i99c380c1cdd64bc68dfdb4fc5dc13a5a_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i83c483fda79b4c16ad3d9442173642b8_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6cafb301e8bc4a1e878470c9b0f12baa_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie10d8c01e16442feaeac308109be67d6_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3396192359714cebba9f9044f46388b8_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:context id="i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2dd1c78a8dac4b7489425c0a1175d608_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibdf20ffabe0140baa5b07542eeab1510_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i11371f462a3a4f459626f35247d98cda_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if0c970818f314feb8775caa6ef94fd81_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8ad0b431492b4370a00a89fa2d331434_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i70b167eedebd4c72b9f4d3f02442f179_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f7584f5954340dba177cf82b494e611_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idd6c27d712d943b78475ea6b7bcb2516_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3bd6a226ce54f36b775c95518c27470_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifeb5bb631eb2470babf9f8d080f9964f_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0351d4cb2134494ba29863d99c874739_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i54323ff73fd948188ef473dee8b6e814_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e5051bdb62a4adea3b1ba61cad3e07b_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib2310c9c82ca42f09d4e1cb96f939ad9_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i821ee440df88470196800293d930e33c_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i753195995e5e4556a95e622429f0db57_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5fd1ae2034d9412089e998f08d56e5c3_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i27c364af82884e9e8ba8d4a627f277bf_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibd0a23e145ff4ca084f0c9961d8b3a54_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9542af44b304776a9c4bb52e4768814_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i354e779a90704e25ab4430a20741de7a_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ice75da26c51d4900838a61e74a5f0c32_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2f30e6eb82e64b79b27523cafe87fb10_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7b5f040ea73842e8abdcba995add3e6d_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3bee6b43f04331a2af7c80b4a7370d_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i13094e1db8884f879f12d67dad15c701_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bdd8100f1f84c43aa6914f739d17d31_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb756ebdb26146dd872e8d96bcb1edf2_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia6d4a34bdbe3414db629b89c722ea436_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia210e74e223e424a970e3e3560d85886_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2d909f0df4c749f5ad2943003106be6d_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia8ed993e6ef846f0842723b5499f1a51_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic3d6c5f034c743549e0b3580f3088770_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3be0c4f6862744d381c6a9c8ad69d360_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i922effb845ac486685bc2d4ca1e2b64e_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i041977232d9d47f689aa8e5e54cf51c8_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ied845544fcad4e209b2f843ae011069a_D20200104-20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i576124c34cb14293a07e65c0e116b0fd_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie1f3b07b878f446983ae8ea6c24a8523_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i926a2dcdbc7642d3b461dd3a6194ac74_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7962cd8f612a4e7a93a1cb357a042730_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if8f782da2d2a45809e36bb66021e8e95_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23fea2b017ea462db2fa2ac8224cb0a7_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i1e515978877241b1a3bbbf6c7c87a132_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3e0390849b8b485ebe8240a57d0c0e15_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ibf21142c44dc4ed588e7f49495659845_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8b04dfce356a48a3a67d32e955e37c0f_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5b57543585624c4cbf46aba4e36a40d0_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4f2944cc9b084ae18eb84c3b0937c4bb_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4abad55b764942b8838caffe168cd460_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i602ab887907347eca4f8dd2743045d20_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia4e3544936884787b393e216680bae75_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic9861d7e9fc04d7797b39b96e817870b_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4494448a3d77442ea673dc4306f40517_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85570133db6f426dbb8f7b796098289a_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6779e8b939fb444986c5b5f6762bedae_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifcab21398b064807b6664b9e08c18372_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ie35769b7587040d5aa523942d229c867_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib42e12234ac143a0a44b01d6e7a03fe1_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i48d197193a8a45b38af10e48f5f51e93_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7befdb6164974b9db88347431a84c705_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i48b0f026980e4e8db846617663617dce_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5ffbaddc0eb14e9991b7a519b99dcf9d_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i33ef18170a4944cd8de075cf4a5344d3_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia09e442b2e1243bc84dac0b50e653260_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i54e9688fa5234b7dabc087b18bea682e_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7e90ca7353d7420d850374043f19414f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i23ea9da53f1644eaa0a98b9259aa475f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9fb9e5548a364e8db87e699888c741d9_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iee0e69c31a264295b5d40ec7776fd3db_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i438def86d067426f867cc300503942e3_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icb3fd2d979fa40adaac2298fd1f78f5d_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i85a056bb651c463991c7d6520faca86c_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i60418fc014944675b95a4a327939d6f7_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ia354da424ce0441fa29d3af61c66a49e_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iac88bbff875241b399770a9f80cb04da_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ide45679cbd134e15ad7dde1405959e1c_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ieb8d9802463f431b8dc5673038d02b02_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib4773d352b9649cf82f5f26e75db0cbd_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0afcc09b5a14464ab0ffad06802a0d9a_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c2c134629c04167a6ee6e580563d23a_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i96369905ff694894be26d03937eba3aa_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4eace4464d1b4cebb1f6aa87ef46edfa_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i7c567665f16245dfbbaa6cfb4be14af9_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifd4fe90f4c8b4002917a160364e89c7b_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i37fca3eb6b164203b94981e459883e27_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6b587653d3b346778dc4850b1f98eaa1_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8682433791e74a77ab1fb7164ad65f64_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i36f2a9ffc2004bfba433dc45cecfe4e7_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic6774c6769c74754bf25b006ddeb034a_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i086ec86c38f3430bbc22864119abfbea_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib55ad4a520414e63a49c07b1087faa2c_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3a69004f4ba64701a17a5818d5af4f24_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ib115b2c1778640cc80452356877f9218_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i957e8d926e9948e49c867df19f90d50a_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ic78371ad98574f0f8204b52ff32e63c9_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iceb9d21701e5414cadd958696df005c4_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic65851a71fcb4a37a10e68a564581e81_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7bda6107aee140518bf785e603a9f752_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id37c5c0878604fd4a7ac63cf01049767_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia4f74740d9b3489982fe849d428b0c61_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4acd99a8477349aa9356042fc2d2b74a_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i2a7078826e91452db52a24c7cbbe97de_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i149eb5d8fd5e40fa9fb480344495f84a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6fe4968ea10a4a2e846882843c6487fa_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8eec5258de424553baf107e5e554b35a_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i56912199faad49c0be4543e8883c2d26_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="investment"><xbrli:measure>exel:investment</xbrli:measure></xbrli:unit><xbrli:context id="icc9727a7b4814f58b8af72b38460bca0_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i4e91c1139a56409d95f01dc2177e91d2_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="id53a0786827d478e814c805cc8cd0afb_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9dc7c2c162434fe38126e2d6f15ae9bb_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i950c47d917ec494488175b4cdbe0c129_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i550ee82623734ffe9f05bdbde43fba7d_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iad4faa5c3b4a426aad73596700ef7140_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iffc0af7755c040318682d07ce7adc16d_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6c48c5faa613472abda97540d85b1a43_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac6e199ed30442d3aea617ff04d7c031_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a06f360ba44412d9bbdf897884ec918_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i68ab09d76ab342579d2258fdbf2c378c_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i353b0bfaee7d45d3976a470abaef3b27_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i7549b8270e70414ca9988e4dbb8aa47f_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i461e78644dac46b59b980d4bf5e337b4_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5b52c97911274efa88b507b4b137edec_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ic67977ad378747debfe28bbf32306bd3_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i6cfecbfae6504e7dac8dae1b622df61b_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iae9f679824f7428da09abd42de1550ae_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib1444ac4a7464905b1d3c72e3eadd436_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9acdde179aaf4fdc8bbfce84bea41c94_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i284bab61e8734898a70c2fcec89c67c2_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i5ed62cb99076473f80954b556b50f8c4_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iac2529e3f7d44eb5a9f3e462363e4bef_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i8290d5383c23424f8de0d1411e5defda_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf572e25486645ec8191ae913a4d5273_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i9ecbc8770d4f4636ac3bd47cc6e7a318_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i60c12cafde1f455185fb18b04e0ee5cf_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="if81d88ee2f624302a41cbb273629023e_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ib31966a54bf84f61b847e6dc212903cc_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iace3e234989f44a18209f335a3858e67_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ibf3b9823001c4ababc937b8119958bcd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i18e4500f722142808c3c50a9a09c4590_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10577d8c6f0a44c29a3ded5c80584629_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i10fce4b7140142ae8b453252c5a9aa1f_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaed63e180d5c44929716ad53c8d1a9a3_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i98ada18f5c9f4383a40c65d6ad47b375_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="iaf994d5e216c490ebc4de2ede7eb66ab_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i94140ba1405e4bbabc2a2ce63c52a2cf_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i43efb9d920154cdd94ec40616b7279ab_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="forwardcontract"><xbrli:measure>exel:forwardContract</xbrli:measure></xbrli:unit><xbrli:context id="ic668b647625e4bde9c974a9c70e123ee_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:unit id="eur"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit><xbrli:context id="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i38f66ecf6b3d46bfbf2bdb0f567643a6_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i3a9ad4a65b6e4c889ee3d1e4d70baafd_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i01981fa8e6c344ba974b2f8d40f68058_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ie6f3c04a508a4cfcada935eafb00cbba_I20210101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-01-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ieca864111b874024a399be99230353ae_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2cd6d6f2194144d995d98bdace4f2a41_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2de5b4fa16f7460680d4046f0519a111_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5334bcd0ce864909917f7d16cd9888e7_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0f9135f913a844cf9141b680dfeb2cea_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4941e12d857a41d3ac2f0ff6bbe78328_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="idb3a79263fd94414b9fae499fb7a8ed4_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4037354e5adc450194ea75e59903a4c2_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i3bef33e85fa14e96ae49c48c326d27de_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i19afc667658d40998a38958b53efb61e_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i4134486a3c824f2181dcb53797e46891_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i75db9e248ada421fb6801122acc77816_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i873e7a2c3edf40ecb5bbd511274cbf4f_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="id9124f541cea43cfb250f0c46a24ea95_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i6ced14542a07421e8805f7ee34d1747f_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i10aae8da808c4e4a9bdc5ee3346228a9_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i996fd974645e4c3db9f8f6b13e514f51_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i8d55c4bf90594514b0b8f4b81adf037e_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i2457de481e214911a4d49d6872661199_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i17e867cac56f4c6fbee7d87303f4e416_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i5d96596fd611426fba7a4e5d05b69795_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="ife5de7f12696428c822881cfca50b36d_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i167594f9829443bdb7383a81ca5f83e5_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="i32a62386d90e4627a31537ead3413cd9_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i06bb3436aa3243dc82099b2b7e64415a_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="iba0fcc072d1d49eea6319ba9d01188e7_D20210301-20210331"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="icdc25c9244d74752a7a86d0fc1f9a390_I20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-03</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0c6782e60aa74aa18a2400a167db7d7e_D20200404-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="i0d82c6e6cf824115b296671898dbd282_D20210102-20210702"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-02</xbrli:startDate><xbrli:endDate>2021-07-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="if3e6164d65ce46689c7c42db6169a463_D20200104-20200703"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0000939767</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-04</xbrli:startDate><xbrli:endDate>2020-07-03</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i164d1fcc16004d86847619b30cbdc0ba_1"></div><div style="min-height:40.5pt;width:100%"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:199.50pt"><tr><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td><td style="width:1.0pt"></td><td style="width:97.75pt"></td><td style="width:1.0pt"></td></tr><tr style="height:21pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM </span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:DocumentType" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTY5MzBiNjgyZjMzNDJjNThjYTM5OGY5OTgzMTEzZTIvdGFibGVyYW5nZTo5NjkzMGI2ODJmMzM0MmM1OGNhMzk4Zjk5ODMxMTNlMl8wLTEtMS0xLTA_9a77f6d7-472c-4a6d-9514-05ac1c65c6ea">10-Q</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:boolballotbox" name="dei:DocumentQuarterlyReport" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ZTkzNzY1NWQ1NDcyNGM4ODhlMzMwNGE3ZWZlYjRlN2QvdGFibGVyYW5nZTplOTM3NjU1ZDU0NzI0Yzg4OGUzMzA0YTdlZmViNGU3ZF8wLTAtMS0xLTA_63ed3bb6-3369-4171-b498-d48e8971fc5e">&#9746;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;For the quarterly period ended <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8yNzQ4Nzc5MDcxMzcy_d1fc469e-21ad-443c-bad3-1a63dc44498b">July 2, 2021</ix:nonNumeric></span></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">or</span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:0.1%"></td><td style="width:2.180%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:96.520%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:boolballotbox" name="dei:DocumentTransitionReport" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6M2RkYmU2ZDBiZDFkNDgwNDg0NDEyMDU3ZjQxMGRjMTgvdGFibGVyYW5nZTozZGRiZTZkMGJkMWQ0ODA0ODQ0MTIwNTdmNDEwZGMxOF8wLTAtMS0xLTA_4b30968e-2160-41af-a365-cd26fa2a927a">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">&#160;&#160;&#160;TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </span></td></tr></table></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:-36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityFileNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgx_10939a2d-98dd-4a41-aeb0-7b379fc3a5a0">000-30235</ix:nonNumeric></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"> </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:200.25pt"><tr><td style="width:1.0pt"></td><td style="width:198.25pt"></td><td style="width:1.0pt"></td></tr><tr style="height:54pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"><div style="margin-top:9pt;text-align:center"><img src="exel-20210702_g1.jpg" alt="exel-20210702_g1.jpg" style="height:64px;margin-bottom:5pt;vertical-align:text-bottom;width:188px"/></div></td></tr><tr style="height:20pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityRegistrantName" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6MmE5ZDRlY2E5MDE0NDM0ZjgxMGI2OTRkODYxODViZDYvdGFibGVyYW5nZToyYTlkNGVjYTkwMTQ0MzRmODEwYjY5NGQ4NjE4NWJkNl8xLTAtMS0xLTA_e0996ae9-f0c5-4748-83fe-e1539e0ac11e">EXELIXIS, INC.</ix:nonNumeric></span></td></tr><tr style="height:14pt"><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.974%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTEyMzJlNWM0MDBlNDUzNWI1NWM2NTExZjI5NThiODEvdGFibGVyYW5nZTo5MTIzMmU1YzQwMGU0NTM1YjU1YzY1MTFmMjk1OGI4MV8wLTAtMS0xLTA_ded611ce-0033-4b16-9086-3e0d3ff035c6">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityTaxIdentificationNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTEyMzJlNWM0MDBlNDUzNWI1NWM2NTExZjI5NThiODEvdGFibGVyYW5nZTo5MTIzMmU1YzQwMGU0NTM1YjU1YzY1MTFmMjk1OGI4MV8wLTEtMS0xLTA_8a9260bf-8e9a-47bb-b6f4-2cbd91fb4266">04-3257395</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification Number)</span></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityAddressAddressLine1" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg2_b9350acd-6b69-4d34-8c0b-a4fd53dfee53">1851 Harbor Bay Parkway</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityAddressCityOrTown" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg3_84641968-c459-428b-80ad-1bb6d7d10220">Alameda,</ix:nonNumeric> <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityAddressStateOrProvince" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgy_a5d3cb40-7e93-481d-8d2c-c3973d3ed5b8">CA</ix:nonNumeric> <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityAddressPostalZipCode" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgz_a57c5f4c-1026-41a9-93ea-b1f14b70ee65">94502</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:CityAreaCode" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg0_a5a599fd-7b5c-4f11-b7c9-05e1d0aca403">650</ix:nonNumeric>) <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:LocalPhoneNumber" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg1_aa23e5e0-c387-43ad-8033-5d9c89dd4a2c">837-7000</ix:nonNumeric></span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%">(Address, including zip code, and telephone number, including area code, of registrant&#8217;s principal executive offices)</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.851%"><tr><td style="width:1.0%"></td><td style="width:38.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.721%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:38.990%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:Security12bTitle" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTAtMS0xLTA_c7aeaec9-f10d-40e6-b94e-c17fd5d5d0c0">Common Stock $.001 Par Value per Share</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:TradingSymbol" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTEtMS0xLTA_6f23459d-40ba-4f03-bb56-9b2071c91cc4">EXEL</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTItMS0xLTA_5030c9ca-9880-4c8e-b208-140c4ca6cd04">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityCurrentReportingStatus" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg4_a6ded526-3f2d-47bb-973a-e4c66d6c6e0d">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).&#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="dei:EntityInteractiveDataCurrent" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg5_b773fc09-35db-40b6-80e3-a910caa8266f">Yes</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253; </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2&#160;of the Exchange Act.</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.917%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:25.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:2.322%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.695%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:entityfilercategoryen" name="dei:EntityFilerCategory" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8wLTAtMS0xLTA_ffc46169-0ae3-45d8-bdd0-f27f5fabfe81">Large accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9746;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accelerated&#160;filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#9744;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Smaller&#160;reporting&#160;company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:boolballotbox" name="dei:EntitySmallBusiness" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8xLTQtMS0xLTA_4abe733d-c1de-47ea-9677-6c6f15aaa633">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8yLTEtMS0xLTA_471f73a0-f648-48c4-b80b-264308935fbf">&#9744;</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:4pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Securities Act.    </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#168;</span></div><div style="margin-top:6pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" format="ixt-sec:boolballotbox" name="dei:EntityShellCompany" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODkw_3e1ceb02-e414-4837-a43c-094a9f16e50a">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">No&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#253;</span></div><div style="margin-top:9pt;text-indent:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">As of July&#160;26, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i57cc8f2d4f634e00aa1fbe4e770ca58b_I20210726" decimals="INF" format="ixt:numdotdecimal" name="dei:EntityCommonStockSharesOutstanding" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODI2_73296773-5bc6-4075-8dd0-47581d2bea72">315,048,788</ix:nonFraction> shares of the registrant&#8217;s common stock outstanding. </span></div><div style="height:40.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_7"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">QUARTERLY REPORT ON FORM 10-Q</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INDEX</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:8.855%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:78.989%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.856%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_10">PART I - FINANCIAL INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_13">Financial Statements</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_13">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_943">Condensed Consolidated Balance Sheets (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_943">3</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_19">Condensed Consolidated Statements of Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_19">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_22">Condensed Consolidated Statements of Comprehensive Income (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_22">4</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_25">Condensed Consolidated Statements of Stockholders&#8217; Equity (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_25">5</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_31">Condensed Consolidated Statements of Cash Flows (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_31">7</a></span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:11.25pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_34">Notes to Condensed Consolidated Financial Statements (Unaudited)</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_34">8</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_70">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_70">21</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_85">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_85">35</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_88">Controls and Procedures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_88">35</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_91">PART II - OTHER INFORMATION</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_94">Legal Proceedings</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_94">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;1A.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_97">Risk Factors</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_97">36</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_100">Unregistered Sales of Equity Securities and Use of Proceeds</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_100">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_103">Defaults Upon Senior Securities</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_103">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_106">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_106">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_109">Other Information</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_109">55</a></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item&#160;6.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_112">Exhibits</a></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_112">56</a></span></div></td></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_115">SIGNATURES</a></span></div></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_10"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I - FINANCIAL INFORMATION</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_13"></div><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> Item 1. Financial Statements</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_943"></div><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzctMS0xLTEtMjUzOQ_d462ec24-af44-4c99-a2e8-210d174d5caf">492,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzctMy0xLTEtMjUzOQ_60bae02c-dd08-4faa-ab1a-1ff1d68da303">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Short-term investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzgtMS0xLTEtMjUzOQ_b2b114a8-03ef-4b73-b358-158d9621c0c2">854,171</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShortTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzgtMy0xLTEtMjUzOQ_ca1e8820-768e-4602-b9ac-a6bed8f47d08">887,319</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzktMS0xLTEtMjUzOQ_0fcfe7dd-c367-4053-8be9-fe5f90d49eb8">171,753</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ReceivablesNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzktMy0xLTEtMjUzOQ_2b408bb0-8cc9-4411-9863-1c493c8f7724">160,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEwLTEtMS0xLTI1Mzk_23820a07-071e-452e-8a5c-a292e5fae61f">24,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEwLTMtMS0xLTI1Mzk_55741ffa-f7e0-472b-91b1-17af97d1aefa">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEyLTEtMS0xLTI1Mzk_8d75ef76-69c2-45c8-b4d2-895400b4cbd6">49,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEyLTMtMS0xLTI1Mzk_03bb60c1-40e1-4eb0-8527-4a09df320775">57,011</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEzLTEtMS0xLTI1Mzk_bffc2d1f-dd0a-43e0-bb42-6ffb2b590430">1,593,246</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEzLTMtMS0xLTI1Mzk_9588273c-df7f-4917-b09d-33252e60190c">1,445,395</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE0LTEtMS0xLTI1Mzk_156470a2-f7cb-4949-93db-ecf4c7de3d64">345,613</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LongTermInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE0LTMtMS0xLTI1Mzk_3378dd93-14eb-4d24-b989-7d8c06226c47">330,751</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE1LTEtMS0xLTI1Mzk_be636d6c-be19-420f-b9ee-483ad9f43b7f">95,133</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE1LTMtMS0xLTI1Mzk_e865ddb6-0666-4067-ae1e-c42429a16ee3">67,384</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred tax assets, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE2LTEtMS0xLTI1Mzk_b9f16155-ff94-43cb-8a8d-199e5e085de7">134,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxAssetsNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE2LTMtMS0xLTI1Mzk_c79e9cbb-bc31-4167-bc00-c62a3b5ced17">156,711</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE3LTEtMS0xLTI1Mzk_385bd4b3-f97c-4dfb-bbfc-de2d7f63a652">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Goodwill" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE3LTMtMS0xLTI1Mzk_c27506d9-1238-418f-b78d-30a202a9451b">63,684</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE4LTEtMS0xLTI1Mzk_015f94cf-7a74-45c9-a62f-f1d912a1f00b">134,928</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE4LTMtMS0xLTI1Mzk_56d9079e-7fda-40a1-863a-388e19738b58">73,408</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE5LTEtMS0xLTI1Mzk_b8ff70b8-41e1-422b-b68b-11eff8fcea27">2,367,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE5LTMtMS0xLTI1Mzk_3f3089b6-8182-4fc9-8bf9-1ae39432a587">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:100%">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIyLTEtMS0xLTI1Mzk_e8e7d8ed-1ce6-4850-aeb0-8a987208baa2">20,450</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIyLTMtMS0xLTI1Mzk_70520dea-506f-4211-97c2-9cf9b6dc2dcf">23,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued compensation and benefits</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIzLTEtMS0xLTI1Mzk_0fa0e466-c634-4e66-9102-dcfb4cdccca0">48,324</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccruedEmployeeBenefitsCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIzLTMtMS0xLTI1Mzk_882c4ddf-067c-4ddc-a5c7-22c2ace4c599">51,189</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued clinical trial liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI0LTEtMS0xLTI1Mzk_2caa708f-89ab-4e53-bb00-0c93066098d8">67,075</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedClinicalLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI0LTMtMS0xLTI1Mzk_6ab29279-6be2-4365-9f09-59f08cb920ed">52,251</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Rebates and fees due to customers</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI1LTEtMS0xLTI1Mzk_74ed8028-648f-442c-964d-e3a0e0118c01">31,197</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CustomerRefundLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI1LTMtMS0xLTI1Mzk_ddbd15f9-7961-4071-bd78-53fb4785a0c0">20,683</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued collaboration liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI2LTEtMS0xLTI1Mzk_0deeaa9c-af52-4910-a4e3-496c1802355f">24,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:AccruedCollaborationLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI2LTMtMS0xLTI1Mzk_de27daa7-682c-4742-9973-90f1b891c910">12,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI4LTEtMS0xLTI1Mzk_e6dd7bbb-60d1-40dc-9a8b-e6b54900db57">63,852</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI4LTMtMS0xLTI1Mzk_a706073a-e3fd-412d-b79c-c2c7ef7b9292">44,447</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI5LTEtMS0xLTI1Mzk_0b52fa32-1999-4690-ab72-d19c4de8f5eb">255,326</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI5LTMtMS0xLTI1Mzk_4e759fae-02e7-46c3-a518-9785dca63f73">204,658</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of deferred revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMwLTEtMS0xLTI1Mzk_58710ded-4a72-4c1e-9d0b-1d2e30f35bd8">8,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMwLTMtMS0xLTI1Mzk_535a813b-2d0d-4843-9745-dcf2f6004c73">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion of operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMxLTEtMS0xLTI1Mzk_be451f43-77b7-48f9-97d1-ae1baf3fa57d">53,223</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMxLTMtMS0xLTI1Mzk_eec57c9b-fa21-4c8e-add8-3b679a488134">49,086</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other long-term liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMyLTEtMS0xLTI1Mzk_d31a328f-b7f4-453d-9cb7-2e4ca7b4472b">7,068</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMyLTMtMS0xLTI1Mzk_c038d900-53e3-4dbf-b549-24fbca81a0e1">721</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMzLTEtMS0xLTI1Mzk_25559c09-08db-45e1-a800-9ca6ceb77add">324,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMzLTMtMS0xLTI1Mzk_c1607e2a-2444-4715-a54d-cc6dc8631ed6">258,220</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commitments and contingencies </span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM0LTEtMS0xLTI1Mzk_b260f83d-224b-4eb9-b372-63cff8122b13"></ix:nonFraction></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM0LTMtMS0xLTI1Mzk_003d17ae-8d5f-4c8e-b4ff-39352b6f6952"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stockholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8yMQ_1368b030-e5f2-436a-9546-2755041cb5bc"><ix:nonFraction unitRef="usdPerShare" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8yMQ_6f55d49d-576b-49c9-b38f-b67f128580bf">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8zNQ_14a77070-d8b6-4c4e-9c90-fc4415a93342"><ix:nonFraction unitRef="shares" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8zNQ_fe019911-657d-43d3-9b0d-42f19953499c">10,000</ix:nonFraction></ix:nonFraction> shares authorized and <ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF82MA_580ea7b6-2845-4ab2-a96b-d2c4a1da8577"><ix:nonFraction unitRef="shares" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF82MA_a1ef0e96-b676-4cdf-a5b0-8728db7d5c9c">no</ix:nonFraction></ix:nonFraction> shares issued</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTEtMS0xLTI1Mzk_2faadb88-046f-4fef-a299-3adda828cc8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:PreferredStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTMtMS0xLTI1Mzk_bea9dae5-e188-459d-a3de-e38bedaf1524">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8xOA_f61183f5-e1c1-4357-9090-d933acf28fcb"><ix:nonFraction unitRef="usdPerShare" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8xOA_f64655d3-22d7-47fc-b6a4-ddad90ebe69d">0.001</ix:nonFraction></ix:nonFraction> par value; <ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8zMg_3df4a145-1a3d-4061-8b1b-47c2e626b770"><ix:nonFraction unitRef="shares" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8zMg_43a2d469-78c7-44d7-bb42-1ca5a478bef2">400,000</ix:nonFraction></ix:nonFraction> shares authorized; issued and outstanding: <ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl83OA_2501d21c-865f-455d-94d0-cce809377307"><ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl83OA_3b3a3f28-a98d-478a-ad24-eab6762b6f39">314,822</ix:nonFraction></ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl84Ng_8e20548c-fb18-4c3b-afe9-46689d362201"><ix:nonFraction unitRef="shares" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl84Ng_d41ebf9d-ab8e-4b34-9743-f2d858ce23f8">311,627</ix:nonFraction></ix:nonFraction> at June&#160;30, 2021 and December&#160;31, 2020, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTEtMS0xLTI1Mzk_2d0562f4-d2d7-4f8f-a662-af8f9bc00a86">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTMtMS0xLTI1Mzk_5b886499-af26-4d9d-92eb-eab417028da1">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM4LTEtMS0xLTI1Mzk_7716d030-9a7e-40aa-b00b-3980e8070199">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM4LTMtMS0xLTI1Mzk_948d9cc2-4286-48db-b3ed-714fdcaf79e7">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM5LTEtMS0xLTI1Mzk_753ebb4a-a00b-4949-8466-06863861227f">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM5LTMtMS0xLTI1Mzk_0022c9aa-e4aa-45bf-adeb-95f70cd747ba">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQwLTEtMS0xLTI1Mzk_6f49018a-2d75-449b-9776-9dce2fb30f32">349,877</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQwLTMtMS0xLTI1Mzk_129ff8f6-2b3a-440c-8ee9-6a0613e63391">447,570</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stockholders&#8217; equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQxLTEtMS0xLTI1Mzk_a78c31d1-2bc8-412e-b03d-9898bd5c8e60">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQxLTMtMS0xLTI1Mzk_2bacb1ac-02f3-4a56-a7d5-4f828836aae1">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 30.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total liabilities and stockholders&#8217; equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQyLTEtMS0xLTI1Mzk_f383ee2f-1212-4ed4-823b-d0c3f609ad45">2,367,271</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQyLTMtMS0xLTI1Mzk_cf9a102a-ad96-4ab1-9086-1bd4a16e53f1">2,137,333</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_19"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except per share amounts)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy0xLTEtMS0w_81b7b574-0ab0-40d7-b45d-922aa94ca8aa">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy0zLTEtMS0w_e29ee029-6bd1-477f-ac3d-28c252ab6086">178,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy01LTEtMS0w_4a7f7bcb-1812-4899-901a-ad00973424f7">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy03LTEtMS0w_162c88aa-d38c-43c5-aff6-72bb5da9d725">372,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9259a9d7933146308c821508a3ddee27_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC0xLTEtMS0w_25a9c531-4764-481d-9b4d-c23fcb04c8d5">39,640</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC0zLTEtMS0w_4477f2f7-a126-4799-b420-44726188e029">59,234</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21d371856cc48a68b4309847396fa80_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC01LTEtMS0w_d41abdee-e1b2-42e5-b3b8-b61fe84f62df">67,168</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC03LTEtMS0w_e118cf53-8d86-453d-83c4-bbf22d123399">80,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS0xLTEtMS0w_da4b0944-a101-45d9-9594-bf753ef1a570">61,289</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS0zLTEtMS0w_c1ca5a4e-5eec-443e-b7c5-453b4eab8703">21,515</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS01LTEtMS0w_0c57e564-98fe-4d40-a3e1-8840faafe6c8">76,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35c76885c08464e8536056814cc87b0_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS03LTEtMS0w_c18378f9-e035-4603-97c8-c78127f1851c">33,671</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi0xLTEtMS0w_e9ac2e12-d9c7-450d-9a53-b205a23c4183">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi0zLTEtMS0w_179cf3cb-ab99-414b-823f-a3718a32dfca">259,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi01LTEtMS0w_25ae4691-3068-4047-89b6-6a24dbf57c0c">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi03LTEtMS0w_70eec2a0-54e7-4d9c-9d3d-33a9e4a1992e">486,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC0xLTEtMS0w_f32cb374-3991-4f5f-86b1-9dec73c643df">14,884</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC0zLTEtMS0w_6ede8e0c-d016-40f7-bfeb-0e85f9fad6d7">9,221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC01LTEtMS0w_ba875cc4-363a-416d-af2f-53b6caea7c9d">28,082</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC03LTEtMS0w_9e6212dd-7396-4b7c-b1e4-3bc94dda2f92">18,510</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS0xLTEtMS0w_49ef8ac0-b450-487d-ab6d-97523445fabe">148,790</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS0zLTEtMS0w_77c82a40-c39b-4307-b78e-320e17b9e189">114,933</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS01LTEtMS0w_72bc7537-6eeb-4da7-a024-b437bd01e091">308,078</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS03LTEtMS0w_85ffdb19-01c6-4397-abb0-a6879405d485">216,810</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtMS0xLTEtMA_9e9bd71d-b834-4523-9493-41a5f05176e9">98,495</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtMy0xLTEtMA_4e67c7ae-76a9-4f34-a1b8-3bdb6e494f9f">59,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtNS0xLTEtMA_f9f5070f-827f-4282-9ab4-bcecb2351ee8">200,846</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:SellingGeneralAndAdministrativeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtNy0xLTEtMA_3858a665-4225-4411-a26d-3aa391a695db">122,731</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtMS0xLTEtMA_b793cfb4-3fc0-4c40-ad71-3ad95ca02012">262,169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtMy0xLTEtMA_35b8d8e9-186f-43ac-93b2-cb9407520b86">183,945</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtNS0xLTEtMA_302fffee-b5de-4112-aac2-4f5d840be20d">537,006</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CostsAndExpenses" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtNy0xLTEtMA_bb9ed111-8199-4032-b87f-2cac6c83158a">358,051</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income from operations</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItMS0xLTEtMA_9c9a02a4-30ca-4757-aefe-1036278b6973">123,008</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItMy0xLTEtMA_7e1ef3cd-dfb2-47dd-8783-f0d16a2341cd">75,534</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItNS0xLTEtMA_0b87d318-467a-45e4-8471-50b61d8a70a4">118,401</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItNy0xLTEtMA_3c66bac1-2cd1-4381-83ab-1c28bff8b7ab">128,343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtMS0xLTEtMA_050e02f8-69d7-4bc2-82c1-eb6e86e22faa">1,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtMy0xLTEtMA_7817068a-fab8-4dd4-815f-13f1545dce90">5,162</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtNS0xLTEtMA_725ed289-159e-48d6-b729-d059f56b2d73">4,573</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestIncomeOther" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtNy0xLTEtMA_ea6a6e1d-b56d-4661-a784-23dd06f217b6">12,382</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtMS0xLTEtMA_7405bf4b-2fe2-4efc-bc24-fdd1f5298121">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:zerodash" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtMy0xLTEtMA_9b8eb078-3a3a-490d-9486-27d5d28e30c2">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtNS0xLTEtMA_fea97cf9-4a06-40c3-b54f-67bad3dcbabe">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtNy0xLTEtMA_e6f086de-6bc3-4867-a87c-be0747e1f78f">6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income before income taxes</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtMS0xLTEtMA_0758fb06-ea16-4120-ba50-9cd35c2dbae8">124,888</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtMy0xLTEtMA_33222874-c188-4203-b43f-485364a459b5">80,696</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtNS0xLTEtMA_2fef8825-5e4c-4d50-ab3c-669409892020">122,873</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtNy0xLTEtMA_9a5dbef4-3c6c-40b3-bb64-822c21fcfdc8">140,731</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtMS0xLTEtMA_c77ac110-c588-401d-868d-2237f1f53808">28,796</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtMy0xLTEtMA_abdc1ad8-2000-4063-b998-d5e7113f1f41">13,875</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtNS0xLTEtMA_504a4677-05f2-4cac-ad83-eebbe970df53">25,180</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtNy0xLTEtMA_d5baf900-3db6-4f30-8c83-45f5d1df4cc6">25,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctMS0xLTEtMA_8c59a938-ba77-46f6-bfe2-d1973b4ebadf">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctMy0xLTEtMA_0ed6bc29-5d72-4285-846f-ae3ed36c72fc">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctNS0xLTEtMA_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctNy0xLTEtMA_440a50f1-946b-426a-8c74-53c935a85e7f">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktMS0xLTEtMA_db364df9-420c-4664-ba8f-4dba8f3d3d5e">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktMy0xLTEtMA_a8181d0d-a138-44ff-8fb3-35d1836987a7">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktNS0xLTEtMA_897385f8-22ab-4504-bf49-eb4a6bd32c5b">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktNy0xLTEtMA_bbc6ce9a-fefe-412b-8516-d5361bb8b0ce">0.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtMS0xLTEtMA_beecd631-c0bd-4197-a468-ed60af27687c">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtMy0xLTEtMA_a372761b-f96f-44e0-afcc-29e5a02bd2fe">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtNS0xLTEtMA_2a732a89-e223-41ba-a0a9-5210dae65758">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtNy0xLTEtMA_119fc0ce-5935-4989-a55d-0c6842d0a25b">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItMS0xLTEtMA_29e2868a-8b38-4875-a887-d7c75f9af8f0">314,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItMy0xLTEtMA_4e3f1f2a-e580-44d9-9acf-364bac526287">307,807</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItNS0xLTEtMA_0c983555-5ab8-4398-810b-60e29450066d">313,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItNy0xLTEtMA_579d327e-e1b5-40c8-b5e1-07460774ef43">306,598</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtMS0xLTEtMA_176fe79f-65fe-45a7-a45a-b70d9633959c">322,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtMy0xLTEtMA_8d71706a-07ff-44a6-8d6e-8a16b9b04603">318,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtNS0xLTEtMA_9fa59a67-6375-47c0-b124-ab89c973a39d">322,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtNy0xLTEtMA_a282183a-71c2-430e-8509-8d3fd1d9e176">316,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_22"></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.757%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi0xLTEtMS0w_8c59a938-ba77-46f6-bfe2-d1973b4ebadf">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi0zLTEtMS0w_0ed6bc29-5d72-4285-846f-ae3ed36c72fc">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi01LTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi03LTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income (loss):</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of ($<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzg5Mw_e1aed19c-f537-4f9f-8cd8-802c4947cd41">257</ix:nonFraction>), $<ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzg5OA_f662d2e7-6e1a-456e-8fd0-f6bc61ff7ff1">2,287</ix:nonFraction>, ($<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzkxMQ_3d9531dc-d268-46cb-b621-aa722f43bfd8">756</ix:nonFraction>) and $<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfOTM_016cff06-27c2-4fdb-8d18-0e5fcad1529a">1,346</ix:nonFraction>, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0xLTEtMS0w_d5a044e9-e116-42e0-876c-da7e448a3d18">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0zLTEtMS0w_6ee63066-50c3-445a-911a-88d7a74244e5">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC01LTEtMS0w_28763dae-a620-43f3-9178-273f67bd34b1">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC03LTEtMS0w_8aa3a92b-0df2-4d75-8275-8cb854496ba3">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Comprehensive income</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi0xLTEtMS0w_f915a778-7ea7-4804-8e41-f9837b84b02e">95,337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi0zLTEtMS0w_8a3527d1-8195-4ae7-a942-22ba358f7eaa">74,883</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi01LTEtMS0w_b4926d54-dccc-4f23-9321-086bc3a4b628">95,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi03LTEtMS0w_9617b239-7153-485c-8081-ad8340a14e88">120,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_25"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.232%"><tr><td style="width:1.0%"></td><td style="width:41.220%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.513%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.406%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2021</span></td></tr><tr style="height:29pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at March&#160;31, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i18f71f314ed04df18bb6962c37407e37_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMS0xLTEtNjU_45e92784-b07a-4d49-b890-bd9e9f89fac2">313,262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18f71f314ed04df18bb6962c37407e37_I20210402" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMy0xLTEtNjU_5d46fa70-057f-40c7-a0bf-d8094bfd7670">313</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d1d3b56237f4f60b09904a6c28afefa_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtNS0xLTEtNjU_ff5ef394-1230-4b8e-97c5-789a88280458">2,354,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia7f72b97be95433eb01da77344b924b4_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtNy0xLTEtNjU_fbb928f0-2ad2-46f6-8a9d-79e56f43b679">2,740</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9055e59c6448472b8afad20e904571c0_I20210402" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtOS0xLTEtNjU_4c3367ed-56e6-44f2-a34f-1aa72499cee1">445,969</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic2d314200efc414286c58e02a72592ae_I20210402" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMTEtMS0xLTY1_b1b9110e-1cc4-43db-b9d2-53a02823cfba">1,911,187</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i44dd4e95f4af402e9f077cd335eb7007_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjQtOS0xLTEtNjU_699fb1c3-6fc2-4a27-9374-cb4c5e3e8a8c">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjQtMTEtMS0xLTY1_76441df4-f3f5-464c-8c78-039bc2ea06d3">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i53be24f47fe943889e3a6dda67c33519_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjUtNy0xLTEtNjU_79ddf047-b110-4502-a5f8-1a6decf672bd">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjUtMTEtMS0xLTY1_0147ca42-5fc3-471a-9687-598f078dbaad">755</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i506073af88c340ebb62b33816c074aaf_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMS0xLTEtNjU_ab25e987-984e-400e-a119-cb637b35ff7f">1,560</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i506073af88c340ebb62b33816c074aaf_D20210403-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMy0xLTEtNjU_2772e28a-2c7b-450d-875b-3f9bebd347a8">2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtNS0xLTEtNjU_794d63dc-a69d-4a98-804a-fa2396098f83">11,283</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMTEtMS0xLTY1_13b7d573-5c1d-443c-ba2c-ba636e52aa7c">11,285</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjctNS0xLTEtNjU_ce1a4dac-34a3-4c00-8136-258dd19fa033">2,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjctMTEtMS0xLTY1_3a2f867b-0ee6-4cd7-9deb-7e22889b3f21">2,767</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjgtNS0xLTEtNjU_50169e7b-7aac-4cb1-8e2f-2daf13cfa997">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjgtMTEtMS0xLTY1_801aee67-b05b-4bd0-8ff4-308af33ede28">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMS0xLTEtNjU_913b87f5-3e24-4f0d-be62-c5c3da425caf">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMy0xLTEtNjU_84287cba-bb1e-487c-a87f-083ee960ed44">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693dc4f870124e0b9ddd7456d2a2738c_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktNS0xLTEtNjU_7dd74ebe-96b7-4f20-b1b6-18f213786abd">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktNy0xLTEtNjU_fb90982b-5ebb-49d0-9153-bcd2fd0d5dbe">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748018c371b647b38103dedba2c84de1_I20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktOS0xLTEtNjU_5c965796-8c10-49c5-a6da-b245a148a8ab">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMTEtMS0xLTY1_ab40f25e-4bb3-454a-92c5-1c419ebe3bee">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.224%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.535%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.671%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.238%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.667%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30, 2020</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated Other Comprehensive Income (Loss)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:27pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at March&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ic45af8276000456da83f9b42424d83fd_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMS0xLTEtNjU_d3b6f3e1-89c8-4082-b042-d01716bd3340">305,780</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic45af8276000456da83f9b42424d83fd_I20200403" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMy0xLTEtNjU_a6389dc6-87c7-4d08-92e7-825fb8e8f036">306</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iccf0f3d464b14f8689aace6957954839_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtNS0xLTEtNjU_2473f130-6f8a-4f88-a06b-dc7e86470518">2,258,307</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i0f53374fa9494a2bbfec8a0dac4cec86_I20200403" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtNy0xLTEtNjU_34a8871b-50c0-42ba-8e96-acf48b7692b1">222</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if4476ab3366d4b4aa330a4b0fa517edf_I20200403" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtOS0xLTEtNjU_b78842bc-a394-41ed-af10-78993325bc7b">510,739</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i946cc6b151944fdc8ee643e1575173c6_I20200403" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMTEtMS0xLTY1_c03dc60c-780c-4b56-8730-0398ce94c3a0">1,747,652</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib54c97a496384e2f8bf53ca6af61aaca_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjQtOS0xLTEtNjU_7794ef1c-998e-4c07-9909-74c8f22c8f30">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjQtMTEtMS0xLTY1_c4528241-a445-4b16-9c27-277a37fcca81">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36169ffce5154dfabab0771e977ca089_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjUtNy0xLTEtNjU_9c239474-506a-4bc5-93e1-aa80b5a13c22">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjUtMTEtMS0xLTY1_da440c46-1f16-4880-b1a5-362c716b6def">8,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i664240e571634cfbaf15ac1e52615971_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMS0xLTEtNjU_40caa541-c2e5-4de7-a8fa-e4fe8df1a5e1">3,106</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i664240e571634cfbaf15ac1e52615971_D20200404-20200703" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMy0xLTEtNjU_67da3b8c-814c-4079-bb48-68f6658eb58b">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtNS0xLTEtNjU_2360b11d-9d57-4215-9c58-dec94ab59354">13,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMTEtMS0xLTY1_83cb430f-5cd4-4b5f-8074-814fdadf0b8a">13,783</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjctNS0xLTEtNjU_5ebeba59-5928-4f24-87b3-9cbf29475bb5">19,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjctMTEtMS0xLTY1_98cd6260-022b-4e62-b681-7014cf8547f1">19,148</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjgtNS0xLTEtNjU_6aa05206-1fc0-45f0-bc0f-cf625d6f1e65">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjgtMTEtMS0xLTY1_cce37210-2131-4f26-bed9-5d2467d3603c">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Balance at June&#160;30, 2020</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMS0xLTEtNjU_cdbed083-589a-491d-8ab4-3bb953111a56">308,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMy0xLTEtNjU_575d0406-4286-4ada-81ce-01f4bf126046">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493e0445ef74439faa8e33e8d3bd99fc_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktNS0xLTEtNjU_45ff283c-494b-4002-91fc-bc67d7db5f63">2,269,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56aa11bddb1f4538a589748b0433902b_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktNy0xLTEtNjU_1ff57827-feec-4de4-97b0-bacb1b567ed6">7,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35af602dfdfc44a7b9bc433d59cbc821_I20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktOS0xLTEtNjU_15c4fbf7-31d7-46a3-bc8f-4108344d1094">443,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMTEtMS0xLTY1_4675ffd2-d719-4378-a518-980968b8a00e">1,833,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Continued on next page</span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:9pt;text-indent:36pt"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY - Continued</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.451%"><tr><td style="width:1.0%"></td><td style="width:42.560%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.933%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.720%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.241%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.722%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2021</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i081256c453a249839e8537f1c0153e9f_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMS0xLTEtMA_dae18e75-8f75-4985-8784-3bbaf2135180">311,627</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081256c453a249839e8537f1c0153e9f_I20210101" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMy0xLTEtMA_98edd32f-238b-4397-9a87-de0ab534d2a8">312</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a0940ae62e5401b9c203c706d89df2f_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtNS0xLTEtMA_6f89e452-ca62-4951-8136-9c6584896eb1">2,321,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i058b3f9310334495bbc354761bd6647b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtNy0xLTEtMA_90b85a01-b262-413a-9559-b8cd80ddf55d">4,476</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="if0687bdba44c461687736aa0a7fa9b21_I20210101" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtOS0xLTEtMA_ee670de0-f868-4a01-a285-89615189f746">447,570</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMTEtMS0xLTA_f90097ae-6c92-4cf1-8711-e74a29c217d2">1,879,113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjQtOS0xLTEtMA_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjQtMTEtMS0xLTA_4ad9cbad-4d35-4f1b-8d80-84848d2cc81a">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ief41d78e50cb4a93a62920da7cecefef_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjUtNy0xLTEtMA_c3e6be1b-d465-41a6-8e1e-8ecc54e0d91a">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjUtMTEtMS0xLTA_dc7a095e-3552-4eb2-a0ec-57c3ec3a7c4e">2,491</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ifa16a9d12d014d909104f7045186de11_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMS0xLTEtMA_735d3013-e415-417b-b64e-d40bff4a3071">3,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifa16a9d12d014d909104f7045186de11_D20210102-20210702" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMy0xLTEtMA_3ba27226-955f-4c65-a62f-da43e929dc6a">3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtNS0xLTEtMA_f14f863a-8af4-4226-9221-db40bacac4fb">15,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMTEtMS0xLTA_26c56fe4-739b-4362-b484-a970d080c935">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjctNS0xLTEtMA_d0ad8d97-c10a-42f3-b3fb-8489b906595e">9,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjctMTEtMS0xLTA_7bfb4227-b53e-4fc9-a645-9f5cef5fc315">9,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjgtNS0xLTEtMA_59acf739-a5da-4ec2-940f-febff406bfc6">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjgtMTEtMS0xLTA_076a2dbb-f61a-4ce0-a5db-e35357b803e1">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMS0xLTEtMA_913b87f5-3e24-4f0d-be62-c5c3da425caf">314,822</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMy0xLTEtMA_84287cba-bb1e-487c-a87f-083ee960ed44">315</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i693dc4f870124e0b9ddd7456d2a2738c_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktNS0xLTEtMA_9b29e1cb-55e0-4e75-92dd-339921b60a87">2,390,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktNy0xLTEtMA_fb90982b-5ebb-49d0-9153-bcd2fd0d5dbe">1,985</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i748018c371b647b38103dedba2c84de1_I20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktOS0xLTEtMA_5c965796-8c10-49c5-a6da-b245a148a8ab">349,877</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMTEtMS0xLTA_c52d65dc-24b0-4e90-af21-3e3d12e363dd">2,043,077</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.903%"><tr><td style="width:1.0%"></td><td style="width:42.691%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.545%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.769%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.243%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.773%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30, 2020</span></td></tr><tr style="height:26pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Common Stock</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additional<br/>Paid-in<br/>Capital</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Income</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated<br/>Deficit</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Stockholders&#8217;<br/>Equity</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2019</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMS0xLTEtMA_975fc149-6cb1-4fcc-b8a4-85d1e20e74a1">304,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMy0xLTEtMA_51449ea0-e354-4e66-a62a-6a7d804debf6">305</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i84739d5f149041178c34597093926bd6_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtNS0xLTEtMA_1da7f7d0-9047-4744-8922-bc6595737a78">2,241,947</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5556cef549ed44c18c579369e37ccdf2_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtNy0xLTEtMA_472a9ebd-ab39-4457-9b08-315540e2f55a">3,069</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i3025b4065aaf4cdba68bd29f0237a548_I20200103" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtOS0xLTEtMA_677f2e99-3b2a-414c-8f52-d97759af6311">559,351</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13daa675eb9480989a9cdb6f2a297e6_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMTEtMS0xLTA_b74998b4-a743-461d-814d-6a0010c71516">1,685,970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i80c8d20e80cc4ad7bca1dc91ecf75437_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjQtOS0xLTEtMA_8f20deb6-56c2-4b58-89fc-ac7b5c34467b">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjQtMTEtMS0xLTA_4fea6dc4-9270-4c60-913e-a2a4e28af547">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other comprehensive income</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i081971405e1741eeb1fc749632c1c0aa_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjUtNy0xLTEtMA_e9063691-825f-4818-be37-78a35180f16b">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjUtMTEtMS0xLTA_164a602f-c4f8-40b4-a12d-e84eda18db10">4,771</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Issuance of common stock under equity incentive and stock purchase plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMS0xLTEtMA_584faf3c-d980-4fc8-bdec-c2c510aa5e4f">4,055</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMy0xLTEtMA_fed21181-3047-47e1-b6c2-6240fa2a0846">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtNS0xLTEtMA_08ecf893-1c5e-4e0e-9ffe-7fc42e5ad14a">17,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMTEtMS0xLTA_573bdd49-4454-45bc-948a-b8b43a8124fd">17,955</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock transactions associated with taxes withheld on equity awards</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjctNS0xLTEtMA_f8af50f9-f43c-4c8c-aca7-105ac988c951">20,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjctMTEtMS0xLTA_851cf588-bb1d-4476-827a-461a54bb6455">20,941</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjgtNS0xLTEtMA_0ee15f6a-3840-4ede-bf7c-3e3291d07128">30,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjgtMTEtMS0xLTA_f3efe646-bf4b-4008-b43b-63f273556776">30,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2020</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMS0xLTEtMA_cdbed083-589a-491d-8ab4-3bb953111a56">308,886</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMy0xLTEtMA_575d0406-4286-4ada-81ce-01f4bf126046">309</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i493e0445ef74439faa8e33e8d3bd99fc_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtNS0xLTEtMA_45ff283c-494b-4002-91fc-bc67d7db5f63">2,269,093</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56aa11bddb1f4538a589748b0433902b_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtNy0xLTEtMA_1ff57827-feec-4de4-97b0-bacb1b567ed6">7,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i35af602dfdfc44a7b9bc433d59cbc821_I20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtOS0xLTEtMA_15c4fbf7-31d7-46a3-bc8f-4108344d1094">443,918</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMTEtMS0xLTA_4675ffd2-d719-4378-a518-980968b8a00e">1,833,324</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="text-align:center"><span><br/></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_31"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income </span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMi0xLTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMi0zLTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments to reconcile net income to net cash provided by operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNC0xLTEtMS0w_847f75a9-adce-473d-9c09-cb59673782b3">6,895</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNC0zLTEtMS0w_d1b229e2-ff93-4a3d-bcf6-0e2936b30f9a">4,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNS0xLTEtMS0w_5fe158ce-aa4d-4d35-a48e-5a04a6a67e99">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNS0zLTEtMS0w_a9b9b610-b080-4046-a88b-328feb74fe4a">30,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash lease expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNi0xLTEtMS0w_825fa57a-0a13-4497-8c0c-7be77fc3fae5">2,586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="exel:NoncashLeaseExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNi0zLTEtMS0w_bf9da8b7-7c30-4044-90e6-99bd8e0ddec7">2,383</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred taxes</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNy0xLTEtMS0w_f9c60263-be8a-4efc-8f1a-0399613feaca">22,800</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNy0zLTEtMS0w_e0b874de-0f31-454c-827a-5e3c89973e02">22,793</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfOC0xLTEtMS0w_fe7dff11-ac77-4c60-b40c-3560bbdf3eae">22,831</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" sign="-" name="us-gaap:OtherNoncashIncomeExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfOC0zLTEtMS0w_098bb764-9c02-40d9-8b39-32c5945cc7ec">726</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trade receivables, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTAtMS0xLTEtMA_14a51825-ed95-47e2-ba16-3cb2e215f1e2">12,313</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTAtMy0xLTEtMA_7e5e1028-7cfc-4ab4-bdd6-d9fb0944b3f7">2,014</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventory</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTEtMS0xLTEtMA_819c7ad9-85f7-4136-b2bd-4d1b83a722c0">8,020</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInInventories" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTEtMy0xLTEtMA_271c20a6-62a9-4083-8537-7c09c9056c5f">7,049</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTMtMS0xLTEtMA_e6994081-10e3-4b2d-8592-3255c65e3d53">12,296</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTMtMy0xLTEtMA_cb87af9f-03c6-4b02-a9c7-02033803a2d6">18,954</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTUtMS0xLTEtMA_4a8b70b3-f4fc-4df8-862f-7797f42a45cd">9,346</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTUtMy0xLTEtMA_4b2d3bd9-0af6-4039-884c-293c61c73e55">9,659</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and other liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTYtMS0xLTEtMA_b52b9a46-fc05-439c-9494-2146af754a27">28,835</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTYtMy0xLTEtMA_c1ebde8a-4583-4773-80f8-c980d66db7f7">262</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTctMS0xLTEtMA_fd75be72-2074-4a7c-a4d4-ac65dd6e1c43">221,045</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTctMy0xLTEtMA_fb0a854b-d1af-4bf2-895d-dd58d86a3ddb">157,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of property, equipment and other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTktMS0xLTEtMA_e74bff06-0aeb-49ae-a327-d6d3956fcafa">33,768</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTktMy0xLTEtMA_fd28fc45-b739-4264-aef2-296547d9f2a2">9,925</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Purchases of investments</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjEtMS0xLTEtMA_7e00e430-302c-4547-a0bd-ef1021052b22">688,903</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjEtMy0xLTEtMA_877c38cb-4454-47a3-b4dd-e0ba9c36a26d">433,154</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from maturities and sales of investments</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjItMS0xLTEtMA_4b59ae5d-1785-4e83-88e2-0ec69cc63126">714,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjItMy0xLTEtMA_6bc86ff1-f5ca-4459-9f8a-8ceab3c42dd2">548,973</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjMtMS0xLTEtMA_b432c59d-6ac1-49ce-8b37-4d2e258ea6ba">8,590</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjMtMy0xLTEtMA_7573fe91-9a80-4a65-a404-a497c5fd5f70">105,894</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Proceeds from issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjUtMS0xLTEtMA_1df475d1-92a7-493c-b4f0-1421ce031e7e">15,487</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjUtMy0xLTEtMA_5978517e-66a9-4bb4-9acc-3180c9304e75">17,938</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Taxes paid related to net share settlement of equity awards</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjYtMS0xLTEtMA_d96dca9f-d05e-4815-a09e-f9d22e04dbf1">9,413</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjYtMy0xLTEtMA_46553725-f1e1-4852-9fac-5d48140ee9b7">20,941</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjktMS0xLTEtMA_aecbe15c-6a20-4977-934f-c4c4d01561d1">6,074</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjktMy0xLTEtMA_239e4674-477c-4ac4-a54f-e3356981a582">3,003</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net increase in cash, cash equivalents and restricted cash equivalents</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzAtMS0xLTEtMA_09c5f763-c682-4b63-acf0-30a3d120387d">218,529</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzAtMy0xLTEtMA_79896bb6-bddc-488a-9aa0-1bb23e814b8f">260,642</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at beginning of period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzEtMS0xLTEtMA_1a5c73ec-afa9-46c5-b7e9-25308332de16">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if13daa675eb9480989a9cdb6f2a297e6_I20200103" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzEtMy0xLTEtMA_a70558e3-4025-4763-9ebf-d77b7f2e1ad1">268,137</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents and restricted cash equivalents at end of period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzItMS0xLTEtMA_1dd605b6-8614-4a92-890e-de1bd826fa19">539,301</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9.5pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzItMy0xLTEtMA_1ffbe429-99a7-4f72-b0ba-195b064f2980">528,779</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Supplemental cash flow disclosures:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Right-of-use assets obtained in exchange for lease obligations</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzctMS0xLTEtMA_9b583287-bf80-4107-a5ef-d8ac65a69016">4,893</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="exel:RightOfUseAssetObtainedInExchangeForLeaseLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzctMy0xLTEtMA_101b53fe-0f10-4b58-bd66-f945e2829f37">1,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-cash investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for purchases of property and equipment</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzgtMS0xLTEtMjc3MA_98533434-ccc2-40ec-b410-f4ae783994eb">5,125</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzgtMy0xLTEtMjAxNA_ad59ad49-7d3d-43b6-b37c-14e1c39fe0fa">804</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred in asset acquisition</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzktMS0xLTEtNTQzNw_0e8a445c-7134-4cc3-81e1-7b33e194e7eb">9,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:zerodash" name="us-gaap:LiabilitiesAssumed1" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzktMy0xLTEtNTQzNw_36b49663-64e9-4424-a4ef-11acdb03d03f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Unpaid liabilities incurred for unsettled investment purchases</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNDEtMS0xLTEtNTYzNA_61b0d98e-9b04-4d4f-bc09-d3a0ae8e5f0d">7,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:zerodash" name="exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNDEtMy0xLTEtNTYzNA_c3e8d09a-02a4-410d-a809-7afde07656c3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_34"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXELIXIS, INC.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_37"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0OA_93d2a485-06ce-41ee-bd80-fc1c1bb8c9ad" continuedAt="i4fe87241cfe34adf83d1c01599e762df" escape="true">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</ix:nonNumeric></span></div><ix:continuation id="i4fe87241cfe34adf83d1c01599e762df" continuedAt="ib9805515b5de452ba5060d0e65db880b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, <ix:nonFraction unitRef="product" contextRef="i0788ba9b7348408294dc259c3a82acb4_D20210102-20210702" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfNTcw_ebfc52fc-05d7-4974-8099-6b6105bbbe11">four</ix:nonFraction> products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other <ix:nonFraction unitRef="product" contextRef="ibb1fe7255a2442e295f20f47559b739d_D20210102-20210702" decimals="INF" format="ixt-sec:numwordsen" name="exel:NumberofProductsinCommercialMarket" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfMTU5Mg_7af42b17-da61-42d1-852e-0d69f5359a13">two</ix:nonFraction> products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ConsolidationPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODUzOA_dca9379e-4bb8-4646-95c1-fae7b4201ae8" escape="true">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU1OQ_a968e502-2a8d-41fa-ab33-f21a47b537a8" escape="true">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:FiscalPeriod" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0MA_8d55af34-6332-4923-af8c-72c221189455" continuedAt="idf99cd2624ff497996dc78ca51795312" escape="true"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span></ix:nonNumeric><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf99cd2624ff497996dc78ca51795312">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended  July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</ix:continuation> </span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU2MA_f945a887-7e1d-44c5-8ac5-de369bd26d82" continuedAt="idf1bae9639aa43279db9a9f7246c3952" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in <ix:nonFraction unitRef="segment" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfNDE1OA_f16a0223-bc71-4520-9302-25ace9fc3f07">one</ix:nonFraction> business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="ib9805515b5de452ba5060d0e65db880b"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idf1bae9639aa43279db9a9f7246c3952">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</ix:continuation></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:UseOfEstimates" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU1Ng_e01ea541-87cb-47d7-9152-9ed013047630" escape="true"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div></ix:nonNumeric><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU4Mg_0024d841-589e-44ea-874b-6f3b6dcb53ec" continuedAt="i9429222775404f90b47411285f339fec" escape="true">Reclassifications</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i9429222775404f90b47411285f339fec">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.</ix:continuation> </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:DerivativesPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0Ng_ea43e18d-0116-4927-bb52-d84961b0a369" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU2Mw_ea0973a1-c211-41d6-80f6-1479b981a8b8" escape="true"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_40"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk4NQ_81d10b30-7fe2-4913-8b71-9714fedb3794" continuedAt="ibe70dac171284f78964f65c193e1e73e" escape="true">REVENUES</ix:nonNumeric></span></div><ix:continuation id="ibe70dac171284f78964f65c193e1e73e" continuedAt="i76422126015d47e5a7c910f67759efa3"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:DisaggregationOfRevenueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMg_5a932b68-d59c-4ce4-bcca-120b21541beb" continuedAt="i34aecce180434079961fc4671afe562c" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.715%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i947f11dce7724c8a92d7f9d767d30430_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy0xLTEtMS0w_6417ffc6-19c9-4af6-9d93-7f7d66598a35">380,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibab3c993c7644d7a946dcb256efda5b9_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy0zLTEtMS0w_cf519e6b-fcc8-4b6f-9a33-f8762557bf6a">229,898</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib167b52f75e74c39838cc0b9a5bafec1_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy01LTEtMS0w_5e8b6020-22e9-41f7-86ba-b30fc0e41fe1">694,409</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic4d233c682dd4c8e86078cfa757643ba_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy03LTEtMS0w_d176ffb8-f371-4e35-8971-3e238bd80bb3">482,464</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id8f066b777054049b67a402360c6a782_D20210403-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC0xLTEtMS0w_0e95e048-fe63-465c-a88d-1ae78bf6fe1b">95,956</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i88bdab6e93514c5ca7163e90e6740f46_D20200404-20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC0zLTEtMS0w_62515ee5-8e52-49e8-bcf3-04c3fc6cb108">51,168</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="id31ef9d0f4694bdf8921fc58940a8cd7_D20210102-20210702" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC01LTEtMS0w_b4d903f1-1534-43e4-bd73-21e5d060a2b6">182,949</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i99c380c1cdd64bc68dfdb4fc5dc13a5a_D20200104-20200703" decimals="-3" sign="-" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC03LTEtMS0w_e45f03a8-cdea-4d1c-86d0-f789794abc22">109,854</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS0xLTEtMS0w_81b7b574-0ab0-40d7-b45d-922aa94ca8aa">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS0zLTEtMS0w_e29ee029-6bd1-477f-ac3d-28c252ab6086">178,730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS01LTEtMS0w_4a7f7bcb-1812-4899-901a-ad00973424f7">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS03LTEtMS0w_162c88aa-d38c-43c5-aff6-72bb5da9d725">372,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9259a9d7933146308c821508a3ddee27_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy0xLTEtMS0w_25a9c531-4764-481d-9b4d-c23fcb04c8d5">39,640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy0zLTEtMS0w_4477f2f7-a126-4799-b420-44726188e029">59,234</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia21d371856cc48a68b4309847396fa80_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy01LTEtMS0w_d41abdee-e1b2-42e5-b3b8-b61fe84f62df">67,168</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy03LTEtMS0w_e118cf53-8d86-453d-83c4-bbf22d123399">80,113</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC0xLTEtMS0w_da4b0944-a101-45d9-9594-bf753ef1a570">61,289</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC0zLTEtMS0w_c1ca5a4e-5eec-443e-b7c5-453b4eab8703">21,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC01LTEtMS0w_0c57e564-98fe-4d40-a3e1-8840faafe6c8">76,779</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic35c76885c08464e8536056814cc87b0_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC03LTEtMS0w_c18378f9-e035-4603-97c8-c78127f1851c">33,671</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i83c483fda79b4c16ad3d9442173642b8_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS0xLTEtMS0w_d333cd14-fd0e-4811-8852-8dd2b9ae8b6a">100,929</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cafb301e8bc4a1e878470c9b0f12baa_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS0zLTEtMS0w_50a1d802-a79d-4a51-a6a3-bcdcc55dfca4">80,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie10d8c01e16442feaeac308109be67d6_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS01LTEtMS0w_4a5bbfa6-9944-4980-bf04-d8816e463c9d">143,947</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3396192359714cebba9f9044f46388b8_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS03LTEtMS0w_fc10d8d9-96bb-46c4-bab2-d6dd060eafa2">113,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtMS0xLTEtMA_e9ac2e12-d9c7-450d-9a53-b205a23c4183">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtMy0xLTEtMA_179cf3cb-ab99-414b-823f-a3718a32dfca">259,479</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtNS0xLTEtMA_25ae4691-3068-4047-89b6-6a24dbf57c0c">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtNy0xLTEtMA_70eec2a0-54e7-4d9c-9d3d-33a9e4a1992e">486,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMw_c00c1af8-322d-499b-a633-d76f38ec2fd7" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.039%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0xLTEtMS0zOTI_5eeca8a9-1483-4aa2-b677-55584e4e292c">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2dd1c78a8dac4b7489425c0a1175d608_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0zLTEtMS0zOTI_1728153b-a704-42ab-b8b2-64a3cc859c16">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibdf20ffabe0140baa5b07542eeab1510_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi01LTEtMS0zOTI_9591811f-f61c-431b-9bc4-947980391497">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i11371f462a3a4f459626f35247d98cda_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi03LTEtMS0zOTI_efc723ce-b6c4-4381-8762-485a5996cc07">17</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if0c970818f314feb8775caa6ef94fd81_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0xLTEtMS00MDc0_cb26d66b-03e5-4f3c-aecb-ffb3b0d26547">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i8ad0b431492b4370a00a89fa2d331434_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0zLTEtMS00MDc0_a64f8218-7866-4d53-85e9-1e19457fe321">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i70b167eedebd4c72b9f4d3f02442f179_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy01LTEtMS00MDc0_ac479bbd-7ba2-47a3-8a3b-edee39bd3719">14</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5f7584f5954340dba177cf82b494e611_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy03LTEtMS00MDc0_31d49d12-2b7c-464f-88ac-4dc24ca677d3">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idd6c27d712d943b78475ea6b7bcb2516_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0xLTEtMS0w_f638ba70-d3c2-4bfc-9f1f-855a685d7de1">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="if3bd6a226ce54f36b775c95518c27470_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0zLTEtMS0w_da65492d-92f2-4374-a360-f15e4e2a16ab">13</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ifeb5bb631eb2470babf9f8d080f9964f_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi01LTEtMS0w_aa4665d6-c9e8-4cdb-b8a8-3375ea242b7b">14</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0351d4cb2134494ba29863d99c874739_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi03LTEtMS0w_0e298a7b-adca-4a59-822a-9a7e2ee83e0f">15</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i54323ff73fd948188ef473dee8b6e814_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0xLTEtMS0w_a3a78f9b-5982-4ea0-aa78-c8c9e3e64289">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i0e5051bdb62a4adea3b1ba61cad3e07b_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0zLTEtMS0w_bdbc4299-8eee-409e-aa48-bc6982c7d46a">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ib2310c9c82ca42f09d4e1cb96f939ad9_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy01LTEtMS0w_f153c498-c7e4-4803-91df-8888424b4605">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i821ee440df88470196800293d930e33c_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy03LTEtMS0w_fe03ba1d-3492-43f6-be0e-ce83bc72f2b4">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i753195995e5e4556a95e622429f0db57_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC0xLTEtMS0w_9008d65f-bb91-4443-9b76-2d8efdda1e75">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i5fd1ae2034d9412089e998f08d56e5c3_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC0zLTEtMS0w_35088beb-5923-42f2-a1ff-483290ba3db4">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i27c364af82884e9e8ba8d4a627f277bf_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC01LTEtMS0w_8dc4121b-e6be-4ec6-bde4-cc2beb2fe577">9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ibd0a23e145ff4ca084f0c9961d8b3a54_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC03LTEtMS0w_298f5b04-e2ba-4120-a5d6-e6178cd7ebe1">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="id9542af44b304776a9c4bb52e4768814_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy0xLTEtMS00MDg3_dfe4952a-3562-4d17-9ffc-fec8865d0c86">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i354e779a90704e25ab4430a20741de7a_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy0zLTEtMS00MDg3_ca945435-5cb5-4a59-9956-bfd345e38472">10</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ice75da26c51d4900838a61e74a5f0c32_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy01LTEtMS00MDg3_ccd9f835-817d-4a4d-999a-97b731ee2edc">8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2f30e6eb82e64b79b27523cafe87fb10_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy03LTEtMS00MDg3_bae796c1-f7f1-4eea-b94c-9c37d89ae297">9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i7b5f040ea73842e8abdcba995add3e6d_D20210403-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS0xLTEtMS0w_d12c235c-1414-4382-963b-7de9ba4cec00">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="idb3bee6b43f04331a2af7c80b4a7370d_D20200404-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS0zLTEtMS0w_40d86044-1788-4d4b-ba37-8bdbe0d18a35">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i13094e1db8884f879f12d67dad15c701_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS01LTEtMS0w_af98e053-8dae-45c6-b794-6eec3bedb15e">2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3bdd8100f1f84c43aa6914f739d17d31_D20200104-20200703" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS03LTEtMS0w_bddcacb1-8e52-4daa-950c-ccefb1c49ede">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ieb756ebdb26146dd872e8d96bcb1edf2_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMS0xLTEtMS0w_7929087c-af6f-4062-b38c-f860583aec35">24</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia6d4a34bdbe3414db629b89c722ea436_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMS0zLTEtMS0w_887a03d8-b25f-48d6-ae4b-2a1036146e90">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia210e74e223e424a970e3e3560d85886_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMi0xLTEtMS0w_5e549616-e915-4ba0-8ba6-fa0816337985">21</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i2d909f0df4c749f5ad2943003106be6d_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMi0zLTEtMS0w_f4d6122a-175d-41ba-92d1-735c3f741988">12</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ia8ed993e6ef846f0842723b5499f1a51_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMy0xLTEtMS0w_2b4dc1db-27f7-4068-9615-b99bb4e59f30">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ic3d6c5f034c743549e0b3580f3088770_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMy0zLTEtMS0w_f40b3d97-1266-4aba-bc28-01fc22d270bb">11</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i3be0c4f6862744d381c6a9c8ad69d360_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNC0xLTEtMS0w_1f75db4b-40c4-4ee7-a5c1-d7c97b8ba6c4">13</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i922effb845ac486685bc2d4ca1e2b64e_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNC0zLTEtMS0w_065a7957-3352-41fe-847f-117225d63153">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="i041977232d9d47f689aa8e5e54cf51c8_D20210102-20210702" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNS0xLTEtMS0w_ebbea5b0-5697-49e4-95d6-f07caa7b597f">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="ied845544fcad4e209b2f843ae011069a_D20200104-20210101" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNS0zLTEtMS0w_11649b9c-abaa-428f-aa8f-351329a3dcbb">10</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk5OQ_70b84e7c-dde8-4cb3-ae42-58f454b234ff" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i576124c34cb14293a07e65c0e116b0fd_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi0xLTEtMS0w_7a7b5177-c02c-45ad-9d0a-6431f79b97b7">287,190</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie1f3b07b878f446983ae8ea6c24a8523_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi0zLTEtMS0w_3403601e-e135-4769-8a1f-3ebc9414f28f">181,231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i926a2dcdbc7642d3b461dd3a6194ac74_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi01LTEtMS0w_22401169-d645-454f-aaf3-3dc217115b8d">517,147</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7962cd8f612a4e7a93a1cb357a042730_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi03LTEtMS0w_57688ddf-b27b-4476-8200-e287e889bcf4">377,827</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if8f782da2d2a45809e36bb66021e8e95_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy0xLTEtMS0w_c05ecf44-b047-4e82-bd7d-ff48286bcb13">90,921</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23fea2b017ea462db2fa2ac8224cb0a7_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy0zLTEtMS0w_860a6e18-2bb6-4dd9-b281-67a96d6ed4ee">52,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i1e515978877241b1a3bbbf6c7c87a132_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy01LTEtMS0w_14a6db31-0d65-4e52-a0eb-82032a889bf3">124,727</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3e0390849b8b485ebe8240a57d0c0e15_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy03LTEtMS0w_f22149a8-96e0-435b-965a-d052b7a536d6">81,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf21142c44dc4ed588e7f49495659845_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC0xLTEtMS0w_106dd95a-a44d-4ca3-8a63-77ae058fbffd">7,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8b04dfce356a48a3a67d32e955e37c0f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC0zLTEtMS0w_b01892ba-6b7e-4d80-8939-5430b1919741">25,331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b57543585624c4cbf46aba4e36a40d0_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC01LTEtMS0w_821f1f73-ef71-4c18-aba5-20ce1375113b">13,533</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4f2944cc9b084ae18eb84c3b0937c4bb_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC03LTEtMS0w_2eb5a3a2-61b9-4133-9390-4bd0f58b8e3a">26,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS0xLTEtMS0w_9e442324-1edc-47f7-8b5b-f6b99b350d9c">385,177</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS0zLTEtMS0w_586386a5-bc58-4b53-b6b7-732161e76fb1">259,479</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS01LTEtMS0w_aca202f0-5ce6-47ca-89b3-e4a2eab8efee">655,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS03LTEtMS0w_e874e222-0aa2-4384-a0a8-52f39c288bd9">486,394</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="i76422126015d47e5a7c910f67759efa3" continuedAt="ie672d18794e148c6b255f140e94ea6d3"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk4Mg_c7fda0a9-66f0-4877-ab27-6dd295981e85" continuedAt="ia76047a94b2c4806a1d03dda0e428d1f" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div></ix:nonNumeric><ix:continuation id="i34aecce180434079961fc4671afe562c"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.864%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4abad55b764942b8838caffe168cd460_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi0xLTEtMS0w_c81c4309-5a9c-4c6a-97e5-7cb736aaa4a8">275,614</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i602ab887907347eca4f8dd2743045d20_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi0zLTEtMS0w_f0ed5766-8ac8-40e6-90c2-9c5911171883">173,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4e3544936884787b393e216680bae75_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi01LTEtMS0w_47ef7c62-b155-47e1-83ae-b78e0627ae57">499,209</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic9861d7e9fc04d7797b39b96e817870b_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi03LTEtMS0w_50e6ae42-7009-47b9-8596-9fbe6855376d">362,826</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4494448a3d77442ea673dc4306f40517_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy0xLTEtMS0w_3a88050a-94ad-4095-8f03-8d1543c2de88">8,634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85570133db6f426dbb8f7b796098289a_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy0zLTEtMS0w_e54819a9-5c67-4543-9f43-48b1280f763e">5,120</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6779e8b939fb444986c5b5f6762bedae_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy01LTEtMS0w_c54befc7-0149-4bf8-b401-35755d00a84e">12,251</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifcab21398b064807b6664b9e08c18372_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy03LTEtMS0w_296fce7c-0704-48e8-ad59-7bac759ab847">9,784</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC0xLTEtMS0w_1faefa15-e71f-4d8a-86dd-d5351ec8a4fc">284,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC0zLTEtMS0w_8b235087-ccb0-4f93-baa8-f14151cf5126">178,730</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC01LTEtMS0w_55fe970f-589c-44b1-959a-e7296307ac9a">511,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC03LTEtMS0w_3caedc0f-bf22-4a37-8f1a-3a45d60757c6">372,610</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMA_326b5964-894a-446b-a9a1-80846d923cd4" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:41.905%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.590%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie35769b7587040d5aa523942d229c867_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS0xLTEtMS0w_6fa04a40-124d-4064-96da-6d5ff159e186">9,853</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib42e12234ac143a0a44b01d6e7a03fe1_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS0zLTEtMS0w_5e65c466-0cef-47d7-a155-9d726446b2b9">3,279</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48d197193a8a45b38af10e48f5f51e93_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS01LTEtMS0w_32260c8d-acbd-49b5-b939-c94fe5896688">17,404</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS05LTEtMS0w_ce469fcd-31d3-45d3-abfe-3a10b8865a1d">30,536</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy0xLTEtMS0w_fe0154d6-6754-41e0-9c55-f85d06680c86">114,489</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy0zLTEtMS0w_940a9f48-3f06-4e51-a08d-d9398ca8d1bc">15,392</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy01LTEtMS0w_17822436-b4f3-45ae-9018-3db457d14217">51,355</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy05LTEtMS0w_8a1cd2d6-95c5-49d7-9a9d-e0042e9ca315">181,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC0xLTEtMS0w_28f2845c-82a4-42a5-b4bc-9d4bfbdd7a4b">40</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702" decimals="-3" sign="-" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC0zLTEtMS0w_7d2f7677-db3a-46ed-928b-cf308a9593c3">164</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC01LTEtMS0w_f04ad7d5-bb99-4d01-887a-a560f8e3c274">1,917</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC05LTEtMS0w_a3011cbe-504d-4a93-99c4-bd8e223c3835">1,713</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS0xLTEtMS0w_6cf74253-6f72-45f1-8c2b-3f96544b3b9e">108,487</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS0zLTEtMS0w_65e97ea8-d838-47da-8c64-814c8f47ac54">11,637</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS01LTEtMS0w_4b506085-abe9-4d85-9c5e-734f4a2a8b7f">46,349</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesDeductions" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS05LTEtMS0w_2abffffa-b001-47e3-b8e9-70638ef8a161">166,473</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ffbaddc0eb14e9991b7a519b99dcf9d_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi0xLTEtMS0w_980a897b-6b9a-49ad-83d0-5f684221f2db">15,815</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i33ef18170a4944cd8de075cf4a5344d3_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi0zLTEtMS0w_eb74281f-1b74-4ed4-8111-a477f46f85b1">6,870</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia09e442b2e1243bc84dac0b50e653260_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi01LTEtMS0w_57f7497d-a510-4d48-b454-8e02c6dde851">24,327</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowancesAndReservesBalance" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi05LTEtMS0w_cbe51c3a-f803-4fac-b119-740e7ece8652">47,012</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><ix:continuation id="ia76047a94b2c4806a1d03dda0e428d1f"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</span></div></ix:continuation></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="ie672d18794e148c6b255f140e94ea6d3"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk5Mw_aa10d57a-dbd0-4a2d-ac26-39c0607a8dee" continuedAt="i146c66aa32564c1bb2f67b92453d397f" escape="true">Contract assets and liabilities were as follows (in thousands):</ix:nonNumeric></span></div><ix:continuation id="i146c66aa32564c1bb2f67b92453d397f" continuedAt="ibc36ec1c3f34408d90c35e173e93cdfb"><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMi0xLTEtMS00MjA3_d0a2ca67-2454-49ef-a3d0-8982132c1239">9,749</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMi0zLTEtMS00MjA3_4c9f9778-c8e8-4af8-a6b1-da694170cf3f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMy0xLTEtMS00MjE2_5b185a04-09ba-4497-822c-f516d306aa81">948</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNetNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMy0zLTEtMS00NDQ3_ebd54bdf-06de-4a88-b544-e672d72b7605">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0xLTEtMS00MjE2_2895e1d2-86f4-49da-b4f7-9947e9a4c480">10,697</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:ContractWithCustomerAssetNet" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0zLTEtMS00NDQ3_f67bbf5c-298f-4b74-962a-06d35e650553">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0xLTEtMS0w_0c34ea72-2d93-4876-be0b-c2635e7ee432">6,314</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0zLTEtMS0w_c9fd48d5-fcf0-4425-aaf2-47dc6aa1ac54">1,790</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNS0xLTEtMS0w_8f4ff0bb-e40b-4ec5-af30-10113159e2a8">8,577</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNS0zLTEtMS0w_f104dffc-5b98-4599-a708-c1240cf5bb81">3,755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNi0xLTEtMS0w_ada91b61-3415-4a6a-bc85-eac84253fa0c">14,891</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerLiability" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNi0zLTEtMS0w_e8cbb5ec-3915-445d-83c8-d4549953bdee">5,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets.</span></div></ix:continuation><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"><ix:continuation id="ibc36ec1c3f34408d90c35e173e93cdfb">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.</ix:continuation> </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets as of June&#160;30, 2021 are primarily related to a $<ix:nonFraction unitRef="usd" contextRef="i54e9688fa5234b7dabc087b18bea682e_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzNDUwOQ_c1804dc2-a87e-4db2-87ca-b9df920b8dfa">12.5</ix:nonFraction> million development milestone that we deemed probable of achievement and recognized $<ix:nonFraction unitRef="usd" contextRef="i7e90ca7353d7420d850374043f19414f_D20210403-20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDM5ODA0NjUyMDg1OQ_9a226340-1d8a-4614-8d4b-680b815ef0fa">11.8</ix:nonFraction>&#160;million of revenues during the three months ended June 30, 2021. Contract liabilities as of June&#160;30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda). </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021 and 2020, we recognized $<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMzg5OQ_fa7ac5d2-99f4-4711-850d-ff89a2f263ca">4.8</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-5" format="ixt:numdotdecimal" name="exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMjk4Nw_e2203119-938d-4054-a237-d588d09975c4">3.4</ix:nonFraction> million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIzMg_0d0d69ac-df56-415c-a4ce-cec43c77977a">40.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDA1Nw_9723c8cd-eed8-4caf-ba82-8d5f87b81601">67.8</ix:nonFraction> million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $<ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIxNQ_74ec900e-0d55-4cce-ac59-fd7dcde0cc68">62.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIyMg_d4b7aaf9-b691-408d-a19d-5e3cb249b8c3">82.2</ix:nonFraction> million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDQ4Mg_e3781dcb-74f4-4457-825e-a56327dc0fb7">86.9</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_43"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 3. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTkzMg_4c3647c7-c747-46bf-9c61-1bd19128df4f" continuedAt="i1e2676124e3745a2ad06d0617d294502" escape="true">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</ix:nonNumeric></span></div><ix:continuation id="i1e2676124e3745a2ad06d0617d294502" continuedAt="ieddc47b035564c9e8eddac683e0b5e1e"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="ieddc47b035564c9e8eddac683e0b5e1e" continuedAt="ic5c8a487abb5493cb856fda7977c0e30"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine differentiated thyroid cancer who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen is now obligated to reimburse us for their share of the COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt into and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the three and six months ended June 30, 2021, includes a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period.</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTkxNg_9dc4ddaa-90cf-4588-a9db-577c614e469e" continuedAt="ie962207c29d64bbdaa44b6e076dcb9f6" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i23ea9da53f1644eaa0a98b9259aa475f_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi0xLTEtMS0w_79b4ce6c-deb7-44ef-8e5f-b9c2cb9f3f3e">33,656</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9fb9e5548a364e8db87e699888c741d9_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi0zLTEtMS0w_f09eb09c-22b3-4e81-aa1a-5228ca04c886">33,597</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iee0e69c31a264295b5d40ec7776fd3db_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi01LTEtMS0w_9dabdbc4-9f08-4b49-bb15-f41939faaec5">56,107</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i438def86d067426f867cc300503942e3_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi03LTEtMS0w_7fcb4f3f-aad8-4ff9-be25-9d8b558e8d46">51,546</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icb3fd2d979fa40adaac2298fd1f78f5d_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy0xLTEtMS0w_b7a6e799-e81f-4849-b0c3-6548321abde6">57,265</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i85a056bb651c463991c7d6520faca86c_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy0zLTEtMS0w_e93f55ae-e656-42d1-9e0e-7517f43b0b84">19,320</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60418fc014944675b95a4a327939d6f7_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy01LTEtMS0w_3f416156-89b4-4ffe-9644-70218bf3d78b">68,620</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia354da424ce0441fa29d3af61c66a49e_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy03LTEtMS0w_2a236b42-f963-4869-b025-c9345a1590ff">30,407</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e90ca7353d7420d850374043f19414f_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC0xLTEtMS0w_816ff97e-d61a-4c92-9f5a-bd0dfab0fc97">90,921</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac88bbff875241b399770a9f80cb04da_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC0zLTEtMS0w_c0cf2f08-6c67-4145-a53d-dd483056ae88">52,917</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ide45679cbd134e15ad7dde1405959e1c_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC01LTEtMS0w_3736ea8d-c69f-4eca-a326-4d74752387d2">124,727</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieb8d9802463f431b8dc5673038d02b02_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC03LTEtMS0w_da904eb7-ae26-45b9-8894-a301b9d2d7b6">81,953</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="i54e9688fa5234b7dabc087b18bea682e_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTg2Ng_de223a2f-d922-4eff-bb7d-775df2a0390d">46.2</ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><ix:continuation id="ie962207c29d64bbdaa44b6e076dcb9f6" continuedAt="i5502a991d50a4d98a641099c088b7886"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib4773d352b9649cf82f5f26e75db0cbd_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi0xLTEtMS0w_238d617e-03c0-43ec-b359-c4c56f2b92ca">2,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0afcc09b5a14464ab0ffad06802a0d9a_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi0zLTEtMS0w_ea284596-8a55-400e-b98d-e8db2781a8f7">22,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0c2c134629c04167a6ee6e580563d23a_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi01LTEtMS0w_8b8da1d0-0168-4afe-8982-f038de5bce16">3,398</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i96369905ff694894be26d03937eba3aa_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi03LTEtMS0w_ce417e2d-b7cb-4f55-b89c-588946fb01fd">22,946</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4eace4464d1b4cebb1f6aa87ef46edfa_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy0xLTEtMS0w_91e5d06b-3611-460c-85f5-63c4b72c3901">4,024</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7c567665f16245dfbbaa6cfb4be14af9_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy0zLTEtMS0w_d99185df-8fe9-4972-b789-e0ee27b82dfb">2,195</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifd4fe90f4c8b4002917a160364e89c7b_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy01LTEtMS0w_4c3157a1-ecae-44fd-9bbb-35ae94a5dea1">8,159</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i37fca3eb6b164203b94981e459883e27_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy03LTEtMS0w_8e0b377c-d6fd-483a-91a6-f86558e9484f">3,264</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6b587653d3b346778dc4850b1f98eaa1_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC0xLTEtMS0w_688adafe-b4b2-4cfd-b418-bfbea4c3c81d">6,121</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8682433791e74a77ab1fb7164ad65f64_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC0zLTEtMS0w_16985a81-2012-4b23-b689-612d677c11c9">25,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i36f2a9ffc2004bfba433dc45cecfe4e7_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC01LTEtMS0w_dbf59149-a381-4705-9c0f-4e795ff7e05c">11,557</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic6774c6769c74754bf25b006ddeb034a_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC03LTEtMS0w_30150856-399e-4dfe-893f-b8314ab7a53b">26,210</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:continuation><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, $<ix:nonFraction unitRef="usd" contextRef="i086ec86c38f3430bbc22864119abfbea_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMzA4Mw_f23c4dda-0820-4c87-9d56-daca53e317aa">40.7</ix:nonFraction> million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a <ix:nonFraction unitRef="number" contextRef="ib55ad4a520414e63a49c07b1087faa2c_D20210102-20210702" decimals="2" name="exel:CollaborationAgreementPercentOfRoyaltyOnNetSale" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMzM4MQ_3b2f0fd8-f66f-4973-a05d-0dcba47ea093">3</ix:nonFraction>% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $<ix:nonFraction unitRef="usd" contextRef="i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzgyOQ_8be617f0-8bab-4140-b08a-f681efdb1b72">12.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i3a69004f4ba64701a17a5818d5af4f24_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzg3MQ_4f859d67-afa5-4a14-ab41-07a0c7b3ef63">22.2</ix:nonFraction> million during the three and six months ended June&#160;30, 2021, respectively, as compared to $<ix:nonFraction unitRef="usd" contextRef="ib115b2c1778640cc80452356877f9218_D20200404-20200703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzgzOA_450acd63-9b13-4cfb-8d3f-c20ad8407327">7.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i957e8d926e9948e49c867df19f90d50a_D20200104-20200703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RoyaltyExpense" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzg1Mw_18d30672-532e-4c8d-b23b-14bc0b3af70b">15.7</ix:nonFraction> million in the corresponding periods in 2020. </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="ic5c8a487abb5493cb856fda7977c0e30"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. <ix:continuation id="i5502a991d50a4d98a641099c088b7886" continuedAt="ibc3d0e76c5c54c3eaeb2fb191f221289">License revenues under the collaboration agreement with Genentech were as follows (in thousands):</ix:continuation></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ibc3d0e76c5c54c3eaeb2fb191f221289"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.822%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:13.780%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.846%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.743%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi0xLTEtMS0w_c9ea6dfb-5729-45c9-b76b-d29ed7896b9e">2,160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi0zLTEtMS0w_8b263e16-ac3b-496a-a9f2-db7c942fb2a2">1,376</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi01LTEtMS0w_9b3ed2aa-2532-4148-8568-9a9b6d6b4cbe">3,954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementIncomeLossFromAgreement" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi03LTEtMS0w_c4d94e10-e359-4dca-b34f-ae5599fd75b0">2,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy0xLTEtMS0w_d44968e4-c737-4860-ab8a-75e4985951a5">782</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy0zLTEtMS0w_12b613bd-ea8a-48b4-9616-9648e32a470a">1,125</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy01LTEtMS0w_000c6dd8-603c-44be-b41e-f0adbfcd8692">1,733</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy03LTEtMS0w_31072183-f21e-4336-9f88-7ac6492969e6">2,434</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, in support of our development pipeline, we entered into additional collaboration and in-licensing arrangements with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Limited (WuXi Bio), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMjc0ODc3OTEwNDE2OA_7904c9c8-8361-42ae-b25b-3d09df5be190">17.0</ix:nonFraction>&#160;million and will make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNDM5ODA0NjUzOTk4OA_9c3b3ed9-f537-41d6-a159-5a9bf1486097">58.5</ix:nonFraction>&#160;million, regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMjc0ODc3OTEwNDE4NQ_9ef618a1-fb5e-4a9d-ab6a-ede39f12af4a">139.0</ix:nonFraction>&#160;million and commercial milestones of up to $<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTQ5NzU1ODE2NTQ4Nw_fbe22b1c-147d-4056-ae48-4f63ef090c87">377.5</ix:nonFraction>&#160;million, each in the aggregate per product, as well as royalties on future net product sales. Additionally, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $<ix:nonFraction unitRef="usd" contextRef="ic78371ad98574f0f8204b52ff32e63c9_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireProductiveAssets" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQyMQ_c691202a-cfab-4d72-ba9f-5432e32e9493">5.0</ix:nonFraction>&#160;million for the initial technology transfer, and subject to certain conditions, will make a $<ix:nonFraction unitRef="usd" contextRef="iceb9d21701e5414cadd958696df005c4_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:AssetAcquisitionPaymentUponClosingOfTransaction" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQ1MA_97c2bcbd-521e-41ba-9830-3665628b5ca6">9.0</ix:nonFraction>&#160;million payment upon closing of the transaction. We will also make payments for potential future development milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iceb9d21701e5414cadd958696df005c4_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQzNQ_07838d51-b441-4207-81f2-55374fe37fea">42.0</ix:nonFraction>&#160;million and regulatory milestones of up to $<ix:nonFraction unitRef="usd" contextRef="iceb9d21701e5414cadd958696df005c4_I20210702" decimals="-5" format="ixt:numdotdecimal" name="exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQ2NA_d6a57e62-8a60-4006-9368-de20799d9ec7">22.5</ix:nonFraction>&#160;million, per product.</span></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_46"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 4. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Nw_d9ba2e99-bab0-4e5f-b0e4-dd57d47bceef" continuedAt="ifffef8713d3140ecb0e2d8e049abd956" escape="true">CASH AND INVESTMENTS</ix:nonNumeric></span></div><ix:continuation id="ifffef8713d3140ecb0e2d8e049abd956" continuedAt="if17f05a9954f4038a8686c59e5af1da1"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY3NA_f5a1af70-e1cf-4d13-916d-7a5e32ca46ee" continuedAt="ib7b9c6c2b5524235947088c17a698f50" escape="true"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Mw_8f00ab4a-cd84-4442-b58a-39d9d9303089" continuedAt="ic3eb547de0ba4d55abb7e4ff11ee2b1e" escape="true">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</ix:nonNumeric></ix:nonNumeric></span></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="ib7b9c6c2b5524235947088c17a698f50"><ix:continuation id="ic3eb547de0ba4d55abb7e4ff11ee2b1e"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMS0xLTEtMS0w_d462ec24-af44-4c99-a2e8-210d174d5caf">492,462</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMS0zLTEtMS0w_60bae02c-dd08-4faa-ab1a-1ff1d68da303">319,217</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMy0xLTEtMS0w_914b60d0-47a0-4589-a9c6-d4c08b013763">46,839</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsNoncurrent" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMy0zLTEtMS0w_8bed8d7a-48ac-4b82-91ca-ccb5eedf10db">1,555</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfNC0xLTEtMS0w_7d6cae72-e277-4fc6-944e-46d7603caec5">539,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfNC0zLTEtMS0w_66274bec-c86f-4f04-8451-eebf0b5162e9">320,772</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of June&#160;30, 2021, restricted cash equivalents included $<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:RestrictedCashEquivalentsCurrent" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfNDM5ODA0NjUxNDE3NA_1114a399-4bf2-483d-8dbb-a9cca16bd818">45.3</ix:nonFraction>&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="if17f05a9954f4038a8686c59e5af1da1" continuedAt="i41d519b7038d42e98a2d49e18d99c37a"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY5Mg_4c039127-4aac-4fd1-84a7-f0bc3850baa7" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy0xLTEtMS0w_5c3dd2e9-5ce6-4432-8b9d-2f8aa4e62c05">716,916</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy0zLTEtMS0w_7f416c26-e5c5-46f5-892d-a5d3d76f0cb2">141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy01LTEtMS0w_b27da61a-8b9a-4ea9-ba3c-81b31fd439fd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy03LTEtMS0w_6dc7e7c9-9fbf-43db-8604-e7a69be47e61">717,057</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC0xLTEtMS0w_7dc91d2f-fa8c-448c-bcbb-21b74f849ad4">489,678</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC0zLTEtMS0w_644a6442-2847-4e5e-bfdb-f9a45142a0e0">2,630</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC01LTEtMS0w_4e9a4efa-92c6-4807-b66b-472be6e58c37">166</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC03LTEtMS0w_ec2e821d-26e1-4e3e-9721-5e6fa1e4a2ae">492,142</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS0xLTEtMS0w_bf09a0b6-d05b-456f-b4ab-57a4d1dd2d18">132,036</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS0zLTEtMS0w_3be1d1d7-6095-4a71-9a4e-1c3ef3cfad7c">43</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS01LTEtMS0w_46a38210-f38d-493e-bb4f-5ef5965b501e">13</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS03LTEtMS0w_a3a3cfcb-77e5-40a9-86d0-6b4d2bae0710">132,066</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi0xLTEtMS0w_d7f98ac5-082c-4e91-82c6-442da34f73ae">14,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi0zLTEtMS0w_88a4935e-292a-4995-a63d-a12f0f149719">41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi01LTEtMS0w_9c74ae89-b962-4040-bba6-056a9032106b">4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi03LTEtMS0w_82e6583f-909c-4d01-9687-7ceab5ffd4ff">14,298</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy0xLTEtMS0w_7720ecab-6a25-4610-ae4e-22eb617a7f43">1,352,891</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy0zLTEtMS0w_dcac80b7-f61d-4c33-8f7f-3d8ff67d09f8">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy01LTEtMS0w_c9af8221-5f9c-4591-9634-c24c8edd5c57">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy03LTEtMS0w_8952f002-9c04-4dfa-a4b8-3ad27848f4ee">1,355,563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC0xLTEtMS0w_c411440a-df29-47bb-ab7f-b4b5037807d2">88,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC0zLTEtMS0w_1d325f93-b46b-4b1c-b0c0-5732b3e40ae9">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC01LTEtMS0w_9ce27b81-2e63-4d6a-aa1f-6896be85635f">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC03LTEtMS0w_72b50ef0-d38e-4740-b347-d045995c620d">88,511</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS0xLTEtMS0w_67580807-a798-4e3d-a932-2a096193d9d1">179,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS0zLTEtMS0w_9bdca96f-6a54-4e21-b4f7-cd9951b8f1ea">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS01LTEtMS0w_b064ee71-0708-4285-822a-cae6c5c3ba8a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS03LTEtMS0w_d920dcb9-4629-4565-a0ed-216209066eae">179,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMS0xLTEtMA_05147d24-52b7-4f60-a6c4-63134a329f56"><ix:nonFraction unitRef="usd" contextRef="i2a7078826e91452db52a24c7cbbe97de_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMS0xLTEtMA_98982da9-e5b2-4cc5-955d-a9ba552cb5fb">115,706</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMy0xLTEtMA_26cbb1cb-41e7-449b-8716-7ab6233bdf55">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtNS0xLTEtMA_ef878214-fe83-4119-8899-dfa085a315b0">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtNy0xLTEtMA_8b585b05-c8b2-408b-82f9-93b46f641d7e">115,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtMS0xLTEtMA_e5ba80bd-5b7f-4662-9d01-eda832097e87">1,736,414</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtMy0xLTEtMA_d9975c48-a0a1-4e56-9b34-5f3699492097">2,855</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtNS0xLTEtMA_ef78bacf-8dfd-4db2-82e5-757e17f0d820">183</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtNy0xLTEtMA_eeb7fe1c-6a3e-4a75-ade1-3197ee5e844d">1,739,086</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.495%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.808%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy0xLTEtMS0w_c5165d0c-159b-4784-b177-450c4e21cf3b">569,456</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy0zLTEtMS0w_888d813b-9282-42bb-92cc-704508041a11">372</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy01LTEtMS0w_c060d0ea-3360-4053-b8dc-982be58149a7">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy03LTEtMS0w_caa4a8ed-69b9-4555-b95b-269c028c9207">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC0xLTEtMS0w_999a6765-e80c-4bc6-bc08-0fe304d092bb">543,520</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC0zLTEtMS0w_160b93e9-dd71-4439-b700-9c902439199a">5,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC01LTEtMS0w_dafd6fc2-de84-4725-8ce3-430e98391154">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC03LTEtMS0w_d0d1f49d-1870-4f57-9e4d-c92e19a6b89d">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS0xLTEtMS0w_5ebeb4c3-0fc6-4724-b782-19f3d1b631e8">208,326</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS0zLTEtMS0w_81c0530c-22a4-47b3-84dd-b45e700652e9">232</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS01LTEtMS0w_f290d5c6-084c-4c88-a0fb-26ef84053cb5">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS03LTEtMS0w_f50548fe-3d4c-4e08-bfc4-3c3449a43d00">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi0xLTEtMS0w_ded18d6b-4bc5-43d6-9a0f-a0ff0bc679d9">28,680</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi0zLTEtMS0w_da15b30f-43e9-42a7-bb80-ffbe0437cb31">83</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi01LTEtMS0w_46069ec7-bbed-41b4-8e01-9791d8464f07">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi03LTEtMS0w_0278336f-73ad-43d7-9b93-9aa478e89dce">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy0xLTEtMS0w_79194393-49ff-40cc-8bae-27a82f9630a0">1,349,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy0zLTEtMS0w_bc4a8cae-c8c9-4f24-a658-854b618b7393">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy01LTEtMS0w_fdef1bfa-b923-412d-9bd2-10673f1ba96f">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy03LTEtMS0w_85aded54-1843-48bc-bb08-f28c69848896">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eec5258de424553baf107e5e554b35a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC0xLTEtMS0w_a40c071a-fba8-46dc-b393-73c20eab4a76">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eec5258de424553baf107e5e554b35a_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC0zLTEtMS0w_ccecf450-1369-4346-a60c-bcfc0d0f6774">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eec5258de424553baf107e5e554b35a_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC01LTEtMS0w_c482e138-fae4-49a7-a4b5-f64eb4fb7968">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8eec5258de424553baf107e5e554b35a_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC03LTEtMS0w_948e09b7-1df8-4489-967e-416e2f755fe4">82,176</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56912199faad49c0be4543e8883c2d26_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS0xLTEtMS0w_91b01a63-5991-43a4-bc13-425511941865">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56912199faad49c0be4543e8883c2d26_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS0zLTEtMS0w_9acedf7c-ec8e-4bbd-b2c6-2547ca765834">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56912199faad49c0be4543e8883c2d26_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS01LTEtMS0w_64c244a7-f7ca-47e3-8b09-4ec753342dbf">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i56912199faad49c0be4543e8883c2d26_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS03LTEtMS0w_2bc9c4a7-af97-4fc8-86a6-067972ae10f4">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtMS0xLTEtMA_aefac6cf-73f3-4ace-b6a6-d565199953c6">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtMy0xLTEtMA_4dee9000-8a8e-49a7-8647-d6a374981c0b">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101" decimals="-3" format="ixt:zerodash" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtNS0xLTEtMA_6ba02ce2-8a42-42a7-80a7-6d01f71182c8">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtNy0xLTEtMA_a466af2a-961b-4711-b9a1-dd37d6739656">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtMS0xLTEtMA_398a8ec6-96e4-4ec9-93bc-9ae28d8fb618">1,532,923</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtMy0xLTEtMA_ebb62359-b010-4601-97d1-df77b582c413">5,931</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtNS0xLTEtMA_51bbfd73-816d-4455-b775-cf0250714231">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtNy0xLTEtMA_9ca204db-7504-4c64-a347-a62ea4902130">1,538,842</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTE5NQ_c89acd81-18d7-4640-b4af-c7079b331339">3.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InterestReceivable" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTIwMg_7c911998-466b-4ebc-882e-31cab7974d49">4.5</ix:nonFraction> million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2021 and 2020.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="i41d519b7038d42e98a2d49e18d99c37a"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY1Nw_181d2b2e-f86a-4c76-a67c-8c2f5e6eeed3" continuedAt="i347b6a97d53545f993c8b71ee9f7defe" escape="true">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i347b6a97d53545f993c8b71ee9f7defe" continuedAt="i346bf18cd92845b8bf83d00c96cb3a0a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.376%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.692%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMi05LTEtMS0w_6158ad44-84fb-4610-904f-7d76393b2519">1,002</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMi0xMS0xLTEtMA_cb763301-4aaa-48bf-b571-01f8bfbfd611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMy05LTEtMS0w_dfa14272-ce11-4108-ab54-0786cea49648">154,767</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMy0xMS0xLTEtMA_c4cf9bbc-e662-4325-bc87-f115db1e4911">166</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNC05LTEtMS0w_b5ac856b-a857-4427-ba3f-d8e35e019f9b">38,088</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNC0xMS0xLTEtMA_a0b63407-1c80-4d72-9c03-27cf749d6a30">13</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNS05LTEtMS0w_c39f007a-fc0c-445b-8b9d-2ca7ce20da23">5,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNS0xMS0xLTEtMA_fff6e5f3-35bd-4aa5-869e-9847f5b6a255">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNi05LTEtMS0w_6853b8d2-a843-45ba-b30f-3d0b7f790c34">199,754</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNi0xMS0xLTEtMA_40845f31-6b5d-4a94-92a1-3ec61bb53599">183</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-align:center"><ix:continuation id="i346bf18cd92845b8bf83d00c96cb3a0a"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.227%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMi05LTEtMS0w_d2a47a0a-a0dc-41cb-8ed2-de4928fd957a">28,445</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMi0xMS0xLTEtMA_22472bf4-f99c-434f-a930-d1395ef526e9">7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMy05LTEtMS0w_356876cb-be1c-4757-8652-4b6b27fe2a46">21,989</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMy0xMS0xLTEtMA_0b6c7c99-e302-4ba6-9247-3507e48f87f2">4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNC05LTEtMS0w_77d00f6c-6668-45f1-a78b-d2a000855d4d">5,865</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNC0xMS0xLTEtMA_8d48e06d-47a6-4250-b70a-93baac214103">1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNS05LTEtMS0w_4a15e477-96f9-4e5b-8581-a7fcf73a6bc8">56,299</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNS0xMS0xLTEtMA_4330977c-538c-48e3-9ee7-f3d1ccec0391">12</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></ix:continuation></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were <ix:nonFraction unitRef="investment" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTkyNg_72f1392c-c8ca-41e9-9ddd-5099542369f6">53</ix:nonFraction> and <ix:nonFraction unitRef="investment" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="INF" name="us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTkzMw_a286dba6-1f8b-4682-89fc-a39628bcc0ac">14</ix:nonFraction> investments in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020, respectively. During the six months ended June&#160;30, 2021 and 2020, we did <ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjA0Mg_520fa795-6a7f-42b3-b884-72aed8d60dca"><ix:nonFraction unitRef="usd" contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjA0Mg_8b6f7313-8ab0-457e-917c-0570f549d287">no</ix:nonFraction></ix:nonFraction>t record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Mg_9aa6e840-5943-4daf-9c49-176ea097cdb0" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMS0xLTEtMS0w_8dfe1b34-3d6d-4cbb-bdbb-892500a13802">1,015,650</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMS0zLTEtMS0w_910200c0-f091-48c8-be2e-1b0228c28b0f">1,034,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMi0xLTEtMS0w_dac28f7d-69c9-4083-b2f1-5a7f7d0e987d">339,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMi0zLTEtMS0w_7d1d9130-b587-4e0e-b04b-0821e8ab000c">321,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMy0xLTEtMS0w_24d7bc21-056f-4f66-a478-435705c19afa">1,355,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMy0zLTEtMS0w_1b0b96c5-f433-4522-9e9b-a7266034dc10">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_52"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 5. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:FairValueDisclosuresTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTUzOQ_b87a422c-3a57-436f-9c49-73abca8f9caf" continuedAt="ice7468f26db042129296d3315d128fb0" escape="true">FAIR VALUE MEASUREMENTS</ix:nonNumeric></span></div><ix:continuation id="ice7468f26db042129296d3315d128fb0" continuedAt="ifa0c637ced534d24b55f585b22530393"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="ifa0c637ced534d24b55f585b22530393"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTU0MQ_3c426857-b32e-435f-883a-356532e98888" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="icc9727a7b4814f58b8af72b38460bca0_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi0xLTEtMS0w_4ebe6a17-f6e7-40df-b3f4-622c77caf1a3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4e91c1139a56409d95f01dc2177e91d2_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi0zLTEtMS0w_3c89bf87-cf8d-4ea3-9a67-807f50110fa6">717,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id53a0786827d478e814c805cc8cd0afb_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi01LTEtMS0w_223057d7-fe1b-4ed0-9eed-52a982a29389">717,057</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9dc7c2c162434fe38126e2d6f15ae9bb_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy0xLTEtMS0w_3276386e-1052-435c-a41b-878128a5dcb3">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i950c47d917ec494488175b4cdbe0c129_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy0zLTEtMS0w_e04af92e-f2fc-4d5c-8116-68c011f0c62a">492,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i550ee82623734ffe9f05bdbde43fba7d_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy01LTEtMS0w_b9b2d5a5-371e-436b-8992-897f266fe00a">492,142</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iad4faa5c3b4a426aad73596700ef7140_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC0xLTEtMS0w_cc71a6a4-1575-4ffb-9afe-7c0e344962de">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iffc0af7755c040318682d07ce7adc16d_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC0zLTEtMS0w_a86416a8-efc2-4a04-aa22-a06d9c9ed04d">132,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6c48c5faa613472abda97540d85b1a43_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC01LTEtMS0w_98fa3b20-780d-4f79-afd5-2917c750ad93">132,066</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac6e199ed30442d3aea617ff04d7c031_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS0xLTEtMS0w_c9d3e6ee-6c9e-4155-9a59-c5d1e738fe19">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7bda6107aee140518bf785e603a9f752_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS0zLTEtMS0w_82e6583f-909c-4d01-9687-7ceab5ffd4ff">14,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a06f360ba44412d9bbdf897884ec918_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS01LTEtMS0w_04c8c780-54a4-4a3e-84da-6cf040e7e14f">14,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ab09d76ab342579d2258fdbf2c378c_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi0xLTEtMS0w_d874db70-4d79-40f9-81c5-af85f5ce29fa">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353b0bfaee7d45d3976a470abaef3b27_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi0zLTEtMS0w_7bb62a30-6cff-444f-8285-76cb692d7955">1,355,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7549b8270e70414ca9988e4dbb8aa47f_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi01LTEtMS0w_d2dc349c-ce42-4c4d-bfa1-7a3992d72359">1,355,563</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i461e78644dac46b59b980d4bf5e337b4_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0xLTEtMS0w_1ca713e6-f214-426f-bb84-179b66baa36c"><ix:nonFraction unitRef="usd" contextRef="i461e78644dac46b59b980d4bf5e337b4_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0xLTEtMS0w_fd1c3b5f-4569-44ce-bece-4fb03f1e188e">179,306</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5b52c97911274efa88b507b4b137edec_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0zLTEtMS0w_b5d7c539-4d28-42c3-aace-dc6e8297579d">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ic67977ad378747debfe28bbf32306bd3_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy01LTEtMS0w_5063f8b5-944c-42f6-88bd-724f5a9450f8">179,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6cfecbfae6504e7dac8dae1b622df61b_I20210702" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0xLTEtMS0w_474cf517-a7b6-4c19-a833-5341845c3457">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702" decimals="-3" format="ixt:numdotdecimal" name="exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0zLTEtMS0w_05147d24-52b7-4f60-a6c4-63134a329f56"><ix:nonFraction unitRef="usd" contextRef="i2a7078826e91452db52a24c7cbbe97de_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0zLTEtMS0w_98982da9-e5b2-4cc5-955d-a9ba552cb5fb">115,706</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iae9f679824f7428da09abd42de1550ae_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC01LTEtMS0w_edc4bdf5-b644-40ba-afe5-825b015df06a">115,706</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i68ab09d76ab342579d2258fdbf2c378c_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS0xLTEtMS0w_437b9ae6-df13-454f-a751-e2c9b963e39a">179,306</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i353b0bfaee7d45d3976a470abaef3b27_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS0zLTEtMS0w_2efff23e-85e9-4334-880a-08a350564470">1,471,269</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7549b8270e70414ca9988e4dbb8aa47f_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS01LTEtMS0w_00a3c5fd-3302-4be9-96ce-6148a4a1568a">1,650,575</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.804%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.807%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib1444ac4a7464905b1d3c72e3eadd436_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi0xLTEtMS0w_44035070-5eb6-4948-b0cb-14f310f9d62c">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9acdde179aaf4fdc8bbfce84bea41c94_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi0zLTEtMS0w_5c18dc12-13c7-486d-9db6-ef1544dc1c87">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i284bab61e8734898a70c2fcec89c67c2_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi01LTEtMS0w_2a5d2f62-771f-4c04-97cc-c47cc0cdaf96">569,828</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5ed62cb99076473f80954b556b50f8c4_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy0xLTEtMS0w_c5faa5e8-2d4a-4c92-90e9-9b4bed2de196">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iac2529e3f7d44eb5a9f3e462363e4bef_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy0zLTEtMS0w_030eb8f2-d431-4b3b-b4a5-13ad742117cc">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8290d5383c23424f8de0d1411e5defda_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy01LTEtMS0w_b10419b4-e96f-4f18-9d9b-07c7d653f4b1">548,757</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf572e25486645ec8191ae913a4d5273_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC0xLTEtMS0w_4bcecf20-dba7-46c4-9c4c-2fd26b4e062a">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9ecbc8770d4f4636ac3bd47cc6e7a318_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC0zLTEtMS0w_075c9215-9669-412c-9867-cd357a903efe">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i60c12cafde1f455185fb18b04e0ee5cf_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC01LTEtMS0w_7fb6ac2a-d705-4825-98e6-725f7625d5c4">208,554</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="if81d88ee2f624302a41cbb273629023e_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS0xLTEtMS0w_a3adcad3-0af8-41c0-a9db-14f0d0053222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ib31966a54bf84f61b847e6dc212903cc_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS0zLTEtMS0w_d2e55348-725c-453c-ae09-b4fcb305857f">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iace3e234989f44a18209f335a3858e67_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS01LTEtMS0w_7ca58488-0f27-44f6-911f-f689362475c8">28,762</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3b9823001c4ababc937b8119958bcd_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi0xLTEtMS0w_f1dc07cd-c650-4844-bc90-3b53af083f81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4500f722142808c3c50a9a09c4590_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi0zLTEtMS0w_05498bcf-cdfa-472c-807d-cfe491cb0423">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10577d8c6f0a44c29a3ded5c80584629_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi01LTEtMS0w_23be8567-e16e-4b11-bc57-8c9190bd91c5">1,355,901</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10fce4b7140142ae8b453252c5a9aa1f_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy0xLTEtMS0w_7c4177ec-26ff-431e-a964-e2aa9bb3dffe">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaed63e180d5c44929716ad53c8d1a9a3_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy0zLTEtMS0w_cc37beb4-be9d-4811-bead-a12bd63f687e">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i98ada18f5c9f4383a40c65d6ad47b375_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy01LTEtMS0w_389c38a3-abf8-45fa-9559-79df90d9da17">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="iaf994d5e216c490ebc4de2ede7eb66ab_I20210101" decimals="-3" format="ixt:zerodash" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC0xLTEtMS0w_94c71f58-754d-49d3-af31-1a147df838dd">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i94140ba1405e4bbabc2a2ce63c52a2cf_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC0zLTEtMS0w_50b75ade-66ee-4ea7-a9fb-861a00ecb057">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i43efb9d920154cdd94ec40616b7279ab_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC01LTEtMS0w_559e802b-1fa4-47bd-b715-c9bec0576fd0">60,004</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ibf3b9823001c4ababc937b8119958bcd_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS0xLTEtMS0w_11d17575-2ce8-43c8-bbab-1cb686a66e0e">40,761</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i18e4500f722142808c3c50a9a09c4590_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS0zLTEtMS0w_0a4893b2-45c3-4001-8aa9-54d5e14eee08">1,415,905</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10577d8c6f0a44c29a3ded5c80584629_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsFairValueDisclosure" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS01LTEtMS0w_ebea89d4-cc87-427c-be58-e23f813be51c">1,456,666</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had <ix:nonFraction unitRef="forwardcontract" contextRef="ic668b647625e4bde9c974a9c70e123ee_I20210702" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:DerivativeNumberOfInstrumentsHeld" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYyOTY0Nw_cc97c475-275c-48cc-a9e7-1dd5cbbbdd0a">one</ix:nonFraction> forward contract outstanding to sell &#8364;<ix:nonFraction unitRef="eur" contextRef="ic668b647625e4bde9c974a9c70e123ee_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DerivativeNotionalAmount" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYzMDI2NQ_010e298b-34eb-4d05-8e56-77f5e1c47075">9.3</ix:nonFraction>&#160;million. The forward contract has a maturity of <ix:nonNumeric contextRef="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702" format="ixt-sec:durwordsen" name="us-gaap:DerivativeTermOfContract" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYyOTc0Ng_f887782b-8472-4934-9674-52fecfbf24ce">three months</ix:nonNumeric>, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of June 30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June&#160;30, 2021, we recognized $<ix:nonFraction unitRef="usd" contextRef="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:GainOnDerivativeInstrumentsPretax" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYzMDA5NQ_c8ef9f0f-70e5-4ecb-9538-6c665a6748ca">0.3</ix:nonFraction>&#160;million net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_55"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 6. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:InventoryDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTkx_27dd3665-0964-48b9-b4fb-ecc57a24e7ad" continuedAt="ie0370551198d49b5b84a1f265592b3ab" escape="true">INVENTORY</ix:nonNumeric></span></div><ix:continuation id="ie0370551198d49b5b84a1f265592b3ab"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTg2_7d449ade-8bdd-4513-8c0c-7c5b182eed4c" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMS0xLTEtMS0w_78cbe570-344f-46e9-9f92-4b28153392a9">6,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryRawMaterials" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMS0zLTEtMS0w_1effd33e-c7db-4273-a367-c9fb7002dbf0">7,773</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMi0xLTEtMS0w_38f6d464-918e-4d00-8e07-acea4b1004c0">25,951</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryWorkInProcess" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMi0zLTEtMS0w_39b7735d-9833-4da9-a9fa-89b7b642a075">20,610</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMy0xLTEtMS0w_c64a90dc-28a6-48fc-8c49-238f99429319">8,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryFinishedGoods" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMy0zLTEtMS0w_adef18bb-72d2-4a28-bac7-5c32c903d1b3">7,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNC0xLTEtMS0w_83857c20-4024-446f-b306-d6db72e7114c">41,443</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNC0zLTEtMS0w_e9ed5723-a8a7-484d-b82f-f5444f91ec7d">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i38f66ecf6b3d46bfbf2bdb0f567643a6_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNy0xLTEtMS0w_56d64eab-c8a3-4fce-ad36-d597dcef95d9">24,982</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3a9ad4a65b6e4c889ee3d1e4d70baafd_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNy0zLTEtMS0w_2484182e-6123-41dd-a856-24a14c6d7fb4">20,973</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i01981fa8e6c344ba974b2f8d40f68058_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOC0xLTEtMS0w_96f4ba4f-3120-482f-8be7-f147487eb2b2">16,461</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ie6f3c04a508a4cfcada935eafb00cbba_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOC0zLTEtMS0w_cb17408a-2cab-4310-b7e2-b839ac516324">14,701</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOS0xLTEtMS0w_4a0d3b5d-9d51-4d7a-8162-0715d10218b7">41,443</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InventoryGross" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOS0zLTEtMS0w_e3c4ba18-3102-482f-9690-3246f3a78729">35,674</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $<ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTM2_d6bb2afc-1da6-4750-bd65-eb08fc1ca97b">2.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:InventoryWriteDown" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTQz_7c7e5d7b-b543-4999-9364-84e7e45f61d6">1.3</ix:nonFraction> million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_58"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU0NQ_dca8f231-3b76-4e08-abe7-30a494962f6e" continuedAt="i998b300365d04b34a9a6d8dc1c195c84" escape="true">STOCK-BASED COMPENSATION</ix:nonNumeric></span></div><ix:continuation id="i998b300365d04b34a9a6d8dc1c195c84" continuedAt="i34b1d546183e4791b4d7fa9725f546ce"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU4Mg_24f39cd3-bf37-4d8a-93f0-5199066d8d4f" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ieca864111b874024a399be99230353ae_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi0xLTEtMS0w_dbeae02a-e0a2-405c-8b8d-64dcce1c6720">13,667</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2cd6d6f2194144d995d98bdace4f2a41_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi0zLTEtMS0w_bd83aecb-b3f8-4550-8e00-619bf8653f24">6,112</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2de5b4fa16f7460680d4046f0519a111_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi01LTEtMS0w_131fd686-75bd-40e3-b8c9-b44aa2110250">26,063</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5334bcd0ce864909917f7d16cd9888e7_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi03LTEtMS0w_e10a4ad5-1d80-47d5-a2e2-cbd81715ceb0">11,198</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i0f9135f913a844cf9141b680dfeb2cea_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy0xLTEtMS0w_4c590d49-88d7-4229-bb58-c23a9b764bc4">14,368</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4941e12d857a41d3ac2f0ff6bbe78328_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy0zLTEtMS0w_9c4a9f9f-c099-4e5a-a421-643bdfaeaf91">10,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="idb3a79263fd94414b9fae499fb7a8ed4_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy01LTEtMS0w_0adf698b-fd0b-46c1-a431-7f02d11f4a00">36,625</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4037354e5adc450194ea75e59903a4c2_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy03LTEtMS0w_19e6dd2a-ba95-4b3c-bb02-7e6cacf4bf80">18,938</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC0xLTEtMS0w_f206cad9-7d43-4f2e-9a68-05dfde0be2e6">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC0zLTEtMS0w_e54d042f-5f27-4fa9-85b4-437ed7c19d0e">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC01LTEtMS0w_6131e7e5-8fc4-440a-978b-593382ec2be0">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC03LTEtMS0w_bbfa8beb-3025-4b8e-8c05-b3ca05cdd4f8">30,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.593%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i3bef33e85fa14e96ae49c48c326d27de_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi0xLTEtMS03MjM_1e958a5a-fa85-42eb-97d9-7bd507d34dd0">5,902</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i19afc667658d40998a38958b53efb61e_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi0zLTEtMS03MTk_ce8beb28-c73c-4aac-8814-16847919274b">5,301</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi01LTEtMS0w_15f2d1a3-406a-4d79-a650-de043276e467">10,596</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i75db9e248ada421fb6801122acc77816_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi03LTEtMS0w_53a8dfc6-1ab9-4205-9820-9587a3f706ec">10,295</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i873e7a2c3edf40ecb5bbd511274cbf4f_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy0xLTEtMS03MjM_69dd9e27-dcb8-4bed-9711-3013b8cd8296">15,412</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="id9124f541cea43cfb250f0c46a24ea95_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy0zLTEtMS03MTk_0d1e2358-d9f5-4d50-8c9b-b52001197a86">8,599</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy01LTEtMS0w_b2f4f895-f694-428a-97c5-72bd33c64d1b">27,081</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i6ced14542a07421e8805f7ee34d1747f_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy03LTEtMS0w_265f81f0-4b9a-474c-b194-d1db5ed7a02f">16,396</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i10aae8da808c4e4a9bdc5ee3346228a9_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC0xLTEtMS03MjM_03b159d3-d62a-4b2c-8438-1cdc28ada02c">4,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i996fd974645e4c3db9f8f6b13e514f51_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC0zLTEtMS03MTk_d935174f-a291-4eb5-8285-d6420c4efdee">1,429</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC01LTEtMS0w_a66b50e0-fabd-4dd4-b4f5-fc2c8769594c">22,645</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i8d55c4bf90594514b0b8f4b81adf037e_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC03LTEtMS0w_6b2f1df4-fb40-45c9-8af7-13acb5096f84">1,925</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i2457de481e214911a4d49d6872661199_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS0xLTEtMS03MjM_b1feeaba-a6c2-4d9c-a6c9-36975b14d317">2,023</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i17e867cac56f4c6fbee7d87303f4e416_D20200404-20200703" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS0zLTEtMS03MTk_a4142861-9062-4a4c-b4bf-9c0e40a1c1d1">825</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i5d96596fd611426fba7a4e5d05b69795_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS01LTEtMS0w_5f01d5f2-af57-48d4-8e41-2a679b56464c">2,366</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="ife5de7f12696428c822881cfca50b36d_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS03LTEtMS0w_52c78030-6bb8-4ced-8ce3-766d2d5d5304">1,520</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi0xLTEtMS0yNzkz_990aa24e-96e1-4dd7-887e-53dbab244c13">28,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi0zLTEtMS0yNzkz_fd611719-78f7-4155-8e8e-922aa449cdcc">16,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi01LTEtMS0w_61f14d23-1808-4bb4-9b1d-a3c5b5e136e0">62,688</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi03LTEtMS0w_0f99774e-4ede-41df-a21d-ab2f1c3e5034">30,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzI5_e8ca0d60-1cf9-46c1-9b12-d70e150882a6">8,254,455</ix:nonFraction> sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by <ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNDkw_970699a4-d6cd-4626-8e96-026207b826d3">1</ix:nonFraction> share for each share issued pursuant to a stock option and <ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="INF" name="exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNTUy_3db96262-c0f9-41a6-8569-de9f096eebbc">1.5</ix:nonFraction> shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNjY4_78e2597a-d86b-40f1-9301-5d8c2abe60b6">1,733,554</ix:nonFraction> stock options with a weighted average exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNzI3_8eb6709f-68d2-4361-b540-e47496e9effc">22.50</ix:nonFraction> per share and a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNzg4_72cf4103-aff4-42af-bfa7-f7283fa8cf49">9.70</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of June&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i167594f9829443bdb7383a81ca5f83e5_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfODIz_29bd3254-7255-4ab5-a1c5-8c84858624b0">15,443,578</ix:nonFraction> stock options outstanding and $<ix:nonFraction unitRef="usd" contextRef="i167594f9829443bdb7383a81ca5f83e5_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfODU2_1f32733f-eb88-4193-bd78-e96bf843fb25">32.2</ix:nonFraction> million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we granted <ix:nonFraction unitRef="shares" contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfOTM1_52d491db-0607-4ec3-bea6-02edbc42f0e2">3,575,190</ix:nonFraction> service-based RSUs with a weighted average grant&#160;date fair&#160;value of $<ix:nonFraction unitRef="usdPerShare" contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTAzMQ_a006c3bd-6f86-4f8e-9728-25163c1db4ff">21.76</ix:nonFraction> per share. As of June&#160;30, 2021, there were <ix:nonFraction unitRef="shares" contextRef="i32a62386d90e4627a31537ead3413cd9_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTA2Ng_d9fb3449-bbd5-4e57-acbb-1d4ab50bbe69">8,314,774</ix:nonFraction> RSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="i32a62386d90e4627a31537ead3413cd9_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTA5MA_ba291f61-c4bc-4824-9563-fad43b98e048">149.0</ix:nonFraction> million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the six months ended June&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to </span></div></ix:continuation><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="i34b1d546183e4791b4d7fa9725f546ce"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded <ix:nonFraction unitRef="shares" contextRef="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTQ3MA_bfc83232-2383-424d-901b-c940086e4828">1,027,650</ix:nonFraction> (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to <ix:nonFraction unitRef="number" contextRef="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331" decimals="2" name="exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTY4NA_e27867d6-825a-4203-be75-d8d67ac6f7fe">200</ix:nonFraction>% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. <ix:nonFraction unitRef="number" contextRef="i06bb3436aa3243dc82099b2b7e64415a_D20210301-20210331" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjA5MA_6599a3ac-5f5e-424c-9f8d-ee941f4cd043">Fifty</ix:nonFraction> percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately <ix:nonNumeric contextRef="iba0fcc072d1d49eea6319ba9d01188e7_D20210301-20210331" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjI2MA_7410cdf8-2add-46d6-ae1c-76e1c7c00a41">one year</ix:nonNumeric> later subject to employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU0MQ_2fe32b4e-bf4e-4d10-9d00-ce5c30d3a3c9" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $<ix:nonFraction unitRef="usdPerShare" contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjUyMg_7f4432d1-dd54-4b3e-aba1-d0c7137bbb91">24.54</ix:nonFraction> for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:90.120%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.680%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702" decimals="2" name="us-gaap:SharePrice" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMC0xLTEtMS0w_51008774-c67e-42bd-b4fa-f40a902b8533">21.31</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMS0xLTEtMS0w_3a7d4ab4-f7a9-437e-a1b6-f55e2490253c">49</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMi0xLTEtMS0w_7cccef68-73f4-4aa4-9953-bbe0cb707ac3">0.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="number" contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702" decimals="INF" format="ixt:zerodash" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMy0xLTEtMS0w_c003d16a-153a-4fba-a111-4fc90d0c13e9">&#8212;</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2021, there were&#160;<ix:nonFraction unitRef="shares" contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzAzMQ_99c62133-712a-4f8c-9502-a26c6397ca6c">8,709,765</ix:nonFraction> PSUs outstanding and $<ix:nonFraction unitRef="usd" contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzA1NQ_d694ca41-9011-4d2d-9fe8-29a8dc4ecbda">155.7</ix:nonFraction> million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_61"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:IncomeTaxDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfNTQ3_5a3f81ca-f3f1-454d-90de-6842ece5bb15" continuedAt="idabe5ce64a8e4e94beba490abb06d79b" escape="true">PROVISION FOR INCOME TAXES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="idabe5ce64a8e4e94beba490abb06d79b">The effective tax rate for the three and six months ended June&#160;30, 2021 was <ix:nonFraction unitRef="number" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ3Nw_c6151505-9d53-46c6-9984-7014c8f21d4b">23.1</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ3MA_054f7427-1156-4e40-a395-009b56b2eca9">20.5</ix:nonFraction>%, respectively, as compared to <ix:nonFraction unitRef="number" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ1Mg_68ab8a8c-fead-49f6-9832-fecdb7c3e530">17.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="3" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ2MA_b14f4187-14e8-4d38-8b4c-2411ddb4bdf8">18.0</ix:nonFraction>% for the corresponding periods in 2020. The effective tax rate for the three and six months ended June&#160;30, 2021 and 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.</ix:continuation> </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_64"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:EarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzMw_2c1c4263-bed9-47cf-9087-b4abf518bafb" continuedAt="iff7dce9fcff94daea25544dc4f6d736c" escape="true">NET INCOME PER SHARE</ix:nonNumeric></span></div><ix:continuation id="iff7dce9fcff94daea25544dc4f6d736c"><ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzI2_6f0ed830-435c-43ce-8077-dfe923ba88c9" escape="true"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.417%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy0xLTEtMS0w_8c59a938-ba77-46f6-bfe2-d1973b4ebadf">96,092</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy0zLTEtMS0w_0ed6bc29-5d72-4285-846f-ae3ed36c72fc">66,821</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy01LTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e">97,693</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy03LTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f">115,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS0xLTEtMS0w_29e2868a-8b38-4875-a887-d7c75f9af8f0">314,117</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS0zLTEtMS0w_4e3f1f2a-e580-44d9-9acf-364bac526287">307,807</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS01LTEtMS0w_0c983555-5ab8-4398-810b-60e29450066d">313,295</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS03LTEtMS0w_579d327e-e1b5-40c8-b5e1-07460774ef43">306,598</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi0xLTEtMS0w_f44493d5-36b6-492d-bc86-dbfc1fc6f384">8,824</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi0zLTEtMS0w_affa1734-a967-49ba-90ee-036588548552">10,337</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi01LTEtMS0w_e33b2df5-4891-4872-8171-147dcd190375">8,819</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi03LTEtMS0w_a5079d44-88f7-4d2c-92e2-d72a279fd830">10,394</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy0xLTEtMS0w_45b5ca19-1534-46ab-bcdf-72a8335df827">322,941</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy0zLTEtMS0w_6e9738ab-361c-4682-aade-f523e052cadf">318,144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy01LTEtMS0w_8db72b6a-fb8d-4d73-a589-67acaa0cb364">322,114</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy03LTEtMS0w_4a589885-e699-4bb0-84c0-b3fd0ee5f665">316,992</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS0xLTEtMS0w_db364df9-420c-4664-ba8f-4dba8f3d3d5e">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS0zLTEtMS0w_a8181d0d-a138-44ff-8fb3-35d1836987a7">0.22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS01LTEtMS0w_897385f8-22ab-4504-bf49-eb4a6bd32c5b">0.31</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS03LTEtMS0w_bbc6ce9a-fefe-412b-8516-d5361bb8b0ce">0.38</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtMS0xLTEtMA_beecd631-c0bd-4197-a468-ed60af27687c">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtMy0xLTEtMA_a372761b-f96f-44e0-afcc-29e5a02bd2fe">0.21</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtNS0xLTEtMA_2a732a89-e223-41ba-a0a9-5210dae65758">0.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtNy0xLTEtMA_119fc0ce-5935-4989-a55d-0c6842d0a25b">0.36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div></ix:nonNumeric><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and Performance Stock Options, unvested RSUs and PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzM3_e1c06b9c-6f3c-4cb0-9b4c-68e305562025" continuedAt="i333e76b3e0fc48dcb35c8332fad85f83" escape="true">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</ix:nonNumeric></span><ix:continuation id="i333e76b3e0fc48dcb35c8332fad85f83"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.566%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.436%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.742%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi0xLTEtMS0w_e690bd63-c034-4a85-b27c-dd67f4b808c0">12,285</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0c6782e60aa74aa18a2400a167db7d7e_D20200404-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi0zLTEtMS0w_2b83636f-8ce0-4308-8f85-8c283a2fdf03">8,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="i0d82c6e6cf824115b296671898dbd282_D20210102-20210702" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi01LTEtMS0w_3cab26b5-a961-4798-9650-98f856a9e4ac">11,146</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="if3e6164d65ce46689c7c42db6169a463_D20200104-20200703" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi03LTEtMS0w_d7039ac6-70db-4f94-981a-f60226d17733">10,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></ix:continuation></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_67"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10. <ix:nonNumeric contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82Ny9mcmFnOjg2NjBiMWM3YTgwNjQxMmFhYjE3ZmM3MmFmMWIzYWMyL3RleHRyZWdpb246ODY2MGIxYzdhODA2NDEyYWFiMTdmYzcyYWYxYjNhYzJfNDMzMw_c46b819f-2167-4398-93bc-fa7a4bbfb82d" continuedAt="i09b28fc9df094b76801e191d8e5c5354" escape="true">COMMITMENTS AND CONTINGENCIES</ix:nonNumeric></span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="i09b28fc9df094b76801e191d8e5c5354" continuedAt="i29420468b0fa4bd0b88dbf960cf9f55e">In September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. </ix:continuation></span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><ix:continuation id="i29420468b0fa4bd0b88dbf960cf9f55e"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited, asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Teva Pharmaceutical Industries Limited </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div></ix:continuation><div id="i164d1fcc16004d86847619b30cbdc0ba_70"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This Quarterly Report on Form 10-Q contains forward-looking statements. These statements are based on Exelixis, Inc.&#8217;s (Exelixis, we, our or us) current expectations, assumptions, estimates and projections about our business and our industry and involve known and unknown risks, uncertainties and other factors that may cause our company&#8217;s or our industry&#8217;s results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in, or contemplated by, the forward-looking statements. Our actual results and the timing of events may differ significantly from the results discussed in the forward-looking statements. Factors that might cause such a difference include those discussed in &#8220;Risk Factors&#8221; in Part II, Item&#160;1A of this Quarterly Report on Form 10-Q, as well as those discussed elsewhere in this report. These and many other factors could affect our future financial and operating results. We undertake no obligation to update any forward-looking statement to reflect events after the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">This discussion and analysis should be read in conjunction with our condensed consolidated financial statements and accompanying notes included in this report and the consolidated financial statements and accompanying notes thereto included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020 submitted to the Securities and Exchange Commission (SEC) on February&#160;10, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol-Myers Squibb Company&#8217;s (BMS) OPDIVO&#174; (nivolumab), and for previously treated hepatocellular </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">carcinoma (HCC); and COMETRIQ&#174; (cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cabozantinib Franchise</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 22, 2021, the FDA approved CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC. This regulatory milestone expands upon the FDA&#8217;s prior approvals of CABOMETYX as a monotherapy for previously treated patients with advanced RCC in April 2016 and for previously untreated patients with advanced RCC in December 2017. Additionally, in January 2019, the FDA approved CABOMETYX for the treatment of patients with HCC who have been previously treated with sorafenib.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To develop and commercialize CABOMETYX and COMETRIQ outside the U.S., we have entered into license agreements with Ipsen Pharma SAS (Ipsen) and Takeda Pharmaceutical Company Limited (Takeda). We granted to Ipsen the rights to develop and commercialize cabozantinib outside of the U.S. and Japan, and to Takeda the rights to develop and commercialize cabozantinib in Japan. Both Ipsen and Takeda also contribute financially and operationally to the further global development and commercialization of the cabozantinib franchise in other potential indications, and we continue to work closely with them on these activities. Utilizing its regulatory expertise and established international oncology marketing network, Ipsen has continued to execute on its commercialization plans for CABOMETYX, having received regulatory approvals and launched in multiple territories outside of the U.S., including in the European Union (EU) and Canada, as a treatment for advanced RCC and for HCC in adults who have previously been treated with sorafenib. In addition, in March 2021, Ipsen and BMS received regulatory approval from the European Commission (EC) for CABOMETYX in combination with OPDIVO as a first-line treatment for patients with advanced RCC, and both Ipsen and BMS plan to submit applications to approve the combination in other territories beyond the EU. With respect to the Japanese market, Takeda received Manufacturing and Marketing Approvals in 2020 from the Japanese Ministry of Health, Labour and Welfare (MHLW) of CABOMETYX as a treatment of patients with curatively unresectable or metastatic RCC and as a treatment of patients with unresectable HCC who progressed after cancer chemotherapy. In October 2020, Takeda and Ono Pharmaceutical Co., Ltd., BMS&#8217; development and commercialization partner in Japan, submitted a supplemental application to the Japanese MHLW for Manufacturing and Marketing Approval of CABOMETYX in combination with OPDIVO for the treatment of patients with unresectable, advanced or metastatic RCC.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our regulatory and commercialization efforts in the U.S. and the support provided to our collaboration partners for rest-of-world regulatory and commercialization activities, we are also pursuing other indications for cabozantinib that have the potential to increase the number of cancer patients who could benefit from this medicine. We are evaluating cabozantinib, both as a single agent and in combination with other therapies, in a broad development program comprising over 100 ongoing or planned clinical trials across multiple indications. We, along with our collaboration partners, sponsor some of the trials, and independent investigators conduct the remaining trials through our Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute&#8217;s Cancer Therapy Evaluation Program (NCI-CTEP) or our investigator-sponsored trial (IST) program. Informed by the available data from these clinical trials, we advanced the development program for the cabozantinib franchise with potentially label-enabling trials. One pivotal trial that has resulted from this effort is COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) who have progressed after up to two VEGF receptor-targeted therapies. In December 2020, we announced that COSMIC-311 had met the primary endpoint of demonstrating significant improvement in progression-free survival (PFS), and in February 2021, we announced the FDA had granted Breakthrough Therapy Designation to cabozantinib as a potential treatment for patients with RAI-refractory DTC who have progressed following prior therapy. Study results from COSMIC-311 were presented at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and published in </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The Lancet Oncology. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">They further served as the basis for the supplemental New Drug Application (sNDA) we submitted to the FDA in June 2021 seeking approval for CABOMETYX to treat patients 12 and older with DTC who have progressed following prior therapy and who are RAI-refractory (if RAI is </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appropriate), and in August 2021, we announced that the FDA had accepted our sNDA, granted Priority Review and assigned a Prescription Drug User Fee Act (PDUFA) goal date, or target action date, of December 4, 2021. Building on preclinical and clinical observations that cabozantinib in combination with immune checkpoint inhibitors (ICIs) may promote a more immune-permissive tumor environment, we initiated numerous pivotal studies to further explore these combination regimens. The first of these studies to deliver results was CheckMate -9ER, a phase 3 pivotal trial evaluating the combination of cabozantinib and nivolumab compared to sunitinib in previously untreated advanced or metastatic RCC. We, along with our collaboration partner, BMS, announced in April 2020 that the trial met its primary endpoint of PFS at final analysis, as well as the secondary endpoints of overall survival (OS) at a pre-specified interim analysis and objective response rate (ORR), and showed that the combination of cabozantinib with nivolumab significantly improved the three key efficacy outcomes as compared with sunitinib, doubling PFS and ORR and reducing the risk of disease progression or death by 40% compared with sunitinib. Data from CheckMate -9ER served as the basis for the FDA&#8217;s and EC&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC in January 2021 and March 2021, respectively. We are also collaborating with BMS on COSMIC-313, a phase 3 pivotal trial evaluating the triplet combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk RCC. Enrollment for COSMIC-313 was completed in March 2021, and we expect to report top-line results of the event-driven analyses from the trial in the late 2021 or early 2022 timeframe.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to expand our exploration of combinations with ICIs, we also initiated multiple trials evaluating cabozantinib in combination with F. Hoffmann-La Roche Ltd.&#8217;s (Roche) ICI, atezolizumab. COSMIC-021 is a broad phase 1b study evaluating the safety and tolerability of cabozantinib in combination with atezolizumab in patients with a wide variety of locally advanced or metastatic solid tumors. Based on encouraging efficacy and safety data that has emerged from the trial, certain cohorts have been or may be further expanded, including the cohorts of patients with non-small cell lung cancer (NSCLC) who have been previously treated with an ICI and metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with enzalutamide and/or abiraterone acetate and experienced radiographic disease progression in soft tissue (Cohort 6). Data from Cohort 6, announced in May 2021, resulted in an investigator assessed ORR of 27% and a blinded independent radiology committee assessed ORR of 18%. We intend to discuss these data with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for patients with high-risk mCRPC and plan to present detailed results of the COSMIC-021 trial at a medical meeting in the second half of 2021. Since the initiation of the trial, data from COSMIC-021 have been instrumental in guiding our clinical development strategy for cabozantinib in combination with ICIs, including supporting the initiation of COSMIC-312, a phase 3 pivotal trial evaluating cabozantinib in combination with atezolizumab versus sorafenib in previously untreated advanced HCC, and three phase 3 pivotal trials in collaboration with Roche, CONTACT-01, CONTACT-02 and CONTACT-03, evaluating the combination of cabozantinib with atezolizumab in patients with metastatic NSCLC, mCRPC and advanced RCC, respectively. CONTACT-01 and CONTACT-03 are sponsored by Roche and co-funded by us; CONTACT-02 is sponsored by us and co-funded by Roche. In June 2021, we announced results from COSMIC-312. The trial met one of the primary endpoints, demonstrating significant improvement in PFS at the planned primary analysis, reducing the risk of disease progression or death by 37% compared with sorafenib (hazard ratio: 0.63; 99% confidence internal: 0.44-0.91; P=0.0012). A prespecified interim analysis for the second primary endpoint of OS, conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination of cabozantinib and atezolizumab but did not reach statistical significance. Safety for the combination appeared to be consistent with the known safety profiles of the individual medicines, and no new safety signals were identified. Based on the preliminary OS data, we anticipate that the probability of reaching statistical significance at the time of the final analysis is low, but the trial will continue as planned to the final analysis of OS, with results anticipated in early 2022. We plan to present the trial results at a future medical meeting and intend to discuss the results with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for patients with previously untreated advanced HCC. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pipeline Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our small molecule discovery programs are supported by a robust and expanding infrastructure, including a library of 4.6 million compounds. We have extensive experience in the identification and optimization of drug candidates against multiple target classes for oncology, inflammation and metabolic diseases. The first compound to advance from our recent drug discovery efforts is XL092, a next-generation oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER and other kinases implicated in cancer&#8217;s growth and spread. In designing XL092, we sought to build upon our experience with cabozantinib, retaining the target profile of cabozantinib while improving key characteristics, including the pharmacokinetic half-life. To date, we have announced two large phase 1b clinical trials studying XL092, STELLAR-001 and STELLAR-002. STELLAR-001 is a phase 1b clinical trial evaluating XL092, both as a monotherapy and in combination with </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">either atezolizumab or avelumab, an ICI developed by Merck KGaA, Darmstadt, Germany and Pfizer Inc., which is currently enrolling patients with advanced solid tumors. We expect that once recommended doses of single-agent XL092 and XL092 in combination with atezolizumab or avelumab are established, the trial will begin to enroll expansion cohorts for patients with clear cell and non-clear cell RCC, colorectal cancer (CRC), hormone-receptor positive breast cancer, mCRPC and urothelial carcinoma (UC). STELLAR-002 is a phase 1b clinical trial that will evaluate XL092 in combination with either nivolumab, nivolumab and ipilimumab, or nivolumab and bempegaldesleukin, an investigational CD122-preferential IL-2&#8211;pathway agonist developed by Nektar Therapeutics (Nektar). We expect to begin enrolling patients with advanced solid tumors in dose-escalation cohorts for STELLAR-002 during the second half of 2021. Depending on the dose-escalation results, STELLAR-002 may enroll expansion cohorts for patients with clear cell and non-clear cell RCC, mCRPC and UC, and to better understand the individual contribution of the therapies, treatment arms in the expansion cohorts may include XL092 as a single-agent, XL092 in combination with nivolumab, XL092 in combination with nivolumab and ipilimumab, and XL092 in combination with nivolumab and bempegaldesleukin.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We augment our small molecule discovery activities through research collaborations and in-licensing arrangements with other companies. The most advanced compound to emerge from these arrangements is XL102 (formerly AUR102), the lead program targeting cyclin-dependent kinase 7 under our collaboration with Aurigene Discovery Technologies Limited (Aurigene). In December 2020, based on encouraging preclinical data, we exercised our exclusive option to license XL102 from Aurigene. Following the FDA&#8217;s acceptance of our Investigational New Drug (IND) application in December 2020, we initiated a phase 1 clinical trial of the compound in January 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond small molecules, we have also launched rigorous efforts to discover and advance biologic drug candidates, such as bispecific antibodies, antibody drug conjugates (ADCs) and other innovative biologics that have the potential to become anti-cancer therapies. ADCs in particular present a unique opportunity for new cancer treatments, given their capabilities to deliver anti-cancer payload drugs to targets with increased precision while minimizing impact on healthy tissues, and have been validated by the multiple regulatory approvals for the commercial sale of ADCs since the beginning of 2020. To facilitate the growth of these biologics programs, we have established multiple research collaborations and in-licensing arrangements, expanding our access to antibodies or other binders, which are the starting point for use with additional technology platforms that we employ to generate next-generation ADCs or bispecific antibodies. We have already made significant progress under these arrangements and believe we will continue to do so. For example, based on promising preclinical data for XB002 (formerly known as ICON-2), the lead Tissue Factor ADC program under our research collaboration with Iconic Therapeutics, Inc. (Iconic), we exercised our exclusive option to license XB002 in December 2020. Following the FDA&#8217;s acceptance of our IND for XB002 in April 2021, we initiated a phase 1 clinical trial in June 2021. We have expanded our access to antibodies through arrangements with WuXi Biologics Ireland Limited (WuXi Bio), focused on leveraging WuXi Bio&#8217;s panel of monoclonal antibodies against an undisclosed target for the development of ADC, bispecific and certain other novel tumor-targeting biologics, and through the execution of an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), under which we will, upon the closing of the asset purchase and subject to certain conditions, acquire all rights, title and interest in GamaMabs&#8217; antibody program directed at anti-M&#252;llerian hormone receptor 2 (AMHR2), a novel oncology target with relevance in multiple forms of cancer. These antibodies, as well as those originating from collaboration with Invenra, Inc., provide starting points for the construction of ADCs through our collaborations with NBE-Therapeutics AG and/or Catalent, Inc.&#8217;s wholly owned subsidiaries Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC and Catalent Pharma Solutions, Inc., utilizing their site-specific conjugation technologies and payloads. In addition, our collaboration with Adagene Inc. (Adagene), focused on using Adagene&#8217;s SAFEbody</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> technology to develop novel masked ADCs or other innovative biologics, provides potential for developing ADCs or other biologics with improved therapeutic index.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure. In total, we are advancing drug candidates across approximately 20 ongoing discovery programs toward and through preclinical development, and subject to preclinical data, we have the potential to submit multiple INDs later in 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COVID-19 Update </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic continues to have a modest impact on our business operations, in particular with respect to our clinical trial and commercial activities. We have and continue to undertake considerable efforts to mitigate the various problems presented by this crisis, including as described below:</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Clinical Trials.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> To varying degrees and at different rates across our global clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. Beginning during the second quarter of 2020 and since that time, however, that trend reversed, and screening and enrollment activity began to increase. As a result, we and our collaboration partners, including principal investigators and personnel at clinical trial sites, have been successful overall in preventing material delays to our ongoing and planned clinical trials due to the COVID-19 pandemic. We have done this through ongoing assessment of the COVID-19 pandemic&#8217;s impact and, wherever possible, taking proactive steps in compliance with guidance issued by the FDA, EMA and other regulatory agencies to support the safety of our patients and their access to treatment, as well as to maintain the high quality of our clinical trials. We recognize, however, that we may have to make further operational adjustments to our ongoing and planned clinical trials and that patient enrollment, and new clinical trial site initiations may again be slowed due to recurring COVID-19 outbreaks and potential reintroduction of certain restrictions intended to mitigate the spread of COVID-19.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Drug Discovery and Preclinical Development</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have fully resumed drug discovery in our laboratories following a temporary suspension of these activities while we observed the shelter in place orders issued by the State of California and Alameda County. While this temporary suspension combined with interruptions in the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19 caused us to experience modest delays in the advancement of certain of our early-stage programs, we continued to substantially progress our product pipeline despite the COVID-19 pandemic, including the submission of INDs for XL102 and XB002.</span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Commercial Activities</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Despite the challenges posed by the COVID-19 pandemic, including requiring us to temporarily shift to telephonic and virtual interactions with healthcare professionals, we believe our commercial business was only modestly impacted. Our field employees have now partially resumed their in-person promotional activities while supplementing these activities with telephonic and virtual interactions and we believe they are well-positioned to execute on our commercial objectives. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Supply Chain.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We have not experienced production delays or seen any significant impairment to our supply chain as a result of the COVID-19 pandemic. In addition, we continue to maintain substantial safety stock inventories for our commercial drug substance and drug products, which should be sufficient to maintain robust long-term supply. We continue to work closely with our third-party contract manufacturers, distributors, suppliers, comparator drug sourcing vendors and collaboration partners to safeguard both the timely production and delivery of our products. </span></div><div style="margin-top:9pt;padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Business Operations. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have taken numerous precautions, some temporary and others still in place, to help mitigate the risk of transmission of the virus, including: initially reducing the number of our employees working on-site at our Alameda headquarters; maintaining enhanced safety and social distancing protocols for those employees who have returned to working on-site and initiating an on-site COVID-19 testing program; and restricting non-essential business. Most of our employees worked remotely during much of 2020 and early 2021, and many employees continue to do so on a part-time or full-time basis, which has required that we devise new ways of working and collaborating. However as of the date of this Quarterly Report on Form 10-Q, the COVID-19 pandemic has only had a modest impact on our productivity and has not caused significant interruptions in our general business operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The circumstances surrounding the COVID-19 pandemic continue to be subject to rapid change, and we will continue to monitor new developments that could pose additional risks for us, including the spread of the Delta variant in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent. Despite our mitigation efforts, we may experience delays or an inability to execute on our clinical and preclinical development plans, reduced revenues or other adverse impacts to our business, which are described in more detail in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q. We recognize that this pandemic will continue to present unique challenges for us throughout 2021, and potentially into 2022.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Second Quarter 2021 Business Updates and Financial Highlights </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, we continued to execute on our business objectives, generating significant revenues from operations and enabling us to continue to seek to maximize the clinical and commercial potential of our products and expand our product pipeline. Significant business updates and financial highlights for the quarter and subsequent to quarter-end include:</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Business Updates</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In April 2021, we announced the FDA&#8217;s acceptance of the IND for XB002 and initiated a phase 1 trial in June 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2021, we announced an asset purchase agreement with GamaMabs to acquire GamaMabs&#8217; antibody program directed at AMHR2.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In May 2021, we announced additional phase 1b results from the mCRPC Cohort 6 of COSMIC-021, in which ORR for cabozantinib in combination with atezolizumab in high-risk patients was 27% and 18% per investigator assessment and Blinded Independent Radiology Committee (BIRC) assessment, respectively, and the disease control rate was 88% and 84% per investigator assessment and BIRC assessment, respectively. In continuation of prior regulatory interaction and feedback from the FDA, we intend to discuss the phase 1b data with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for patients with high-risk mCRPC and plan to present detailed results of the trial at a medical meeting in the second half of 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, cabozantinib was the subject of multiple data presentations at the 2021 ASCO Annual Meeting, which included: (i) a post-hoc exploratory analysis of CheckMate -9ER demonstrating that efficacy benefits of the combination compared with sunitinib were observed across analyzed subgroups, including those based on International Metastatic Renal Cell Carcinoma Database Consortium risk status, site of metastases and extent of tumor burden at baseline; (ii) another post-hoc analysis of CheckMate -9ER demonstrating that CABOMETYX in combination with OPDIVO resulted in a statistically significant and clinically meaningful increase in quality-adjusted survival compared with sunitinib for patients with previously untreated advanced RCC; (iii) positive results from a phase 2 IST showing promising efficacy and an acceptable safety profile of CABOMETYX in combination with OPDIVO in patients with advanced or metastatic non-clear cell RCC with papillary, unclassified or translocation-associated histologies; and (iv) detailed results from COSMIC-311 evaluating cabozantinib in patients with RAI-refractory DTC, which served as the basis for an sNDA we submitted to the FDA in June 2021.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, we announced a clinical trial collaboration and supply agreement with BMS to evaluate XL092 in combination with either nivolumab, nivolumab and ipilimumab, or nivolumab and bempegaldesleukin in patients with advanced solid tumors as part of the new STELLAR-002 phase 1b dose escalation study.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, we filed a patent lawsuit against Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva), along with Teva Pharmaceutical Industries Limited, following receipt of two Paragraph IV certification notice letters from Teva informing us that it had filed an Abbreviated New Drug Application (ANDA) with the FDA requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book, and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. We are </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">seeking, among other relief, an order that the effective date of any FDA approval of the ANDA would be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> the </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">latest</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which expires on July 9, 2033, and equitable relief enjoining Teva and Teva Pharmaceutical Industries Limited from infringing these patents. For a more detailed discussion of this litigation matter, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In June 2021, we announced phase 3 results from COSMIC-312, in which the combination of cabozantinib and atezolizumab met one of the primary endpoints, demonstrating significant improvement in PFS versus sorafenib at the planned primary analysis. A prespecified interim analysis for the second primary endpoint of OS, conducted at the same time as the primary analysis for PFS, showed a trend favoring the combination but did not reach statistical significance. The trial will continue as planned to the final analysis of OS; results are anticipated in early 2022. We plan to present the trial results at a future medical meeting and intend to discuss the results with the FDA to determine next steps toward a potential regulatory submission for the combination regimen for patients with previously untreated advanced HCC.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">In August 2021, we announced that the FDA had accepted our sNDA for CABOMETYX as a treatment for patients 12 and older with DTC who have progressed following prior therapy and who are RAI-refractory (if RAI is appropriate), granted Priority Review and assigned a PDUFA goal date of December 4, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net product revenues for the second quarter of 2021 were $284.2 million, compared to $178.7 million for the second quarter of 2020.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Total revenues for the second quarter of 2021 were $385.2 million, compared to $259.5 million for the second quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Research and development expenses for the second quarter of 2021 were $148.8 million, compared to $114.9 million for the second quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Selling, general and administrative expenses for the second quarter of 2021 were $98.5 million, compared to $59.8 million for the second quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Provision for income taxes for the second quarter of 2021 was $28.8 million, compared to $13.9 million for the second quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Net income for the second quarter of 2021 was $96.1 million, or $0.31 per share, basic and $0.30 per share, diluted, compared to net income of $66.8 million, or $0.22 per share, basic and $0.21 per share diluted, for the second quarter of 2020.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Cash, cash equivalents, restricted cash equivalents and investments were $1.7 billion as of June&#160;30, 2021, compared to $1.5 billion as of December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Results of Operations&#8221;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> below for a discussion of the detailed components and analysis of the amounts above.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Challenges and Risks </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the challenges and risks imposed by the COVID-19 pandemic and described under &#8220;&#8212;COVID-19 Update&#8221; above, we will also continue to face challenges and risks that may impact our ability to execute on our 2021 business objectives, and some of these risks to our business have been or may be exacerbated by the COVID-19 pandemic. In particular, for the foreseeable future, we expect our ability to generate sufficient cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone or in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. In addition, CABOMETYX will only continue to be commercially successful if private third-party and government payers continue to provide coverage and reimbursement. However, as is the case for all innovative pharmaceutical therapies, obtaining and maintaining coverage and reimbursement for CABOMETYX is becoming increasingly difficult, both within the U.S. and in foreign markets, because of growing concerns over healthcare cost containment and corresponding policy initiatives and activities aimed at limiting access to, and restricting the prices of, pharmaceuticals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Achievement of our 2021 business objectives will also depend on our ability to maintain a competitive position with respect to the shifting landscape of therapeutic strategy for the treatment of cancer, which we may not be able to do. While we have had success in adapting our development strategy for the cabozantinib franchise and other product candidates to address the expanding role of therapies that combine targeted agents with ICIs and/or with other mechanisms of action, it is uncertain whether current and future clinical trials will lead to regulatory approvals, or whether physicians will prescribe regimens containing our products instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors. In the longer term, we may eventually face competition from potential manufacturers of generic versions of our marketed products, including the proposed generic versions of CABOMETYX tablets that are the subject of ANDAs submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN) and Teva, and the approval of either MSN&#8217;s or Teva&#8217;s ANDA could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. Separately, our research and development objectives may be impeded by the challenges of scaling our organization to meet the demands of expanded drug development, unanticipated delays in clinical testing and the inherent risks and uncertainties associated with drug discovery operations, all of which may be increased as a result of the COVID-19 pandemic. In connection with efforts to expand our product pipeline, we may be unsuccessful in discovering new drug candidates or identifying appropriate candidates for in-licensing or acquisition.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of these challenges and risks are specific to our business, and others are common to companies in the biotechnology, biopharmaceutical and pharmaceutical industries with development and commercial operations. As described under &#8220;&#8212;COVID-19 Update&#8221; above, these risks have been or may be exacerbated by the COVID-19 pandemic. For </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a more detailed discussion of challenges and risks we face, including those relating to the COVID-19 pandemic, see &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fiscal Year Convention</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that ends on the Friday closest to December 31st. Fiscal year 2021, which is a 52-week fiscal year, will end on December 31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021 are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_73"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by category were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.423%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.953%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></div></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-33&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-16&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">185&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">48&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Net Product Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Gross product revenues, discounts and allowances, and net product revenues were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.660%"><tr><td style="width:1.0%"></td><td style="width:22.278%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.553%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.927%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.403%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.625%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.554%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.897%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,898&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,464&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,168)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,854)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in net product revenues for CABOMETYX for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> primarily related to increases in the number of units sold that was driven by the strong uptake for the combination therapy of CABOMETYX and OPDIVO following approval by the FDA in January 2021. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in net product revenues for COMETRIQ for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were due to increases in the number of COMETRIQ units sold, due to a comparator purchase of the product for use in a clinical trial.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our net product revenues for the remainder of 2021 may increase relative to the corresponding prior year period, primarily as a result of the increase in demand for CABOMETYX following the FDA&#8217;s approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, as well as an increase in selling price for CABOMETYX.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize product revenues net of discounts and allowances that are described in &#8220;Note&#160;1.&#160;Organization and Summary of Significant Accounting Policies&#8221; to our&#160;&#8220;Notes to Consolidated Financial Statements&#8221;&#160;included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020. The increases in discounts and allowances for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were primarily the result of increases in Public Health Service hospital utilization and the dollar amount of the related chargebacks and, to a lesser extent, an increase in Medicaid utilization and the dollar amount of related Medicaid rebates. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our discounts and allowances as a percentage of gross revenues may increase during the remainder of 2021 relative to the corresponding prior year period as the number of patients participating in government programs continues to increase and as the discounts given and rebates paid to government payers also increase.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">License Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">License revenues include the recognition of the portion of milestone payments allocated to the transfer of intellectual property licenses for which it had become probable in the related period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and the profit on the U.S. commercialization of COTELLIC from Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Milestone revenues, which are allocated between license revenues and collaboration services revenues, were $12.9 million and $13.5 million for the three and six months ended June&#160;30, 2021, respectively, as compared to $43.5 million and $43.6 million for the corresponding prior year periods. Milestone revenues by period included the following:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and six months ended June&#160;30, 2021 included $11.8 million in revenues recognized in connection with a $12.5 million regulatory milestone we determined was probable of achievement.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Milestone revenues for the three and six months ended June 30, 2020 included $23.7 million in revenues recognized in connection with $31.0 million in milestones we achieved upon Takeda&#8217;s first commercial sale of CABOMETYX as a treatment for patients with curatively unresectable or metastatic RCC in Japan and $18.8 million in revenues recognized in connection with a $20.0 million development milestone from Ipsen we determined was probable of achievement.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalties increased primarily as a result of increases in Ipsen&#8217;s net sales of cabozantinib outside of the U.S. and Japan. Ipsen royalties were $22.8 million and $45.3 million for the three and six months ended June&#160;30, 2021, compared to $16.3 million and $34.2 million for the corresponding prior year periods. Ipsen&#8217;s net sales of cabozantinib have continued to grow since their first commercial sale of the product in the fourth quarter of 2016, primarily due to increased demand of CABOMETYX, which, as of June&#160;30, 2021, is approved in 61 countries outside of the U.S. Royalties also increased due to the commercial launch of CABOMETYX for the treatment of patients with curatively unresectable or metastatic RCC in Japan by Takeda during the second quarter of 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our share of profits on the U.S. commercialization of COTELLIC under our collaboration agreement with Genentech was $2.2 million and $4.0 million for the three and six months ended June&#160;30, 2021, compared to $1.4 million and $2.8 million for the corresponding prior year periods. We also earned royalties on ex-U.S. net sales of COTELLIC by Genentech of $0.8 million and $1.7 million for the three and six months ended June&#160;30, 2021, compared to $1.1 million and $2.4 million for the corresponding prior year periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to uncertainties surrounding the timing and achievement of regulatory and development milestones, it is difficult to predict future milestone revenues and milestones can vary significantly from period to period. We project our license revenues for the remainder of 2021 to decrease, relative to fiscal 2020, as a result of the anticipated achievement of fewer milestones in 2021, partially offset by an increase in royalty revenues related to an increase in sales of CABOMETYX by Ipsen and Takeda.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Collaboration Services Revenues</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments that have been allocated to research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs and the royalties we pay on sales by Ipsen and Takeda of products containing cabozantinib. We received notification that, effective January 1, 2021, Royalty Pharma plc acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Development cost reimbursements were $62.5 million and $80.9 million for the three and six months ended June&#160;30, 2021, relative to $19.6 million and $34.0 million for the corresponding prior year periods. The increases in development cost reimbursements were primarily a result of the reimbursements from Ipsen associated with their decision to opt in and co-fund COSMIC-311 development costs. Ipsen is now responsible for 35% of the global development costs of COSMIC-311 and is obligated to reimburse Exelixis for these costs, as well as an additional payment calculated as a percentage of COSMIC-311 development costs, triggered by the timing of the exercise of its option. Accordingly, collaboration services revenues for the three and six months ended June 30, 2021, includes a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period. Development costs reimbursements also increased as a result of the reimbursements from Takeda associated with their decision to opt in and co-fund CONTACT-02 and additional cohorts of COSMIC-021 studies in the third quarter of 2020 and their respective share of the increase in spending on the CONTACT-02 study. The increases in development cost reimbursements were partially offset by a decrease in total spending on COSMIC-021 and COSMIC-312 studies.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration services revenues were reduced by $3.5 million and $6.9 million for the 3% royalty we are required to pay on the net sales by Ipsen and Takeda of any product incorporating cabozantinib for the three and six months ended June&#160;30, 2021, respectively, compared to $2.3 million and $4.7 million for the corresponding prior year periods. As royalty generating sales of cabozantinib by Ipsen and Takeda have increased as described above, our royalty payments have also increased.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our collaboration services revenues may increase for the remainder of 2021, relative to fiscal 2020, primarily as a result of increased development cost reimbursements related to Ipsen&#8217;s opt-in and co-funding of COSMIC-311 as well as projections related to our other collaboration arrangements</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Goods Sold</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The cost of goods sold and our gross margin were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,884&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,082&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,510&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross margin</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">95&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of goods sold is related to our product revenues and consists primarily of a 3% royalty payable on U.S. net sales of any product incorporating cabozantinib, as well as the cost of inventory sold, indirect labor costs, write-downs related to expiring and excess inventory, and other third-party logistics costs. The increases in cost of goods sold for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year peri</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ods, were primarily the result of   increases in royalties as a result of increased U.S. CABOMETYX sales and certain other period costs. We do not project our gross margin to change significantly during the remainder of 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not track fully burdened research and development expenses on a project-by-project basis. We group our research and development expenses into three categories: (1) development; (2) drug discovery; and (3) other. Our development group leads the development and implementation of our clinical and regulatory strategies and prioritizes disease indications in which our compounds are being or may be studied in clinical trials. Our drug discovery group utilizes a variety of technologies, including in-licensed technologies, to enable the rapid discovery, optimization and extensive characterization of lead compounds such that we are able to select development candidates with the best potential for further evaluation and advancement into clinical development.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses by category were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.239%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.489%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.841%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Change</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Development:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Clinical trial costs</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,606&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-21&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">110,259&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,950&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Personnel expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,175&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">58,059&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Consulting and outside services</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,646&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,811&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,055&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other development costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,534&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,194&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,818&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,935&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,923&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">92,221&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195,071&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,838&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Drug discovery:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License and other collaboration costs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,466&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">224&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,904&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,252&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">324&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other drug discovery</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"> (1)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,724&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23,011&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">75&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 28pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total drug discovery</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,646&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">158&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">74,915&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,393&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">195&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,677&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">128&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total research and development expenses</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">148,790&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,933&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">308,078&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">216,810&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Primarily includes personnel expenses, consulting and outside services and laboratory supplies.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Includes stock-based compensation, the allocation of general corporate costs to research and development, and development cost reimbursements in connection with our collaboration arrangement with Roche executed in December 2019.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in research and development expenses for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were primarily related to increases in license and other collaboration costs, personnel expenses and stock-based compensation expense, partially offset by decreases in clinical trial costs. License and other collaboration costs increased primarily due to the acquisition of GamaMabs assets, and increases in upfront license fees, program initiation fees and research funding commitments related to business development activities. Personnel expenses increased primarily due to increases in headcount to support our expanding discovery and development organization. Stock-based compensation expense increased primarily due to the performance-based restricted stock units (PSUs) granted in 2019 that became probable of achievement in the second half of 2020 and the first half of 2021. Clinical trial costs, which include services performed by third-party contract research organizations and other vendors who support our clinical trials, decreased primarily due to lower costs associated with COSMIC-312. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to reviewing the three categories of research and development expenses described above, we principally consider qualitative factors in making decisions regarding our research and development programs. These factors include enrollment in clinical trials for our drug candidates, preliminary data and final results from clinical trials, the potential indications for our drug candidates, the clinical and commercial potential for our drug candidates, and competitive dynamics. We also make our research and development decisions in the context of our overall business strategy. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are focusing a significant amount of our development efforts on cabozantinib to maximize the therapeutic and commercial potential of this compound and, as a result, we project that a substantial portion of our research and development expenses will relate to the continuing clinical development program of cabozantinib, which includes over 100 ongoing or planned clinical trials across multiple indications. Notable ongoing company-sponsored studies resulting from this program include: COSMIC-313, for which BMS is providing nivolumab and ipilimumab free of charge and CONTACT-02 for which Roche is sharing the development costs and providing atezolizumab free of charge.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action. In this regard, we conduct drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. In addition, we will continue to engage in business development initiatives aimed at acquiring and in-licensing promising oncology platforms and assets and then further characterize and develop them utilizing our established preclinical and clinical development infrastructure.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our research and development expenses may continue to increase for the remainder of 2021 compared to 2020, primarily driven by our ongoing clinical evaluation of cabozantinib, the initiation of new clinical trials and expansion of ongoing clinical trials evaluating other product candidates in our pipeline, including XL092, XL102, XB002 and anticipated business development activities.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The length of time required for clinical development of a particular product candidate and our development costs for that product candidate may be impacted by the scope and timing of enrollment in clinical trials for the product candidate, our decisions to develop a product candidate for additional indications and whether we pursue development of the product candidate or a particular indication with a collaborator or independently. For example, cabozantinib is being developed in multiple indications, and we do not yet know for how many of those indications we will ultimately pursue regulatory approval. In this regard, our decisions to pursue regulatory approval of cabozantinib for additional indications depend on several variables outside of our control, including the strength of the data generated in our prior, ongoing and potential future clinical trials. Furthermore, the scope and number of clinical trials required to obtain regulatory approval for each pursued indication is subject to the input of the applicable regulatory authorities, and we have not yet sought such input for all potential indications that we may elect to pursue. Even after having given such input, applicable regulatory authorities may subsequently require additional clinical studies prior to granting regulatory approval based on new data generated by us or other companies, or for other reasons outside of our control. As a condition to any regulatory approval, we may also be subject to post-marketing development commitments, including additional clinical trial requirements. As a result of the uncertainties discussed above, we are unable to determine the duration of, or total costs associated with the development of cabozantinib or any of our other research and development projects. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our potential therapeutic products are subject to a lengthy and uncertain regulatory process that may not result in our receipt of the necessary regulatory approvals. Failure to receive the necessary regulatory approvals would prevent us from commercializing the product candidates affected, including cabozantinib in any additional indications. In addition, clinical trials of our potential product candidates may fail to demonstrate safety and efficacy, which could prevent or significantly delay regulatory approval. A discussion of the risks and uncertainties with respect to our research and development activities and the consequences to our business, financial position and growth prospects can be found in &#8220;Risk Factors&#8221; in Part II, Item 1A of this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Selling, General and Administrative Expenses</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98,495&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,791&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">65&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">200,846&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">122,731&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses consist primarily of personnel expenses, stock-based compensation, marketing costs and certain other administrative costs. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increases in selling, general and administrative expenses for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were primarily related to increases in personnel expenses, marketing costs, corporate giving and stock-based compensation expense. Personnel expenses increased primarily due to increases in administrative headcount to support our commercial and research and development organizations. Marketing costs increased primarily due to increased marketing activities in support of the launch of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> combination therapy of CABOMETYX and OPDIVO for the treatment of advanced RCC following approval by the FDA in January 2021.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The increase in stock-based compensation expense was primarily due to the PSUs granted in 2019 that became probable of achievement in the second half of 2020 and the first half of 2021. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project our selling, general and administrative expenses may continue to increase for the remainder of 2021 relative to 2020 in support of our continued commercial investment in CABOMETYX and the growth in the broader organization.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-operating Income</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-operating income was as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest income</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,891&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,573&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,382&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-63&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income (expense), net</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">n/a</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-operating income</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,880&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,162&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,472&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">-64&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decreases in non-operating income for the three and six months ended June&#160;30, 2021, relative to the corresponding prior year periods, were primarily the result of the decreases in interest income due to lower interest rates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provision for Income Taxes</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes and effective income tax rates were as follows (dollars in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:24.941%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.739%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.786%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.441%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.544%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:6.791%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Percent Change</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision for income taxes</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,796&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,875&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">108&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,180&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,298&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Effective tax rate</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.0&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The increase in the provision for income taxes for the </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">three months ended</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, relative to the corresponding prior year period, was primarily due to an increase in pre-tax income. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision for income taxes for the six months ended June 30, 2021 was flat, relative to the corresponding prior year period. The effective tax rate for the three and six months ended June&#160;30, 2021 and 2020 differed from the U.S. federal statutory rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes. </span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_76"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had $1.7 billion in cash, cash equivalents, restricted cash equivalents and investments, compared to $1.5 billion as of December&#160;31, 2020. We anticipate that the aggregate of our current cash and cash equivalents, short-term investments available for operations, net product revenues and collaboration revenues will enable us to maintain our operations for a period of at least 12 months following the filing date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We project we may continue to spend significant amounts of cash to fund the continued development and commercialization of cabozantinib. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including additional research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise. Financing these activities could materially impact our liquidity and capital resources and may require us to incur debt or raise additional funds through the issuance of equity. Furthermore, even though we believe we have sufficient funds for our current and future operating plans, we may choose to incur debt or raise additional funds through the issuance of equity due to market conditions or strategic considerations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Letters of Credit</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have obtained standby letters of credit related to our lease obligations and certain other obligations with combined credit limits of $46.8 million and $1.6 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively.  </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we entered into a standby letter of credit as guarantee of our obligation to fund our portion of the tenant improvements related to our build-to-suit lease at our corporate campus. The letter of credit is secured by our short-term investments, which are recorded as restricted cash equivalents and presented in other long-term assets in our Condensed Consolidated Balance Sheets and will be reduced as we fund our portion of the tenant improvements. As of June&#160;30, 2021, restricted cash equivalents included $45.3 million of short-term investments as collateral under our standby letter of credit for our portion of the tenant improvements.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources and Uses of Cash</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flow activities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:64.673%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.715%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.395%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:15.717%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by operating activities</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">221,045&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">157,751&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by investing activities</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(8,590)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">105,894&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by (used in) financing activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,074&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,003)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Operating Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash flows provided by operating activities represent the cash receipts and disbursements related to all of our activities other than investing and financing activities. Cash provided by operating activities is derived by adjusting our net income for: non-cash operating items such as deferred taxes, stock-based compensation, depreciation, non-cash lease expense and changes in operating assets and liabilities which reflect timing differences between the receipt and payment of cash associated with transactions and when they are recognized in our Condensed Consolidated Statements of Income. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by operating activities for the six months ended June&#160;30, 2021 increased relative to the corresponding prior year period, primarily due to an increase in cash received on sales of our products, an increase in cash received from our commercial collaboration arrangements, and net favorable changes in operating assets and liabilities, partially offset by an increase in cash paid for operating expenses.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in investing activities for the six months ended June&#160;30, 2021 consisted of cash used in investment purchases of $688.9 million and purchases of property, equipment and other of $33.8 million, partially offset by maturities and sales of investments of $714.1 million.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by investing activities for the six months ended June&#160;30, 2020 consisted of cash provided by the maturities and sales of investments of $549.0 million, partially offset by cash used in investment purchases of $433.2 million and purchases of property and equipment and other of $9.9 million.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Financing Activities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash provided by financing activities for the six months ended June&#160;30, 2021 consisted of $15.5 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans, partially offset by $9.4 million of withholding taxes paid related to net share settlements of equity awards.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash used in financing activities for the six months ended June&#160;30, 2020 included $20.9 million of withholding taxes paid related to net share settlements of equity awards, partially offset by $17.9 million in proceeds from the issuance of common stock under our equity incentive and stock purchase plans.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_79"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contractual Obligations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no material changes outside of the ordinary course of business in our contractual obligations as of June&#160;30, 2021 from those disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Off-Balance Sheet Arrangements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we did not have any material off-balance-sheet arrangements, as defined by applicable SEC regulations.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_82"></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of our Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S. which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. An accounting policy is considered to be critical if it requires an accounting estimate to be made based on assumptions about matters that are highly uncertain at the time the estimate is made, and if different estimates that reasonably could have been used, or changes in the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting estimates that are reasonably likely to occur periodically, could materially impact our Condensed Consolidated Financial Statements. On an ongoing basis, management evaluates its estimates including, but not limited to: those related to revenue recognition, including determining the nature and timing of satisfaction of performance obligations, and determining the standalone selling price of performance obligations, and variable consideration such as rebates, chargebacks, sales returns and sales allowances as well as milestones included in collaboration arrangements; the amounts of revenues and expenses under our profit and loss sharing agreement; recoverability of inventory; the accrual for certain liabilities including accrued clinical trial liabilities; and valuations of equity awards used to determine stock-based compensation, including certain awards with vesting subject to market or performance conditions; and the amounts of deferred tax assets and liabilities including the related valuation allowance. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Our senior management has discussed the development, selection and disclosure of these estimates with the Audit Committee of our Board of Directors. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our critical accounting policies relating to revenue recognition, inventory, clinical trial accruals, stock-based compensation and income taxes reflect the most significant estimates and assumptions used in the preparation of our Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been no significant changes in our critical accounting policies and estimates during the six months ended June&#160;30, 2021, as compared to the critical accounting policies and estimates disclosed in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For a description of the expected impact of recent accounting pronouncements, see &#8220;Note 1. Organization and Summary of Significant Accounting Policies&#8221; in the &#8220;Notes to Condensed Consolidated Financial Statements&#8221; contained in Part I, Item 1 of this Quarterly Report on Form 10-Q.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_85"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Quantitative and Qualitative Disclosures About Market Risk</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our market risks as of June&#160;30, 2021 have not changed significantly from those described in Item&#160;7A of our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_88"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Controls and Procedures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of disclosure controls and procedures.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Based on the evaluation of our disclosure controls and procedures (as defined in Rules 13a-15(e) or 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act) required by Rules 13a-15(b) or 15d-15(b) of the Exchange Act, our Chief Executive Officer and Chief Financial Officer have concluded that as of the end of the period covered by this report, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Limitations on the effectiveness of controls.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A control system, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Because of inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues, if any, within an organization have been detected. Accordingly, our disclosure controls and procedures are designed to provide reasonable, not absolute, assurance that the objectives of our disclosure control system are met and, as set forth above, our principal executive officer and principal financial officer have concluded, based on their evaluation as of the end of the period covered by this report, that our disclosure controls and procedures were effective to provide reasonable assurance that the objectives of our disclosure control system were met.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in internal control over financial reporting. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting that occurred during our most recent fiscal quarter that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting. </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_91"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II. OTHER INFORMATION</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_94"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Legal Proceedings</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2019, we received a notice letter regarding an ANDA submitted to the FDA by MSN, requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. 8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited, asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Teva Pharmaceutical Industries Limited </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_97"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">In addition to the risks discussed elsewhere in this report, the following are important factors that make an investment in our securities speculative or risky, and that could cause actual results or events to differ materially from those contained in any forward-looking statements made by us or on our behalf. The risks and uncertainties described below are not the only ones we face. Additional risks and uncertainties not currently known to us or that we deem immaterial also may impair our business operations. If any of the following risks or such other risks actually occur, our business and the value of your investment in our company could be harmed.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We are subject to healthcare laws, regulations and enforcement, as well as laws and regulations relating to privacy, data collection and processing of personal data; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks. For example, we rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S. In addition, our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:13.02pt">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Products</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow our company is critically dependent upon the commercial success of CABOMETYX in its approved indications and the further clinical development, regulatory approval and commercial success of the cabozantinib franchise in additional indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We anticipate that for the foreseeable future, our ability to maintain or meaningfully increase cash flow to fund our business operations and growth will depend upon the continued commercial success of CABOMETYX, both alone and in combination with other therapies, as a treatment for the highly competitive indications for which it is approved, and possibly for other indications for which cabozantinib has been or is currently being evaluated in potentially label-enabling clinical trials, if warranted by the data generated from these trials. In this regard, part of our strategy is to pursue additional </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">indications for the cabozantinib franchise to increase the number of cancer patients who could benefit from this medicine. However, we cannot be certain that the clinical trials we and our collaboration partners are currently conducting, or may conduct in the future, will demonstrate adequate safety and efficacy in these additional indications to receive regulatory approval in the major commercial markets where CABOMETYX is approved. Even if we and our collaboration partners receive the required regulatory approvals to market cabozantinib for additional indications, we and our collaboration partners may not be able to commercialize CABOMETYX effectively and successfully in these additional indications. If revenue from CABOMETYX decreases or remains flat, or if we are unable to expand the labeled indications in major commercial markets where CABOMETYX is approved, or if we or our collaboration partners fail to achieve anticipated product royalties and collaboration milestones, whether as a result of the COVID-19 pandemic or otherwise, we may need to reduce our operating expenses, access other sources of cash or otherwise modify our business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our ability to grow revenues from sales of CABOMETYX will depend upon the degree of market acceptance among physicians, patients, healthcare payers, and the medical community.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to increase or maintain revenues from sales of CABOMETYX for its approved indications is, and if approved for additional indications will be, highly dependent upon the extent of market acceptance of CABOMETYX among physicians, patients, government healthcare payers such as Medicare and Medicaid, commercial healthcare plans and the medical community. Market acceptance for CABOMETYX could depend on numerous factors, including the effectiveness and safety profile, or the perceived effectiveness and safety profile, of CABOMETYX compared to competing products, the strength of CABOMETYX sales and marketing efforts and changes in pricing and reimbursement for CABOMETYX. If CABOMETYX does not continue to be prescribed broadly for the treatment of its approved RCC and HCC indications, our product revenues could flatten or decrease, which could have a material adverse impact on our business, financial condition and results of operations. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our competitors may develop products, combination therapies and technologies that impair the relative value of our marketed products and any future product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology, biopharmaceutical and pharmaceutical industries are competitive and are characterized by constant technological change and diverse offerings of products, particularly in the area of novel oncology therapies. Many of our competitors have greater capital resources, larger research and development staff and facilities, deeper regulatory expertise and more extensive product manufacturing and commercial capabilities than we do, which may afford them a competitive advantage. Further, our competitors may be more effective at in-licensing and developing new commercial products that could render our products, and those of our collaboration partners, obsolete and noncompetitive. We face, and will continue to face, intense competition from biotechnology, biopharmaceutical and pharmaceutical companies, as well as academic research institutions, clinical reference laboratories and government agencies that are pursuing scientific and clinical research activities similar to ours.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, the specific indications for which CABOMETYX is currently or may be approved, based on the results from clinical trials currently evaluating cabozantinib, are highly competitive. Several novel therapies and combinations of therapies have been approved, are in advanced stages of clinical development or are under expedited regulatory review in these indications, and these other therapies are currently competing or are expected to compete with CABOMETYX. Given the shifting landscape of therapeutic strategy following the advent of ICIs, we believe our future success will depend upon our ability to achieve positive clinical trial results for therapies combining cabozantinib with ICIs across multiple indications, and if approved, successfully commercialize such combination therapies. While we have had success in adapting our development strategy for the cabozantinib franchise to address the expanding role of therapies that combine ICIs with other targeted agents, including the FDA approval of CABOMETYX in combination with OPDIVO as a first-line treatment of patients with advanced RCC, it is uncertain whether current and future clinical trials, including those evaluating cabozantinib in combination with an ICI in HCC, NSCLC and mCRPC, will lead to regulatory approvals, or whether physicians will prescribe regimens containing cabozantinib instead of competing product combinations. Moreover, the complexities of such a development strategy have required and are likely to continue to require collaboration with some of our competitors.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to maintain or increase our sales, marketing, market access and product distribution capabilities for our products, we may be unable to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maintaining our sales, marketing, market access and product distribution capabilities requires significant resources, and there are numerous risks involved with maintaining and continuously improving such a commercial organization, including our potential inability to successfully recruit, train, retain and incentivize adequate numbers of qualified and effective sales and marketing personnel. We are competing for talent with numerous commercial- and precommercial-stage, oncology-focused biotechnology companies seeking to build out and maintain their commercial organizations, as well as other large pharmaceutical and biotechnology organizations that have extensive, well-funded and more experienced sales and marketing operations, and we may be unable to maintain or adequately scale our commercial organization as a result of such competition. Also, to the extent that the commercial opportunities for CABOMETYX grow over time, we may not properly scale the size and experience of our commercialization teams to market and sell CABOMETYX successfully in an expanded number of indications. If we are unable to maintain or scale our commercial function appropriately, or should we have to revert back to primarily telephonic and virtual interactions in lieu of in-person meetings with healthcare professionals for an extended period of time as a result of the COVID-19 pandemic, we may not be able to maximize product revenues, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain or maintain coverage and reimbursement for our products from third-party payers, our business will suffer.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize our products successfully is highly dependent on the extent to which health insurance coverage and reimbursement is, and will be, available from third-party payers, including governmental payers, such as Medicare and Medicaid, and private health insurers. Third-party payers continue to scrutinize and manage access to pharmaceutical products and services and may limit reimbursement for newly approved products and indications. Patients are generally not capable of paying for CABOMETYX or COMETRIQ themselves and rely on third-party payers to pay for, or subsidize, the costs of their medications, among other medical costs. Accordingly, market acceptance of CABOMETYX and COMETRIQ is dependent on the extent to which coverage and reimbursement is available from third-party payers. These entities could refuse, limit or condition coverage for our products, such as by using tiered reimbursement or pressing for new forms of contracting. If third-party payers do not provide coverage or reimbursement for CABOMETYX or COMETRIQ, our revenues and results of operations will suffer. In addition, even if third-party payers provide some coverage or reimbursement for CABOMETYX or COMETRIQ, the availability of such coverage or reimbursement for prescription drugs under private health insurance and managed care plans, which often varies based on the type of contract or plan purchased, may not be sufficient for patients to afford CABOMETYX or COMETRIQ.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current healthcare laws and regulations in the U.S. and future legislative or regulatory reforms to the U.S. healthcare system may affect our ability to commercialize our marketed products profitably.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Federal and state governments in the U.S. are considering legislative and regulatory proposals to change the U.S. healthcare system in ways that could affect our ability to continue to commercialize CABOMETYX and COMETRIQ profitably. Similarly, among policy makers and payers, there is significant interest in promoting such changes with the stated goals of containing healthcare costs, improving quality and expanding patient access. The life sciences industry and specifically the market for the sale, insurance coverage and distribution of pharmaceuticals has been a particular focus of these efforts and would likely be significantly affected by any major legislative or regulatory initiatives.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For instance, efforts to repeal, substantially modify or invalidate some or all of the provisions of the Patient Protection and Affordable Care Act of 2010, as amended (PPACA), some of which have been successful, create considerable uncertainties for all businesses involved in healthcare, including our own. Although such efforts have not significantly impacted our business to date, it is possible that the PPACA will be subject to judicial or legislative challenges in the future, which may have a material adverse impact on our business, financial condition and results of operations, and we cannot predict how future healthcare reform measures of the Biden administration and federal or state legislative or administrative changes relating to healthcare reform will affect our business.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are pending federal and state-level legislative proposals that would significantly expand government-provided health insurance coverage, ranging from establishing a single-payer, national health insurance system to more limited &#8220;buy-in&#8221; options to existing public health insurance programs, each of which could have a significant impact on the healthcare industry. It is also possible that additional governmental actions will be taken in response to the ongoing </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">COVID-19 pandemic, and that such actions would have a significant impact on these public health insurance programs. While we cannot predict how future legislation (or enacted legislation that has yet to be implemented) will affect our business, such proposals could have the potential to impact access to and sales of our products. Furthermore, the expansion of the 340B Drug Discount Program through the PPACA has increased the number of purchasers who are eligible for significant discounts on branded drugs, including our marketed products. Because we participate in the 340B Drug Discount Program to sell a portion of our marketed products, changes in the administration of the program could have a material adverse impact on our revenues, including the implementation of the program&#8217;s Administrative Dispute Resolution Process, which is in part intended to resolve claims by covered entities that manufacturers have overcharged them for covered outpatient drugs. Due to general uncertainty in the current regulatory and healthcare policy environment, and specifically regarding positions that the Biden Administration may take with respect to these issues, we are unable to predict the impact of any legislative, regulatory, third-party payer or policy actions, including potential cost containment and healthcare reform measures. If enacted, we and any third parties we may engage may be unable to adapt to any changes implemented as a result of such measures, and we may have difficulties in sustaining profitability or otherwise experience a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pricing for pharmaceutical products in the U.S. has come under increasing attention and scrutiny by federal and state governments, legislative bodies and enforcement agencies. This may result in actions that have the effect of reducing our revenue or harming our business or reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There continue to be U.S. Congressional inquiries, hearings and proposed and enacted federal legislation and rules, as well as executive orders, designed to, among other things: reduce or limit the prices of drugs and make them more affordable for patients (including, for example, by tying the prices that Medicare reimburses for physician-administered drugs to the prices of drugs in other countries); reform the structure and financing of Medicare Part D pharmaceutical benefits, including through increasing manufacturer contributions to offset Medicare beneficiary costs; bring more transparency to drug pricing rationale and methodologies; implement data collection and reporting under Section 204 of Title II of Division BB of the Consolidated Appropriations Act, 2021, which requires, among other things, health plans and issuers to disclose rebates, fees and other remuneration provided by drug manufacturers related to certain pharmaceutical products; enable the government to negotiate prices under Medicare; revise rules associated with the calculation of average manufacturer price and best price under Medicaid, which affect the amount of rebates that we pay on prescription drugs under Medicaid and to covered entities under the 340B Drug Discount Program; eliminate the Anti-Kickback Statute (AKS) discount safe harbor protection for manufacturer rebate arrangements with Medicare Part D plan sponsors; create new AKS safe harbors applicable to certain point-of-sale discounts to patients and fixed fee administrative fee payment arrangements with pharmacy benefit managers; and facilitate the importation of certain lower-cost drugs from other countries. While we cannot know the final form or timing of any such legislative, regulatory and/or administrative measures, some of the pending and enacted legislative proposals or executive rulemaking, such as those incorporating International Pricing Index or Most-Favored-Nation models, if implemented without successful legal challenges, would likely have a significant and far-reaching impact on the biopharmaceutical industry and therefore also likely have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures have increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including restrictions on pricing or reimbursement at the state government level, limitations on discounts to patients, marketing cost disclosure and transparency measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing, including the National Medicaid Pooling Initiative. In particular, the obligation to provide notices of price increases to purchasers under laws such as California&#8217;s SB-17 may influence customer ordering patterns for CABOMETYX and COMETRIQ, which in turn may increase the volatility of our revenues as a reflection of changes in inventory volumes. Furthermore, adoption of these drug pricing transparency regulations, and our associated compliance obligations, may increase our general and administrative costs and/or diminish our revenues. Implementation of these federal and/or state cost-containment measures or other healthcare reforms may limit our ability to generate product revenue or commercialize our products, and in the case of drug pricing transparency regulations, may result in fluctuations in our results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lengthy regulatory pricing and reimbursement procedures and cost control initiatives imposed by governments outside the U.S. could delay the marketing of and/or result in downward pressure on the price of our approved products, resulting in a decrease in revenue.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Outside the U.S., including major markets in the EU and Japan, the pricing and reimbursement of prescription pharmaceuticals is generally subject to governmental control. In these countries, pricing and reimbursement negotiations with governmental authorities or payers can take six to 12 months or longer after the initial marketing authorization is </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">granted for a product, or after the marketing authorization for a new indication is granted. This can substantially delay broad availability of the product. To obtain reimbursement and/or pricing approval in some countries, our collaboration partners Ipsen and Takeda may also be required to conduct a study or otherwise provide data that seeks to establish the cost effectiveness of CABOMETYX compared with other available established therapies. The conduct of such a study could also result in delays in the commercialization of CABOMETYX. Additionally, cost-control initiatives, increasingly based on affordability and accessibility, as well as post-marketing assessments of the added value of CABOMETYX as compared to existing treatments, could decrease the price we and Ipsen might establish for CABOMETYX, or the indications for which we are able to obtain reimbursement, which would result in lower license revenues to us. New legislative and policy initiatives in the EU aimed at increasing accessibility and affordability of medicinal products, and the increased cooperation between the EU Member States, may further impact the price and reimbursement status of CABOMETYX in the future.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Legislation and regulatory action designed to reduce barriers to the development, approval and adoption of generic drugs in the U.S., and the entrance of generic competitors, could limit the revenue we derive from our products, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Federal Food, Drug, and Cosmetic Act (FDCA), the FDA can approve an ANDA for a generic version of a branded drug without the applicant undertaking the human clinical testing necessary to obtain approval to market a new drug. The FDA can also approve a New Drug Application (NDA) under section 505(b)(2) of the FDCA that relies in part on the agency&#8217;s findings of safety and/or effectiveness for a previously approved drug, where at least some of the information required for approval comes from studies not conducted by or for the applicant and for which the applicant has not obtained a right of reference or use. Both the ANDA and 505(b)(2) NDA processes are discussed in more detail in &#8220;Item 1. Business&#8212;Government Regulation&#8212;FDA Review and Approval&#8221; in our Annual Report on Form 10-K for the fiscal year ended December 31, 2020 submitted to the SEC on February 10, 2021. In either case, if an ANDA or 505(b)(2) NDA applicant submits an application referencing one of our marketed products prior to the expiry of one or more our Orange Book-listed patents for the applicable product, we may litigate with the potential generic competitor to protect our patent rights, which would result in substantial costs, divert the attention of management, and could have an adverse impact on our stock price. For example, MSN and Teva have separately submitted ANDAs to the FDA requesting approval to market their respective generic versions of CABOMETYX tablets. For a more detailed discussion of these litigation matters, see &#8220;Legal Proceedings&#8221; in Part II, Item 1 of this Quarterly Report on Form 10-Q. It is possible that MSN, Teva or other companies, following FDA approval of an ANDA or 505(b)(2) NDA, could introduce generic or otherwise competitor versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and we expect that generic cabozantinib products would be offered at a significantly lower price compared to our marketed cabozantinib products. Therefore, regardless of the regulatory approach, the introduction of a generic version of cabozantinib could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. federal government has also taken numerous legislative and regulatory actions to expedite the development and approval of generic drugs and biosimilars. For instance, the FDA Reauthorization Act of 2017 includes, inter alia, measures to expedite the development and approval of generic products, where generic competition is lacking even in the absence of exclusivities or listed patents. In addition, the Ensuring Innovation Act, enacted on April 23, 2021, amended the FDA&#8217;s statutory authority for granting new chemical entity (NCE) exclusivity to reflect the agency&#8217;s existing regulations and longstanding interpretation that award NCE exclusivity based on a drug&#8217;s active moiety, as opposed to its active ingredient, which is intended to limit the applicability of NCE exclusivity, thereby potentially facilitating generic competition. The FDA has also released a Drug Competition Action Plan, which proposes actions to broaden access to generic drugs and lower consumers&#8217; healthcare costs by, among other things, improving the efficiency of the generic drug approval process and supporting the development of complex generic drugs, and the FDA has taken and continues to take steps to implement this plan. Moreover, both Congress and the FDA are considering various legislative and regulatory proposals focused on drug competition, including legislation focused on drug patenting and provision of drug to generic applicants for testing. For example, the Further Consolidated Appropriations Act, 2020, which incorporated the framework from the Creating and Restoring Equal Access To Equivalent Samples (CREATES) legislation, was signed into law as part of the 2019 year-end federal spending package. The legislation purports to promote competition in the market for drugs and biological products by facilitating the timely entry of lower-cost generic and biosimilar versions of those drugs and biological products, including by allowing ANDA, 505(b)(2) NDA or biosimilar developers to obtain access to branded drug and biological product samples. While the full impact of these provisions is unclear at this time, its provisions do have the potential to facilitate the development and future approval of generic versions of our products, introducing generic competition that could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Healthcare Regulatory and Other Legal Compliance Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to healthcare laws, regulations and enforcement; our failure to comply with those laws could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to federal and state healthcare laws and regulations, which laws and regulations are enforced by the federal government and the states in which we conduct our business. Should our compliance controls prove ineffective at preventing or mitigating the risk and impact of improper business conduct or inaccurate reporting, we could be subject to enforcement of the following, including, without limitation:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the federal AKS;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the FDCA and its implementing regulations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal civil and criminal false claims laws, including the civil False Claims Act, and the Civil Monetary Penalties Law;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">federal criminal laws that prohibit executing a scheme to defraud any healthcare benefit program or making false statements relating to healthcare matters;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Health Insurance Portability and Accountability Act of 1996 (HIPAA) and its implementing regulations, as amended; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state law equivalents of each of the above federal laws;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the Open Payments program of the PPACA;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and local laws and regulations that require drug manufacturers to file reports relating to marketing activities, payments and other remuneration and items of value provided to healthcare professionals and entities; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">state and federal pharmaceutical price and price reporting laws and regulations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may be subject to the Foreign Corrupt Practices Act, a U.S. law which regulates certain financial relationships with foreign government officials (which could include, for example, medical professionals employed by national healthcare programs) and its foreign equivalents, as well as federal and state consumer protection and unfair competition laws.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These federal and state healthcare laws and regulations govern drug marketing practices, including off-label promotion. If our operations are found, or even alleged, to be in violation of the laws described above or other governmental regulations that apply to us, we, or our officers or employees, may be subject to significant penalties, including administrative civil and criminal penalties, damages, fines, regulatory penalties, the curtailment or restructuring of our operations, exclusion from participation in Medicare, Medicaid and other federal and state healthcare programs, imprisonment, reputational harm, additional reporting requirements and oversight, any of which would adversely affect our ability to sell our products and operate our business and also adversely affect our financial results. Furthermore, responding to any such allegation and/or defending against any such enforcement actions can be time-consuming and would require significant financial and personnel resources. Therefore, if any state or the federal government initiates an enforcement action against us, our business may be impaired, and even if we are ultimately successful in our defense, litigating these actions could result in substantial costs and divert the attention of management.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Enhanced governmental and private scrutiny over, or investigations or litigation involving, pharmaceutical manufacturer patient assistance programs and donations to patient assistance foundations created by charitable organizations could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To help patients afford our products, we have a patient assistance program and also occasionally make donations to independent charitable foundations that help financially needy patients. These types of programs designed to assist patients with affording pharmaceuticals have become the subject of Congressional interest and enhanced government scrutiny. The U.S. Department of Health and Human Services Office of Inspector General established guidelines permitting pharmaceutical manufacturers to make donations to charitable organizations that provide co-pay assistance to Medicare patients, provided that manufacturers meet certain specified compliance requirements. In the event we make such donations but are found not to have complied with these guidelines and other laws or regulations respecting the operation of these programs, we could be subject to significant damages, fines, penalties or other criminal, civil or administrative sanctions or enforcement actions. We also rely on a third-party hub provider and exercise oversight to monitor patient assistance program activities. Hub providers are generally hired by manufacturers to assist patients with insurance coverage, financial assistance and treatment support after the patients receive a prescription from their healthcare </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">professional. For manufacturers of specialty pharmaceuticals (including our marketed products), the ability to have a single point of contact for their therapies helps ensure efficient medication distribution to patients. Accordingly, our hub activities are also subject to scrutiny and may create risk for us if not conducted appropriately. A variety of entities, including independent charitable foundations and pharmaceutical manufacturers, but not including our company, have received subpoenas from the U.S. Department of Justice and other enforcement authorities seeking information related to their patient assistance programs and support. Should we or our hub providers receive a subpoena or other process, regardless of whether we are ultimately found to have complied with the regulations governing patient assistance programs, this type of government investigation could negatively impact our business practices, harm our reputation, divert the attention of management and increase our expenses.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to laws and regulations relating to privacy, data protection and the collection and processing of personal data. Failure to maintain compliance with these regulations could create additional liabilities for us.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The legislative and regulatory landscape for privacy and data protection continues to evolve in the U.S. and other jurisdictions around the world. For example, the California Consumer Privacy Act of 2018 (CCPA) went into operation in 2020 and affords California residents expanded privacy rights and protections, including civil penalties for violations and statutory damages under a private right of action for data security breaches. These protections will be expanded by California Privacy Rights Act of 2020 (CPRA), which will be operational in most key respects on January 1, 2023. Similar legislative proposals have passed or are being advanced in other states and Congress is also considering federal privacy legislation. In addition, most healthcare professionals and facilities are subject to privacy and security requirements under HIPAA. Although we are not considered to be a covered entity or business associate under HIPAA, we could be subject to penalties if we use or disclose individually identifiable health information in a manner not authorized or permitted by HIPAA. Other countries also have, or are developing, laws governing the collection, use and transmission of personal information. For example, the EU General Data Protection Regulation 2016/679 (GDPR) regulates the processing of personal data of individuals within the EU, even if, under certain circumstances, that processing occurs outside the EU, and also places restrictions on transfers of such data to countries outside of the EU, including the U.S. Should we fail to provide adequate privacy or data security protections or maintain compliance with these laws and regulations, including the CCPA, CPRA and GDPR, we could be subject to sanctions or other penalties, litigation or an increase in our cost of doing business.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Growth of Our Product Portfolio and Research and Development</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical testing of cabozantinib for new indications, or of new product candidates, is a lengthy, costly, complex and uncertain process that may fail ultimately to demonstrate safety and efficacy data for those products sufficiently differentiated to compete in our highly competitive market environment.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are inherently risky and may reveal that cabozantinib, despite its approval for certain indications, or a new product candidate, is ineffective or has an unacceptable safety profile with respect to an intended use. Such results may significantly decrease the likelihood of regulatory approval of that product for a particular indication. Moreover, the results of preliminary studies do not necessarily predict clinical or commercial success, and late-stage or other potentially label-enabling clinical trials may fail to confirm the results observed in early-stage trials or preliminary studies. Although we have established timelines for manufacturing and clinical development of cabozantinib and our other product candidates based on existing knowledge of our compounds in development and industry metrics, we may not be able to meet those timelines.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may experience numerous unforeseen events, during or as a result of clinical investigations, that could delay or prevent commercialization of cabozantinib (or of other product candidates) in new indications, and in some cases, as described in the risk factor titled, &#8220;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth,</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; the COVID-19 pandemic has already increased and may further increase the potential for such developments to occur. These may include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lack of acceptable efficacy or a tolerable safety profile;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">negative or inconclusive clinical trial results that require us to conduct further testing or to abandon projects;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">discovery or commercialization by our competitors of other compounds or therapies that show significantly improved safety or efficacy compared to cabozantinib or our other product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to identify and maintain a sufficient number of trial sites; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">lower-than-anticipated patient registration or enrollment in our clinical testing; </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additional complexities posed by clinical trials evaluating cabozantinib or our other product candidates in combination with other therapies, including extended timelines to provide for collaboration on clinical development planning, the failure by our collaboration partners to provide us with an adequate and timely supply of product that complies with the applicable quality and regulatory requirements for a combination trial; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">failure of our third-party contract research organizations or investigators to satisfy their contractual obligations, including deviating from any trial protocols; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">withholding of authorization from regulators or institutional review boards to commence or conduct clinical trials or delays, suspensions or terminations of clinical research for various reasons, including noncompliance with regulatory requirements or a determination by these regulators and institutional review boards that participating patients are being exposed to unacceptable health risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If there are further delays in or termination of the clinical testing of cabozantinib or our other product candidates due to any of the events described above or otherwise, our expenses could increase and our ability to generate revenues could be impaired, either of which could adversely impact our financial results. Furthermore, we rely on our collaboration partners to fund a significant portion of our clinical development programs. Should one or all of our collaboration partners decline to support future planned clinical trials, we will be entirely responsible for financing the further development of the cabozantinib franchise or our other product candidates and, as a result, we may be unable to execute our current business plans, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to pursue the further development of the cabozantinib franchise or our other product candidates or meet current or future requirements of the FDA or regulatory authorities in other jurisdictions in accordance with our stated timelines or at all. Our planned clinical trials may not begin on time, or at all, may not be completed on schedule, or at all, may not be sufficient for registration of our product candidates or may not result in an approvable product. The duration and the cost of clinical trials vary significantly as a result of factors relating to the clinical trial, including, among others: characteristics of the product candidate under investigation; the number of patients who ultimately participate in the clinical trial; the duration of patient follow-up; the number of clinical sites included in the trials; and the length of time required to enroll eligible patients.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay could limit our ability to generate revenues, cause us to incur additional expense and cause the market price of our common stock to decline significantly. Our partners under our collaboration agreements may experience similar risks with respect to the compounds we have out-licensed to them. If any of the events described above were to occur with such programs or compounds, the likelihood of receipt of milestones and royalties under such collaboration agreements could decrease.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval processes of the FDA and comparable foreign regulatory authorities are lengthy and uncertain and may not result in regulatory approvals for additional cabozantinib indications or our other product candidates, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities associated with the research, development and commercialization of the cabozantinib franchise and our other product candidates are subject to extensive regulation by the FDA and other regulatory agencies in the U.S., as well as by comparable authorities in other territories. The processes of obtaining regulatory approvals in the U.S. and other foreign jurisdictions is expensive and often takes many years, if approval is obtained at all, and they can vary substantially based upon the type, complexity and novelty of the product candidates involved. For example, before an NDA or sNDA can be submitted to the FDA, or a marketing authorization application to the EMA or any application or submission to regulatory authorities in other jurisdictions, the product candidate must undergo extensive clinical trials, which can take many years and require substantial expenditures.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any clinical trial may fail to produce results satisfactory to the FDA or regulatory authorities in other jurisdictions. The FDA has substantial discretion in the approval process and may refuse to approve any NDA or sNDA or decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, we may encounter delays or rejections based upon changes in policy, which could cause delays in the approval or rejection of an application for cabozantinib or for our other product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if the FDA or a comparable authority in another jurisdiction approves cabozantinib for one or more new indications, such approval may be limited, imposing significant restrictions on the indicated uses, conditions for use, labeling, distribution, and/or production of the product and could impose requirements for post-approval studies, including additional research and clinical trials, all of which may result in significant expense and limit our and our collaboration partners&#8217; ability to commercialize cabozantinib in one or more new indications. For example, subject to ongoing discussions </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with the FDA with respect to clinical data from COSMIC-021, we intend to submit an sNDA to the FDA seeking accelerated approval of cabozantinib in an mCRPC indication in 2021. We expect that as a condition of any potential accelerated approval, the FDA will require us to perform confirmatory post-marketing clinical trials to confirm the clinical benefit, if any, of cabozantinib in combination with Roche&#8217;s atezolizumab in patients with locally advanced or metastatic solid tumors, such as mCRPC. Failure to complete post-marketing requirements of the FDA in connection with a specific approval in accordance with the timelines and conditions set forth by the FDA could significantly increase costs or delay, limit or ultimately restrict the commercialization of cabozantinib in that indication. Regulatory agencies could also impose various administrative, civil or criminal sanctions for failure to comply with regulatory requirements, including withdrawal of product approval. Further, current or any future laws or executive orders enacted or executed in response to the COVID-19 pandemic could have a material adverse impact on our business, financial condition, and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be unable to expand our development pipeline, which could limit our growth and revenue potential.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is focused on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. In this regard, we have invested in substantial technical, financial and human resources toward drug discovery activities with the goal of identifying new product candidates to advance into clinical trials. Notwithstanding this investment, many programs that initially show promise will ultimately fail to yield product candidates for multiple reasons. For example, product candidates may, on further study, be shown to have inadequate efficacy, harmful side effects, suboptimal pharmaceutical profiles or other characteristics suggesting that they are unlikely to be commercially viable products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Apart from our drug discovery efforts, our strategy to expand our development pipeline is also dependent on our ability to successfully identify and acquire or in-license relevant product candidates and technologies. However, the in-licensing and acquisition of product candidates and technologies is a highly competitive area, and many other companies are pursuing the same or similar product candidates and technologies to those that we may consider attractive. In particular, larger companies with more capital resources and more extensive clinical development and commercialization capabilities may have a competitive advantage over us. Furthermore, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We may also be unable to in-license or acquire additional product candidates and technologies on acceptable terms that would allow us to realize an appropriate return on our investment. Even if we succeed in our efforts to obtain rights to suitable product candidates and technologies, the competitive business environment may result in higher acquisition or licensing costs, and our investment in these potential products and technologies will remain subject to the inherent risks associated with the development and commercialization of new medicines. In certain circumstances, we may also be reliant on the licensor for the continued development of the in-licensed technology and their efforts to safeguard their underlying intellectual property.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to acquisitions, we may not be able to integrate the target company successfully into our existing business, maintain the key business relationships of the target company, or retain key personnel of the acquired business. Furthermore, we could assume unknown or contingent liabilities or otherwise incur unanticipated expenses. Any acquisitions or investments made by us also could result in our spending significant amounts, issuing dilutive securities, assuming or incurring significant debt obligations and contingent liabilities, incurring large one-time expenses and acquiring intangible assets that could result in significant future amortization expense and significant write-offs, any of which could harm our financial condition and results of operations. If our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities, do not result in suitable product candidates, our business and prospects for growth could suffer.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Financial Matters and Capital Requirements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our profitability could be negatively impacted if expenses associated with our extensive clinical development, business development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates, grow more quickly than the revenues we generate.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we reported net income of $96.1 million and $97.7 million for the three and six months ended June&#160;30, 2021 and $111.8 million for the year ended December&#160;31, 2020, we may not be able to maintain or increase profitability on a quarterly or annual basis, and we are unable to predict the extent of future profits or losses. The amount of our net profits or losses will depend, in part, on: the level of sales of CABOMETYX and COMETRIQ in the U.S.; our achievement of clinical, regulatory and commercial milestones, if any, under our collaboration agreements; the amount of royalties from sales of CABOMETYX and COMETRIQ outside of the U.S. under our collaboration agreements; other collaboration revenues; and the level of our expenses, including those associated with our extensive drug discovery, clinical development, business </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development and commercialization activities, both for the cabozantinib franchise and our earlier-stage product candidates. For example, we reported a net loss for the quarter ended September 30, 2020, primarily due to substantial increases in clinical trial costs, license and other collaboration costs, and personnel expenses relative to the prior fiscal quarters, and it is possible that we may experience net losses in future fiscal quarters or fiscal years, whether due to increases in costs and expenses or otherwise. We expect to continue to spend substantial amounts to fund the continued development of the cabozantinib franchise for additional indications and the commercialization of our approved products. In addition, we intend to continue to expand our oncology product pipeline through our drug discovery efforts, including research collaborations, in-licensing arrangements and other business development activities that align with our oncology drug development, regulatory and commercial expertise, which efforts could involve substantial costs. To offset these costs in the future, we will need to generate substantial revenues. If these costs exceed our current expectations, or we fail to achieve anticipated revenue targets, the market value of our common stock may decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If additional capital is not available to us when we need it, we may be unable to expand our product offerings and maintain business growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment of cash resources to CABOMETYX and the reinvestment in our product pipeline through the continued development of the cabozantinib franchise and increasing drug discovery activities, as well as through the execution of business development transactions, could require us to obtain additional capital. We may seek such additional capital through some or all of the following methods: corporate collaborations; licensing arrangements; and public or private debt or equity financings. Our ability to obtain additional capital may depend on prevailing economic conditions and financial, business and other factors beyond our control. Disruptions in the U.S. and global financial markets, including disruptions that have resulted and may continue to result from the COVID-19 pandemic and the related volatility in the U.S. and global economy, as well as future potential U.S. federal government shutdowns, rising interest rate environments, inflation rates, increased or changed tariffs and trade restrictions or otherwise, may adversely impact the availability and cost of credit, as well as our ability to raise additional funds in the capital markets. Economic and capital markets conditions have been, and continue to be, volatile. Continued instability in these market conditions may limit our ability to access the capital necessary to fund and grow our business. In particular, our inability to access additional funds, whether due to the COVID-19 pandemic or otherwise, could in the future inhibit our ability to engage in larger-scale strategic transactions or investments. We do not know whether additional capital will be available when needed, or that, if available, we will obtain additional capital on terms favorable to us or our stockholders. If we are unable to raise additional funds when we need them, we may be unable to expand our product offerings and maintain business growth, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Relationships with Third Parties</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on Ipsen and Takeda for the commercial success of CABOMETYX in its approved indications outside of the U.S., and are unable to control the amount or timing of resources expended by these collaboration partners in the commercialization of CABOMETYX in its approved indications outside of the U.S.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely upon the regulatory, commercial, medical affairs, market access and other expertise and resources of our collaboration partners, Ipsen and Takeda, for commercialization of CABOMETYX in their respective territories outside of the U.S. We cannot control the amount and timing of resources that our collaboration partners dedicate to the commercialization of CABOMETYX, or to its marketing and distribution, and our ability to generate revenues from the commercialization of CABOMETYX by our collaboration partners depends on their ability to obtain and maintain regulatory approvals for, achieve market acceptance of, and to otherwise effectively market, CABOMETYX in its approved indications in their respective territories. Further, the operations of our collaboration partners, and ultimately their sales of CABOMETYX in their respective territories outside of the U.S., could be adversely affected by the degree and effectiveness of their respective corporate responses to the COVID-19 pandemic, as well as by the imposition of governmental price or other controls, political and economic instability, trade restrictions or barriers and changes in tariffs, escalating global trade and political tensions, or other factors. If our collaboration partners are unable or unwilling to invest the resources necessary to commercialize CABOMETYX successfully in the EU, Japan and other international territories where it has been approved, this could reduce the amount of revenue we are due to receive under these collaboration agreements, thus resulting in harm to our business and operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our clinical, regulatory and commercial collaborations with major companies make us reliant on those companies for their continued performance and investments, which subjects us to a number of risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established clinical and commercial collaborations with leading biotechnology, biopharmaceutical and pharmaceutical companies for the development and commercialization of our products, and our dependence on these collaboration partners subjects us to a number of risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; decision to terminate our collaboration, or their failure to comply with the terms of our collaboration agreements and related ancillary agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our inability to control the amount and timing of resources that our collaboration partners devote to the development or commercialization of our products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may stop or delay clinical trials, fail to supply us on a timely basis with product required for a combination trial (including as a result of the COVID-19 pandemic), or deliver product that fails to meet appropriate quality and regulatory standards;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our collaboration partners that result in the delay or termination of the development or commercialization of our drug candidates, or that diminish or delay receipt of the economic benefits we are entitled to receive under the collaboration, or that result in costly litigation or arbitration;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our collaboration partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic that prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; inability to obtain regulatory approvals in a timely manner, or at all; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to comply with legal and regulatory requirements relevant to the authorization, marketing, distribution and supply of our marketed products in the territories outside the U.S. where they are approved; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our collaboration partners&#8217; failure to properly maintain or defend our intellectual property rights or their use of our intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property rights or expose us to potential litigation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not receive collaboration revenues or otherwise realize anticipated benefits from such collaborations, and our product development efforts and prospects for growth could be delayed or disrupted, all of which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our growth potential is dependent in part upon companies with which we have entered into research collaborations, in-licensing arrangements and similar business development relationships.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To expand our early-stage product pipeline, we have augmented our drug discovery activities with multiple research collaborations and in-licensing arrangements with other companies. Our dependence on our relationships with these research and in-licensing partners subjects us to numerous risks, including, but not limited to:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; decision to terminate our relationship, or their failure to comply with the terms of our agreements, either intentionally or as a result of negligent performance;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">disputes that may arise between us and our research and in-licensing partners that result in the delay or termination of research activities with respect to any in-licensed assets or supporting technology platforms;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the possibility that our research and in-licensing partners may experience financial difficulties, including, without limitation, difficulties arising from the impact of the COVID-19 pandemic, which prevent them from fulfilling their obligations under our agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to properly maintain or defend their intellectual property rights or their use of third-party intellectual property rights or proprietary information in such a way as to invite litigation that could jeopardize or invalidate our license to develop these assets or utilize technology platforms</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">laws, regulations or practices imposed by countries outside the U.S. that could impact or inhibit scientific research or the development of healthcare products by foreign competitors or otherwise disadvantage healthcare products made by foreign competitors, as well as general political or economic instability in those countries, any of which could complicate, interfere with or impede our relationships with our ex-U.S. research, development and in-licensing partners; and</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our research and in-licensing partners&#8217; failure to comply with applicable healthcare laws, as well as established guidelines, laws and regulations related to Good Manufacturing Practice and Good Laboratory Practice.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of these risks materialize, we may not be able to expand our product pipeline or otherwise realize a return on the resources we will have invested to develop these early-stage assets, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third parties upon which we rely to perform clinical trials for cabozantinib in new indications or for new product candidates do not perform as contractually required or expected, we may not be able to obtain regulatory approval for or commercialize cabozantinib or other product candidates beyond currently approved indications.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not have the ability to conduct clinical trials for cabozantinib or for new potential product candidates independently, so we rely on independent third parties for the performance of these trials, such as the U.S. federal government (including NCI-CTEP, a department of the National Institutes of Health, with whom we have our CRADA), third-party contract research organizations, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, whether as a result of the COVID-19 pandemic or otherwise, or if the third parties must be replaced or if the quality or accuracy of the data they generate or provide is compromised due to their failure to adhere to our clinical trial or data security protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or commercialize cabozantinib beyond currently approved indications or obtain regulatory approval for our other product candidates. In addition, due to the complexity of our research initiatives, we may be unable to engage with third-party contract research organizations that have the necessary experience and sophistication to help advance our drug discovery efforts, which would impede our ability to identify, develop and commercialize our potential product candidates.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We lack our own manufacturing and distribution capabilities necessary for us to produce materials required for certain preclinical activities and to produce and distribute our products for clinical development or for commercial sale, and our reliance on third parties for these services subjects us to various risks.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate manufacturing facilities, distribution facilities or resources for chemistry, manufacturing and control development activities, preclinical, clinical or commercial production and distribution for our current products and new product candidates. Instead, we rely on various third-party contract manufacturing organizations to conduct these operations on our behalf. As our operations continue to grow in these areas, we continue to expand our supply chain through secondary third-party contract manufacturers, distributors and suppliers. To establish and manage our supply chain requires a significant financial commitment, the creation of numerous third-party contractual relationships and continued oversight of these third parties to fulfill compliance with applicable regulatory requirements. Although we maintain significant resources to directly and effectively oversee the activities and relationships with the companies in our supply chain, we do not have direct control over their operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our third-party contract manufacturers may not be able to produce material on a timely basis or manufacture material with the required quality standards, or in the quantity required to meet our preclinical, clinical development and commercial needs and applicable regulatory requirements, including as a result of the COVID-19 pandemic. Although we have not yet experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers, distributors and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. If our third-party contract manufacturers, distributors and suppliers do not continue to supply us with our products or product candidates in a timely fashion and in compliance with applicable quality and regulatory requirements, or if they otherwise fail or refuse to comply with their obligations to us under our manufacturing, distribution and supply arrangements, we may not have adequate remedies for any breach. Furthermore, their failure to supply us could impair or preclude meeting commercial or clinical product supply requirements for us or our partners, which could delay product development and future commercialization efforts and have a material adverse impact on our business, financial condition and results of operations. In addition, through our third-party contract manufacturers and data service providers, we continue to provide serialized commercial products as required to comply with the Drug Supply Chain Security Act (DSCSA). If our third-party contract manufacturers or data service providers fail to support our efforts to continue to comply with DSCSA and any future federal or state electronic pedigree requirements, we may face legal penalties or be restricted from selling our products.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If third-party scientific advisors and contractors we rely on to assist with our drug discovery efforts do not perform as expected, the expansion of our product pipeline may be delayed.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We work with scientific advisors at academic and other institutions, as well as third-party contractors in various locations throughout the world, that assist us in our research and development efforts, including in drug discovery and preclinical development strategy. These third parties are not our employees and may have other commitments or contractual obligations that limit their availability to us. Although these third-party scientific advisors and contractors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. There has also been increased scrutiny surrounding the disclosures of payments made to medical researchers from companies in the pharmaceutical industry, and it is possible that the academic and other institutions that employ these medical researchers may prevent us from engaging them as scientific advisors and contractors or otherwise limit our access to these experts, or that the scientific advisors themselves may now be more reluctant to work with industry partners. Even if these scientific advisors and contractors with whom we have engaged intend to meet their contractual obligations, their ability to perform services may be impacted by external factors, as we experienced in the early stages of the COVID-19 pandemic. If we experience additional delays in the receipt of services, lose work performed by these scientific advisors and contractors or are unable to engage them in the first place, our discovery and development efforts with respect to the matters on which they were working or would work in the future may be significantly delayed or otherwise adversely affected.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Information Technology and Intellectual Property</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Data breaches, cyber-attacks and other failures in our information technology operations and infrastructure could compromise our intellectual property or other sensitive information, damage our operations and cause significant harm to our business and reputation.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we and our third-party service providers, such as contract research organizations, collect, maintain and transmit sensitive data on our networks and systems, including our intellectual property and proprietary or confidential business information (such as research data and personal information) and confidential information with respect to our customers, clinical trial patients and our collaboration partners. We have also outsourced significant elements of our information technology infrastructure to third parties and, as a result, such third parties may or could have access to our confidential information. The secure maintenance of this information is critical to our business and reputation, and while we have enhanced and are continuing to enhance our cybersecurity efforts commensurate with the growth and complexity of our business, our systems and those of third-party service providers may be vulnerable to a cyber-attack. The level of vulnerabilities that exist under normal conditions may have been exacerbated by the fact that, during the COVID-19 pandemic, the portion of our workforce operating remotely has increased, at least temporarily, and some phishing attacks are specifically designed to target remote workers. In addition, we are heavily dependent on the functioning of our information technology infrastructure to carry out our business processes, such as external and internal communications or access to clinical data and other key business information. Accordingly, both inadvertent disruptions to this infrastructure and cyber-attacks could cause us to incur significant remediation or litigation costs, result in product development delays, disrupt critical business operations, expend key information technology resources and divert the attention of management. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although the aggregate impact of cyber-attacks on our operations and financial condition has not been material to date, we and our third-party service providers have frequently been the target of threats of this nature and expect them to continue. Any data breach and/or unauthorized access or disclosure of our information or intellectual property could compromise our intellectual property and expose our sensitive business information or sensitive business information of our collaboration partners, which may lead to significant liability for us. A data security breach could also lead to public exposure of personal information of our clinical trial patients, employees or others and result in harm to our reputation and business, compel us to comply with federal and/or state breach notification laws and foreign law equivalents including the GDPR, subject us to investigations and mandatory corrective action, or otherwise subject us to liability under laws and regulations that protect the privacy and security of personal information, which could disrupt our business, result in increased costs or loss of revenue, and/or result in significant financial exposure. Furthermore, the costs of maintaining or upgrading our cybersecurity systems (including the recruitment and retention of experienced information technology professionals, who are in high demand) at the level necessary to keep up with our expanding operations and prevent against potential attacks are increasing, and despite our best efforts, our network security and data recovery measures and those of our third-party service providers may still not be adequate to protect against such security breaches and disruptions, which could cause material harm to our business, financial condition and results of operations.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to adequately protect our intellectual property, third parties may be able to use our technology, which could adversely affect our ability to compete in the market.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success will depend in part upon our ability to obtain patents and maintain adequate protection of the intellectual property related to our technologies and products. The patent positions of biopharmaceutical companies, including our patent position, are generally uncertain and involve complex legal and factual questions. We will be able to protect our intellectual property rights from unauthorized use by third parties only to the extent that our technologies are covered by valid and enforceable patents or are effectively maintained as trade secrets. We will continue to apply for patents covering our technologies and products as, where and when we deem lawful and appropriate. However, these applications may be challenged or may fail to result in issued patents. Our issued patents have been and may in the future be challenged by third parties as invalid or unenforceable under U.S. or foreign laws, or they may be infringed by third parties, and we are from time to time involved in the defense and enforcement of our patents or other intellectual property rights in a court of law, U.S. Patent and Trademark Office </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review or reexamination proceeding, foreign opposition proceeding or related legal and administrative proceeding in the U.S. and elsewhere. The costs of defending our patents or enforcing our proprietary rights in post-issuance administrative proceedings and litigation can be substantial and the outcome can be uncertain. An adverse outcome may allow third parties to use our intellectual property without a license and/or allow third parties to introduce generic and other competing products, any of which would negatively impact our business. Third parties may also attempt to invalidate or design around our patents, or assert that they are invalid or otherwise unenforceable, and seek to introduce generic versions of cabozantinib. For example, we received Paragraph IV certification notice letters from MSN and Teva concerning the respective ANDAs that each had filed with the FDA seeking approval to market their respective generic versions of CABOMETYX tablets. Should MSN, Teva or any other third parties receive FDA approval of an ANDA or a 505(b)(2) NDA with respect to cabozantinib, it is possible that such company or companies could introduce generic versions of our marketed products before our patents expire if they do not infringe our patents or if it is determined that our patents are invalid or unenforceable, and the resulting generic competition could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, because patent applications can take many years to issue, third parties may have pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our product candidates. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products. They may also be negatively impacted by the decisions of foreign courts, which could limit the protection contemplated by the original regulatory approval and our ability to thwart the development of competing products. Furthermore, others may independently develop similar or alternative technologies or design around our patents. In addition, our patents may be challenged or invalidated or may fail to provide us with any competitive advantages, if, for example, others were the first to invent or to file patent applications for closely related inventions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some foreign countries do not protect intellectual property rights to the same extent as the laws of the U.S., and many companies have encountered significant problems in protecting and defending such rights in foreign jurisdictions. Many countries, including certain countries in Europe, have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties (for example, the patent owner has failed to &#8220;work&#8221; the invention in that country or the third party has patented improvements). In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of the patent. Initiatives seeking compulsory licensing of life-saving drugs are also becoming increasingly prevalent in developing countries either through direct legislation or international initiatives. Governments in those developing countries could require that we grant compulsory licenses to allow competitors to manufacture and sell their own versions of our products or product candidates, thereby reducing our product sales. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the aggressive enforcement of patent and other intellectual property protection, which makes it difficult to stop infringement. We rely on trade secret protection for some of our confidential and proprietary information. We have taken security measures to protect our proprietary information and trade secrets, but these measures may not provide adequate protection. While we seek to protect our proprietary information by entering into confidentiality agreements with employees, partners and consultants, we cannot provide assurance that our proprietary information will not be disclosed, or that we can meaningfully protect our trade secrets. In addition, our competitors may independently develop substantially equivalent proprietary information or may otherwise gain access to our trade secrets.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation or third-party claims of intellectual property infringement could require us to spend substantial time and money and adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to avoid infringing patents and proprietary rights of third parties and not to breach any licenses that we have entered into with regard to our technologies and the technologies of third parties. Other parties have filed, and in the future are likely to file, patent applications covering products and technologies that we have developed or intend to develop. If patents covering technologies required by our operations are issued to others, we may have to obtain licenses from third parties, which may not be available on commercially reasonable terms, or at all, and may require us to pay substantial royalties, grant a cross-license to some of our patents to another patent holder or redesign the formulation of a product candidate so that we do not infringe third-party patents, which may be impossible to accomplish or could require substantial time and expense. In addition, we may be subject to claims that our employees or independent contractors have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers, or that they used or sought to use patent inventions belonging to their former employers. Furthermore, third parties may obtain patents that relate to our technologies and claim that use of such technologies infringes on their patents or otherwise employs their proprietary technology without authorization. Regardless of their merit, such claims could require us to incur substantial costs and divert the attention of management and key technical personnel in defending ourselves against any such claims or enforcing our own patents. In the event of any third party&#8217;s successful claim of patent infringement or misappropriation of trade secrets, we may lose valuable intellectual property rights or personnel, which could impede or prevent the achievement of our product development goals, or we may be required to pay damages and obtain one or more licenses from these third parties, subjecting us to substantial royalty payment obligations. We may not be able to obtain these licenses on commercially reasonable terms, or at all. Defense of any lawsuit or failure to obtain any of these licenses could adversely affect our ability to develop and commercialize products.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Operations, Managing Our Growth and Employee Matters</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the COVID-19 pandemic is further prolonged or becomes more severe, our business operations and corresponding financial results could suffer, which could have a material adverse impact on our financial condition and prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the COVID-19 pandemic has had a modest impact on our business operations, in particular with respect to our clinical trial, drug discovery and commercial activities. For example, to varying degrees and at different rates across our clinical trials, we experienced declines in screening and enrollment activity during the early days of the COVID-19 pandemic, as well as delays in new site activations and restrictions on the access to treatment sites that is necessary to monitor clinical study progress and administration. As the COVID-19 pandemic continues to have a significant presence in various parts of the world, the impact on our clinical development operations could continue or grow more severe. We anticipate that a further prolonged, or more severe, global public health crisis could limit our ability to identify and work with clinical investigators at clinical trial sites globally to enroll, initiate and maintain treatment per protocol of patients for our ongoing clinical trials. Disruptions to medical and administrative operations at clinical trial sites and the implementation of crisis management initiatives have and may continue to reduce personnel and other resources necessary to conduct our clinical trials, which could delay our clinical trial plans or require certain trials to be temporarily suspended. Moreover, quarantines and travel restrictions have impeded and may continue to impede patient movement or interrupt healthcare services, which we anticipate over time, could also interfere with and potentially negatively impact clinical trial execution, and ultimately results. In addition, increased costs connected with our efforts to mitigate the adverse impacts resulting from the COVID-19 pandemic on our clinical trials could cause the expenses we incur in conducting those clinical trials to increase considerably. Specifically, with respect to our clinical trials evaluating cabozantinib in combination with therapies that must be administered via professional intravenous infusion, such as COSMIC-312, COSMIC-313, COSMIC-021, CONTACT-01, CONTACT-02, CONTACT-03, our early-stage trials evaluating XL092, XL102 and other product candidates to the extent they may incorporate additional therapies that must be administered via professional intravenous infusion, or our early-stage trial evaluating XB002 that must be administered via professional intravenous infusion, limited patient movement or interrupted healthcare services at medical institutions have delayed in some instances, and may continue to delay or prevent, on-site infusion of XB002 or therapies being evaluated in combination with cabozantinib or our other product candidates. If a sizable portion of patients in our combination studies are unable or unwilling to receive all components of the combination therapy being tested in accordance with the applicable clinical trial protocol, it could cause those studies to be delayed, suspended or prevented from producing statistically significant results.</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the duration and severity of the COVID-19 pandemic, we could also experience delays in the commencement of new clinical trials of cabozantinib, or our earlier-stage investigative product candidates. The COVID-19 pandemic could also impede clinical operations and delay our planning and preparation timelines for new clinical trials, as well as adversely affect our ability to </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obtain regulatory approval for clinical protocols and increase the operating expenses associated with these new clinical trials.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the COVID-19 pandemic caused us to suspend drug discovery work in our laboratories temporarily while we observed the shelter in place orders issued by the State of California and Alameda County. We also experienced some modest delays with respect to the portion of drug discovery work outsourced to third-party contractors in regions first impacted by COVID-19. While both drug discovery work in our laboratories and outsourced drug discovery activities have since fully resumed, we may be unable to maximize the potential of these programs due to the imposition of increased safety protocols, and should the COVID-19 pandemic grow in severity, we may have to again scale back or suspend activities in the future. We are also reliant on laboratory materials manufactured and distributed from areas impacted by both the COVID-19 pandemic and other natural disasters, for which supply has become limited. If we are unable to obtain the requisite materials to conduct our planned drug discovery activities, we may be required to redirect the focus of, or even suspend, such activities. With respect to the preclinical development work and drug discovery activities outsourced to third-party contractors, the COVID-19 pandemic could again impede these third parties from providing timely deliverables to us in the future. Should the COVID-19 pandemic be further prolonged or grow in severity, we may ultimately be unable to achieve our drug discovery and preclinical development objectives within the previously disclosed timelines, which could have a material adverse impact on our prospects for growth.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we believe that our commercial business has, to date, only experienced a modest impact related to the COVID-19 pandemic, it remains possible that over a longer period, changes to our standard sales and marketing practices, including any shifts from in-person back to primarily telephonic and virtual interactions with healthcare professionals, could negatively impact the flow of important information regarding our medicines, which along with obstacles to patient access to healthcare professionals, could diminish sales of our marketed products.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although as of the date of this Quarterly Report on Form 10-Q, we continue to maintain substantial safety stock inventories for our drug substance and drug products and have not experienced production delays or seen significant impairment to our supply chain as a result of the COVID-19 pandemic, our third-party contract manufacturers and suppliers could experience operational delays due to facility closures and other hardships as a result of the COVID-19 pandemic, which could impact our supply chain by potentially causing delays to or disruptions in the supply of our commercial or clinical products or product candidates. These delays or disruptions could be further exacerbated if the COVID-19 pandemic begins to impact essential distribution systems, which could substantially increase delivery times and costs, or otherwise adversely affect our ability to provide our products to customers and clinical trial sites and generate product revenues. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In response to the COVID-19 pandemic, we have taken numerous precautions, some temporary and others still in place, to help mitigate the risk of transmission of the virus, including: initially reducing the number of our employees working on-site at our Alameda headquarters; maintaining enhanced safety and social distancing protocols for those employees who have returned to working on-site and initiating an on-site COVID-19 testing program; restricting non-essential business travel for our employees; and partially limiting the circumstances under which our field employees may engage in in-person promotional activities with healthcare professionals. Over a longer period, these measures could delay our research and development programs, reduce engagements with potential prescribers for our products, and impede our ability to execute on our long-term business plans. Further, extended periods of primarily remote work could impede the focused attention of management or reduce the productivity of teams that would otherwise be working closely together. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a result of broad economic shifts during and as a consequence of efforts to address unemployment and other negative economic effects of the COVID-19 pandemic, we may experience reductions in the net price of our products. For example, there may be a substantial shift from private health insurance coverage to government insurance coverage, or additional downward pressure on the prices government purchasers will pay for our products due to significant increases in government debt incurred in connection with relief efforts, as well as significant increases in demand for our patient assistance and/or free drug program or other impacts that may not be foreseeable, all or any of which would adversely affect our product revenues.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we expect the COVID-19 pandemic to continue to have varying degrees of adverse impact on our business operations and, potentially in the future, our financial results, the extent of such adverse impact will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time. Such developments include continued spread of the Delta variant in the U.S. and other countries and the potential emergence of other SARS-CoV-2 variants that may prove especially contagious or virulent, the ultimate duration of the pandemic and resulting disruptions to normal business and personal activities in the U.S. and in other countries, and the effectiveness of actions taken globally to contain and treat the disease, including the rate at which vaccinations are made available, the percentage of the </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">population that becomes vaccinated and the effectiveness of the vaccines against Delta or other SARS-CoV-2 variants. These continuing or future effects could materially and adversely affect our business, financial condition, results of operations and growth prospects, and exacerbate the other risks and uncertainties described elsewhere in this &#8216;&#8216;Risk Factors&#8217;&#8217; section.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to manage our growth, there could be a material adverse impact on our business, financial condition and results of operations, and our prospects may be adversely affected.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have experienced and expect to continue to experience growth in the number of our employees and in the scope of our operations, in particular as we continue to expand the cabozantinib franchise into new indications and grow our pipeline of product candidates. This growth places significant demands on our management and resources, and our current and planned personnel and operating practices may not be adequate to support our growth. To effectively manage our growth, we must continue to improve existing, and implement new, facilities, operational and financial systems, and procedures and controls, as well as expand, train and manage our growing employee base, and there can be no assurance that we will effectively manage our growth without experiencing operating inefficiencies or control deficiencies. We plan to increase our management personnel to oversee our expanding operations, and recruiting and retaining qualified individuals is difficult. If we are unable to manage our growth effectively, including as a result of the COVID-19 pandemic or otherwise, or we are unsuccessful in recruiting qualified management personnel, there could be a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The loss of key personnel or the inability to retain and, where necessary, attract additional personnel could impair our ability to operate and expand our operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent upon the principal members of our management, as well as clinical, commercial and scientific staff, the loss of whose services might adversely impact the achievement of our objectives. Also, we may not have sufficient personnel to execute our business plans. Retaining and, where necessary, recruiting qualified clinical, commercial, scientific and pharmaceutical operations personnel will be critical to support activities related to advancing the development program for the cabozantinib franchise and our other product candidates, successfully executing upon our commercialization plan for the cabozantinib franchise and our proprietary research and development efforts. Competition is intense for experienced clinical, commercial, scientific and pharmaceutical operations personnel, and we may be unable to retain or recruit such personnel with the expertise or experience necessary to allow us to successfully develop and commercialize our products. Similarly, the COVID-19 pandemic could negatively impact the health of key personnel or make it difficult to recruit qualified personnel for critical positions. Further, all of our employees are employed &#8220;at will&#8221; and, therefore, may leave our employment at any time.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Environmental and Product Liability</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We use hazardous chemicals and biological materials in our business. Any claims relating to improper handling, storage or disposal of these materials could be time consuming and costly.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research and development processes involve the controlled use of hazardous materials, including chemicals and biological materials, and our operations can produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge, or any resultant injury from these materials, and we may face liability under applicable laws for any injury or contamination that results from our use or the use by our collaboration partners or other third parties of these materials. Such liability may exceed our insurance coverage and our total assets, and in addition, we may be required to indemnify our collaboration partners against all damages and other liabilities arising out of our development activities or products produced in connection with our collaborations with them. Moreover, our continued compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face potential product liability exposure far in excess of our limited insurance coverage.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be held liable if any product we or our collaboration partners develop or commercialize causes injury or is found otherwise unsuitable during product testing, manufacturing, marketing or sale. Regardless of merit or eventual outcome, product liability claims could result in decreased demand for our products and product candidates, injury to our reputation, withdrawal of patients from our clinical trials, product recall, substantial monetary awards to third parties and the inability to commercialize any products that we may develop in the future. We maintain limited product liability insurance coverage for our clinical trials and commercial activities for cabozantinib. However, our insurance may not be sufficient to reimburse us for expenses or losses we may suffer. Moreover, if insurance coverage becomes more expensive, </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to liability.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our stock price has been and may in the future be highly volatile.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our common stock has been highly volatile, and it may remain highly volatile or fluctuate substantially due to factors such as the following, many of which we cannot control:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of FDA or other regulatory approval or non-approval, or delays in the FDA or other regulatory review process with respect to cabozantinib, our collaboration partners&#8217; product candidates being developed in combination with cabozantinib, or our competitors&#8217; product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the commercial performance of both CABOMETYX and COMETRIQ and the revenues we generate from those approved products, including royalties paid under our collaboration and license agreements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">adverse or inconclusive results or announcements related to our or our collaboration partners&#8217; clinical trials or delays in those clinical trials;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing of achievement of our clinical, regulatory, partnering, commercial and other milestones for the cabozantinib franchise or any of our other programs or product candidates;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to make future investments in the expansion of our pipeline through drug discovery, including future research collaborations, in-licensing arrangements and other business development activities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">our ability to obtain the materials and services, including an adequate product supply for any approved drug product, from our third-party vendors or do so at acceptable prices;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the timing and amount of expenses incurred for clinical development and manufacturing of cabozantinib;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">actions taken by regulatory agencies, both in the U.S. and abroad, with respect to cabozantinib or our clinical trials for cabozantinib; </span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">unanticipated regulatory actions taken by the FDA as a result of changing FDA standards and practices concerning the review of product candidates, including approvals at earlier stages of clinical development or with lesser developed data sets and expedited reviews;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of new products or clinical trial data by our competitors;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of regulatory applications, such as MSN&#8217;s and Teva&#8217;s respective ANDAs, seeking approval of generic versions of our marketed products;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">quarterly variations in our or our competitors&#8217; results of operations;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in our relationships with our collaboration partners, including the termination or modification of our agreements, or other events or conflicts that may affect our collaboration partners&#8217; timing and willingness to develop, or if approved, commercialize our products and product candidates out-licensed to them;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the announcement of an in-licensed product candidate or strategic acquisition;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">litigation, including intellectual property infringement and product liability lawsuits, involving us;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">changes in earnings estimates or recommendations by securities analysts, or financial guidance from our management team, and any failure to achieve the operating results projected by securities analysts or by our management team;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the entry into new financing arrangements;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">developments in the biotechnology, biopharmaceutical or pharmaceutical industry;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">sales of large blocks of our common stock or sales of our common stock by our executive officers, directors and significant stockholders;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">additions and departures of key personnel or board members;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the disposition of any of our technologies or compounds; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">general market, economic and political conditions and other factors, including factors unrelated to our operating performance or the operating performance of our competitors, such as the impact of the COVID-19 pandemic on financial markets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These and other factors could have material adverse impact on the market price of our common stock. In addition, the stock markets in general, and the markets for biotechnology and pharmaceutical stocks in particular, have historically </span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">experienced significant volatility that has often been unrelated or disproportionate to the operating performance of particular companies. Likewise, as a result of significant changes in U.S. or global political and economic conditions, including the effects of the COVID-19 pandemic, policies governing foreign trade and healthcare spending and delivery, or future potential U.S. federal government shutdowns, the financial markets could continue to experience significant volatility that could also continue to negatively impact the markets for biotechnology and pharmaceutical stocks. These broad market fluctuations have adversely affected and may in the future adversely affect the trading price of our common stock. Excessive volatility may continue for an extended period of time following the date of this report.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past, following periods of volatility in the market price of a company&#8217;s securities, securities class action litigation has often been instituted. A securities class action suit against us could result in substantial costs and divert the attention of management, which could have a material adverse impact on our business, financial condition and results of operations.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent or deter attempts by our stockholders to replace or remove our current management, which could cause the market price of our common stock to decline.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our corporate charter and bylaws may discourage, delay or prevent an acquisition of us, a change in control, or attempts by our stockholders to replace or remove members of our current Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. These provisions include:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">a prohibition on actions by our stockholders by written consent;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">the ability of our Board of Directors to issue preferred stock without stockholder approval, which could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our Board of Directors; and</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">advance notice requirements for director nominations and stockholder proposals.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_100"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Unregistered Sales of Equity Securities and Use of Proceeds&#160;&#160;&#160;&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_103"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Defaults Upon Senior Securities</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_106"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div id="i164d1fcc16004d86847619b30cbdc0ba_109"></div><div style="margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Other Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_112"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="-sec-extract:summary;margin-top:15pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. Exhibits</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.404%"><tr><td style="width:1.0%"></td><td style="width:8.480%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:30.187%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.828%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.548%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.833%"></td><td style="width:0.1%"></td></tr><tr style="height:14pt"><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit Description</span></div></td><td colspan="3" rowspan="2" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incorporation by Reference</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" rowspan="2" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filed</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Herewith</span></div></td></tr><tr style="height:32pt"><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Form</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">File Number</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exhibit/</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Appendix</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Reference</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Filing Date</span></div></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210526ex31restatedce.htm">Restated Certificate of Incorporation of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/939767/000093976721000028/exhibit31amendedandrestate.htm">Amended and Restated Bylaws of Exelixis, Inc.</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8-K</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">000-30235</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3/3/2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit41exel20210630sto.htm">Specimen Common Stock Certificate</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.1</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210630exhibit311.htm">Certification of Principal Executive Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31.2</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210630exhibit312.htm">Certification of Principal Financial Officer Pursuant to Exchange Act Rules 13a-14(a) and Rule 15d-14(a)</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exel20210630exhibit321.htm">Certifications of Principal Executive Officer and Principal Financial Officer Pursuant to 18 U.S.C. Section 1350</a></span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.INS</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The XBRL instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">X</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cover Page Interactive Data File</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Formatted as Inline XBRL and contained in Exhibit 101.</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:4.852%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:92.948%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8225;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">This certification accompanies this Quarterly Report on Form 10-Q, is not deemed filed with the SEC and is not to be incorporated by reference into any filing of Exelixis, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of this Quarterly Report on Form 10-Q), irrespective of any general incorporation language contained in such filing. </span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><div id="i164d1fcc16004d86847619b30cbdc0ba_115"></div><hr style="page-break-after:always"/><div style="min-height:54pt;width:100%"><div style="margin-top:15pt"><span style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="color:#0000ff;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:120%;text-decoration:underline" href="#i164d1fcc16004d86847619b30cbdc0ba_7">Table of Contents</a></span></div></div><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.&#160;</span></div><div style="margin-top:5pt;text-align:right;text-indent:36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:71.428%"><tr><td style="width:1.0%"></td><td style="width:26.608%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:7.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:54.526%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">E</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">XELIXIS, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">I</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">NC.</span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">August 5, 2021</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Christopher J. Senner</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief&#160;Financial&#160;Officer </span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">(Duly Authorized Officer and Principal Financial and Accounting Officer)</span></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-top:9pt;text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-3.1
<SEQUENCE>2
<FILENAME>exel20210526ex31restatedce.htm
<DESCRIPTION>EX-3.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i1a3b0d80f2d548fc96762dba497dddb3_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="margin-bottom:6pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXELIXIS, INC.</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Exelixis, Inc., a Delaware corporation, hereby certifies that&#58;</font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.&#160;&#160;&#160;&#160;The present name of the corporation is Exelixis, Inc. The corporation was incorporated under the name &#34;Exelixis Pharmaceuticals, Inc.&#8221; by filing its original Certificate of Incorporation with the Secretary of State of the State of Delaware on November 15, 1994. </font></div><div style="margin-bottom:12pt;padding-right:0.7pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.&#160;&#160;&#160;&#160;Attached hereto as </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit &#34;A&#34;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> is the Restated Certificate of Incorporation of the corporation, which only restates and integrates and does not further amend </font><font style="background-color:#ffffff;color:#333333;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(except as permitted under &#167;242(a)(1) and &#167;242(b)(1) of the Delaware General Corporation Law)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> the provisions of the Certificate of Incorporation of this corporation as previously amended or supplemented.  There is no discrepancy between the provisions of the Certificate of Incorporation of this corporation as previously amended or supplemented and the provisions of this Restated Certificate of Incorporation.  This Restated Certificate of Incorporation has been duly adopted by the corporation's Board of Directors in accordance with Section 245 of the Delaware General Corporation Law.  The Certificate of Incorporation of the corporation is hereby integrated and restated to read in its entirety as set forth in Exhibit A.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, said corporation has caused this Restated Certificate of Incorporation to be signed by its duly authorized officer on this 26th day of May, 2021.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Exelixis, Inc.</font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-252pt"><font><br></font></div><div style="margin-bottom:12pt;padding-left:252pt;text-indent:-252pt"><font><br></font></div><div style="margin-bottom:18pt;padding-left:252pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">By&#58; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">&#47;s&#47; Michael M. Morrissey&#160;&#160;&#160;&#160;<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">       Michael M. Morrissey<br>       President and Chief Executive Officer </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><div id="i1a3b0d80f2d548fc96762dba497dddb3_4"></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div></div><div style="margin-bottom:12pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">EXHIBIT &#34;A&#34;</font></div><div style="margin-bottom:12pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> RESTATED CERTIFICATE OF INCORPORATION</font></div><div style="padding-left:0.75pt;padding-right:0.75pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">OF</font></div><div style="margin-bottom:12pt;margin-top:6pt;padding-left:0.72pt;padding-right:0.72pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">EXELIXIS, INC.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The name of the Corporation is Exelixis, Inc. (the &#8220;Corporation&#8221;).</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The address of the registered office of the Corporation in the State of Delaware is&#58;  251 Little Falls Drive, in the City of Wilmington, County of New Castle, 19808.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The name of the registered agent of the Corporation at such address is Corporation Service Company.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of the Corporation is to engage in any lawful act or activity for which corporations may be organized under the General Corporation Law of the State of Delaware.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Classes of Stock.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Corporation is authorized to issue two classes of stock to be designated, respectively, &#8220;Common Stock&#8221; and &#8220;Preferred Stock.&#8221; The total number of shares which this Corporation is authorized to issue is four hundred and ten million (410,000,000)&#160;shares. Four hundred million (400,000,000)&#160;shares shall be Common Stock, each having a par value of one-tenth of one cent ($0.001). Ten million (10,000,000)&#160;shares shall be Preferred Stock, each having a par value of one-tenth of one cent ($0.001).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preferred Stock.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Preferred Stock may be issued from time to time in one or more series. The Board of Directors is hereby authorized, by filing a certificate (a &#8220;Preferred Stock Designation&#8221;) pursuant to the Delaware General Corporation Law (&#8220;DGCL&#8221;), to fix or alter from time to time the designation, powers, preferences, and rights of the shares of each such series and the qualifications, limitations or restrictions of any wholly unissued series of Preferred Stock, and to establish from time to time the number of shares constituting any such series or any of them&#59; and to increase or decrease the number of shares of any series subsequent to the issuance of shares of that series, but not below the number of shares of such series then outstanding. In case the number of shares of any series shall be decreased in accordance with the foregoing sentence, the shares constituting such decrease shall resume the status that they had prior to adoption of the resolution originally fixing the number of shares of such series.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Board of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  For the management of the business and the conduct of the affairs of the Corporation, and in further definition, limitation and regulation of the powers of the </font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Corporation, of its directors and of its stockholders or any class thereof, as the case may be, it is further provided that&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Powers</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The management of the business and the conduct of the affairs of the Corporation shall be vested in its Board of Directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Number of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The number of directors which shall constitute the whole Board of Directors shall be fixed exclusively by one or more resolutions adopted by the Board of Directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">Election of Directors.&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances and the remaining provisions of this section 3, until the Corporation&#8217;s 2020 annual meeting of stockholders, the directors shall be divided into three classes designated as Class I, Class II and Class III, respectively.&#160;At each annual meeting of stockholders held following the closing of the initial public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale of Common Stock to the public (the Initial Public Offering) and prior to or at the Corporation&#8217;s 2019 annual meeting of stockholders, each director was elected for a three year term, expiring at the third annual meeting of stockholders following his or her election. Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the term of each director then in office shall expire at the Corporation&#8217;s 2020 annual meeting of stockholders, notwithstanding that such director may have been elected for a term that extended beyond the date of such annual meeting.&#160;Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, commencing at the Corporation&#8217;s 2020 annual meeting of stockholders, each director elected at such meeting and at each annual meeting of stockholders thereafter to succeed those directors whose terms then expire shall be elected for a term expiring at the next annual meeting of stockholders following their election.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Notwithstanding the foregoing provisions of this section, each director shall serve until his or her successor is duly elected and qualified or until his or her death, resignation or removal. No decrease in the number of directors constituting the Board of Directors shall shorten the term of any incumbent director.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Removal of Directors</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Subject to the rights of the holders of any series of Preferred Stock then outstanding, any director or the entire Board of Directors may be removed by the holders of a majority of the shares then entitled to vote at an election of directors.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5. </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Vacancies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">a.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Subject to the rights of the holders of any series of Preferred Stock, any vacancies on the Board of Directors resulting from death, resignation, disqualification, removal or other causes and any newly created directorships resulting from any increase in the number of directors, shall, unless the Board of Directors determines by resolution that any such vacancies or newly created directorships shall be filled by the stockholders, except as otherwise provided by law, be filled only by the affirmative vote of a majority of the directors then in office, even though less than a quorum of the Board of Directors, and not by the stockholders. Any director elected in accordance with the preceding sentence shall hold office for the remainder of the full term of the director for which the vacancy was created or occurred and until such director&#8217;s successor shall have been elected and qualified.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">b.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;If at the time of filling any vacancy or any newly created directorship, the directors then in office shall constitute less than a majority of the whole board (as constituted immediately prior to any such increase), the Delaware Court of Chancery may, upon application of any stockholder or stockholders holding at least ten percent (10%)&#160;of the total number of the shares at the time outstanding having the right to vote for such directors, summarily order an election to be held to fill any such vacancies or newly created directorships, or to replace the directors chosen by the directors then in offices as aforesaid, which election shall be governed by Section&#160;211 of the DGCL.</font></div><div style="margin-bottom:12pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Bylaw Amendments</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Subject to paragraph (h)&#160;of Section&#160;43 of the Bylaws, the Bylaws may be altered or amended or new Bylaws adopted by the affirmative vote of at least sixty-six and two-thirds percent (66-2&#47;3%) of the voting power of all of the then-outstanding shares of the voting stock of the corporation entitled to vote. The Board of Directors shall also have the power to adopt, amend, or repeal Bylaws.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Election of Directors by Written Ballot</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The directors of the corporation need not be elected by written ballot unless the Bylaws so provide.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Action by Written Consent of the Stockholders</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No action shall be taken by the stockholders of the corporation except at an annual or special meeting of stockholders called in accordance with the Bylaws or by written consent of stockholders in accordance with the Bylaws prior to the closing of the Initial Public Offering and following the closing of the Initial Public Offering no action shall be taken by the stockholders by written consent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Notice of Meetings</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the corporation shall be given in the manner provided in the Bylaws of the corporation.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Indemnification</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  A director of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability (i)&#160;for any breach of the director&#8217;s duty of loyalty to the Corporation or its stockholders, (ii)&#160;for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii)&#160;under Section&#160;174 of the Delaware General Corporation Law, or (iv)&#160;for any transaction from which the director derived an improper personal benefit. If the Delaware General Corporation Law is amended after approval by the stockholders of this Article to authorize corporate action further eliminating or limiting the personal liability of directors, then the liability of a director shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Amendments to Articles VII of the Certificate of Incorporation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Any repeal or modification of this Article VI shall be prospective and shall not affect the rights under this Article VI in effect at the time of the alleged occurrence of any act or omission to act giving rise to liability or indemnification.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div><hr style="page-break-after:always"><div style="min-height:57.6pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Courier New',monospace;font-size:10pt;font-weight:700;line-height:120%">Exhibit 3.1</font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A. &#160;&#160;&#160;&#160;Amendments to Certificate of Incorporation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The Corporation reserves the right to amend, alter, change or repeal any provision contained in this Certificate of Incorporation, in the manner now or hereafter prescribed by statute, except as provided in paragraph B. of this Article VIII, and all rights conferred upon the stockholders herein are granted subject to this reservation.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B. &#160;&#160;&#160;&#160;Amendments to Articles V, VI, and VII of the Certificate of Incorporation</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provisions of this Certificate of Incorporation or any provision of law which might otherwise permit a lesser vote or no vote, but in addition to any affirmative vote of the holders of any particular class or series of the voting stock required by law, this Certificate of Incorporation or any Preferred Stock Designation, the affirmative vote of the holders of at least sixty-six and two-thirds percent (66-2&#47;3%) of the voting power of all of the then-outstanding shares of the voting stock, voting together as a single class, shall be required to alter, amend or repeal Articles V, VI, VII and VIII.</font></div><div style="height:57.6pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div><div><font><br></font></div><div><img alt="image_0a.jpg" src="image_0a.jpg" style="height:26px;margin-bottom:5pt;vertical-align:text-bottom;width:268px"></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>exhibit41exel20210630sto.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit41exel20210630sto</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1365;"><!-- exhibit41exel20210630sto001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit41exel20210630sto001.jpg" title="slide1" width="1365" height="829">
<DIV><FONT size="1" style="font-size:1pt;color:white">THIS CERTIFIES THAT is the owner of CUSIP DATED  COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER&#8200;AGENT AND&#8200;REGISTRAR, FULLY PAID AND NONASSESSABLE SHARES OF COMMON STOCK, $.001 PAR VALUE, OF  EXELIXIS, INC. transferable on the books of the Corporation by the holder hereof in person or by duly authorized attorney upon surrender of this certificate properly endorsed. This certificate is not valid until countersigned by the Transfer Agent and registered by the Registrar. WITNESS the facsimile seal of the Corporation and the facsimile signatures of its duly authorized officers.  COMMON STOCK PAR VALUE $0.001 COMMON STOCK SEE REVERSE FOR CERTAIN DEFINITIONS Certificate Number Shares . EXELIXIS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE  President and Chief Executive Officer Senior Vice President, Corporate Legal Affairs and Secretary By AUTHORIZED&#8200;SIGNATURE NOVEMBER, 1994 DELAWARE C ORPORATE E XELIXIS, INC . ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# 30161Q 10 4 DD-MMM-YYYY * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * * * * * * * * 0 0 0 0 0 0 * * * * * * * * * * * * * * ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample **** Mr. Sample **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares*** *000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** 000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0 00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00 0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000 000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00000 0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000 **Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000* *Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000** Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S * *ZERO&#8200;HUNDRED THOUSAND ZERO HUNDRED AND ZERO** MR. SAMPLE &amp; MRS  SAMPLE &amp; MR. A PLE &amp; MRS. SAMPLE ZQ00000000 Certificate Num bers 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Total Transaction Num /No. 123456 Denom . 123456 Total 1234567 MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 PO BOX 505006, Louisville, KY 40233-5006 CUSIP/IDENTIFIER  XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value  1,000,000.00 Num ber of Shares 123456 DTC 12345678  123456789012345 THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT www.computershare.com SPECIFMEN Exhibit 4.1 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit41exel20210630sto002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit41exel20210630sto002.jpg" title="slide2" width="829" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">The IRS requires that the named transfer agent (&#8220;we&#8221;) report the cost basis of certain shares or units acquired after January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested.  If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis.  If you do not keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state. For value received, ____________________________hereby sell, assign and transfer unto ________________________________________________________________________________________________________________________________ ________________________________________________________________________________________________________________________________ ________________________________________________________________________________________________________________________________ _______________________________________________________________________________________________________________________ Shares _______________________________________________________________________________________________________________________ Attorney Dated:  __________________________________________20__________________ Signature: ____________________________________________________________ Signature: ____________________________________________________________ Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint to transfer the said stock on the books of the within-named Company with full power of substitution in the premises. . EXELIXIS, INC. Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT  - ............................................Custodian ................................................ (Cust) (Minor) TEN ENT   - as tenants by the entireties under Uniform Gifts to Minors Act ........................................................ (State) JT TEN      - as joint tenants with right of survivorship UNIF&#8200;TRF MIN ACT   - ............................................Custodian (until age ................................) and not as tenants in common (Cust)      .............................under Uniform Transfers to Minors Act ................... (Minor) (State) Additional abbreviations may also be used though not in the above list. SPEC ME </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>4
<FILENAME>exel20210630exhibit311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i0e630d8567f443b48d9fd09e1a1b3431_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Michael M. Morrissey, Ph.D., certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160; Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>5
<FILENAME>exel20210630exhibit312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="ie48b805839b74fe5aa7a7694a19e59d8_1"></div><div style="min-height:54pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXCHANGE ACT RULES 13a-14(a) and 15d-14(a),</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Christopher J. Senner, certify that&#58;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Form 10-Q of Exelixis, Inc.&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and</font></div><div style="margin-top:9pt;padding-left:18pt;text-indent:-9pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:5pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt;text-align:right"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.601%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="margin-top:4pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; August&#160;5, 2021 </font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>6
<FILENAME>exel20210630exhibit321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2021 Workiva -->
<title>Document</title></head><body><div id="i15f25d0233a0416bb109fe0674b1e36b_1"></div><div style="min-height:49.5pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:9pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michael M. Morrissey, Ph.D., the President and Chief Executive Officer of Exelixis, Inc. (the &#8220;Company&#8221;), and Christopher J. Senner, the Executive Vice President and Chief Financial Officer of the Company, each hereby certifies that, to the best of his knowledge&#58;</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   1.&#160;&#160;&#160;&#160;The Company&#8217;s Quarterly Report on Form 10-Q for the period ended July&#160;2, 2021, to which this Certification is attached as Exhibit 32.1 (the &#8220;Report&#8221;), fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d) of the Securities Exchange Act of 1934, as amended&#59; and</font></div><div style="margin-top:5pt;padding-left:54pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">   2. &#160;&#160;&#160;&#160;The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="margin-top:9pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In Witness Whereof, the undersigned have set their hands hereto as of the 5th day of August 2021.</font></div><div style="text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:43.410%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.241%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.618%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.413%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47; Christopher J. Senner</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Michael M. Morrissey, Ph.D.</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Christopher J. Senner</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer<br>(Principal Executive Officer)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Executive Vice President and Chief Financial Officer<br>(Principal Financial Officer)</font></td></tr></table></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>7
<FILENAME>exel-20210702.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:exel="http://www.exelixis.com/20210702" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.exelixis.com/20210702">
  <xs:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xs:import namespace="http://www.w3.org/1999/xlink" schemaLocation="http://www.xbrl.org/2003/xlink-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2021" schemaLocation="https://xbrl.sec.gov/dei/2021/dei-2021.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210702_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210702_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210702_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="exel-20210702_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.exelixis.com/role/CoverPage">
        <link:definition>0001001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheets" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets">
        <link:definition>1001002 - Statement - Condensed Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedBalanceSheetsParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical">
        <link:definition>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome">
        <link:definition>1003004 - Statement - Condensed Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncome" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome">
        <link:definition>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical">
        <link:definition>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofStockholdersEquity" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity">
        <link:definition>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CondensedConsolidatedStatementsofCashFlows" roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows">
        <link:definition>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies">
        <link:definition>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OrganizationandSummaryofSignificantAccountingPoliciesDetails" roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails">
        <link:definition>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Revenues" roleURI="http://www.exelixis.com/role/Revenues">
        <link:definition>2104102 - Disclosure - Revenues</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesTables" roleURI="http://www.exelixis.com/role/RevenuesTables">
        <link:definition>2305301 - Disclosure - Revenues (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesbyDisaggregatedCategoryDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails">
        <link:definition>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
        <link:definition>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
        <link:definition>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesNetProductRevenuesDisaggregatedbyProductDetails" roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
        <link:definition>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
        <link:definition>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenuesContractAssetsandLiabilitiesDetails" roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails">
        <link:definition>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities">
        <link:definition>2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables">
        <link:definition>2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
        <link:definition>2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
        <link:definition>2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
        <link:definition>2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
        <link:definition>2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails">
        <link:definition>2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
        <link:definition>2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails">
        <link:definition>2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestments" roleURI="http://www.exelixis.com/role/CashandInvestments">
        <link:definition>2121104 - Disclosure - Cash and Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsTables" roleURI="http://www.exelixis.com/role/CashandInvestmentsTables">
        <link:definition>2322303 - Disclosure - Cash and Investments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails">
        <link:definition>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsNarrativeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails">
        <link:definition>2424416 - Disclosure - Cash and Investments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsInvestmentsbySecurityTypeDetails_1" roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1">
        <link:definition>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
        <link:definition>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails">
        <link:definition>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.exelixis.com/role/FairValueMeasurements">
        <link:definition>2128105 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables">
        <link:definition>2329304 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails">
        <link:definition>2430420 - Disclosure - Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsNarrativesDetails" roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails">
        <link:definition>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventory" roleURI="http://www.exelixis.com/role/Inventory">
        <link:definition>2132106 - Disclosure - Inventory</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryTables" roleURI="http://www.exelixis.com/role/InventoryTables">
        <link:definition>2333305 - Disclosure - Inventory (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoryDetails" roleURI="http://www.exelixis.com/role/InventoryDetails">
        <link:definition>2434422 - Disclosure - Inventory (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensation" roleURI="http://www.exelixis.com/role/StockBasedCompensation">
        <link:definition>2135107 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationTables" roleURI="http://www.exelixis.com/role/StockBasedCompensationTables">
        <link:definition>2336306 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
        <link:definition>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationBasedCompensationExpenseDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails">
        <link:definition>2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationNarrativeDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails">
        <link:definition>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="StockBasedCompensationEstimateGrantDateFairValueDetails" roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails">
        <link:definition>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxes" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes">
        <link:definition>2141108 - Disclosure - Provision For Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ProvisionForIncomeTaxesDetails" roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails">
        <link:definition>2442427 - Disclosure - Provision For Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShare" roleURI="http://www.exelixis.com/role/NetIncomePerShare">
        <link:definition>2143109 - Disclosure - Net Income Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareTables" roleURI="http://www.exelixis.com/role/NetIncomePerShareTables">
        <link:definition>2344307 - Disclosure - Net Income Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails">
        <link:definition>2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
        <link:definition>2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.exelixis.com/role/CommitmentsandContingencies">
        <link:definition>2147110 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" abstract="false" name="RightOfUseAssetObtainedInExchangeForLeaseLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" abstract="false" name="ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofCVSHealthCorporationMember" abstract="true" name="AffiliatesofCVSHealthCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_OtherLongtermAssetsMember" abstract="true" name="OtherLongtermAssetsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithIpsenMember" abstract="true" name="CollaborativeArrangementwithIpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedClinicalLiabilitiesCurrent" abstract="false" name="AccruedClinicalLiabilitiesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductGrossMember" abstract="true" name="ProductGrossMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_GlaxoSmithKlineMember" abstract="true" name="GlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" abstract="false" name="UnsettledInvestmentPurchasesIncurredButNotYetPaid" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ResultingFromDiscoveryEffortsMember" abstract="true" name="ResultingFromDiscoveryEffortsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" abstract="false" name="ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_AssetAcquisitionPaymentUponClosingOfTransaction" abstract="false" name="AssetAcquisitionPaymentUponClosingOfTransaction" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" abstract="false" name="SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" abstract="true" name="ValuationAllowancesAndReservesAdditionsToProvisionAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="exel_CometriqMember" abstract="true" name="CometriqMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsUpfrontPayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborationMember" abstract="true" name="CollaborationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_TakedaMember" abstract="true" name="TakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="exel_CotellicMember" abstract="true" name="CotellicMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementIncomeLossFromAgreement" abstract="false" name="CollaborativeArrangementIncomeLossFromAgreement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_OrganizationAndSummaryOfSignificantPoliciesTable" abstract="true" name="OrganizationAndSummaryOfSignificantPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" abstract="true" name="CollaborativeAgreementWithGamaMabsPharmaSAMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementswithGlaxoSmithKlineMember" abstract="true" name="CollaborativeArrangementswithGlaxoSmithKlineMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" abstract="false" name="CollaborationAgreementPercentOfRoyaltyOnNetSale" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="exel_NoncashLeaseExpense" abstract="false" name="NoncashLeaseExpense" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofMcKessonCorporationMember" abstract="true" name="AffiliatesofMcKessonCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_NumberofProductsinCommercialMarket" abstract="false" name="NumberofProductsinCommercialMarket" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithGenentechMember" abstract="true" name="CollaborativeArrangementwithGenentechMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" abstract="false" name="CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" abstract="false" name="CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesOfAmerisourceBergenCorporationMember" abstract="true" name="AffiliatesOfAmerisourceBergenCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AffiliatesofOptumSpecialtyPharmacyMember" abstract="true" name="AffiliatesofOptumSpecialtyPharmacyMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CabometyxMember" abstract="true" name="CabometyxMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AllowanceForProductRebatesMember" abstract="true" name="AllowanceForProductRebatesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AccruedCollaborationLiabilityCurrent" abstract="false" name="AccruedCollaborationLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" abstract="true" name="AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_IpsenMember" abstract="true" name="IpsenMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" abstract="false" name="CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ChargebacksAndDiscountsForPromptPaymentMember" abstract="true" name="ChargebacksAndDiscountsForPromptPaymentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ProductsDerivedFromOtherCompoundsMember" abstract="true" name="ProductsDerivedFromOtherCompoundsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" abstract="false" name="CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ProductSalesDiscountsAndAllowancesMember" abstract="true" name="ProductSalesDiscountsAndAllowancesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_AccredoHealthIncorporatedMember" abstract="true" name="AccredoHealthIncorporatedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" abstract="false" name="ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="exel_CollaborativeArrangementwithTakedaMember" abstract="true" name="CollaborativeArrangementwithTakedaMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>8
<FILENAME>exel-20210702_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_dc3374b8-b0ab-4cc4-8f75-3b2cd37beddd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_us-gaap_AccountsPayableCurrent_dc3374b8-b0ab-4cc4-8f75-3b2cd37beddd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_26feec7e-1db2-4a58-b46f-67f5b506e381" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_26feec7e-1db2-4a58-b46f-67f5b506e381" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_f2a5cd3e-6cf0-43e4-95f1-e863c11f0c49" xlink:href="exel-20210702.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_f2a5cd3e-6cf0-43e4-95f1-e863c11f0c49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_b987f34b-08fe-404d-9e48-b4b5c9be7c42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_b987f34b-08fe-404d-9e48-b4b5c9be7c42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_71734e67-75d3-42ec-818c-52caefee8c43" xlink:href="exel-20210702.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_71734e67-75d3-42ec-818c-52caefee8c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39a3d1a1-9dd6-4c23-86f0-7cd72ffdaa87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_18fef1e3-c8a5-4d42-a9b4-4f39e6ba68c6" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_39a3d1a1-9dd6-4c23-86f0-7cd72ffdaa87" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_4da1bfa2-8f4d-40e2-8736-15478a6dd62a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_56457f5e-562e-4e18-8412-9fc72a12238c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4da1bfa2-8f4d-40e2-8736-15478a6dd62a" xlink:to="loc_us-gaap_Liabilities_56457f5e-562e-4e18-8412-9fc72a12238c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_a2361903-e96f-4703-88ec-5dcf9f6650d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4da1bfa2-8f4d-40e2-8736-15478a6dd62a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_a2361903-e96f-4703-88ec-5dcf9f6650d3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a37b6832-4d29-4dad-ab1d-bab43c1d7b5a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_4da1bfa2-8f4d-40e2-8736-15478a6dd62a" xlink:to="loc_us-gaap_StockholdersEquity_a37b6832-4d29-4dad-ab1d-bab43c1d7b5a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_f917938c-0f13-459e-b8ac-01119ba3d0e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:to="loc_us-gaap_ShortTermInvestments_f917938c-0f13-459e-b8ac-01119ba3d0e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_8112e25f-bfb1-41da-aa1c-ba93389a5cbb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:to="loc_us-gaap_ReceivablesNetCurrent_8112e25f-bfb1-41da-aa1c-ba93389a5cbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_2d4682db-eb3f-4142-a5cc-9213db3fbb93" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:to="loc_us-gaap_InventoryNet_2d4682db-eb3f-4142-a5cc-9213db3fbb93" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a0ff71d-87c6-47ca-bda1-c06eea1b1d06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9a0ff71d-87c6-47ca-bda1-c06eea1b1d06" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_91138aa2-a5d1-4b59-94e3-aa710abb3f26" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_58879513-2560-4d71-bef3-2e0df0086d23" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_91138aa2-a5d1-4b59-94e3-aa710abb3f26" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_87affb84-c64e-4ae6-a91b-d27790497173" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:to="loc_us-gaap_PreferredStockValue_87affb84-c64e-4ae6-a91b-d27790497173" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_63f47fd2-25b5-43b4-b2c1-992508c63c95" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:to="loc_us-gaap_CommonStockValue_63f47fd2-25b5-43b4-b2c1-992508c63c95" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_c098ce17-25a9-4892-b2fb-887af6dff82c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_c098ce17-25a9-4892-b2fb-887af6dff82c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d0d98d0-5a65-47ed-9439-444926d1b638" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_9d0d98d0-5a65-47ed-9439-444926d1b638" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94a51c9-312e-414e-8474-7a6b693d700b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_f4804218-16d5-4cf2-8063-ac7887634c6c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_b94a51c9-312e-414e-8474-7a6b693d700b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_f9b8d353-bdb2-4d45-b14c-58091787d33e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_AssetsCurrent_f9b8d353-bdb2-4d45-b14c-58091787d33e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_f0b1fcb9-2b24-4382-8e31-f8b44f43c7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_LongTermInvestments_f0b1fcb9-2b24-4382-8e31-f8b44f43c7a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_05cea34f-89d4-4369-9974-28217444748d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_05cea34f-89d4-4369-9974-28217444748d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_6761c971-0f5c-43d4-9569-d20072429a04" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_6761c971-0f5c-43d4-9569-d20072429a04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_80040419-0152-4a23-9513-c40e16d35757" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_Goodwill_80040419-0152-4a23-9513-c40e16d35757" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_d786f83b-316c-495d-b5a6-ee66160f70d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17904e92-27f0-407d-9091-514e85307cdc" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_d786f83b-316c-495d-b5a6-ee66160f70d4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_7a50400e-9f77-4d0e-a7ff-7014d8d271ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_8c658e72-f83b-43d0-9742-cb8c1b186a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7a50400e-9f77-4d0e-a7ff-7014d8d271ca" xlink:to="loc_us-gaap_LiabilitiesCurrent_8c658e72-f83b-43d0-9742-cb8c1b186a45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d96bb6e5-8fd7-4252-b998-c9e28066c437" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7a50400e-9f77-4d0e-a7ff-7014d8d271ca" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_d96bb6e5-8fd7-4252-b998-c9e28066c437" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a180d22-18f5-4ed1-92a3-d429124d1aef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7a50400e-9f77-4d0e-a7ff-7014d8d271ca" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_0a180d22-18f5-4ed1-92a3-d429124d1aef" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_e95832bc-644b-4f18-94cf-81dcfa0c8606" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_7a50400e-9f77-4d0e-a7ff-7014d8d271ca" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_e95832bc-644b-4f18-94cf-81dcfa0c8606" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_98a083b1-66c7-4b00-9fff-5050b2b80ac1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_fdff63e7-498c-4c21-907a-eb14c3ee5861" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_98a083b1-66c7-4b00-9fff-5050b2b80ac1" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_fdff63e7-498c-4c21-907a-eb14c3ee5861" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_e61aed80-b548-4d67-8c4f-30d20c7249f5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_98a083b1-66c7-4b00-9fff-5050b2b80ac1" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_e61aed80-b548-4d67-8c4f-30d20c7249f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a7eb86c-7116-4e25-912c-4070b66d70ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses_98a083b1-66c7-4b00-9fff-5050b2b80ac1" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7a7eb86c-7116-4e25-912c-4070b66d70ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_effcf74b-1629-4860-bec5-2007d1fc7477" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_8679ef28-6b6f-40d0-807b-9268c262b49d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_effcf74b-1629-4860-bec5-2007d1fc7477" xlink:to="loc_us-gaap_CostsAndExpenses_8679ef28-6b6f-40d0-807b-9268c262b49d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d33d595-23bb-4396-98c9-5c5230637c01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_effcf74b-1629-4860-bec5-2007d1fc7477" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_6d33d595-23bb-4396-98c9-5c5230637c01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_04617567-6e88-4bcc-a470-409c7a6189db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_93327719-d5c5-4d43-9126-58d89edfa66f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_04617567-6e88-4bcc-a470-409c7a6189db" xlink:to="loc_us-gaap_OperatingIncomeLoss_93327719-d5c5-4d43-9126-58d89edfa66f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_1001b643-d4d9-468a-ad96-cba27d638f7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_04617567-6e88-4bcc-a470-409c7a6189db" xlink:to="loc_us-gaap_InterestIncomeOther_1001b643-d4d9-468a-ad96-cba27d638f7a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_e77e7d20-0232-44d6-9ccb-63c06940010f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_04617567-6e88-4bcc-a470-409c7a6189db" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_e77e7d20-0232-44d6-9ccb-63c06940010f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8a00f9f9-9d8b-4c6a-9a08-a73f870bd672" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ae6387ca-a0a8-41be-8cdf-6d8b30605991" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a00f9f9-9d8b-4c6a-9a08-a73f870bd672" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ae6387ca-a0a8-41be-8cdf-6d8b30605991" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_71580626-8e14-4c5a-aa05-cc428035ccaa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_8a00f9f9-9d8b-4c6a-9a08-a73f870bd672" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_71580626-8e14-4c5a-aa05-cc428035ccaa" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_79985d38-8559-4b15-a2ea-9db811d59cc6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4e636745-f55d-4bc3-ac44-3d9ad17de556" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_79985d38-8559-4b15-a2ea-9db811d59cc6" xlink:to="loc_us-gaap_NetIncomeLoss_4e636745-f55d-4bc3-ac44-3d9ad17de556" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7a0eab7-e6bb-4c85-9114-ef5b65fdc6f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_79985d38-8559-4b15-a2ea-9db811d59cc6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_c7a0eab7-e6bb-4c85-9114-ef5b65fdc6f4" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6a0da89b-fccc-48e9-8a6e-4d63984e5547" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_NetIncomeLoss_6a0da89b-fccc-48e9-8a6e-4d63984e5547" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_389f2aec-c6f5-4be6-a3f4-1e3eed881541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_389f2aec-c6f5-4be6-a3f4-1e3eed881541" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_1ff5a912-b279-4448-817b-1866162b2dd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_ShareBasedCompensation_1ff5a912-b279-4448-817b-1866162b2dd1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_e8e4c607-7b86-4268-814a-c80fa2e92b55" xlink:href="exel-20210702.xsd#exel_NoncashLeaseExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_exel_NoncashLeaseExpense_e8e4c607-7b86-4268-814a-c80fa2e92b55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_d5707b89-3346-433b-b7e0-ea9316106e00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:calculationArc order="5" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_d5707b89-3346-433b-b7e0-ea9316106e00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2af900ee-e80d-4f29-8fce-466bb1a2a9ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2af900ee-e80d-4f29-8fce-466bb1a2a9ec" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_062aab50-264d-482e-9fe9-8f48dc30139f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_062aab50-264d-482e-9fe9-8f48dc30139f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_05855df9-b8e5-4c92-9671-fe426f5e5df6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_05855df9-b8e5-4c92-9671-fe426f5e5df6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6519c46c-3daa-4351-8e63-d11f587083b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6519c46c-3daa-4351-8e63-d11f587083b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_38a4349a-3798-4c61-aab2-f3cf34a87efb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="10" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_38a4349a-3798-4c61-aab2-f3cf34a87efb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_69179a7c-e2c6-491b-9181-b0995d952e9c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_30095e0e-1173-49a5-9ceb-8e775efb11bc" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_69179a7c-e2c6-491b-9181-b0995d952e9c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4dc3064-a6ad-4423-bdb1-6411f01ed05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e587959-5e99-4d51-9b5d-09e3818c8663" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4dc3064-a6ad-4423-bdb1-6411f01ed05d" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_8e587959-5e99-4d51-9b5d-09e3818c8663" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f1b6aa39-0b8d-48e6-901f-768b09a6b2bb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4dc3064-a6ad-4423-bdb1-6411f01ed05d" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f1b6aa39-0b8d-48e6-901f-768b09a6b2bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7c08ce65-7381-46b0-bc82-1af98080daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_f4dc3064-a6ad-4423-bdb1-6411f01ed05d" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_7c08ce65-7381-46b0-bc82-1af98080daf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae83e77-bd90-40bd-9ed1-d3a0fb457933" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8989cb-e654-4192-a883-66384a252c43" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae83e77-bd90-40bd-9ed1-d3a0fb457933" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_8e8989cb-e654-4192-a883-66384a252c43" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4dc6536d-d646-4b29-91f5-74b8425b784e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae83e77-bd90-40bd-9ed1-d3a0fb457933" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_4dc6536d-d646-4b29-91f5-74b8425b784e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d1aae18-faaa-413b-9cd2-a5c50dfb7eea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_cae83e77-bd90-40bd-9ed1-d3a0fb457933" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_8d1aae18-faaa-413b-9cd2-a5c50dfb7eea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a1cb578-e41a-4bb5-83cb-625406728caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c83c2030-960e-4425-b3cd-cea44f5cd5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a1cb578-e41a-4bb5-83cb-625406728caf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_c83c2030-960e-4425-b3cd-cea44f5cd5a2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8364d109-49e0-46f4-95d2-c5450090f4c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_4a1cb578-e41a-4bb5-83cb-625406728caf" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_8364d109-49e0-46f4-95d2-c5450090f4c0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_061f0760-d4c8-4d1f-9e90-2dce0fe20e79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a0bc2ed1-3cf7-460f-81c4-99d887b4ef42" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_061f0760-d4c8-4d1f-9e90-2dce0fe20e79" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_a0bc2ed1-3cf7-460f-81c4-99d887b4ef42" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_505df3f7-2a75-4ac4-859c-f44f9007e2a7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerLiability_061f0760-d4c8-4d1f-9e90-2dce0fe20e79" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_505df3f7-2a75-4ac4-859c-f44f9007e2a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_ee2653d6-6606-4fae-bda2-875e850938fc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_e3d37d75-8dcb-472e-be91-0d2b96c47b28" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_ee2653d6-6606-4fae-bda2-875e850938fc" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_e3d37d75-8dcb-472e-be91-0d2b96c47b28" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_badcdb1c-9caf-4aa3-9239-99937e79f889" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet_ee2653d6-6606-4fae-bda2-875e850938fc" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_badcdb1c-9caf-4aa3-9239-99937e79f889" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae30def9-9dbf-4195-aa52-cdde66aa6a7a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92cf98e9-fc79-4030-b482-465f0b8084c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae30def9-9dbf-4195-aa52-cdde66aa6a7a" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_92cf98e9-fc79-4030-b482-465f0b8084c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_cc0e21b0-cc45-45d5-92b6-42e74baad119" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_ae30def9-9dbf-4195-aa52-cdde66aa6a7a" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_cc0e21b0-cc45-45d5-92b6-42e74baad119" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92a37131-4afc-42bb-a729-9f1a1bee48cb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c047c66-45e3-4c63-b4b0-1ef5578c3ff9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92a37131-4afc-42bb-a729-9f1a1bee48cb" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_2c047c66-45e3-4c63-b4b0-1ef5578c3ff9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b6d5d457-dcca-4a9b-919b-125e5e8483c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92a37131-4afc-42bb-a729-9f1a1bee48cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_b6d5d457-dcca-4a9b-919b-125e5e8483c4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_483c8389-13e4-4f0c-955b-34566b983b71" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_92a37131-4afc-42bb-a729-9f1a1bee48cb" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_483c8389-13e4-4f0c-955b-34566b983b71" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_240e9e7c-478c-4763-91fc-83f8f59f2a80" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_5d67ea02-f0bb-4c13-a5d2-8ccdd733a956" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_240e9e7c-478c-4763-91fc-83f8f59f2a80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_5d67ea02-f0bb-4c13-a5d2-8ccdd733a956" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1296aa99-7e5e-4933-b096-706d76f326b5" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_240e9e7c-478c-4763-91fc-83f8f59f2a80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_1296aa99-7e5e-4933-b096-706d76f326b5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_2dcc72bd-02f2-42c8-aa5b-eaac28cdff6f" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_240e9e7c-478c-4763-91fc-83f8f59f2a80" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_2dcc72bd-02f2-42c8-aa5b-eaac28cdff6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ef87126a-d516-4eae-9b53-1c4911b8ecd4" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_658ec053-1ea6-4430-b25c-9a6265c6c446" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ef87126a-d516-4eae-9b53-1c4911b8ecd4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_658ec053-1ea6-4430-b25c-9a6265c6c446" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e09d4a7-79b0-4411-ab75-27ca8a864162" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ef87126a-d516-4eae-9b53-1c4911b8ecd4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4e09d4a7-79b0-4411-ab75-27ca8a864162" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b83ec6e5-9636-4bd6-81ff-0ee8b377ad25" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_ef87126a-d516-4eae-9b53-1c4911b8ecd4" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b83ec6e5-9636-4bd6-81ff-0ee8b377ad25" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c67bfeb-fc04-47da-9731-3d224ab66929" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_00030571-cd87-40e3-8e4d-6c736420c3fe" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c67bfeb-fc04-47da-9731-3d224ab66929" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_00030571-cd87-40e3-8e4d-6c736420c3fe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7d66aa8-dd90-4026-9cd8-ca971abc2c55" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_3c67bfeb-fc04-47da-9731-3d224ab66929" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_f7d66aa8-dd90-4026-9cd8-ca971abc2c55" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575a9cb8-4c5e-4232-89f2-676bed1da87e" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5e68f848-ff54-4a59-8ef0-b924056bb274" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575a9cb8-4c5e-4232-89f2-676bed1da87e" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_5e68f848-ff54-4a59-8ef0-b924056bb274" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06bb0a93-dfc6-4a74-b9ab-de0debc1e36b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_575a9cb8-4c5e-4232-89f2-676bed1da87e" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_06bb0a93-dfc6-4a74-b9ab-de0debc1e36b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_85accbfa-4799-43f7-9279-7183ce0ef3b1" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fd4a4af0-43d4-48c7-bf81-c621ece40370" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_85accbfa-4799-43f7-9279-7183ce0ef3b1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fd4a4af0-43d4-48c7-bf81-c621ece40370" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9440d3b2-91a5-419e-a3c7-73611b8adf8e" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_85accbfa-4799-43f7-9279-7183ce0ef3b1" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_9440d3b2-91a5-419e-a3c7-73611b8adf8e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_880035f9-601f-4d3f-9fd7-a414b6f3b41c" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a08ff244-b121-4546-af49-d8fee093ffe8" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_880035f9-601f-4d3f-9fd7-a414b6f3b41c" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_a08ff244-b121-4546-af49-d8fee093ffe8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f8f96d3-3aab-4f0d-9f6c-a882ccd6f60a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_880035f9-601f-4d3f-9fd7-a414b6f3b41c" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2f8f96d3-3aab-4f0d-9f6c-a882ccd6f60a" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce6893f0-c459-4b76-b1ef-4e2d5ca29c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ec926e8d-28f6-47ba-8a87-9e95bddfcc60" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce6893f0-c459-4b76-b1ef-4e2d5ca29c1c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_ec926e8d-28f6-47ba-8a87-9e95bddfcc60" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_337d6710-8b1d-4bf6-9637-cc5b8cee7772" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_ce6893f0-c459-4b76-b1ef-4e2d5ca29c1c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_337d6710-8b1d-4bf6-9637-cc5b8cee7772" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_4c5b645b-bc38-4d1d-a4fe-f6f641ee419b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_698500b2-7b87-4394-a48e-fbe1588ee422" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c5b645b-bc38-4d1d-a4fe-f6f641ee419b" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_698500b2-7b87-4394-a48e-fbe1588ee422" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_133547bd-ec4b-441b-bb02-54be6a4623c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_4c5b645b-bc38-4d1d-a4fe-f6f641ee419b" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_133547bd-ec4b-441b-bb02-54be6a4623c1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#InventoryDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_364d1474-08dd-460a-b075-eac68412ccdd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_859a2c41-7d61-4965-85fb-1b3fec0cf7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_364d1474-08dd-460a-b075-eac68412ccdd" xlink:to="loc_us-gaap_InventoryRawMaterials_859a2c41-7d61-4965-85fb-1b3fec0cf7c1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_a763fe69-1b4a-42c4-bd53-a4ae66654e91" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_364d1474-08dd-460a-b075-eac68412ccdd" xlink:to="loc_us-gaap_InventoryWorkInProcess_a763fe69-1b4a-42c4-bd53-a4ae66654e91" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_2761b7ce-2c9f-43cd-b7d8-0f8a65325387" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryGross_364d1474-08dd-460a-b075-eac68412ccdd" xlink:to="loc_us-gaap_InventoryFinishedGoods_2761b7ce-2c9f-43cd-b7d8-0f8a65325387" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:calculationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb56de51-aeb6-4a0b-b2ee-2bd6a887bf63" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e94f6e06-f60f-410d-998b-fdf0fb05459b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb56de51-aeb6-4a0b-b2ee-2bd6a887bf63" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_e94f6e06-f60f-410d-998b-fdf0fb05459b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9b17a25c-3a4e-4a53-a560-4edba8345dbf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_eb56de51-aeb6-4a0b-b2ee-2bd6a887bf63" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_9b17a25c-3a4e-4a53-a560-4edba8345dbf" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>9
<FILENAME>exel-20210702_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended" id="i5142c3bf09ed4059acaab09fd310a40d_CondensedConsolidatedStatementsofIncome">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_870a95f3-f5cf-435c-80a5-10de082a1336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_870a95f3-f5cf-435c-80a5-10de082a1336" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6cc3567a-a53f-447c-b28b-82c981a48b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6cc3567a-a53f-447c-b28b-82c981a48b24" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4a6ad3f5-b967-487b-b0b0-f77f8190185f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4a6ad3f5-b967-487b-b0b0-f77f8190185f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e11ed3e-473d-43a8-883b-67b412bc0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e11ed3e-473d-43a8-883b-67b412bc0fa5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_395e6c32-27d0-44cb-a70c-9ca114963446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_CostsAndExpenses_395e6c32-27d0-44cb-a70c-9ca114963446" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd3a9fb3-dfda-476c-9d09-c16c0ac6e153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OperatingIncomeLoss_fd3a9fb3-dfda-476c-9d09-c16c0ac6e153" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_965a267e-531a-4b02-b681-43ef37653820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_InterestIncomeOther_965a267e-531a-4b02-b681-43ef37653820" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_05e1a760-91b0-4b6a-b921-8cef658a357b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_05e1a760-91b0-4b6a-b921-8cef658a357b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a7be83d5-259b-4ba6-a48c-89eb56cf744b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a7be83d5-259b-4ba6-a48c-89eb56cf744b" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50fe4073-210c-43e7-9ab5-e78dc45c694a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50fe4073-210c-43e7-9ab5-e78dc45c694a" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc02d046-6d6a-4f0c-956f-e4c48eedaa73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_NetIncomeLoss_dc02d046-6d6a-4f0c-956f-e4c48eedaa73" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d169830f-c3da-4bb3-bb79-f2894ee51912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:to="loc_us-gaap_EarningsPerShareBasic_d169830f-c3da-4bb3-bb79-f2894ee51912" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_795a9ac3-908d-47d2-ac64-7842133f2e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_795a9ac3-908d-47d2-ac64-7842133f2e35" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18a44779-4ccc-498d-812d-241962187a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18a44779-4ccc-498d-812d-241962187a2a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23586cbb-9cd2-4214-a81f-4a609ff8d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23586cbb-9cd2-4214-a81f-4a609ff8d4dc" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:to="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_93b00a8b-84b6-46af-aa14-76072e313ccc_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:to="loc_srt_ProductsAndServicesDomain_93b00a8b-84b6-46af-aa14-76072e313ccc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:to="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0d267660-f3d8-417c-9004-d862dacb9618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_ProductMember_0d267660-f3d8-417c-9004-d862dacb9618" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f01e7bf9-8d9c-49f9-a51a-a1ebb68cecd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_LicenseMember_f01e7bf9-8d9c-49f9-a51a-a1ebb68cecd0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dd931a16-17cf-49e4-8d95-86d578ec121a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_ServiceMember_dd931a16-17cf-49e4-8d95-86d578ec121a" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended" id="i2911301edc9d48c9846049109f5b713a_CondensedConsolidatedStatementsofStockholdersEquity">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39d34215-46fd-44a3-b631-c0c9a2a9b9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39d34215-46fd-44a3-b631-c0c9a2a9b9b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1590fa8d-3043-455d-834c-0bacba35e127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockholdersEquity_1590fa8d-3043-455d-834c-0bacba35e127" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e01c09a-3701-4bea-beb5-0aebfc0cca62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_NetIncomeLoss_1e01c09a-3701-4bea-beb5-0aebfc0cca62" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ec75dff-6683-422b-8800-f188ed161ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ec75dff-6683-422b-8800-f188ed161ec2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3edb99e1-8061-464c-bd41-fc6ffea59568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3edb99e1-8061-464c-bd41-fc6ffea59568" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_34f4232e-9258-44ef-917b-1b3225700d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_34f4232e-9258-44ef-917b-1b3225700d09" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0a17865a-fc6a-47dd-b8a8-ff1b612fc6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0a17865a-fc6a-47dd-b8a8-ff1b612fc6ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4b990ffc-d051-4f40-9cd6-ee68d34f53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4b990ffc-d051-4f40-9cd6-ee68d34f53f2" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b0ce9907-0ad9-4f76-8f78-f3e97cfe5276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5fa907d-24a0-4d49-b7a8-63ffa8c67c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:to="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b49b8867-fd9f-4924-83ec-1da5f5cecc01_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:to="loc_us-gaap_EquityComponentDomain_b49b8867-fd9f-4924-83ec-1da5f5cecc01_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:to="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_81b9f18b-51fe-4679-b209-34ed52f3fece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_CommonStockMember_81b9f18b-51fe-4679-b209-34ed52f3fece" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_955ff713-1cf1-4638-bb0b-344d2d22ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_955ff713-1cf1-4638-bb0b-344d2d22ea8d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_634783d0-4050-4d89-ab1e-dadd41f4b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_634783d0-4050-4d89-ab1e-dadd41f4b7d3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b00f2a90-fc8b-416e-a24f-ee88f5094978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_RetainedEarningsMember_b00f2a90-fc8b-416e-a24f-ee88f5094978" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended" id="i6c4a9fdeb3c845468c5933a615a042c6_OrganizationandSummaryofSignificantAccountingPoliciesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_1e2da1a8-ebb3-4aa7-a002-e2362a9cb197" xlink:href="exel-20210702.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:to="loc_exel_NumberofProductsinCommercialMarket_1e2da1a8-ebb3-4aa7-a002-e2362a9cb197" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6f17cf63-b04c-4191-89e4-6e9fb581f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6f17cf63-b04c-4191-89e4-6e9fb581f5c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:to="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:to="loc_srt_ProductsAndServicesDomain_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:to="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_8facfba1-9260-4d8e-9c75-e4eda7c2018e" xlink:href="exel-20210702.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_8facfba1-9260-4d8e-9c75-e4eda7c2018e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_64237584-f557-4ff3-9dbe-d780c7724741" xlink:href="exel-20210702.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_64237584-f557-4ff3-9dbe-d780c7724741" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended" id="ibe299fb4bd9d4ae881c014907bb9b9ca_RevenuesRevenuesbyDisaggregatedCategoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acdeebbc-985c-405f-ad55-5e8b87aa8652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acdeebbc-985c-405f-ad55-5e8b87aa8652" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:to="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:to="loc_srt_ProductsAndServicesDomain_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:to="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_39b64cd6-8e27-4912-9111-c6dea5e23232" xlink:href="exel-20210702.xsd#exel_ProductGrossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_ProductGrossMember_39b64cd6-8e27-4912-9111-c6dea5e23232" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_ebea96d1-f661-4f5d-867b-fd73df002695" xlink:href="exel-20210702.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_ebea96d1-f661-4f5d-867b-fd73df002695" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f1c9120c-8a88-4451-88ec-c2c9e872f4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_ProductMember_f1c9120c-8a88-4451-88ec-c2c9e872f4ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8676da13-255c-41bb-96c4-490ceb8342e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_LicenseMember_8676da13-255c-41bb-96c4-490ceb8342e5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_87f768d8-8a44-41fa-ab57-78601ca4b306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_ServiceMember_87f768d8-8a44-41fa-ab57-78601ca4b306" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_eb546266-840a-40ff-9e0e-c114233dee89" xlink:href="exel-20210702.xsd#exel_CollaborationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_CollaborationMember_eb546266-840a-40ff-9e0e-c114233dee89" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended" id="i9fa189fadc964ebb90efbf5e2d3e446a_RevenuesRevenuesDisaggregatedbySignificantCustomerDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f8e429f3-2929-4167-9dde-2c90ad149c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f8e429f3-2929-4167-9dde-2c90ad149c0e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_fbc15300-48ee-4efe-b5d1-d5610da33d87_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:to="loc_srt_NameOfMajorCustomerDomain_fbc15300-48ee-4efe-b5d1-d5610da33d87_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:to="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_14314765-ba5b-4061-84d9-68f3a5edcb49" xlink:href="exel-20210702.xsd#exel_IpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_IpsenMember_14314765-ba5b-4061-84d9-68f3a5edcb49" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_d403e3b4-9168-4fba-9946-2da79dc441e5" xlink:href="exel-20210702.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_d403e3b4-9168-4fba-9946-2da79dc441e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_2b8db387-3dce-4f7e-bca7-534b4799a505" xlink:href="exel-20210702.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_2b8db387-3dce-4f7e-bca7-534b4799a505" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_29b9325e-a67a-4d47-a63f-946d536377a1" xlink:href="exel-20210702.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_29b9325e-a67a-4d47-a63f-946d536377a1" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_4399f7e0-4ed8-4a64-be7a-5cb6013a48c1" xlink:href="exel-20210702.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_4399f7e0-4ed8-4a64-be7a-5cb6013a48c1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_e17871ae-bd11-49cf-b3df-a31ac51b1266" xlink:href="exel-20210702.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AccredoHealthIncorporatedMember_e17871ae-bd11-49cf-b3df-a31ac51b1266" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_861bb422-392b-4a22-9279-eccab525fa37" xlink:href="exel-20210702.xsd#exel_TakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_TakedaMember_861bb422-392b-4a22-9279-eccab525fa37" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_76ed5fb4-c8d1-4828-8904-4a98a55355af_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_76ed5fb4-c8d1-4828-8904-4a98a55355af_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_021fe65f-c197-434a-953c-bb4a69ad9789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_021fe65f-c197-434a-953c-bb4a69ad9789" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1d103146-1f01-4323-9e54-2f8bb404560d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:to="loc_us-gaap_AccountsReceivableMember_1d103146-1f01-4323-9e54-2f8bb404560d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_161f9e57-1091-46cc-afdb-c52892d93ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_161f9e57-1091-46cc-afdb-c52892d93ec4" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended" id="i914a907465d2495e9b60130d3a43c909_RevenuesRevenuesDisaggregatedbyGeographicRegionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda2044e-71a7-4f67-b5c2-d357b4061453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda2044e-71a7-4f67-b5c2-d357b4061453" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:to="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b0641e4c-dc82-4092-8518-316f11176269_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:to="loc_srt_SegmentGeographicalDomain_b0641e4c-dc82-4092-8518-316f11176269_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:to="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ee08c92-2e56-4295-aed4-a35713d9405c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_country_US_2ee08c92-2e56-4295-aed4-a35713d9405c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_260ec9e9-7b59-440d-b6fb-71092bd2c9de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_srt_EuropeMember_260ec9e9-7b59-440d-b6fb-71092bd2c9de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0ed24f5a-83d5-4b05-8a61-bbcf76e1c60c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_country_JP_0ed24f5a-83d5-4b05-8a61-bbcf76e1c60c" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended" id="id022f512db34432da1b950ccdf1dfbf9_RevenuesNetProductRevenuesDisaggregatedbyProductDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_731e082b-6850-4f53-929d-e90e2c039665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_731e082b-6850-4f53-929d-e90e2c039665" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:to="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f5161f3b-4853-400b-98db-9df82f507703_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:to="loc_srt_ProductsAndServicesDomain_f5161f3b-4853-400b-98db-9df82f507703_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:to="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_2635b2aa-e409-41cd-9a4a-b33888f8f946" xlink:href="exel-20210702.xsd#exel_CabometyxMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_exel_CabometyxMember_2635b2aa-e409-41cd-9a4a-b33888f8f946" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_b209129c-bf74-4ddd-b20e-10203e88b478" xlink:href="exel-20210702.xsd#exel_CometriqMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_exel_CometriqMember_b209129c-bf74-4ddd-b20e-10203e88b478" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6daeed51-e4c6-4dca-8c99-0e5e79c0f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_us-gaap_ProductMember_6daeed51-e4c6-4dca-8c99-0e5e79c0f7cc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended" id="i98bfd5d397934c01aad25e53657f26ef_RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_19224e67-8baa-49a4-8f65-8e85ca432438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_19224e67-8baa-49a4-8f65-8e85ca432438" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_dae41558-0271-4eee-9503-96784206916e" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_dae41558-0271-4eee-9503-96784206916e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_fa98980c-c8e8-4f3a-a611-2d9ffe9ee4c1" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_fa98980c-c8e8-4f3a-a611-2d9ffe9ee4c1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_88f73652-fc64-4dfe-8553-27ca4314b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_88f73652-fc64-4dfe-8553-27ca4314b0c6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5eba6197-2114-4b35-a7ec-5274f5fc11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_1b82375a-18ac-4c06-8b60-2635635492b7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_1b82375a-18ac-4c06-8b60-2635635492b7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_cab5b821-d8b0-48d4-a213-1583d49e65e4" xlink:href="exel-20210702.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_cab5b821-d8b0-48d4-a213-1583d49e65e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_7ec9e77a-4ccb-44d9-92a5-066b68073653" xlink:href="exel-20210702.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_7ec9e77a-4ccb-44d9-92a5-066b68073653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_416e13c7-bddc-41f3-944f-52458889d9b4" xlink:href="exel-20210702.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_AllowanceForProductRebatesMember_416e13c7-bddc-41f3-944f-52458889d9b4" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended" id="i8666ecc523554d2d9b88f18d1a385a44_RevenuesContractAssetsandLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_5915d98e-db6c-4f10-86f3-ad56997d2103" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_5915d98e-db6c-4f10-86f3-ad56997d2103" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_5c74a300-c136-40a1-b907-4e2d57e7588f" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_5c74a300-c136-40a1-b907-4e2d57e7588f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_fb285c80-bd30-4b53-9436-80deb6810652" xlink:href="exel-20210702.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_fb285c80-bd30-4b53-9436-80deb6810652" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_0e6424af-f720-4840-aee1-800098c6e8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_0e6424af-f720-4840-aee1-800098c6e8e0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_496baf1c-fca6-4239-8d59-ef27b25e1ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_496baf1c-fca6-4239-8d59-ef27b25e1ad4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cfeea0f-6514-4538-9ac6-d42ff143d7a9_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6cfeea0f-6514-4538-9ac6-d42ff143d7a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_82b9ec15-6a9c-4763-afcd-52818ac73e89" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_82b9ec15-6a9c-4763-afcd-52818ac73e89" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended" id="i53aa816f23454ea7be896ef2c2ece270_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4104b2f8-4e64-4ab3-a972-77a0695660f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4104b2f8-4e64-4ab3-a972-77a0695660f4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:to="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_fb95c8e9-27b2-4fc9-ad39-077e71f35b23_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:to="loc_srt_ProductsAndServicesDomain_fb95c8e9-27b2-4fc9-ad39-077e71f35b23_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:to="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c216ad20-ce81-4319-b64a-e587d62c3252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:to="loc_us-gaap_LicenseMember_c216ad20-ce81-4319-b64a-e587d62c3252" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7709025a-78dd-4f28-a40d-2d1099f5d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:to="loc_us-gaap_ServiceMember_7709025a-78dd-4f28-a40d-2d1099f5d0f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86b61925-93a5-4f07-8f8f-6a675bfa4060_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_86b61925-93a5-4f07-8f8f-6a675bfa4060_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_752875e3-1032-446c-b623-fea04e398f42" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_752875e3-1032-446c-b623-fea04e398f42" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended" id="ibf37efdeb1df480a9e770a0230774b57_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_62f37536-d68c-4394-bc72-a881bd32c5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_62f37536-d68c-4394-bc72-a881bd32c5ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afd40a6e-bb5e-4f42-ba81-2924bda851e1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_afd40a6e-bb5e-4f42-ba81-2924bda851e1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_36a48547-fc48-439f-8ca3-92cc39d2e68e" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_36a48547-fc48-439f-8ca3-92cc39d2e68e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended" id="i4926158ffdf940daba8134236aa987c5_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aba490c8-a7a3-40e3-96b2-35ddc826dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aba490c8-a7a3-40e3-96b2-35ddc826dc87" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:to="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_0b894621-7b3a-418a-9cb5-e60e5bca0285_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:to="loc_srt_ProductsAndServicesDomain_0b894621-7b3a-418a-9cb5-e60e5bca0285_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:to="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cf4d23b4-19ae-4721-9744-949ff81d75ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:to="loc_us-gaap_LicenseMember_cf4d23b4-19ae-4721-9744-949ff81d75ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e158c25b-d0a0-42ce-b7d6-58759f5b0f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:to="loc_us-gaap_ServiceMember_e158c25b-d0a0-42ce-b7d6-58759f5b0f13" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:to="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75d8f0bd-d0f7-4ea9-822b-129c0b25a541_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_75d8f0bd-d0f7-4ea9-822b-129c0b25a541_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_e14d598b-1cf7-42f8-932e-6df3a39918d3" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_e14d598b-1cf7-42f8-932e-6df3a39918d3" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended" id="i2c209ffc9acc40e38055cee6161edd2e_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_813dca27-502e-486a-955f-c825c20a69f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_813dca27-502e-486a-955f-c825c20a69f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15850678-ddc9-4784-b063-57917965ea06_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_15850678-ddc9-4784-b063-57917965ea06_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c0bb96bc-2aaa-4382-80dc-7bcb8b4b8df0" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c0bb96bc-2aaa-4382-80dc-7bcb8b4b8df0" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended" id="ic69afceec703411c8d651ee6c7654128_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3d6454fe-f186-4bf7-85ad-d8370cd94594" xlink:href="exel-20210702.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3d6454fe-f186-4bf7-85ad-d8370cd94594" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_fed1abe5-07cb-4827-80f8-fd6f9dad08d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:to="loc_us-gaap_RoyaltyExpense_fed1abe5-07cb-4827-80f8-fd6f9dad08d5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:to="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_ebce0c04-5cd9-41e1-a2e0-7b1a92161748_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:to="loc_srt_NameOfMajorCustomerDomain_ebce0c04-5cd9-41e1-a2e0-7b1a92161748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:to="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_fc35d227-249d-42c2-b432-be2bc46f6d4d" xlink:href="exel-20210702.xsd#exel_GlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:to="loc_exel_GlaxoSmithKlineMember_fc35d227-249d-42c2-b432-be2bc46f6d4d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_368ecd37-3ff0-40f1-98f5-65613f8577c8_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_368ecd37-3ff0-40f1-98f5-65613f8577c8_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_c1d1d16d-2d72-48dc-b3d8-9909feba5d5e" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_c1d1d16d-2d72-48dc-b3d8-9909feba5d5e" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended" id="i5537a9fe57c84713afa7ab56ec06aaa2_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_16791c8c-9690-430d-8d4b-12fcef1af4e7" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_16791c8c-9690-430d-8d4b-12fcef1af4e7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b92b2dd6-ba91-4f04-a67b-3f7fc1e16c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b92b2dd6-ba91-4f04-a67b-3f7fc1e16c97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78fd1c59-8d55-4f55-a190-d10f5e05c2bc_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_78fd1c59-8d55-4f55-a190-d10f5e05c2bc_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_07c610e6-b662-4095-97e7-fdedffc0352b" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_07c610e6-b662-4095-97e7-fdedffc0352b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:to="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_f2fcd934-fe63-4480-a78e-0e8a1deb8b21_default" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:to="loc_srt_ProductsAndServicesDomain_f2fcd934-fe63-4480-a78e-0e8a1deb8b21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:to="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_2df3d9fe-1bda-4707-9d96-45ed6a8d8196" xlink:href="exel-20210702.xsd#exel_CotellicMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:to="loc_exel_CotellicMember_2df3d9fe-1bda-4707-9d96-45ed6a8d8196" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="extended" id="ib71263bcd42048f9914fbbcb4b58358e_CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7cacd2db-ba39-4feb-b9de-52935829fe0b" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7cacd2db-ba39-4feb-b9de-52935829fe0b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_da1ea57f-4505-4415-add8-0ff0bec0e44a" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_da1ea57f-4505-4415-add8-0ff0bec0e44a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_439a2efc-62d6-4917-9a95-e16d3116422f" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_439a2efc-62d6-4917-9a95-e16d3116422f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_0c3fb155-5fec-4114-9307-6c26676d6207" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_0c3fb155-5fec-4114-9307-6c26676d6207" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_f4803b47-60ba-4b09-a2dc-05d3b7b93bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_f4803b47-60ba-4b09-a2dc-05d3b7b93bcc" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_07c84340-fe01-469f-b201-1797a170b316" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_07c84340-fe01-469f-b201-1797a170b316" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c4773bf5-f52b-49c2-8497-5502c604ca82" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c4773bf5-f52b-49c2-8497-5502c604ca82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_487ac798-59be-4db7-9c55-7f365d2bf11a" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_487ac798-59be-4db7-9c55-7f365d2bf11a" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:to="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_03171b45-5852-4baa-a5b9-c55ce1cce9b0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_03171b45-5852-4baa-a5b9-c55ce1cce9b0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_ed105fa4-467b-45e5-9de4-b3803b168679" xlink:href="exel-20210702.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_ed105fa4-467b-45e5-9de4-b3803b168679" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended" id="i24dea02ce1834fb6aa51e8425db31ae4_CashandInvestmentsInvestmentsbySecurityTypeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a63493e-432d-4091-a689-49cff33f91ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a63493e-432d-4091-a689-49cff33f91ac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_381d0ea1-2eed-442a-a08e-91ca95061e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_381d0ea1-2eed-442a-a08e-91ca95061e3b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34e5a19-35c5-4375-ab0a-f6213c46ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34e5a19-35c5-4375-ab0a-f6213c46ff89" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c06a8aa4-1504-480f-b802-d3610481444c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c06a8aa4-1504-480f-b802-d3610481444c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_556250cd-2d1f-4269-b57f-d9330d71afac" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_556250cd-2d1f-4269-b57f-d9330d71afac" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_adc531b7-b7f8-445f-bec9-e676bc9083ba" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_adc531b7-b7f8-445f-bec9-e676bc9083ba" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_b64e80b0-eb8e-4dd0-a572-9052fcc4a0ea" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_b64e80b0-eb8e-4dd0-a572-9052fcc4a0ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8c2d2fd-d935-443c-86cb-c500df047c89" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8c2d2fd-d935-443c-86cb-c500df047c89" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3f8f7110-081f-4bbe-b3b1-366a695c7077" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3f8f7110-081f-4bbe-b3b1-366a695c7077" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ac1079cb-3bf6-48ba-a639-5fb3dacaf399" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ac1079cb-3bf6-48ba-a639-5fb3dacaf399" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e218b21d-454b-47f5-8c7f-7bce54d0422e" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e218b21d-454b-47f5-8c7f-7bce54d0422e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a82f257f-b173-4aac-b685-e2ebfa742418" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a82f257f-b173-4aac-b685-e2ebfa742418" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99e12468-ded0-4dfe-b93a-9b2e441dc977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_99e12468-ded0-4dfe-b93a-9b2e441dc977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2bc1d561-1a64-419e-8032-d826d6d14520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CommercialPaperMember_2bc1d561-1a64-419e-8032-d826d6d14520" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_dcc89a99-6649-41aa-9784-330f8e4a102c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_dcc89a99-6649-41aa-9784-330f8e4a102c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8016f534-7403-412e-a273-1d5e6c9bcb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8016f534-7403-412e-a273-1d5e6c9bcb13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_cd26eedb-1398-4760-912c-d02aa4c279c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_MunicipalBondsMember_cd26eedb-1398-4760-912c-d02aa4c279c4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5aa3d81e-4401-456f-9fad-033c08ee3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CashMember_5aa3d81e-4401-456f-9fad-033c08ee3c19" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_312016a1-7163-427f-b935-5d0cf3ca5ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_312016a1-7163-427f-b935-5d0cf3ca5ae6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_db87502e-dc71-420a-a913-e5c9bc849ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_db87502e-dc71-420a-a913-e5c9bc849ff0" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended" id="icdde13aa23404fbcba0043469727e476_CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1806ade4-989e-436f-a676-b7676f61c45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1806ade4-989e-436f-a676-b7676f61c45c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_cf6fc394-dab5-4db0-a4b0-a0dac7ea6230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_cf6fc394-dab5-4db0-a4b0-a0dac7ea6230" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb9dc7d6-279e-4d41-be02-d7606c2b195c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_eb9dc7d6-279e-4d41-be02-d7606c2b195c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_36c263a4-8c30-42c6-925d-c7e4525ec69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_CommercialPaperMember_36c263a4-8c30-42c6-925d-c7e4525ec69d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_35284dda-2f9b-49a1-97c7-5aeac1ccd96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_35284dda-2f9b-49a1-97c7-5aeac1ccd96c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_cfaae1da-cc93-4e34-a548-bcb280d60960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_cfaae1da-cc93-4e34-a548-bcb280d60960" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_bed81887-b673-4c9d-aa07-c979835e2052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_MunicipalBondsMember_bed81887-b673-4c9d-aa07-c979835e2052" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended" id="i84d850e6e64d4f5ea72bf9da0e6cf5a4_FairValueMeasurementsDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c5cdbb6-affe-4cf7-a7f7-b543260ec80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c5cdbb6-affe-4cf7-a7f7-b543260ec80c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4dcdc9b-fb4f-44d1-a481-fd21010a2226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4dcdc9b-fb4f-44d1-a481-fd21010a2226" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5ed96270-5f12-4b15-9c87-e4b192d9ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5ed96270-5f12-4b15-9c87-e4b192d9ab3a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27f64ac9-5e7e-473e-b91f-f53fb876223b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_27f64ac9-5e7e-473e-b91f-f53fb876223b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_15473f4c-f625-43a8-887b-0687c1ae63c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CommercialPaperMember_15473f4c-f625-43a8-887b-0687c1ae63c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_35e59a32-7a10-4439-98c9-68c1420c6ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_35e59a32-7a10-4439-98c9-68c1420c6ad7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c799c064-a55e-4bdb-a897-c48b85f4d404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c799c064-a55e-4bdb-a897-c48b85f4d404" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_b9be2342-71b3-4da2-881a-8609c80739e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_MunicipalBondsMember_b9be2342-71b3-4da2-881a-8609c80739e4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_096cb6ed-df4c-478c-8001-7e06fc81d650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_096cb6ed-df4c-478c-8001-7e06fc81d650" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_93800ff3-68b7-4f12-8419-fd3d4d401309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_93800ff3-68b7-4f12-8419-fd3d4d401309" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87287994-7425-412a-b6d9-4c58a4ea2479_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_87287994-7425-412a-b6d9-4c58a4ea2479_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1909b857-9930-4546-923e-ca4ecdc10e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1909b857-9930-4546-923e-ca4ecdc10e1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ad0412f-767d-4e65-b664-ecc19d81f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ad0412f-767d-4e65-b664-ecc19d81f7c5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_72d99986-d3ba-476b-9054-eb5cae55de54_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_72d99986-d3ba-476b-9054-eb5cae55de54_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ff614c7d-d994-4968-86b6-813d6d35147f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ff614c7d-d994-4968-86b6-813d6d35147f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended" id="i068c3567bccf45db927bee8aab5f0153_FairValueMeasurementsNarrativesDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8ea7ef48-89cf-4544-ab62-2750a65702fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8ea7ef48-89cf-4544-ab62-2750a65702fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7c61b37d-6de4-428f-9bf5-ae9fe5eb324b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7c61b37d-6de4-428f-9bf5-ae9fe5eb324b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_6bae5a20-9d05-4d94-b858-b4ba64d8121a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeTermOfContract_6bae5a20-9d05-4d94-b858-b4ba64d8121a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_0ab30afe-ed65-4a95-8d8f-558f9744c632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_0ab30afe-ed65-4a95-8d8f-558f9744c632" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_fe507d79-9a68-43a8-94c7-99c6ccc29d4f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_fe507d79-9a68-43a8-94c7-99c6ccc29d4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f3fe8dd6-de82-4802-9730-851c217118d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f3fe8dd6-de82-4802-9730-851c217118d2" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#InventoryDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended" id="i57801d1bc53c4209bbe0ceb205ee8f8a_InventoryDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0ff92708-24d2-4c75-a73c-18f687f522c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryRawMaterials_0ff92708-24d2-4c75-a73c-18f687f522c3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_36ee1784-3880-4b69-b88f-2cc1cb6d52fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryWorkInProcess_36ee1784-3880-4b69-b88f-2cc1cb6d52fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_79b43dae-80f3-4eeb-a731-13f2fe305ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryFinishedGoods_79b43dae-80f3-4eeb-a731-13f2fe305ee1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_963108a1-331c-4624-9483-02ed4e5d62d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryGross_963108a1-331c-4624-9483-02ed4e5d62d2" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6f5f1542-384c-4d69-ba52-e032fbabc63d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6f5f1542-384c-4d69-ba52-e032fbabc63d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_eeed4b0e-3b7a-43a1-a671-d1a680af27d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:to="loc_us-gaap_InventoriesMember_eeed4b0e-3b7a-43a1-a671-d1a680af27d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_a1850bc8-ee6a-47a8-bcdf-a1e2d067c6f8" xlink:href="exel-20210702.xsd#exel_OtherLongtermAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:to="loc_exel_OtherLongtermAssetsMember_a1850bc8-ee6a-47a8-bcdf-a1e2d067c6f8" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended" id="i36cd9630cc4c4ddd891a62536829156b_StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23938477-b22a-4258-b19f-5c516b066db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23938477-b22a-4258-b19f-5c516b066db0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0ecddc92-2a24-40ad-ada5-4766970e2cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0ecddc92-2a24-40ad-ada5-4766970e2cc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_46f00815-26ad-4afe-9b22-8ab9b92cd39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_46f00815-26ad-4afe-9b22-8ab9b92cd39c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended" id="i1ae277a10be9421f8ea71b0637dc73f8_StockBasedCompensationBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_349351b8-ce24-4b27-81d5-7252a5a33a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_349351b8-ce24-4b27-81d5-7252a5a33a5d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:to="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86939ffc-63b3-4c60-832b-a2ae2e48d69f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86939ffc-63b3-4c60-832b-a2ae2e48d69f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4d50d79f-5cb8-4d55-ac24-e25d5fed55cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4d50d79f-5cb8-4d55-ac24-e25d5fed55cf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8630ace0-238b-438b-b695-3a82accd9938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8630ace0-238b-438b-b695-3a82accd9938" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e7dc619e-0414-4f3f-a25c-0c117688f13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_PerformanceSharesMember_e7dc619e-0414-4f3f-a25c-0c117688f13a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c4af8f2-ce88-4dfe-b4a7-5e917a52dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_EmployeeStockMember_9c4af8f2-ce88-4dfe-b4a7-5e917a52dfbd" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended" id="id70fec88f71e43bdbc7664c52bb2162a_StockBasedCompensationNarrativeDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0652d429-eb8a-4825-849a-9692945387e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0652d429-eb8a-4825-849a-9692945387e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_0114d08e-1d6a-4f87-b7ac-1f4856b9babf" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_0114d08e-1d6a-4f87-b7ac-1f4856b9babf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_775a15a0-007d-4aa1-af1c-eb826248dbc7" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_775a15a0-007d-4aa1-af1c-eb826248dbc7" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_198c9f78-2674-4ca4-9556-7e45e1b7eeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_198c9f78-2674-4ca4-9556-7e45e1b7eeb3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38ddd07a-523b-4c79-9036-f6d53b37e717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38ddd07a-523b-4c79-9036-f6d53b37e717" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08983d4d-e5df-4dd6-acbd-537ad478f760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08983d4d-e5df-4dd6-acbd-537ad478f760" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8993734-6488-4896-9ff2-2acf4eaf74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8993734-6488-4896-9ff2-2acf4eaf74d1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db0c4920-93e0-4923-bd5d-f0b1e18b92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db0c4920-93e0-4923-bd5d-f0b1e18b92ad" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33332058-66a5-41f8-b696-599c0ca94fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33332058-66a5-41f8-b696-599c0ca94fd9" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6192e724-2b07-4743-944d-3f592267fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6192e724-2b07-4743-944d-3f592267fd9a" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_509308ca-8475-480d-a570-c27768703442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_509308ca-8475-480d-a570-c27768703442" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_247221f5-a0d4-442e-86b1-0d9780b82b08" xlink:href="exel-20210702.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_247221f5-a0d4-442e-86b1-0d9780b82b08" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d227cf38-6251-4247-9c6f-2093fa0201ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d227cf38-6251-4247-9c6f-2093fa0201ad" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_06a06958-881b-4081-95ca-b2636c262aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_06a06958-881b-4081-95ca-b2636c262aa8" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8cb873f-e09f-4dd7-bcc4-bc180d01b243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8cb873f-e09f-4dd7-bcc4-bc180d01b243" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:to="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ad61194-7a0c-473f-9f9c-d4c149d38045_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_5ad61194-7a0c-473f-9f9c-d4c149d38045_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7d20957f-254b-4544-8888-cd2957402191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7d20957f-254b-4544-8888-cd2957402191" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_400d0887-b301-4c21-b5ee-9d396e60b5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_400d0887-b301-4c21-b5ee-9d396e60b5a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6b6797b4-baf1-4e5b-8a8c-e11be6c96bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_PerformanceSharesMember_6b6797b4-baf1-4e5b-8a8c-e11be6c96bf9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:to="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_02f40f68-b776-426f-8567-efdbe8609294_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:to="loc_us-gaap_VestingDomain_02f40f68-b776-426f-8567-efdbe8609294_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:to="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a5f8b483-06db-40aa-8036-a0e54fa1778b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a5f8b483-06db-40aa-8036-a0e54fa1778b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3ae41086-846e-463b-b097-ea9cf4ce4277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3ae41086-846e-463b-b097-ea9cf4ce4277" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended" id="ia01c4ad5fc634c72b5dd8ef4ba948307_StockBasedCompensationEstimateGrantDateFairValueDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dd7934c3-93b6-4fb2-9fd5-cae65085daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dd7934c3-93b6-4fb2-9fd5-cae65085daf8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e07e0238-9be5-409f-91a6-890de4345833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_SharePrice_e07e0238-9be5-409f-91a6-890de4345833" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0bc07674-6e86-4ab3-98a3-83f2dff174b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0bc07674-6e86-4ab3-98a3-83f2dff174b8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02d8c254-8e76-499e-9382-93149577d614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02d8c254-8e76-499e-9382-93149577d614" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d774f9d-26a0-46f2-bbde-ea16e2d1e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d774f9d-26a0-46f2-bbde-ea16e2d1e4fa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:to="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8bb0e5-0b41-4135-b598-568748ee6c9d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7b8bb0e5-0b41-4135-b598-568748ee6c9d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3dddeaed-8b79-451a-aefa-4b6942f5fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:to="loc_us-gaap_PerformanceSharesMember_3dddeaed-8b79-451a-aefa-4b6942f5fe1f" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended" id="i6641e1b9c9e1408792aebe88aa169736_NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e4be1206-ab32-4b6d-8ed5-d15452e59bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e4be1206-ab32-4b6d-8ed5-d15452e59bb5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2241b7be-dae5-4fcb-b8b1-9e03aa77575b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_2241b7be-dae5-4fcb-b8b1-9e03aa77575b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_edca0eec-a9f9-428f-a75e-11c2037926cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:to="loc_us-gaap_StockCompensationPlanMember_edca0eec-a9f9-428f-a75e-11c2037926cc" xlink:type="arc" order="0"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>exel-20210702_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_68364736-7459-4cc9-8f2d-299c49e3ccdd_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental cash flow disclosures:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_9fc288a5-c795-49e9-b9d6-a4af68f9c414_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionAxis" xlink:to="lab_us-gaap_AssetAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_74542e01-0375-4a35-9e2a-3f01c0ae2516_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_82917567-aeb0-43da-b8e5-b41171d1f60b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcess_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcess" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Work in Process, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcess" xlink:to="lab_us-gaap_InventoryWorkInProcess" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_6c1de871-bf87-44a7-8976-fce4d4dd24e9_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Profits on U.S. commercialization</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) From Agreement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementIncomeLossFromAgreement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Income (Loss) from Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:to="lab_exel_CollaborativeArrangementIncomeLossFromAgreement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_527cfab6-e41f-453f-b7ef-c82b5603882a_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_cacfff18-0e76-4962-9d92-c46391749b4e_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d055e4b3-19f2-43e5-b34d-244f5f911bbb_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_d15ffc31-5e4f-48cc-81e8-e3702a34e7f8_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_6de391a1-84fd-4a00-a863-e7ec9526040a_netLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_5e277b6f-1214-4287-9e9d-a8c9908f7f67_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_f993e4a2-b50e-43d7-9fe8-448149bf3382_terseLabel_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on derivative instruments, pretax</link:label>
    <link:label id="lab_us-gaap_GainOnDerivativeInstrumentsPretax_label_en-US" xlink:label="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gain on Derivative Instruments, Pretax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:to="lab_us-gaap_GainOnDerivativeInstrumentsPretax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_68a748d5-c884-4c3c-9a88-a4a1b28ffc79_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract liabilities:</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable and Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_91db6007-578f-4ee1-acb9-a4a9cd263a85_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_22413e37-d2cc-4cb9-b0d9-8e29d574957f_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_34c13212-735c-4e12-b753-438cd911820a_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_12b2ac56-41df-426e-a9b6-d3608bbeb2be_terseLabel_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products derived from other compounds</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_label_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:label id="lab_exel_ProductsDerivedFromOtherCompoundsMember_documentation_en-US" xlink:label="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Products Derived From Other Compounds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:href="exel-20210702.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductsDerivedFromOtherCompoundsMember" xlink:to="lab_exel_ProductsDerivedFromOtherCompoundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_IpsenMember_0bd1c807-e89d-4f70-9a31-5f2baa36f287_terseLabel_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen Pharma SAS</link:label>
    <link:label id="lab_exel_IpsenMember_label_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:label id="lab_exel_IpsenMember_documentation_en-US" xlink:label="lab_exel_IpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember" xlink:href="exel-20210702.xsd#exel_IpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_IpsenMember" xlink:to="lab_exel_IpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_81ade758-f30f-4eb4-bca9-0ba77e5a17b4_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_05b1f344-cc81-499f-874b-d856582f0660_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Other Assets and Other Liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9d90e782-5806-43af-bca1-e47ea1231764_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_29335aee-f936-438b-bd18-090a41e8521c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Numerator:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract" xlink:to="lab_us-gaap_EarningsPerShareReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_358a95fc-0c22-4317-9002-82483a10ca10_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_08523dc0-8176-4eff-aa02-3fc42af34fc5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_b91bb08a-8b75-41d6-837c-8240f922d4c2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Currency Forward Contracts for Non-Designated Hedges</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_816efb74-141f-4444-9e12-4cfb1565b386_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_b13321ea-f754-4960-b54b-ac5c7e5c3abc_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of shares available for grant (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_e7724577-3f16-44de-a4ad-dba868011e50_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1bdfd686-5793-4aab-80ad-80d55d29e10e_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net increase in cash, cash equivalents and restricted cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoriesMember_7a96c89c-f76d-4d0d-9b33-1583f23bf9f6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion included in inventory</link:label>
    <link:label id="lab_us-gaap_InventoriesMember_label_en-US" xlink:label="lab_us-gaap_InventoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoriesMember" xlink:to="lab_us-gaap_InventoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_a741975a-3949-484a-92e5-e208438f8477_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_68ce7fdf-7c12-4f95-8e5b-4e67d6faaa6e_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0ca4c0c1-83a3-4c22-ad88-276847ea3b95_terseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_0cfcbd12-58d3-4764-8329-bbdb7f99d5ba_verboseLabel_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of deposit</link:label>
    <link:label id="lab_us-gaap_CertificatesOfDepositMember_label_en-US" xlink:label="lab_us-gaap_CertificatesOfDepositMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Certificates of Deposit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CertificatesOfDepositMember" xlink:to="lab_us-gaap_CertificatesOfDepositMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestIncomeOther_1faa2faf-ff53-424e-b8a1-f034d7946c4c_terseLabel_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InterestIncomeOther_label_en-US" xlink:label="lab_us-gaap_InterestIncomeOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Income, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestIncomeOther" xlink:to="lab_us-gaap_InterestIncomeOther" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_2dfe58f1-36dd-4a26-ac88-b5c74b19461d_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_41516200-a5af-4dfc-80c1-578cf32a6a96_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_5ed5ed54-00ee-443d-801a-26daa4129f4e_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CASH AND INVESTMENTS</link:label>
    <link:label id="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:to="lab_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_95f08f12-3763-43e2-8959-4dec1373d5f3_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OtherLongtermAssetsMember_e9dd9a5b-c6ab-4e94-8509-27f09f2aa202_terseLabel_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion included in other long-term assets</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_label_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:label id="lab_exel_OtherLongtermAssetsMember_documentation_en-US" xlink:label="lab_exel_OtherLongtermAssetsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Long-term Assets [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember" xlink:href="exel-20210702.xsd#exel_OtherLongtermAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OtherLongtermAssetsMember" xlink:to="lab_exel_OtherLongtermAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_24cbf1e8-021c-4082-8bc9-4adb48086955_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Anti-dilutive securities and contingently issuable shares excluded (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_6a6f5be9-dd66-41b5-a615-c8b62de9cb17_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_fb1661e6-d3d3-40fd-b899-f6bdaf6b7fcb_terseLabel_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued collaboration liabilities</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_label_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:label id="lab_exel_AccruedCollaborationLiabilityCurrent_documentation_en-US" xlink:label="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Collaboration Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:href="exel-20210702.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedCollaborationLiabilityCurrent" xlink:to="lab_exel_AccruedCollaborationLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_af198d15-b097-4a96-903b-e2750413aa20_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_864f0491-8911-4921-8b36-f3cf13fbc587_terseLabel_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_label_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:label id="lab_exel_AllowanceForProductRebatesMember_documentation_en-US" xlink:label="lab_exel_AllowanceForProductRebatesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Product Rebates [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember" xlink:href="exel-20210702.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForProductRebatesMember" xlink:to="lab_exel_AllowanceForProductRebatesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_26755a13-5d6e-4d77-915f-dcdc48be0b95_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant date fair value, awarded (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MunicipalBondsMember_9732c355-3bc4-4354-9e81-1942cfd62171_terseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_0a635f91-cacb-4b1f-aed0-41f9b2e4fc6f_verboseLabel_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal bonds</link:label>
    <link:label id="lab_us-gaap_MunicipalBondsMember_label_en-US" xlink:label="lab_us-gaap_MunicipalBondsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Municipal Bonds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MunicipalBondsMember" xlink:to="lab_us-gaap_MunicipalBondsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_f5338705-c57f-4223-994f-397f7c3f7b39_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Milestone receivable upon achievement of development achievement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Amount Receivable From Collaboration For Development And Regulatory Milestone Achievement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Amount Receivable From Collaboration For Development And Regulatory Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:to="lab_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2aa29862-8cb2-49e9-8c2f-7eece3805eb5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of ($257), $2,287, ($756) and $1,346, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4957d04b-0e69-4e1c-9598-8d0ecb987996_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_cec40db7-bdc7-4248-9553-8bce940fbcad_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_5027a520-5382-4adc-aef0-4b2aa4b034d3_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash operating activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_8e91207e-4e21-4dfa-bd90-64bfd707d462_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_908ee3c4-2e21-4302-97a4-08480c25c9fb_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_eb4b521e-44f3-4d0f-b854-cd8d8a2c118b_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_a45916f9-7334-4c93-86eb-56979bf1646f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_665f33fa-8b6f-46c0-8065-ac035f868710_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_d5fc4862-fe06-40b8-8bc1-0052448f7c9c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_e571b944-15ed-43a8-924b-dc27ec48fb12_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8e875474-9c5c-4d2f-90dc-086caf3d7f8c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_e612a289-175f-42d9-81be-e442d7d5c522_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_b3e55b59-8e64-4229-a74b-c71fd0d03474_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_61dc84bb-df92-4ef0-8acd-939dccc06940_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_c9a45ca5-c907-4c3d-9aa0-968c887ff832_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt securities available-for-sale:</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2eaf6c7a-5475-4a74-92fb-a98bc68f35e3_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationMember_139e9de3-14c5-442d-8d4d-1642dfda1ff7_verboseLabel_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total collaboration revenues</link:label>
    <link:label id="lab_exel_CollaborationMember_label_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:label id="lab_exel_CollaborationMember_documentation_en-US" xlink:label="lab_exel_CollaborationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember" xlink:href="exel-20210702.xsd#exel_CollaborationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationMember" xlink:to="lab_exel_CollaborationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_53f4c713-ccf4-4f43-9bdd-606faf9509cb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_882bdf07-2284-4c82-978e-4f08bad09044_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryCurrentTable_321abdfb-394f-4ab2-b3ff-0dde1192f40c_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:label id="lab_us-gaap_InventoryCurrentTable_label_en-US" xlink:label="lab_us-gaap_InventoryCurrentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Current [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryCurrentTable" xlink:to="lab_us-gaap_InventoryCurrentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_bcfe3fb5-cfa9-42d6-8164-c9ed715eae41_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_9414f7ff-e932-4dab-912e-f84b40093326_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_901ce7cf-ef70-4e1a-a418-3f087976d160_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting award percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_5dbab89b-32c4-40f3-a429-7ac4cbf65823_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_4436c42a-9866-421a-9352-fdad871da904_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_119a3c56-ff66-4b66-8634-8f22a6cef48b_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment upon closing of transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_label_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:label id="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Payment Upon Closing Of Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:to="lab_exel_AssetAcquisitionPaymentUponClosingOfTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_e1c5bd65-a7a0-4c18-bf37-da7b6e941a95_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of business segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_f5a1e9a1-0392-44e4-a339-ae3fb41defe4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_bca3990d-c5c2-40e3-a09a-48c47884ce51_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_7a860aba-2655-4781-9f7b-4ada7a223135_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_d76fc763-b98c-4cc9-a281-eccf2b63d330_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_b2f91922-5b08-42d3-a896-95e541067db0_verboseLabel_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S. Treasury and government-sponsored enterprises</link:label>
    <link:label id="lab_us-gaap_USTreasuryAndGovernmentMember_label_en-US" xlink:label="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">US Treasury and Government [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasuryAndGovernmentMember" xlink:to="lab_us-gaap_USTreasuryAndGovernmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_ca7acc62-18aa-4abe-b355-e215dd9eb805_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">REVENUES</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_c318f6b4-2f83-4c17-8a3e-b55d91568876_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:to="lab_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_a621fbd5-f84f-4676-ba9d-9c55b18739ff_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of awards outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_eac1b544-81af-4661-ba13-db70ab76dd8b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_ded0bc76-0f56-4766-b677-c528e853dfa7_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_9d1dac5d-74bc-43d8-abf0-f662c53645e6_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Disaggregation of Revenue</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:to="lab_us-gaap_DisaggregationOfRevenueTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterials_a2eea056-cb86-4cfb-9eb4-8fa2d5a8d29e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Raw materials</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterials_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterials" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Raw Materials, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterials" xlink:to="lab_us-gaap_InventoryRawMaterials" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_fcd78543-f5a1-45eb-8f39-7c6f6c684982_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommercialPaperMember_4cddd10c-29c4-4b15-a18f-7aad20848377_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_fc0fafcc-3063-41db-9774-1ffac315c7f0_verboseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember" xlink:to="lab_us-gaap_CommercialPaperMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_aa389b8b-e71a-4b33-b6ed-71f0c2c5534b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock transactions associated with taxes withheld on equity awards</link:label>
    <link:label id="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Decrease for Tax Withholding Obligation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_faf23738-e8a5-4cf5-b04e-7629a0d8bcce_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_58245136-ce0e-47d8-9a0f-d84900c68e85_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after stock option or stock appreciation award (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_c95ecb1f-0fe0-42cd-aa5a-9bf2a2d28b5f_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trade receivables, net</link:label>
    <link:label id="lab_us-gaap_ReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_ReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesNetCurrent" xlink:to="lab_us-gaap_ReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_a3089955-40dd-418b-896a-eae9b55d3c81_terseLabel_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Discounts and allowances</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_label_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:label id="lab_exel_ProductSalesDiscountsAndAllowancesMember_documentation_en-US" xlink:label="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Sales Discounts And Allowances [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:href="exel-20210702.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductSalesDiscountsAndAllowancesMember" xlink:to="lab_exel_ProductSalesDiscountsAndAllowancesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_97c40822-9c8e-4558-a806-8b6ffdff978f_terseLabel_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Customer Credits/Fees and Co-pay Assistance</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_label_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:label id="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_documentation_en-US" xlink:label="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:href="exel-20210702.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:to="lab_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_TakedaMember_1386a43e-ede3-4e8d-a08f-8960364422c8_terseLabel_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda Pharmaceutical Company Limited</link:label>
    <link:label id="lab_exel_TakedaMember_label_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:label id="lab_exel_TakedaMember_documentation_en-US" xlink:label="lab_exel_TakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember" xlink:href="exel-20210702.xsd#exel_TakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_TakedaMember" xlink:to="lab_exel_TakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_4a4b4254-9ef1-4c58-8dd6-47ab66740525_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total financial assets carried at fair value</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_e14d7e39-9574-4470-b8c5-2f4596fe609c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_3e2cf854-cd83-4eea-8b66-8437e2aa8cfa_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_dd50f196-e663-4b06-bacb-e1ba973ee564_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_2c75757e-2451-4b5a-a842-daa7bca05bc6_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_13ddb1d6-54e8-4d82-97de-d0e00aa2c449_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash equivalents included in other long-term assets</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsNoncurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0b7bbee5-9125-4419-9622-fd2ea2d14d2e_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities and stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_2fa83fa9-333f-490a-8b62-4b74889add98_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_af0783d4-8429-4a3d-a125-5f0a2d4589e3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_8e90e48b-1ddd-415b-a568-f32dfdb31662_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_56dfd696-1323-4565-8956-cb0443904a0d_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_89ca6f7f-296b-428f-87c3-56737c91f988_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ServiceMember_dc3f37f1-1a0e-4cdc-9226-ac4586fe76af_terseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_c985f777-16ed-4ece-9cc1-6d5e470a59c3_verboseLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_25ae187e-e783-4f38-81aa-6fbc002c0240_netLabel_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration services revenues</link:label>
    <link:label id="lab_us-gaap_ServiceMember_label_en-US" xlink:label="lab_us-gaap_ServiceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Service [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ServiceMember" xlink:to="lab_us-gaap_ServiceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_dadca188-49d2-4881-b477-d79c7ade732e_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_cf4ac91a-a901-47c6-971b-f89099467d2e_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofMcKessonCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of McKesson Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:href="exel-20210702.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofMcKessonCorporationMember" xlink:to="lab_exel_AffiliatesofMcKessonCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_8c5214be-501e-43a1-86a7-dfcf3c93b6f1_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_0c30b3ab-a044-468e-a310-7b560c538130_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable and other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_880a9733-c48e-46ea-b696-48251120c6e7_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_76a5a617-4a10-459f-8336-925c855d7567_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">NET INCOME PER SHARE</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4e206fd5-5afc-41df-9bcc-902698c771ff_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_ca1fb20e-f867-4a25-924a-9aa67f853d39_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_label_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of Optum Specialty Pharmacy [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:href="exel-20210702.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:to="lab_exel_AffiliatesofOptumSpecialtyPharmacyMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_de3665c0-df08-49c8-b554-c320acd8c62d_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain" xlink:to="lab_us-gaap_BalanceSheetLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_c72d6460-5f4b-4e3f-a389-39188919f7a1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_2f09839e-37c2-4fa2-9745-f0f5cc181c36_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_7d0c1dfc-404b-408e-926c-04543bea16a1_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0cc6578f-a3fb-43c6-be9e-cf5c3d3d706a_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss):</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_e36ec3e9-ce99-4aa0-8afc-2d778cc22d87_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_afdfd119-b491-4a12-9ac8-b42468628110_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_b9bb20a3-52c6-4381-b40e-d32640693ba8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_1fc353fa-8616-4914-a5dc-2058faf20ba4_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NoncashLeaseExpense_0d004fff-1337-4837-a4d4-bcbd9905809b_terseLabel_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash lease expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_label_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:label id="lab_exel_NoncashLeaseExpense_documentation_en-US" xlink:label="lab_exel_NoncashLeaseExpense" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Noncash Lease Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense" xlink:href="exel-20210702.xsd#exel_NoncashLeaseExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NoncashLeaseExpense" xlink:to="lab_exel_NoncashLeaseExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_c52e7d98-a032-464a-9c48-93aa4087664e_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_3d67d703-f78b-401f-94e3-17b8f1731ebe_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_78edcb2f-9fa4-4975-9404-2dff428a00f1_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued compensation and benefits</link:label>
    <link:label id="lab_us-gaap_AccruedEmployeeBenefitsCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Employee Benefits, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="lab_us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_233c51c2-58cc-41f4-a749-75e99f00e98f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred tax assets, net</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxAssetsNet_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred Income Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxAssetsNet" xlink:to="lab_us-gaap_DeferredIncomeTaxAssetsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_a2a8610c-dec1-4e3c-b4ce-f60fa9ed25d4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_38d295f9-e2bb-45a3-bb35-6f5be46c1867_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">STOCK-BASED COMPENSATION</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_17df39e3-c9d8-4c31-9ef2-37274789bccc_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">INVENTORY</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_528edb79-48fa-439d-adc9-b5820c99ad95_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_be16880f-d17f-40ed-9c0b-f3f70353540e_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_4cec751d-5d90-4852-9e33-c1848a212f62_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 314,822 and 311,627 at June&#160;30, 2021 and December&#160;31, 2020, respectively</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_b6fe2802-1906-4449-a623-e0e63ebfcf9a_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueLineItems_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems" xlink:to="lab_us-gaap_DisaggregationOfRevenueLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_a6a1a424-44ad-422a-b290-d4537748ef3b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_e2f1aa4f-bbf3-4838-8498-37aa2cd3800d_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_1fe8879c-e301-4d27-b5b2-6bf45b4b68b2_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance stock units</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_c95e1791-0d9a-4d98-81c6-f44ad69b6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_3e302c1e-21e1-4528-8b2f-6c075e56b871_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_50536db0-7646-4dd8-91d9-6c40a15cb6c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted cash short-term investments</link:label>
    <link:label id="lab_us-gaap_RestrictedCashEquivalentsCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Cash Equivalents, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashEquivalentsCurrent" xlink:to="lab_us-gaap_RestrictedCashEquivalentsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWriteDown_e3c08c0e-f982-4c60-a524-4e0b257207c6_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory write-down</link:label>
    <link:label id="lab_us-gaap_InventoryWriteDown_label_en-US" xlink:label="lab_us-gaap_InventoryWriteDown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Write-down</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWriteDown" xlink:to="lab_us-gaap_InventoryWriteDown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_e198f4b8-a9b1-4255-b26b-504e2cc2c37b_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_8f355cc0-4131-413a-afac-5c1fa3ee4f60_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_c19d0eaf-abfb-4391-bfde-00c97f2bc8ef_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetAbstract_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostsAndExpenses_44f54bad-1493-4bf8-94c5-e9d8a790552a_totalLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_CostsAndExpenses_label_en-US" xlink:label="lab_us-gaap_CostsAndExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Costs and Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="lab_us-gaap_CostsAndExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_896bb8ab-18ed-4f8c-bcd7-0402b0594d90_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Revenues Disaggregated by Geographic Region</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RoyaltyExpense_510212fc-6995-4b98-815f-2e1714e0875d_verboseLabel_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty expense</link:label>
    <link:label id="lab_us-gaap_RoyaltyExpense_label_en-US" xlink:label="lab_us-gaap_RoyaltyExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyExpense" xlink:to="lab_us-gaap_RoyaltyExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_024e53c0-151d-4fcf-bd5a-27904bef12ea_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_490549c6-0da0-4dfb-b2be-8409cd06a050_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_e8017d5c-25aa-42e8-9716-e8990fbcb9e9_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to acquire assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_843a7ecf-1c17-4b7c-b62b-7eed0dc7e0c0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_12120d21-a91d-447e-94d0-7795e163123f_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_29d103fe-dde8-4016-b451-365e99706f30_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_0e287725-9fa4-473e-b852-f00a226ae929_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_a39519e8-5306-4460-a091-ba47b553609c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c26bbc64-8051-4215-9dee-66083d200852_netLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_460fbcf3-91cd-4e9c-89b0-a1ac9e5d2ae5_verboseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Royalty revenues on ex-U.S. sales</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_5af30149-9f37-46e0-9e4b-541e78daecb5_terseLabel_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-of-use assets obtained in exchange for lease obligations</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_label_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:label id="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_documentation_en-US" xlink:label="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Right-Of-Use Asset Obtained In Exchange For Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:href="exel-20210702.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:to="lab_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_cc8c7f33-6db5-4fb1-a740-6350721e84d2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_0ddb6e3c-564d-4aaa-9131-58bcc65da080_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_c7e5fa01-ef41-4ccc-baab-edde90085f97_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithGenentechMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Genentech [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithGenentechMember" xlink:to="lab_exel_CollaborativeArrangementwithGenentechMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_d28eb709-7911-4adb-aceb-00972eb13935_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_81be91d9-f6c6-40f1-b0dc-4f41ec74178d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_076d7294-3c64-4ac8-8e82-59bd8a1204f2_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_3e3d331d-0539-48b9-a1dc-c190a82abea0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_30ceef5b-4679-44d5-9646-b5f992e1bc33_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing after one year through five years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3c04f2a7-e359-4efb-868c-fe6d3d99bbc5_negatedLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_d003b61e-f37e-413d-a87e-c8133f7f9f70_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_6d026196-90de-4cda-8dba-22795c505da6_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate regulatory milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_0c68a7cd-dd09-4a31-a154-de78c37266e8_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_5ef4c349-2883-4642-b02e-65355189bb22_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_4bd4bc28-4340-4720-bf39-0d7aee8c431a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_fe73ce65-a101-400f-8b11-bed65b36ee4d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithIpsenMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Ipsen [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithIpsenMember" xlink:to="lab_exel_CollaborativeArrangementwithIpsenMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_e4a10c64-0cb5-41d3-a2eb-7446248ed57c_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c5ab4f29-fc89-43a6-8b6e-4d7d49d7fd98_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_7c9170aa-59c1-43f4-9e23-a64380ab0d54_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_18f58c08-d08a-42be-9c57-efeae0dd9d17_totalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_08d7cbc8-2bbd-4a7e-a0d1-b4997498366b_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashAndCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CometriqMember_376923c9-b97c-4b2f-bb8b-5c36908be4fc_terseLabel_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">COMETRIQ</link:label>
    <link:label id="lab_exel_CometriqMember_label_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:label id="lab_exel_CometriqMember_documentation_en-US" xlink:label="lab_exel_CometriqMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cometriq [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember" xlink:href="exel-20210702.xsd#exel_CometriqMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CometriqMember" xlink:to="lab_exel_CometriqMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_e0b5dd69-6a90-4a45-947c-4314739a8c48_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_99511065-f164-4c98-a7ee-5418c4edfdd6_negatedTerseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8ec382f3-d052-40ee-8bf0-e89425dc4890_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_afc65ac4-16d7-4ef7-9986-ad6759c70c56_terseLabel_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting from discovery efforts</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_label_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:label id="lab_exel_ResultingFromDiscoveryEffortsMember_documentation_en-US" xlink:label="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Resulting From Discovery Efforts [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:href="exel-20210702.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ResultingFromDiscoveryEffortsMember" xlink:to="lab_exel_ResultingFromDiscoveryEffortsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_58369649-638a-4c99-be1e-29af19487c97_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount" xlink:to="lab_us-gaap_DerivativeNotionalAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_385af4a9-14d1-40e8-a73f-eb65d2282f5e_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other income (expense), net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_e3cbc13b-5f58-4ec5-96d1-6bc226d113aa_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of property, equipment and other</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_383d15ea-121e-49ed-a20f-4a095509a6c8_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_672e2a15-6764-413f-a989-8f2ccaf0d2a2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Collaborative Revenues Under Collaboration Agreement</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_8ec61a66-9658-4823-988c-e978eb411e0f_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_country_JP_2928dbfa-649e-4d5c-8980-e604645d577d_terseLabel_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Japan</link:label>
    <link:label id="lab_country_JP_label_en-US" xlink:label="lab_country_JP" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP" xlink:to="lab_country_JP" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_1833fdbf-bf91-416f-93d6-5f2be9fd0fe2_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_ce21cdb2-8a10-4fb1-ab65-a564c0057398_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ProductGrossMember_37892270-f320-42ad-8c67-90c4105198d5_terseLabel_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross product revenues</link:label>
    <link:label id="lab_exel_ProductGrossMember_label_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:label id="lab_exel_ProductGrossMember_documentation_en-US" xlink:label="lab_exel_ProductGrossMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product, Gross [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember" xlink:href="exel-20210702.xsd#exel_ProductGrossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ProductGrossMember" xlink:to="lab_exel_ProductGrossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_b55ac5a5-a058-4852-a551-bf0d8f1e848b_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_26211080-c9b9-41b9-9c6c-62a0862c0a25_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stockholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_18efd1aa-6486-4bc3-8397-8541cc0783cb_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e226b6b1-962e-4ee7-b2b0-d0f374f6a9b6_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_fdd6d40a-8689-45f8-8f15-9f2154de14c3_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_666ac4d7-ef28-4ade-83ef-afcb40818c51_terseLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_456d141c-aea9-479f-8f4e-966db0e94b96_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_ee5336b4-153b-49fc-9dfb-670e9970137a_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="lab_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_9450f2f1-5ea0-4597-8d24-8075066acbaf_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Upfront Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_a67bed40-dc57-4b63-8f8a-7e8d0e97802b_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_f991ac8d-3729-471c-95e8-507aa4795c3a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues recognized for performance obligations satisfied in previous periods</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Performance Obligation Satisfied in Previous Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:to="lab_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_0e639c65-fee6-4639-81c1-b9cd90d6c73e_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis" xlink:to="lab_us-gaap_BalanceSheetLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_03965667-56f6-4d31-893e-960ed19c3687_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_e6bfc38e-e306-4410-8cb1-f0e82b236977_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CotellicMember_c3500470-414e-46f1-bcf3-e9785020935c_terseLabel_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic</link:label>
    <link:label id="lab_exel_CotellicMember_label_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:label id="lab_exel_CotellicMember_documentation_en-US" xlink:label="lab_exel_CotellicMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cotellic [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember" xlink:href="exel-20210702.xsd#exel_CotellicMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CotellicMember" xlink:to="lab_exel_CotellicMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_702599b3-29cd-4fd3-aaab-d4acbbb85862_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharePrice_81b3e89e-c73b-4adb-9aaf-aa73a4da2781_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair value of the Company's common stock on grant date (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_label_en-US" xlink:label="lab_us-gaap_SharePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice" xlink:to="lab_us-gaap_SharePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_bc34c2ec-f40c-4586-891d-f5e39e1af532_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_d7768938-4564-4ed5-94e1-f63be8f604ab_terseLabel_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement</link:label>
    <link:label id="lab_us-gaap_StockCompensationPlanMember_label_en-US" xlink:label="lab_us-gaap_StockCompensationPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockCompensationPlanMember" xlink:to="lab_us-gaap_StockCompensationPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_479bf89a-6ea7-44b8-aa1a-8ed11a631592_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted stock units</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_ecebf154-e79f-4db2-a610-8941a298c326_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_b700fc7e-c485-4f7e-ad41-e6e4f296ca19_terseLabel_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_label_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA [Member]</link:label>
    <link:label id="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_documentation_en-US" xlink:label="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Agreement With GamaMabs Pharma SA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:href="exel-20210702.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:to="lab_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_23937d97-680d-4978-a10c-9924e11f062e_terseLabel_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Percent of royalty on net sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_label_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:label id="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_documentation_en-US" xlink:label="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement, Percent Of Royalty On Net Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:href="exel-20210702.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:to="lab_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_148c4e5b-826b-4cd2-9343-72fb3b632b38_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_8ae58240-34a3-4bd4-8291-71777bba8e82_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_697fa2b8-7e66-4b54-8340-8ca369812843_terseLabel_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract revenue recognized, including revenue from deferred revenue beginning balance</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_label_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:label id="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_documentation_en-US" xlink:label="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract With Customer, Liability, Including New Contract Revenue, Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:href="exel-20210702.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:to="lab_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_b45e1f95-27f8-4afb-bcdc-62d8087738e8_terseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_caa1fae1-1d30-4222-af69-d5687d6d4af5_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_0be3cc0d-f1ef-420a-869e-dca4b9df7b17_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_bcbdb90d-b397-434d-bed3-57170c12f772_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_1ce0c358-3cbb-45cb-82db-308c883f15fe_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_f915ca76-c983-47e1-a359-ae451b95d709_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeNumberOfInstrumentsHeld_label_en-US" xlink:label="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Number of Instruments Held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:to="lab_us-gaap_DerivativeNumberOfInstrumentsHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_4d8ca88e-647b-4b8d-98a9-93920d6f356d_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaboration Agreement with GlaxoSmithKline</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangements with Glaxo Smith Kline</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:to="lab_exel_CollaborativeArrangementswithGlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_f0ae05a2-f154-4378-8d79-3f4538ea4952_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Current Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_9981f69c-4844-488c-a404-a0c053b257de_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision related to sales made in:</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions To Provision [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_01ca68ab-d5d4-4b16-ab5e-ed5145c3cca4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments and customer credits issued</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShortTermInvestments_2d643d98-e3dc-4c37-ad5d-02c5786df5e1_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments" xlink:to="lab_us-gaap_ShortTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_543ee67f-d71a-43b9-88b0-2dd94db101ae_terseLabel_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Prior periods</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_label_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:label id="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_documentation_en-US" xlink:label="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Valuation Allowances And Reserves, Additions For Sales In Prior Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:to="lab_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_ea9b5f9a-b9ec-48eb-ae2f-b25afd6d6cd2_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract" xlink:to="lab_us-gaap_DerivativeTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_9b87739f-d5d2-42d3-ad07-50237281381b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Provision for income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_652ba95f-b491-4528-ab05-931296caf07f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f7aeacf1-dd35-42b6-a05b-35e9187a1bb4_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_0861c8ee-b325-49be-805a-21fbfcfea36f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_8f52fde1-a759-4c63-9f45-eeb4b83ef53f_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_6d9d6017-fdc4-40ee-baab-825b35fc27fa_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_fd53db3f-ed1d-42e8-95ec-0435c4a43abc_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_788d0fef-f375-4443-be2e-30ec42f8e68f_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_35a5164c-5306-4b60-8a18-1de643d0b652_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_f15dfe23-24c1-4564-a0e7-251e7f2cc0ae_terseLabel_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:label id="lab_us-gaap_DisaggregationOfRevenueTable_label_en-US" xlink:label="lab_us-gaap_DisaggregationOfRevenueTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Disaggregation of Revenue [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable" xlink:to="lab_us-gaap_DisaggregationOfRevenueTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_38e64b4e-53d2-43d7-863f-d81adbb83098_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_0022af4b-47d8-472d-82e1-526a962f1ec8_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Denominator:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_a0a379ef-c3f6-4d7d-8dad-29ec5b8ee2cf_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionTable_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionTable" xlink:to="lab_us-gaap_AssetAcquisitionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_eb683ad3-2ae7-4d77-a380-37992273161e_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_552ced77-e117-482b-a93d-777ed422afdf_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_b3f3acd3-fd06-4387-8fc0-bb4b54fca1e6_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_b098909a-889f-4955-bc35-e199f7141c41_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_0483fef1-9c52-4ede-9ac1-136750797758_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_7907bec4-1705-4874-b704-10c440102040_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_3ce946a5-a613-4ade-94f6-744df22a719f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_a8092463-8bae-457a-84e2-b36e8efcf560_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_20e4b65e-867d-4565-aefc-545678a21ecd_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6a577124-54f2-4c65-b7ef-24d050be3799_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_660144b4-2ec2-4c8c-bfe9-9c8408817079_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_47f7a46a-2ecd-4d21-b063-ed6e368d3c1a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_d287bed1-3f83-4ec2-8e2c-db01cf1eca93_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_aaa97f71-0ff6-49ff-96a6-2c4ef5aa7d5c_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid_9356bd6c-ec2f-4869-8cfb-6d93cbaa0afe_terseLabel_en-US" xlink:label="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred for unsettled investment purchases</link:label>
    <link:label id="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid_label_en-US" xlink:label="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsettled Investment Purchases Incurred But Not Yet Paid</link:label>
    <link:label id="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid_documentation_en-US" xlink:label="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unsettled Investment Purchases Incurred But Not Yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:href="exel-20210702.xsd#exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:to="lab_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_0f8c623a-3639-463c-b90b-69e3be4075f6_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_fecb8dc4-d7fe-4139-8356-6b08f5525de1_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_a81c5de0-3607-42e9-ac0d-077775c2ba14_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Purchases of investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireInvestments_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payments to Acquire Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireInvestments" xlink:to="lab_us-gaap_PaymentsToAcquireInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_59d14224-d3a6-473e-a32d-d86dc5e9d881_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Issuance of common stock under equity incentive and stock purchase plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_93a7973f-84fc-4fe2-8967-75957b855684_terseLabel_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset acquisition, maximum aggregate development milestone payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_label_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:label id="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_documentation_en-US" xlink:label="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition, Maximum Aggregate Development Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:to="lab_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_GlaxoSmithKlineMember_58b72e7f-1993-4698-81ec-ed9b4b72f8d7_terseLabel_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">GSK</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_label_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member]</link:label>
    <link:label id="lab_exel_GlaxoSmithKlineMember_documentation_en-US" xlink:label="lab_exel_GlaxoSmithKlineMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Glaxo Smith Kline [Member].</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember" xlink:href="exel-20210702.xsd#exel_GlaxoSmithKlineMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_GlaxoSmithKlineMember" xlink:to="lab_exel_GlaxoSmithKlineMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_19887c61-3975-4280-ad93-defacf09212a_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_215f992f-9b29-4cf1-a610-8e526a8822a6_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e8e28ece-2f46-456f-8c10-69e3bcfc4c10_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total debt securities available-for-sale</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_1942b63b-7c7e-4d85-8530-18168a7f76b9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from maturities and sales of investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_507840c6-93fc-4099-9a58-82cf3e5c8324_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_62287fdf-9c0e-4311-b4d0-323ae4a9a5c9_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Level&#160;2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_a440fef3-71cb-4bde-8d43-edf7986df11f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion of deferred revenues</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_68c86803-bd6a-4145-88e3-7563836c6371_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_bec42fc9-d34d-419d-8d19-2ea55e5e4dd0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_3a40f33d-835b-4027-b1c4-f00418db6d28_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_c6833e5c-b449-4f3b-839c-14f12457a6b7_terseLabel_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of products that entered in the commercial marketplace</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_label_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:label id="lab_exel_NumberofProductsinCommercialMarket_documentation_en-US" xlink:label="lab_exel_NumberofProductsinCommercialMarket" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of Products in Commercial Market</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket" xlink:href="exel-20210702.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_NumberofProductsinCommercialMarket" xlink:to="lab_exel_NumberofProductsinCommercialMarket" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_35a5323d-feb3-4124-a8cf-01e7c4840862_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_7962b1cf-7d0c-4f7a-8325-581c8868a62f_verboseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_485a344b-2e32-4cc8-b21a-d49c7110ba78_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_ba5b827f-6fc3-49d7-9049-a250a3a09a39_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Options granted in the period (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_2e0eb896-946a-4890-8072-679c4bf21285_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_360dad0f-f13a-40b2-81f9-8a3f0353623b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_7d841794-bbbc-4651-a789-5916309c8ba5_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other comprehensive income (loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_4654fe0b-1994-4b78-886d-979ce12615bc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Allocated Employee Stock-Based Compensation Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_4a02c0d8-1e03-47c5-af31-dbadb03c3b98_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_111b58c9-7d23-4025-b97a-ba5cbd3e25e4_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_e7172df2-601b-4643-ba50-7be508d17a99_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_0f1adf54-8350-4091-87f1-07a16270a5d4_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CabometyxMember_a171cb1b-fcc2-4064-a61b-88dea675a3c1_terseLabel_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">CABOMETYX</link:label>
    <link:label id="lab_exel_CabometyxMember_label_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:label id="lab_exel_CabometyxMember_documentation_en-US" xlink:label="lab_exel_CabometyxMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cabometyx [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember" xlink:href="exel-20210702.xsd#exel_CabometyxMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CabometyxMember" xlink:to="lab_exel_CabometyxMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_101a55f6-65d7-4335-bf13-fcd95a38f327_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_439a8e46-44d0-4050-bd35-527757ad71bb_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_b215c59e-6bba-40b5-8257-d195e30b542d_terseLabel_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reduction in share reserve after all other awards (in shares)</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_label_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards</link:label>
    <link:label id="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_documentation_en-US" xlink:label="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:to="lab_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_e98098ee-2441-469d-a3a6-869b0ecb2f9d_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain" xlink:to="lab_us-gaap_DerivativeContractTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_b6c1af25-f364-4743-b9dc-59e39c517cef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_44cd2b96-8c56-44bf-8b69-bbae77e6788b_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, revenue recognized upon development milestone achievement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Recognized Upon Development Milestone Achievement</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Revenue Recognized Upon Development Milestone Achievement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:to="lab_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashMember_af066498-91fe-47c7-9db9-bc033c3596fc_terseLabel_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash</link:label>
    <link:label id="lab_us-gaap_CashMember_label_en-US" xlink:label="lab_us-gaap_CashMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashMember" xlink:to="lab_us-gaap_CashMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_f74ad78f-a6c6-45ef-a96c-d6afcf41b524_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_391bf54a-b784-464d-95b5-2a7ccba4a36a_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_5d1cf429-3d8c-4f47-af62-ff6d696741da_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_d0fb453d-2792-4a5d-a2a0-541fe382f05d_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_51190138-8eb6-40d1-a373-4a59cfe6662e_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_1fbb144d-eaa3-442c-869e-5d03543512cd_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_2eb099cd-46b1-43da-882e-630758bc1dc5_terseLabel_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_label_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:label id="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_documentation_en-US" xlink:label="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:href="exel-20210702.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:to="lab_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_6e72f1eb-e339-4de2-8b8a-bdf50d9d0bbc_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_426aadae-0476-490c-94cc-7e956ae6b3a9_terseLabel_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued clinical trial liabilities</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_label_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:label id="lab_exel_AccruedClinicalLiabilitiesCurrent_documentation_en-US" xlink:label="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accrued Clinical Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:href="exel-20210702.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccruedClinicalLiabilitiesCurrent" xlink:to="lab_exel_AccruedClinicalLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_958b0cd9-22a2-434b-8357-3cf92b338737_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_2b044f09-86e5-4dd9-810a-fe1d835a0e5a_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_d9dea4e2-bf49-4358-84f5-a07931cab42c_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_75e10530-7822-466b-9851-14853cab1113_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_e4c1bf4b-97ca-4e0b-809b-d4ce1c4a56c1_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Dilutive securities (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_a13ba933-1d46-4ccd-a3af-ec3b90fa03ef_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProductMember_3c5f88a3-99a3-4e02-a175-35cc5fe2d71f_verboseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_9fe437f8-6830-4973-823f-9730a8901b44_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_74a4a9e0-71b2-4381-95e4-e670093ae1d3_netLabel_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net product revenues</link:label>
    <link:label id="lab_us-gaap_ProductMember_label_en-US" xlink:label="lab_us-gaap_ProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember" xlink:to="lab_us-gaap_ProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_df1fd052-886f-4979-85fa-ad1dd1194dc9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive income</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_2091c680-dd06-4efc-86bb-336847f87fde_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract liabilities</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_4aa60980-578f-4b85-a4a2-ee73c3823e1b_terseLabel_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks, Discounts for Prompt Payment and Other</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_label_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:label id="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember_documentation_en-US" xlink:label="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Chargebacks And Discounts For Prompt Payment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:href="exel-20210702.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:to="lab_exel_ChargebacksAndDiscountsForPromptPaymentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_994b6a90-80a5-4a08-925b-77fac9cbf096_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash provided by (used in) financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_3e1cdb76-d5d7-477c-85dc-919db09906b2_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_28381bbf-8529-4238-8891-87b5c6c4b0b1_terseLabel_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of AmerisourceBergen Corporation</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates Of Amerisource Bergen Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:href="exel-20210702.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:to="lab_exel_AffiliatesOfAmerisourceBergenCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_7c9651a2-8d87-4df7-b934-f0d45fffa245_terseLabel_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_label_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:label id="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable_documentation_en-US" xlink:label="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Organization And Summary Of Significant Policies [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:to="lab_exel_OrganizationAndSummaryOfSignificantPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_5bfd8e1a-7172-452c-a12c-d38170e13bb8_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">FAIR VALUE MEASUREMENTS</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_43a1627e-c618-413f-aa91-9bd83f81391e_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_c78149b5-d076-453d-91cf-d20d318edc3e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_8a832a8c-8329-4dd7-a4d0-f6607c55cf9b_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_3d92b95f-71c3-44ad-9170-fbdce9880c35_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Assets Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="lab_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_9ccbae57-7b42-40e8-a9b9-385ac373e8c7_terseLabel_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:href="exel-20210702.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_1335b0e0-bdf2-4a48-9b5b-e6919f234db4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_fc53b798-f3a9-4b1e-9ee2-ef9fb96f1bfb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_123556fe-32b1-41c0-853d-d6198a5ae911_totalLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total contract assets</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_0ea29c67-d192-485d-b681-0fce5eb3d131_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a95e82c0-9e63-40d6-9a9f-a9646039663f_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_49695d2b-5aa3-471b-8200-4efe6a501d64_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_60d99b7d-eef9-41f9-ba69-e2f3c6cc191c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Investments by Security Type</link:label>
    <link:label id="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrealized Gain (Loss) on Investments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:to="lab_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermInvestments_27746657-12bd-4b67-bc4c-f6e3627ca721_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments" xlink:to="lab_us-gaap_LongTermInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_ceb81501-3f69-4a21-a01f-198c41f83b6e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_b25b55e6-4bc9-4c84-819f-1c4c653a4dc4_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unpaid liabilities incurred in asset acquisition</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAssumed1_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAssumed1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities Assumed</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAssumed1" xlink:to="lab_us-gaap_LiabilitiesAssumed1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_2038056a-5cf0-4a28-b6b7-56b3785b4538_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of goods sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesAbstract_57312ad9-c6a1-4002-a4d8-ca45aa395a96_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues:</link:label>
    <link:label id="lab_us-gaap_RevenuesAbstract_label_en-US" xlink:label="lab_us-gaap_RevenuesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesAbstract" xlink:to="lab_us-gaap_RevenuesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_307c26b0-6ee3-4946-bf16-9de3f3a39f4c_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_label_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:label id="lab_exel_CollaborativeArrangementwithTakedaMember_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement with Takeda [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementwithTakedaMember" xlink:to="lab_exel_CollaborativeArrangementwithTakedaMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_9edd4bc1-04e9-4a61-b043-a4b2eac3ba4e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_204d5747-0aeb-44db-a988-aa3d2f28aa00_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_9a2bf971-9371-4a2d-b253-6acb48d936e0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_f4c50606-cee8-46fd-b968-921c04401be8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestReceivable_15ee6ee7-1055-446a-954c-af6f98fe6690_terseLabel_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest receivable</link:label>
    <link:label id="lab_us-gaap_InterestReceivable_label_en-US" xlink:label="lab_us-gaap_InterestReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Interest Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestReceivable" xlink:to="lab_us-gaap_InterestReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_434f7eb9-7b90-44a3-a568-1f6e054c45ba_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_e1c58131-88a9-4418-a9d8-afc062ef8e00_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other long-term liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_4e48dda3-a0fb-4976-b6a9-6e28b3a36750_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FiscalPeriod_7229e2c3-5931-4772-8df9-59d9dd318946_terseLabel_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period</link:label>
    <link:label id="lab_us-gaap_FiscalPeriod_label_en-US" xlink:label="lab_us-gaap_FiscalPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fiscal Period, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiscalPeriod" xlink:to="lab_us-gaap_FiscalPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_c5acdf8c-8610-4021-962b-fcbefc289114_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_86925a64-587b-4926-bfb0-afa214116964_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net income per share:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryGross_43716e64-3b01-4569-bd18-74c415d70a7a_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_InventoryGross_label_en-US" xlink:label="lab_us-gaap_InventoryGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryGross" xlink:to="lab_us-gaap_InventoryGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_23a415d7-f998-46a1-9f66-c517b06b020c_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_cd29102f-3724-4f1c-b9ef-0bdc0856993d_terseLabel_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maximum potential to vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_label_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:label id="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_documentation_en-US" xlink:label="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:href="exel-20210702.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:to="lab_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentQuarterlyReport_2154b13b-24f7-4fbe-9fe9-467d5a04173f_terseLabel_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:label id="lab_dei_DocumentQuarterlyReport_label_en-US" xlink:label="lab_dei_DocumentQuarterlyReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Quarterly Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentQuarterlyReport" xlink:to="lab_dei_DocumentQuarterlyReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_e598f1db-7119-40e5-a7ec-86c9cf184a3f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_001560fc-0c42-4178-ab93-045123b54966_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoods_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoods" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory, Finished Goods, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoods" xlink:to="lab_us-gaap_InventoryFinishedGoods" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_eff3526c-bd5d-4686-94b4-2f797f021e9a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_e27a495d-00c7-4eeb-b1e4-4703617f71c8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Number of investments in an unrealized loss position</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_7a6661f7-b3a8-4f4d-a5af-b530c6734929_negatedTotalLabel_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:label id="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_documentation_en-US" xlink:label="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_6f82a2ff-ab6b-43d3-9de3-3b1759e9d245_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionDomain_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionDomain" xlink:to="lab_us-gaap_AssetAcquisitionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_ce530f29-7dca-4bb1-bbcf-ecc62556daaa_verboseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_65cbea61-b796-4e5a-a674-c0288b08b646_netLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_a885cb0b-f632-464f-adfa-f27a5d26d0d3_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_bbe6f271-99ea-44ee-a2b7-cd90df10f4ea_terseLabel_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative arrangement, maximum aggregate commercial milestone payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_label_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</link:label>
    <link:label id="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_documentation_en-US" xlink:label="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:to="lab_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_42bc5697-1a7e-4813-bbc9-60e63163d885_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_1c74fb18-3668-4cb7-a2c6-40b6e77e6010_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_8b9f6c9b-5b83-4332-b513-f176d9daf446_terseLabel_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_AssetAcquisitionLineItems_label_en-US" xlink:label="lab_us-gaap_AssetAcquisitionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Asset Acquisition [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetAcquisitionLineItems" xlink:to="lab_us-gaap_AssetAcquisitionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_ef74b631-7b5e-4667-b297-99769ef65a76_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_61cc2860-eec6-4931-b22d-b5517fb480ca_verboseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current portion</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNetCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="lab_us-gaap_ContractWithCustomerAssetNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5e0447a1-665f-4a5e-a9c6-6e0b58ac3a4a_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c62645ec-56c1-4ce9-9dac-c9924744c104_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents and restricted cash equivalents at end of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_71506bcd-e280-4225-a1c7-b90825577300_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_68453d76-2770-407a-b926-16ac5faf54bf_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_9f4ad442-c712-4f9b-a017-678f5c221272_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_ffd9cf2a-f25b-436c-be97-da9684e2f00c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Allowance for credit losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-sale, Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_f66a78cc-753d-4211-912e-18aa5323aec9_terseLabel_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Concentration Risks</link:label>
    <link:label id="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_label_en-US" xlink:label="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedules of Concentration of Risk, by Risk Factor [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:to="lab_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_36775d65-06be-4f0b-a894-b4aa072afa98_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_98288643-aba4-4d62-aee5-05bbcf658883_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_c2c26623-245f-4a4e-aadd-0f4bea6b7ade_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_8a9714d6-85ca-4c9a-b6b8-2624297365c9_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e3cfc259-8fe6-4d22-8880-d3adfa61d400_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cash and Cash Equivalents, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="lab_us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_90db44c0-96bd-43cb-9c4d-37d28f9dea8b_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Rebates and fees due to customers</link:label>
    <link:label id="lab_us-gaap_CustomerRefundLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Customer Refund Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerRefundLiabilityCurrent" xlink:to="lab_us-gaap_CustomerRefundLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_681d1174-9421-4ca9-a527-6294ff168762_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_21dad55d-6e3b-4382-b2e4-056be62bb827_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_96b5a4a5-fbcf-4a77-856f-2516c0974c0b_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_bea0ecc0-b519-4b7f-a7ca-548e2f885259_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_ac085095-c71d-4c6a-b166-a0e0aee95164_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">PROVISION FOR INCOME TAXES</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_678f1fbd-0708-41e7-be63-4135db889c69_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_bc320c24-4321-461a-ac04-234f863abc42_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Non-cash investing activities:</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Additional Cash Flow Elements, Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:to="lab_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_b43a9ea1-1b7e-4af5-b972-7421f752e012_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_75b35ef6-53a7-4413-8b3e-b44cca5440d4_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_fc40dc5b-339f-4aaa-81cb-8cc5316982d3_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net cash (used in) provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_54b76c09-3d91-4f7e-99a8-90f3f04dc3cf_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_58376ae1-d3f0-4ae3-b3fd-006bcb635193_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Basis of Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_11783b7d-bee0-4256-8e3b-fe467b4309c1_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_cef82085-f1dd-48b1-8f89-d0b2234fb263_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_34f08e63-28d8-4d34-a744-06578ccc77a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Taxes paid related to net share settlement of equity awards</link:label>
    <link:label id="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Payment, Tax Withholding, Share-based Payment Arrangement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="lab_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_e6eb2031-21a1-4b73-bafd-d593bd96c3bd_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeForwardMember_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeForwardMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Foreign Exchange Forward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeForwardMember" xlink:to="lab_us-gaap_ForeignExchangeForwardMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_699539f6-17d4-4f2e-a501-b5d47a81bf3d_terseLabel_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_label_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:label id="lab_exel_AccredoHealthIncorporatedMember_documentation_en-US" xlink:label="lab_exel_AccredoHealthIncorporatedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Accredo Health, Incorporated [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember" xlink:href="exel-20210702.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AccredoHealthIncorporatedMember" xlink:to="lab_exel_AccredoHealthIncorporatedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_91177a16-bd05-4c12-a907-c5b4666259a0_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_983e7e3a-ae74-4fe1-86fe-274653517038_verboseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money market funds</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember" xlink:to="lab_us-gaap_MoneyMarketFundsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_9d959177-91d8-478b-aac1-026d0c50bee3_terseLabel_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_label_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:label id="lab_exel_AffiliatesofCVSHealthCorporationMember_documentation_en-US" xlink:label="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Affiliates of CVS Health Corporation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:href="exel-20210702.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_exel_AffiliatesofCVSHealthCorporationMember" xlink:to="lab_exel_AffiliatesofCVSHealthCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_9944307b-cfa3-423c-bedd-1a10d1d231d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_018cff85-da8f-4370-92df-725d4e450711_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_1e4e8c77-eedf-47b8-aafc-6ebab2523976_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_1f969510-bda5-4f15-b8d7-751059558dbf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_b78280f0-cc78-474e-94f7-28a7c5b4da51_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f3289046-0f2d-4af5-abb7-994e5b71669d_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_78faf809-96e5-4646-ac7e-0dcb7564d331_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_4c5a36c5-ada3-4d2e-9888-0c9e2f6fa31b_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_4e59fa5f-868f-4ab6-a15f-6487a70a8100_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at December&#160;31, 2020</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_9b525669-434a-47ae-857f-527e03e66aae_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Balance at June&#160;30, 2021</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_66553af4-e2d4-4708-b579-fe4fcb69d04e_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_089fa91c-a0b4-4587-93c1-4e63321063ea_verboseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_6b840816-c905-4304-8f81-50773944f9d4_netLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License revenues</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ee594dd4-f872-43a1-ab66-e4ce3e3b7a94_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to reconcile net income to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_9c84b22e-3e6a-49e7-8a10-e7bdb24be8ff_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Maturing in one year or less</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_6db8bd28-c182-4faa-aca9-e7e04db816a1_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryLineItems_b50127be-8365-4af4-a36b-ae32ced62e4b_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:label id="lab_us-gaap_InventoryLineItems_label_en-US" xlink:label="lab_us-gaap_InventoryLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Inventory [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryLineItems" xlink:to="lab_us-gaap_InventoryLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_af8d648e-4e42-4724-bebf-cd6c1d4a943b_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xmlns:xml="http://www.w3.org/XML/1998/namespace" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>11
<FILENAME>exel-20210702_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with Wdesk from Workiva-->
<!--Copyright 2021 Workiva-->
<!--r:bc27c0f4-614e-423b-9a9d-739acc8b0062,g:8a6c9018-6394-4ede-a81c-8595204a57b8-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.exelixis.com/role/CoverPage" xlink:type="simple" xlink:href="exel-20210702.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_c53ea335-fc55-4a37-8cca-210f98feceac" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentType_c53ea335-fc55-4a37-8cca-210f98feceac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentQuarterlyReport_6f4bb355-e6b0-4869-bd17-5738e14483c6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentQuarterlyReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentQuarterlyReport_6f4bb355-e6b0-4869-bd17-5738e14483c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_5788381e-7f67-4e88-b2e8-391567672c12" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentPeriodEndDate_5788381e-7f67-4e88-b2e8-391567672c12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_4481a55a-bf23-4f51-9b87-7dd50c9f2d59" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentTransitionReport_4481a55a-bf23-4f51-9b87-7dd50c9f2d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_e4e4a7c1-80e1-495d-aa45-498fcd4a5bf5" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityFileNumber_e4e4a7c1-80e1-495d-aa45-498fcd4a5bf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_77111af0-03ce-49fd-bf02-814827dd8c65" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityRegistrantName_77111af0-03ce-49fd-bf02-814827dd8c65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_67fdcb8d-b246-40cc-a578-4abd83276542" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityIncorporationStateCountryCode_67fdcb8d-b246-40cc-a578-4abd83276542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_176814f0-7d5e-4649-8d2b-ea9acb4dee0e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityTaxIdentificationNumber_176814f0-7d5e-4649-8d2b-ea9acb4dee0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_371445ca-5f30-430b-b04b-ae7a566192d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityAddressAddressLine1_371445ca-5f30-430b-b04b-ae7a566192d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_5aad5651-80f6-4186-b555-a62fdf1a7e9d" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityAddressCityOrTown_5aad5651-80f6-4186-b555-a62fdf1a7e9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_e749c59b-b9ee-43ab-ab93-87247219e1d0" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityAddressStateOrProvince_e749c59b-b9ee-43ab-ab93-87247219e1d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_d893f98a-c8ba-4400-923e-3344cfcb01de" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityAddressPostalZipCode_d893f98a-c8ba-4400-923e-3344cfcb01de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_cb8e54f2-4a6a-4bac-886c-a67777fbbfc6" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_CityAreaCode_cb8e54f2-4a6a-4bac-886c-a67777fbbfc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_50e48d18-bc26-4f73-bb81-d135e3df53e1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_LocalPhoneNumber_50e48d18-bc26-4f73-bb81-d135e3df53e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_89af38d7-42f4-4276-9024-5e392eded00f" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_Security12bTitle_89af38d7-42f4-4276-9024-5e392eded00f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_f2f440e4-2c3a-4f7b-bc72-e04a61472677" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_TradingSymbol_f2f440e4-2c3a-4f7b-bc72-e04a61472677" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_c401de79-697e-4891-a321-b35137ec11d3" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_SecurityExchangeName_c401de79-697e-4891-a321-b35137ec11d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_e983a2f9-2310-4576-8b7f-eb60767acb33" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityCurrentReportingStatus_e983a2f9-2310-4576-8b7f-eb60767acb33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_a9163ad3-5678-4f4f-ba7e-6a2a6c97b32e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityInteractiveDataCurrent_a9163ad3-5678-4f4f-ba7e-6a2a6c97b32e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_1ad1d4c5-1762-4b3d-a964-0686d0c29b6a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityFilerCategory_1ad1d4c5-1762-4b3d-a964-0686d0c29b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_dc85ca84-2148-4587-8790-ed6058167079" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntitySmallBusiness_dc85ca84-2148-4587-8790-ed6058167079" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_c61244f7-0c5c-410e-82a2-41f5ce8b618a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityEmergingGrowthCompany_c61244f7-0c5c-410e-82a2-41f5ce8b618a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_42f119b1-8679-42aa-8675-59ade4294374" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityShellCompany_42f119b1-8679-42aa-8675-59ade4294374" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_bbb83f49-1b9b-4845-b352-b2c2f43090d1" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_bbb83f49-1b9b-4845-b352-b2c2f43090d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_9c210ff9-172c-4554-aaae-3cc17b6ed90e" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_AmendmentFlag_9c210ff9-172c-4554-aaae-3cc17b6ed90e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_87b32508-b634-42e9-885d-36fb667bcfdc" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentFiscalYearFocus_87b32508-b634-42e9-885d-36fb667bcfdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_359f2b8f-94b4-4016-a09e-4942e0c94ed4" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_DocumentFiscalPeriodFocus_359f2b8f-94b4-4016-a09e-4942e0c94ed4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_f08eb28c-95e1-4512-b4ff-6a73de62912a" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_EntityCentralIndexKey_f08eb28c-95e1-4512-b4ff-6a73de62912a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_08a55e5a-3bb8-4080-87d2-4ae98b653659" xlink:href="https://xbrl.sec.gov/dei/2021/dei-2021.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_38e89492-444b-4341-ab46-f95cbb15e546" xlink:to="loc_dei_CurrentFiscalYearEndDate_08a55e5a-3bb8-4080-87d2-4ae98b653659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_40a63db0-1f1c-4750-8f39-dc1f10fe8b0b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40a63db0-1f1c-4750-8f39-dc1f10fe8b0b" xlink:to="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbfc8fc8-f5e9-4d69-b715-77bb2dcab89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_cbfc8fc8-f5e9-4d69-b715-77bb2dcab89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShortTermInvestments_d35918c3-3b4a-45b3-8f56-f0bf400cb85e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_ShortTermInvestments_d35918c3-3b4a-45b3-8f56-f0bf400cb85e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReceivablesNetCurrent_2fcc6469-a32d-49ff-bdad-d98e824c4a06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ReceivablesNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_ReceivablesNetCurrent_2fcc6469-a32d-49ff-bdad-d98e824c4a06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_324e766e-3b77-416a-a053-c9a1269722f7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_InventoryNet_324e766e-3b77-416a-a053-c9a1269722f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1c7a152-b972-49af-9ae4-e408f5409a85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c1c7a152-b972-49af-9ae4-e408f5409a85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_ecef944f-c30a-4699-8879-8cfd19dbde80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_252b436e-7b00-4cb3-a17c-8c96bf97208b" xlink:to="loc_us-gaap_AssetsCurrent_ecef944f-c30a-4699-8879-8cfd19dbde80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermInvestments_94c2a4be-2988-426a-873a-9790f15fbe49" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_LongTermInvestments_94c2a4be-2988-426a-873a-9790f15fbe49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_0b826d3c-2348-4602-960a-325e2a34cb3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_0b826d3c-2348-4602-960a-325e2a34cb3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxAssetsNet_63b88a49-7e66-4348-b39c-a129f4b41c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxAssetsNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_DeferredIncomeTaxAssetsNet_63b88a49-7e66-4348-b39c-a129f4b41c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_1bd65758-cc90-4afe-b0da-cb4448779636" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_Goodwill_1bd65758-cc90-4afe-b0da-cb4448779636" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_ec2758fe-aa33-4559-b2a1-eb79538fd20f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_ec2758fe-aa33-4559-b2a1-eb79538fd20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_b5cd3973-213e-4d9a-b58e-6140237c65a8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_423d97a3-21b7-481d-b315-f675602eb067" xlink:to="loc_us-gaap_Assets_b5cd3973-213e-4d9a-b58e-6140237c65a8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_40a63db0-1f1c-4750-8f39-dc1f10fe8b0b" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_9cde06d7-3f62-4862-9a57-ce13a1593eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_us-gaap_AccountsPayableCurrent_9cde06d7-3f62-4862-9a57-ce13a1593eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedEmployeeBenefitsCurrent_23ff8301-d4e7-4a52-84e3-8e6562210b8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_us-gaap_AccruedEmployeeBenefitsCurrent_23ff8301-d4e7-4a52-84e3-8e6562210b8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedClinicalLiabilitiesCurrent_6544bd8e-a832-4278-b95c-5abe7f2096a0" xlink:href="exel-20210702.xsd#exel_AccruedClinicalLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_exel_AccruedClinicalLiabilitiesCurrent_6544bd8e-a832-4278-b95c-5abe7f2096a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerRefundLiabilityCurrent_4ba51026-d69c-4b79-aab9-c25ab1b1f72f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerRefundLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_us-gaap_CustomerRefundLiabilityCurrent_4ba51026-d69c-4b79-aab9-c25ab1b1f72f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccruedCollaborationLiabilityCurrent_7d964fbd-3a17-49a7-843d-43940b2acc1d" xlink:href="exel-20210702.xsd#exel_AccruedCollaborationLiabilityCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_exel_AccruedCollaborationLiabilityCurrent_7d964fbd-3a17-49a7-843d-43940b2acc1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fd9ba95f-69b7-4520-a9ad-d9ac943db6c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_fd9ba95f-69b7-4520-a9ad-d9ac943db6c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_5091ac1d-cec7-407b-b545-a016c4185352" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_a6735e67-9005-4e39-a36b-3979bd6ad1ee" xlink:to="loc_us-gaap_LiabilitiesCurrent_5091ac1d-cec7-407b-b545-a016c4185352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b10087f9-8abe-491e-8da0-ced63e4bc544" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_b10087f9-8abe-491e-8da0-ced63e4bc544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9423d32c-56ed-465f-9972-2d0c3fd00196" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_9423d32c-56ed-465f-9972-2d0c3fd00196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_67f31c9c-c7e1-4e85-99a0-45359cef728c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_67f31c9c-c7e1-4e85-99a0-45359cef728c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_26696ba2-8b05-4a93-9e6e-44a232a3f3a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_Liabilities_26696ba2-8b05-4a93-9e6e-44a232a3f3a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_c52ed6e2-1c2b-4734-9ccd-95c1cbdf94c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_CommitmentsAndContingencies_c52ed6e2-1c2b-4734-9ccd-95c1cbdf94c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_859a73c3-f663-43a2-a49c-528f25d25613" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_PreferredStockValue_859a73c3-f663-43a2-a49c-528f25d25613" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_59094cf7-cf17-44ec-ac17-f56f179aec75" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_CommonStockValue_59094cf7-cf17-44ec-ac17-f56f179aec75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_b1d39059-7a03-494f-b0ce-f05c72e53a2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_AdditionalPaidInCapital_b1d39059-7a03-494f-b0ce-f05c72e53a2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd59b2c4-e8fc-46d7-ba9d-a1022ce45a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cd59b2c4-e8fc-46d7-ba9d-a1022ce45a5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fa399be5-53e3-4b38-b267-c237b7f4ff97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_fa399be5-53e3-4b38-b267-c237b7f4ff97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_3a843d5d-4788-4d0e-b831-229915c861ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_9c1edc6b-4022-4f4b-8a49-f8d4de2c667c" xlink:to="loc_us-gaap_StockholdersEquity_3a843d5d-4788-4d0e-b831-229915c861ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e9f75f0-aab0-476e-a0f9-71871c80650b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_606e40be-8d95-4234-ad4b-3e791979d8fa" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2e9f75f0-aab0-476e-a0f9-71871c80650b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_c5a57598-88d7-4026-91ea-e0c61cdba89f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c8f0287-133a-44d4-b138-e130d35d3961" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_c5a57598-88d7-4026-91ea-e0c61cdba89f" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c8f0287-133a-44d4-b138-e130d35d3961" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_4e03b06d-e76a-4021-98fe-202f58e251ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_1c8f0287-133a-44d4-b138-e130d35d3961" xlink:to="loc_us-gaap_StockholdersEquityAbstract_4e03b06d-e76a-4021-98fe-202f58e251ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1c965bcb-6d90-4bde-b459-3105dfd1c4ce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e03b06d-e76a-4021-98fe-202f58e251ae" xlink:to="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1c965bcb-6d90-4bde-b459-3105dfd1c4ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_036f4c43-fa9e-42bb-8d0f-4d1570b4c7f3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1c965bcb-6d90-4bde-b459-3105dfd1c4ce" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_036f4c43-fa9e-42bb-8d0f-4d1570b4c7f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_33e2baf8-7592-44d0-9c89-333a73e31d92" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1c965bcb-6d90-4bde-b459-3105dfd1c4ce" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_33e2baf8-7592-44d0-9c89-333a73e31d92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_06578c95-1120-4da6-8c24-9430e510c61d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_1c965bcb-6d90-4bde-b459-3105dfd1c4ce" xlink:to="loc_us-gaap_PreferredStockSharesIssued_06578c95-1120-4da6-8c24-9430e510c61d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_4e03b06d-e76a-4021-98fe-202f58e251ae" xlink:to="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_c7a6075e-7b6b-4e6a-8c40-59070232431f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_c7a6075e-7b6b-4e6a-8c40-59070232431f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8974a012-1047-46bd-9e00-74e02cb50f3f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8974a012-1047-46bd-9e00-74e02cb50f3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_360fcbfc-e133-42e6-be75-469c5b0ae81f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:to="loc_us-gaap_CommonStockSharesIssued_360fcbfc-e133-42e6-be75-469c5b0ae81f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_61448e3b-3ae4-4d1f-98c8-ecdd3fba3ea0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_6695df97-673e-49eb-88ee-9cc6f07c8b35" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_61448e3b-3ae4-4d1f-98c8-ecdd3fba3ea0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_cf37c765-cd01-4db0-9280-2226fb2b1a1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_cf37c765-cd01-4db0-9280-2226fb2b1a1d" xlink:to="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:to="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_93b00a8b-84b6-46af-aa14-76072e313ccc" xlink:to="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_0d267660-f3d8-417c-9004-d862dacb9618" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_ProductMember_0d267660-f3d8-417c-9004-d862dacb9618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_f01e7bf9-8d9c-49f9-a51a-a1ebb68cecd0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_LicenseMember_f01e7bf9-8d9c-49f9-a51a-a1ebb68cecd0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_dd931a16-17cf-49e4-8d95-86d578ec121a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7cde95fd-2423-4eb7-8024-b7ec3e9b56a3" xlink:to="loc_us-gaap_ServiceMember_dd931a16-17cf-49e4-8d95-86d578ec121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_da933384-793c-4b34-8820-e1d97830f22e" xlink:to="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenuesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_870a95f3-f5cf-435c-80a5-10de082a1336" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesAbstract_9e611091-ead2-4f87-a93e-64eaab114eba" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_870a95f3-f5cf-435c-80a5-10de082a1336" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_6cc3567a-a53f-447c-b28b-82c981a48b24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_6cc3567a-a53f-447c-b28b-82c981a48b24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4a6ad3f5-b967-487b-b0b0-f77f8190185f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4a6ad3f5-b967-487b-b0b0-f77f8190185f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e11ed3e-473d-43a8-883b-67b412bc0fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_9e11ed3e-473d-43a8-883b-67b412bc0fa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostsAndExpenses_395e6c32-27d0-44cb-a70c-9ca114963446" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CostsAndExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_2532a6e3-336c-4da1-84a0-7973f678ad1c" xlink:to="loc_us-gaap_CostsAndExpenses_395e6c32-27d0-44cb-a70c-9ca114963446" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fd3a9fb3-dfda-476c-9d09-c16c0ac6e153" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OperatingIncomeLoss_fd3a9fb3-dfda-476c-9d09-c16c0ac6e153" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestIncomeOther_965a267e-531a-4b02-b681-43ef37653820" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeOther"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_InterestIncomeOther_965a267e-531a-4b02-b681-43ef37653820" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_05e1a760-91b0-4b6a-b921-8cef658a357b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_05e1a760-91b0-4b6a-b921-8cef658a357b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a7be83d5-259b-4ba6-a48c-89eb56cf744b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a7be83d5-259b-4ba6-a48c-89eb56cf744b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_50fe4073-210c-43e7-9ab5-e78dc45c694a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_50fe4073-210c-43e7-9ab5-e78dc45c694a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dc02d046-6d6a-4f0c-956f-e4c48eedaa73" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_NetIncomeLoss_dc02d046-6d6a-4f0c-956f-e4c48eedaa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_d169830f-c3da-4bb3-bb79-f2894ee51912" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:to="loc_us-gaap_EarningsPerShareBasic_d169830f-c3da-4bb3-bb79-f2894ee51912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_795a9ac3-908d-47d2-ac64-7842133f2e35" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_9ef612a1-f44d-4021-9401-e47870d95bd9" xlink:to="loc_us-gaap_EarningsPerShareDiluted_795a9ac3-908d-47d2-ac64-7842133f2e35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_286dfa58-7708-4a33-9526-88e8ee1c850b" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18a44779-4ccc-498d-812d-241962187a2a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_18a44779-4ccc-498d-812d-241962187a2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23586cbb-9cd2-4214-a81f-4a609ff8d4dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_193ada34-ef60-4547-a612-1c2a67bb48b3" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_23586cbb-9cd2-4214-a81f-4a609ff8d4dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofComprehensiveIncome"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea05765f-de3f-483f-94fe-ecc8a3f115ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8e2c8bc7-c813-40e6-b9fb-764744c5f567" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea05765f-de3f-483f-94fe-ecc8a3f115ef" xlink:to="loc_us-gaap_NetIncomeLoss_8e2c8bc7-c813-40e6-b9fb-764744c5f567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_40315729-e7c9-41e4-a221-d24f6cc31704" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea05765f-de3f-483f-94fe-ecc8a3f115ef" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_40315729-e7c9-41e4-a221-d24f6cc31704" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a51da539-1bf7-4466-b982-431339ef7c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_40315729-e7c9-41e4-a221-d24f6cc31704" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a51da539-1bf7-4466-b982-431339ef7c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_0999b643-a19d-4f8c-a99b-a76b8c8993d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ea05765f-de3f-483f-94fe-ecc8a3f115ef" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_0999b643-a19d-4f8c-a99b-a76b8c8993d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdf5ecb2-5788-4f17-a930-dc049843f474" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b52d5f10-c1a8-4836-99c9-dacfd709c17c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_bdf5ecb2-5788-4f17-a930-dc049843f474" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b52d5f10-c1a8-4836-99c9-dacfd709c17c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_43146d23-f319-4f5d-88f7-bd983b0c56e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_43146d23-f319-4f5d-88f7-bd983b0c56e5" xlink:to="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_b49b8867-fd9f-4924-83ec-1da5f5cecc01" xlink:to="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_81b9f18b-51fe-4679-b209-34ed52f3fece" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_CommonStockMember_81b9f18b-51fe-4679-b209-34ed52f3fece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_955ff713-1cf1-4638-bb0b-344d2d22ea8d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_955ff713-1cf1-4638-bb0b-344d2d22ea8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_634783d0-4050-4d89-ab1e-dadd41f4b7d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_634783d0-4050-4d89-ab1e-dadd41f4b7d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_b00f2a90-fc8b-416e-a24f-ee88f5094978" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_0e3a9704-61b6-4e42-9a73-5289e50b8531" xlink:to="loc_us-gaap_RetainedEarningsMember_b00f2a90-fc8b-416e-a24f-ee88f5094978" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_cd08d20a-a7bb-4de5-82f6-aae5491878ef" xlink:to="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_750184a1-5755-4a92-9539-4b8171828b2f" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_39d34215-46fd-44a3-b631-c0c9a2a9b9b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_39d34215-46fd-44a3-b631-c0c9a2a9b9b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_1590fa8d-3043-455d-834c-0bacba35e127" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockholdersEquity_1590fa8d-3043-455d-834c-0bacba35e127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1e01c09a-3701-4bea-beb5-0aebfc0cca62" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_NetIncomeLoss_1e01c09a-3701-4bea-beb5-0aebfc0cca62" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ec75dff-6683-422b-8800-f188ed161ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_3ec75dff-6683-422b-8800-f188ed161ec2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3edb99e1-8061-464c-bd41-fc6ffea59568" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_3edb99e1-8061-464c-bd41-fc6ffea59568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_34f4232e-9258-44ef-917b-1b3225700d09" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_34f4232e-9258-44ef-917b-1b3225700d09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0a17865a-fc6a-47dd-b8a8-ff1b612fc6ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation_0a17865a-fc6a-47dd-b8a8-ff1b612fc6ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4b990ffc-d051-4f40-9cd6-ee68d34f53f2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_4b990ffc-d051-4f40-9cd6-ee68d34f53f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_b0ce9907-0ad9-4f76-8f78-f3e97cfe5276" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_b0ce9907-0ad9-4f76-8f78-f3e97cfe5276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_a5fa907d-24a0-4d49-b7a8-63ffa8c67c64" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6eea591c-82c8-4651-b684-037a509fc610" xlink:to="loc_us-gaap_StockholdersEquity_a5fa907d-24a0-4d49-b7a8-63ffa8c67c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="exel-20210702.xsd#CondensedConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_4b9bf8e1-58c5-4833-8634-e5452d1a9a66" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_NetIncomeLoss_4b9bf8e1-58c5-4833-8634-e5452d1a9a66" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1244b7c9-f6bf-4767-8299-d50977a35d23" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1244b7c9-f6bf-4767-8299-d50977a35d23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_9ac781a2-182a-4d38-9fb7-efb86db29feb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_us-gaap_ShareBasedCompensation_9ac781a2-182a-4d38-9fb7-efb86db29feb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NoncashLeaseExpense_8ab13c67-0fc6-4c85-8da6-168c23921f91" xlink:href="exel-20210702.xsd#exel_NoncashLeaseExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_exel_NoncashLeaseExpense_8ab13c67-0fc6-4c85-8da6-168c23921f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_00742534-7a2f-4580-a89a-fa69cb23a70b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_00742534-7a2f-4580-a89a-fa69cb23a70b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_7d53ecc8-4c3a-41c9-891b-a86b889f2176" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashIncomeExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_7d53ecc8-4c3a-41c9-891b-a86b889f2176" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ebc907cd-fcae-437a-80fd-3daa0a3b5b4f" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_55700c65-5f4f-47d3-9606-f7e5cfee61ae" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_55700c65-5f4f-47d3-9606-f7e5cfee61ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_b9b0865d-cbfc-432c-9700-5425006ccde3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_b9b0865d-cbfc-432c-9700-5425006ccde3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e339128-48e9-4ef8-b6ec-761af8e4659f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_0e339128-48e9-4ef8-b6ec-761af8e4659f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a942ad33-4237-45b3-a450-f2c1f7fdd364" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_a942ad33-4237-45b3-a450-f2c1f7fdd364" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c8698025-6c26-42ed-88ff-ead4b08185a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_4a8696c7-b5e6-4667-b278-a2ef34942fe0" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_c8698025-6c26-42ed-88ff-ead4b08185a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1573de2d-558b-4b0c-be30-ddd96952e800" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_1573de2d-558b-4b0c-be30-ddd96952e800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aba890aa-d9f7-4b4d-9148-2d02b0863219" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_aba890aa-d9f7-4b4d-9148-2d02b0863219" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireInvestments_f514f045-7d1f-481e-b7ca-7b2f72ba13e2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:to="loc_us-gaap_PaymentsToAcquireInvestments_f514f045-7d1f-481e-b7ca-7b2f72ba13e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_abb7f997-e0b4-4a84-90d1-be592b732caf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_abb7f997-e0b4-4a84-90d1-be592b732caf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c67c8f1a-4ee1-4d03-aa49-16f28c702f80" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_02251cd4-1bd8-4eef-8c7a-ba2299d0a26e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_c67c8f1a-4ee1-4d03-aa49-16f28c702f80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1c7f773b-6031-4789-a0f6-4b0b418c4491" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1c7f773b-6031-4789-a0f6-4b0b418c4491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f9c01538-c19b-4db5-addf-6df1f85ecd0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1c7f773b-6031-4789-a0f6-4b0b418c4491" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_f9c01538-c19b-4db5-addf-6df1f85ecd0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_15df547b-93c7-4867-a709-7f6b11206c72" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1c7f773b-6031-4789-a0f6-4b0b418c4491" xlink:to="loc_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_15df547b-93c7-4867-a709-7f6b11206c72" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bef40f10-8d7e-40a6-a3b7-e00d63b2c389" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_1c7f773b-6031-4789-a0f6-4b0b418c4491" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_bef40f10-8d7e-40a6-a3b7-e00d63b2c389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65b13605-0de0-4d96-9d55-5759456cdbda" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_65b13605-0de0-4d96-9d55-5759456cdbda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f53c7ea5-8732-4b2a-9548-e1305f058a41" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_f53c7ea5-8732-4b2a-9548-e1305f058a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f2be3c9-8e44-4c16-bb51-6808d9e738f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4f2be3c9-8e44-4c16-bb51-6808d9e738f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7252d150-bcf0-41c8-a640-a82e67e75e3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_8b85670e-12ba-499d-ab63-8464d180bcff" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7252d150-bcf0-41c8-a640-a82e67e75e3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_d7ce7e7a-a8d4-422d-9f9f-57c53e0fd936" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7252d150-bcf0-41c8-a640-a82e67e75e3d" xlink:to="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_d7ce7e7a-a8d4-422d-9f9f-57c53e0fd936" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_3d3d5a4e-6096-4f7a-a916-1660a6e80ff7" xlink:href="exel-20210702.xsd#exel_RightOfUseAssetObtainedInExchangeForLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract_d7ce7e7a-a8d4-422d-9f9f-57c53e0fd936" xlink:to="loc_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability_3d3d5a4e-6096-4f7a-a916-1660a6e80ff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5e3b1931-16fd-4be4-aa0a-5b449342e080" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7252d150-bcf0-41c8-a640-a82e67e75e3d" xlink:to="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5e3b1931-16fd-4be4-aa0a-5b449342e080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8fa1995e-66ab-4973-8797-a9406f42d99e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5e3b1931-16fd-4be4-aa0a-5b449342e080" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_8fa1995e-66ab-4973-8797-a9406f42d99e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAssumed1_189d0eba-69fa-4444-85f2-7b0b57ce13e6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAssumed1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5e3b1931-16fd-4be4-aa0a-5b449342e080" xlink:to="loc_us-gaap_LiabilitiesAssumed1_189d0eba-69fa-4444-85f2-7b0b57ce13e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid_120f2c27-6e4d-4585-8407-0fbb514897c1" xlink:href="exel-20210702.xsd#exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract_5e3b1931-16fd-4be4-aa0a-5b449342e080" xlink:to="loc_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid_120f2c27-6e4d-4585-8407-0fbb514897c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="exel-20210702.xsd#OrganizationandSummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38f13b7d-c4fc-49e7-816d-b4b67dc5f54d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_012ddf3d-88f6-4728-a3ee-cd913d338e7e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_38f13b7d-c4fc-49e7-816d-b4b67dc5f54d" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_012ddf3d-88f6-4728-a3ee-cd913d338e7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="exel-20210702.xsd#OrganizationandSummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_81c68c3c-4902-4d8c-afc8-96c9c85ca05d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_81c68c3c-4902-4d8c-afc8-96c9c85ca05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dd798279-e5da-4f8d-9084-de997ea0aed3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_dd798279-e5da-4f8d-9084-de997ea0aed3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FiscalPeriod_47878af7-5ac2-4f99-a6e4-460a6ea2caad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiscalPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_FiscalPeriod_47878af7-5ac2-4f99-a6e4-460a6ea2caad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68d89411-576c-4f84-a28e-6f88e8b91863" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_68d89411-576c-4f84-a28e-6f88e8b91863" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_48ae941a-c455-4c5b-bb4f-4efb0b9c182b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_UseOfEstimates_48ae941a-c455-4c5b-bb4f-4efb0b9c182b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8c492e97-a3fc-45f3-b7c3-65938064b6d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_8c492e97-a3fc-45f3-b7c3-65938064b6d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_0017fef4-722c-460f-a8a7-7b93668abd05" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativesPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_0017fef4-722c-460f-a8a7-7b93668abd05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6a238810-383c-40f9-8d21-4fef24d1f582" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6a238810-383c-40f9-8d21-4fef24d1f582" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d9491cfa-65d2-4023-bbde-bbc64e2c7359" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_780f95c5-afde-4a2e-9570-3fac379c9388" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_d9491cfa-65d2-4023-bbde-bbc64e2c7359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#OrganizationandSummaryofSignificantAccountingPoliciesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_412ad432-9d0e-46e4-b1c4-3f22aea2be15" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_412ad432-9d0e-46e4-b1c4-3f22aea2be15" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:to="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0b53f08a-d8a2-4819-9c0d-68cf6eaefdab" xlink:to="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ResultingFromDiscoveryEffortsMember_8facfba1-9260-4d8e-9c75-e4eda7c2018e" xlink:href="exel-20210702.xsd#exel_ResultingFromDiscoveryEffortsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:to="loc_exel_ResultingFromDiscoveryEffortsMember_8facfba1-9260-4d8e-9c75-e4eda7c2018e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductsDerivedFromOtherCompoundsMember_64237584-f557-4ff3-9dbe-d780c7724741" xlink:href="exel-20210702.xsd#exel_ProductsDerivedFromOtherCompoundsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_6c99d5b0-9264-4894-a8fc-2ac5b755fd2d" xlink:to="loc_exel_ProductsDerivedFromOtherCompoundsMember_64237584-f557-4ff3-9dbe-d780c7724741" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:href="exel-20210702.xsd#exel_OrganizationAndSummaryOfSignificantPoliciesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesTable_b73da699-86c4-4c5e-9dd8-b2160477178f" xlink:to="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_NumberofProductsinCommercialMarket_1e2da1a8-ebb3-4aa7-a002-e2362a9cb197" xlink:href="exel-20210702.xsd#exel_NumberofProductsinCommercialMarket"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:to="loc_exel_NumberofProductsinCommercialMarket_1e2da1a8-ebb3-4aa7-a002-e2362a9cb197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_6f17cf63-b04c-4191-89e4-6e9fb581f5c7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems_318a8615-c3e4-4356-b1e9-eda52217c192" xlink:to="loc_us-gaap_NumberOfOperatingSegments_6f17cf63-b04c-4191-89e4-6e9fb581f5c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Revenues" xlink:type="simple" xlink:href="exel-20210702.xsd#Revenues"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Revenues" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba746c0d-dd7a-47a4-8873-0eaa30634cce" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_519bae9e-147e-4ce1-9283-cc360cae8293" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ba746c0d-dd7a-47a4-8873-0eaa30634cce" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_519bae9e-147e-4ce1-9283-cc360cae8293" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesTables" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7b1d2283-5be0-4aec-8de8-a26eba27ce03" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:to="loc_us-gaap_DisaggregationOfRevenueTableTextBlock_7b1d2283-5be0-4aec-8de8-a26eba27ce03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_153b260f-25f6-4476-b76f-5877ed656191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:to="loc_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock_153b260f-25f6-4476-b76f-5877ed656191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c4d09497-bca0-46f8-8a0d-4b1d5953eae2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_c4d09497-bca0-46f8-8a0d-4b1d5953eae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_33d3ffcd-4655-40c3-ae90-abfb88361874" xlink:href="exel-20210702.xsd#exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:to="loc_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock_33d3ffcd-4655-40c3-ae90-abfb88361874" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_12fceda5-1156-4133-a7eb-66ffec3f70f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_ec92cf76-34d9-43c5-8419-47c337306146" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_12fceda5-1156-4133-a7eb-66ffec3f70f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesbyDisaggregatedCategoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_62e88496-b22b-4a2b-b4d8-affb26b95ee5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_62e88496-b22b-4a2b-b4d8-affb26b95ee5" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:to="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_1f56c7ea-0d1c-44a1-9ffc-3e894f1c5517" xlink:to="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductGrossMember_39b64cd6-8e27-4912-9111-c6dea5e23232" xlink:href="exel-20210702.xsd#exel_ProductGrossMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_ProductGrossMember_39b64cd6-8e27-4912-9111-c6dea5e23232" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ProductSalesDiscountsAndAllowancesMember_ebea96d1-f661-4f5d-867b-fd73df002695" xlink:href="exel-20210702.xsd#exel_ProductSalesDiscountsAndAllowancesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_ProductSalesDiscountsAndAllowancesMember_ebea96d1-f661-4f5d-867b-fd73df002695" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_f1c9120c-8a88-4451-88ec-c2c9e872f4ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_ProductMember_f1c9120c-8a88-4451-88ec-c2c9e872f4ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_8676da13-255c-41bb-96c4-490ceb8342e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_LicenseMember_8676da13-255c-41bb-96c4-490ceb8342e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_87f768d8-8a44-41fa-ab57-78601ca4b306" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_us-gaap_ServiceMember_87f768d8-8a44-41fa-ab57-78601ca4b306" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationMember_eb546266-840a-40ff-9e0e-c114233dee89" xlink:href="exel-20210702.xsd#exel_CollaborationMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_97ef7383-340b-4c81-bacd-46b1914a12b2" xlink:to="loc_exel_CollaborationMember_eb546266-840a-40ff-9e0e-c114233dee89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_21c5dbef-08ca-49ee-a5aa-33769dcdbb6d" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acdeebbc-985c-405f-ad55-5e8b87aa8652" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_1fa884fd-40bf-4f38-aab0-25002088e358" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_acdeebbc-985c-405f-ad55-5e8b87aa8652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9542d5bd-be12-445c-8ec2-a5c39b6907dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9542d5bd-be12-445c-8ec2-a5c39b6907dc" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_fbc15300-48ee-4efe-b5d1-d5610da33d87" xlink:to="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_IpsenMember_14314765-ba5b-4061-84d9-68f3a5edcb49" xlink:href="exel-20210702.xsd#exel_IpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_IpsenMember_14314765-ba5b-4061-84d9-68f3a5edcb49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofMcKessonCorporationMember_d403e3b4-9168-4fba-9946-2da79dc441e5" xlink:href="exel-20210702.xsd#exel_AffiliatesofMcKessonCorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofMcKessonCorporationMember_d403e3b4-9168-4fba-9946-2da79dc441e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofCVSHealthCorporationMember_2b8db387-3dce-4f7e-bca7-534b4799a505" xlink:href="exel-20210702.xsd#exel_AffiliatesofCVSHealthCorporationMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofCVSHealthCorporationMember_2b8db387-3dce-4f7e-bca7-534b4799a505" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_29b9325e-a67a-4d47-a63f-946d536377a1" xlink:href="exel-20210702.xsd#exel_AffiliatesOfAmerisourceBergenCorporationMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesOfAmerisourceBergenCorporationMember_29b9325e-a67a-4d47-a63f-946d536377a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_4399f7e0-4ed8-4a64-be7a-5cb6013a48c1" xlink:href="exel-20210702.xsd#exel_AffiliatesofOptumSpecialtyPharmacyMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AffiliatesofOptumSpecialtyPharmacyMember_4399f7e0-4ed8-4a64-be7a-5cb6013a48c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AccredoHealthIncorporatedMember_e17871ae-bd11-49cf-b3df-a31ac51b1266" xlink:href="exel-20210702.xsd#exel_AccredoHealthIncorporatedMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_AccredoHealthIncorporatedMember_e17871ae-bd11-49cf-b3df-a31ac51b1266" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_TakedaMember_861bb422-392b-4a22-9279-eccab525fa37" xlink:href="exel-20210702.xsd#exel_TakedaMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_88b87f1b-5bfa-4219-90cf-2d1f02920cb1" xlink:to="loc_exel_TakedaMember_861bb422-392b-4a22-9279-eccab525fa37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_76ed5fb4-c8d1-4828-8904-4a98a55355af" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_021fe65f-c197-434a-953c-bb4a69ad9789" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_021fe65f-c197-434a-953c-bb4a69ad9789" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_1d103146-1f01-4323-9e54-2f8bb404560d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_ccda7fd9-6ae3-4158-8270-dcbac0ebe03d" xlink:to="loc_us-gaap_AccountsReceivableMember_1d103146-1f01-4323-9e54-2f8bb404560d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_9d28c3e1-1b66-42ef-a2fe-b476666f0fcb" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_161f9e57-1091-46cc-afdb-c52892d93ec4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_a4ccbfbc-bfaf-4fae-8bfe-8b88e2083c74" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_161f9e57-1091-46cc-afdb-c52892d93ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable_0ce267ea-fcdc-483c-81d7-b4501592f21c" xlink:to="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f8e429f3-2929-4167-9dde-2c90ad149c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems_55726a7d-c996-40a7-a9c9-416afbaef7c8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f8e429f3-2929-4167-9dde-2c90ad149c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f81803b8-9d93-4577-814e-6276b9585816" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_f81803b8-9d93-4577-814e-6276b9585816" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:to="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b0641e4c-dc82-4092-8518-316f11176269" xlink:to="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_2ee08c92-2e56-4295-aed4-a35713d9405c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_country_US_2ee08c92-2e56-4295-aed4-a35713d9405c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_260ec9e9-7b59-440d-b6fb-71092bd2c9de" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_EuropeMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_srt_EuropeMember_260ec9e9-7b59-440d-b6fb-71092bd2c9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_JP_0ed24f5a-83d5-4b05-8a61-bbcf76e1c60c" xlink:href="https://xbrl.sec.gov/country/2021/country-2021.xsd#country_JP"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_32261dcc-f8a6-4e07-a550-7faf78cc27fc" xlink:to="loc_country_JP_0ed24f5a-83d5-4b05-8a61-bbcf76e1c60c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_f7f12a79-ba1b-4585-abb9-1f14c4e4e63e" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda2044e-71a7-4f67-b5c2-d357b4061453" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_5ea3bc04-0ab4-4539-9b71-ac3b001b31e8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_bda2044e-71a7-4f67-b5c2-d357b4061453" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesNetProductRevenuesDisaggregatedbyProductDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3ecc133c-5865-4bb2-bdf6-ea0d7d2b75f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_3ecc133c-5865-4bb2-bdf6-ea0d7d2b75f9" xlink:to="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:to="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f5161f3b-4853-400b-98db-9df82f507703" xlink:to="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CabometyxMember_2635b2aa-e409-41cd-9a4a-b33888f8f946" xlink:href="exel-20210702.xsd#exel_CabometyxMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_exel_CabometyxMember_2635b2aa-e409-41cd-9a4a-b33888f8f946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CometriqMember_b209129c-bf74-4ddd-b20e-10203e88b478" xlink:href="exel-20210702.xsd#exel_CometriqMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_exel_CometriqMember_b209129c-bf74-4ddd-b20e-10203e88b478" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProductMember_6daeed51-e4c6-4dca-8c99-0e5e79c0f7cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProductMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_89838b06-5483-48b0-8b6b-9249d8dd76e0" xlink:to="loc_us-gaap_ProductMember_6daeed51-e4c6-4dca-8c99-0e5e79c0f7cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisaggregationOfRevenueLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueTable_69ddeab5-2e7d-4f9b-95aa-9f965858d000" xlink:to="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_731e082b-6850-4f53-929d-e90e2c039665" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisaggregationOfRevenueLineItems_8e9c8446-70d7-4bab-9642-22f48b4292cf" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_731e082b-6850-4f53-929d-e90e2c039665" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90ab86c0-4fda-45ea-b578-b203a1de5a56" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_90ab86c0-4fda-45ea-b578-b203a1de5a56" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_1b82375a-18ac-4c06-8b60-2635635492b7" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_cab5b821-d8b0-48d4-a213-1583d49e65e4" xlink:href="exel-20210702.xsd#exel_ChargebacksAndDiscountsForPromptPaymentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_ChargebacksAndDiscountsForPromptPaymentMember_cab5b821-d8b0-48d4-a213-1583d49e65e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_7ec9e77a-4ccb-44d9-92a5-066b68073653" xlink:href="exel-20210702.xsd#exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember_7ec9e77a-4ccb-44d9-92a5-066b68073653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AllowanceForProductRebatesMember_416e13c7-bddc-41f3-944f-52458889d9b4" xlink:href="exel-20210702.xsd#exel_AllowanceForProductRebatesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_651c3b06-75f9-4339-adde-d98f9169c837" xlink:to="loc_exel_AllowanceForProductRebatesMember_416e13c7-bddc-41f3-944f-52458889d9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_5165b605-bb55-4e27-827a-e42f658650ac" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_c5cf8c14-3c3c-4c5b-a392-678f13c6c4d4" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_19224e67-8baa-49a4-8f65-8e85ca432438" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_19224e67-8baa-49a4-8f65-8e85ca432438" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_dae41558-0271-4eee-9503-96784206916e" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod_dae41558-0271-4eee-9503-96784206916e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_fa98980c-c8e8-4f3a-a611-2d9ffe9ee4c1" xlink:href="exel-20210702.xsd#exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract_4d2be687-7811-4d3e-97c0-1c3524ae5d8f" xlink:to="loc_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod_fa98980c-c8e8-4f3a-a611-2d9ffe9ee4c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_88f73652-fc64-4dfe-8553-27ca4314b0c6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_88f73652-fc64-4dfe-8553-27ca4314b0c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_5eba6197-2114-4b35-a7ec-5274f5fc11fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_8477d535-67f1-44d2-a378-4f4dca1bd7df" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_5eba6197-2114-4b35-a7ec-5274f5fc11fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#RevenuesContractAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_70e5669e-7e18-476a-ba80-cd547056a13b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8118b8ec-dc90-48f8-b6be-3aca93f312dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_70e5669e-7e18-476a-ba80-cd547056a13b" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8118b8ec-dc90-48f8-b6be-3aca93f312dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd69a261-c8ee-46b4-8875-a06a7de9ee90" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8118b8ec-dc90-48f8-b6be-3aca93f312dc" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetCurrent_dd69a261-c8ee-46b4-8875-a06a7de9ee90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7e16271c-1cc2-455d-b8dc-99fa957946b1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNetNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8118b8ec-dc90-48f8-b6be-3aca93f312dc" xlink:to="loc_us-gaap_ContractWithCustomerAssetNetNoncurrent_7e16271c-1cc2-455d-b8dc-99fa957946b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_2a7f4483-edd1-49b7-8429-e85b17e00e5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ContractWithCustomerAssetNetAbstract_8118b8ec-dc90-48f8-b6be-3aca93f312dc" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_2a7f4483-edd1-49b7-8429-e85b17e00e5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_84b34cac-ae90-41ed-b48e-4d1e7519af4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_70e5669e-7e18-476a-ba80-cd547056a13b" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_84b34cac-ae90-41ed-b48e-4d1e7519af4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_58a1bf31-c8f1-4302-ba18-809e0707b5e8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_84b34cac-ae90-41ed-b48e-4d1e7519af4f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_58a1bf31-c8f1-4302-ba18-809e0707b5e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6a5c7e83-5076-4dd1-b112-216875c76f5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_84b34cac-ae90-41ed-b48e-4d1e7519af4f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_6a5c7e83-5076-4dd1-b112-216875c76f5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_57ed8daf-332d-4712-8ef6-77cf2f1faaf6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract_84b34cac-ae90-41ed-b48e-4d1e7519af4f" xlink:to="loc_us-gaap_ContractWithCustomerLiability_57ed8daf-332d-4712-8ef6-77cf2f1faaf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_70e5669e-7e18-476a-ba80-cd547056a13b" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6cfeea0f-6514-4538-9ac6-d42ff143d7a9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_82b9ec15-6a9c-4763-afcd-52818ac73e89" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_44097990-30d5-4b78-a0e1-877edaadf403" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_82b9ec15-6a9c-4763-afcd-52818ac73e89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7c6a7cf1-b8ba-4647-bb1f-2d5d4005d899" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_5915d98e-db6c-4f10-86f3-ad56997d2103" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement_5915d98e-db6c-4f10-86f3-ad56997d2103" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_5c74a300-c136-40a1-b907-4e2d57e7588f" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement_5c74a300-c136-40a1-b907-4e2d57e7588f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_fb285c80-bd30-4b53-9436-80deb6810652" xlink:href="exel-20210702.xsd#exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized_fb285c80-bd30-4b53-9436-80deb6810652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_0e6424af-f720-4840-aee1-800098c6e8e0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod_0e6424af-f720-4840-aee1-800098c6e8e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_496baf1c-fca6-4239-8d59-ef27b25e1ad4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_b8dea86d-7b14-4dbb-9964-f05143454484" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_496baf1c-fca6-4239-8d59-ef27b25e1ad4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad9e25a-b15f-4478-b49d-59827d8027d4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9af9ed73-21fc-4e9d-b5a6-7bac22e3180e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_aad9e25a-b15f-4478-b49d-59827d8027d4" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_9af9ed73-21fc-4e9d-b5a6-7bac22e3180e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbb8ae37-a50c-4256-acde-76790eb55b86" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cfbd2ee0-1b08-448a-950b-cab1adeccede" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_cbb8ae37-a50c-4256-acde-76790eb55b86" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_cfbd2ee0-1b08-448a-950b-cab1adeccede" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3b7f30e-7b2c-4bdf-8052-27aedfd3e0b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b3b7f30e-7b2c-4bdf-8052-27aedfd3e0b6" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:to="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_fb95c8e9-27b2-4fc9-ad39-077e71f35b23" xlink:to="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_c216ad20-ce81-4319-b64a-e587d62c3252" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:to="loc_us-gaap_LicenseMember_c216ad20-ce81-4319-b64a-e587d62c3252" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_7709025a-78dd-4f28-a40d-2d1099f5d0f6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_753a189e-c460-47a7-a002-439abb5f1e77" xlink:to="loc_us-gaap_ServiceMember_7709025a-78dd-4f28-a40d-2d1099f5d0f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:to="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_86b61925-93a5-4f07-8f8f-6a675bfa4060" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_752875e3-1032-446c-b623-fea04e398f42" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_f1754065-24a4-498b-ad59-36e46640c244" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_752875e3-1032-446c-b623-fea04e398f42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_62be7645-85c5-4d1f-a8de-97b8cf3241ab" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4104b2f8-4e64-4ab3-a972-77a0695660f4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1db3189c-e7ca-4982-b61a-b4e327978836" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4104b2f8-4e64-4ab3-a972-77a0695660f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6019f1e-dfad-4b54-aff6-1b2009ad16c0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_b6019f1e-dfad-4b54-aff6-1b2009ad16c0" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:to="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_afd40a6e-bb5e-4f42-ba81-2924bda851e1" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithIpsenMember_36a48547-fc48-439f-8ca3-92cc39d2e68e" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithIpsenMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1f4472b0-3974-40c4-a852-e525f7a62499" xlink:to="loc_exel_CollaborativeArrangementwithIpsenMember_36a48547-fc48-439f-8ca3-92cc39d2e68e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_7f160a41-6c9b-40ac-8028-9ddd0377813e" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_62f37536-d68c-4394-bc72-a881bd32c5ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_7feb4d8e-3bbf-4fec-8229-84ad004dabd2" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_62f37536-d68c-4394-bc72-a881bd32c5ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6726b79-b149-428d-b271-62677d085d24" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_c6726b79-b149-428d-b271-62677d085d24" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:to="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0b894621-7b3a-418a-9cb5-e60e5bca0285" xlink:to="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_cf4d23b4-19ae-4721-9744-949ff81d75ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:to="loc_us-gaap_LicenseMember_cf4d23b4-19ae-4721-9744-949ff81d75ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ServiceMember_e158c25b-d0a0-42ce-b7d6-58759f5b0f13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ServiceMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_9e1bcf22-a93f-47fb-8ac1-b8eb409140f4" xlink:to="loc_us-gaap_ServiceMember_e158c25b-d0a0-42ce-b7d6-58759f5b0f13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:to="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_75d8f0bd-d0f7-4ea9-822b-129c0b25a541" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_e14d598b-1cf7-42f8-932e-6df3a39918d3" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_1eab7913-702d-4490-b0d2-5a55100f69db" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_e14d598b-1cf7-42f8-932e-6df3a39918d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_d0e6f05a-feb5-4729-ae9c-cf127d219719" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aba490c8-a7a3-40e3-96b2-35ddc826dc87" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_4aa0fd8e-fbd6-4205-90eb-2557951603b8" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_aba490c8-a7a3-40e3-96b2-35ddc826dc87" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a852ddb8-dc54-4724-9530-f96671064612" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_a852ddb8-dc54-4724-9530-f96671064612" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_15850678-ddc9-4784-b063-57917965ea06" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithTakedaMember_c0bb96bc-2aaa-4382-80dc-7bcb8b4b8df0" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithTakedaMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_35092531-b15c-480d-916e-8ed6d9c8bf3b" xlink:to="loc_exel_CollaborativeArrangementwithTakedaMember_c0bb96bc-2aaa-4382-80dc-7bcb8b4b8df0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_c427b2c1-7fd8-4f54-a2dd-b9c2ceb327f1" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_813dca27-502e-486a-955f-c825c20a69f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_d0a2f930-1a2d-4161-97a7-7009c2f76e01" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_813dca27-502e-486a-955f-c825c20a69f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1808ddac-f61f-4bee-8066-d36442588670" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_1808ddac-f61f-4bee-8066-d36442588670" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:to="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_ebce0c04-5cd9-41e1-a2e0-7b1a92161748" xlink:to="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_GlaxoSmithKlineMember_fc35d227-249d-42c2-b432-be2bc46f6d4d" xlink:href="exel-20210702.xsd#exel_GlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_5fd11405-c608-4a44-8e56-8586092db310" xlink:to="loc_exel_GlaxoSmithKlineMember_fc35d227-249d-42c2-b432-be2bc46f6d4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:to="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_368ecd37-3ff0-40f1-98f5-65613f8577c8" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_c1d1d16d-2d72-48dc-b3d8-9909feba5d5e" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementswithGlaxoSmithKlineMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_a89ee055-aac5-414f-a343-f83ff104d095" xlink:to="loc_exel_CollaborativeArrangementswithGlaxoSmithKlineMember_c1d1d16d-2d72-48dc-b3d8-9909feba5d5e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_6bcb7b8f-7280-4d8f-8827-ab0b23983e27" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3d6454fe-f186-4bf7-85ad-d8370cd94594" xlink:href="exel-20210702.xsd#exel_CollaborationAgreementPercentOfRoyaltyOnNetSale"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:to="loc_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale_3d6454fe-f186-4bf7-85ad-d8370cd94594" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RoyaltyExpense_fed1abe5-07cb-4827-80f8-fd6f9dad08d5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RoyaltyExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_0079eff4-7c67-43bf-937d-3bf9f739bd9a" xlink:to="loc_us-gaap_RoyaltyExpense_fed1abe5-07cb-4827-80f8-fd6f9dad08d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663adadd-e27e-44e9-ab25-9f7ad2e37cb1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_663adadd-e27e-44e9-ab25-9f7ad2e37cb1" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:to="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_78fd1c59-8d55-4f55-a190-d10f5e05c2bc" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementwithGenentechMember_07c610e6-b662-4095-97e7-fdedffc0352b" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementwithGenentechMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_957ab144-7a80-4903-8283-cfc8c3f280c9" xlink:to="loc_exel_CollaborativeArrangementwithGenentechMember_07c610e6-b662-4095-97e7-fdedffc0352b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:to="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_f2fcd934-fe63-4480-a78e-0e8a1deb8b21" xlink:to="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CotellicMember_2df3d9fe-1bda-4707-9d96-45ed6a8d8196" xlink:href="exel-20210702.xsd#exel_CotellicMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_178ae6dd-35cc-4d01-a3eb-258c3a259f33" xlink:to="loc_exel_CotellicMember_2df3d9fe-1bda-4707-9d96-45ed6a8d8196" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_2376dd8b-50f9-4d7c-8426-c18ba19941ec" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_16791c8c-9690-430d-8d4b-12fcef1af4e7" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementIncomeLossFromAgreement"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:to="loc_exel_CollaborativeArrangementIncomeLossFromAgreement_16791c8c-9690-430d-8d4b-12fcef1af4e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b92b2dd6-ba91-4f04-a67b-3f7fc1e16c97" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_1c7abaaf-03a4-4540-93cb-97feddf626ca" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b92b2dd6-ba91-4f04-a67b-3f7fc1e16c97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a1198bd-c593-4a1a-b0ed-d71a80cb6e7c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4a1198bd-c593-4a1a-b0ed-d71a80cb6e7c" xlink:to="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:to="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionAxis_03171b45-5852-4baa-a5b9-c55ce1cce9b0" xlink:to="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_ed105fa4-467b-45e5-9de4-b3803b168679" xlink:href="exel-20210702.xsd#exel_CollaborativeAgreementWithGamaMabsPharmaSAMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionDomain_b49555d3-edfb-406b-93cc-26dd152b1934" xlink:to="loc_exel_CollaborativeAgreementWithGamaMabsPharmaSAMember_ed105fa4-467b-45e5-9de4-b3803b168679" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetAcquisitionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionTable_5101a025-2b02-4326-a910-b65daf2151db" xlink:to="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7cacd2db-ba39-4feb-b9de-52935829fe0b" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment_7cacd2db-ba39-4feb-b9de-52935829fe0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_da1ea57f-4505-4415-add8-0ff0bec0e44a" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments_da1ea57f-4505-4415-add8-0ff0bec0e44a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_439a2efc-62d6-4917-9a95-e16d3116422f" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments_439a2efc-62d6-4917-9a95-e16d3116422f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_0c3fb155-5fec-4114-9307-6c26676d6207" xlink:href="exel-20210702.xsd#exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments_0c3fb155-5fec-4114-9307-6c26676d6207" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_f4803b47-60ba-4b09-a2dc-05d3b7b93bcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_f4803b47-60ba-4b09-a2dc-05d3b7b93bcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_07c84340-fe01-469f-b201-1797a170b316" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionPaymentUponClosingOfTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionPaymentUponClosingOfTransaction_07c84340-fe01-469f-b201-1797a170b316" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c4773bf5-f52b-49c2-8497-5502c604ca82" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments_c4773bf5-f52b-49c2-8497-5502c604ca82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_487ac798-59be-4db7-9c55-7f365d2bf11a" xlink:href="exel-20210702.xsd#exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetAcquisitionLineItems_8974cd77-bf28-4bfe-8596-ed30512651d2" xlink:to="loc_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments_487ac798-59be-4db7-9c55-7f365d2bf11a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestments" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestments"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ab6e9f47-c465-45e5-8791-51b4c85f3a6c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_d57e3bbc-98e7-44a0-8546-3111d6530a45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_ab6e9f47-c465-45e5-8791-51b4c85f3a6c" xlink:to="loc_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock_d57e3bbc-98e7-44a0-8546-3111d6530a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_68ff369c-60bc-4777-b12d-aadd3136651d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_68ff369c-60bc-4777-b12d-aadd3136651d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_628fe514-6e25-4542-b360-8e5a242ea7ba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_628fe514-6e25-4542-b360-8e5a242ea7ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ea266678-517b-47b3-bd76-d67cc879a8d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:to="loc_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock_ea266678-517b-47b3-bd76-d67cc879a8d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bc0bfa8c-17dd-488d-9312-56ea1b4a5eef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock_bc0bfa8c-17dd-488d-9312-56ea1b4a5eef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_313b71a7-8783-41a2-aae9-6fa265c53fe0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_bff9ddab-5681-4c56-8a3e-770de1366dcc" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_313b71a7-8783-41a2-aae9-6fa265c53fe0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a3f3b60-17ec-4a51-86c6-62c7a2b73d52" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_be8c9938-70b4-4f01-b22b-428bf6ce4268" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_4a3f3b60-17ec-4a51-86c6-62c7a2b73d52" xlink:to="loc_us-gaap_CashAndCashEquivalentsAbstract_be8c9938-70b4-4f01-b22b-428bf6ce4268" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e033d5a8-2c0e-4a31-888b-e8bae8c40e98" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be8c9938-70b4-4f01-b22b-428bf6ce4268" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_e033d5a8-2c0e-4a31-888b-e8bae8c40e98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_5102b706-0041-4d97-8780-0dd5e036064f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be8c9938-70b4-4f01-b22b-428bf6ce4268" xlink:to="loc_us-gaap_RestrictedCashEquivalentsNoncurrent_5102b706-0041-4d97-8780-0dd5e036064f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0bc6754-17a7-4efe-a693-ac7ff457c6b6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_be8c9938-70b4-4f01-b22b-428bf6ce4268" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b0bc6754-17a7-4efe-a693-ac7ff457c6b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e5d373c-8285-4641-9649-35c112084af0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashEquivalentsCurrent_c081e7ce-d03d-4321-a107-9e42dea60922" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashEquivalentsCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e5d373c-8285-4641-9649-35c112084af0" xlink:to="loc_us-gaap_RestrictedCashEquivalentsCurrent_c081e7ce-d03d-4321-a107-9e42dea60922" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestReceivable_6eec00f3-8b3e-4b5d-97c2-0f72399124ed" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivable"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e5d373c-8285-4641-9649-35c112084af0" xlink:to="loc_us-gaap_InterestReceivable_6eec00f3-8b3e-4b5d-97c2-0f72399124ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8a29599a-be00-4f1a-87e8-81a441d9352f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e5d373c-8285-4641-9649-35c112084af0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions_8a29599a-be00-4f1a-87e8-81a441d9352f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a39b8503-5471-4d60-9365-a1645f583c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_7e5d373c-8285-4641-9649-35c112084af0" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_a39b8503-5471-4d60-9365-a1645f583c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_23e7ebbf-d955-41b8-a8ea-0f4c134ce9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_23e7ebbf-d955-41b8-a8ea-0f4c134ce9e7" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:to="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_99e12468-ded0-4dfe-b93a-9b2e441dc977" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_2bc1d561-1a64-419e-8032-d826d6d14520" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CommercialPaperMember_2bc1d561-1a64-419e-8032-d826d6d14520" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_dcc89a99-6649-41aa-9784-330f8e4a102c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_dcc89a99-6649-41aa-9784-330f8e4a102c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_8016f534-7403-412e-a273-1d5e6c9bcb13" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_8016f534-7403-412e-a273-1d5e6c9bcb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_cd26eedb-1398-4760-912c-d02aa4c279c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_MunicipalBondsMember_cd26eedb-1398-4760-912c-d02aa4c279c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashMember_5aa3d81e-4401-456f-9fad-033c08ee3c19" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CashMember_5aa3d81e-4401-456f-9fad-033c08ee3c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_312016a1-7163-427f-b935-5d0cf3ca5ae6" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_MoneyMarketFundsMember_312016a1-7163-427f-b935-5d0cf3ca5ae6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_db87502e-dc71-420a-a913-e5c9bc849ff0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_b58a38c7-ddcc-403c-ad52-53a052d42ef2" xlink:to="loc_us-gaap_CertificatesOfDepositMember_db87502e-dc71-420a-a913-e5c9bc849ff0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_bbebc4ad-c356-4065-9b49-24c1f86c0a8b" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a63493e-432d-4091-a689-49cff33f91ac" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_5a63493e-432d-4091-a689-49cff33f91ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_381d0ea1-2eed-442a-a08e-91ca95061e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_381d0ea1-2eed-442a-a08e-91ca95061e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34e5a19-35c5-4375-ab0a-f6213c46ff89" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_f34e5a19-35c5-4375-ab0a-f6213c46ff89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c06a8aa4-1504-480f-b802-d3610481444c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesAbstract_ad4138a9-e25a-4cf9-9fd0-586926a9c2b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c06a8aa4-1504-480f-b802-d3610481444c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_556250cd-2d1f-4269-b57f-d9330d71afac" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost_556250cd-2d1f-4269-b57f-d9330d71afac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_adc531b7-b7f8-445f-bec9-e676bc9083ba" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain_adc531b7-b7f8-445f-bec9-e676bc9083ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_b64e80b0-eb8e-4dd0-a572-9052fcc4a0ea" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss_b64e80b0-eb8e-4dd0-a572-9052fcc4a0ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8c2d2fd-d935-443c-86cb-c500df047c89" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_86d6e9ca-c082-4a20-864f-7c4bf0d5f1b2" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure_a8c2d2fd-d935-443c-86cb-c500df047c89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3f8f7110-081f-4bbe-b3b1-366a695c7077" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis_3f8f7110-081f-4bbe-b3b1-366a695c7077" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ac1079cb-3bf6-48ba-a639-5fb3dacaf399" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_ac1079cb-3bf6-48ba-a639-5fb3dacaf399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e218b21d-454b-47f5-8c7f-7bce54d0422e" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_e218b21d-454b-47f5-8c7f-7bce54d0422e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a82f257f-b173-4aac-b685-e2ebfa742418" xlink:href="exel-20210702.xsd#exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_80f4bc2f-6262-4218-b7c7-ce7f29194804" xlink:to="loc_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities_a82f257f-b173-4aac-b685-e2ebfa742418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsInvestmentsbySecurityTypeDetails_1"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1" xlink:type="extended"/>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_165ecc93-0b1d-43e4-9cff-a744bc361f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_165ecc93-0b1d-43e4-9cff-a744bc361f3d" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:to="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_eb9dc7d6-279e-4d41-be02-d7606c2b195c" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_36c263a4-8c30-42c6-925d-c7e4525ec69d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_CommercialPaperMember_36c263a4-8c30-42c6-925d-c7e4525ec69d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_35284dda-2f9b-49a1-97c7-5aeac1ccd96c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_35284dda-2f9b-49a1-97c7-5aeac1ccd96c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_cfaae1da-cc93-4e34-a548-bcb280d60960" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_cfaae1da-cc93-4e34-a548-bcb280d60960" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_bed81887-b673-4c9d-aa07-c979835e2052" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_31a06eb6-be42-4654-9145-7c599c1f8d85" xlink:to="loc_us-gaap_MunicipalBondsMember_bed81887-b673-4c9d-aa07-c979835e2052" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_c44899e4-55c4-4d33-8fd8-eecce73aa259" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_186e02cc-7bcb-453c-a865-0b0623e739a4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1806ade4-989e-436f-a676-b7676f61c45c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition_1806ade4-989e-436f-a676-b7676f61c45c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_cf6fc394-dab5-4db0-a4b0-a0dac7ea6230" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract_7b19c843-7bdc-4821-92ea-10249768fff3" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss_cf6fc394-dab5-4db0-a4b0-a0dac7ea6230" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3efb494a-f805-4e28-be91-d2894bab21a9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8d27ae6b-ed77-4c0f-9a5b-b537a5ae0d45" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3efb494a-f805-4e28-be91-d2894bab21a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_8d27ae6b-ed77-4c0f-9a5b-b537a5ae0d45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_165668d8-441d-4918-adc6-fda20b1ae96b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3efb494a-f805-4e28-be91-d2894bab21a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_165668d8-441d-4918-adc6-fda20b1ae96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ea20c88-78b3-4aeb-aa88-5a88417ef2de" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3efb494a-f805-4e28-be91-d2894bab21a9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_3ea20c88-78b3-4aeb-aa88-5a88417ef2de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_83648b69-fea7-4d04-ac0a-677adee21188" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_5c96f03b-128e-4017-9f5d-d9d1cf07c4ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_83648b69-fea7-4d04-ac0a-677adee21188" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_5c96f03b-128e-4017-9f5d-d9d1cf07c4ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_af96fe8d-9dcb-4d60-9957-d15839ca1075" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1e81b8d4-0de5-4a88-aaa9-2ad83c46566f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_af96fe8d-9dcb-4d60-9957-d15839ca1075" xlink:to="loc_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_1e81b8d4-0de5-4a88-aaa9-2ad83c46566f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_965c0e13-325e-4994-b28b-c875f5444691" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_965c0e13-325e-4994-b28b-c875f5444691" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_27f64ac9-5e7e-473e-b91f-f53fb876223b" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommercialPaperMember_15473f4c-f625-43a8-887b-0687c1ae63c1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CommercialPaperMember_15473f4c-f625-43a8-887b-0687c1ae63c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_35e59a32-7a10-4439-98c9-68c1420c6ad7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_35e59a32-7a10-4439-98c9-68c1420c6ad7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USTreasuryAndGovernmentMember_c799c064-a55e-4bdb-a897-c48b85f4d404" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USTreasuryAndGovernmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_USTreasuryAndGovernmentMember_c799c064-a55e-4bdb-a897-c48b85f4d404" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MunicipalBondsMember_b9be2342-71b3-4da2-881a-8609c80739e4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MunicipalBondsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_MunicipalBondsMember_b9be2342-71b3-4da2-881a-8609c80739e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MoneyMarketFundsMember_096cb6ed-df4c-478c-8001-7e06fc81d650" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_MoneyMarketFundsMember_096cb6ed-df4c-478c-8001-7e06fc81d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CertificatesOfDepositMember_93800ff3-68b7-4f12-8419-fd3d4d401309" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CertificatesOfDepositMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_63e96499-c7b5-44e1-bf8e-41f324de42dc" xlink:to="loc_us-gaap_CertificatesOfDepositMember_93800ff3-68b7-4f12-8419-fd3d4d401309" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_87287994-7425-412a-b6d9-4c58a4ea2479" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_1909b857-9930-4546-923e-ca4ecdc10e1d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_1909b857-9930-4546-923e-ca4ecdc10e1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0ad0412f-767d-4e65-b664-ecc19d81f7c5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_b112c2c5-407a-4301-867b-d13b2fc287ef" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0ad0412f-767d-4e65-b664-ecc19d81f7c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_72d99986-d3ba-476b-9054-eb5cae55de54" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_ff614c7d-d994-4968-86b6-813d6d35147f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_2435353b-cf23-45f5-97c0-32c31ef35e17" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_ff614c7d-d994-4968-86b6-813d6d35147f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b7e97687-e069-4491-b6ea-e47f07c379f8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c5cdbb6-affe-4cf7-a7f7-b543260ec80c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_9c5cdbb6-affe-4cf7-a7f7-b543260ec80c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4dcdc9b-fb4f-44d1-a481-fd21010a2226" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_CashAndCashEquivalentsFairValueDisclosure_e4dcdc9b-fb4f-44d1-a481-fd21010a2226" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_5ed96270-5f12-4b15-9c87-e4b192d9ab3a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_45cc337c-0007-4a45-a1ec-0fd464a6fea2" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_5ed96270-5f12-4b15-9c87-e4b192d9ab3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#FairValueMeasurementsNarrativesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_7d34bdb3-e39b-4ea9-bb25-4081ec2464d3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_7d34bdb3-e39b-4ea9-bb25-4081ec2464d3" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_fe507d79-9a68-43a8-94c7-99c6ccc29d4f" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignExchangeForwardMember_f3fe8dd6-de82-4802-9730-851c217118d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignExchangeForwardMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_a44dc671-e3cf-4ccf-816b-afc58716174a" xlink:to="loc_us-gaap_ForeignExchangeForwardMember_f3fe8dd6-de82-4802-9730-851c217118d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_ef16ffe1-208a-4c22-994c-cc6c185c8c94" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8ea7ef48-89cf-4544-ab62-2750a65702fd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNumberOfInstrumentsHeld"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeNumberOfInstrumentsHeld_8ea7ef48-89cf-4544-ab62-2750a65702fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeNotionalAmount_7c61b37d-6de4-428f-9bf5-ae9fe5eb324b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeNotionalAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeNotionalAmount_7c61b37d-6de4-428f-9bf5-ae9fe5eb324b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DerivativeTermOfContract_6bae5a20-9d05-4d94-b858-b4ba64d8121a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeTermOfContract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_DerivativeTermOfContract_6bae5a20-9d05-4d94-b858-b4ba64d8121a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainOnDerivativeInstrumentsPretax_0ab30afe-ed65-4a95-8d8f-558f9744c632" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainOnDerivativeInstrumentsPretax"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_f9b96922-045a-4aca-9fc8-ecba72a45cba" xlink:to="loc_us-gaap_GainOnDerivativeInstrumentsPretax_0ab30afe-ed65-4a95-8d8f-558f9744c632" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/Inventory" xlink:type="simple" xlink:href="exel-20210702.xsd#Inventory"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/Inventory" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_c0bf7138-e190-4a62-a8ed-8b7d567f15c8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_258e9ed1-694a-4cbd-be8b-a51b8d5ba254" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_c0bf7138-e190-4a62-a8ed-8b7d567f15c8" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_258e9ed1-694a-4cbd-be8b-a51b8d5ba254" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryTables" xlink:type="simple" xlink:href="exel-20210702.xsd#InventoryTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_47abd1aa-a90a-4ab7-b17b-f294c496de77" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_11f2e91a-2ec2-403e-b312-11ede445e042" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_47abd1aa-a90a-4ab7-b17b-f294c496de77" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_11f2e91a-2ec2-403e-b312-11ede445e042" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/InventoryDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#InventoryDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/InventoryDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_fd367978-5377-49ee-b903-e9cae6a85bc9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryCurrentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fd367978-5377-49ee-b903-e9cae6a85bc9" xlink:to="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_6f5f1542-384c-4d69-ba52-e032fbabc63d" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoriesMember_eeed4b0e-3b7a-43a1-a671-d1a680af27d7" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:to="loc_us-gaap_InventoriesMember_eeed4b0e-3b7a-43a1-a671-d1a680af27d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_OtherLongtermAssetsMember_a1850bc8-ee6a-47a8-bcdf-a1e2d067c6f8" xlink:href="exel-20210702.xsd#exel_OtherLongtermAssetsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_76a5752a-06a2-4d37-9692-e4ef809caf96" xlink:to="loc_exel_OtherLongtermAssetsMember_a1850bc8-ee6a-47a8-bcdf-a1e2d067c6f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryCurrentTable_b0776176-d553-469b-a8cd-2091cc842020" xlink:to="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterials_0ff92708-24d2-4c75-a73c-18f687f522c3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryRawMaterials"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryRawMaterials_0ff92708-24d2-4c75-a73c-18f687f522c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcess_36ee1784-3880-4b69-b88f-2cc1cb6d52fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWorkInProcess"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryWorkInProcess_36ee1784-3880-4b69-b88f-2cc1cb6d52fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoods_79b43dae-80f3-4eeb-a731-13f2fe305ee1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryFinishedGoods"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryFinishedGoods_79b43dae-80f3-4eeb-a731-13f2fe305ee1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryGross_963108a1-331c-4624-9483-02ed4e5d62d2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryLineItems_66ab56a1-3e56-4b6c-a568-78a9ccf0404e" xlink:to="loc_us-gaap_InventoryGross_963108a1-331c-4624-9483-02ed4e5d62d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWriteDown_b80e1460-ad64-41fa-a226-a1e38059fcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InventoryWriteDown"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_fd367978-5377-49ee-b903-e9cae6a85bc9" xlink:to="loc_us-gaap_InventoryWriteDown_b80e1460-ad64-41fa-a226-a1e38059fcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a440658f-a741-405d-a193-641fdbe75805" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0cc3dd42-bdca-48d7-a087-96e9eb33e0e3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a440658f-a741-405d-a193-641fdbe75805" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_0cc3dd42-bdca-48d7-a087-96e9eb33e0e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c899d6a-6981-4c09-8065-9a53a1a2cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1e788a5d-a5f3-4773-a387-c7a45f53e89d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c899d6a-6981-4c09-8065-9a53a1a2cae8" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1e788a5d-a5f3-4773-a387-c7a45f53e89d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_74eec51d-e8d5-4f67-881c-743e0ca41b6c" xlink:href="exel-20210702.xsd#exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0c899d6a-6981-4c09-8065-9a53a1a2cae8" xlink:to="loc_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock_74eec51d-e8d5-4f67-881c-743e0ca41b6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d3c5d6b-df45-4998-a958-6a9b704e3ef9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9d3c5d6b-df45-4998-a958-6a9b704e3ef9" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6ac2b844-42ab-45b7-8b66-2cff50cf1fd1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0ecddc92-2a24-40ad-ada5-4766970e2cc0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_0ecddc92-2a24-40ad-ada5-4766970e2cc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_46f00815-26ad-4afe-9b22-8ab9b92cd39c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_1839def1-0780-4ebb-a79f-9ff0a93405fa" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_46f00815-26ad-4afe-9b22-8ab9b92cd39c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_dc917718-10da-4a52-8f3f-3f7ec76313ad" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_23938477-b22a-4258-b19f-5c516b066db0" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_390766ec-f228-4e8c-878e-7f283536d71d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_23938477-b22a-4258-b19f-5c516b066db0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationBasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6cbbc25-77b2-474a-82b6-8378f97c78df" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b6cbbc25-77b2-474a-82b6-8378f97c78df" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:to="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_86939ffc-63b3-4c60-832b-a2ae2e48d69f" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4d50d79f-5cb8-4d55-ac24-e25d5fed55cf" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4d50d79f-5cb8-4d55-ac24-e25d5fed55cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_8630ace0-238b-438b-b695-3a82accd9938" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_8630ace0-238b-438b-b695-3a82accd9938" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_e7dc619e-0414-4f3f-a25c-0c117688f13a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_PerformanceSharesMember_e7dc619e-0414-4f3f-a25c-0c117688f13a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_9c4af8f2-ce88-4dfe-b4a7-5e917a52dfbd" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cf1aa290-2569-4e6e-8389-101ddc6c96b9" xlink:to="loc_us-gaap_EmployeeStockMember_9c4af8f2-ce88-4dfe-b4a7-5e917a52dfbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c7744e15-e23f-48a4-ab6e-16a70ccebcb8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_349351b8-ce24-4b27-81d5-7252a5a33a5d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f5da6294-0f98-4840-bfec-bc67b1a2979d" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_349351b8-ce24-4b27-81d5-7252a5a33a5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b35305b3-f1d0-441b-8b55-19d199af767c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b35305b3-f1d0-441b-8b55-19d199af767c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:to="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_5ad61194-7a0c-473f-9f9c-d4c149d38045" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_7d20957f-254b-4544-8888-cd2957402191" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_EmployeeStockOptionMember_7d20957f-254b-4544-8888-cd2957402191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_400d0887-b301-4c21-b5ee-9d396e60b5a2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_400d0887-b301-4c21-b5ee-9d396e60b5a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_6b6797b4-baf1-4e5b-8a8c-e11be6c96bf9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1aa5b757-7104-4cac-817a-10a31e8b9430" xlink:to="loc_us-gaap_PerformanceSharesMember_6b6797b4-baf1-4e5b-8a8c-e11be6c96bf9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:to="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_02f40f68-b776-426f-8567-efdbe8609294" xlink:to="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a5f8b483-06db-40aa-8036-a0e54fa1778b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_a5f8b483-06db-40aa-8036-a0e54fa1778b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3ae41086-846e-463b-b097-ea9cf4ce4277" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_596feda5-8814-4e6b-9344-dd2e9307a2f9" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_3ae41086-846e-463b-b097-ea9cf4ce4277" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_722f1f1a-b03f-4abc-9c26-d226a711c116" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0652d429-eb8a-4825-849a-9692945387e5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_0652d429-eb8a-4825-849a-9692945387e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_0114d08e-1d6a-4f87-b7ac-1f4856b9babf" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward_0114d08e-1d6a-4f87-b7ac-1f4856b9babf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_775a15a0-007d-4aa1-af1c-eb826248dbc7" xlink:href="exel-20210702.xsd#exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards_775a15a0-007d-4aa1-af1c-eb826248dbc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_198c9f78-2674-4ca4-9556-7e45e1b7eeb3" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_198c9f78-2674-4ca4-9556-7e45e1b7eeb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38ddd07a-523b-4c79-9036-f6d53b37e717" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_38ddd07a-523b-4c79-9036-f6d53b37e717" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08983d4d-e5df-4dd6-acbd-537ad478f760" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_08983d4d-e5df-4dd6-acbd-537ad478f760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8993734-6488-4896-9ff2-2acf4eaf74d1" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_b8993734-6488-4896-9ff2-2acf4eaf74d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db0c4920-93e0-4923-bd5d-f0b1e18b92ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_db0c4920-93e0-4923-bd5d-f0b1e18b92ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33332058-66a5-41f8-b696-599c0ca94fd9" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_33332058-66a5-41f8-b696-599c0ca94fd9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6192e724-2b07-4743-944d-3f592267fd9a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6192e724-2b07-4743-944d-3f592267fd9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_509308ca-8475-480d-a570-c27768703442" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_509308ca-8475-480d-a570-c27768703442" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_247221f5-a0d4-442e-86b1-0d9780b82b08" xlink:href="exel-20210702.xsd#exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest_247221f5-a0d4-442e-86b1-0d9780b82b08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d227cf38-6251-4247-9c6f-2093fa0201ad" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_d227cf38-6251-4247-9c6f-2093fa0201ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_06a06958-881b-4081-95ca-b2636c262aa8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_06a06958-881b-4081-95ca-b2636c262aa8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8cb873f-e09f-4dd7-bcc4-bc180d01b243" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_04b708bb-eccd-4fe3-b71f-7c859b100315" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_d8cb873f-e09f-4dd7-bcc4-bc180d01b243" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#StockBasedCompensationEstimateGrantDateFairValueDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea839d8-50e7-4fae-8f63-110dc8f39156" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3ea839d8-50e7-4fae-8f63-110dc8f39156" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:to="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7b8bb0e5-0b41-4135-b598-568748ee6c9d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_3dddeaed-8b79-451a-aefa-4b6942f5fe1f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_7e98176a-2306-4938-b43f-9259ca6efc08" xlink:to="loc_us-gaap_PerformanceSharesMember_3dddeaed-8b79-451a-aefa-4b6942f5fe1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_d15f18c9-bd5c-4794-b6e3-05bdf4d7048a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dd7934c3-93b6-4fb2-9fd5-cae65085daf8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dd7934c3-93b6-4fb2-9fd5-cae65085daf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharePrice_e07e0238-9be5-409f-91a6-890de4345833" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_SharePrice_e07e0238-9be5-409f-91a6-890de4345833" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0bc07674-6e86-4ab3-98a3-83f2dff174b8" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_0bc07674-6e86-4ab3-98a3-83f2dff174b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02d8c254-8e76-499e-9382-93149577d614" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_02d8c254-8e76-499e-9382-93149577d614" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d774f9d-26a0-46f2-bbde-ea16e2d1e4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_f2a59d37-384a-4fa6-8255-c4114b215d0d" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_4d774f9d-26a0-46f2-bbde-ea16e2d1e4fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="simple" xlink:href="exel-20210702.xsd#ProvisionForIncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_91c01273-c6a7-4f7e-8379-726d85bd448e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_a644ce95-088c-4205-8b51-8a59e22f532c" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_91c01273-c6a7-4f7e-8379-726d85bd448e" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_a644ce95-088c-4205-8b51-8a59e22f532c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#ProvisionForIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_74e2a97b-20f7-44f5-8ac7-bda9d39a1e38" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_068c3d10-3210-49ea-9a2d-d179c5a43913" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_74e2a97b-20f7-44f5-8ac7-bda9d39a1e38" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_068c3d10-3210-49ea-9a2d-d179c5a43913" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerShare"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_a580c656-2f3e-4dfa-946e-9751a21d6923" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_3dca3080-9f0e-4d72-a2b8-a50dcc8d7043" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_a580c656-2f3e-4dfa-946e-9751a21d6923" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_3dca3080-9f0e-4d72-a2b8-a50dcc8d7043" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerShareTables"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_99196111-92f2-45a1-ac67-4d4c1501da1b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6758923e-6957-468f-9f6e-27adeefa5330" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99196111-92f2-45a1-ac67-4d4c1501da1b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_6758923e-6957-468f-9f6e-27adeefa5330" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0ccba821-ff9f-4be1-842c-2cdb444c2cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_99196111-92f2-45a1-ac67-4d4c1501da1b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_0ccba821-ff9f-4be1-842c-2cdb444c2cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_804f8bc9-744e-4701-a8b5-df4ff03efe79" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareReconciliationAbstract_15f31117-53ee-4166-8d69-4c2ca22d277b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_804f8bc9-744e-4701-a8b5-df4ff03efe79" xlink:to="loc_us-gaap_EarningsPerShareReconciliationAbstract_15f31117-53ee-4166-8d69-4c2ca22d277b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_9ba0720a-c3a6-488f-aafb-ba2ed66e5de2" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareReconciliationAbstract_15f31117-53ee-4166-8d69-4c2ca22d277b" xlink:to="loc_us-gaap_NetIncomeLoss_9ba0720a-c3a6-488f-aafb-ba2ed66e5de2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_32d2b013-6559-4fd2-ae3b-ba6feba43d58" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_804f8bc9-744e-4701-a8b5-df4ff03efe79" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_32d2b013-6559-4fd2-ae3b-ba6feba43d58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7393cfb-1d04-4153-a37f-382517b9a7c4" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_32d2b013-6559-4fd2-ae3b-ba6feba43d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_d7393cfb-1d04-4153-a37f-382517b9a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_24d54edd-d375-4f78-85c7-ffb42a80c05e" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_32d2b013-6559-4fd2-ae3b-ba6feba43d58" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_24d54edd-d375-4f78-85c7-ffb42a80c05e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9cea6c80-ee59-4617-81e9-8ecd3e0771ec" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_32d2b013-6559-4fd2-ae3b-ba6feba43d58" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9cea6c80-ee59-4617-81e9-8ecd3e0771ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_8ee56263-2e68-42d1-b7ff-81cb6e462d2f" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_804f8bc9-744e-4701-a8b5-df4ff03efe79" xlink:to="loc_us-gaap_EarningsPerShareBasic_8ee56263-2e68-42d1-b7ff-81cb6e462d2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_59c0c518-985d-41d7-b0b1-accbce99fe00" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_804f8bc9-744e-4701-a8b5-df4ff03efe79" xlink:to="loc_us-gaap_EarningsPerShareDiluted_59c0c518-985d-41d7-b0b1-accbce99fe00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="simple" xlink:href="exel-20210702.xsd#NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b29a8ab4-cc3d-4bf9-aa9f-49100af2ff67" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b29a8ab4-cc3d-4bf9-aa9f-49100af2ff67" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2241b7be-dae5-4fcb-b8b1-9e03aa77575b" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockCompensationPlanMember_edca0eec-a9f9-428f-a75e-11c2037926cc" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockCompensationPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_1185d66f-4c1b-48a2-ab2f-ecd447d12860" xlink:to="loc_us-gaap_StockCompensationPlanMember_edca0eec-a9f9-428f-a75e-11c2037926cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_d7068d3a-e1c4-43d1-bcbf-849caf7f590a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e4be1206-ab32-4b6d-8ed5-d15452e59bb5" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_d53df9e7-7d02-4848-a97e-f1de9efd48ea" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e4be1206-ab32-4b6d-8ed5-d15452e59bb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="exel-20210702.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.exelixis.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a3d97fe-2a3b-4811-b01c-d87c0f759c10" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a67e9fda-1ee4-408e-b444-83dd3bdbfe83" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6a3d97fe-2a3b-4811-b01c-d87c0f759c10" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_a67e9fda-1ee4-408e-b444-83dd3bdbfe83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>exel-20210702_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exel-20210702_g1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_[0 L4&AO=&]S:&]P(#,N,  X0DE- ^T
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M;G1R4D="(%A96B 'S@ "  D !@ Q  !A8W-P35-&5     !)14,@<U)'0@
M                ]M8  0    #3+4A0("
M                                     !%C<')T   !4    #-D97-C
M   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:   "&    !1G
M6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D;61D   "Q
M (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^    !1M96%S   $
M#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $/   " QB5%)#
M   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(97=L971T+5!A
M8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V,3DV-BTR+C$
M             !)S4D="($E%0S8Q.38V+3(N,0
M                                            6%E:(        /-1
M  $    !%LQ865H@                     %A96B        !OH@  ./4
M  .06%E:(        &*9  "WA0  &-I865H@        )*    ^$  "VSV1E
M<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:               %DE%
M0R!H='1P.B\O=W=W+FEE8RYC:
M                          !D97-C         "Y)14,@-C$Y-C8M,BXQ
M($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(              "Y)
M14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M                            9&5S8P         L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0              +%)E
M9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$
M                             '9I97<      !.D_@ 47RX $,\4  /M
MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A<P         !
M                         H\    "<VEG(     !#4E0@8W5R=@
M  0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H 3P!4 %D 7@!C
M &@ ;0!R '< ? "! (8 BP"0 )4 F@"? *0 J0"N +( MP"\ ,$ Q@#+ -
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MUTD=26-)J4GP2C=*?4K$2PQ+4TN:2^),*DQR3+I- DU*39--W$XE3FY.MT\
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MNL+#Q,7&Q\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$
M P$! 0$! 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0
M 0)W  $" Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E
M\1<8&1HF)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W
M>'EZ@H.$A8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'
MR,G*TM/4U=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]
M_**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M*.(L5GN:5LUQC]^K)NW1+:,5Y15DO)!1117K'@A1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY2I[]%'7\:^/:*_%,P\3N(\7*[Q#@NT$HI?-+F^]L_I;*/!'@W 045@U4?\
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M5D?Y@YACZ^-Q-3&8J7-4J2<I-]6W=O[PHHHKH.,**** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKE?C?X\_X57\&O%?B4;=V@Z1=7Z
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MTL DV[EMX_O22L/[J(&8^RFOW/\ A9\-=*^#GPYT;POHL/V?2]#M4M8%/WF
MZLQ[LS$L3W+$U\>?\$9?V5/^$)\ 7?Q,U>WVZIXF1K725=>8+)6&Z3D<&5UX
M_P!B-2.'-?<E?U1X1<*_V=EO]HUU^]KV:\H?97_;WQ/RY>Q_"?TA.._[7SG^
MQ\+*]#"MIVVE4VD_^W?A79\W1A1117Z\?SV%%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0H YK^AO ?FOC>W[O[_?/Y%^E5R6RQ?:_??=^Z+%%%%?T,?R"%%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M_A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_16OB9_X5-]_P#':/\ AM;XR?\ 16OB9_X5-]_\=KS+YO:CYO:BR"[/3?\
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M5-]_\=KS+YO:CYO:BR"[/3?^&UOC)_T5KXF?^%3??_':/^&UOC)_T5KXF?\
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MXI?$:\L[SQ%I\$\$_B2\DBGC:YC5D93(0RD$@@C!!K]YJ_G4_9>_Y.5^'?\
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M5E9205((()!K]UJ_GG_8I_Y/(^$O_8Y:/_Z70U_0Q6-3<TAL%%%%9EA1110
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M66\G^2Z)+HE9):)!1117<>6%%%% !1110 5^<?\ P5H_;Y_MBYO/A3X-OO\
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M5.S/V:HHHK,L**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MV_:@^("^-?%5GN\ ^&;@8AE7Y=:NUPPAP>#$G!D['(3G+$?LJB+$BJJA548
M X K#^%_PST3X-_#_2?"_ARQBTW1-$MUMK2WCZ(HY))ZLS$EF8\LS$G))-;U
M<\I7-HQL%%%%24%%%% !7E?[;'[0@_9<_9@\7>-$\MK[3;3RM.23E9+N5A%#
MD?Q .X8C^ZK=.M>J5^?_ /P<%^-I-,_9^\$^'XV*KK&NO>2 9^<6\#+@^V9P
M<>H'I51U=A2=D?E#JVJW.NZI<WU[<375Y>2M//-*Q9YI&)9F8GDDDDD]R:@^
M;VH^;VH^;VKI, ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:
MCYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;
MVH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;
MVH^;VH /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#NOV7O^3E?AW_V,VF_^
ME45?T5U_/!^Q[H<WB3]K+X96,.?,N/%6F+D#.P?:HRS8]  3]!7]#]8U#2F%
M%%%9&@4444 %%%% !7X6_P#!5O\ :7N/VC_VP?$/DW#R:!X1E?0M+CW9C A8
MK-*.W[R8.V[J4$8YVBOVR^+'BQO 7PL\3:['_K-%TJZOUP,\Q0NXX/\ NU_-
MW/.]S-))([222,69F.68GDDGUK2FNIG4$^;VH^;VH^;VH^;VK<S#YO:CYO:C
MYO:CYO:@ ^;VH^;VH^;VH^;VH ]-_8I_Y/(^$O\ V.6C_P#I=#7]#%?SS_L4
M_P#)Y'PE_P"QRT?_ -+H:_H8K"IN:T]@HHHK,L**** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ JOJFIV^B:9<7EW-';VMI$TTTKG"Q(H)9B?0 $_A
M5BO!?^"GGCR;X<_L$_$S4;=F62;2UTW*]0+N:.U;])C1N!^,O[9G[2FH?M9?
MM%^(O&5X\PM;R<P:9;N?^/.RC)$,8'0';\S8ZN[GO7EWS>U'S>U'S>U=2.</
MF]J/F]J/F]J/F]J8!\WM1\WM1\WM1\WM0 ?-[5T_P5_Y+'X2_P"PS9_^CTKF
M/F]JZ?X*_P#)8_"7_89L_P#T>E(#^CZBBBN4Z HHHH **** / ?^"B?[),?[
M5OP'N+>QAC;Q5X?WWVBR$#=(X'[RWSZ2J .H =8R> :_&6YMI+.XDAFCDBEB
M8I)&Z[60C@@@]"*_H8K\N?\ @L'^R%_PK'XC+\1]#M=N@^*YRFI)&ORVE^06
M+_28 M_OJ^?O 5^"^,G!_M:2SS"Q]Z-E42ZQZ2^6S\K=$?U9]''Q"^KUWPOC
MI>Y-N5)OI+>4/27Q+^\FMY'Q31117\VG]F!1110 4444 %%%% 'ZB?\ !'K]
MK[_A9GP[?X;:[=;M=\+0[]+DD;+7EAD#8,]6A)"_[C( /E8U]L5^ _PA^*FL
M?!'XEZ/XJT&?[/JFBW"W$)/W9!T:-AW1U+*P[AB*_<;X"?&G2/VAOA)HOB[1
M6_T+6(!(T3-E[64?+)"_^TC J>QQD<$&OZN\)>+_ .TL#_9N)?[VBE;O*&R?
MK'9^5GNV?P;](#P]_L;-?[:P4;8?$MWMM&INUY*>LEY\RT21V5%%%?KQ_/(4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7BW[;_ .V'I/['_P )
MI-4F\F\\1:D'@T73F/\ Q\3 <NX'/E)D%B,9R%!!8&NY^.GQMT']GGX8ZGXJ
M\1W(M]/TY,J@/[RZE/W(8U_B=CP!TZDX )'XJ?M,?M&Z]^U'\6+[Q5KTFUIO
MW5G:(Q,5A;@G9$GTSDG^)B3WK\Q\2..HY'A?J^&?^T5%I_=7\S_**ZO79,_;
M?!GPMGQ1C_KF-BU@Z+][ISRW4$_QDULM-&TURGCCQOJWQ)\7ZCKVN7TVI:MJ
MT[7-U<RGYI7;D^P Z #       K)HHK^1*E24Y.<W=O5M[M]V?Z#TJ4*4%3I
MI*,4DDM$DM$DNB04445!H%?IY_P1H_96_P"$"^'-U\2M8M]NK>*4-OI0<?-!
M8JW+CT,KK_WS&A'#'/PW^Q5^S7<_M4_M Z/X959%TM&^VZO.G_+"SC(W\]F<
ME8U/9I >QK]NM(TBUT#2;6PLH([6SLHE@@AC&U(HT 55 [   #Z5^Z>#/"OM
M\3+.L0O=IZ0\Y=7_ -NIV7F^Z/Y<^DAQY]4P<.&L)+WZUI5+=()^['_M]J[_
M +JL])%JBBBOZ8/XJ"BBB@ HHHH *BO+R+3[66XGD2&&!#)([G:J*!DDGL *
MEKQ/_@HUXYN/AU^PW\3=3M6*3G19+)&'5/M!6WR/<>;D>XHW _&']N']IR^_
M:V_:2\0>+IIIFTUYC::/"_'V:QC8B%<=B02[#^_(U>2?-[4?-[4?-[5U+0YP
M^;VH^;VH^;VH^;VI@'S>U'S>U'S>U'S>U !\WM73_!7_ )+'X2_[#-G_ .CT
MKF/F]JZ?X*_\EC\)?]AFS_\ 1Z4@/Z/J***Y3H"BBB@ HHHH **** "BBB@
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MYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OVC_X(E_
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MF]J/F]J #YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]JU? W@;6/B9XOT
M[P_X?TZZU;6=6F6WM+2W3=),Y[#VZDDX  ). ":0'UG_ ,$0O@'-\4_VPHO$
MTT!?2? -H]_(Y'R&YE5H8$_WN9)!_P!<?P/[.UX;_P $^?V.K3]BW]GNQ\.L
MT-UXAU!OM^N7<?W9KIE V(3SY<:@(O3."V 6(KW*N>4KLVBK(****DH****
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M1110 4444 %4M?U^Q\*:'>:GJ5U;V.GV$+3W%S.X2."-1EF8G@  5=K\O_\
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M-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M'S>U'S>U !\WM4NG:C<:3J$-W:3S6MU:R+-#-"Y22)U.596'(8$ @CD$9J+Y
MO:K.AZ)>>)M:M-.T^UFO+^_F2WM[>%"\D\CD*J*!R220 /4T ?K1_P $D/\
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M"OA'2X=)T?3Q\L:?,\SG[TDCGEY&QRQY.!V  ZRBBLS0**** "BBB@ HHHH
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MQ#:V=G$T\\\SA(X8U!+,S'@* "23P *_$/\ X*@_M]W7[9OQ:-CH\\T/P_\
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M[DRV/RZ^;VH^;VH^;VH^;VKI,0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J
M#YO:CYO:CYO:OT"_X(5?L_>!_CJ?BE_PF7A70O$W]E_V3]C_ +1M$N/LWF?;
M=^S<#C=L3..NT>E*3LKC2N?G[\WM1\WM7] O_#O[X(_]$K\"_P#@HB_PH_X=
M_?!'_HE?@7_P41?X5G[5%^S9_/U\WM1\WM7] O\ P[^^"/\ T2OP+_X*(O\
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M_P#T>E<Q\WM73_!7_DL?A+_L,V?_ */2D!_1]1117*= 4444 %%%% !1110
MV2,2JRLH96&"".M?CA_P4I_9%;]EOXZS3:7:F/P?XG+WNDE1\EJ<_O;7/_3-
MB-H_N,G)(-?LC7E?[8O[--A^U9\"]5\+W7DPZAM^U:5=.,_9+M =C9[*V2C8
M_A=N^*^#\0N$XY[E;ITU^^IWE!^?6/I):>MGT/U3PAX^EPMGD:M9_P"SU;0J
MKLKZ3]8/7ORN26Y^&]%:'BKPOJ'@GQ+J&CZK:RV6I:7<26MU;R##0R(Q5E/T
M(-9]?QC.,H2<9*S6Y_I%3J1G%3@[IZIK9I]4%%%%24%%%% !1110!Z=^R)^T
MEJ'[*OQRTGQ59^;-9QM]GU.T1L?;;1R/,3ZC 9<]&1?>OV\\(^+-/\=>%M/U
MK2;J.^TO5K>.[M+B/[LL3J&5O7D'H>17\^M?H1_P1F_:^^SW$WPEUZZ_=R&2
M\\/22-]UN6FM1]?FD7W$@[J*_;/!_C#ZGB_['Q,OW=5^XWTGV]);>J7=G\T_
M2(\/?[1P"XBP4?WU!6FEO*GW]8/7_"W?9(_12BBBOZ@/X="BBB@ HHHH ***
M* "BBB@ HHHH ***^>_^"@W[;=C^R'\,=EC)#<^--<1H])M2 P@'1KF0?W$[
M _?; Y <KY^:YIALNPD\;BY<L(*[?Z+NV]$NK/6R'(\;G&/I9;E\.:K4=DOS
M;?1):M]$FSR?_@JQ^WW_ ,*IT*X^''@^^V^)]4AVZM=PM\VE6[C_ %:MVFD4
M]1RBG/!92/R_J[XA\07WBS7;S5-2NI[[4-0F:XN;B9]TDTC'+,Q[DG-4J_BW
MB_BK$Y]CWBZVD5I"/2,?\WNWU?DDE_I1X>\"8/A3*8Y?AO>F]:D[:SEW]%M%
M=%YMME%%%?*GW04444 365E-J5Y#;V\4DUQ<.(XXT7<TC$X"@=R20,5^UW[!
MO[,,/[*O[/>EZ)+%'_;^H8U#6I5Y+W+@93/]V-=J#'!VEL L:^%?^"/7[*O_
M  M;XOR^/=7M?,T'P9(#9AURMUJ!&4Z]?*4^9V(8Q=>17ZI5_2?@OPK[*A+.
M\0O>G>,/*/VI?-JR\D^C/XQ^DEQY]8Q,.&,)+W:=IU;=9->['_MU/F:[M=8A
M1117[R?RJ%%%% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?
M\HX_B-_W#?\ TYVE5'= ?AI\WM1\WM1\WM1\WM72<X?-[4?-[4?-[4?-[4 '
MS>U'S>U'S>U'S>U !\WM73_!7_DL?A+_ +#-G_Z/2N8^;VKI_@K_ ,EC\)?]
MAFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH **** .7^-/Q6TWX&_";Q%XPU=O^)?
MX=L);Z50<-+L4E8U_P!IVPH]V%?SQ_%GXG:M\:?B;KOBS7)O/U;Q!>R7MRPS
MM5G;.U1V51A5'90!VK]0/^"_7Q[;PM\&?"_P]LYMMQXKO&U&_"M_RZVV-B,/
M1YG5A[P&OR>^;VK:G'2YE-ZV#YO:CYO:CYO:CYO:M2 ^;VH^;VH^;VH^;VH
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M* "BBB@#^?G_ (*!_P#)[GQ5_P"QFOO_ $:U>0?-[5Z__P % _\ D]SXJ_\
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MH#GCY4\Z3\I)I!_P&OE+YO:NW_:;\7GX@?M'>/M<,GF#5O$5_=J<Y&U[B1E
MZ\ $ >PKB/F]JZH[&#W#YO:CYO:CYO:CYO:F(/F]J/F]J/F]J/F]J #YO:CY
MO:CYO:CYO:@#[)_X(Y?L.V?[3WQANO%7B:U6Z\'^"7CD-M(,QZE>M\T43#^*
M- "[CO\ (I!5FK]G%4(N!P!T'I7S7_P2/^%T/PO_ &#/!02-4NO$,<NMW;C_
M ):O/(2A/TA6%?\ @-?2E<TI79M%604445)04444 %%%% !1110 4444 >7_
M +1_[&_PY_:NT7[+XU\-V>H7,:;+?48AY-_:?[DR_-@'G:<H3U4U^<?[2_\
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ML%%%% PHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH *\G_ &S/V2M!_;*^"5]X3UC;;W8_TC2M1";I--N@#MD'
MJIY5E_B5CT."/6** /YO_C!\(]>^!'Q*U?PGXFLFT_6M%G,%Q$>5/=70_P 2
M,I#*W0J0>]<U\WM7[3_\%8?^">Z?M:?#3_A)_#-JO_"PO"\#&W5!SK%L,LUJ
M?]L'+1G^\2O ?*_BU<6\EI<20S1O#-$Q1T<;61AP01V(KIC*Z,91L-^;VH^;
MVH^;VH^;VJB0^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:OU9_X(P_\
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MK_R6/PE_V&;/_P!'I7,?-[5T_P %?^2Q^$O^PS9_^CTI ?T?4445RG0%%%%
M!1110 4444 ?S.W5S)>W4DTK&269B[L>K,3DDTSYO:G7%O):7$D4BM')&Q1U
M88*D<$&F_-[5UG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-
M[4?-[4 ?O[_P3LU^U\2_L-?"VXLS&88_#UM:MY9./,A7R9.YYWQMGWSTZ#VB
MOR]_X(=?MSZ;X6@F^#OBB]CLUO+IKOPU<SOMC:60CS+/)X4LWSH/XF:09W%
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ML%%%%24%%%% !1110 4444 %%%% !1110 5^;_\ P<0_\B9\+?\ K\U'_P!
MMZ_2"OS?_P"#B'_D3/A;_P!?FH_^@6]5'<F6Q^77S>U'S>U'S>U'S>U=)B'S
M>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[5^F?_!NGT^,7_<%_]R%?F9\W
MM7Z9_P#!NGT^,7_<%_\ <A45/A*CN?IE1117.;!1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX9_\#9_\*/\ B(7\9?\ 1._#/_@;/_A1R,.9'ZM45^4O_$0OXR_Z)WX9_P#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M% !1110 4444 %?,O_!8K_E''\1O^X;_ .G.TKZ:KYE_X+%?\HX_B-_W#?\
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M_K,_@,**** "BBB@ HHHH **** "BBB@ HHHH *^9?\ @L5_RCC^(W_<-_\
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M?L1?#W0[J-H;Y]-_M&Y1AATDNI'N2K?[2B4+[;<5E4V+I[GN-%%%8FH4444
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M]M3P=^VG\/?[9\,W#6^H6>U-4TBX8?:M-D.<!AT9&P=LB\, >C!E'K]?SD?
MOXZ>)OV<?B9IWBSPGJ,FFZQIK<'[T=Q&?O12KT>-@,%3[$8(!'[G_L.?MH^'
M_P!M?X/PZ_I?EV6M6.V#6M*+[I-/G(SQW:-\$H_<9!PRL!C.%C:,KGM%%%%9
ME!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(:?:W5JTGA'P[)'J.O2L/W;Q*V4M\_WIF7;CKM#L/NU^[JJ$7 X Z#TKS?\
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M% !1110 5^;_ /P<0_\ (F?"W_K\U'_T"WK](*_-_P#X.(?^1,^%O_7YJ/\
MZ!;U4=R9;'Y=?-[4?-[4?-[4?-[5TF(?-[4?-[4?-[4?-[4 'S>U'S>U'S>U
M'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\W
MM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U'S>U'S>U !\WM1\WM1\W
MM1\WM0 ?-[4?-[4?-[4?-[4 'S>U7?#'AG4/&GB.QTC2;.?4-3U*=+:UMH5W
M23RN0JJH]22*L^!? 6M?$[Q59Z'X=TN^UK5]0<1V]I9PF660^P'8=23P!R<
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MVH^;VH^;VH /F]JZ?X*_\EC\)?\ 89L__1Z5S'S>U=/\%?\ DL?A+_L,V?\
MZ/2D!_1]1117*= 4444 %%%% !1110 4444 %%%% !6+X^^'6@_%3PO<:+XD
MT?3==TFZ&);2^MUGB;T.U@<,.Q'(/(Q6U10!^>?[3?\ P0/\->*WN-2^%NO2
M^&+QR772-4+7-@3_ '4E&9HAU^]YN?:O@7]H/]@WXK_LQ2S/XJ\(:E'ID)/_
M !-;-?M>GL.<$S1Y5,X)P^UL#I7] U#*'7!Y!ZCUK15&B7!,_F:^;VH^;VK]
MY_CK_P $QO@K^T!YTVJ>"['2M2FR3J.B_P#$ON-QZNPCQ'(WO(C5\@?&?_@W
MNO(7FN/A[X]M[A.?+L?$%L8V4>]Q""&)_P"N*_KQHJB(Y&?FO\WM1\WM7O?Q
M?_X)B_'+X+-(^I> -8U*SCR1=Z,%U*)E[L1"6=!_OJO3\:\)U#3KC2;V2VNH
M)K6XA;;)%*A1T/H0>0:I.^Q!%\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #
MYO:CYO:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J/F]J/F]J/F]J #YO:CYO:C
MYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J]4_8W_ &KM=_8Z^.&F^+=':2:U5A;Z
MK8;]L>I6C$;XSV#<;E;^%U4\C(/E?S>U'S>U+<#^DCX:?$?1_B]\/]'\3^'[
MQ;[1M<M4N[2=>-R,,X(_A8<@J>000>0:W:_,3_@@I^UFUOJ.L?!_6+K,=P'U
M?P]YC?=<<W-NOU7$H X&V8]Z_3NN:2LS=.Z"BBBD,**** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /Y^?\ @H'_ ,GN?%7_ +&:^_\ 1K5Y!\WM7K__  4#_P"3W/BK_P!C
M-??^C6KR#YO:NJ.QSA\WM1\WM1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:
MCYO:CYO:@#] OV?O^"%7_"]?@?X5\9?\+2_LO_A)M,@U'['_ ,(UY_V;S$#;
M-_VI=V,XSM&?05V/_$.G_P!5B_\ +4_^[*^TO^"?O_)D/PJ_[%BQ_P#1*U[!
M7/SLV458_,W_ (AT_P#JL7_EJ?\ W91_Q#I_]5B_\M3_ .[*_3*BESR#E1^9
MO_$.G_U6+_RU/_NRC_B'3_ZK%_Y:G_W97Z944<\@Y4?F;_Q#I_\ 58O_ "U/
M_NRC_B'3_P"JQ?\ EJ?_ '97Z944<\@Y4?F;_P 0Z?\ U6+_ ,M3_P"[*/\
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M9_\ !NGT^,7_ '!?_<A42=D5'</^(=/_ *K%_P"6I_\ =E'_ !#I_P#58O\
MRU/_ +LK],J*QYY&G*C\S?\ B'3_ .JQ?^6I_P#=E'_$.G_U6+_RU/\ [LK]
M,J*.>0<J/S-_XAT_^JQ?^6I_]V4?\0Z?_58O_+4_^[*_3*BCGD'*C\S?^(=/
M_JL7_EJ?_=E'_$.G_P!5B_\ +4_^[*_3*BCGD'*C\S?^(=/_ *K%_P"6I_\
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MK^ABL*FYK3V"BBBLRPHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%1116)H%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MG_Z/2N8^;VKI_@K_ ,EC\)?]AFS_ /1Z4@/Z/J***Y3H"BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** */B3PQIOC'1+
MC3=8T^QU73;I=D]K>0+/!,OHR,"K#ZBOAO\ :X_X(9^"_B9;W.K?#&X7P3KI
M!?\ LZ9GFTN[;.<#.7@//5=R#  0=:^\J*:DUL%KG\XOQI^!_BK]GGQ_=^&?
M&&CW6BZQ9\F*5<K,A) DC<?+)&<'#*2#@]P<<I\WM7] O[:7[&OAG]M'X27'
MA_6H8K;5K=6ET?5ECS-IEQC@CNT;8 =,X8>C!6'X+_%#X:ZQ\'?B'K/A?7[4
MV>L:#=O9W474!U.,@]U(P0>A!!K>,KF,HV,+YO:CYO:CYO:CYO:K)#YO:CYO
M:CYO:CYO:@ ^;VH^;VH^;VH^;VH /F]J_4W_ (-Y/&C7GPW^)7ATR'9INI6>
MHHA/&;B*2-B/_ 9<_A7Y9?-[5^B/_!O+J#Q_%;XD6H*^7-I-I*1W)29P/_0S
M^8J*GPE1W/U4HHHKG-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _GY_X*!_\GN?%7_L
M9K[_ -&M7D'S>U>O_P#!0/\ Y/<^*O\ V,U]_P"C6KR#YO:NJ.QSA\WM1\WM
M1\WM1\WM3 /F]J/F]J/F]J/F]J #YO:CYO:CYO:CYO:@#^@7_@G[_P F0_"K
M_L6+'_T2M>P5X_\ \$_?^3(?A5_V+%C_ .B5KV"N0WCL%%%% PHHHH ****
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MS>U?IG_P;I]/C%_W!?\ W(5%3X2H[GZ94445SFP4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110!PO[4'_)M/Q$_[%G4O
M_266OYU/F]J_HK_:@_Y-I^(G_8LZE_Z2RU_.I\WM6U(SJ!\WM1\WM1\WM1\W
MM6IF'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0!Z;^Q3_P GD?"7_L<M'_\
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M_P#H]*YCYO:NG^"O_)8_"7_89L__ $>E(#^CZBBBN4Z HHHH **** "BBB@
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MBFNZQ(S,P55&22> * &WEY#IUI+<7$L<-O"ADDDD8*D:@9))/  '.37X&?\
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MT>WT^ZEM+&S:!Y(T"L4+72L5R.,J#["N\_XB /@W_P!"S\3/_!=8_P#R77Y
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M>S0<[/U__P"(@#X-_P#0L_$S_P %UC_\ET?\1 'P;_Z%GXF?^"ZQ_P#DNOR
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M0>"#51E9W$U<_F@^;VH^;VKZQ_X*I?\ !/N;]C[XH#7/#]O*_P /?$\[&P8
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M!\&_^A9^)G_@NL?_ )+K\@/F]J/F]J/9H.=GZ_\ _$0!\&_^A9^)G_@NL?\
MY+H_XB /@W_T+/Q,_P#!=8__ "77Y ?-[4?-[4>S0<[/U_\ ^(@#X-_]"S\3
M/_!=8_\ R71_Q$ ?!O\ Z%GXF?\ @NL?_DNOR ^;VH^;VH]F@YV?K_\ \1 '
MP;_Z%GXF?^"ZQ_\ DNC_ (B /@W_ -"S\3/_  76/_R77Y ?-[4?-[4>S0<[
M/U__ .(@#X-_]"S\3/\ P76/_P ET?\ $0!\&_\ H6?B9_X+K'_Y+K\@/F]J
M/F]J/9H.=GZ__P#$0!\&_P#H6?B9_P""ZQ_^2Z/^(@#X-_\ 0L_$S_P76/\
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M<G1K9N?*'I*W!<]1]WLQ;QS_ ()+_L#?VM<6?Q6\8V2M:PGS/#EC.F?.<?\
M+XZG^%?^68/4_/QM0G]&J_I#PFX!]E&.>9A'WG_#B^B?VWYO[/9:]5;^-?'[
MQ6^L3GPOE$_<B[5I+[37_+M/LG\?=^[LG<HHHK]\/Y1"BBB@ HHHH **** "
MBBB@ HHHH *X/]I/X#:3^TK\&M:\(:LJK'J46;:XVY:SN%YBF7W5L9 ZJ67H
M37>45SXK"TL31EAZ\>:,DTT^J>C1U8''5\'B(8O#2<:D&I1:W33NG\F?S_\
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MIMW&.6:'?[_>Z^O.9]FQ^T1^Z-%?BG9?\%O?CY:VRI)K'AZY89_>2:-$&/\
MWS@?I27_ /P6[^/EY!MCUGP_:MG.^+1H2WT^;</TH]FQ\Z/VMJ#4M2M]'L);
MJ\N(;6U@4O+-,XCCC4=RQX ^M?A1XL_X*O?M!>,XVCN/B/J5K&V<+86=K9%
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MSI&AEUY%NC9N)1[/(J(#U'DOV:OT:KGJ/6QM%:!1114%!1110 4444 %%%%
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MWM1\WM1\WM0!)9V<VH7<5O;Q23S3N(XXXU+/(Q. H Y))(&!UK]J_P#@E/\
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MFS_]'I7,?-[5U?P(LY-1^.'@VWA7S)KC7;&.-<@;F-P@ R?>D!_1U1117*=
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MWA?P$\VK_P!HXZ/^SP>B?VY+I_A77N_=[V_GOQQ\5ED&$>3Y9/\ VNJM6O\
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M ,EC\)?]AFS_ /1Z5S'S>U=/\%?^2Q^$O^PS9_\ H]*0']'U%%%<IT!1110
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M=I'96D"_\LXT4*O/<\<D\DDD\FMBBBN<V"BBB@ HHHH **** "BBB@ HHHH
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M--+^#7PTT+PIHL9ATOP_916-L&.6*HH7<Q[LV"Q/<DFNAKF;N[G0M$%%%%(
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M1W0'X:?-[4?-[4?-[4?-[5TG.'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#^?G_@H'_R>Y\5?^QFOO_1K5Y!\WM7Z(_M4_P#!
M&CXO?&;]I'QQXLTBY\'KI?B+6;F_M1<:C*DHCDD++N41$!L'IDUP/_#ASXW?
M\_?@7_P:2_\ QFNA21CRL^+/F]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\
M.'/C=_S]^!?_  :2_P#QFGS(.5GQ9\WM1\WM7VG_ ,.'/C=_S]^!?_!I+_\
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M/C=_S]^!?_!I+_\ &:/^'#GQN_Y^_ O_ (-)?_C-',@Y6?%GS>U'S>U?:?\
MPX<^-W_/WX%_\&DO_P 9H_X<.?&[_G[\"_\ @TE_^,T<R#E9\6?-[4?-[5]I
M_P##ASXW?\_?@7_P:2__ !FC_APY\;O^?OP+_P"#27_XS1S(.5GQ9\WM1\WM
M7VG_ ,.'/C=_S]^!?_!I+_\ &:FL/^""/QJO)]DFJ?#^U7&=\NIW!7Z?+;L?
MTI<R#E9\3?-[5>\+^%M2\;>(;32='L+S5-4U"00VUI:Q-+-.YZ*JKDDU^B_P
MJ_X-ZM2ENX9?&_Q"LK>!2#+:Z'9M*\@[A9IMH7ZF)OI7W%^S!^PO\-/V1-/V
M^#O#\<6IR1^7<:O>-]HU"Y'<&4_<4X&4C"(2 =N:3J);#4&>!_\ !*[_ ()?
M?\,LVJ>.O'$4%QX_OH2EM: K)'H,3C# -T:=AD,P.%!*C.6)^VJ**Q;N[FNP
M4444@"BBL;X@76N6?@C5)/#5K8WWB!;=_P"SX;V8PVSSXPGF,H)" X)P"2!Q
M0!\A_P#!7C_@H:/V:? 3>!?"=]M\>>)+8^=/"WSZ):-P9,_PS.,A.ZC+\83/
MXWLVXY/)/))[U]W?$G_@C%^T1\7?'FJ^)O$6M>"]3UK6KAKF[N9-5EW2.>P'
MDX"@8"J,!5  P !6)_PX<^-W_/WX%_\ !I+_ /&:WBXI&4KL^+/F]J/F]J^T
M_P#APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QFJYD+E9\6?-[4
M?-[5]I_\.'/C=_S]^!?_  :2_P#QFC_APY\;O^?OP+_X-)?_ (S1S(.5GQ9\
MWM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-',@Y6?
M%GS>U:7@WP=JGQ"\5Z?H>B6-QJ6K:M<):VEK NZ2>1CA5'X]SP.^*^P?^'#G
MQN_Y^_ O_@TE_P#C-?7O_!+_ /X)92?LB:I?^+O&\FE:IXVDW6NG"T=IK?2[
M<C#.K,JDRR9()Q\JC /S-2=1) HL]9_X)Z_L/Z7^Q+\%H=,_T>\\6:P$N=>U
M%!GS9L<0QDC/DQY(7.,DLV 6P/?***Y]S8**** "BBB@ HHHH **** "BBB@
M HHHH **** "J'B?PQI_C3PY?:/JUG!J&EZG ]K=6TZ[HYXG!5E8>A!(J_10
M!^.?_!0S_@D)XA_9WU"^\5?#VUOO$G@0DS2VR9FOM%'4AP/FDB'.) "5 ^?I
MO;XF^;VK^F6OF_\ ::_X)4_!_P#:<O)]1O-$D\,^()R6?4]"9;629O62,J8I
M"3U8IO/]X5K&IW,Y0['X5?-[4?-[5^BOQ$_X-Z/$UG<2-X3^(>@ZA$>8TU>R
MELV7KP6B\W/;G:/IVK@]0_X((?&JRE58]6^'UX&&2T6IW( ]OGMU/Z5?.B>5
MGQ-\WM1\WM7VG_PX<^-W_/WX%_\ !I+_ /&:/^'#GQN_Y^_ O_@TE_\ C-/F
M0<K/BSYO:CYO:OM/_APY\;O^?OP+_P"#27_XS1_PX<^-W_/WX%_\&DO_ ,9H
MYD'*SXL^;VKZ]_X)/?\ !0>3]DKXE_\ ",^);IO^%?>*)U%RSG(T>Y.%6Z'^
MP1A9!_= ;DIAM;_APY\;O^?OP+_X-)?_ (S1_P .'/C=_P _?@7_ ,&DO_QF
MDY1:L"31^QUO<1WD$<T,B2PRJ'1T;<KJ>001U!J2OG7_ ()R?";XM_ +X0MX
M+^)TVA:E::+M30[VQOWN)DM^0;>0-&ORI@;#D_*=O 5<_15<YL%%%% !7YO_
M /!Q#_R)GPM_Z_-1_P#0+>OT@KY"_P""LW[#GC3]M?P]X)M?!TNB12>'[B[E
MNO[1NG@!$JQ!=NU&S]PYZ=JJ.Y,MC\5_F]J/F]J^T_\ APY\;O\ G[\"_P#@
MTE_^,T?\.'/C=_S]^!?_  :2_P#QFM^9&?*SXL^;VH^;VK[3_P"'#GQN_P"?
MOP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/F]J/F]J^T_\ APY\
M;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0<K/BSYO:CYO:OM/_
M (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\ \9HYD'*SXL^;VH^;
MVK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\ !I+_ /&:.9!RL^+/
MF]J/F]J^T_\ APY\;O\ G[\"_P#@TE_^,T?\.'/C=_S]^!?_  :2_P#QFCF0
M<K/BSYO:CYO:OM/_ (<.?&[_ )^_ O\ X-)?_C-'_#ASXW?\_?@7_P &DO\
M\9HYD'*SXL^;VH^;VK[3_P"'#GQN_P"?OP+_ .#27_XS1_PX<^-W_/WX%_\
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M(.5GQ9\WM1\WM7VG_P .'/C=_P _?@7_ ,&DO_QFC_APY\;O^?OP+_X-)?\
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M,4 \J]@G;<P5B/DC;'!YQ]:<=P/Y_P#YO:CYO:OM/_APY\;O^?OP+_X-)?\
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M:ZH_LWZ-O GL,-/B?%Q]ZI>%*_2*?O2_[>:Y5ULGTD%%%%?@I_58445]>?\
M!+S]@EOVAO%R>-/%5F?^$(T.<>3!*ORZU<J<[,=X4.-YZ,<)S\^WV,AR/%9O
MC88'"*\I?<EU;[)?\!:M'S_%/$V!X?RVIFF82M""VZR?2,5U;>WWNR39[)_P
M29_8'_X1ZTL_BIXQLO\ 3[E/,\/6,R_\>\9'_'VX/\;#/E@]%.[J5(^_*9'&
ML"*B*JJHPJ@8  ["GU_:G#/#N%R7 1P.%6VK?64NK?Z=E9=#_-/C7C''<39K
M4S3'/5Z1CTA%;17IU?5W;W"BBBOH#Y,**** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH *\;_;)_8R\._MA_#_ /L_4MNGZ[8!FTK5DCW2V;GJ
MK#(WQ-QN3/N,$ U[)17'F&7X?'8>6$Q<%*$E9I_UH^J:U3U1Z64YMC,LQE/'
MX"HZ=6#O&2W7Z-/9IZ-:-6/PD_:&_9C\9?LO^,6T?Q;I4EKN)^RWD>9+.^4?
MQ128PW8E3AER-P'2O/J_H"\>_#[0_B?X8N-%\1:58ZUI=V/WMK=PB2-CV.#T
M8=01@@\@BOD'XT_\$2O _BZZFN_!NO:IX1FD;<+2=/[0LU]EW,LB_4NWTK^;
M^)/!;'4:CJY/)5(=(R:4EY7=HOUNGY']D<&?24RO$THT.(H.C46\XIR@_.RO
M*+\K27GT/R[HK[,\1_\ !$/XHZ=<?\2[7O!>I0YP&:YN()/J5,)'IT8_UK,_
MX<K_ !A_Y^?!O_@QE_\ C-? 3\/^(HOE>$G\E?\ %:'ZU3\6N#IQYHYA3^;L
M_N:3/D:BOKG_ (<K_&'_ )^?!O\ X,9?_C-'_#E?XP_\_/@W_P &,O\ \9J/
M]0>(?^@.I_X":?\ $5N$/^AC2_\  CY&HKZY_P"'*_QA_P"?GP;_ .#&7_XS
M1_PY7^,/_/SX-_\ !C+_ /&:/]0>(?\ H#J?^ A_Q%;A#_H8TO\ P(^2 =IR
M/E*]#7[ ?\$P/VO?^&E_@@NF:Q=>=XO\(HEI?EV^>\AQB&YYY)(&US_?4DXW
M+7QM_P .5_C#_P _/@W_ ,&,O_QFO2?V3?\ @G'\<OV6_CCH_BRQNO!\D%N_
MD:C:C4Y0+RT? DC_ -5UQAESP&53SBONO#_+>(\BS2-6>$J>RG[LUR].DO6+
MU]+KJ?E_BUG'!O%.1SP]/,*7UBG>=)\R^*VL;]IK3M?E;V/T:HHHK^I#^%PH
MHHH *^9?^"Q7_*./XC?]PW_TYVE?35>-?\% ?@-KG[3?[(OB[P/X;:QCUK6_
ML?V=KR4Q0#RKV"=MS!6(^2-L<'G'UIQW _G_ /F]J/F]J^T_^'#GQN_Y^_ O
M_@TE_P#C-'_#ASXW?\_?@7_P:2__ !FNCF1CRL^+/F]J/F]J^T_^'#GQN_Y^
M_ O_ (-)?_C-'_#ASXW?\_?@7_P:2_\ QFCF0<K/BSYO:CYO:OO?PG_P;Z?$
MN^NU&N>,_ ^FV[$;FLC=7DBCO\K11#(_WOQKZF_9K_X(F_"GX)7MOJ7B0W?Q
M"UB [E_M.-8M/5AW%LI(;OQ*\@]N,TG42#E9\+_\$Y?^"77B']KGQ!9>)/$=
MO=:'\-[68/+<R*8YM:"GF*V[[3C:TO1>0-S @?M#X8\,:?X+\.6.CZ39P:?I
M>F0):VMM NV.") %55'H  *MVMK'8VT<,,<<,,*A(XT4*J*!@  <  =A4E8R
MDV:1C8****DH**** "BBB@ HHHH **** "H[JUCOK:2&:..:&92DD;J&5U(P
M00>"".QJ2B@#X_\ VGO^"+?PH^.[7.H>'89?AYKTQ+^=I<8>QD8_W[4D*![1
M&/WS7Y^_M$?\$@?C/\!7GN;;0AXUT:/)%[H&ZYD"]MUO@3 ^NU648/S=Z_<*
MBJ4VB7%,_F?OK"?2[R2WN89K>XA8I)%*A1XV'4$'D&HOF]J_HE^,W[*OPY_:
M%@9?&?@W0=>E*[1<SVP6Z08QA9UQ*HQZ,.@]!7R3\8/^" OPY\5R2W'@WQ/X
MA\(S29*P7"KJ5HGH%#%)?SD;_'55%U)]FS\D/F]J/F]J^U?BC_P0C^,G@UY)
M/#]QX9\86X_U:VU[]CN&^JSA4!^DAKY]^(/[#WQ@^%K-_;GPW\86L:G!GBTV
M2XMP?^NL09/U[5?,B+,\L^;VH^;VI]S:R65PT4T<D,L9PR.I5E/H0:9\WM3$
M'S>U'S>U'S>U'S>U !\WM1\WM1\WM1\WM0 ?-[4?-[4?-[4?-[4 'S>U'S>U
M26=G-J-TD-O#)/-(<)'&I9F/L!R:]:^''[ ?QH^++0_V+\-?%<D5QCRY[NS-
MC;N#W$L^Q,>^[%*]@/(?F]J/F]J^[_A!_P $"/B5XK>.;QAXB\.>$;5C\T4!
M;4KQ?7Y5VQ?E*?IZ_77P)_X(H_!?X1-#=:S8ZCX[U./#&36)L6H;_9MX]JE?
M]F0R=?RGVB*46?D;\$_V;/'G[1VN_P!G^"?"^K>()E8++);PXM[<GG][,V(X
M_P#@;#-?H=^R;_P06T[1GM=8^+NL#5)U(D_L#29&CMAWVS7'#OZ%8PF".'85
M^B7AKPOIG@S1H--T?3K'2=.M5VPVMG;I!#$/144!0/H*O5FZC9HH)&3X*\#:
M-\-O#%IHOA_2['1=)L4V6]G9P+##$/95 ')R2>I)).:UJ**S*"BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% &3XI\!Z'XXM_)UK1=)UB'&-E[:1W"XY[.".Y_,U
MYKXE_8 ^"?BQV:\^%O@A6<Y9K;2HK5F//),04YY/U_ 5[!11=@?-&L?\$?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#D?CE\8-+^ ?PEUSQ=K#?Z#HEL9RF[:UP_P!V
M.)3_ 'G<J@]V%?AC\5/B5JGQC^(VL^*-:F^T:IKET]U.P^ZI/15'957"@=@H
M':OL;_@LY^U3_P )GX]L_ACH]P6TWPVRW6KLC?+/>,OR1GU$:-G_ 'I"",I7
MPS7\H^+W%7]H9E_9U!_NJ%T^SG]I_P#;OPKL[]S^]/H]\"?V1DW]L8J-J^*2
M:OO&GO%?]O?$^ZY>J"BBBOR$_H0N:!H%]XJURSTW3;6XOM0OYE@MK>!"\D\C
M'"JH')))%?L;_P $^OV);']D/X8!KZ."X\::Y&LFKW:G=Y ZK;1G^XG<C[[<
MG@*!Y+_P2F_8%_X53HEO\2/&%B5\3:I#G2;.=/FTNW<?ZQ@>DTBGZHAQP68#
M[=K^G_"G@'ZC26<8^/[V2]R+^Q%]7_>DON6F[:7\0>/'BO\ VI6EP[E,_P#9
MX/\ >23TJ27V5WA%_*4M=DFRBBBOVT_F8**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MR;U;;U;;[MA1116QSA1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %?FS_P6B_:J.N>);+X5Z1<'[+I)2_UMD;B2X*YA@/J$5MY'(W.G=:^_
M/C3XWU'X=_"O7-9T?1K_ ,0ZM96K&RTZS@::6ZG/RQKM7G;N(+'LH8]J_+#P
M=_P3-^.7[1/CB\UCQ!I/_"/MK%R]Y>ZEKDZQL[R-N<^4NZ4L<G V@9XR.WY/
MXIXW,:N$CDV54ISG6^)Q3:4%T;V7,][O9.^Y^^>!.6Y/0Q\^),]Q%.G3P^D%
M.23E4:W46[OE6UD_>::U3/GOX8?#+6OC'X]TOPUX=L9-0UC5YA!!"OKW9CT5
M% +,QX502>E?M+^QY^RGH_[(_P (K7P_I^RZU*XVW&KZAMPU]<8Y/J$7[J+V
M'J2Q.-^QS^P?X1_8\T-FT\'6/$UXFR]UJYB"S.O!,<2Y/E1Y .T$DD#<3@8]
MQH\-_#S^Q(/&XZSQ$E;35079/JWU:TZ+2[9XS>+W^LU199E;<<'!WN]'4DMF
MUNHK[*>M_>:O91****_6#\#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
##__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>exhibit41exel20210630sto001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit41exel20210630sto001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,]!54# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** *$]I+)KMG=KCRHH94;GG+%,?^@FK]4)H
M$;6[2<W"*Z0RJ(2>7!*9(^F/UJ_5S>D?3]69P5G+U_1!1114&@4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M]<5;HH YG7M*TY/L^W3[49W=(5'I[45KZE8-?>5MD";,]1G.<?X44#+]%%%
M@HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** *$ZVIURS9W<70AE$:C[I7*;B??[OY
MFK]4)Y;==<LXGA+7#0RE)<_=4%-PQ[Y'Y5?JY[1]/U9G#>7K^B"BBD8$J0&*
MDC@CM4&@M%%% $<XF,#BW9$F*G8TBEE![9 (R/Q%<PFN:I;7U\UU-97&GZ=
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M!(R/WB'KT-=7XHT6]U^PM8+2]AM/+N4N)$N+<S),%Y",H=>-VUNO\..E;U%
M'"^%[?Q#X?MM?N-2MA?-/JK/%#:6_E,X<JK2#=(1LQSCJ-IY.>)/%%S>_P#"
M8>'Y[?1-3NH--GEEFE@C4J0\#H-N6&3EAG\:[:B@ '2BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *4T\BZS:P"
M -&\,C-+MY0@K@9[9R?RJ[5.7[9_:UMY?_'GY4GF]/OY7;[_ -[I5RKELOZZ
MD0WEZ_H@HHHJ"PHHHH **,BBBX!11FC- !11D44 %%%&: "BC-% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M =D^M&3ZTWYO8_I1N/=2*8#LGUHR?6D# ]"*6@ R?6C)]:** #)]:,GUHHH
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M8?@*0#LGUHR?6F' ^\Q_/%'R=AG]: '[L#)--\Q?[X_.D&T<A?QQ2[O8_E0
M>8O]\?G1YB_WQ^=&[V/Y4;AZ'\J %#9&0WZTN3ZFFY1CSMS[T;5[#\J '9/K
M1D^M-P1T8_C1EAU&?I0 [)]:K7I<0L5=E^0C(/(Y%6 P)QW]ZKWRYMWYQ\AQ
MSWR*4OA8X_$CFOM-T$Q%+,J=AEO1O;_.*=!=:A<-Y*2M)QR'/3*\=<'U_.B*
MT-S+\JA50@DXX&#D?S(_*IY+A( (+9/E&,G.2V".>_8UXT5+XI-V/5DX[):E
ME)K5B(7,I/7=O(R>N!WJI-#&)647TT6/O+)DX ^GOBBTMQ:1B>[X48 3IDYQ
MTP/1:MI);:HQ<P$3C#8!ZK_DYK=>^DI6OV,O@=U>Q2-M.#M&I L,Y!)Y9O\
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M/F]1^5 !N]0?RHWCOQ]1BCYO0'\:,M_=_6@!0RGN*6FY'=2/PI $)XP/IQ0
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M<?\  @* .NP!V84F\= P)],5R&C^(+RZETZTNIM]T+R2WNOW+1[U\EY$958
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M).8W8$_7Z?7!]J3ORDU93^KQBUIW_I%JH[B&.XMY89@#%(A1P3U!&#4E07L
MN;"XMRX02Q,FX]L@C-0<<?B6MC AT $6UK<:]/<V-NZ-%;,(QDH04#,!E@"!
M]<<UTU>3Z5I>GSZI:1K<:'')YEN@:")\L86W%HW*A2S\@@=@.37K%:5%8[\P
MING))RO\K?UZ^04445F><%>"_%+_ )'FY_ZY1_\ H(KWJO-O&_P[U'Q#KQU+
M3[FV421JKI.S+@CCC .1BMJ$E&5V>UD.)I8?%.55V5FOR.NNO^1'F_[!K?\
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MYK^F2V!^?-3:DQV6L9_A0=>G(_SVKP7[-N4FKV/97.K13W+.HQ0LT=P]POE
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M07/L7_A+?#7_ $,.D_\ @;'_ /%4?\);X:_Z&'2?_ V/_P"*KY*_X1?Q!_T
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MIT]* $8D8!Y&>M.."/:D^\WL!1C'3IZ4 )R']0!7)ZE96VH>,VCN8Q*BV2L
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M !H_X1K2/^?)/S/^-.\+Z@-7\+Z=?AYI/.@5B\Z!'8]"2!QSCMQ6MMH Q_\
MA&M(_P"?)/S/^-)_PC6D?\^2?F?\:V=M&VF!C_\ "-:1_P ^2?F?\:RKVQL-
M)US39(;<(AWEP">>*ZW;7/:[&CZSIJ22K$I67+L,@<5G5OR.VY=/XU<+BZ,\
MQ9MOE)D;0W0 X/IV(J[9R?Z#=]>% W'V8CKS_DU4%K 2X^W1,I)/ ;GE?7_/
M-7+1@VEW+O*H/ ,>0-OS=23Z_E]:\?"\WMES'I8CE]D[&EX:S_8-OD8/S?\
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M7QCX@FU.[@F5/N00A6Q%&.@^O<^II)!<QKFYO]>UAYYFDNK^\ER2!EI'8\
M?E@5Z%XL^#U]X=\'6NL12FXN8DW:C"HR(\]"N.H7H3[9KLO@Q\/#IL">)]5A
M(NYE(LX77!B0_P 9]SV]!]>/8I$26-HY$5T8%65AD$'J"*;8CY$\">,[OP5X
M@CO8]\EG)A+JW!XD3U';<.H_+O7UGI^H6NJZ=;W]E*LMM<()(W7N#7S9\4/A
MO<^&=8DOM+M99=&N#O4HI86[$\H<=!GH??':K_P@\;W/AS41H>I)*-+NY/DD
M93BWD/&>GW3P#Z=?6AJXSLOV@?\ D3]-_P"O\?\ HMZ\U^#'_)3]-_ZYS?\
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M[0_ 4=G=1M#+<3O<,C##*I  !_!<_C6=XQU,W5ZFG0Y*Q'+8YW.>WX?UIVU
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MF>A7J<U)FCX:_P"0#;\$?>Z_[QK6K)\-C&A0?\"_]"-:U>P>6%%%% !1110
M4444 97B&=+;2S))J,^GKO \Z"+S&^F-K?RK*T^PN]4M!=6GBW4WA)(!:VC0
MY'LT8-:^O77V33#+_:L.F?.!]HFC#K],$CK698>+-&@M!'>^)K"[G!.95VQ@
MCL-H)K17Y=#T**J>PO3C=W[7_P#;7_Z5\C>LH);:TCAFNI+J1<YFD #-SWP
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MP#@^K _THA-*,D^I6"QM&EAL12F]9;>>YC?&;_CQTG_KI)_):U?A)_R)K_\
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ME2L #C@_A2!=W/Y>U*V6XSQ2AB?K1H @SWZBDP2=W?M0V6/';K_A3@V1UI@
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M$MXA'&,#N?6I:0P*@C!--R!P3S_.G8--V[CG/3I0 H  I"VWC'7I2C'0GFD
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M3Q0 B'(SW-#9 X[\8IQ]1UIN0SXZ$#- #@01TIH&')'0<4XKW'6FH<YSUS0
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M#I2Y)Z=/4T (O""AERISVY I$'!]<G^=4]9U(:3I-S?>491"N2@;&>0.OXT
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MS,\'C.W'TYH F\1_#Y=7\0+K^DZU=Z+JQC$4D\"AEE4=-RY&>@[]AQQ4>D>
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M[4   W%OPR:=GT% 4#&>3VIK-D[1R3Z4 "C.23G)IQ8#ZTF"?8>@H( 7''-
M"(I*#<< \X%4]9TX:KH]S8>;Y(F7;OVYQR#T_"KVXGH/SIK+D8)R30!R^H>"
MXM1L'A%X\4YO'NDN%3E0[ M&1GYE(&/J >H%6?\ A'K^!KB&RU86^GSW#7#Q
MB#]\I9M[JDF["AF)/*DC<<'ICH^G6FN21CUH YN;PM<O:7>EQ:FL>CW;R-+!
M]GS*%D8M(BR;L!6+-U4D;C@],$_A"V,-U+#*D-^UX;RWNUA&^!N,+U^9< @C
M(R"1Q72TC#(QZ\4 8^F>'+'3KFXNVM[::\FN9)_M!@42+O.=N[D\=.M43X6N
M?L7]E?VDG]BK)O%O]G_>[ VX1^9NQLSQ]W..,]ZZC@4USD8]>* .=7P?!"B3
M6\R1:C'?S7D=VL(W8DE9VC89RRE7*]>P/! J*+P7;VWV.Z2Z?^TX+K[5)=?,
M1*S$^8-F[ #!F'MQUQ744C#Y:8CG[KPNTVBS6$5Y&KOJ/V]7E@WJ#Y_G;2NX
M9';J*CG\/:I)#:O_ &CIL5Q9W?VJ)H=-94/[MXR&7S<GA\YR.G>NFXIKXV&@
M#/TG2I=/:[N+FY%S>7<@DFE$>Q>%"JJKDX  [DG)/-9=EX7N;9]/MYM1CETW
M3I3+:PK;%9,[650[[B&"AST49P,^_38I?H: .3B\#PPMX?DCO7672K=+>0B/
MBZ"PM&I89X(WL1U^\1WX=9>%+V.STVSO]5BN;;38?+MDAM#%\PB,0=R7;<0K
M-P,#)SZ5U-&* .1C\(WW_"/SZ+-?Z=]GEL6LO,@TTQRX*;0Q;S2#ZD8Y]JV+
M;08+'6VU"P*6T4T7EW-LD8"2L/N/QC# 9&<'((]!6OT]Z0G- %&330VO0:IY
MO,5K);^7MZ[V1LY]MG3WK,@\*PPZ;IUH)5WV5RMQYPB +X8MCKQUZUT(!HXH
M XBW\/76A16T#75M<0HI4.MJ4<CT)WGGIS_*@0W,.HM=V]Q$NX(&5XBWW<]P
MP]:Z^^M_M-JR#EAROUKFN<\T 0GPT(;.VO([AI9U?S99MN,L2=WRYP <D>WO
M5$:(GV58/.) F\S.WJN-NWZ;>*ZK1[@?-;M_O+G]14>HZ<8B9H1\G\2C^'_Z
MU,#FKW2C?$I+,C0EUD >/+QD8/R-GY>1UQD5TES;MK$EI?65RMIJ%GN"L\?F
M(5<#<K+D$@[5/!!RH^ASOK3X97@D$D9PPH F3PF)+V"^O[I+JZ6\-U.3!A)/
MW+0JBJ2=J@-GDL<@^O'11I'"@2-%5!T51@#\*@L[Q;N/(X<?>7TJSQ2 P8O#
M2+I^EV;W =;&[:YR8O\ 69\SY<9X_P!9UYZ57U#PF9[JXN[:YC5WG69(GARB
M@1;"N 1UZYKINO2CIWH XN.WEBA>&9D#\C,4?E[?PR>:KV]A(EVMQ--&[JA0
M%(MA;..6.3GI[5UU_8"Z7S$ $H'_ 'U6"RE6*L""."*8%:UT>UN6L+6]E)M+
M62:9(TRFZ60DABP((P&<>^ZM2S\+)9+I\45TWV>PU"2\@C*9*J\<B>7DGH#*
MQ!] !CO5.M;3M2QB"=N.BL>WL:5@*<7AV_MM6N[NVO--\JYNOM!6?3C)(IPH
M(#B4?W>..,U<UC3I)KNUU*UO$M+RU21 \L7F(T;[=RLH*D\JI&"""/J*U9'2
M*,N[84=2:YV^O6NY1U$8SM']30!C#3&:Z:YNKA;B>2=IY6,6U68H$ "Y.T!5
M7 R>G7)J>[M?M%H]NK"/<N =N0.?2K/%7;#3S<N)),B+_P!"I@9:>&[O589I
M);R-)"FR*3R"47Y@3\N[)S@9Y'2KL_AW5)X41M0TR.6*>.XB>#361=R'HP\T
M[LY]1CWKI@H10H& . !2$X=3^%(#GY/#!U*]6ZUVYCO62 PQQV\;VZ+N;+G'
MF,3D!!C/\/O4.G^$$L]1L+B:\:Y6TLS:B-X\;P"PC8G)Y5)'4^N[/'2NHR#U
MIK## _A2&<KI_@:VMK?3X+J[ENHK-92!S&SR.1ARRMG*H-@]B:6S\#V,#^5=
MF.\LEMY+:&"6+/EQ-(7"[B2?E!V@\' %=52'A@?PH Y,>%-1BN()X]4M+B6*
MU%J6OK S%D5V93Q(OS8(!/?&>,UT]JLD<*1RM&TJHH8QIL4GOA<G ]LGZU/U
MIC 9!/TH 7:#R.#302K,&'OFEY'O1N!.: %X-(N1D=<&E*\\<4TDJ=Q''<B@
M!3A@5/Y&D4'''Y&F7-U:VEN9KJXB@A& 9)7"*/Q-56U?38[B*'^TK/S9@ICC
M,Z[G#?=*C.3GMZT 7B0>O7WHP1]T\>AJK9ZMIVH,R6=]:W#(,L(9E?'UP:A3
M6](:&2:/5K$PQX,CBX0JF3@9.>,GB@"]D X88]#3B".VX54AU2PN;=YHKRVE
MA1=[R)*K*J\\D@\#Y3S['TJ Z[I"&4+JUD3%_K%%PA*<XYYXY('..30!?*[N
M5Y([=#49N"#MY/N.OY50?7-,D@CG>_M4@D;9')YR[78=@<\GV%21ZE8RWALH
M[VUDN5R#%YR^8,=?ESD4 7T(V@\,3T -.^[RQR:RQJ=A]IF@CO[99X@3*IG7
M<@'4D9R,>XH.NV$=LMPU_8O"S%5E^TH%8CJ,YP30!J $G<W3L*4DL-J\>_I5
M.34;6*U%U/<Q16Q (E9QL(/0YSCFH_[<TL211#4;023!6B5IU!D#< J"<G/;
M% &A@)2#+G)X4=JH?V]HQC>0ZO8;8\;V^TIA<],G/%36^IV5X$^RWD$P=69#
M'(K;E! )&#T!(!^M%@+9( Q^5-4$G+?@*@CO;21"Z7,#*&525D!&6 *C/J0R
MD>N1ZTU]3L1>BR-[;K=GI;^:OF'C/W<YZ4 6BV/<^E"J2,MUZUGKKNC%))!J
MU@4CQO87*87)P,G/'-6(M3L9C%Y-[;RF7B,)*IW\$\<\\*Q_ ^E %DG KD=0
MO+>Q\:.]S,D2M8JH9CC)WYKH;C5]+M1ON=2LX0>ADG51W'<^Q_(U#=76A/"+
MRZGTYHLA1-*Z$9(W ;C[$'Z'--:,&9O_  D&D_\ 00@_[ZH_X2#2?^@A!_WU
M6HMMHIW?N; E=N?E3C=]W\^WK38(M"NI98K:/3II(3MD2)48H?0@=.AZ^E5S
M$V,W_A(-*_Z"$'_?5'_"0:3_ -!"#_OJMH:5I_4V%KG_ *XK_A0=,TX?\N-K
M_P!^5_PHYAV,7_A(-*_Z"$'_ 'U1_P )!I7_ $$(/^^JVAI6G]386N?^N*_X
M57O--L4B9EL+0GRR #$H&>/:DYI*X*+;L9W_  D&E?\ 00@_[ZI/[?TK_H(0
M?]]5G)':0P^4;"VEV]':/G&"?RIS26<D B&FVR$@X:.,9/R^X_KVKC684^J.
MKZE4Z&A_;^E?]!"W_P"^Z3_A(-*_Z"$'_?5,&B63QB+]PK@Y(\KMFJ<NAG/[
MNVMI%.!N4+VY-5+&.*OR?B*.&3^T7_\ A(-*_P"@A!_WU1_PD&E?]!"#_OJL
MS^RG7YCID?\ $YPJGKT%6HM)0VTK?8(\C  \GKVJ8X[F^PQRPEOM(L_\)!I7
M_00@_P"^J7^W]*_Z"$'_ 'W6:-,9CE=-CQR#\@&-PQ^E(FAR$?-80KP!EMH^
M[_C2^OWV@Q_4^\T:7_"0:3_T$(/^^JQ]4U."ZUC3WL;J.1XQ(<J<XXK4BT2R
MC7?(;8;N!B,']:A*VVFRN!90R'G[R #IVP"?3\Z=3%>XU)6N%/#^_H[V("Y)
M>1@QD#-C)/9@1U'O6E:Y6SNP2I^4$(,=-QQZ=O\ )JH+R(;V^Q0@989"GCE?
M\_A5VQ&W3+J+;QP3( 22<]"/;&/3Z5PX.WME9W.K$W]D[HT?#7_( MNG\73_
M 'C6M63X;_Y -MSG[W./<UK5[9Y(4444 %%%% !1110!G:TLS:>1 E@S[AQ?
M9\O].]0:9IT$UDKWMEI339.3:1ADQVP2,U-KMLUUIIC72[;4CO!\BY<*GUR0
M>1]*R;.37M/MQ;V?A;3K>$$D1Q7X503UX$=6MM#MI1<J-HM)W[I?F_T.EBBC
MAC$<4:QHO14& /PI]5[*2YEM(WO+=+>X.=\22;PO/][ SQ[58J#CDFFTPHHH
MH$%%%% !1110 4444 %%%% !5?4%#Z;=*T;RJ87!C3[S#!X'N:L5'<))+;2Q
MQ2>5(R%5D SM)'!Q[4(J+M),\^LY-(D_LM;2QNFE:6W\ZW@>40E@1R?E 9TP
MK-D+]3C%>BUQVF0:Y>B*W&IVZQZ?<I%.8WE:0LF"V68#=N#8(.0.""2*[&KF
M=V823DDGWZM_U_7D%%%%0>>%>.?%/Q+J0UE]$AG:&R2-2ZH<&0D9Y/I[5['7
M/3^#=)O/$DFMWL7VF<A0D<GW$VC&<=S]:TIR47=GI97B:.&K^UK*]EIZGD'A
M?X?:KXB*3NIL[ _\MY%Y8?[*]_KTKO-3^$>DS:>B:;/-;W4:X\R1MZRG_:';
M\/R->B  # & **J5>;=T=&(S[&5:BG"7*ELE^O<\$MV\3?#;50\L+"!VPRYW
M0S@>A['\B*];T/7]&\9:=YD<<<C)CS;:= S1GZ'J/0BMNXMX;NW>"XB26%QA
MD=<@CW%<#J?PWDL;X:KX3O&L;M#D0.QV'U /OZ'(^E-SC4WT9I4QF'S!?OOW
M=7I);/UZKU_X8]!1$C0(BJJ@8"J, 4ZN8\/>*VOIQI6LVK:?K*#F%^%F_P!I
M#T/T_G73UBTT]3QJU&=&?+-:_GYI]0HHHI&04444 4)WMAKEFCQN;HPRF-P>
M%7*;@>>_R_E5^J,TX76[2#[.C%X96\XCE,%. ??/Z5>JY[1]/U9G#>7K^B"N
M;N\?\)='G/\ JEZ<?Q5TE<Y=E_\ A+HPN<>4N?\ OKZ']/SJ#0S)X<R%1PQ8
MCD#N,>A]C^-6H[:*V5)[C!F8Y6/@'+#V]Q4MD\:ZAM=%);(1F'1NU/FL)Y[@
M[) X'7YON].WX#]:\2-*Z<HJ[N>M*IKRMV123S;V\#X)#8))!XR ?3_>K1EA
MM[LJL5R%N(1RV."1G\^]9]S>QQ!X+,?*/O,!RV.?RQD57@+12*XY*GC!ST_/
MT'?O4JI&+Y7KW_X!3@Y+F6G8MFTN0"L4Z[ -JX?D+U/'J::D.I[SM9P?16P
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MW4LQ2'5O,=9&\T;S\F00O&>S \=^G:HRNAVTT-Q]HDRI !QD#G>H.1[ #N0
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MW=>C8W<C&,G!/3@=Q5J:/3KV))H9)Y1&$MP(=H)]!D@>O(SZ<9ICO);W_P#
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MMK1IWC4$>5>CSC(TL8?>H!*C/.5P0.';KCFG#X:U#[)):R21QJ;E95E%VQ(
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M>RN3>6D=P;>>W+Y_=3J%=><<@$U8K-G!/FYGS;A11102%%%% !1110 4444
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M*YP6]R,UL?)CT^O%)\G]_P#\>H Q[WPEH>HWTM[=Z=#)<RX\R0[@6P !G!]
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M//+"CRW$'V:4D??BY^4^WS'\S5[!'0Y^M(>?O+_6@!D4$=O"D4<2JB*%4+V
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MV\I*@R[<G*GD<#DXSZ5M:]'KMU<Z7?0Z6DTMA*9?(+@+)E,9R3P02<9],YY
MK'?2O$$GBRWUQ-!2)!*IEMC.,.V"OG$ E0<'U/3-$;<MOU-*#IO#NFY)7N_B
M6_;?R6O35=SN;+58[JZ2VBMWC'EEOFP, $ <=>]4/[;MKH0Q7-GYDCR86-"'
M4-C/7@=R/\D"W--JBK%)'$QD\I6,2*-A;)W DG/ QC!&33?MNL&-2UBJD/RR
MG(*G(SC.>,9Q[CWK*R/)C&.]E_X$5SKEC!;>6-/E4(L<ABVKPI.1P"?K]<"K
M/D6]U;+<6FFP2";<S+(0N3VSP<\_H:9)<:G%+&ZP;V:% X*@ -WSW.">F?H#
M36O=65%8V,8+CA5!)5L\ X/H.OO[46[#<>L+?^!#Y+46]G>3-IEOE(V=4W[O
M,/)P3CC.%]>OM2:3<VUQ<RB*P$'ED;7.!NRO''KC=^ J>TDU2<3QSJMN0%\N
M3&[GOD=#5F*"]64&2]5TSDJ(0,]>^?<?E[TKF<I6BXR>OJ_^"6<G^[^M<S\/
MB1X+L_E_Y:W'_H]ZZ;!_O5R_P_Q_PA=GE\?O;CC/_3=Z@Y3J"&ST 'UINX$D
M;QD=0*HZY+)!H.H36Y<31VTC(R@D@A3@BJRZ#HT?V2>"U@A:)U>.="%:0]MS
M=7SGN3D\]: -@ 'C:3]::5P,E@GTKD9M.L1X(UY?LEL"7O25$2\N'DV'IU Q
MC\,5HZCIL-QJ?[NSL-06*W1/L=P<"$9;#+\K ;@,=!]P<T ;H&#Q\Q]_\:=E
MB.1M^G-8$=II]WX1\D6:M;0QR!(KH"0QNNY3ZC(((R#3X=.L8?!S0):VZPR6
MF]XUC4*S;!R0!@G@<^U" VOW6[C!;]:7:QZ,5'YUS.AZ>=^GW%KH\>FQQQ?O
MF&Q3< I@*53((R0V3R,8 Y-=-Y8/4D?[IQ0!%+=V\,Z0R7$(FD^ZC. S?0=3
M1<745M'YES)'!'G&Z1P!G\35#6[>0:7=- L(1E+7!9?F90.2I_O #@GOBI6'
MF:[ 7"G%J[1@C'5E#?IM_/WJK=3>-.+BI>OX%T&)1O) '7<>!3E*.H:.3*D9
M!4Y!%9VF0Q3Z4L4L*2P)-((E8!@%61@F,^@ Q1I[NOA>S,<>Z062%!C.3L&*
M+$RII75]G8N_:8/M/V87,7GXSY6X;\>N.M2!P9#&)$+@9*]P/I6)H\KV]O8H
M\,0BNTW*4R7W;=V7/1B1DDCH>.<YJU#!;P:](8HHXM\ 9BHV[B7/)]31:S*G
M246UV-+GU7\J7#>H_*LB.SL[^\OFO8XYI(Y?+42?-Y:[5(V^F<YS[^U6-)D$
MFFQLTI< NJ.SDET#$*V>^5 .>^:31,J:4;W[?B:&&(ZC\J8C+("4E5@#@[<'
M!]*&6*1&1]KJP(*L<@CZ5GZ5%#"]]''&J1K<X557 'R)VHMH3&*<6^Q<^TVW
MVC[.;F/S\9\OS!NQZXJ7*CH.OH*P (QI:R!,2_VGG<!SN^T;3S_NY7Z<=*Z#
M)(X7\S0U8JI34=O3[@R>R_F:8CK*"R2JZ@D$H<C(ZBJNJ33PV1$*OOD8)OB0
MN8P>K8 SP,XXZXJKH A%K<1P)(D4=PRJKHR8 QZ@&BVEP5/]VYFOA5]!7+_#
MHG_A7VBX'_+#J?\ >-=0% Z 5S'PZ_Y)]HO_ %P_]F-(R.GVYZG-5-0R+>3!
MP/*;C=M[COVJY56^1G@=5!)*$ #ZBIE\+*C\2.<TZ0K?1A1@,=ORKZ\=3_G\
M*L6MX\=\]N3OA9BI#<@<]<G^E5(;>>.]BDDB<!9%Y*D]#_\ 7I]RK0ZKEA@A
MA@\_Y'X#_P"MXT)2C%/LSU91C*37=$XAMIG9(V,-PIPPP2,_7ZBH;2TDU-S"
M)1;QH<%""6<#'!_*H=2)347;'# $9'L/6A+ID=;CS#N!"NV3T/0_@>_O2<X<
M]I+;?S&HRY;Q>Y9U9]*%P8T$@G'0Q<X-5C:SD@+<@KCD,JY/U_R:$6*S::YX
M8R$XSSGGM4;M.[!Y)G5^>$.0.WX]*F<E)W:^XJ*<4DG]Y)"UC!=JMXUP[D@
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M\O/(2,@XY[Y]U_(^M2WT9G*;491D]?5_\$N$<4E._AIN*AG&+GUH/6DI3UH
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M12GK24  ZT'DT"B@ I124=J $I:**$ 4444 %5+X$Q,%0LVPD 'KR*MU4O\
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MYXXZ_EC-5AY9&?-BYY*[ASV/Z5E*5I--+[C2,;QO=EE9+"('*SNP.[TY7O\
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M*JZC<M_R7R+5)0235OS9.6F6'S;!XQM'(QG_ #_GI5R+5+>_TMGO8!(\? W
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M9A<1<AE*8)..F3G/0LQNG66E]+6MY?IZ[EZ[T>]UAE&H3);P 2'R[8ACEE"
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MNK+I5H\\@B#:6[[X[AP6;,/S,<#!P3SSU--79M3=6?+RR7W6[_Y&G%H-U+/
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M P[@9'_?(J=#*3HMJRT3^;7WE&/Q"AMY)9("FVV,RJ&R6=6*O&..JMM'ON%
M\0%9KZ.2V :V@>1"),B5D4&11QQ@L!GOSQQ4X\/Z>)$*QLBI/]H6-#A0V!P
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M"4Y0JJZ)Q-2,J>A=\-$G0;<GK\W_ *$:UJR?#8QH5O\ \"_F:UJ]@\L****
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M/]9,Q+NTMY[22/<_F;B\<A0Y1OKCVK-U"Q?4=/M9 ZV>HVA9D.WY&Z*<X['
M%=)<^?:,ZRV[+M!.=PQCGG]/UJB9;=F.Z'))(/S'ZG_ZU1&36J..A7J4Y*4>
MGI\_DS-EU#6;N$Q1:4;:ZE:3-Q).IB1F3$C8 W$ 8./X>^:W_#VD:3HVGP0&
MYEN0N'D+P,59R&(.,<##$X^AJ&VO+:-@)+7S%." 9",%N.OH1U]?>MP7L=GI
MVY-/=+:0<%I0=PP?3+?= XQQ[8JW*ZLCKJ8IU(>SA'E\D]_O;?H<_J&GV=_X
MPTV\A:)-/C@=Y<[8PO.%PIP2"5ZX/UZ4>*=%BO= N8+._2YNFD4A&G1<?O%W
M')(&1MQ6O)<:*T9CFM9CN9\@L6+;<G.=V3GFE']CW3&*'3Y7E8-&$)*;L'=C
M)./4_@:.9II]BHXBI"4))/W/3H[ZZ_Y&'JEC)I^MPZWID+:B\8>.>UG1E+)D
ML"K$8R&0GGVQU%4[M9?$>HV*W6FKHEA9R&:3D.\C* % "C  P!SUZ#.,5WLM
M_<0QN[V$BHH)+&1<#[W/7V'_ 'U[&L=KO39&8O8,2Q.[]Z3G/+<?7E1WZC%$
M9/L%'%3LGRW:5D[W?YVZ]4S&L].MHO%VJ74DTBVUPD063;]YPA#C'5< _A6;
M<>'UM?%&G7>GLT^E&=+BZ1HL"-@#AL$=QSQWY[BNI%WIQPWV#YC@\SG&3QU]
M".I[G@YJZ]VEAI^/[/>.W<$ O+R1@^F6^ZH^@],'!SM%_6ZL)72>JY;.W:WW
M]?4XEX[JV\2:Q<V>E)<6-UY4D8^UQVX"K@9VMVW#KC^=6K+1+C5]7^WZW>6U
MI' 7:"U2Z61P[85F9A@=@.._Z]$\^BO'Y4UI*2[,I4L6+$?-DG=GFG*=(NW*
MPV$KRN"H4DINZ-U)QTY_"GSOL.6,GRZ1:=K7ZVM;J[;+5V,SPU:6^G76MR7U
MLS":^>:"1X2[,G)!S@XY4G\O451ETZ#3O%C2:>I&DWH/VF.-=OV>11PZ@_PD
MXX'7!'/ KM9;^XA0N]A(JC^(R+@=>N#TX'Y^QK&-YIKG>U@WS?,?WIS\W!X]
M<]!^(Q4J3NV8T\14E.4VMU9V::_X=;G':?)JNFFYA.BR7*O=O(LBW21@JQR>
M"#CW/\/M6ANN=3T'58KK29;61K0K"KR+()'*MCH!MP!W]C70_:].'/V#D<_Z
M\XR..OH1U/<\&KTMVNGV!0V#QV[9&7EY(^;/3+=%!]LCI@XIS\C>KBVVFJ=I
M777M_P!O6_ X>TN=7.GQ6RZ)%%Y5LB;I=0C1. J^85QDC*@YZ\]>E;NC>'K2
MTLYOMVL12ZA<S--</'( -Y/('? Q^?Y5H--HLD0@ELY296*E-Q))(W<G=W]:
M>K:1>28AL)7E<  $E-PX/4D \<_A2<F^EB*N)E)-1BXK=V_S;?Z&$FD6EYXK
MN;G5+9Y],MX-EJLT)?>S99FQ@GC:1SW/'457\1Z'IL4MCJ'ARV2&]M;@;H88
M]@E3N.0!R.GKR!FNXDO[B) TE@Z+D+N,JX!/ S@],X_/VK%^VZ8P\TV#X($G
M$IS@G;T]0>@].1BDI.]R:6*K<ZFKV2M9--/U7GU,;1M,M(=7UB>YFDCAN)8O
M)?'WXPO)X'R\\$]O:J-CX?32_&MI=19FT2(2S?/"1Y#LK9&TC/5,C'3^?4&Z
MTU,_Z ,KN&/..,IU_P" G]3UYYJ_-=+I]D8WL7CMV)&6FR2#N).1ELX&?^!#
MI@X?._O+EBZJ;LG[RM;3M:Z\S@K)+^PO-66'2%FM9;N:>'_3HH $; !VMTQ@
M8/'7Z5J:3H+7^K2ZMK=_;P3G*6]M#<AO+SPQ8C&6^G&>?:MTRZ++$D$EG,6E
M.-FXDEG ;D[N_J?2I(VTB\F @L97E8+@$E-PXQU(SP,_04W-]AU,9-IVBXM[
MOR^;MKU,_7&>W\.W*:/;FZU!^(VE@.4!Y)!8=0,GD]3^%<WIUQ>Z79VUI:>%
MI5,3*6;[=&3+)@E6/R\YR?J, =*]'DO[F)0TFGN@)5<M*N 2<#.">,D5B?;M
M,VB;[ X78)>)3D#.P<9Z@]!V'(QTI1EI:QGA\2U3<'#F5^_7Y-?(Y'4HKJ6Y
MT/48=.ED\B*036WVA%*!CA3YF,')SD@<=.#6G9ZQJ<=PLMQX6E,6YFD:2Y0A
M"6RS8V]O+/'MZD5N-<::F5.GC*;U($Q*_N^2/]T]1ZGJ.]:,UV+"T\F2Q>.!
MB02TV20=Q)R"6SQG_@748.&Y]+&E3%<T5!T[[VU:TNWTEY_YG-Z?IEK+XMUN
M^DE2WLI(X5MQN5 <1;2=O4;<C!Z?6J]_H M/$EMJ6E7J7$=U)LOH5G1"1CAQ
MR,L.OUQQ6]YNBRQQP26<VZ4C]WN)):0 C)W?Q #D^G:I(6TB\F46]A*\K*C
M$E,J, 'D\X4 _0>M+F9'UFI&7-9VM;96LE9=?*]^YS@M)/#VJ7-YIM@NK65X
M1)+;R1E)8WQ]Y2PP<@\CUS33'+XAU>VFN[5-(L+>2.46ZCS'GE )CR%& ,$\
M=3_+MWO[F) TFGN@)5<M*N 6( S@GC)Q6*+[2_+\X6#A=@F&)3D -L'?J#T]
M!T(Z4*3?0*>*G+WN6\MKIW?YVO;RN(+?1_)"_;IO*\I5SY9_U>_.<X_O\9[=
M*N0KIL$CSRR22@%Y'#VYPKD[F/3C'E].V/<56-QIB%D.GCY"Z$"4X_=_,P^G
M<>IZ@=:OS78LK3RI;)XX6)!+39)!W%CD$G/?/OU&*EG//F>FNOFBK]GTFYE>
M07JPQJ.(N(PF4 ! /H,8(_,\85=.TUMW_$U#N\@((E YP1@8/?KQW /M4?FZ
M++'%!)9R[I2#Y>XD[I ",G=W ')]*?$^D7DR?9K&5Y65& )*948 /)YPH!^@
M]:-4#<DOM?@36W]EPP!'1I^X:6U8G'7'*Y_B/XDU'+_9,MPCPS&$AXV"QP'!
M<9*=NX8_7BM&2_N8T5Y+!T!*KEI5P"Q &<$\9./PK%%]I@C$HL'"A!,,2G(
M;8._4'IZ#H>U)7W(IJ4FY:_)IB?9M'\D+]OF\KR@F?+/^KWYSG']_C/X5J:7
M;VXNI9H9I';+EPT94!G;YNH]4Z=OQK-:XTQ"T9T\?*7C($IQ^[^9A].X]3UQ
MUK?L0ZH8S:O B\C?('+$DD]R??GUHEL%>34.NO>Q:[8I*6CK69YX"CK110 E
M*.!1B@T !KE5T+5)+PQSW+?8G9HF"RG=Y2_-%C_:RQ!]@*ZJC%-2:-J5:5*_
M+U.3AT?7"))+FX#2[/M"J)3@W ("CV3:B@_[QJQ8Z9J]M;74,EP6E>(Q03&3
M.QF5G9S_ ,#8 #T45T=+UJN=LUEC)R332^XY:72KUT_=6+QQ^7(JP_;#E92$
M"R9SQC#=.><XR31-X?O98YF:1GG:.X^<3,,N<>6<9XP03[$UU/04E'.P6-J*
MUOU_S.273]2N3<O!')'(LT^9'F(\X;_E4#L..O3TZFG7>CZI=7$ETL?E2N)E
M7]\-R*QB(&1TR$<<="WXUUG6@]*.=C^NS3NDCE8]#O7B?S/. $,PA3[1M*,Q
M7&, @'&['4#-,30;^2%W= DL<$BVV)"I5BP*D@$@'@]./IG%=92XHYV'UVIY
M')-HVJS7TK.#'%(Q$FV8@.//C8$<D_<#CG&,X  JS9:9J%GJTLY\R2-3*5_>
M@*Z'[B8// P.<8QU.372'K24.;$\9-KE:5CFYM+OV>;]RSL9F=Y?M)'G1F4,
M(P,]D&WG'3'1C48T*]EW&4NH#1^4@G.8T\]F9<@]?+('Z#BNI%)1SL2QE1*R
M*>EVTEI9>1)_#+*4&[.$,C%!^"D"KE%%0<\I.4G)]0HHHH)"BBB@ JEJ)Q!)
M_P!<V.?Q%7:IZAQ;R8/_ "S/&<=QWJ9_"RH?$CE[9&:_A'.#(.GU]JEE/F:K
MUX+8)_'U'3\?_P!4FG0[[Y9""=@+?,I!X]Q5FVL]L[ZA<DI&F2,]<_X?6O%I
MTG**MW/5G42D[]C/NXC<ZG*J ?*0O ] !V^E206;SW A10^TY<@Y&1P![XZY
MIXU% NR!0K'J[<L3T_QZ>AJ&VFN;/Y[)B%8[FB*9XX)P?QJ?W?/=Z][%>_RV
MV[#%G5KB:UNAY8R0N[OSB@P7:'RT5'0\%C^F?7VJWJ%]:7LC-!9),X&-[=OQ
M_I5(33G8PFB4*!\H3/?C&?>E+E3:O?S14>9J]K>3'3.EC"0&#W3GIZY_S_A4
M\EM*;6&ZDB(61-K>P/.?P..*BMKB*.7SKJRBD53GS%)..:LWVHSWQ9(',=F5
MQ]T$LV.0/\:J/)RMM^B_5DOFYDDO5_H4)[=HP),@AN000P/XGBK>IG=-%*.C
MH&X_SBB"\2VC$'E!H@2 IZ]2..X[?G5D6\6IV(-L?GA)PC<X!YQ_^NB--2BU
M#=]!2FU).6RZE7409'MY 20T(Z<YY]>G^>*GL"QT^ZQDX1>0??UI+R)GL;=W
M7#)F,[@2?6G6@(L;LDD':O+'GK^.*WH)K$I_UL8U6G0:_K<T_#/_ " +;  ^
M]P/]XUK5D^&QC0;?_@7_ *$:UJ]@\P**** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** *,T&[6K2?[0J[(95\DGE\E.0/;'ZU>JA.EL=<LW>5A="&41Q@
M<,I*;B>.WR_G5^KGM'T_5F<-Y>OZ(*YJ[V_\)A$><^4O09/WO:NEKG+PX\6Q
MCKF)>,=/F_SVJ#0BM'AAOR\QP2"%; X/K^M%W-=I<*=Y /"E?<@=OQ_[YJA,
MY#LV<,"6R?89[#U-3Q7J8%M< -&K,-YZC P.I]2:\)559PO8]=TW=2M<?)#'
MJ :2+Y)3RR\C=G\N<#]:K6D$DDWEE3DGYCC[O4G^9_*IO(>VN0T1RN<*5[X
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ME<'[WS$C.>$:F!-5NRO7M)/[T9^\O]16-J]S+87<$(G@@@E0NMU*I9&Z8 Y
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M4I?"QQW1R4V&GED'W7D=E!]"QJ:PBD>_A R,,&)P>@_S[U86>Q>9(H[5A\P
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MKV#RPHHHH **S=;UVP\/V*W>H2E(GE6)-JDEG8X %7O.CWJOF)N;[HW#)[T
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M9;I=[S('"]'/5@.@8]R!GF@#A0=0OM%TS5K_ %6YN6F\010I;L$$<:I>%%P
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MYGN5EGU21H9 IW&,RD 8 (R1D^Y/TKT*/P]I$5X]W'80K.]Q]I9P.LN&7?\
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MC<VTBH$)^S-*NP!00<H!G/.34EGJ&JQZ7X8UI]<GNI-:FBCN+8A/* E0G]V
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M)[\UWUIH.DV(@^R6$$(MW=X1&N!&SC#$#MD4ESX>TF\@>&XL(7C>X^U,"/\
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M-X\*M<0JR1R$<JK8W ?7:OY5F'PAX?>Y>=M*MS(\GG$E>!)G=N Z*V1G(P:
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MK+F)Q'(Z3<31\-?\@&W_ .!=_P#:-:U9/AG']@6^,8^;O_M&M:O8/+"BBB@
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MWXXIJ5Y(N&)E7Q$&[Z>K;W?7[CGK6^AU[6M+2670+)+:Y$P2UNUEEF< A5&
M,#FO1*\UM6T&;5+:&SU2T-S)K7VY$\ET8H5QY8^7U_"O2J*G0>9)*4$DTK;-
M/]=0HHHK,\P**** *4T,S:Q:S+.%A2*17BW$%B2N#CH<8/YU=JA/# VN6<S3
M[9TAE5(L?>!*9/X8'YU?JY;+T_5F<-Y>OZ(*YN[./%\>%)S$HX/3YO\ /?\
M.NDKG+K/_"7Q_,!^Y7CO][WS^GYBH-"*RN5@U H[8#Y7KG:3_+M4S::+BZ;;
M+R,[PR\_K]!^594S^7,Q#;0"2,?(/\?\^E6[^=H+]9XSLW!6W=!^?4UXD:D>
M5J:NDSUI0?,G%V;1!>7C.S0P*4B!^5>A/<?U'XBHX(Y%(*#E3@87_P#5[5HW
M5Q"L^+F$GS%#AU 4CVZ^H-5#;*]^('E:.U?[KIU<?7MC%9U(/GO>^I<)+EM:
MPV]F@NG!9"KX(,QQM?&.,^O&*J(DJ,"%._D\="3UY_3\:V-0N;*PBBL$@%RR
M@!1GG!]>.:SQ9Q-&K O;!N2N\_Y__72JT_?W3?4JE.T-K+H51%T)(5".'?@#
MN,^XZ5HQW4:6Q@MXG3.205 +C.>GXXJ!ECLV6=K5KDC.7+'C'.?\_I6FZZ?J
MVFI,K& P]/+/(;'0\<TZ4'K9J_\ 7456:T;6ACR1LDG(QCJ>AQTS^0/?O6E9
MN=1S;RKF0#Y7*^F.#^@_"J]L$"-->9*%OD*X!D'KUJRUV8]/DE@00J[;  ,<
M>N1GGGZ4Z44GS-Z=A5&WHEKW+5K%'8B21I"3&#O '!]!5.P?S;TN"?XCP>.<
M_P!?:HE;9I#L< R.%)Z9[]1UZ4NED_:E).200"2,]#W[_P">PK53O.$4M#)P
MM";9U0^XOTHH'0?2BO69YH4444 8OBW7!X=\+7^I[D62./;#O( ,C':F<]MQ
M&?;-<EX5\46.AZ5KUB^L)K$6D0"]CN([@3-+&R99=V3R) W7H&6NUU31H=6N
MM.EN)'\NRN/M(B&-LCA2%W?3=GZ@51\0>&;;5&%Z(3)/%:7%N;8.(UNDD7!C
M=L' R 0>QIH1G2>*M8TF\MEUS3[.*VFM)[MGM9F=HA$@8H00,G!ZC@^U4[;Q
MG>:@L23I9QK=)O5+>5G>+Y=VUR0,G'!([\5G6^GW-[J%E<7<^JR1VUK+;F._
M,0VAPH*CRQ\QPO+'KQ6E!ISQ% ][/)'&I5$. ,8QS@?-QZT 5[;4[R463R00
MJEXI\O#DE3M+#/'0XJ[X;CN]0T^$RL&8Y)?)/&>]266B><;"&-VQ9CACW&TK
MS^!KH-#T@Z+9/:BZ>XC\UGC+HH**?X> ,XYY//-#8'*?\)G)IFKV]BRZ5LDO
MULVM8[OS+I S[%D?:"H[';V!QG/%66\7ZPJW&H-IUF-+MM5.G2'SF\YAY_DB
M11C'4C@GGGI4\7@-(X+>T76+P6%K>K>P6X2,8<2>9AFVY<9SU/?O@5H2>%;9
M](NM--Q-Y=QJ'V]FXR'\\3;1[9&/I0!S7B3Q!K.HZ!J5S8V\$6FP7ZVGFB=E
MG.R=4=P ,;=P(QG.,GVKK?$^LRZ!X>N-2@MA<RQO$JQ%MH8O(J=>WWJRKWP0
MET+JWCU>\M].NKG[7)9QJA7S=P<X8C<%+#)7/7/;BMS6=)BUO2I+":1XT=XW
M+)C.4=7'7W44 <IJ'C6_TS4$TF[;1;;4([<7$[S7+K#\S,$1/EW$D+DDC ]Z
ML6/C"_\ $#6D>AV-N)7LEO+C[9*RK'EV01@J#DED?YNF #@YK6U'P])<ZJ=4
MT_4[C3KQX!;S-$B.LJ DKE6!^8%FP?<]:YW4[/\ L^^MFT^34I)(K/[)+=K,
MLKSJ&SA]XZ@DD,/[Q'2@!J^)[C4(+;4'L)(;QK"<O LK'&) -N.A)P.<9Z@=
M:IW6M:A+X?U06-W!%+]G.V:WD.4)SV/(([&K%CHYCLH!-))'*MN\1V/RNY@V
M<^HQ5J#PZVH23K-<22O+#Y+2;57:OX#DTP&ZAX^GM+V6R4Z5'/:P))/]JN&C
M$SL"=D7RGH!]X]R..M6H/&5YJ&HH;&RMTTY-/@U*YFN)&$B1R;\J% .6 0]3
MC@U<;PG.DKRV6NWMG+<0K%=-&B'S=N<. P.QL$C(]N.*OVOAVUM;ZYN#+-,)
M[*&R=)GWY2/?@ECR2=YR32 Y?2?B0M[=:>;G^S_L]_G;';3EYK;Y"Z^8,8.0
M,''0D#GK2/K>N:I/X2U"6V@M=-O[]98A%.QD"&"4HL@P <C!XZ$8YZUNZ;X5
MDL&M(7UJ_N-/LE*V]H^U5V[2H#LH!D !P ?;.2*AM/!0M9M,7^V+V2QTJ;S;
M.T94VH-K*%+8W, &(&3P/6@!GC=KQ9_#R:?&CW$^I>45=]BLOD2D[B 3@8#8
M_P!FL<:I=VLT]OJ$$2S6M]%:3M"Q*8E4&-P2!@$L%(/0UUNNZ%_;8L66]GLY
MK*Y^TPRPA2=^QEP0P((^<Y'>L76= >T\+:O;QPWFL:GJ[$23#8A$FS;&QZ!$
M3:O3)'7FBX$=G<M=BXD5/W,<S0HXY#%3M;\F##\*Q9+F^(<EE9AJ2H@#D#&.
MA]NGZUZ#HNEIHVAV>G(V\6\01G/5V_B8^Y.3^-9/_"'Q?;YIS?W!ADOTOQ 5
M7".!AE!QDJW'!]*+@<]+K,EI'.ES'$)XY4C4AR$.X9!)(R,<Y^E6])O9-3N)
MK9%CDDB"MNA)*D'/KTZ5M7OA&TO9KZ;[3<02W$D,T3Q;0;=XA\I7((Y[@@@U
M=TK2KBPFN)[O5+J_GGV@F7"H@7. B+P.IR>I_ 47 X:^FM[;Q3J-OJ.GZK=Q
MVUK#,18*SA V_.=K#^[[U)I?B:70/"@OB0;75-2*Z2M]=!A%"R[LR."W VN<
M9)Y ^G;VVD16VO7VK+(YEO(88F0XVJ(]^"/KO/Y5E'P1:)#/':WMS;+]N^WV
MGE[?]$F((;8""-K9;*GCYCTS1<#,MO'\MS!+:V\%G=:E]LBM(7@F8V\AD5F#
M[L9  1\C!/R]>:2\\1ZAYMY8:K80++97VG('MKAPLGG3 !NQ &/NG@X(.15K
M6/#]W%I+RO<:EJU]]LBN!+%*D<EN5X#0H1LX&<J?O9.2>*I:)X7O-1N=5O-4
MDOT6ZN[.:)KH1B9_L[;\E4^55)X ZX&>IH M6?C.[N_$SZ88M/A9;J2 VDT[
M1W0120)0& #J< X7/!ZFLW1_$OB.+2[&$PV=Y?:AJMY;1-+,X5 CRGDXS@;"
M !V Z5T,OA#[1?P27.KWEQ9V]Y]MAMI0C%) VX#S"-VT$\#/3 SCBBR\(165
M[;3B_N)([6^GO8(65<(9@X=<@9(S(Q&>>E &/KWCN]T%[G[2NCJ;79OM/MA:
MXF!"EF10#M')QNY.,G&:VK#6M5U#Q5J5A':6B:=ITRPRS-*WFN6A5QM7&."V
M#D]#5._\")>P:O:+K%Y;V.J2M//!&D>?,.,_.5SMR <?AG'%:ZZ"83J\EK?S
MV]QJ4JS-*BJ3$PC1/E!!'1!USUH V12'K24I]#0 4K>M-I<\"@ S2GD4G7I0
M.E !TI3SS2=:.U  #S2D4G6CM0 O44"@<T4P C(S3:?FD(I,!M%%%(84N:2@
M<F@!0,FE_E2]!2'I5"#K2'KBEI/84@%Z"DZT&CO0 I]*3%% Y- "FDHZFB@!
M3Q24&B@!1TI":7/%-I **4XS2#B@]:8!2]J;2GI0 4#K24H%( [T&@FDI@*.
MAHH'0TF: %S0:2E-" *44F:!UHN E%%%(8O:DI>U)38@I324I[4AB4HZTE*.
MHH 3O1110 HZ4E*.AI* "E/:DI3T% "4HZTE ZT *>M)2GK24 %%%% !52_&
M8'Z_</3ZBK=4]0 -O(#C!C/49'4=JF?PL</B1EZ;.LD4UN6VLWS@CDG@4+81
M(DERS>9"G& O/IC!_P \51LI=E_$&)^9]N"<=?85+;7#6VJ-&AVJS$;<8R/8
M?XUY4:D7&*DO(]*4&I/E]2I<7,UXXR,#G:G9<_\ U\'\:FM9'MW$R_*NW<6(
MP,<'O]1V[58:2U:5K:9#%*I(\Q< 'WQFHK&Q2\NFAO9'B\L@K$N,>V3WZ5DH
M2Y]'=FCE'DLU9%:Z,,\C-#&8G)R(W&,Y &1_GO4(C8*Z[6"M@,,8QV'^-:.I
MZA:7-TUO%9"<CAG5L8.?I^M5S8H",321XZ)N;\?\>U14A>;Y7?\  N$[17,K
M?B5EC4,QF&!R0N,ELC! 'UP?2M"6Z^TQ*D,92-3@QX^Z>O//UJ%)K?3;@%['
M<C,,REJNZI;VDL*ZA;SE))$"J%'RL.G(Q5TX-0ERM>:ZDSE>:NO0RT,EO('0
ME2#C=C'(X_F6-:L40U.W:79Y;I][<."/_P!55XVAMX5>ZC8SMDF(,,#Z\^_Z
MT^^NI$M88N$60;]H '7MZ&G32@FY;=B9MS:Y=^Y:=H[+39,/O$N5&1@9(Y/(
M_P YJO:Y:QNV49RJC!^89S_GM4-ZVRVM8E.T["Y 8H>N.E2V9_T&\Y"G8"21
MCOW (_PKII3O7BNQA4C:BWW-3PT<Z#;_ / OYFM:LGPU_P @"V[_ 'OYFM:O
M5/."BBB@ HHHH **** /-=<U!;;Q;J,DMG:R/L:V7_B7/*VUH<ARXX;YCL*^
MAKO]+DEFTFSEFMQ;RO C/"!@1DJ,KCMCI7&Z[$?[5UF2^U)T>.)7T]8]3$&P
M[?NE,C!SDY.00177:)<B[T6SE-W#=R>2@EFA8%6?:-Q_.M9_"CUL;9X>FTMD
ME^']7\S&OX;BSUF[NHK5)%G*DR3V;38PH&%9"6"\="HY).>:N>'XH!+>3QW5
MI)-*4,D-JGEK%@'&5))W'G).,X''%32W5[/J5Q:V-_INZ$*7ADC9I$R <G#C
M@_2C0OM(AN8[G4K:^,<S*&A!S$<G*-ECT]^<5+>AA.;=&SWLONZ=/U,[4H+B
MUUFXO(K5)5F5 7GM#-C QA2A+ >Q7KDYYJUH$4'VJ\N5NK1YY0@D@M8_+6/;
MNP64G.XY/)QP ,<5//=7LNIRVEC?Z:'C4,T$L;-(H/<X<<?A2:']J7[7'<ZE
M;7NR8@"$'="3R4;+'IVSR!0WH$YMT6GO9?=TZ?J4=4@N+?69;V&U6421HA::
MT,P7&?NE"6 YY&WKSFIM!CA-]=70NK-KB1$5[>UC,80 G!92=Q;G&2!P,5:N
M;J[DU-[.ROM.61$#M!,C-( >_##C\*;HOVM9KV.ZU.UO-LN=D2D- 3R5.6)Q
MW /3Z8HOH$IMT6F];+[ON_4I:O;SPZR;Z&V64-"L9::U,RK@L?EV'<O7GY2#
MQ4FAQPOJ5Q=&YL_M+Q!&M[:(Q%0#G<ZL=Q/.,D#%6[NZNFU/['97VGI*(A(8
M)T9I,9(W<,../2F:/]L6\OH[K4[6[VN#Y42D- 2/NG+$X/4 _P J+Z YMT6G
MO9?=]WZE76;>>/5UOH;83?N!&3+;&95PS'Y=IW*>>?E(.%]*-$2&35I;IKFR
M%T8=AMK:$Q-MR#N<,=Q(Z#@8R?6KU[=77]I)9V=]I\<QB\SR)T9I",D;@ PX
MX]*BTG[:FI7T=UJ=I=8*L8(E(: D#CEB0I'.#^%%] YW[%I[V_#[OU*^MV\Z
MZI%?0VPF*P^6?-MO.1><_*%.Y3ZX4@C'I3=&2*;6#=O<V270@:/[-;PF)BI*
MG<X;YCC&!P,9/K6A?75R-0BL[2]L(IGC+B&X0L[#/4 ,.*ATO[<FK7D=WJEG
M<<*QMHE(:$D#GEB0I'./7I1?0%-^QL^WX?=^ID>-]<@T86[/K%[:3.I\NWM8
MXSYO/4EP0 /K53P5J-Y?:@[7OB>"\9D)2PC*.R#CEG51DCV&.:O^*[C4(M3L
MHX9-2CLVB<R-I]F)GWY&,D@X&,UJ^'"SZ9O>2^D?>1OOK<12=OX0!Q5:*!T.
M4(8%>ZKOKI?=_P!W3[[^9KT445D>0%<QXMU6?3+C2@UX]CI\LK_:KI(]Y7:,
MJO0XW'(S[5T]<_XH9EBML'6AEF'_ !*RH/;[V[]/QJH;G3@^7VRYE=:_E\S$
MT'6]=OM=L)+B20V]^)IFM#;[5MX!D1-OQG)(Z$\YJ]X\@TR[L+6WU%-1D+.S
M1K8J&;Y5RQ8'@@#M1X6T[46N9KV]N]:6))2+>"^F7+H5 RZ@=0Q..>PIWCF.
MV:QM'NFL@B2DC[7>26XR1C@IR3C-::<ZL>BY0^O05/2W\OS]/)?\$A\+"\AN
MWM+*ZL)]/@91+FS^SR@,FY&79\K Y'.!WKL:XCP470NFF0:-]AWC[1);7DLS
M@A<*/G7V QGI7;U%3XCCS%6KO_@7^=M/^ %9FO6^K76G>3HUY#:7+,-TLJ;L
M+@YQ[YQ^M:=8OB:&RGTV-;[2;G4XA,"(;==S*<'YOO#CJ.O>ICN<^'_BQ_R3
M_!V1SVG:7?>&=0LYKZ32Y9;RX6![IHYI+B1B"<;BQQP#Z"N[KSN#2-+EU;3)
M+#PQJVFRPW:2M-) "I49X)\S@<@YP>E>B5=0Z\Q?-*,F[NVNB7Y-_F%%%%9G
MG!1110!0G-K_ &Y9AU?[489?+(^Z%RF[/O\ =_6K]4)YXUURS@-NK2/#*RS'
MJ@!3('UR/RJ_5SVCZ?JS.%KR]?T05S=Y@^+H@2?]4IP/][OS725SEUN_X2^/
M'(\D?^A5!H4Y=,NG8O$@9#R'5Q_^NI-1M9O+MI"C9V ' Z8]ZK7FV.X*1DB)
MU$B#KM#9R/S%)#J-S X97;Y?X<\'\/\ #/UKP&Z:;BT]3V4JC2DB2^#&VM)0
MI&%*Y'X?6JB,S@QG.[[RGT(Y%:NI74PD08#POAPA4'GK44[01I#.(557.-H8
M]1^-.K!.;:>P4YM12:W*BW%JS"[W+O4=SSWXQ_GK43[I1YEP2=W(4G&WW/OQ
M36L+21R%DEC). .&P:UK>2$VL N(-\R@@NIY.#M_E6<(N>DK(TG*,-8W9G).
M]NNUV_<R';\W\)]/_K^U(&@C_P!%@(*N<D*<_*.M6K](KJ*"",>1 @+M@9)Q
MP/YFJT$-I;,S@.YVX^=N@/L*4DXOEOIW"+3C?KV(WF9S\IP/05=GC==,MD"'
M)!;CKWI\C10VD;_9U+RKO!)S@5974+B/33,S9=B$3Y<8'J.*UA!*ZD^AG.;=
MN5=2)[&X.EP1HAW-(6(^[CZTZPLI;6Z1IP$)+!1N&3P?2LTW,LC@O*QQZG/^
M?KR/6K^EL PD;+EV:&//\("Y8_G54I0E4C9=B:BG&F[G3#[H^@HI%^XOT%+7
MLL\H****0!5#57G6VQ$/D/WR.HK(\9IY%MI>KKPVFZA#*Q'41N?*D_#;(3^%
M<K!J(TG7KGQA<,39ZHU[;MN/R[(%S#^8@E/OOIH1T=%8%KI[6<^B6-]^]N9]
M*DFN%*\;BT?F?^/-3K+2[ :U? 6D.(O**#8/E.">*H#O-,E@:V"1C:Z_>'<^
M]7LBO+M,GETV-Y&D;[-=2S)G_GG)O8#\&''U^M4(-.AO+_PW;-X>77(K;0?+
M\F5D4*0\8#Y?C../7FDT![ #2!E<95@P]0<UP=YH ?PG]ALM&LM#DFOHV.GR
M3JB7H7!,9://W@I&.?N\C%0Z7'8:=JUY;G2YO"=[<:?+A$DC-G(%QF8%>-Z9
M'7:<'G/9#/0@ZEBH8%AU&>13AT->5V.EVWA]](?5O#IT^:&>%1KNF3I(L[DA
M?WQ(#[9"<'(/WNHZUU'B_4)'TT06DH3]_$'?!.?G' P1QG&?49%"$:>HZCG,
M$#<=&8?R%95<\9[VT;5[F)X2D,H=U9#ER(UR <\<?6GWVM74;W9M89'^S#"Q
MI9RS&5]N[&4!V^F2#ZU0'2VUL]U($3IW;L*Z"VABAA"0D$#J0<Y-86L&7_A7
MU_<6.;.=]/>8>=&2R?)D@C((;&1['UQBN9L;ZZ\/:/I6E6-WI5HS6"W)2WTN
M6>25VZ9BC;*C &7).XYX&*3 ])'6E/6N&TOQ/K7B4:;#IQLK&:72X]0N))X6
MF7+L55%4,O&48DDGC%1:UXI\0:7.BWGV'346U23SI+6:XMIICG>AE0CRE&!R
MP/7/;%(#O:45P%]XAO+/5=5.F6VG_:);[3[996#,L@F4#<Q!&<9XQCBH[WQ'
MXITZ#Q"[SZ5*-!VR.PM74W2M&'V@>9^[(!(S\V>.!CD0'H5%>=ZI<B;Q-)&(
M(8_)\262ET!#29M5;+<\D9QQC@"DT[QWJ=_+:WL4#2VES=B'[''I=SN2(OM$
MGGX\LD?>(QC&1G(HL,]'_AIM8GBK4]0TO2$GTV RR&=$E98&G,,9SN?RU(9\
M<< ]\]JYA_'=TNEV:0W=G=W5U>O;"YM[*=Q&BIO)>W'SB3'&W..0<XXIB/0A
MUI2>:X-?%^I_V/.TS6UK+'>I;I>W=E/"DR,N[<D#?.SCE=H/;.<<5G2:_>:S
M]FM[PI(]CX@LXUG%K);&164."8W^93R?KP10!Z92Y 4DG ')-87B+5;W3ETZ
MUL!!]LU&[%M&\RDI%\C.S$ @G"H<#(R2.:X_Q7>ZQ>Z7J6@7MQ8M);7>G^9*
MMLVRXAFF"@%-_P I#*=PR0PXXSP(#TP,&4$$$'H117(^-8;G3OAQ?16$T%JT
M%LJ?N82BA1@$(H8;1Z<G'O63)+XAL_$7BBYLKO3A):V=M-.TMLY$S+&YVJH?
MY <'G+'D4AGHIHZUY[=>.M0N[SR;!5M1%907#;M-N+SS))4WA,Q<(H&.3DG/
M XKJ(M8N+CPA_:WV*6WNVLC/]FE0ADDV9V$'GKQ3$;&Y0VS<-Q&<9YI:X+2/
M">@:CX+M-3OBHO[BT2[FUG>!<1R%0YD$IY4 ]N@ QC%79M9UR^N=7_L:XL!:
MZ2$7-Q$9#=N8ED/S*RA%PR@$ \Y/3B@#L>M!ZUPEIXJUG6;JXN-/^Q6^G6^G
M6]^5GB9Y'\V-FV9# #&WKBEM_%.M6%CHNIZS]BEM-4A9C#:PLKV["%IA\Q8[
MP0C \#!QVH [FE[5QEEKVNPKH-_J9L'LM9D2,001,KVQ="Z?.6(<<8/ ZY%4
M;'Q1K[^%++6KZ]T>U_M!XUB4V\C&($-NPH8F5C@$*,8YY..0#T"E!YKR^\\0
MZUJ]@($O(HI[37[.W\\V,L/G(_ENI:)G#+RW()^8#C&<UIV^N7RZG<:5IL%E
M;WEWK%Q";AHF9 L<*.TC+NRSG( &0/RY-@.\Z4H/K7"7/BG7H+A=( T]M335
M8K![@Q/Y31R0-*L@3=D,,<KN['D9R-SP[J6H75WJ^G:F]O+<:=<K%Y\$9C61
M6C20':2V"-V#SVH WR,4 UP'BGQEJ.D3ZJ]I=V+#3T#BS2RFN'D 4,WF2(0L
M/?&0<#!/7%3:EXA\0FX\1R:<^G16NC0I.J3P.[SYA$A0D. O?G!ZCCCD [D\
M4OWJX+4]:UG7;/78],-G;VUE8KYD<\3.\[20^80&# ( K  X/.?2MFT,Z_#>
MV:UE$4XTE"DC*3M/E#G (_G0!T?L:7VKR_0TUV?5?#HMK^S6Z?PVKO<36S.
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M&;:ZO[)UM4M)'M)PIFC084/D'D GYA@\]:V[.VM[*RAL[9/+AA01QH23A0,
M<]:GSCKQ0P!Z]*!'+-X!TLQM:BZU%=,9RS::MR1;G)R5QC(7/\(./:K.H^$+
M*^NKB=+F]M1=QK'=16LWEI<*HV@-QQ\O&5P<<9K?QBG ]J8&(V@6EM#J36$9
MCFN[-+81YP@6-65 /3[QK.\-^#(=.L-*.H375S<6=HL203S>9% Q0*^P8Y[C
MDG .!@5U9&>#29QUY'K1<9@6'@[3]/N;207%[/#8DFSMIYM\5OD%?E&,G )
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M,3W)))_&KO?)ZTX4#.<MO!6FVMQ;E9KQ[6UF\^WL7FS!#)DD%5QG@DX!) [
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MM0\XW0:>/98/%)&J)\HZ[B,-OSDGC&,=ZTM$74$DN%NKMKJWV1F&5BAR<'>
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M+].: %!!/R9_'_Z].^?!W ?AS3<ENBAA2X)/#_A0@$V+_>/Y_P!* 0G10?\
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M=%)#%*4,D2.4.Y2R@[3ZCTIP  P  /:EHK,\R["BBB@04444 %%%% !1110
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MX@R/<4)@8(-:^DW)8&W=CQROT]*R*DMY#%/')V4\_2J$=-\H/ R?SIPW$8
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M*>5+'FHWAB8\*-P_B[B@!X/9!GV/%+@XZ[#[5 5EB&6D.S]: Q8<8<=<O_\
M6H ERO1AN]^HI>0,J5 ]S4/G/CA@P] /ZT*96R454)Z%@?\ /\J!DQ8'Y3N/
MT'%)TZ8/^\<TPHY)$C;L]@*<(\#Y6)'HU A00W' /^Z:4ENS''^[2X&/F'-&
M".A)% "!\\;\'T8<T\;L]C3<ANN/K2D%>GZ4( )Y^9?ZT  CY21]#0#ZXI<<
M\<&@!1D D\TG#=?UI<\X[TA&?K0 F".AS[&E!S_A0#V/6@C-( QW'% /8]:
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M?/\ *]OP,/6=+GO+V.?[+!?VZQ[#:SS%%5LYW#@AB1QR.,<'K3=(TJ>UU W
ML[?3[;RBAMH)BXD8D$,1@!< $<9SN]JWJ*.9VL'UF?)R=/G^5[?@%%%%2<X4
M45FZE=S175K;6]]8V\\^[9'<H6,F,?=PR],^_6FE<J$'-V1I45B60U"/7I$N
M]6LI=\(9K..-E9<9 =<N2 >A[<>M;=#5BJD.1VO?^O,****1F%%%% !1110
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MVA:K=2+=Z/+:0RK'Y)%TC&-ESGHI!XY_.@#3L+$SMND!$0Z^K5OH BA5QL'
M'I7G^H7/B3PEJ&E:CKFM&]T9W>*]BM-/"I;90[&&T,Y&X8)SZ>M:%O\ $CP\
M]RD=PU[902DK#=7EH\,,AST#L,?GBD,[$@$Y'#4H8X]1ZBLJ^\2Z)IMFUQ>Z
MI:)"HX;S02WL .2?8=:P[>X\3^)V6YM99/#^DL,Q>9 CW<WN5<%8U]!@D^U
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M 8/>DS2\CK1Q0 =:,4<T8(H ,XZ4=:.*#3 ,49QTI,4N1WYI '6C%'7I28-
M"[O2C@T9]:/IQ3 ,49I.:7ZT@$X-*,T<4F#0,7(]*3KWHYI>*8@Y]::_W?Q%
M.Z]Z1@=IQ0,,TC=.G<?SIPY&>U(Q^4T@%Z4USP/J*7.>:1CA2?3FBX"TC#I]
M:7)I&Z?B* %XI&/*_6E/%-8$D$G ST% "Y[#DTTKN9<\\YI_ Z"F%BS#'YT
M/)"TS)9QV &:<% YZGUI/^6A^E "@ &D!RYQSBEQZ\T@."WUH 7&3R<TT,,D
MCD].*#G:23CV%.X0 ?I0 A!QENGH* <# &3[4ARS $\#G I2<#"C- "'G@G
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MBB@ HHHH **** "BBB@ HHHH **YGQ;K+Z,D,BZU;V.X$"!K7SY)C_L@,/\
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M:0I>3($EF"#>ZCH">]6P.YZTTMAQCZ4@'$]AUIJC!8GUZT[  S^=-7DG/3/
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MOXA=[+3&Y32;>3#./^F\@Z_[B\>I-=):6L%C!':VT,<,,:[8XXU"JH'8 =*
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MH%,J2/(K9/#,,,?Q%/FCV-)8G#/:'X+R_#3\6<OIGB.]63SKZ3S;=[")U4*
M3-Y0<@8'\66X_P!FM'2M0N;O24LKB^"ZLWG*)5B&,K(Z@XQC'R]*T8]%TT11
MHMHH2)XV0$DX,8PAZ]AQ5J""*UA9(4V1EV; YR6))_,DG\:4I1>R)K5Z$E[D
M+/3MT3_IKJ84%YK&JV\]Q 5M'@_=+"0K+-.I^?)P2%R"H(P>I]*(K[4KG3'U
MN$F.$$2)9LJY>)<[\MU#'DCG'RKZFMZTM8K=6$2;0SLY&>[')/XDTL=E;PV7
MV-(P(-I39D]#U%+F78S=>G=VBM^W3K^GXF')J&I6VFIKDC%[8MYCV:JN5@8
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MJTW"Z9U^GZ@+E1')@2@?]]5?KD@2C*P.".X[5O6&H"X7RY#B4?\ CU=C.,N
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M234#!'<6[12VNTOY:Q,O#H^["EN<,.3CBH+TZAI]MXNGCUO4)&TNS=[82.A
M8VY;)^7G#<CZ4 =W(NY:8'R$;WP:XF^GU6R\/7MR!KT,V8$0W4ULQ.Z5 0FQ
MCAL$CYL#FL^?5-7AM]7CAEU2)8)K*'R+IX?M*O).H8H5^7:R-@$G&<],&@#T
M=N,>A-.([C\:XN?^T8XM/MWGUJR^U:@D3-=2P-)L\MR=IC+ #('7GBM/2KF_
MCU34=*-P;V*UEBQ/<$*ZHZ$E257#," 1D#AN3QR ="O^K%(3\P4_7ZTIX.?S
MI  V3^5(!2.XI%^9B?PI=V <]J "!D=>] !]WZ?RH7#9/K03QQU/% &P<=/Y
M4 '3KT]: -P)]:&Y&/6@?+QV[4 &<'!_.A.A/J<T/R,>O% XX_*@!QJG=D>2
MY,;2#8S%1U(R*M,3C ZGBH+DNH!CZXP!_P "%#V8UNCG@--#I*CSYR'R=N/\
M^]6)+2&_N#+;3*,#=L9<'_Z]94P"W$ZC/EB1PO';<?\ /]*ET\D7T(7G<XR/
M4?GS^OX5XD:J;Y'%6N>O*FTN9,MZC:-/=!X&$NY1D*V<$8'3/M^E4)(KB.VD
M)C8/& P&WICC^1-3W!*:A)Y3G=GTZ_Y_R*FO7D2_RA(4QAB?<CG_ #FE-1;E
M+S"#DDHF6+\W#) %6+>V&;/K5^2QN8VV" J$Z #U]/7WILA::"03J&C";BQ'
M0_7_ #]*OO<W"LZ^;)R.G./N_I13@G?G;"I.UN1&3=NVF7(C9 ?,3+1Y^Z?_
M *^*2W::[$LVQ@ !&O' [D_7I^=79=_VJYE4!I0ZJS%<E1@?E43S7#[%).-V
M" >@_P __KJ7&TMW8M2O';4;%I\S.K2+Y:N?OD[1CUK3N[*.28W37*"+. >I
M/TQUJEJ1;[6R$G8" J]O\_YR*74V*K;HIPACR"#UY_7]?ZUJN2$9*U[&3YIN
M+O:Y-<MIT\X8O-@(%&P 8_/Z]/:I(A";&[,.5A4*HE<@%F![=O\ Z]8RD]1]
MX<?_ %NO^?:M>W9A9,J[BHM(R #CDL=U:X6ISU4VC/$0Y:=DS1\-<:#;CGC=
MU_WC6M63X: &@VX"A1\W QZGTK6KV#RPHHHH **** "BBB@ HHHH R;S04NI
M;IDOKNWBN_\ CYAB*;9?E"YR5)4E0!\I'2K=IIT-G<3SHTC/-M!+D?*JYVJ,
M=AD^_/6K=%.[-76FX\K>G]?Y(RKS1/M-Q/+#?W=I]H $ZP[,28&,_,I(..,C
M%6+/2[:QN'F@#*6AB@VDY 6/=MQ_WT:NT478.M-QY6]#+U'0+74[RWN9IKQ'
M@?<HANI(U^ZR] >/O'D8/OC(J33=%LM)>=[03!ISND,EP\FX^OS$\^]:%%%W
M:P.O4<>3F=NQEW^B)>W$DR7EU:F:,13B KB5!G .Y3@_,>1@\_2GZ?HUOITI
MDCEGE;RQ$AFDW>6@Z*/;ZY/ YK1HHN]@=:IR\E]#/NM%L[VZGGN5:3SH$A9"
M< !69@1CD-ENN>PI++21:77VF2\NKN41^4C7#*=B$@D#:HSD@<G)X'-:-%%V
M'MI\O+?0IWFEV=_(KW,;LRC VRLO'X$5'9:+I^GW3W-K 4F==C.9&8L.P.2:
MT**+O87M:G+R\SMVN<=XTATM[JU?4+RTA<(P2.YAD<,,\\HRD?K2>$=:L#<C
M1K!--$85I/\ 1)9,]LDJZ ^G.XT[QU>7UO%;0VNMP::DV0P\MVFDQC[NP$@>
MI _&E\%V<D, N+?^QWLI0=T]JLAF=\_Q,Y)/?(-:_8U/6LOJ"=1M]M=+_<M?
M*[^1U]9>J7\T5U!86]O;RRW$;R'[3+L3:NW(X!R?F'&.F36I4%W8VE_$(KRU
MAN(P<A9HPX!]<&LE:^IY-*48RO-71R.ASZ?=ZW97-O8QVN\3"-+>[#J&'#EH
MP,*#CAAUXSU%=K44=K;PR&2*")'8!2RH 2!T&:EIR=V:8FLJLDXJR];A1114
MG.%%%% !1110 4444 %%%% !1110!3EBNFU:VE1\6JQ2"5<]6)7:<?@WYU<J
MA/ C:Y9SFX572&55A/5P2F2/I@?G5^KELO3]69PWEZ_H@KF[L'_A+XR.GDKG
M/^]]:Z2N;O I\7Q9SGREZ#/\7L*@T()[>%Y)'GO8S,Y)8 9 ] #3C;V-BL,T
MC22[QN5 N/S[UG7*GSGW$#KUX_GQ5G4_D:",\!8UZ\=NW8_Y]J\'F7O/EU/8
MY7HN;1EJ_N+<117(BS*[$C<W0?I5$ZDSRAI BA0  $'0<],5#?W+3^1%&&"Q
MICC.3_GTJJ(OG\E<;OXAZ5T.E.4KMV,54A&-DAK7%[+&Q:>0@]1N(S6E!K,D
M$$,-M$%1%QP1D_7CUK/G#V\PW#,?K32@;YHG #>M5&C&#=KW%*JYI7M8N7]^
M;Z" ?<N$?AUXX[DX_"B&2]AN D\IDC<%>3N&>W7Z53)2%26.YSTJ:W6=K<N3
MSG(!_/-9SPSE+FB]2X5U&/+):%T:A(L9B:-&3.02,<GT_P#K5HFXLH+-/W3>
M7*G*ALX/M^598@%U$TL0)=.'51RI_7CZ5*X9]&B+<-&Y!R"/?O6,)SC>^NAK
M.,)6MW+$EE:+%'.LY5),XW+TQSV_^O4!L40>9:SK,#D2*!@@@=0*'&_1X^/N
MR\'MT/K3M*R+I2",8//8_*?7^E:TJBC5CRK>QG4@W3=WM<9_#^%*K$$,"01Z
M=JU=0T[ \^%>,99!_.LD\<UZYY8II]O!)<2B-!ECU]JC'K6QI4T(C* ;9>I_
MVA0!=MK6.UAV*,L?O-W-3)QP>O>E7U]:1LCD=:D8K?-\H_/TH7ICN*5<8XIK
M=>.G>@ (W<^G2E+<<=3TI<C&>U-'#9/0]/:@  VM]>]!&X9_*AQN&WUZTN?E
MZ<],4 )]_P"E,9R4#=>PIP^0%?RIC_*NW^Z<_P"?SH&3*H"@#H!2T"C/K3$%
M4M8GDM]$OYXL^;%;R.F/4*2*NX]*:Z+(C(X!5A@@]Q0!D>$;:.U\&Z)#",(M
MC#CW^09/U[ULUQNB:E+X5LET+5K.^\FS_=6=Y!:R7"3PC[F?+#%6 P""!TR"
M:O2^)[R[ 31-!O[MVX\Z[C-I"G.,DR .?7Y5.: -G4M2L](L);Z^G6"WB&6=
MOT '4D] !R:Q-&L[W5=6_P"$BU:)X-J-'I]C(.;>,]9'_P"FC#M_"..N:EL?
M#4DFH)JFO78U&^0Y@C";;>U_ZYH<_-_MDD_3I70XH B; F4YZ@TJ_*N>QY%-
ME^^ONI'\J=@E%7N/Z4@% V#!Z'^= &1N[FE)W #UHW #D<TP#=N('IUH)V\X
MX[T8"\_G2XW'@\"@ 7&,GJ:0X7@'K^E&-OTI0IZD=: %  '!IA'.,_+WI>5^
M7UZ4H7 Q0 N/<4S'S;NWI_6C!SMYQ3\4 ''J*;CG=28.[&/EI^#0 9&,YIN
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MH;+%S'B9C'+NP6:,G&<8X/!(J;2],O;3Q7;)::5?;1>W#S0WMAQ:A@^9([H
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M HHHH **** "BBB@ HHHH Y_6=.GNM<LY["XN;.\6%T^TK LL.PD$JP)&#D
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MPP!WGKN.X>E36WAC4K.Z_M"%+)[IS.LD$]Q+(F)%B&XR,"68>2/X5!#$<=2
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M/?16L:7#/I6\F0* Q+;.3G/-:OC'QWH4?PFN6\,%(H+J5M/A2.'R0A(W287
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M)\-?\@&WS_M=O]HUK5[9Y(4444 %%%% !1110 4444 8E]H,US+?B"^6&#4
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M:1C:,<^_U^M;4*:A6CYF56HYTF:/AL8T*WR"/O=?]XUJUD>&0!H%L ,?>_\
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MV>W%W?)I,DGFR:5'*! S9SQQN5<\X!QFK%O\/?"D'W=$MI.",S%I<?\ ?9-
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MJ&52P#-T!/)I0P)(!!(X(!Z4"L+13?,3S?*WKY@&[9GG'KCTI0ZLS*&!*\$
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MM);6ZA2:"52DD;C*LIZ@BIJ* ."N(IO";NMV8GA,#6^G:[/$))++/W8YVZ[
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MQGZY'L:&U="J5(.M&2>B]?/KK?[O(PK+2H/#^KVFS4%NI;A1&%O#OF"@=8F
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M"&P.QR.?>@9;W>BG\:,$]3CZ498]%Q]31@GJ?RH 7A?:DR3T'XFE"@=J6@!
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MZ'2 U@H7HA'^Z:7('\;#ZUE[-<'2[TX?6W?_ .+IWEZ]C_CZTT_]N[__ !=
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M\O\ C 9@,Y#8&?04Z]\3:O/8:E:0):0WEI;73S3%F"GRSM!3N#W).<<=<YH
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M+B<$$@9QGH*.5A='545RL_B76K8,9M!V;8VD.9QPJ]3^HIO_  D^M?9?M/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@"A/';G7+.1YB+E891''CAE)
M3<<^V!^=7ZH3O:C7+-'C<W1AE,;@\!<IN!Y[_+^57ZN>T?3]69PWEZ_H@HHH
MJ#0**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %-==Z%<D9&,BG44 9^D:/:Z'IZV5F'\I69LNV223DDG
MZTFGZ-:Z9>WUU;[P][()906R-V,9 [5HT4#NRI>6$-[+:R2ALVTPFCP<?-@C
MG\&-37$"7-O) ^=DBE6P<'!&*EHH"[.9A\%P6\*0PZQK,<2*%1%O" H'0#BM
ME],MY]+.G76^Y@9-C^<V2X]SZU=HH&YR>[,"'PEI\=Q#+++>7*P,'BCN+EY$
M1AT(!/4>^:W^U%% G)O<I_V; =7&I8;[0(?(Z\;=V[I]:K:KH%GJTT,\WG17
M$.1'/!*8W4'J,CM[5JT4 I-:F;I6AV>C^<UN)'FF(,LTTA=W(]2?Y5#J/ANR
MU&\%X6N+>[V>69[:8QLR^AQU%;%% ^9WN4],TNTTBR6TLX]D0)8Y8L68G)))
MY))JY17/7?BC[+=RP?8]WEN5W>;C./PH%N6==EDB^S^6[+G=G!QGI17.:QXG
1^T>3_H>W;N_Y:Y]/:BD!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>exhibit41exel20210630sto002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 exhibit41exel20210630sto002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55 ST# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?S/\/\C,:YUH01LNG6IE).]3=D!1QC!V<]_RJ1I]4%Q*JV-N80I,;FY.6..
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MO:)+#-(S;C'L4D%!QZT .U#Q;<:)):SZE:^987UNOV9K9&+_ &G&?)(R?O\
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MW3VLNY>0?O+ZT =+14<$Z7$0DC.0?TJ2@ HHHH **** "BBB@ HHHH ****
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M_2[ML-;Z9;ND3O,SRRR-@9?(Q@#=@Y/+GICFYJOA[3]9NK:XO$9WMTEC4!L
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MUK%N;/R,4)SQR<HOZU7?PO8RWC3/+<- TS7!M"X\KS2I!?INSR3C.,G.,\T
M<_>:FL @\F)Y#,D$R@X!\N5L GGKP?QI]Y?K92H'#%3&S[57).&0=<_[73_#
MG5B\&V443(U[?2MY<,222.I:-(F+(%PN.,GD@DYY-5-3T=?M"^=N("E493@$
M%E;^:B@ T[570S21PR*T3;)(7QDG ..#CH1SGO4FB^+#-H?VK4XV^U(D#S"&
M(*H\YBJA?G.0/4D'&. >!!' D4DSKG,S[VSZ[0O\E%5/['MS''#YMPL"B%7C
M1P!((F#)GCL1VZT ;/AW7[K5M0N;>X2%4BA\Q2@(.?/GC[GTB7\2:Z.LC1M)
ML+*22[LVD+2IY;!VS@>9))^>Z5OPQ6O0 4444 %%%% !1110!5T__CV?_KO-
M_P"C&JU573_^/9_^N\W_ *,:K5 !1110 4444 %58_\ D+7'_7"+_P!"DJU5
M6/\ Y"UQ_P!<(O\ T*2@"U1110!Y[>^(M:3Q&\=A)+,!<7$/V20+_!!(R?($
MRJET7#%_FW<#GB5=9GV6BKXAO'LI'3[9>M;1J;=C&YV;MFU<LJ@@C*Y S\PQ
MWM% '!)K>J&Z4?VC=-<">U2UM7M5C^UP,(_,E9=NX'YI,X("[!QV-2>^U8Z%
M;G4M9O(DO+">4N+>/YIOE"P@;.F"3M^\QS@\8KTBB@#S[2&U6:\CL(KJ>Q@9
M_GD@@C#$+9VQ7)93D[F;DY/&.PQ#%XBUA[;3KB\U"XM;J:33%2V6V7RYTE\G
MS6)*D@[GD7@C;M'KSZ/6?-H>G7&H"^E@+3AE?_6,$++]UBF=I8<8)&1@>E '
M.>+9[ZQU^TN[*:=9!IEVL:+&'4OOA/3!)8+N8#OL^H.GX=OIKF;45%[+J%C"
MR?9[IT4%R5RZ@JH# ''('4D=JZ"B@#RU/%6L>1)*=2G2&6&WD,K(CO S7,2.
M-HC 5MCG*9<CCOR;[:]=#48K>?7[F#3&:Z^SWJPQEKA46 J<["" [RJ" -VT
M#DGGO;JU@O81#<1B2,.DFTG^)&#*?P90?PH>U@DO(KMHP9XD>-'S]U6*EA^.
MU?RH \W2^UV+[3?"R*ZG(#,\?V?<5E_L^$D*,9X;(P#SC%7[[7)XTB@L==O+
MF*21L7;I'$N0BG9Y@B8,<G(54))R,\8KOZ* /,M+U74GN$O3>3QZG=IISFR$
M"A)RR()2<KG@%LX(VXR:CM-4UZRALK2WE2UC2"(V\<I(^T,TC!QM$3E^ !A2
MI .>^1ZC10!R7BVYGL=3M;R 3!HM/N\/%&&*$O  >>/4\\8!.#BL2'7?$/D7
M'DW3SJUX;&"1564*98D,<NX1H&59-PSC'S$$G&:](HH \VGU_P 0/I$-[->-
M9Y=HFC*K$6>.-5<JS1LN3+YF%.-P P1R#T^LZC<IIFD3>?/86]S*HO+@QJ'@
M0QLPR""%RX122#C/XUT5% ''^'+S6-2U=3=WUR+2"W+HODH@N09IT1V^7(S&
ML;87')!P!Q4&M7VNP3ZS<6UY,L$%[!;)&514BB:.)GDW>6QSEF&3D $DCCCM
MZ* /-Y]>UF/2I)KK59+>*.VN9+:ZMH1*+B16^16+1 -@=-JC<,D'BKH\0W[L
MME).YNI+Y%,?DC)MVM@Q/3[N_/S>O&>U=7J.B:?JS*UY"SE5*?+*Z;D.,JVT
MC<IP/E.15\      = * /,M/UK5+<:+9P7$\2Q"PMY+=PHRCQQAF">66(^8C
M>64!AC!QRFEWVH6=I;QK=S)$(88[N\:!#+ #/,'R=O;"CD$*&)]Z]/HH \];
M4M>NH+HP:G=K!;VEW-;3K!'NN?+9?++93!'+#@#< #WJS;:WJ+>)WM[F^E^S
MR!_DA5?]'41;MS(T>X $'#[F#$@8].YHH C@(:WB82&0% 0[#!;CJ< =:DHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***I7U
M\MJNU,&4]!Z>YH L/<PQOL>55;K@FI%=7&58,/8YKE69G8LQ)8\DF@$J<@D'
MVH ZNBN;2^N8_NS-^//\ZLIK$Z_?1&_0T ;=%9B:S$?OQ.OT.:LIJ-K)TE /
M^UQ0!:HIJNCC*,K#V.:=0 4444 %1SP)<1&.09!_2I** .:NK5[67:W*G[K>
MM05U$\"7$1CD&0?TKGKJU>UEVMRI^ZWK0 6MT]K+N7D'[R^M=#!.EQ$)(SD'
MMZ5R]3VMT]K+N7D'[R^M '2T5'!.EQ$)(SD'MZ5)0 4444 %%%% %73_ /CV
M?_KO-_Z,:K55=/\ ^/9_^N\W_HQJM4 %%%% !1110 55C_Y"UQ_UPB_]"DJU
M56/_ )"UQ_UPB_\ 0I* +5%%% !7/2:KK:^)DTM;'3S"\33K*;EPWEJZKRNS
M[WS XSCWKH:I-IRMKD>I^8=Z6SV^S'!#,K9_\=_6@#F=)\:R:G$9M^B<122&
MUCU O<#:"<%-O7CGGBKNC^+EU:+2?]$,,]V[Q7$+/\UNZQF3'3D$8(/&0P-/
ML/#=]8V T[^UUDL1&\7E_90&VL"/O;NV?3M3XO"=K#K&EZG'/(LUC;^0Z@?+
M. A12P]0"V#[X]* );K5M1EU6YL-)LK>=K2-'F>XG,8+-DJBX5N<#))X&1UY
MQ%_;6JWEU+;:=ID EMHHVN5N[C9MD==WE#8K D#&6Z<C&>T]YHER^I37VFZD
MUC+<QK'./)60-MSM8 ]& )&>1TR.*@'ARXM)3)I>KSVSR0QQ3M,@G,FP;1)E
MN=^."3D' R.* *NF>-8M1UV"Q-J8+>:P6Z$TC\I)N<&(CID"-SG/\)K1\,:Z
MWB+2#?M:FVS-(BQELG:K8!/ P2,'':LV?P'826QMX[F>)/)@A5A@N!&9=QSW
M+K-(I/OFMW3=-CTV&XC1RZS7$DY!&,;VSCZ"@"Q=W<-C:R7,[,(HQD[4+'Z
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M@"MO5],35M'N].9S$ES&8RZC)&>] %+5-5U'2/#%SJ,]G;RWL(^6"*8[&)8
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M'#;LYQGTXQ^-3F"[+DB]PNYB!Y0X!&%'X'GWH M45!!%/&Q,UQYH*J -@7!
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M6*%66X/G3*,DKG#)&N=N.3E3CK5FU2^L+B_^S7OG7<4FH$-,B.T'[V#8. "
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M0K,?E" !>,EL\YJ#Q!#/J,]_+YDD3VUMJLL*11)Q(BPA6Y4G=\Q&X8/H1SD
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MMOX//EN7G$FV8-%NBC3Y9!)OR/+SRV&SR.!CH_$<]Q;Z!=26L=P\V% %N<.
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M*DW, /.#SL+GZ GM5JQ75+;2M<@A,\L\$TJV!NB6+#RU9?F;[PWDC)STQVH
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M7ODF;RE.$R?+"R)(N<_Q)*P'H0#SBH+CP4TT$\:WJJ)8K^(?NON_:9UE'?\
MAVX]\]JZZB@#!MO#2VGB^76X+@K#+;R(UKM^42NT9:0'MD1KD>O/4G--_!BL
M6O?MLPU7[?\ ;A/YLGEAMV OE;MO^J_=YQG%=510!SMCH6J6"P6$&J1)I<$W
MF(JP'SC'NW"(MNQCMG&2O'7FM.STTVFJ:E>&4,+QXV"[<;-J!>O?IFK]% !5
M&#3A81,EC)(#)*KN;J:2?C(W ;FRO&<8X!YP:O44 4F34_+;;/:!]DFTF%B
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *B-Q
MK[#-&'W!=I89R1D#ZD5+49@A+[S%&6W!MQ49R!@'ZT ,^VVNW=]IAV[=V?,&
M,9QGZ9XI3=VP)!N(@06!^<?P_>_+OZ4?9+;;M^SQ8QMQL'3.<?GS2FV@)),$
M9)))^0=^OY]Z $%W;$@"XB))  WCJ>1^?:D^VVNW=]IAV[=V?,&,9QGZ9XIP
MMH 01!'D$$?(.HX'Y5QTWB%[>_0/96K6<L<\:1B/#>8)&$:YZ88QD8Q]YQ0!
MV!NK<$@SQ9!(QO'4#)'X"@7=L<8N(CG:!\XYW?=_/MZUQVG^)W>QBDNM.@GG
M$1GN'C C51Y<!D*@Y))\[H<<#!-7H/$$5Q=6=O%I,>^[:-H#O7B/;(0S?+\K
M 1-A>>H&>N #HOMMKMW?:8=NTMGS!C ."?IGBG&ZMPVTSQ;LE<;QG(&2/J!S
M5'2O)OM,226V@#@R0R!8QM)5RK8'H64FKWV: MN\F/.2V=HZD8)_$<4 (+NV
M.,7$1SMQAQSN^[^?;UI#>VH4L;F':%+$^8,8!P3] >*<+6W&,01#&W'R#C;]
MW\NWI5&_>TMHS&MO"TC*5V[!@ G)S]3SB@#"O/%=U"CI&;;STO[B!D*G/E)&
MY4]>N0GMC/K64VIWWGK'-)"9)A$WF[" F_?G(SS]S ^M:[QQR3-,\:-(WWG*
MC)_&D:&-P5:-6# *05SD>E '.IJMW# RH8Y"OG2F0D;6Q*PP"S# &/?&1^/6
M>&EFNY;JYG*!(9FA2+9RI&.2<\]?2KUAHT"*DEQ!&64Y1"@PA]?K6JJ(F=BJ
MNXY.!C)]: .'M]4,F@Z1;"^+7QU@121^;^\PL[%E(SG 53D>@J'_ (275Y-.
ML9;PVDBW]LERJQ1O'Y1%Q"A&0^3D2Y[<CN#BNY6RM%NVNUM81<L,-,(QO(]"
MW6G?9;?:J^1%A!M4;!P,@X'X@'\!0!Y[INKZI807P.H6:2[[^\>>ZC<B7R[A
MXP@!D^4 +SCH"HQQDZ$7B'7;QUDB:SMHYK^.S2*6W9GC#0B0LQWC)&2,8'2N
MPDL;29466U@<(YD0-&#M8G.X>ASWI_D19SY29W;\[1][&,_7'>@#F/#VMZM>
M:A9Q:A):/'=6]TX$,+(4:"5(\Y+'(;?G';&.:AO--MXO&C.K7.!827>PW4NP
MRB08.W=C'MTKK1%#%AA'&FP'!"@8!.3^9 )K$U"\6XE(C4;0-I?'+#T^GM0!
MS-UXHU<Z3$]Q+;M*;9;F5(H"BC=T4[GZ @C(R3Z>MN+Q#JEH3M>U:#S)XD25
M2,%4=E);/ RN#QT-6F@A<J6BC;:,+E0<#T%6+:S-S*$1%X.XG' ]Z ,"?6M3
MU.338+F3$L&HYN+9(2AD46TLJKE)65@2AQ@G^'(XP9;3QAKUU:0D)9I)="U:
M.1E1A'YTJH?D29BPP<@G;RIS[=Q::=:64*1001J$8N,(!\Q&"WUP33H[&TAW
M^5:P)O<2/MC W,.0Q]3[T <WI?B#49/$QTV^DMVB9I8HFAB&UVCQGYA(2K<'
M*LHQP 3WK7&L:E;>)[ZR2^MT2>^AMXVGC++;J;<R$XW#.XKM'3D]^E=>MI;)
M=/<I;Q+<.,/*$ =AZ$]3236-I<>9Y]K!+YBA7WQAMP'(!SU% '+:AJEQJ7P[
MOKR1D$ZF6(2P9"OLE,8=.3@,%R.3UZGK7.F\N99K9'=M]E)+:W(!(#2JDF<_
M@BL/9P:]/\F+R1#Y2>4!M";1MQZ8J.6SMYD='A0AVW'Y1G=C&?KCC- 'G\.H
MW>!)^Z,*RQQ>6%.X[HU;.<^K>E.@U[4+=8G@EMFDN(XV&$)6/<ZKAANY^\<=
M/NFM^[L/L<FW8I0G*L!U_P#KU56")=VV)!N.YL*.3ZT +I7B+4I?$4=A?O 8
M96>*)HH1B1E3<>1(2IX8D,H'3!/>AJ^MWL/BI]3BCO#I6F31VL[HR^1M8'SF
M8;LG:7B.<''EL.YK4MF6UN_M4<:>;C:6VC)'IFNAMS;75JP2-/+?/F1E1@D]
M<COG/XT <3JOB'5)M$OIX]3L;5F:=(X%C;SHA%,$R6W<\ YX&-PQ[]UY\<2)
MYT\08J6R2%# #)(YZ4S[!9[Y7^R0;YEV2MY8RZ^C>H^M2&WA954PQD*I505'
M (P0/;% #1=6Y( GBR2 !O'4C('XBD^VVNW=]IAV[=V?,&,9QGZ9XIPMH 01
M!'D$'.P=0, _@*Q-<NOL)\BUM[-6^R2R@SJ GRL@5>PQN?/4=!TSF@#:-W;
MD&XBR"P(WCJ.OY=Z!=VQ( N(B25 ^<=6Z?GVKD(O$,L$YBNK*WD9/.$H>/RY
M!(3 JJ0N\$GSQG:3D8P,\%$\71F0,-(C*OY8B558MO7S@V<(2 !"=O&>><<X
M .O^VVNW=]IAV[=V?,&,9QGZ9XIQNK<,5,\602N-XZ@9(_ <UF:7/!J#W,;6
ML015C:,&, ^6ZA]K>^[/'TK3^S0$Y,,><DYV#J1@G\10 L<\,Q(BE1R &.U@
M>#T/XU)3(X8HB3'&B$@ [5 X'0?A3Z *NG_\>S_]=YO_ $8U6JJZ?_Q[/_UW
MF_\ 1C5:H **** "BBB@ JK'_P A:X_ZX1?^A25:JK'_ ,A:X_ZX1?\ H4E
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MK;AA3D\<KQGCD8K5\.Z+<Z(][%)*DT$IA:.7<=Y*01Q-N&,#_5@Y!/WCTQR
M6X==TR7[*KWMM#/<J#%!).GF-GH  QS^&:AUGQ+INA,4O)?WOV6:[6)<;G2(
M M@$CG!X'L?0UA67@VZMM,:W>6V,I2P4.,_\N[AF[?7']*O^*M O-;!%HUN
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M<UO:58:AI]U>*_V:2"XNVG\P.P?:4'\.W&=P]>A_"@#9HHHH **** "BBB@
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MU#_GVMO_  (;_P"(JU10!5\S4/\ GVMO_ AO_B*/,U#_ )]K;_P(;_XBK5%
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M(H\S4/\ GVMO_ AO_B*M44 5?,U#_GVMO_ AO_B*/,U#_GVMO_ AO_B*M44
M5?,U#_GVMO\ P(;_ .(H\S4/^?:V_P# AO\ XBK5% %7S-0_Y]K;_P "&_\
MB*/,U#_GVMO_  (;_P"(JU10!5\S4/\ GVMO_ AO_B*/,U#_ )]K;_P(;_XB
MK5% %7S-0_Y]K;_P(;_XBCS-0_Y]K;_P(;_XBK5% %7S-0_Y]K;_ ,"&_P#B
M*/,U#_GVMO\ P(;_ .(JU10!5\S4/^?:V_\  AO_ (BCS-0_Y]K;_P "&_\
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M!_F:A_S[6W_@0W_Q%'F:A_S[6W_@0W_Q%-L;Y;I-K8$HZCU]Q5R@"KYFH?\
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M:)(I(3S_ !!,Y]0/2F3^!A<:A=%[O_0KB>2<KNDWJ70J0!OV#!8D-MSCCWH
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M#Q!I'FW$?]HVX:V5FEW/@*%.&.3Q\IX/H>#69X4TF2SEU&\ECEC2>=DM8I5
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M3_\ HQJ[&N.^%7_),M#_ .N3_P#HQJ[&@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ KAOB%=QZ=J7A74)TF-M;:BSRM%$TA5?*<9PH)ZD5W-% '&
M_P#"T/#/_/34/_!;/_\ $4?\+0\,_P#/34/_  6S_P#Q%=E10!QO_"T/#/\
MSTU#_P %L_\ \15.\\>>'M0E3[.][YN"#OL)E!'U*XKOJ:Z+)&R,,JPP: //
M?^$FTW^]<?\ @/)_A6A%\0M"L[5(KMKS/(&VQE?(]\*:N3Q-!,\;=5.*DLKC
M[-=*_P#">&^E '.OXS\/W%SMLY+T@@G:]C,N/Q*T[_A)M-_O7'_@/)_A7H9
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M=O\ _&J -2BLO^RKS_H/ZE_W[M__ (U1_95Y_P!!_4O^_=O_ /&J -2BLO\
MLJ\_Z#^I?]^[?_XU1_95Y_T']2_[]V__ ,:H U**R_[*O/\ H/ZE_P!^[?\
M^-4?V5>?]!_4O^_=O_\ &J -2BLO^RKS_H/ZE_W[M_\ XU3/[/N/,\O_ (2+
M4-^,[=EOG_T50!KT5E_V5>?]!_4O^_=O_P#&J/[*O/\ H/ZE_P!^[?\ ^-4
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M% &$OA6S283K<7 G#,3*1&2VX*#D%,9^1><9XZU?GT>QN;R6[E@1IY(1 9"
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MV<>_]:O6NDK:W$,HG>01)(JAD1?OE23\H _A].YK1HH **** "BBB@ HHHH
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M,.016_8WRW2;6P)1U'K[BN?I4=D<,I(8<@B@#JZ*IV-\MTFUL"4=1Z^XJY0
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M_P" TG_Q-5;?5)X<*_[Q/0]?SK5M[Z"YX5L-_=;@T 5/^$BTS_GK-_X#2?\
MQ-'_  D6F?\ /6;_ ,!I/_B:U** .8U+5+":1989)2<8;,$@_FM4/[0MO[S_
M /?MO\*[.:)9H6C;HPQ7,2(T4C(P^93@T 7[3Q%8_9T66642*,'$#G^0J?\
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M10 4444 %%%% !1110 4444 %%%% !45PL[0,MM)'',?NO(A=1]0",_G4M%
M&7]GUW_H)Z?_ . #_P#QZC[/KO\ T$]/_P# !_\ X]6I10!E_9]=_P"@GI__
M ( /_P#'J/L^N_\ 03T__P  '_\ CU:E% &7]GUW_H)Z?_X /_\ 'J/L^N_]
M!/3_ /P ?_X]6I10!E_9]=_Z">G_ /@ _P#\>H^SZ[_T$]/_ / !_P#X]6I1
M0!E_9]=_Z">G_P#@ _\ \>H^SZ[_ -!/3_\ P ?_ ./5J44 9?V?7?\ H)Z?
M_P" #_\ QZC[/KO_ $$]/_\  !__ (]6I10!E_9]=_Z">G_^ #__ !ZC[/KO
M_03T_P#\ '_^/5J44 9?V?7?^@GI_P#X /\ _'J/L^N_]!/3_P#P ?\ ^/5J
M44 9?V?7?^@GI_\ X /_ /'J/L^N_P#03T__ , '_P#CU:E% &7]GUW_ *">
MG_\ @ __ ,>H^SZ[_P!!/3__   ?_P"/5J44 9?V?7?^@GI__@ __P >H^SZ
M[_T$]/\ _ !__CU:E% &7]GUW_H)Z?\ ^ #_ /QZC[/KO_03T_\ \ '_ /CU
M:E% &7]GUW_H)Z?_ . #_P#QZC[/KO\ T$]/_P# !_\ X]6I10!E_9]=_P"@
MGI__ ( /_P#'J/L^N_\ 03T__P  '_\ CU:E% &7]GUW_H)Z?_X /_\ 'J/L
M^N_]!/3_ /P ?_X]6I10!E_9]=_Z">G_ /@ _P#\>H^SZ[_T$]/_ / !_P#X
M]6I10!E_9]=_Z">G_P#@ _\ \>H^SZ[_ -!/3_\ P ?_ ./5J44 9?V?7?\
MH)Z?_P" #_\ QZC[/KO_ $$]/_\  !__ (]6I10!E_9]=_Z">G_^ #__ !ZC
M[/KO_03T_P#\ '_^/5J44 9?V?7?^@GI_P#X /\ _'J/L^N_]!/3_P#P ?\
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M]6/6KIVH[<0S'CHK'M[&@!_V?7?^@GI__@ __P >H^S:Z?\ F)Z?_P" #_\
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MO_03T_\ \ '_ /CU'V?7?^@GI_\ X /_ /'JU** ,O[/KO\ T$]/_P# !_\
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M^-']OZ-_T%K#_P "4_QH T:*SO[?T;_H+6'_ ($I_C1_;^C?]!:P_P# E/\
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M_P!!:P_\"4_QH DN-,@GR5'EOZKT_*FV6G+;,9)"'?MCH*;_ &_HW_06L/\
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M&RJYQT& .><#\:BE\-6LFKOJ*W%S$TDJ32Q1LH21T "DG;N'"J" P!QR#SD
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M,DP!@&BB,C-C<-R#&WJ,MQQUK;M-*@M=+:P9Y+B)PXD:8@E]Q);.  !R>
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M40PQP-AD!ECC)V!CLR, [<J5)'4FMD6+2V=W;7=P\R7#2#/W2B-G"@CT!ZT
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MSW$$EJ\K13)L9@)&+.N&4J03CMV%3)X:T];[3[PB5Y;& P1EY"VX8P"^?O,
M7 /^VWK0!03Q;I9@69[&ZB2:%9K3?$N;I&=44H 3R6DC&&VGYQ5+5=1MK6(7
M,FG7=J#O\V.9$41[<?Q;MK9R,!2<\^AQH)X,L!"D4EU>RK#"(+3>ZYM45T=0
MA"CD-'&<MN/R#WI+KP9:7K>9<ZCJ$DS1R122LT99U?&1RF$^Z!\@6@#$BU)&
MNIHW@/E"98TE"C;\R*0#SG.6QT]*+34XIK6%Y8\3.D1*JO4N."/;K^1K7NO"
M\-LPF@EG>(,CM"Q!&Y5"ANF?X0?K63%I@CO;5P (;6'RXR6RS'& 2,8X&?\
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M/,U[_GTTW_P)D_\ C= &I167YFO?\^FF_P#@2_\ \;H\S7O^?33?_ E__C=
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M_P ;H\S7O^?33?\ P)?_ .-T :E%9?F:]_SZ:;_X$R?_ !NCS->_Y]--_P#
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M6ZF9WV(0<)C@$@8[=23GN ;>GW@U#3K:\6)XEGC614D&&4$9&?0U9H  & ,
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MSR::8(B4)B0E#E"5'RGV]* .?\7:O>Z5#:&SFBC\QGW[BF\A5S\OF,JGU(+
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MY)R /+F=%D 238<HS#V/<8ST.1Q0!C2R>&;>WB#:#:B.403[1;1X&\2'<?\
M=59"?;..M-.IZ#<"[LCHMM,MFTC) BQ/F2-A"J[?X&;A5SU'TJ^?#.B!1#=A
MKM1'Y2K<GS B;3M'3C"AL,>?F/))IW]D:'.XA=_.\DL95=MROEUEQ)Q@_,X8
M9]3CO0!5CU30[IFT^WTJ*4,%$49B14E62#=QGC&S"GT!'8U4@U+17E"R:!90
M/?6J2R+(T(:6)LX&.K_<Z?2MJW\/Z/:30/$ KV]R98AYF-C,FS8!_=V@ +_L
MCTI_]BVD+Q+'=SP!;=(#&LBXDC3.,Y&?XCR,=: ,*'5-%EMK.[BT"SF2VBDF
MC:!H9#;I'L8XQT8&0' YK5U/5=,TF\TS37LX2DA46Z@HH3)$8V*>O#_P]LTC
MZ)82&UM9M2NYLPO&B&1?GA8+N4E5'RG8.>O7FGW*Z3J^IA6NIED@!5D *1RA
M7&1N(PV& !VG@\&@".U&@ZM83"72+9;2T51*LT";8G12"F/5%XXXP<#O5 ZE
MX=NKCS;C0XQ<W< \PRVZ;B=_EF-CW8;"<=PGM6Y>1Z9#IES#<2?Z-=.XD )8
MN6.&4 9)R3C'O5+^PO#S*QC15CN+E BQ':JRQ,3A0/N\J^?7+>M %>_N-#TF
M_;31I%@-MMYY7]TA93Y@PJGECP^<?WO<U/=2Z3::@QCT>"2]N%B??Y:+O^^X
MW,>FT0EL^PQS5J>UL=2E:\2]G"SQ+!(D1&)$W,!D;21R[<\4TZ+8NJLU_.\P
M53'<&5=ZA=X!'&",.X.0>#0!G3^*M+A1+22P017);?$SQ ,6$;, ,X=B9N@S
MDYZU',_ARTT_3[=-#TY+>]+3I%*(HD#+M&?FX+?-@8YQFK3Z!HD5M.XN)XX(
M$<7.V0D.C(A8-QD@JBG(]ZC6/28)(TAUB^62!IH8UC&YEP5WQ@;#GG9ZD]J
M)M1AT73KS*Z':2R"(/-((XTV)]P<MC)(! 'HN/3,5W=Z'%NU%]%BEN)D=\K
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M(:%F"GG! STJM8Z=J&K:/>SP#4?+2VOQ9 WC;EF%PXBY#<L   <D>] 'II(
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MXO\ OL4 2T5%]JM_^>\7_?8H^U6__/>+_OL4 2T5%]JM_P#GO%_WV*/M5O\
M\]XO^^Q0!+147VJW_P">\7_?8H^U6_\ SWB_[[% $M%1?:K?_GO%_P!]BC[5
M;_\ />+_ +[% $M%1?:K?_GO%_WV*/M5O_SWB_[[% $M%1?:K?\ Y[Q?]]BC
M[5;_ //>+_OL4 2T5%]JM_\ GO%_WV*/M5O_ ,]XO^^Q0!+147VJW_Y[Q?\
M?8JI>ZK#;IMCE1I#TPP(% #[^_6V78F#*>WI6"S,[%F)+'DDTUIU=BS2J6/)
M):F^;'_?7\Z ']:VM/T_RL33#Y_X5/\ #_\ 7J+3X+>(":::+?\ PJ7'R_\
MUZTOM5O_ ,]XO^^Q0!+147VJW_Y[Q?\ ?8H^U6__ #WB_P"^Q0!+147VJW_Y
M[Q?]]BC[5;_\]XO^^Q0!+6/JMGM8W$8X/WQZ'UK3^U6__/>+_OL4AN;9@09H
MB#P07% ',T D'(."*LWT,,#[HIHVC8\88''M5/S8_P"^OYT ;UAJ(F BF.).
MQ_O?_7K1KD?-C_YZ+^=:=GK*)B.XD4KV?/(^M &W14(N[9E!%Q$0>GSBE^U6
M_P#SWB_[[% $M%1?:K?_ )[Q?]]BC[5;_P#/>+_OL4 2T5%]JM_^>\7_ 'V*
M9)?6L2%VGCP/1@: )994AB:1SA17-W$[7$[2-WZ#T%.O-1%V_P!]5C'W5W55
M\V/^^OYT /K2O[?[/X3U($?.UI*S?]\&HM-C@>3SI98PJG@%AR:NZZROX;U-
ME8,#:2X(.?X#0!%X5_Y$_1/^O"#_ -%K6O61X5_Y$_1/^O"#_P!%K6O0 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!R_@3_D$:C_V
M&+__ -*'KJ*Y?P)_R"-1_P"PQ?\ _I0]=10 4444 %%%% !1110!'/!#<PM#
M<1)+$WWDD4,I^H-.CC2*-8XT5$4855& !Z 4ZB@ HHHH **** *']AZ3_P!
MNR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7
M_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P!
MNR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7
M_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P!
MNR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7
M_@.G^%7Z* *']AZ3_P! NR_\!T_PH_L/2?\ H%V7_@.G^%7Z* *']AZ3_P!
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M 0>%?^1/T3_KP@_]%K6O61X5_P"1/T3_ *\(/_1:UKT %%%% !1110 4444
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MYKJ%\7:.\\4<<TLBR&$"5(',:^;CR\MC W$@<]SSBM6]O(-/M'NKEBL28W$
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M:S2VM09+FX6-MZ2?N5,'G'=A>N.GMSV(K3MO%.GS^2A>1F9$,DD<#M$C-&)
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MV4EM,7&Y(D:/SMO/RY4."/XAQSQ4][XXTR"U\ZTCN;WY()/W4#[0DI4(2VW
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M$79URQZD<+CH0<]JIQ^+-5O;*-9;&V#W8MFA9U9502R!.FXE\;@0PP#@C H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M<>0VW:!OV[RHR3M+8S^ J_;Z+I5IO^SZ;9P[W61O+@5<LIRI.!U!Y![&KU%
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M0 4444 %%%% !1110 4444 %%%% '+^!/^01J/\ V&+_ /\ 2AZZBN7\"?\
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M2 !DGM0  $D #)/:MO3]/$ $LHS*>@_N_P#UZ-/T\0 2RC,IZ#^[_P#7K0H
M**** "BBB@ HHHH **** "BBB@ HHHH *S]?_P"1<U/_ *])?_0#6A6?K_\
MR+FI_P#7I+_Z : (/"O_ ")^B?\ 7A!_Z+6M>LCPK_R)^B?]>$'_ *+6M>@
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M34]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% %.^L5NDW+@2CH?7VK!DC>)RDBE
M6'8UU51RP13KME0,/?M0!R]%;4FC1$_)(R^Q&:C&BC/,_P"2?_7H R:DBADG
M;;&A8^U;46DVR<MN<^YXJXB+&NU%"CT Q0!FVVD*N&N#N/\ ='2M-5"J%4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MWQCFG7FO_8Y;@FU+002>2S^9AB_E[QA<=,$#.>IZ8YI(9M!203QQ1120)P#
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MU->BLRTUF*\U)K2),KM=EE#9# +$V1]?-'Y>]:=2U8Y9PE#22"BBBD0%%%%
M!129&0,\FEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M110 4444 %%%-DD6)"[L !0 ZBJ#/<EHY6;8&<!(AW]<_A5^@ HHHH ****
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MTR,4 245&9XP7!;E,;O;-"3*Y  /(R"1UH DHHI#G!QU[4 5)Y9IF\NV!&&
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M].#2/IVA9GA:Z3;$K&2$W/$6X;68C/!()Y/J?4T7EMHMUY\EQ=*L$VV61_M
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MS%Q#*\9/'1A(3CC]:LRAFD0#)&TD_,1Z>E $[9VG'7M586I0J4<DC'WO4?\
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M7$2WK33P^;<JJ@Q0[53"[0<$G/\ D517QC8R1J8K:ZDD8(!$JKN$CNR",Y;
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MUA>/;)'%<;[GR3$C* 660,0W7H-CY_W>];])IK<SJ4ITG::L%%%%(S"BBB@
MHHHH Y2X^''ABZOKB\EL9O/N',DK+=RKN8G). WO6?>_"?PU=/;M#%/#Y<P>
M3-Q(_F*.J\MQGU'-5X+2^UR]\37,^LZHL=C>2PPVMO-L0JJ*P' SU-6O!46G
M:C\/XX+C4GN?MBEKHR7!WHYX*YSE<8_KWH&=)H7AW3/#EO+!I<#0QROO<-*S
MY.,=6)K5KC? <[";6]/AO)+W3K*[$=I/(^\X* LF[OM/&:[*@04444 %%%%
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M)<>"C-#*JZFZ2W,4\=R_D@A_-8,=HS\N"H]>/?FK4OA.*5G)NG&^>>8X0?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:Z(/+BED>(O$\D1NFS(WDE7.XG^_@^_7M5OQB^H+>.MO/<K#)I5V%CB0D-*
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M*;IK,KM#1.SKM/\ =95 /^UCFH!K6LV@LH8(IES.QD1K=BKJ;EE/S<GA>>V
M0<GI2]ZYDHXA3;NKZ=_/Y_UT-?6=(U6Z\.:?:),\UY!L\^19=OF$(020?O D
MYQD>N<C%9DGAW6!)<O\ 9HGDN4M1*Z7+C[BX<#+9/."-V01UR:JP:SXCM(+>
M!7EE?SI][SV[DLXFP(SA2<;3D8]>#A<5O>*=5U33;JR^PJSQ,"9$CA+NQRN
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M4 %1);PQR32)$BO,09& Y<@8&?7@ 5+10--HC@@BMH(X((UCBC4*B*,!0.@
MI98HYX7AE17CD4JZ,,A@>"#3Z* N[W$1%C1410JJ, #H!2T44""BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN/\
M=W$\'V#R9I(MWF9V.5S]WTH =:>+?+LX$^PYVQJ,^;[?2MG2-9_M5I1Y'E>7
MC^/=G/X"BBD,U:***8@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH YN;Q7Y,\D7V+.QBN?-ZX
</TKE?%^O_;OL?^B[-F__ ):9SG;[>U%%(9__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>image_0a.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0a.jpg
MB5!.1PT*&@H    -24A$4@  !7D   "," 8    I\JJA    "7!(67,  $SE
M  !,Y0%USO"5   $6$E$051XG.W8,0T , S L/(GW7+8,T6R$>3.+
M6?,[      " =R8O     $"8R0L     $&;R @    "$F;P      &$F+P
M  ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P     09O("
M     (29O       828O     $"8R0L     $&;R @    "$F;P      &$F
M+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P     0
M9O("     (29O       828O     $"8R0L     $&;R @    "$F;P
M &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)"P
M   09O("     (29O       828O     $"8R0L     $&;R @    "$F;P
M     &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\     0)C)
M"P     09O("     (29O       828O     $"8R0L     $&;R @    "$
MF;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\
M0)C)"P     09O("     (29O       828O     $"8R0L     $&;R @
M  "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A)B\
M    0)C)"P     09O("     (29O       828O     $"8R0L     $&;R
M @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\      !A
M)B\     0)C)"P     09O("     (29O       828O     $"8R0L
M$&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\
M  !A)B\     0)C)"P     09O("     (29O       828O     $"8R0L
M    $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(     A)F\
M      !A)B\     0)C)"P     09O("     (29O       828O     $"8
MR0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(
MA)F\      !A)B\     0)C)"P     09O("     (29O       828O
M $"8R0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!F\@(
M    A)F\      !A)B\     0)C)"P     09O("     (29O       828O
M     $"8R0L     $&;R @    "$F;P      &$F+P    ! F,D+     !!V
4_&MJ-&BCO]4     245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>exel-20210702_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2021"
  xmlns:dei="http://xbrl.sec.gov/dei/2021"
  xmlns:exel="http://www.exelixis.com/20210702"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="exel-20210702.xsd" xlink:type="simple"/>
    <context id="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i57cc8f2d4f634e00aa1fbe4e770ca58b_I20210726">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-26</instant>
        </period>
    </context>
    <context id="i5bd2889c307341ccba8eaee7f5f573c0_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i7d18f1537d8b43a38ece66de91e63886_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i9259a9d7933146308c821508a3ddee27_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ia21d371856cc48a68b4309847396fa80_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ic35c76885c08464e8536056814cc87b0_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i18f71f314ed04df18bb6962c37407e37_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i8d1d3b56237f4f60b09904a6c28afefa_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ia7f72b97be95433eb01da77344b924b4_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i9055e59c6448472b8afad20e904571c0_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="ic2d314200efc414286c58e02a72592ae_I20210402">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2021-04-02</instant>
        </period>
    </context>
    <context id="i44dd4e95f4af402e9f077cd335eb7007_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i53be24f47fe943889e3a6dda67c33519_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i506073af88c340ebb62b33816c074aaf_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="idaaa8f6eb6fe4306b163861f98903231_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i693dc4f870124e0b9ddd7456d2a2738c_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i748018c371b647b38103dedba2c84de1_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ic45af8276000456da83f9b42424d83fd_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="iccf0f3d464b14f8689aace6957954839_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="i0f53374fa9494a2bbfec8a0dac4cec86_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="if4476ab3366d4b4aa330a4b0fa517edf_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="i946cc6b151944fdc8ee643e1575173c6_I20200403">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-04-03</instant>
        </period>
    </context>
    <context id="ib54c97a496384e2f8bf53ca6af61aaca_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i36169ffce5154dfabab0771e977ca089_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i664240e571634cfbaf15ac1e52615971_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i493e0445ef74439faa8e33e8d3bd99fc_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i56aa11bddb1f4538a589748b0433902b_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i35af602dfdfc44a7b9bc433d59cbc821_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-07-03</instant>
        </period>
    </context>
    <context id="i081256c453a249839e8537f1c0153e9f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i3a0940ae62e5401b9c203c706d89df2f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i058b3f9310334495bbc354761bd6647b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if0687bdba44c461687736aa0a7fa9b21_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ief41d78e50cb4a93a62920da7cecefef_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ifa16a9d12d014d909104f7045186de11_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i84739d5f149041178c34597093926bd6_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i5556cef549ed44c18c579369e37ccdf2_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i3025b4065aaf4cdba68bd29f0237a548_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="if13daa675eb9480989a9cdb6f2a297e6_I20200103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
        </entity>
        <period>
            <instant>2020-01-03</instant>
        </period>
    </context>
    <context id="i80c8d20e80cc4ad7bca1dc91ecf75437_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i081971405e1741eeb1fc749632c1c0aa_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i616ab7befeac4dd19930969171845d06_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i0788ba9b7348408294dc259c3a82acb4_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ResultingFromDiscoveryEffortsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ibb1fe7255a2442e295f20f47559b739d_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductsDerivedFromOtherCompoundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i947f11dce7724c8a92d7f9d767d30430_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ibab3c993c7644d7a946dcb256efda5b9_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ib167b52f75e74c39838cc0b9a5bafec1_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ic4d233c682dd4c8e86078cfa757643ba_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductGrossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="id8f066b777054049b67a402360c6a782_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i88bdab6e93514c5ca7163e90e6740f46_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="id31ef9d0f4694bdf8921fc58940a8cd7_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i99c380c1cdd64bc68dfdb4fc5dc13a5a_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:ProductSalesDiscountsAndAllowancesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i83c483fda79b4c16ad3d9442173642b8_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i6cafb301e8bc4a1e878470c9b0f12baa_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ie10d8c01e16442feaeac308109be67d6_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3396192359714cebba9f9044f46388b8_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2dd1c78a8dac4b7489425c0a1175d608_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ibdf20ffabe0140baa5b07542eeab1510_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i11371f462a3a4f459626f35247d98cda_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="if0c970818f314feb8775caa6ef94fd81_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8ad0b431492b4370a00a89fa2d331434_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i70b167eedebd4c72b9f4d3f02442f179_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5f7584f5954340dba177cf82b494e611_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="idd6c27d712d943b78475ea6b7bcb2516_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="if3bd6a226ce54f36b775c95518c27470_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ifeb5bb631eb2470babf9f8d080f9964f_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i0351d4cb2134494ba29863d99c874739_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i54323ff73fd948188ef473dee8b6e814_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i0e5051bdb62a4adea3b1ba61cad3e07b_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ib2310c9c82ca42f09d4e1cb96f939ad9_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i821ee440df88470196800293d930e33c_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i753195995e5e4556a95e622429f0db57_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5fd1ae2034d9412089e998f08d56e5c3_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i27c364af82884e9e8ba8d4a627f277bf_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ibd0a23e145ff4ca084f0c9961d8b3a54_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofOptumSpecialtyPharmacyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="id9542af44b304776a9c4bb52e4768814_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i354e779a90704e25ab4430a20741de7a_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ice75da26c51d4900838a61e74a5f0c32_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2f30e6eb82e64b79b27523cafe87fb10_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AccredoHealthIncorporatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i7b5f040ea73842e8abdcba995add3e6d_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="idb3bee6b43f04331a2af7c80b4a7370d_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i13094e1db8884f879f12d67dad15c701_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3bdd8100f1f84c43aa6914f739d17d31_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ieb756ebdb26146dd872e8d96bcb1edf2_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ia6d4a34bdbe3414db629b89c722ea436_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:IpsenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia210e74e223e424a970e3e3560d85886_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2d909f0df4c749f5ad2943003106be6d_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofMcKessonCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="ia8ed993e6ef846f0842723b5499f1a51_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ic3d6c5f034c743549e0b3580f3088770_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesOfAmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i3be0c4f6862744d381c6a9c8ad69d360_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i922effb845ac486685bc2d4ca1e2b64e_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:AffiliatesofCVSHealthCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i041977232d9d47f689aa8e5e54cf51c8_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ied845544fcad4e209b2f843ae011069a_D20200104-20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:TakedaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="i576124c34cb14293a07e65c0e116b0fd_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ie1f3b07b878f446983ae8ea6c24a8523_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i926a2dcdbc7642d3b461dd3a6194ac74_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i7962cd8f612a4e7a93a1cb357a042730_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="if8f782da2d2a45809e36bb66021e8e95_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i23fea2b017ea462db2fa2ac8224cb0a7_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i1e515978877241b1a3bbbf6c7c87a132_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3e0390849b8b485ebe8240a57d0c0e15_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ibf21142c44dc4ed588e7f49495659845_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8b04dfce356a48a3a67d32e955e37c0f_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i5b57543585624c4cbf46aba4e36a40d0_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i4f2944cc9b084ae18eb84c3b0937c4bb_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i4abad55b764942b8838caffe168cd460_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i602ab887907347eca4f8dd2743045d20_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ia4e3544936884787b393e216680bae75_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ic9861d7e9fc04d7797b39b96e817870b_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CabometyxMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i4494448a3d77442ea673dc4306f40517_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i85570133db6f426dbb8f7b796098289a_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i6779e8b939fb444986c5b5f6762bedae_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ifcab21398b064807b6664b9e08c18372_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CometriqMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ie35769b7587040d5aa523942d229c867_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib42e12234ac143a0a44b01d6e7a03fe1_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i48d197193a8a45b38af10e48f5f51e93_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i7befdb6164974b9db88347431a84c705_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i48b0f026980e4e8db846617663617dce_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5ffbaddc0eb14e9991b7a519b99dcf9d_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:ChargebacksAndDiscountsForPromptPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i33ef18170a4944cd8de075cf4a5344d3_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ia09e442b2e1243bc84dac0b50e653260_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">exel:AllowanceForProductRebatesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i54e9688fa5234b7dabc087b18bea682e_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i7e90ca7353d7420d850374043f19414f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i23ea9da53f1644eaa0a98b9259aa475f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i9fb9e5548a364e8db87e699888c741d9_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="iee0e69c31a264295b5d40ec7776fd3db_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i438def86d067426f867cc300503942e3_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="icb3fd2d979fa40adaac2298fd1f78f5d_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i85a056bb651c463991c7d6520faca86c_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i60418fc014944675b95a4a327939d6f7_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ia354da424ce0441fa29d3af61c66a49e_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="iac88bbff875241b399770a9f80cb04da_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ide45679cbd134e15ad7dde1405959e1c_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ieb8d9802463f431b8dc5673038d02b02_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithIpsenMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ib4773d352b9649cf82f5f26e75db0cbd_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i0afcc09b5a14464ab0ffad06802a0d9a_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i0c2c134629c04167a6ee6e580563d23a_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i96369905ff694894be26d03937eba3aa_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i4eace4464d1b4cebb1f6aa87ef46edfa_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i7c567665f16245dfbbaa6cfb4be14af9_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ifd4fe90f4c8b4002917a160364e89c7b_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i37fca3eb6b164203b94981e459883e27_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ServiceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i6b587653d3b346778dc4850b1f98eaa1_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8682433791e74a77ab1fb7164ad65f64_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i36f2a9ffc2004bfba433dc45cecfe4e7_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ic6774c6769c74754bf25b006ddeb034a_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i086ec86c38f3430bbc22864119abfbea_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithTakedaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ib55ad4a520414e63a49c07b1087faa2c_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">exel:GlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i3a69004f4ba64701a17a5818d5af4f24_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ib115b2c1778640cc80452356877f9218_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i957e8d926e9948e49c867df19f90d50a_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementswithGlaxoSmithKlineMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">exel:CotellicMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">exel:CollaborativeArrangementwithGenentechMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ic78371ad98574f0f8204b52ff32e63c9_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="iceb9d21701e5414cadd958696df005c4_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AssetAcquisitionAxis">exel:CollaborativeAgreementWithGamaMabsPharmaSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i09bcb5c048774ea58a3a925f982a1ee1_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ic65851a71fcb4a37a10e68a564581e81_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i7bda6107aee140518bf785e603a9f752_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="id37c5c0878604fd4a7ac63cf01049767_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ia4f74740d9b3489982fe849d428b0c61_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i4acd99a8477349aa9356042fc2d2b74a_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i2a7078826e91452db52a24c7cbbe97de_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i149eb5d8fd5e40fa9fb480344495f84a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i6fe4968ea10a4a2e846882843c6487fa_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8eec5258de424553baf107e5e554b35a_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CashMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i56912199faad49c0be4543e8883c2d26_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="icc9727a7b4814f58b8af72b38460bca0_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i4e91c1139a56409d95f01dc2177e91d2_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="id53a0786827d478e814c805cc8cd0afb_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i9dc7c2c162434fe38126e2d6f15ae9bb_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i950c47d917ec494488175b4cdbe0c129_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i550ee82623734ffe9f05bdbde43fba7d_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="iad4faa5c3b4a426aad73596700ef7140_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="iffc0af7755c040318682d07ce7adc16d_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i6c48c5faa613472abda97540d85b1a43_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="iac6e199ed30442d3aea617ff04d7c031_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i3a06f360ba44412d9bbdf897884ec918_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i68ab09d76ab342579d2258fdbf2c378c_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i353b0bfaee7d45d3976a470abaef3b27_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i7549b8270e70414ca9988e4dbb8aa47f_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i461e78644dac46b59b980d4bf5e337b4_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i5b52c97911274efa88b507b4b137edec_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ic67977ad378747debfe28bbf32306bd3_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i6cfecbfae6504e7dac8dae1b622df61b_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="iae9f679824f7428da09abd42de1550ae_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ib1444ac4a7464905b1d3c72e3eadd436_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9acdde179aaf4fdc8bbfce84bea41c94_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i284bab61e8734898a70c2fcec89c67c2_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i5ed62cb99076473f80954b556b50f8c4_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iac2529e3f7d44eb5a9f3e462363e4bef_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i8290d5383c23424f8de0d1411e5defda_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iaf572e25486645ec8191ae913a4d5273_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i9ecbc8770d4f4636ac3bd47cc6e7a318_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i60c12cafde1f455185fb18b04e0ee5cf_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USTreasuryAndGovernmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="if81d88ee2f624302a41cbb273629023e_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ib31966a54bf84f61b847e6dc212903cc_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iace3e234989f44a18209f335a3858e67_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MunicipalBondsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ibf3b9823001c4ababc937b8119958bcd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i18e4500f722142808c3c50a9a09c4590_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i10577d8c6f0a44c29a3ded5c80584629_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i10fce4b7140142ae8b453252c5a9aa1f_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iaed63e180d5c44929716ad53c8d1a9a3_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i98ada18f5c9f4383a40c65d6ad47b375_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="iaf994d5e216c490ebc4de2ede7eb66ab_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i94140ba1405e4bbabc2a2ce63c52a2cf_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i43efb9d920154cdd94ec40616b7279ab_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CertificatesOfDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ic668b647625e4bde9c974a9c70e123ee_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeForwardMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i38f66ecf6b3d46bfbf2bdb0f567643a6_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i3a9ad4a65b6e4c889ee3d1e4d70baafd_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:InventoriesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="i01981fa8e6c344ba974b2f8d40f68058_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ie6f3c04a508a4cfcada935eafb00cbba_I20210101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">exel:OtherLongtermAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-01-01</instant>
        </period>
    </context>
    <context id="ieca864111b874024a399be99230353ae_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i2cd6d6f2194144d995d98bdace4f2a41_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i2de5b4fa16f7460680d4046f0519a111_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i5334bcd0ce864909917f7d16cd9888e7_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i0f9135f913a844cf9141b680dfeb2cea_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i4941e12d857a41d3ac2f0ff6bbe78328_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="idb3a79263fd94414b9fae499fb7a8ed4_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i4037354e5adc450194ea75e59903a4c2_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i3bef33e85fa14e96ae49c48c326d27de_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i19afc667658d40998a38958b53efb61e_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i4134486a3c824f2181dcb53797e46891_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i75db9e248ada421fb6801122acc77816_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i873e7a2c3edf40ecb5bbd511274cbf4f_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="id9124f541cea43cfb250f0c46a24ea95_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i6ced14542a07421e8805f7ee34d1747f_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i10aae8da808c4e4a9bdc5ee3346228a9_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i996fd974645e4c3db9f8f6b13e514f51_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i8d55c4bf90594514b0b8f4b81adf037e_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i2457de481e214911a4d49d6872661199_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i17e867cac56f4c6fbee7d87303f4e416_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i5d96596fd611426fba7a4e5d05b69795_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="ife5de7f12696428c822881cfca50b36d_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i167594f9829443bdb7383a81ca5f83e5_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="i32a62386d90e4627a31537ead3413cd9_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="i06bb3436aa3243dc82099b2b7e64415a_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="iba0fcc072d1d49eea6319ba9d01188e7_D20210301-20210331">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="icdc25c9244d74752a7a86d0fc1f9a390_I20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-02</instant>
        </period>
    </context>
    <context id="ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-03</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="i0c6782e60aa74aa18a2400a167db7d7e_D20200404-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <context id="i0d82c6e6cf824115b296671898dbd282_D20210102-20210702">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-02</startDate>
            <endDate>2021-07-02</endDate>
        </period>
    </context>
    <context id="if3e6164d65ce46689c7c42db6169a463_D20200104-20200703">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000939767</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockCompensationPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-04</startDate>
            <endDate>2020-07-03</endDate>
        </period>
    </context>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="product">
        <measure>exel:product</measure>
    </unit>
    <unit id="segment">
        <measure>exel:segment</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="investment">
        <measure>exel:investment</measure>
    </unit>
    <unit id="forwardcontract">
        <measure>exel:forwardContract</measure>
    </unit>
    <unit id="eur">
        <measure>iso4217:EUR</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y18yLTEtMS0xLTA_8627af2e-2f76-4845-b803-d45ab592a72e">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y180LTEtMS0xLTA_83586d31-097d-424e-ac94-2c3fbe7d1d72">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y181LTEtMS0xLTA_d3fc636a-b4c5-4c0f-8961-b202f2d408eb">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:EntityCentralIndexKey
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y182LTEtMS0xLTA_e256dc68-33e4-4149-a574-c704a71a5ed2">0000939767</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80L2ZyYWc6YzVmNWFkMGJmNmM1NDA1MmIzMTMwNmM3YjRlMmVmNDQvdGFibGU6YTQ1YjVjYWMyOWE1NGMzZWFmYTdjNGE2N2E1NDhiOWMvdGFibGVyYW5nZTphNDViNWNhYzI5YTU0YzNlYWZhN2M0YTY3YTU0OGI5Y183LTEtMS0xLTA_ed049941-2f89-4b12-bc35-281918995c86">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentType
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTY5MzBiNjgyZjMzNDJjNThjYTM5OGY5OTgzMTEzZTIvdGFibGVyYW5nZTo5NjkzMGI2ODJmMzM0MmM1OGNhMzk4Zjk5ODMxMTNlMl8wLTEtMS0xLTA_9a77f6d7-472c-4a6d-9514-05ac1c65c6ea">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ZTkzNzY1NWQ1NDcyNGM4ODhlMzMwNGE3ZWZlYjRlN2QvdGFibGVyYW5nZTplOTM3NjU1ZDU0NzI0Yzg4OGUzMzA0YTdlZmViNGU3ZF8wLTAtMS0xLTA_63ed3bb6-3369-4171-b498-d48e8971fc5e">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8yNzQ4Nzc5MDcxMzcy_d1fc469e-21ad-443c-bad3-1a63dc44498b">2021-07-02</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6M2RkYmU2ZDBiZDFkNDgwNDg0NDEyMDU3ZjQxMGRjMTgvdGFibGVyYW5nZTozZGRiZTZkMGJkMWQ0ODA0ODQ0MTIwNTdmNDEwZGMxOF8wLTAtMS0xLTA_4b30968e-2160-41af-a365-cd26fa2a927a">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgx_10939a2d-98dd-4a41-aeb0-7b379fc3a5a0">000-30235</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6MmE5ZDRlY2E5MDE0NDM0ZjgxMGI2OTRkODYxODViZDYvdGFibGVyYW5nZToyYTlkNGVjYTkwMTQ0MzRmODEwYjY5NGQ4NjE4NWJkNl8xLTAtMS0xLTA_e0996ae9-f0c5-4748-83fe-e1539e0ac11e">EXELIXIS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTEyMzJlNWM0MDBlNDUzNWI1NWM2NTExZjI5NThiODEvdGFibGVyYW5nZTo5MTIzMmU1YzQwMGU0NTM1YjU1YzY1MTFmMjk1OGI4MV8wLTAtMS0xLTA_ded611ce-0033-4b16-9086-3e0d3ff035c6">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6OTEyMzJlNWM0MDBlNDUzNWI1NWM2NTExZjI5NThiODEvdGFibGVyYW5nZTo5MTIzMmU1YzQwMGU0NTM1YjU1YzY1MTFmMjk1OGI4MV8wLTEtMS0xLTA_8a9260bf-8e9a-47bb-b6f4-2cbd91fb4266">04-3257395</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg2_b9350acd-6b69-4d34-8c0b-a4fd53dfee53">1851 Harbor Bay Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg3_84641968-c459-428b-80ad-1bb6d7d10220">Alameda,</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgy_a5d3cb40-7e93-481d-8d2c-c3973d3ed5b8">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODgz_a57c5f4c-1026-41a9-93ea-b1f14b70ee65">94502</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg0_a5a599fd-7b5c-4f11-b7c9-05e1d0aca403">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg1_aa23e5e0-c387-43ad-8033-5d9c89dd4a2c">837-7000</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTAtMS0xLTA_c7aeaec9-f10d-40e6-b94e-c17fd5d5d0c0">Common Stock $.001 Par Value per Share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTEtMS0xLTA_6f23459d-40ba-4f03-bb56-9b2071c91cc4">EXEL</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6ODlkNTNjMWU1NDNhNDdhODhiMjU2N2I1OTUwNGNmY2QvdGFibGVyYW5nZTo4OWQ1M2MxZTU0M2E0N2E4OGIyNTY3YjU5NTA0Y2ZjZF8xLTItMS0xLTA_5030c9ca-9880-4c8e-b208-140c4ca6cd04">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg4_a6ded526-3f2d-47bb-973a-e4c66d6c6e0d">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODg5_b773fc09-35db-40b6-80e3-a910caa8266f">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8wLTAtMS0xLTA_ffc46169-0ae3-45d8-bdd0-f27f5fabfe81">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8xLTQtMS0xLTA_4abe733d-c1de-47ea-9677-6c6f15aaa633">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGFibGU6YzQ5ZWY0MmRkYzY0NGFiM2JlY2M4ODE3NWE4NjcwNTgvdGFibGVyYW5nZTpjNDllZjQyZGRjNjQ0YWIzYmVjYzg4MTc1YTg2NzA1OF8yLTEtMS0xLTA_471f73a0-f648-48c4-b80b-264308935fbf">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODkw_3e1ceb02-e414-4837-a43c-094a9f16e50a">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="i57cc8f2d4f634e00aa1fbe4e770ca58b_I20210726"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xL2ZyYWc6ZjBjNDI5YmYyMGM3NGRjZGI3NzUzNTM1ZDcyODIwNmIvdGV4dHJlZ2lvbjpmMGM0MjliZjIwYzc0ZGNkYjc3NTM1MzVkNzI4MjA2Yl8xODI2_73296773-5bc6-4075-8dd0-47581d2bea72"
      unitRef="shares">315048788</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzctMS0xLTEtMjUzOQ_d462ec24-af44-4c99-a2e8-210d174d5caf"
      unitRef="usd">492462000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzctMy0xLTEtMjUzOQ_60bae02c-dd08-4faa-ab1a-1ff1d68da303"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzgtMS0xLTEtMjUzOQ_b2b114a8-03ef-4b73-b358-158d9621c0c2"
      unitRef="usd">854171000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzgtMy0xLTEtMjUzOQ_ca1e8820-768e-4602-b9ac-a6bed8f47d08"
      unitRef="usd">887319000</us-gaap:ShortTermInvestments>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzktMS0xLTEtMjUzOQ_0fcfe7dd-c367-4053-8be9-fe5f90d49eb8"
      unitRef="usd">171753000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:ReceivablesNetCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzktMy0xLTEtMjUzOQ_2b408bb0-8cc9-4411-9863-1c493c8f7724"
      unitRef="usd">160875000</us-gaap:ReceivablesNetCurrent>
    <us-gaap:InventoryNet
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEwLTEtMS0xLTI1Mzk_23820a07-071e-452e-8a5c-a292e5fae61f"
      unitRef="usd">24982000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEwLTMtMS0xLTI1Mzk_55741ffa-f7e0-472b-91b1-17af97d1aefa"
      unitRef="usd">20973000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEyLTEtMS0xLTI1Mzk_8d75ef76-69c2-45c8-b4d2-895400b4cbd6"
      unitRef="usd">49878000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEyLTMtMS0xLTI1Mzk_03bb60c1-40e1-4eb0-8527-4a09df320775"
      unitRef="usd">57011000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEzLTEtMS0xLTI1Mzk_bffc2d1f-dd0a-43e0-bb42-6ffb2b590430"
      unitRef="usd">1593246000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzEzLTMtMS0xLTI1Mzk_9588273c-df7f-4917-b09d-33252e60190c"
      unitRef="usd">1445395000</us-gaap:AssetsCurrent>
    <us-gaap:LongTermInvestments
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE0LTEtMS0xLTI1Mzk_156470a2-f7cb-4949-93db-ecf4c7de3d64"
      unitRef="usd">345613000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE0LTMtMS0xLTI1Mzk_3378dd93-14eb-4d24-b989-7d8c06226c47"
      unitRef="usd">330751000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE1LTEtMS0xLTI1Mzk_be636d6c-be19-420f-b9ee-483ad9f43b7f"
      unitRef="usd">95133000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE1LTMtMS0xLTI1Mzk_e865ddb6-0666-4067-ae1e-c42429a16ee3"
      unitRef="usd">67384000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE2LTEtMS0xLTI1Mzk_b9f16155-ff94-43cb-8a8d-199e5e085de7"
      unitRef="usd">134667000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxAssetsNet
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE2LTMtMS0xLTI1Mzk_c79e9cbb-bc31-4167-bc00-c62a3b5ced17"
      unitRef="usd">156711000</us-gaap:DeferredIncomeTaxAssetsNet>
    <us-gaap:Goodwill
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE3LTEtMS0xLTI1Mzk_385bd4b3-f97c-4dfb-bbfc-de2d7f63a652"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE3LTMtMS0xLTI1Mzk_c27506d9-1238-418f-b78d-30a202a9451b"
      unitRef="usd">63684000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE4LTEtMS0xLTI1Mzk_015f94cf-7a74-45c9-a62f-f1d912a1f00b"
      unitRef="usd">134928000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE4LTMtMS0xLTI1Mzk_56d9079e-7fda-40a1-863a-388e19738b58"
      unitRef="usd">73408000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE5LTEtMS0xLTI1Mzk_b8ff70b8-41e1-422b-b68b-11eff8fcea27"
      unitRef="usd">2367271000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzE5LTMtMS0xLTI1Mzk_3f3089b6-8182-4fc9-8bf9-1ae39432a587"
      unitRef="usd">2137333000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIyLTEtMS0xLTI1Mzk_e8e7d8ed-1ce6-4850-aeb0-8a987208baa2"
      unitRef="usd">20450000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIyLTMtMS0xLTI1Mzk_70520dea-506f-4211-97c2-9cf9b6dc2dcf"
      unitRef="usd">23632000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIzLTEtMS0xLTI1Mzk_0fa0e466-c634-4e66-9102-dcfb4cdccca0"
      unitRef="usd">48324000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <us-gaap:AccruedEmployeeBenefitsCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzIzLTMtMS0xLTI1Mzk_882c4ddf-067c-4ddc-a5c7-22c2ace4c599"
      unitRef="usd">51189000</us-gaap:AccruedEmployeeBenefitsCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI0LTEtMS0xLTI1Mzk_2caa708f-89ab-4e53-bb00-0c93066098d8"
      unitRef="usd">67075000</exel:AccruedClinicalLiabilitiesCurrent>
    <exel:AccruedClinicalLiabilitiesCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI0LTMtMS0xLTI1Mzk_6ab29279-6be2-4365-9f09-59f08cb920ed"
      unitRef="usd">52251000</exel:AccruedClinicalLiabilitiesCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI1LTEtMS0xLTI1Mzk_74ed8028-648f-442c-964d-e3a0e0118c01"
      unitRef="usd">31197000</us-gaap:CustomerRefundLiabilityCurrent>
    <us-gaap:CustomerRefundLiabilityCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI1LTMtMS0xLTI1Mzk_ddbd15f9-7961-4071-bd78-53fb4785a0c0"
      unitRef="usd">20683000</us-gaap:CustomerRefundLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI2LTEtMS0xLTI1Mzk_0deeaa9c-af52-4910-a4e3-496c1802355f"
      unitRef="usd">24428000</exel:AccruedCollaborationLiabilityCurrent>
    <exel:AccruedCollaborationLiabilityCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI2LTMtMS0xLTI1Mzk_de27daa7-682c-4742-9973-90f1b891c910"
      unitRef="usd">12456000</exel:AccruedCollaborationLiabilityCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI4LTEtMS0xLTI1Mzk_e6dd7bbb-60d1-40dc-9a8b-e6b54900db57"
      unitRef="usd">63852000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI4LTMtMS0xLTI1Mzk_a706073a-e3fd-412d-b79c-c2c7ef7b9292"
      unitRef="usd">44447000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI5LTEtMS0xLTI1Mzk_0b52fa32-1999-4690-ab72-d19c4de8f5eb"
      unitRef="usd">255326000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzI5LTMtMS0xLTI1Mzk_4e759fae-02e7-46c3-a518-9785dca63f73"
      unitRef="usd">204658000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMwLTEtMS0xLTI1Mzk_58710ded-4a72-4c1e-9d0b-1d2e30f35bd8"
      unitRef="usd">8577000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMwLTMtMS0xLTI1Mzk_535a813b-2d0d-4843-9745-dcf2f6004c73"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMxLTEtMS0xLTI1Mzk_be451f43-77b7-48f9-97d1-ae1baf3fa57d"
      unitRef="usd">53223000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMxLTMtMS0xLTI1Mzk_eec57c9b-fa21-4c8e-add8-3b679a488134"
      unitRef="usd">49086000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMyLTEtMS0xLTI1Mzk_d31a328f-b7f4-453d-9cb7-2e4ca7b4472b"
      unitRef="usd">7068000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMyLTMtMS0xLTI1Mzk_c038d900-53e3-4dbf-b549-24fbca81a0e1"
      unitRef="usd">721000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMzLTEtMS0xLTI1Mzk_25559c09-08db-45e1-a800-9ca6ceb77add"
      unitRef="usd">324194000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzMzLTMtMS0xLTI1Mzk_c1607e2a-2444-4715-a54d-cc6dc8631ed6"
      unitRef="usd">258220000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM0LTEtMS0xLTI1Mzk_b260f83d-224b-4eb9-b372-63cff8122b13"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM0LTMtMS0xLTI1Mzk_003d17ae-8d5f-4c8e-b4ff-39352b6f6952"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8yMQ_1368b030-e5f2-436a-9546-2755041cb5bc"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8yMQ_6f55d49d-576b-49c9-b38f-b67f128580bf"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8zNQ_14a77070-d8b6-4c4e-9c90-fc4415a93342"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF8zNQ_fe019911-657d-43d3-9b0d-42f19953499c"
      unitRef="shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF82MA_580ea7b6-2845-4ab2-a96b-d2c4a1da8577"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjphOGVjZjFmMDc4Njk0ZDM3ODgyODViMTBiNjMzMDVhNF82MA_a1ef0e96-b676-4cdf-a5b0-8728db7d5c9c"
      unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTEtMS0xLTI1Mzk_2faadb88-046f-4fef-a299-3adda828cc8a"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM2LTMtMS0xLTI1Mzk_bea9dae5-e188-459d-a3de-e38bedaf1524"
      unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8xOA_f61183f5-e1c1-4357-9090-d933acf28fcb"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8xOA_f64655d3-22d7-47fc-b6a4-ddad90ebe69d"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8zMg_3df4a145-1a3d-4061-8b1b-47c2e626b770"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl8zMg_43a2d469-78c7-44d7-bb42-1ca5a478bef2"
      unitRef="shares">400000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl83OA_2501d21c-865f-455d-94d0-cce809377307"
      unitRef="shares">314822000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl83OA_3b3a3f28-a98d-478a-ad24-eab6762b6f39"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl84Ng_8e20548c-fb18-4c3b-afe9-46689d362201"
      unitRef="shares">311627000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTAtMS0xLTI1MzkvdGV4dHJlZ2lvbjozZTRhZGI0NDg0ZTA0M2NhODIyYmU4NmYwMGUzZjRmZl84Ng_d41ebf9d-ab8e-4b34-9743-f2d858ce23f8"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTEtMS0xLTI1Mzk_2d0562f4-d2d7-4f8f-a662-af8f9bc00a86"
      unitRef="usd">315000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM3LTMtMS0xLTI1Mzk_5b886499-af26-4d9d-92eb-eab417028da1"
      unitRef="usd">312000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM4LTEtMS0xLTI1Mzk_7716d030-9a7e-40aa-b00b-3980e8070199"
      unitRef="usd">2390654000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM4LTMtMS0xLTI1Mzk_948d9cc2-4286-48db-b3ed-714fdcaf79e7"
      unitRef="usd">2321895000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM5LTEtMS0xLTI1Mzk_753ebb4a-a00b-4949-8466-06863861227f"
      unitRef="usd">1985000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzM5LTMtMS0xLTI1Mzk_0022c9aa-e4aa-45bf-adeb-95f70cd747ba"
      unitRef="usd">4476000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQwLTEtMS0xLTI1Mzk_6f49018a-2d75-449b-9776-9dce2fb30f32"
      unitRef="usd">-349877000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQwLTMtMS0xLTI1Mzk_129ff8f6-2b3a-440c-8ee9-6a0613e63391"
      unitRef="usd">-447570000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQxLTEtMS0xLTI1Mzk_a78c31d1-2bc8-412e-b03d-9898bd5c8e60"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQxLTMtMS0xLTI1Mzk_2bacb1ac-02f3-4a56-a7d5-4f828836aae1"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQyLTEtMS0xLTI1Mzk_f383ee2f-1212-4ed4-823b-d0c3f609ad45"
      unitRef="usd">2367271000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV85NDMvZnJhZzo3OWVmZTY5YTZhOGE0NzlkOGI4YjVhNDFhOGZkOGI5Ni90YWJsZTo3ODE3YzJlNDdiYzI0NWJmOWNjNDlmZTJiYTM1NjYwYy90YWJsZXJhbmdlOjc4MTdjMmU0N2JjMjQ1YmY5Y2M0OWZlMmJhMzU2NjBjXzQyLTMtMS0xLTI1Mzk_cf9a102a-ad96-4ab1-9086-1bd4a16e53f1"
      unitRef="usd">2137333000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy0xLTEtMS0w_81b7b574-0ab0-40d7-b45d-922aa94ca8aa"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy0zLTEtMS0w_e29ee029-6bd1-477f-ac3d-28c252ab6086"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy01LTEtMS0w_4a7f7bcb-1812-4899-901a-ad00973424f7"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMy03LTEtMS0w_162c88aa-d38c-43c5-aff6-72bb5da9d725"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9259a9d7933146308c821508a3ddee27_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC0xLTEtMS0w_25a9c531-4764-481d-9b4d-c23fcb04c8d5"
      unitRef="usd">39640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC0zLTEtMS0w_4477f2f7-a126-4799-b420-44726188e029"
      unitRef="usd">59234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia21d371856cc48a68b4309847396fa80_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC01LTEtMS0w_d41abdee-e1b2-42e5-b3b8-b61fe84f62df"
      unitRef="usd">67168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNC03LTEtMS0w_e118cf53-8d86-453d-83c4-bbf22d123399"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS0xLTEtMS0w_da4b0944-a101-45d9-9594-bf753ef1a570"
      unitRef="usd">61289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS0zLTEtMS0w_c1ca5a4e-5eec-443e-b7c5-453b4eab8703"
      unitRef="usd">21515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS01LTEtMS0w_0c57e564-98fe-4d40-a3e1-8840faafe6c8"
      unitRef="usd">76779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35c76885c08464e8536056814cc87b0_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNS03LTEtMS0w_c18378f9-e035-4603-97c8-c78127f1851c"
      unitRef="usd">33671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi0xLTEtMS0w_e9ac2e12-d9c7-450d-9a53-b205a23c4183"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi0zLTEtMS0w_179cf3cb-ab99-414b-823f-a3718a32dfca"
      unitRef="usd">259479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi01LTEtMS0w_25ae4691-3068-4047-89b6-6a24dbf57c0c"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfNi03LTEtMS0w_70eec2a0-54e7-4d9c-9d3d-33a9e4a1992e"
      unitRef="usd">486394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC0xLTEtMS0w_f32cb374-3991-4f5f-86b1-9dec73c643df"
      unitRef="usd">14884000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC0zLTEtMS0w_6ede8e0c-d016-40f7-bfeb-0e85f9fad6d7"
      unitRef="usd">9221000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC01LTEtMS0w_ba875cc4-363a-416d-af2f-53b6caea7c9d"
      unitRef="usd">28082000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOC03LTEtMS0w_9e6212dd-7396-4b7c-b1e4-3bc94dda2f92"
      unitRef="usd">18510000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS0xLTEtMS0w_49ef8ac0-b450-487d-ab6d-97523445fabe"
      unitRef="usd">148790000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS0zLTEtMS0w_77c82a40-c39b-4307-b78e-320e17b9e189"
      unitRef="usd">114933000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS01LTEtMS0w_72bc7537-6eeb-4da7-a024-b437bd01e091"
      unitRef="usd">308078000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfOS03LTEtMS0w_85ffdb19-01c6-4397-abb0-a6879405d485"
      unitRef="usd">216810000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtMS0xLTEtMA_9e9bd71d-b834-4523-9493-41a5f05176e9"
      unitRef="usd">98495000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtMy0xLTEtMA_4e67c7ae-76a9-4f34-a1b8-3bdb6e494f9f"
      unitRef="usd">59791000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtNS0xLTEtMA_f9f5070f-827f-4282-9ab4-bcecb2351ee8"
      unitRef="usd">200846000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTAtNy0xLTEtMA_3858a665-4225-4411-a26d-3aa391a695db"
      unitRef="usd">122731000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:CostsAndExpenses
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtMS0xLTEtMA_b793cfb4-3fc0-4c40-ad71-3ad95ca02012"
      unitRef="usd">262169000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtMy0xLTEtMA_35b8d8e9-186f-43ac-93b2-cb9407520b86"
      unitRef="usd">183945000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtNS0xLTEtMA_302fffee-b5de-4112-aac2-4f5d840be20d"
      unitRef="usd">537006000</us-gaap:CostsAndExpenses>
    <us-gaap:CostsAndExpenses
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTEtNy0xLTEtMA_bb9ed111-8199-4032-b87f-2cac6c83158a"
      unitRef="usd">358051000</us-gaap:CostsAndExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItMS0xLTEtMA_9c9a02a4-30ca-4757-aefe-1036278b6973"
      unitRef="usd">123008000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItMy0xLTEtMA_7e1ef3cd-dfb2-47dd-8783-f0d16a2341cd"
      unitRef="usd">75534000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItNS0xLTEtMA_0b87d318-467a-45e4-8471-50b61d8a70a4"
      unitRef="usd">118401000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTItNy0xLTEtMA_3c66bac1-2cd1-4381-83ab-1c28bff8b7ab"
      unitRef="usd">128343000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeOther
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtMS0xLTEtMA_050e02f8-69d7-4bc2-82c1-eb6e86e22faa"
      unitRef="usd">1891000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtMy0xLTEtMA_7817068a-fab8-4dd4-815f-13f1545dce90"
      unitRef="usd">5162000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtNS0xLTEtMA_725ed289-159e-48d6-b729-d059f56b2d73"
      unitRef="usd">4573000</us-gaap:InterestIncomeOther>
    <us-gaap:InterestIncomeOther
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTMtNy0xLTEtMA_ea6a6e1d-b56d-4661-a784-23dd06f217b6"
      unitRef="usd">12382000</us-gaap:InterestIncomeOther>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtMS0xLTEtMA_7405bf4b-2fe2-4efc-bc24-fdd1f5298121"
      unitRef="usd">-11000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtMy0xLTEtMA_9b8eb078-3a3a-490d-9486-27d5d28e30c2"
      unitRef="usd">0</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtNS0xLTEtMA_fea97cf9-4a06-40c3-b54f-67bad3dcbabe"
      unitRef="usd">-101000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTQtNy0xLTEtMA_e6f086de-6bc3-4867-a87c-be0747e1f78f"
      unitRef="usd">6000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtMS0xLTEtMA_0758fb06-ea16-4120-ba50-9cd35c2dbae8"
      unitRef="usd">124888000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtMy0xLTEtMA_33222874-c188-4203-b43f-485364a459b5"
      unitRef="usd">80696000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtNS0xLTEtMA_2fef8825-5e4c-4d50-ab3c-669409892020"
      unitRef="usd">122873000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTUtNy0xLTEtMA_9a5dbef4-3c6c-40b3-bb64-822c21fcfdc8"
      unitRef="usd">140731000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtMS0xLTEtMA_c77ac110-c588-401d-868d-2237f1f53808"
      unitRef="usd">28796000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtMy0xLTEtMA_abdc1ad8-2000-4063-b998-d5e7113f1f41"
      unitRef="usd">13875000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtNS0xLTEtMA_504a4677-05f2-4cac-ad83-eebbe970df53"
      unitRef="usd">25180000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTYtNy0xLTEtMA_d5baf900-3db6-4f30-8c83-45f5d1df4cc6"
      unitRef="usd">25298000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctMS0xLTEtMA_8c59a938-ba77-46f6-bfe2-d1973b4ebadf"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctMy0xLTEtMA_0ed6bc29-5d72-4285-846f-ae3ed36c72fc"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctNS0xLTEtMA_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTctNy0xLTEtMA_440a50f1-946b-426a-8c74-53c935a85e7f"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktMS0xLTEtMA_db364df9-420c-4664-ba8f-4dba8f3d3d5e"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktMy0xLTEtMA_a8181d0d-a138-44ff-8fb3-35d1836987a7"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktNS0xLTEtMA_897385f8-22ab-4504-bf49-eb4a6bd32c5b"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMTktNy0xLTEtMA_bbc6ce9a-fefe-412b-8516-d5361bb8b0ce"
      unitRef="usdPerShare">0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtMS0xLTEtMA_beecd631-c0bd-4197-a468-ed60af27687c"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtMy0xLTEtMA_a372761b-f96f-44e0-afcc-29e5a02bd2fe"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtNS0xLTEtMA_2a732a89-e223-41ba-a0a9-5210dae65758"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjAtNy0xLTEtMA_119fc0ce-5935-4989-a55d-0c6842d0a25b"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItMS0xLTEtMA_29e2868a-8b38-4875-a887-d7c75f9af8f0"
      unitRef="shares">314117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItMy0xLTEtMA_4e3f1f2a-e580-44d9-9acf-364bac526287"
      unitRef="shares">307807000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItNS0xLTEtMA_0c983555-5ab8-4398-810b-60e29450066d"
      unitRef="shares">313295000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjItNy0xLTEtMA_579d327e-e1b5-40c8-b5e1-07460774ef43"
      unitRef="shares">306598000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtMS0xLTEtMA_176fe79f-65fe-45a7-a45a-b70d9633959c"
      unitRef="shares">322941000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtMy0xLTEtMA_8d71706a-07ff-44a6-8d6e-8a16b9b04603"
      unitRef="shares">318144000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtNS0xLTEtMA_9fa59a67-6375-47c0-b124-ab89c973a39d"
      unitRef="shares">322114000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8xOS9mcmFnOmRlNGVmNWRhYTQxZjRiYmNhOTZjNGI2YmI0NzFlMTI4L3RhYmxlOmM3MDk5NTBiMGJmNzQ5MmE5NDNkYTc3YTNjMTZlMzlkL3RhYmxlcmFuZ2U6YzcwOTk1MGIwYmY3NDkyYTk0M2RhNzdhM2MxNmUzOWRfMjMtNy0xLTEtMA_a282183a-71c2-430e-8509-8d3fd1d9e176"
      unitRef="shares">316992000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi0xLTEtMS0w_8c59a938-ba77-46f6-bfe2-d1973b4ebadf"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi0zLTEtMS0w_0ed6bc29-5d72-4285-846f-ae3ed36c72fc"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi01LTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfMi03LTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzg5Mw_e1aed19c-f537-4f9f-8cd8-802c4947cd41"
      unitRef="usd">-257000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzg5OA_f662d2e7-6e1a-456e-8fd0-f6bc61ff7ff1"
      unitRef="usd">2287000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfMTA5OTUxMTYyNzkxMQ_3d9531dc-d268-46cb-b621-aa722f43bfd8"
      unitRef="usd">-756000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0wLTEtMS0wL3RleHRyZWdpb246OGY1YjRjZWVlM2E5NDI1MGEwMjI1ZDdiYTFmY2RkYjlfOTM_016cff06-27c2-4fdb-8d18-0e5fcad1529a"
      unitRef="usd">1346000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0xLTEtMS0w_d5a044e9-e116-42e0-876c-da7e448a3d18"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC0zLTEtMS0w_6ee63066-50c3-445a-911a-88d7a74244e5"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC01LTEtMS0w_28763dae-a620-43f3-9178-273f67bd34b1"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNC03LTEtMS0w_8aa3a92b-0df2-4d75-8275-8cb854496ba3"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi0xLTEtMS0w_f915a778-7ea7-4804-8e41-f9837b84b02e"
      unitRef="usd">95337000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi0zLTEtMS0w_8a3527d1-8195-4ae7-a942-22ba358f7eaa"
      unitRef="usd">74883000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi01LTEtMS0w_b4926d54-dccc-4f23-9321-086bc3a4b628"
      unitRef="usd">95202000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yMi9mcmFnOjZmZDAwNjZjM2NkZjQ0NDU4OTZhYjI3OTllYmUxZWQyL3RhYmxlOjc3YTc5YzMxZTQ3MTQyYTJiMjUxNDI5NzkzNTI2N2YyL3RhYmxlcmFuZ2U6NzdhNzljMzFlNDcxNDJhMmIyNTE0Mjk3OTM1MjY3ZjJfNi03LTEtMS0w_9617b239-7153-485c-8081-ad8340a14e88"
      unitRef="usd">120204000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i18f71f314ed04df18bb6962c37407e37_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMS0xLTEtNjU_45e92784-b07a-4d49-b890-bd9e9f89fac2"
      unitRef="shares">313262000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i18f71f314ed04df18bb6962c37407e37_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMy0xLTEtNjU_5d46fa70-057f-40c7-a0bf-d8094bfd7670"
      unitRef="usd">313000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i8d1d3b56237f4f60b09904a6c28afefa_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtNS0xLTEtNjU_ff5ef394-1230-4b8e-97c5-789a88280458"
      unitRef="usd">2354103000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia7f72b97be95433eb01da77344b924b4_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtNy0xLTEtNjU_fbb928f0-2ad2-46f6-8a9d-79e56f43b679"
      unitRef="usd">2740000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i9055e59c6448472b8afad20e904571c0_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtOS0xLTEtNjU_4c3367ed-56e6-44f2-a34f-1aa72499cee1"
      unitRef="usd">-445969000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ic2d314200efc414286c58e02a72592ae_I20210402"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjMtMTEtMS0xLTY1_b1b9110e-1cc4-43db-b9d2-53a02823cfba"
      unitRef="usd">1911187000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i44dd4e95f4af402e9f077cd335eb7007_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjQtOS0xLTEtNjU_699fb1c3-6fc2-4a27-9374-cb4c5e3e8a8c"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjQtMTEtMS0xLTY1_76441df4-f3f5-464c-8c78-039bc2ea06d3"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i53be24f47fe943889e3a6dda67c33519_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjUtNy0xLTEtNjU_79ddf047-b110-4502-a5f8-1a6decf672bd"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjUtMTEtMS0xLTY1_0147ca42-5fc3-471a-9687-598f078dbaad"
      unitRef="usd">-755000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i506073af88c340ebb62b33816c074aaf_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMS0xLTEtNjU_ab25e987-984e-400e-a119-cb637b35ff7f"
      unitRef="shares">1560000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i506073af88c340ebb62b33816c074aaf_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMy0xLTEtNjU_2772e28a-2c7b-450d-875b-3f9bebd347a8"
      unitRef="usd">2000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtNS0xLTEtNjU_794d63dc-a69d-4a98-804a-fa2396098f83"
      unitRef="usd">11283000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjYtMTEtMS0xLTY1_13b7d573-5c1d-443c-ba2c-ba636e52aa7c"
      unitRef="usd">11285000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjctNS0xLTEtNjU_ce1a4dac-34a3-4c00-8136-258dd19fa033"
      unitRef="usd">2767000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjctMTEtMS0xLTY1_3a2f867b-0ee6-4cd7-9deb-7e22889b3f21"
      unitRef="usd">2767000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i9ba3b31ac2a548e8ba502f377e67687a_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjgtNS0xLTEtNjU_50169e7b-7aac-4cb1-8e2f-2daf13cfa997"
      unitRef="usd">28035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjgtMTEtMS0xLTY1_801aee67-b05b-4bd0-8ff4-308af33ede28"
      unitRef="usd">28035000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMS0xLTEtNjU_913b87f5-3e24-4f0d-be62-c5c3da425caf"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMy0xLTEtNjU_84287cba-bb1e-487c-a87f-083ee960ed44"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i693dc4f870124e0b9ddd7456d2a2738c_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktNS0xLTEtNjU_7dd74ebe-96b7-4f20-b1b6-18f213786abd"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktNy0xLTEtNjU_fb90982b-5ebb-49d0-9153-bcd2fd0d5dbe"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i748018c371b647b38103dedba2c84de1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktOS0xLTEtNjU_5c965796-8c10-49c5-a6da-b245a148a8ab"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjdlZmE2NDhlZTg4ODQ0ZWRhNzZlZWVjMWY3NGY5NmEwL3RhYmxlcmFuZ2U6N2VmYTY0OGVlODg4NDRlZGE3NmVlZWMxZjc0Zjk2YTBfMjktMTEtMS0xLTY1_ab40f25e-4bb3-454a-92c5-1c419ebe3bee"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ic45af8276000456da83f9b42424d83fd_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMS0xLTEtNjU_d3b6f3e1-89c8-4082-b042-d01716bd3340"
      unitRef="shares">305780000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ic45af8276000456da83f9b42424d83fd_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMy0xLTEtNjU_a6389dc6-87c7-4d08-92e7-825fb8e8f036"
      unitRef="usd">306000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="iccf0f3d464b14f8689aace6957954839_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtNS0xLTEtNjU_2473f130-6f8a-4f88-a06b-dc7e86470518"
      unitRef="usd">2258307000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i0f53374fa9494a2bbfec8a0dac4cec86_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtNy0xLTEtNjU_34a8871b-50c0-42ba-8e96-acf48b7692b1"
      unitRef="usd">-222000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if4476ab3366d4b4aa330a4b0fa517edf_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtOS0xLTEtNjU_b78842bc-a394-41ed-af10-78993325bc7b"
      unitRef="usd">-510739000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i946cc6b151944fdc8ee643e1575173c6_I20200403"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjMtMTEtMS0xLTY1_c03dc60c-780c-4b56-8730-0398ce94c3a0"
      unitRef="usd">1747652000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="ib54c97a496384e2f8bf53ca6af61aaca_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjQtOS0xLTEtNjU_7794ef1c-998e-4c07-9909-74c8f22c8f30"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjQtMTEtMS0xLTY1_c4528241-a445-4b16-9c27-277a37fcca81"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i36169ffce5154dfabab0771e977ca089_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjUtNy0xLTEtNjU_9c239474-506a-4bc5-93e1-aa80b5a13c22"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjUtMTEtMS0xLTY1_da440c46-1f16-4880-b1a5-362c716b6def"
      unitRef="usd">8062000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="i664240e571634cfbaf15ac1e52615971_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMS0xLTEtNjU_40caa541-c2e5-4de7-a8fa-e4fe8df1a5e1"
      unitRef="shares">3106000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i664240e571634cfbaf15ac1e52615971_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMy0xLTEtNjU_67da3b8c-814c-4079-bb48-68f6658eb58b"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtNS0xLTEtNjU_2360b11d-9d57-4215-9c58-dec94ab59354"
      unitRef="usd">13780000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjYtMTEtMS0xLTY1_83cb430f-5cd4-4b5f-8074-814fdadf0b8a"
      unitRef="usd">13783000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjctNS0xLTEtNjU_5ebeba59-5928-4f24-87b3-9cbf29475bb5"
      unitRef="usd">19148000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjctMTEtMS0xLTY1_98cd6260-022b-4e62-b681-7014cf8547f1"
      unitRef="usd">19148000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="iab752072e7054dde811c0ac14ccb2f56_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjgtNS0xLTEtNjU_6aa05206-1fc0-45f0-bc0f-cf625d6f1e65"
      unitRef="usd">16154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjgtMTEtMS0xLTY1_cce37210-2131-4f26-bed9-5d2467d3603c"
      unitRef="usd">16154000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMS0xLTEtNjU_cdbed083-589a-491d-8ab4-3bb953111a56"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMy0xLTEtNjU_575d0406-4286-4ada-81ce-01f4bf126046"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i493e0445ef74439faa8e33e8d3bd99fc_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktNS0xLTEtNjU_45ff283c-494b-4002-91fc-bc67d7db5f63"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56aa11bddb1f4538a589748b0433902b_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktNy0xLTEtNjU_1ff57827-feec-4de4-97b0-bacb1b567ed6"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35af602dfdfc44a7b9bc433d59cbc821_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktOS0xLTEtNjU_15c4fbf7-31d7-46a3-bc8f-4108344d1094"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjU4ZTMzNDYxMzBlZTQ3MWY5YjVlOGZiNDRjNTkwYTU0L3RhYmxlcmFuZ2U6NThlMzM0NjEzMGVlNDcxZjliNWU4ZmI0NGM1OTBhNTRfMjktMTEtMS0xLTY1_4675ffd2-d719-4378-a518-980968b8a00e"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i081256c453a249839e8537f1c0153e9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMS0xLTEtMA_dae18e75-8f75-4985-8784-3bbaf2135180"
      unitRef="shares">311627000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i081256c453a249839e8537f1c0153e9f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMy0xLTEtMA_98edd32f-238b-4397-9a87-de0ab534d2a8"
      unitRef="usd">312000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3a0940ae62e5401b9c203c706d89df2f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtNS0xLTEtMA_6f89e452-ca62-4951-8136-9c6584896eb1"
      unitRef="usd">2321895000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i058b3f9310334495bbc354761bd6647b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtNy0xLTEtMA_90b85a01-b262-413a-9559-b8cd80ddf55d"
      unitRef="usd">4476000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if0687bdba44c461687736aa0a7fa9b21_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtOS0xLTEtMA_ee670de0-f868-4a01-a285-89615189f746"
      unitRef="usd">-447570000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjMtMTEtMS0xLTA_f90097ae-6c92-4cf1-8711-e74a29c217d2"
      unitRef="usd">1879113000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjQtOS0xLTEtMA_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjQtMTEtMS0xLTA_4ad9cbad-4d35-4f1b-8d80-84848d2cc81a"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="ief41d78e50cb4a93a62920da7cecefef_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjUtNy0xLTEtMA_c3e6be1b-d465-41a6-8e1e-8ecc54e0d91a"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjUtMTEtMS0xLTA_dc7a095e-3552-4eb2-a0ec-57c3ec3a7c4e"
      unitRef="usd">-2491000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ifa16a9d12d014d909104f7045186de11_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMS0xLTEtMA_735d3013-e415-417b-b64e-d40bff4a3071"
      unitRef="shares">3195000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ifa16a9d12d014d909104f7045186de11_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMy0xLTEtMA_3ba27226-955f-4c65-a62f-da43e929dc6a"
      unitRef="usd">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtNS0xLTEtMA_f14f863a-8af4-4226-9221-db40bacac4fb"
      unitRef="usd">15484000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjYtMTEtMS0xLTA_26c56fe4-739b-4362-b484-a970d080c935"
      unitRef="usd">15487000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjctNS0xLTEtMA_d0ad8d97-c10a-42f3-b3fb-8489b906595e"
      unitRef="usd">9413000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjctMTEtMS0xLTA_7bfb4227-b53e-4fc9-a645-9f5cef5fc315"
      unitRef="usd">9413000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i09143c7daf60411d87ea5e580d0fa4f3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjgtNS0xLTEtMA_59acf739-a5da-4ec2-940f-febff406bfc6"
      unitRef="usd">62688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjgtMTEtMS0xLTA_076a2dbb-f61a-4ce0-a5db-e35357b803e1"
      unitRef="usd">62688000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMS0xLTEtMA_913b87f5-3e24-4f0d-be62-c5c3da425caf"
      unitRef="shares">314822000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="idaaa8f6eb6fe4306b163861f98903231_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMy0xLTEtMA_84287cba-bb1e-487c-a87f-083ee960ed44"
      unitRef="usd">315000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i693dc4f870124e0b9ddd7456d2a2738c_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktNS0xLTEtMA_9b29e1cb-55e0-4e75-92dd-339921b60a87"
      unitRef="usd">2390654000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i816aad11a5674a79ba8d7d9a5cc08ff3_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktNy0xLTEtMA_fb90982b-5ebb-49d0-9153-bcd2fd0d5dbe"
      unitRef="usd">1985000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i748018c371b647b38103dedba2c84de1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktOS0xLTEtMA_5c965796-8c10-49c5-a6da-b245a148a8ab"
      unitRef="usd">-349877000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOjA3NzgzODAwMjVlMzRjYWY5OTczNDBmNjVlNjk4NTBiL3RhYmxlcmFuZ2U6MDc3ODM4MDAyNWUzNGNhZjk5NzM0MGY2NWU2OTg1MGJfMjktMTEtMS0xLTA_c52d65dc-24b0-4e90-af21-3e3d12e363dd"
      unitRef="usd">2043077000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMS0xLTEtMA_975fc149-6cb1-4fcc-b8a4-85d1e20e74a1"
      unitRef="shares">304831000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMy0xLTEtMA_51449ea0-e354-4e66-a62a-6a7d804debf6"
      unitRef="usd">305000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i84739d5f149041178c34597093926bd6_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtNS0xLTEtMA_1da7f7d0-9047-4744-8922-bc6595737a78"
      unitRef="usd">2241947000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i5556cef549ed44c18c579369e37ccdf2_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtNy0xLTEtMA_472a9ebd-ab39-4457-9b08-315540e2f55a"
      unitRef="usd">3069000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i3025b4065aaf4cdba68bd29f0237a548_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtOS0xLTEtMA_677f2e99-3b2a-414c-8f52-d97759af6311"
      unitRef="usd">-559351000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="if13daa675eb9480989a9cdb6f2a297e6_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjMtMTEtMS0xLTA_b74998b4-a743-461d-814d-6a0010c71516"
      unitRef="usd">1685970000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i80c8d20e80cc4ad7bca1dc91ecf75437_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjQtOS0xLTEtMA_8f20deb6-56c2-4b58-89fc-ac7b5c34467b"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjQtMTEtMS0xLTA_4fea6dc4-9270-4c60-913e-a2a4e28af547"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i081971405e1741eeb1fc749632c1c0aa_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjUtNy0xLTEtMA_e9063691-825f-4818-be37-78a35180f16b"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjUtMTEtMS0xLTA_164a602f-c4f8-40b4-a12d-e84eda18db10"
      unitRef="usd">4771000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMS0xLTEtMA_584faf3c-d980-4fc8-bdec-c2c510aa5e4f"
      unitRef="shares">4055000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="ib1afc183f27d43d9a84b73443065b8dc_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMy0xLTEtMA_fed21181-3047-47e1-b6c2-6240fa2a0846"
      unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtNS0xLTEtMA_08ecf893-1c5e-4e0e-9ffe-7fc42e5ad14a"
      unitRef="usd">17951000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjYtMTEtMS0xLTA_573bdd49-4454-45bc-948a-b8b43a8124fd"
      unitRef="usd">17955000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjctNS0xLTEtMA_f8af50f9-f43c-4c8c-aca7-105ac988c951"
      unitRef="usd">20941000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjctMTEtMS0xLTA_851cf588-bb1d-4476-827a-461a54bb6455"
      unitRef="usd">20941000</us-gaap:AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i616ab7befeac4dd19930969171845d06_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjgtNS0xLTEtMA_0ee15f6a-3840-4ede-bf7c-3e3291d07128"
      unitRef="usd">30136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMjgtMTEtMS0xLTA_f3efe646-bf4b-4008-b43b-63f273556776"
      unitRef="usd">30136000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMS0xLTEtMA_cdbed083-589a-491d-8ab4-3bb953111a56"
      unitRef="shares">308886000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="i9e75ad76a9d5421ba9541cdba21c74ba_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMy0xLTEtMA_575d0406-4286-4ada-81ce-01f4bf126046"
      unitRef="usd">309000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i493e0445ef74439faa8e33e8d3bd99fc_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtNS0xLTEtMA_45ff283c-494b-4002-91fc-bc67d7db5f63"
      unitRef="usd">2269093000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i56aa11bddb1f4538a589748b0433902b_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtNy0xLTEtMA_1ff57827-feec-4de4-97b0-bacb1b567ed6"
      unitRef="usd">7840000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i35af602dfdfc44a7b9bc433d59cbc821_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtOS0xLTEtMA_15c4fbf7-31d7-46a3-bc8f-4108344d1094"
      unitRef="usd">-443918000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8yNS9mcmFnOjczMzQ4NTcxZjA4OTRiZGM5NDc5MzBmMzgzNmQ4ZTY5L3RhYmxlOmE5ZjhkNTk0NWViZDQ3YzNiY2ZmMjQzNWVmYmFlZGMwL3RhYmxlcmFuZ2U6YTlmOGQ1OTQ1ZWJkNDdjM2JjZmYyNDM1ZWZiYWVkYzBfMzAtMTEtMS0xLTA_4675ffd2-d719-4378-a518-980968b8a00e"
      unitRef="usd">1833324000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMi0xLTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMi0zLTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNC0xLTEtMS0w_847f75a9-adce-473d-9c09-cb59673782b3"
      unitRef="usd">6895000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNC0zLTEtMS0w_d1b229e2-ff93-4a3d-bcf6-0e2936b30f9a"
      unitRef="usd">4376000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:ShareBasedCompensation
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNS0xLTEtMS0w_5fe158ce-aa4d-4d35-a48e-5a04a6a67e99"
      unitRef="usd">62688000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNS0zLTEtMS0w_a9b9b610-b080-4046-a88b-328feb74fe4a"
      unitRef="usd">30136000</us-gaap:ShareBasedCompensation>
    <exel:NoncashLeaseExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNi0xLTEtMS0w_825fa57a-0a13-4497-8c0c-7be77fc3fae5"
      unitRef="usd">2586000</exel:NoncashLeaseExpense>
    <exel:NoncashLeaseExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNi0zLTEtMS0w_bf9da8b7-7c30-4044-90e6-99bd8e0ddec7"
      unitRef="usd">2383000</exel:NoncashLeaseExpense>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNy0xLTEtMS0w_f9c60263-be8a-4efc-8f1a-0399613feaca"
      unitRef="usd">-22800000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNy0zLTEtMS0w_e0b874de-0f31-454c-827a-5e3c89973e02"
      unitRef="usd">-22793000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfOC0xLTEtMS0w_fe7dff11-ac77-4c60-b40c-3560bbdf3eae"
      unitRef="usd">-22831000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfOC0zLTEtMS0w_098bb764-9c02-40d9-8b39-32c5945cc7ec"
      unitRef="usd">-726000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTAtMS0xLTEtMA_14a51825-ed95-47e2-ba16-3cb2e215f1e2"
      unitRef="usd">12313000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTAtMy0xLTEtMA_7e5e1028-7cfc-4ab4-bdd6-d9fb0944b3f7"
      unitRef="usd">2014000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTEtMS0xLTEtMA_819c7ad9-85f7-4136-b2bd-4d1b83a722c0"
      unitRef="usd">8020000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTEtMy0xLTEtMA_271c20a6-62a9-4083-8537-7c09c9056c5f"
      unitRef="usd">7049000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTMtMS0xLTEtMA_e6994081-10e3-4b2d-8592-3255c65e3d53"
      unitRef="usd">12296000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTMtMy0xLTEtMA_cb87af9f-03c6-4b02-a9c7-02033803a2d6"
      unitRef="usd">18954000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTUtMS0xLTEtMA_4a8b70b3-f4fc-4df8-862f-7797f42a45cd"
      unitRef="usd">9346000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTUtMy0xLTEtMA_4b2d3bd9-0af6-4039-884c-293c61c73e55"
      unitRef="usd">9659000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTYtMS0xLTEtMA_b52b9a46-fc05-439c-9494-2146af754a27"
      unitRef="usd">28835000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTYtMy0xLTEtMA_c1ebde8a-4583-4773-80f8-c980d66db7f7"
      unitRef="usd">262000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTctMS0xLTEtMA_fd75be72-2074-4a7c-a4d4-ac65dd6e1c43"
      unitRef="usd">221045000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTctMy0xLTEtMA_fb0a854b-d1af-4bf2-895d-dd58d86a3ddb"
      unitRef="usd">157751000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTktMS0xLTEtMA_e74bff06-0aeb-49ae-a327-d6d3956fcafa"
      unitRef="usd">33768000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMTktMy0xLTEtMA_fd28fc45-b739-4264-aef2-296547d9f2a2"
      unitRef="usd">9925000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjEtMS0xLTEtMA_7e00e430-302c-4547-a0bd-ef1021052b22"
      unitRef="usd">688903000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjEtMy0xLTEtMA_877c38cb-4454-47a3-b4dd-e0ba9c36a26d"
      unitRef="usd">433154000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjItMS0xLTEtMA_4b59ae5d-1785-4e83-88e2-0ec69cc63126"
      unitRef="usd">714081000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjItMy0xLTEtMA_6bc86ff1-f5ca-4459-9f8a-8ceab3c42dd2"
      unitRef="usd">548973000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjMtMS0xLTEtMA_b432c59d-6ac1-49ce-8b37-4d2e258ea6ba"
      unitRef="usd">-8590000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjMtMy0xLTEtMA_7573fe91-9a80-4a65-a404-a497c5fd5f70"
      unitRef="usd">105894000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjUtMS0xLTEtMA_1df475d1-92a7-493c-b4f0-1421ce031e7e"
      unitRef="usd">15487000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjUtMy0xLTEtMA_5978517e-66a9-4bb4-9acc-3180c9304e75"
      unitRef="usd">17938000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjYtMS0xLTEtMA_d96dca9f-d05e-4815-a09e-f9d22e04dbf1"
      unitRef="usd">9413000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjYtMy0xLTEtMA_46553725-f1e1-4852-9fac-5d48140ee9b7"
      unitRef="usd">20941000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjktMS0xLTEtMA_aecbe15c-6a20-4977-934f-c4c4d01561d1"
      unitRef="usd">6074000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMjktMy0xLTEtMA_239e4674-477c-4ac4-a54f-e3356981a582"
      unitRef="usd">-3003000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzAtMS0xLTEtMA_09c5f763-c682-4b63-acf0-30a3d120387d"
      unitRef="usd">218529000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzAtMy0xLTEtMA_79896bb6-bddc-488a-9aa0-1bb23e814b8f"
      unitRef="usd">260642000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzEtMS0xLTEtMA_1a5c73ec-afa9-46c5-b7e9-25308332de16"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="if13daa675eb9480989a9cdb6f2a297e6_I20200103"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzEtMy0xLTEtMA_a70558e3-4025-4763-9ebf-d77b7f2e1ad1"
      unitRef="usd">268137000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzItMS0xLTEtMA_1dd605b6-8614-4a92-890e-de1bd826fa19"
      unitRef="usd">539301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzItMy0xLTEtMA_1ffbe429-99a7-4f72-b0ba-195b064f2980"
      unitRef="usd">528779000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzctMS0xLTEtMA_9b583287-bf80-4107-a5ef-d8ac65a69016"
      unitRef="usd">4893000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <exel:RightOfUseAssetObtainedInExchangeForLeaseLiability
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzctMy0xLTEtMA_101b53fe-0f10-4b58-bd66-f945e2829f37"
      unitRef="usd">1824000</exel:RightOfUseAssetObtainedInExchangeForLeaseLiability>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzgtMS0xLTEtMjc3MA_98533434-ccc2-40ec-b410-f4ae783994eb"
      unitRef="usd">5125000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzgtMy0xLTEtMjAxNA_ad59ad49-7d3d-43b6-b37c-14e1c39fe0fa"
      unitRef="usd">804000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzktMS0xLTEtNTQzNw_0e8a445c-7134-4cc3-81e1-7b33e194e7eb"
      unitRef="usd">9000000</us-gaap:LiabilitiesAssumed1>
    <us-gaap:LiabilitiesAssumed1
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfMzktMy0xLTEtNTQzNw_36b49663-64e9-4424-a4ef-11acdb03d03f"
      unitRef="usd">0</us-gaap:LiabilitiesAssumed1>
    <exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNDEtMS0xLTEtNTYzNA_61b0d98e-9b04-4d4f-bc09-d3a0ae8e5f0d"
      unitRef="usd">7378000</exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid>
    <exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zMS9mcmFnOjQzN2M2Yjk5Nzk2MTQ5YTRhMGJjNThjZTllOWYwNWQ0L3RhYmxlOjEyMTMzNjYzNTUwMjRlZWFhMDJmYmYxNzZhNmE5ZmM5L3RhYmxlcmFuZ2U6MTIxMzM2NjM1NTAyNGVlYWEwMmZiZjE3NmE2YTlmYzlfNDEtMy0xLTEtNTYzNA_c3e8d09a-02a4-410d-a809-7afde07656c3"
      unitRef="usd">0</exel:UnsettledInvestmentPurchasesIncurredButNotYetPaid>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0OA_93d2a485-06ce-41ee-bd80-fc1c1bb8c9ad">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Organization&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#xae; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#x2019;s OPDIVO&#xae; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#xae;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The other two products resulting from our discovery efforts are: COTELLIC&#xae; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#xae; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended  July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of our long-lived assets are located in the U.S. See &#x201c;Note 2. Revenues&#x201d; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Reclassifications&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Significant Accounting Policies&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the six months ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, as compared to the significant accounting policies disclosed in Note 1 &#x2013; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
    <exel:NumberofProductsinCommercialMarket
      contextRef="i0788ba9b7348408294dc259c3a82acb4_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfNTcw_ebfc52fc-05d7-4974-8099-6b6105bbbe11"
      unitRef="product">4</exel:NumberofProductsinCommercialMarket>
    <exel:NumberofProductsinCommercialMarket
      contextRef="ibb1fe7255a2442e295f20f47559b739d_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfMTU5Mg_7af42b17-da61-42d1-852e-0d69f5359a13"
      unitRef="product">2</exel:NumberofProductsinCommercialMarket>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODUzOA_dca9379e-4bb8-4646-95c1-fae7b4201ae8">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#x2019; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU1OQ_a968e502-2a8d-41fa-ab33-f21a47b537a8">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:FiscalPeriod
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0MA_8d55af34-6332-4923-af8c-72c221189455">&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;st&lt;/span&gt;. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended  July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.</us-gaap:FiscalPeriod>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU2MA_f945a887-7e1d-44c5-8ac5-de369bd26d82">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and &lt;/span&gt;&lt;/div&gt;allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfNDE1OA_f16a0223-bc71-4520-9302-25ace9fc3f07"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:UseOfEstimates
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU1Ng_e01ea541-87cb-47d7-9152-9ed013047630">&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Use of Estimates&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU4Mg_0024d841-589e-44ea-874b-6f3b6dcb53ec">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#x2019; equity.</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU0Ng_ea43e18d-0116-4927-bb52-d84961b0a369">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Foreign Currency Forward Contracts for Non-Designated Hedges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV8zNy9mcmFnOjY2NzMyOGU0ZDUxMjQ1ZTE4ODBjMzUxODczZmVlN2I3L3RleHRyZWdpb246NjY3MzI4ZTRkNTEyNDVlMTg4MGMzNTE4NzNmZWU3YjdfODU2Mw_ea0973a1-c211-41d6-80f6-1479b981a8b8">&lt;div style="margin-top:9pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 1, 2021, we adopted the Accounting Standards Board&#x2019;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Recent Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk4NQ_81d10b30-7fe2-4913-8b71-9714fedb3794">REVENUES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Product Sales Discounts and Allowances&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Contract assets and liabilities were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Contract assets as of June&#160;30, 2021 are primarily related to a $12.5 million development milestone that we deemed probable of achievement and recognized $11.8&#160;million of revenues during the three months ended June 30, 2021. Contract liabilities as of June&#160;30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda). &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021 and 2020, we recognized $4.8 million and $3.4 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the three and six months ended June&#160;30, 2021, we recognized $40.6 million and $67.8 million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $62.0 million and $82.2 million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$86.9 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of t&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#x201c;Note 3. Collaboration Agreements&#x2014; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMg_5a932b68-d59c-4ce4-bcca-120b21541beb">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Product revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Gross product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;380,204&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;229,898&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;694,409&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482,464&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Discounts and allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(95,956)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(51,168)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(182,949)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(109,854)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration revenues:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;39,640&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;59,234&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;67,168&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,113&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;61,289&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;76,779&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,671&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total collaboration revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100,929&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;80,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;143,947&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;113,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues by product were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.864%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;CABOMETYX&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;275,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;173,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;499,209&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;362,826&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;COMETRIQ&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,120&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,251&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,784&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net product revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;284,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;178,730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;511,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i947f11dce7724c8a92d7f9d767d30430_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy0xLTEtMS0w_6417ffc6-19c9-4af6-9d93-7f7d66598a35"
      unitRef="usd">380204000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibab3c993c7644d7a946dcb256efda5b9_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy0zLTEtMS0w_cf519e6b-fcc8-4b6f-9a33-f8762557bf6a"
      unitRef="usd">229898000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib167b52f75e74c39838cc0b9a5bafec1_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy01LTEtMS0w_5e8b6020-22e9-41f7-86ba-b30fc0e41fe1"
      unitRef="usd">694409000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic4d233c682dd4c8e86078cfa757643ba_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMy03LTEtMS0w_d176ffb8-f371-4e35-8971-3e238bd80bb3"
      unitRef="usd">482464000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id8f066b777054049b67a402360c6a782_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC0xLTEtMS0w_0e95e048-fe63-465c-a88d-1ae78bf6fe1b"
      unitRef="usd">-95956000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i88bdab6e93514c5ca7163e90e6740f46_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC0zLTEtMS0w_62515ee5-8e52-49e8-bcf3-04c3fc6cb108"
      unitRef="usd">-51168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id31ef9d0f4694bdf8921fc58940a8cd7_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC01LTEtMS0w_b4d903f1-1534-43e4-bd73-21e5d060a2b6"
      unitRef="usd">-182949000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i99c380c1cdd64bc68dfdb4fc5dc13a5a_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNC03LTEtMS0w_e45f03a8-cdea-4d1c-86d0-f789794abc22"
      unitRef="usd">-109854000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS0xLTEtMS0w_81b7b574-0ab0-40d7-b45d-922aa94ca8aa"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS0zLTEtMS0w_e29ee029-6bd1-477f-ac3d-28c252ab6086"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS01LTEtMS0w_4a7f7bcb-1812-4899-901a-ad00973424f7"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNS03LTEtMS0w_162c88aa-d38c-43c5-aff6-72bb5da9d725"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9259a9d7933146308c821508a3ddee27_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy0xLTEtMS0w_25a9c531-4764-481d-9b4d-c23fcb04c8d5"
      unitRef="usd">39640000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iba5547c52bf04b609a3c7e6a6b1ad09e_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy0zLTEtMS0w_4477f2f7-a126-4799-b420-44726188e029"
      unitRef="usd">59234000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia21d371856cc48a68b4309847396fa80_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy01LTEtMS0w_d41abdee-e1b2-42e5-b3b8-b61fe84f62df"
      unitRef="usd">67168000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i77ad0c81b63b45719431f33b4f080be7_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfNy03LTEtMS0w_e118cf53-8d86-453d-83c4-bbf22d123399"
      unitRef="usd">80113000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i2b16a2b666ae4a2d80952f51dce2e073_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC0xLTEtMS0w_da4b0944-a101-45d9-9594-bf753ef1a570"
      unitRef="usd">61289000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i064aeff7811a4493a91b7f675e96a244_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC0zLTEtMS0w_c1ca5a4e-5eec-443e-b7c5-453b4eab8703"
      unitRef="usd">21515000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if0c43237e0dd4965943e66f459e395e6_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC01LTEtMS0w_0c57e564-98fe-4d40-a3e1-8840faafe6c8"
      unitRef="usd">76779000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic35c76885c08464e8536056814cc87b0_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOC03LTEtMS0w_c18378f9-e035-4603-97c8-c78127f1851c"
      unitRef="usd">33671000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i83c483fda79b4c16ad3d9442173642b8_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS0xLTEtMS0w_d333cd14-fd0e-4811-8852-8dd2b9ae8b6a"
      unitRef="usd">100929000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6cafb301e8bc4a1e878470c9b0f12baa_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS0zLTEtMS0w_50a1d802-a79d-4a51-a6a3-bcdcc55dfca4"
      unitRef="usd">80749000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie10d8c01e16442feaeac308109be67d6_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS01LTEtMS0w_4a5bbfa6-9944-4980-bf04-d8816e463c9d"
      unitRef="usd">143947000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3396192359714cebba9f9044f46388b8_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfOS03LTEtMS0w_fc10d8d9-96bb-46c4-bab2-d6dd060eafa2"
      unitRef="usd">113784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtMS0xLTEtMA_e9ac2e12-d9c7-450d-9a53-b205a23c4183"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtMy0xLTEtMA_179cf3cb-ab99-414b-823f-a3718a32dfca"
      unitRef="usd">259479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtNS0xLTEtMA_25ae4691-3068-4047-89b6-6a24dbf57c0c"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmJmMGRhMWVjMDQ3MjRiOTA5ZWQ5MTlmMGU0ZjIwNTAyL3RhYmxlcmFuZ2U6YmYwZGExZWMwNDcyNGI5MDllZDkxOWYwZTRmMjA1MDJfMTAtNy0xLTEtMA_70eec2a0-54e7-4d9c-9d3d-33a9e4a1992e"
      unitRef="usd">486394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMw_c00c1af8-322d-499b-a633-d76f38ec2fd7">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.039%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of Optum Specialty Pharmacy&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Accredo Health, Incorporated&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Ipsen Pharma SAS&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of McKesson Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Affiliates of AmerisourceBergen Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Affiliates of CVS Health Corporation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Takeda Pharmaceutical Company Limited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0xLTEtMS0zOTI_5eeca8a9-1483-4aa2-b677-55584e4e292c"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2dd1c78a8dac4b7489425c0a1175d608_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0zLTEtMS0zOTI_1728153b-a704-42ab-b8b2-64a3cc859c16"
      unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibdf20ffabe0140baa5b07542eeab1510_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi01LTEtMS0zOTI_9591811f-f61c-431b-9bc4-947980391497"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i11371f462a3a4f459626f35247d98cda_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi03LTEtMS0zOTI_efc723ce-b6c4-4381-8762-485a5996cc07"
      unitRef="number">0.17</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if0c970818f314feb8775caa6ef94fd81_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0xLTEtMS00MDc0_cb26d66b-03e5-4f3c-aecb-ffb3b0d26547"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i8ad0b431492b4370a00a89fa2d331434_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0zLTEtMS00MDc0_a64f8218-7866-4d53-85e9-1e19457fe321"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i70b167eedebd4c72b9f4d3f02442f179_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy01LTEtMS00MDc0_ac479bbd-7ba2-47a3-8a3b-edee39bd3719"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5f7584f5954340dba177cf82b494e611_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy03LTEtMS00MDc0_31d49d12-2b7c-464f-88ac-4dc24ca677d3"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idd6c27d712d943b78475ea6b7bcb2516_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0xLTEtMS0w_f638ba70-d3c2-4bfc-9f1f-855a685d7de1"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="if3bd6a226ce54f36b775c95518c27470_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi0zLTEtMS0w_da65492d-92f2-4374-a360-f15e4e2a16ab"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ifeb5bb631eb2470babf9f8d080f9964f_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi01LTEtMS0w_aa4665d6-c9e8-4cdb-b8a8-3375ea242b7b"
      unitRef="number">0.14</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0351d4cb2134494ba29863d99c874739_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMi03LTEtMS0w_0e298a7b-adca-4a59-822a-9a7e2ee83e0f"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i54323ff73fd948188ef473dee8b6e814_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0xLTEtMS0w_a3a78f9b-5982-4ea0-aa78-c8c9e3e64289"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i0e5051bdb62a4adea3b1ba61cad3e07b_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy0zLTEtMS0w_bdbc4299-8eee-409e-aa48-bc6982c7d46a"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ib2310c9c82ca42f09d4e1cb96f939ad9_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy01LTEtMS0w_f153c498-c7e4-4803-91df-8888424b4605"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i821ee440df88470196800293d930e33c_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfMy03LTEtMS0w_fe03ba1d-3492-43f6-be0e-ce83bc72f2b4"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i753195995e5e4556a95e622429f0db57_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC0xLTEtMS0w_9008d65f-bb91-4443-9b76-2d8efdda1e75"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i5fd1ae2034d9412089e998f08d56e5c3_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC0zLTEtMS0w_35088beb-5923-42f2-a1ff-483290ba3db4"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i27c364af82884e9e8ba8d4a627f277bf_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC01LTEtMS0w_8dc4121b-e6be-4ec6-bde4-cc2beb2fe577"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ibd0a23e145ff4ca084f0c9961d8b3a54_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNC03LTEtMS0w_298f5b04-e2ba-4120-a5d6-e6178cd7ebe1"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="id9542af44b304776a9c4bb52e4768814_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy0xLTEtMS00MDg3_dfe4952a-3562-4d17-9ffc-fec8865d0c86"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i354e779a90704e25ab4430a20741de7a_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy0zLTEtMS00MDg3_ca945435-5cb5-4a59-9956-bfd345e38472"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ice75da26c51d4900838a61e74a5f0c32_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy01LTEtMS00MDg3_ccd9f835-817d-4a4d-999a-97b731ee2edc"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2f30e6eb82e64b79b27523cafe87fb10_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNy03LTEtMS00MDg3_bae796c1-f7f1-4eea-b94c-9c37d89ae297"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i7b5f040ea73842e8abdcba995add3e6d_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS0xLTEtMS0w_d12c235c-1414-4382-963b-7de9ba4cec00"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="idb3bee6b43f04331a2af7c80b4a7370d_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS0zLTEtMS0w_40d86044-1788-4d4b-ba37-8bdbe0d18a35"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i13094e1db8884f879f12d67dad15c701_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS01LTEtMS0w_af98e053-8dae-45c6-b794-6eec3bedb15e"
      unitRef="number">0.02</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3bdd8100f1f84c43aa6914f739d17d31_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjNiOGQwODcyZWUxMjQzZjFiNTQyZTNlMmM0NGUxMTdiL3RhYmxlcmFuZ2U6M2I4ZDA4NzJlZTEyNDNmMWI1NDJlM2UyYzQ0ZTExN2JfNS03LTEtMS0w_bddcacb1-8e52-4daa-950c-ccefb1c49ede"
      unitRef="number">0.05</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ieb756ebdb26146dd872e8d96bcb1edf2_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMS0xLTEtMS0w_7929087c-af6f-4062-b38c-f860583aec35"
      unitRef="number">0.24</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia6d4a34bdbe3414db629b89c722ea436_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMS0zLTEtMS0w_887a03d8-b25f-48d6-ae4b-2a1036146e90"
      unitRef="number">0.23</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia210e74e223e424a970e3e3560d85886_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMi0xLTEtMS0w_5e549616-e915-4ba0-8ba6-fa0816337985"
      unitRef="number">0.21</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i2d909f0df4c749f5ad2943003106be6d_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMi0zLTEtMS0w_f4d6122a-175d-41ba-92d1-735c3f741988"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ia8ed993e6ef846f0842723b5499f1a51_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMy0xLTEtMS0w_2b4dc1db-27f7-4068-9615-b99bb4e59f30"
      unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ic3d6c5f034c743549e0b3580f3088770_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfMy0zLTEtMS0w_f40b3d97-1266-4aba-bc28-01fc22d270bb"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i3be0c4f6862744d381c6a9c8ad69d360_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNC0xLTEtMS0w_1f75db4b-40c4-4ee7-a5c1-d7c97b8ba6c4"
      unitRef="number">0.13</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i922effb845ac486685bc2d4ca1e2b64e_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNC0zLTEtMS0w_065a7957-3352-41fe-847f-117225d63153"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="i041977232d9d47f689aa8e5e54cf51c8_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNS0xLTEtMS0w_ebbea5b0-5697-49e4-95d6-f07caa7b597f"
      unitRef="number">0.04</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="ied845544fcad4e209b2f843ae011069a_D20200104-20210101"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmM4NzU0NmMxYWVjNjQzYWRhZmE2NDZlNWZkOTU5OTMyL3RhYmxlcmFuZ2U6Yzg3NTQ2YzFhZWM2NDNhZGFmYTY0NmU1ZmQ5NTk5MzJfNS0zLTEtMS0w_11649b9c-abaa-428f-aa8f-351329a3dcbb"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk5OQ_70b84e7c-dde8-4cb3-ae42-58f454b234ff">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues by geographic region were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;287,190&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,231&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;517,147&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;377,827&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Japan&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,533&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;385,177&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;259,479&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;655,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;486,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i576124c34cb14293a07e65c0e116b0fd_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi0xLTEtMS0w_7a7b5177-c02c-45ad-9d0a-6431f79b97b7"
      unitRef="usd">287190000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ie1f3b07b878f446983ae8ea6c24a8523_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi0zLTEtMS0w_3403601e-e135-4769-8a1f-3ebc9414f28f"
      unitRef="usd">181231000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i926a2dcdbc7642d3b461dd3a6194ac74_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi01LTEtMS0w_22401169-d645-454f-aaf3-3dc217115b8d"
      unitRef="usd">517147000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7962cd8f612a4e7a93a1cb357a042730_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMi03LTEtMS0w_57688ddf-b27b-4476-8200-e287e889bcf4"
      unitRef="usd">377827000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="if8f782da2d2a45809e36bb66021e8e95_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy0xLTEtMS0w_c05ecf44-b047-4e82-bd7d-ff48286bcb13"
      unitRef="usd">90921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23fea2b017ea462db2fa2ac8224cb0a7_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy0zLTEtMS0w_860a6e18-2bb6-4dd9-b281-67a96d6ed4ee"
      unitRef="usd">52917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i1e515978877241b1a3bbbf6c7c87a132_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy01LTEtMS0w_14a6db31-0d65-4e52-a0eb-82032a889bf3"
      unitRef="usd">124727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3e0390849b8b485ebe8240a57d0c0e15_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfMy03LTEtMS0w_f22149a8-96e0-435b-965a-d052b7a536d6"
      unitRef="usd">81953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ibf21142c44dc4ed588e7f49495659845_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC0xLTEtMS0w_106dd95a-a44d-4ca3-8a63-77ae058fbffd"
      unitRef="usd">7066000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8b04dfce356a48a3a67d32e955e37c0f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC0zLTEtMS0w_b01892ba-6b7e-4d80-8939-5430b1919741"
      unitRef="usd">25331000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5b57543585624c4cbf46aba4e36a40d0_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC01LTEtMS0w_821f1f73-ef71-4c18-aba5-20ce1375113b"
      unitRef="usd">13533000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4f2944cc9b084ae18eb84c3b0937c4bb_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNC03LTEtMS0w_2eb5a3a2-61b9-4133-9390-4bd0f58b8e3a"
      unitRef="usd">26614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS0xLTEtMS0w_9e442324-1edc-47f7-8b5b-f6b99b350d9c"
      unitRef="usd">385177000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS0zLTEtMS0w_586386a5-bc58-4b53-b6b7-732161e76fb1"
      unitRef="usd">259479000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS01LTEtMS0w_aca202f0-5ce6-47ca-89b3-e4a2eab8efee"
      unitRef="usd">655407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjlkNzc5ZTYxNGFlMjQ2MjE4ZWUzODQxNzZkZDMxZDJjL3RhYmxlcmFuZ2U6OWQ3NzllNjE0YWUyNDYyMThlZTM4NDE3NmRkMzFkMmNfNS03LTEtMS0w_e874e222-0aa2-4384-a0a8-52f39c288bd9"
      unitRef="usd">486394000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk4Mg_c7fda0a9-66f0-4877-ab27-6dd295981e85">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#x2019; headquarters.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net product revenues and license revenues are recorded in accordance with ASC Topic 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contract Assets and Liabilities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4abad55b764942b8838caffe168cd460_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi0xLTEtMS0w_c81c4309-5a9c-4c6a-97e5-7cb736aaa4a8"
      unitRef="usd">275614000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i602ab887907347eca4f8dd2743045d20_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi0zLTEtMS0w_f0ed5766-8ac8-40e6-90c2-9c5911171883"
      unitRef="usd">173610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia4e3544936884787b393e216680bae75_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi01LTEtMS0w_47ef7c62-b155-47e1-83ae-b78e0627ae57"
      unitRef="usd">499209000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic9861d7e9fc04d7797b39b96e817870b_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMi03LTEtMS0w_50e6ae42-7009-47b9-8596-9fbe6855376d"
      unitRef="usd">362826000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4494448a3d77442ea673dc4306f40517_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy0xLTEtMS0w_3a88050a-94ad-4095-8f03-8d1543c2de88"
      unitRef="usd">8634000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85570133db6f426dbb8f7b796098289a_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy0zLTEtMS0w_e54819a9-5c67-4543-9f43-48b1280f763e"
      unitRef="usd">5120000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6779e8b939fb444986c5b5f6762bedae_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy01LTEtMS0w_c54befc7-0149-4bf8-b401-35755d00a84e"
      unitRef="usd">12251000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifcab21398b064807b6664b9e08c18372_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfMy03LTEtMS0w_296fce7c-0704-48e8-ad59-7bac759ab847"
      unitRef="usd">9784000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i78f4b72d37cf428aa3b288b34048ac15_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC0xLTEtMS0w_1faefa15-e71f-4d8a-86dd-d5351ec8a4fc"
      unitRef="usd">284248000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8c3b390841e64904b78be2902aa24aaf_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC0zLTEtMS0w_8b235087-ccb0-4f93-baa8-f14151cf5126"
      unitRef="usd">178730000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i91ceb618932f4d008d28d24a55310ebf_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC01LTEtMS0w_55fe970f-589c-44b1-959a-e7296307ac9a"
      unitRef="usd">511460000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i3897325440364e5b8494cb7cf17e1a8d_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOjM3M2M0OWU5Y2RjMzRmMjRiNjRiZDg2YjFlMzU3ZTA5L3RhYmxlcmFuZ2U6MzczYzQ5ZTljZGMzNGYyNGI2NGJkODZiMWUzNTdlMDlfNC03LTEtMS0w_3caedc0f-bf22-4a37-8f1a-3a45d60757c6"
      unitRef="usd">372610000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNTAwMA_326b5964-894a-446b-a9a1-80846d923cd4">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:41.905%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.590%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Chargebacks, Discounts for Prompt Payment and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Customer Credits/Fees and Co-pay Assistance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at December&#160;31, 2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,853&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,279&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;17,404&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,536&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Provision related to sales made in:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;114,489&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,392&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,355&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;181,236&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Prior periods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(40)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(164)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,713&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Payments and customer credits issued&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(108,487)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(11,637)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(46,349)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166,473)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Balance at June&#160;30, 2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,815&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,870&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,327&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;47,012&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ie35769b7587040d5aa523942d229c867_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS0xLTEtMS0w_6fa04a40-124d-4064-96da-6d5ff159e186"
      unitRef="usd">9853000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ib42e12234ac143a0a44b01d6e7a03fe1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS0zLTEtMS0w_5e65c466-0cef-47d7-a155-9d726446b2b9"
      unitRef="usd">3279000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i48d197193a8a45b38af10e48f5f51e93_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS01LTEtMS0w_32260c8d-acbd-49b5-b939-c94fe5896688"
      unitRef="usd">17404000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMS05LTEtMS0w_ce469fcd-31d3-45d3-abfe-3a10b8865a1d"
      unitRef="usd">30536000</us-gaap:ValuationAllowancesAndReservesBalance>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy0xLTEtMS0w_fe0154d6-6754-41e0-9c55-f85d06680c86"
      unitRef="usd">114489000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy0zLTEtMS0w_940a9f48-3f06-4e51-a08d-d9398ca8d1bc"
      unitRef="usd">15392000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy01LTEtMS0w_17822436-b4f3-45ae-9018-3db457d14217"
      unitRef="usd">51355000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfMy05LTEtMS0w_8a1cd2d6-95c5-49d7-9a9d-e0042e9ca315"
      unitRef="usd">181236000</exel:ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC0xLTEtMS0w_28f2845c-82a4-42a5-b4bc-9d4bfbdd7a4b"
      unitRef="usd">-40000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC0zLTEtMS0w_7d2f7677-db3a-46ed-928b-cf308a9593c3"
      unitRef="usd">-164000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC01LTEtMS0w_f04ad7d5-bb99-4d01-887a-a560f8e3c274"
      unitRef="usd">1917000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNC05LTEtMS0w_a3011cbe-504d-4a93-99c4-bd8e223c3835"
      unitRef="usd">1713000</exel:ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i7befdb6164974b9db88347431a84c705_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS0xLTEtMS0w_6cf74253-6f72-45f1-8c2b-3f96544b3b9e"
      unitRef="usd">108487000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i8f816bb368b94833a7d09b41143f5d84_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS0zLTEtMS0w_65e97ea8-d838-47da-8c64-814c8f47ac54"
      unitRef="usd">11637000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i48b0f026980e4e8db846617663617dce_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS01LTEtMS0w_4b506085-abe9-4d85-9c5e-734f4a2a8b7f"
      unitRef="usd">46349000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesDeductions
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNS05LTEtMS0w_2abffffa-b001-47e3-b8e9-70638ef8a161"
      unitRef="usd">166473000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5ffbaddc0eb14e9991b7a519b99dcf9d_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi0xLTEtMS0w_980a897b-6b9a-49ad-83d0-5f684221f2db"
      unitRef="usd">15815000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i33ef18170a4944cd8de075cf4a5344d3_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi0zLTEtMS0w_eb74281f-1b74-4ed4-8111-a477f46f85b1"
      unitRef="usd">6870000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="ia09e442b2e1243bc84dac0b50e653260_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi01LTEtMS0w_57f7497d-a510-4d48-b454-8e02c6dde851"
      unitRef="usd">24327000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE3Zjc3ZmU4ZmMyNTRlNzA5MDg4MzlkYzRiNWYxMzIzL3RhYmxlcmFuZ2U6YTdmNzdmZThmYzI1NGU3MDkwODgzOWRjNGI1ZjEzMjNfNi05LTEtMS0w_cbe51c3a-f803-4fac-b119-740e7ece8652"
      unitRef="usd">47012000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDk5Mw_aa10d57a-dbd0-4a2d-ac26-39c0607a8dee">Contract assets and liabilities were as follows (in thousands):&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9,749&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;948&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract assets&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,697&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Contract liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,314&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,790&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,577&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total contract liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,545&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;____________________&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%"&gt;(1)&#160;&#160;&#160;&#160;Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;(2)&#160;&#160;&#160;&#160;Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMi0xLTEtMS00MjA3_d0a2ca67-2454-49ef-a3d0-8982132c1239"
      unitRef="usd">9749000</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMi0zLTEtMS00MjA3_4c9f9778-c8e8-4af8-a6b1-da694170cf3f"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetCurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMy0xLTEtMS00MjE2_5b185a04-09ba-4497-822c-f516d306aa81"
      unitRef="usd">948000</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNetNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfMy0zLTEtMS00NDQ3_ebd54bdf-06de-4a88-b544-e672d72b7605"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNetNoncurrent>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0xLTEtMS00MjE2_2895e1d2-86f4-49da-b4f7-9947e9a4c480"
      unitRef="usd">10697000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0zLTEtMS00NDQ3_f67bbf5c-298f-4b74-962a-06d35e650553"
      unitRef="usd">0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0xLTEtMS0w_0c34ea72-2d93-4876-be0b-c2635e7ee432"
      unitRef="usd">6314000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNC0zLTEtMS0w_c9fd48d5-fcf0-4425-aaf2-47dc6aa1ac54"
      unitRef="usd">1790000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNS0xLTEtMS0w_8f4ff0bb-e40b-4ec5-af30-10113159e2a8"
      unitRef="usd">8577000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNS0zLTEtMS0w_f104dffc-5b98-4599-a708-c1240cf5bb81"
      unitRef="usd">3755000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNi0xLTEtMS0w_ada91b61-3415-4a6a-bc85-eac84253fa0c"
      unitRef="usd">14891000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RhYmxlOmE2NmMzYjk4ZWRhZTRhYThiMzU1NGZiYzU0OWUxNjlmL3RhYmxlcmFuZ2U6YTY2YzNiOThlZGFlNGFhOGIzNTU0ZmJjNTQ5ZTE2OWZfNi0zLTEtMS0w_e8cbb5ec-3915-445d-83c8-d4549953bdee"
      unitRef="usd">5545000</us-gaap:ContractWithCustomerLiability>
    <exel:CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement
      contextRef="i54e9688fa5234b7dabc087b18bea682e_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzNDUwOQ_c1804dc2-a87e-4db2-87ca-b9df920b8dfa"
      unitRef="usd">12500000</exel:CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement>
    <exel:CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement
      contextRef="i7e90ca7353d7420d850374043f19414f_D20210403-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDM5ODA0NjUyMDg1OQ_9a226340-1d8a-4614-8d4b-680b815ef0fa"
      unitRef="usd">11800000</exel:CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMzg5OQ_fa7ac5d2-99f4-4711-850d-ff89a2f263ca"
      unitRef="usd">4800000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMjk4Nw_e2203119-938d-4054-a237-d588d09975c4"
      unitRef="usd">3400000</exel:ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIzMg_0d0d69ac-df56-415c-a4ce-cec43c77977a"
      unitRef="usd">40600000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDA1Nw_9723c8cd-eed8-4caf-ba82-8d5f87b81601"
      unitRef="usd">67800000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIxNQ_74ec900e-0d55-4cce-ac59-fd7dcde0cc68"
      unitRef="usd">62000000.0</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfMTA5OTUxMTYzMzIyMg_d4b7aaf9-b691-408d-a19d-5e3cb249b8c3"
      unitRef="usd">82200000</us-gaap:ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80MC9mcmFnOmQ1ZjI3Y2JhMTU1OTRiNmViMTNiNjFiZTM4MjRiOGM4L3RleHRyZWdpb246ZDVmMjdjYmExNTU5NGI2ZWIxM2I2MWJlMzgyNGI4YzhfNDQ4Mg_e3781dcb-74f4-4457-825e-a56327dc0fb7"
      unitRef="usd">86900000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTkzMg_4c3647c7-c747-46bf-9c61-1bd19128df4f">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &#x201c;Note 3. Collaboration Agreements&#x201d; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cabozantinib Collaborations&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Ipsen Collaboration &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#x2019; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#x2019;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#x2019;s ongoing development. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine differentiated thyroid cancer who have progressed after up to two VEGF receptor-targeted therapies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the terms of the Agreement, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Ipsen is now obligated to reimburse us for their share of the COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;triggered by the timing of the exercise of its option. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We determined that the decision to opt into and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the three and six months ended June 30, 2021, includes a cumulative catch up for Ipsen&#x2019;s share of global development costs incurred since the beginning of the study and through the end of the period.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$46.2 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the tr&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Takeda Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#x2019; collaboration is governed through a joint executive committee and appropriate subcommittees.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, $40.7 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;GSK and Royalty Pharma&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $12.1 million and $22.2 million during the three and six months ended June&#160;30, 2021, respectively, as compared to $7.6 million and $15.7 million in the corresponding periods in 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Collaboration&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#x2019;s ZELBORAF&#xae; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#xae; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research Collaborations, In-Licensing Arrangements and Other Business Development Activities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June 30, 2021, in support of our development pipeline, we entered into additional collaboration and in-licensing arrangements with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Limited (WuXi Bio), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $17.0&#160;million and will make payments for potential future development milestones of up to $58.5&#160;million, regulatory milestones of up to $139.0&#160;million and commercial milestones of up to $377.5&#160;million, each in the aggregate per product, as well as royalties on future net product sales. Additionally, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $5.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $9.0&#160;million payment upon closing of the transaction. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.&lt;/span&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTkxNg_9dc4ddaa-90cf-4588-a9db-577c614e469e">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Ipsen were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,656&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;33,597&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,107&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;51,546&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;57,265&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;19,320&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;68,620&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;90,921&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;52,917&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;124,727&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues under the collaboration agreement with Takeda were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;License revenues&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,097&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,398&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,946&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Collaboration services revenues&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,024&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,195&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,264&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,121&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,557&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;License revenues under the collaboration agreement with Genentech were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:39.822%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:13.780%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.990%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:11.846%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.743%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Profits on U.S. commercialization&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,376&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,783&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Royalty revenues on ex-U.S. sales&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;782&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,125&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,733&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,434&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i23ea9da53f1644eaa0a98b9259aa475f_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi0xLTEtMS0w_79b4ce6c-deb7-44ef-8e5f-b9c2cb9f3f3e"
      unitRef="usd">33656000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i9fb9e5548a364e8db87e699888c741d9_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi0zLTEtMS0w_f09eb09c-22b3-4e81-aa1a-5228ca04c886"
      unitRef="usd">33597000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iee0e69c31a264295b5d40ec7776fd3db_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi01LTEtMS0w_9dabdbc4-9f08-4b49-bb15-f41939faaec5"
      unitRef="usd">56107000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i438def86d067426f867cc300503942e3_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMi03LTEtMS0w_7fcb4f3f-aad8-4ff9-be25-9d8b558e8d46"
      unitRef="usd">51546000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="icb3fd2d979fa40adaac2298fd1f78f5d_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy0xLTEtMS0w_b7a6e799-e81f-4849-b0c3-6548321abde6"
      unitRef="usd">57265000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i85a056bb651c463991c7d6520faca86c_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy0zLTEtMS0w_e93f55ae-e656-42d1-9e0e-7517f43b0b84"
      unitRef="usd">19320000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i60418fc014944675b95a4a327939d6f7_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy01LTEtMS0w_3f416156-89b4-4ffe-9644-70218bf3d78b"
      unitRef="usd">68620000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ia354da424ce0441fa29d3af61c66a49e_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfMy03LTEtMS0w_2a236b42-f963-4869-b025-c9345a1590ff"
      unitRef="usd">30407000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7e90ca7353d7420d850374043f19414f_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC0xLTEtMS0w_816ff97e-d61a-4c92-9f5a-bd0dfab0fc97"
      unitRef="usd">90921000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="iac88bbff875241b399770a9f80cb04da_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC0zLTEtMS0w_c0cf2f08-6c67-4145-a53d-dd483056ae88"
      unitRef="usd">52917000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ide45679cbd134e15ad7dde1405959e1c_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC01LTEtMS0w_3736ea8d-c69f-4eca-a326-4d74752387d2"
      unitRef="usd">124727000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ieb8d9802463f431b8dc5673038d02b02_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmVkMjAxYjg5ZWZiNjQzZmM4ZmE5MGI4NzIxOWU4MmIzL3RhYmxlcmFuZ2U6ZWQyMDFiODllZmI2NDNmYzhmYTkwYjg3MjE5ZTgyYjNfNC03LTEtMS0w_da904eb7-ae26-45b9-8894-a301b9d2d7b6"
      unitRef="usd">81953000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i54e9688fa5234b7dabc087b18bea682e_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTg2Ng_de223a2f-d922-4eff-bb7d-775df2a0390d"
      unitRef="usd">46200000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ib4773d352b9649cf82f5f26e75db0cbd_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi0xLTEtMS0w_238d617e-03c0-43ec-b359-c4c56f2b92ca"
      unitRef="usd">2097000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0afcc09b5a14464ab0ffad06802a0d9a_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi0zLTEtMS0w_ea284596-8a55-400e-b98d-e8db2781a8f7"
      unitRef="usd">22946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0c2c134629c04167a6ee6e580563d23a_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi01LTEtMS0w_8b8da1d0-0168-4afe-8982-f038de5bce16"
      unitRef="usd">3398000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i96369905ff694894be26d03937eba3aa_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMi03LTEtMS0w_ce417e2d-b7cb-4f55-b89c-588946fb01fd"
      unitRef="usd">22946000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i4eace4464d1b4cebb1f6aa87ef46edfa_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy0xLTEtMS0w_91e5d06b-3611-460c-85f5-63c4b72c3901"
      unitRef="usd">4024000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i7c567665f16245dfbbaa6cfb4be14af9_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy0zLTEtMS0w_d99185df-8fe9-4972-b789-e0ee27b82dfb"
      unitRef="usd">2195000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ifd4fe90f4c8b4002917a160364e89c7b_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy01LTEtMS0w_4c3157a1-ecae-44fd-9bbb-35ae94a5dea1"
      unitRef="usd">8159000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i37fca3eb6b164203b94981e459883e27_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfMy03LTEtMS0w_8e0b377c-d6fd-483a-91a6-f86558e9484f"
      unitRef="usd">3264000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i6b587653d3b346778dc4850b1f98eaa1_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC0xLTEtMS0w_688adafe-b4b2-4cfd-b418-bfbea4c3c81d"
      unitRef="usd">6121000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i8682433791e74a77ab1fb7164ad65f64_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC0zLTEtMS0w_16985a81-2012-4b23-b689-612d677c11c9"
      unitRef="usd">25141000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i36f2a9ffc2004bfba433dc45cecfe4e7_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC01LTEtMS0w_dbf59149-a381-4705-9c0f-4e795ff7e05c"
      unitRef="usd">11557000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ic6774c6769c74754bf25b006ddeb034a_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmYyODI5Yzc0Yjk1YjQ4YzQ4YWEzZjMyMGU2YWQ0OTQ5L3RhYmxlcmFuZ2U6ZjI4MjljNzRiOTViNDhjNDhhYTNmMzIwZTZhZDQ5NDlfNC03LTEtMS0w_30150856-399e-4dfe-893f-b8314ab7a53b"
      unitRef="usd">26210000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="i086ec86c38f3430bbc22864119abfbea_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMzA4Mw_f23c4dda-0820-4c87-9d56-daca53e317aa"
      unitRef="usd">40700000</us-gaap:RevenueRemainingPerformanceObligation>
    <exel:CollaborationAgreementPercentOfRoyaltyOnNetSale
      contextRef="ib55ad4a520414e63a49c07b1087faa2c_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMzM4MQ_3b2f0fd8-f66f-4973-a05d-0dcba47ea093"
      unitRef="number">0.03</exel:CollaborationAgreementPercentOfRoyaltyOnNetSale>
    <us-gaap:RoyaltyExpense
      contextRef="i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzgyOQ_8be617f0-8bab-4140-b08a-f681efdb1b72"
      unitRef="usd">12100000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i3a69004f4ba64701a17a5818d5af4f24_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzg3MQ_4f859d67-afa5-4a14-ab41-07a0c7b3ef63"
      unitRef="usd">22200000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="ib115b2c1778640cc80452356877f9218_D20200404-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzgzOA_450acd63-9b13-4cfb-8d3f-c20ad8407327"
      unitRef="usd">7600000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense
      contextRef="i957e8d926e9948e49c867df19f90d50a_D20200104-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTYzMzg1Mw_18d30672-532e-4c8d-b23b-14bc0b3af70b"
      unitRef="usd">15700000</us-gaap:RoyaltyExpense>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi0xLTEtMS0w_c9ea6dfb-5729-45c9-b76b-d29ed7896b9e"
      unitRef="usd">2160000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi0zLTEtMS0w_8b263e16-ac3b-496a-a9f2-db7c942fb2a2"
      unitRef="usd">1376000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi01LTEtMS0w_9b3ed2aa-2532-4148-8568-9a9b6d6b4cbe"
      unitRef="usd">3954000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <exel:CollaborativeArrangementIncomeLossFromAgreement
      contextRef="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMi03LTEtMS0w_c4d94e10-e359-4dca-b34f-ae5599fd75b0"
      unitRef="usd">2783000</exel:CollaborativeArrangementIncomeLossFromAgreement>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy0xLTEtMS0w_d44968e4-c737-4860-ab8a-75e4985951a5"
      unitRef="usd">782000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="id19a119ecd3a45faa32c28a0d1c204b6_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy0zLTEtMS0w_12b613bd-ea8a-48b4-9616-9648e32a470a"
      unitRef="usd">1125000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="ida10824f34dc49dd8f2239961ce221e3_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy01LTEtMS0w_000c6dd8-603c-44be-b41e-f0adbfcd8692"
      unitRef="usd">1733000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="i5f8577f744df48dfa3e027962cc54ac5_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RhYmxlOmEyNzk2NmU1YzEzNDRhZjdhY2JjNjE2Mjk1Nzc2ZGIxL3RhYmxlcmFuZ2U6YTI3OTY2ZTVjMTM0NGFmN2FjYmM2MTYyOTU3NzZkYjFfMy03LTEtMS0w_31072183-f21e-4336-9f88-7ac6492969e6"
      unitRef="usd">2434000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMjc0ODc3OTEwNDE2OA_7904c9c8-8361-42ae-b25b-3d09df5be190"
      unitRef="usd">17000000.0</exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNDM5ODA0NjUzOTk4OA_9c3b3ed9-f537-41d6-a159-5a9bf1486097"
      unitRef="usd">58500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMjc0ODc3OTEwNDE4NQ_9ef618a1-fb5e-4a9d-ab6a-ede39f12af4a"
      unitRef="usd">139000000.0</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments>
    <exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfNTQ5NzU1ODE2NTQ4Nw_fbe22b1c-147d-4056-ae48-4f63ef090c87"
      unitRef="usd">377500000</exel:CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="ic78371ad98574f0f8204b52ff32e63c9_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQyMQ_c691202a-cfab-4d72-ba9f-5432e32e9493"
      unitRef="usd">5000000.0</us-gaap:PaymentsToAcquireProductiveAssets>
    <exel:AssetAcquisitionPaymentUponClosingOfTransaction
      contextRef="iceb9d21701e5414cadd958696df005c4_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQ1MA_97c2bcbd-521e-41ba-9830-3665628b5ca6"
      unitRef="usd">9000000.0</exel:AssetAcquisitionPaymentUponClosingOfTransaction>
    <exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments
      contextRef="iceb9d21701e5414cadd958696df005c4_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQzNQ_07838d51-b441-4207-81f2-55374fe37fea"
      unitRef="usd">42000000.0</exel:AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments>
    <exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments
      contextRef="iceb9d21701e5414cadd958696df005c4_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80My9mcmFnOjgyYjJlNzlkMGU3YzQ1YmJhMjYxMjhlZjMwNmQ3NTdkL3RleHRyZWdpb246ODJiMmU3OWQwZTdjNDViYmEyNjEyOGVmMzA2ZDc1N2RfMTA5OTUxMTY2MjQ2NA_d6a57e62-8a60-4006-9368-de20799d9ec7"
      unitRef="usd">22500000</exel:AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments>
    <us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Nw_d9ba2e99-bab0-4e5f-b0e4-dd57d47bceef">CASH AND INVESTMENTS&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents and Restricted Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of June&#160;30, 2021, restricted cash equivalents included $45.3&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash, Cash Equivalents, Restricted Cash Equivalents and Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Interest receivable was $3.3 million and $4.5 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2021 and 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All securities presented have been in an unrealized loss position for less than 12 months. There were 53 and 14 investments in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020, respectively. During the six months ended June&#160;30, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY3NA_f5a1af70-e1cf-4d13-916d-7a5e32ca46ee">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Mw_8f00ab4a-cd84-4442-b58a-39d9d9303089">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,462&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;319,217&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash equivalents included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46,839&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,555&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;539,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;320,772&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMS0xLTEtMS0w_d462ec24-af44-4c99-a2e8-210d174d5caf"
      unitRef="usd">492462000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMS0zLTEtMS0w_60bae02c-dd08-4faa-ab1a-1ff1d68da303"
      unitRef="usd">319217000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMy0xLTEtMS0w_914b60d0-47a0-4589-a9c6-d4c08b013763"
      unitRef="usd">46839000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashEquivalentsNoncurrent
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfMy0zLTEtMS0w_8bed8d7a-48ac-4b82-91ca-ccb5eedf10db"
      unitRef="usd">1555000</us-gaap:RestrictedCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfNC0xLTEtMS0w_7d6cae72-e277-4fc6-944e-46d7603caec5"
      unitRef="usd">539301000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjE4MzI4N2M0NDVjYzQ2NDc5NDEwZjA3OGQ2ZThlMWYwL3RhYmxlcmFuZ2U6MTgzMjg3YzQ0NWNjNDY0Nzk0MTBmMDc4ZDZlOGUxZjBfNC0zLTEtMS0w_66274bec-c86f-4f04-8451-eebf0b5162e9"
      unitRef="usd">320772000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:RestrictedCashEquivalentsCurrent
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfNDM5ODA0NjUxNDE3NA_1114a399-4bf2-483d-8dbb-a9cca16bd818"
      unitRef="usd">45300000</us-gaap:RestrictedCashEquivalentsCurrent>
    <us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY5Mg_4c039127-4aac-4fd1-84a7-f0bc3850baa7">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;716,916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;489,678&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,630&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,352,891&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;88,511&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,736,414&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,855&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,739,086&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:49.495%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.808%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Debt securities available-for-sale:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,456&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;372&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;543,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,244&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,326&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;232&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,680&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;83&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,349,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;82,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total cash, cash equivalents, restricted cash equivalents and investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,532,923&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,931&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,538,842&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy0xLTEtMS0w_5c3dd2e9-5ce6-4432-8b9d-2f8aa4e62c05"
      unitRef="usd">716916000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy0zLTEtMS0w_7f416c26-e5c5-46f5-892d-a5d3d76f0cb2"
      unitRef="usd">141000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy01LTEtMS0w_b27da61a-8b9a-4ea9-ba3c-81b31fd439fd"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMy03LTEtMS0w_6dc7e7c9-9fbf-43db-8604-e7a69be47e61"
      unitRef="usd">717057000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC0xLTEtMS0w_7dc91d2f-fa8c-448c-bcbb-21b74f849ad4"
      unitRef="usd">489678000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC0zLTEtMS0w_644a6442-2847-4e5e-bfdb-f9a45142a0e0"
      unitRef="usd">2630000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC01LTEtMS0w_4e9a4efa-92c6-4807-b66b-472be6e58c37"
      unitRef="usd">166000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNC03LTEtMS0w_ec2e821d-26e1-4e3e-9721-5e6fa1e4a2ae"
      unitRef="usd">492142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS0xLTEtMS0w_bf09a0b6-d05b-456f-b4ab-57a4d1dd2d18"
      unitRef="usd">132036000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS0zLTEtMS0w_3be1d1d7-6095-4a71-9a4e-1c3ef3cfad7c"
      unitRef="usd">43000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS01LTEtMS0w_46a38210-f38d-493e-bb4f-5ef5965b501e"
      unitRef="usd">13000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNS03LTEtMS0w_a3a3cfcb-77e5-40a9-86d0-6b4d2bae0710"
      unitRef="usd">132066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi0xLTEtMS0w_d7f98ac5-082c-4e91-82c6-442da34f73ae"
      unitRef="usd">14261000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi0zLTEtMS0w_88a4935e-292a-4995-a63d-a12f0f149719"
      unitRef="usd">41000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi01LTEtMS0w_9c74ae89-b962-4040-bba6-056a9032106b"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNi03LTEtMS0w_82e6583f-909c-4d01-9687-7ceab5ffd4ff"
      unitRef="usd">14298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy0xLTEtMS0w_7720ecab-6a25-4610-ae4e-22eb617a7f43"
      unitRef="usd">1352891000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy0zLTEtMS0w_dcac80b7-f61d-4c33-8f7f-3d8ff67d09f8"
      unitRef="usd">2855000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy01LTEtMS0w_c9af8221-5f9c-4591-9634-c24c8edd5c57"
      unitRef="usd">183000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfNy03LTEtMS0w_8952f002-9c04-4dfa-a4b8-3ad27848f4ee"
      unitRef="usd">1355563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC0xLTEtMS0w_c411440a-df29-47bb-ab7f-b4b5037807d2"
      unitRef="usd">88511000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC0zLTEtMS0w_1d325f93-b46b-4b1c-b0c0-5732b3e40ae9"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC01LTEtMS0w_9ce27b81-2e63-4d6a-aa1f-6896be85635f"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="id37c5c0878604fd4a7ac63cf01049767_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOC03LTEtMS0w_72b50ef0-d38e-4740-b347-d045995c620d"
      unitRef="usd">88511000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS0xLTEtMS0w_67580807-a798-4e3d-a932-2a096193d9d1"
      unitRef="usd">179306000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS0zLTEtMS0w_9bdca96f-6a54-4e21-b4f7-cd9951b8f1ea"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS01LTEtMS0w_b064ee71-0708-4285-822a-cae6c5c3ba8a"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="ia4f74740d9b3489982fe849d428b0c61_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfOS03LTEtMS0w_d920dcb9-4629-4565-a0ed-216209066eae"
      unitRef="usd">179306000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMS0xLTEtMA_05147d24-52b7-4f60-a6c4-63134a329f56"
      unitRef="usd">115706000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2a7078826e91452db52a24c7cbbe97de_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMS0xLTEtMA_98982da9-e5b2-4cc5-955d-a9ba552cb5fb"
      unitRef="usd">115706000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtMy0xLTEtMA_26cbb1cb-41e7-449b-8716-7ab6233bdf55"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtNS0xLTEtMA_ef878214-fe83-4119-8899-dfa085a315b0"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTAtNy0xLTEtMA_8b585b05-c8b2-408b-82f9-93b46f641d7e"
      unitRef="usd">115706000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtMS0xLTEtMA_e5ba80bd-5b7f-4662-9d01-eda832097e87"
      unitRef="usd">1736414000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtMy0xLTEtMA_d9975c48-a0a1-4e56-9b34-5f3699492097"
      unitRef="usd">2855000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtNS0xLTEtMA_ef78bacf-8dfd-4db2-82e5-757e17f0d820"
      unitRef="usd">183000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjdlNDRmNGVhYWM0NzRmNDQ5NTRiYTQzOTY0NDY0NWU3L3RhYmxlcmFuZ2U6N2U0NGY0ZWFhYzQ3NGY0NDk1NGJhNDM5NjQ0NjQ1ZTdfMTEtNy0xLTEtMA_eeb7fe1c-6a3e-4a75-ade1-3197ee5e844d"
      unitRef="usd">1739086000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy0xLTEtMS0w_c5165d0c-159b-4784-b177-450c4e21cf3b"
      unitRef="usd">569456000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy0zLTEtMS0w_888d813b-9282-42bb-92cc-704508041a11"
      unitRef="usd">372000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy01LTEtMS0w_c060d0ea-3360-4053-b8dc-982be58149a7"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i149eb5d8fd5e40fa9fb480344495f84a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMy03LTEtMS0w_caa4a8ed-69b9-4555-b95b-269c028c9207"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC0xLTEtMS0w_999a6765-e80c-4bc6-bc08-0fe304d092bb"
      unitRef="usd">543520000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC0zLTEtMS0w_160b93e9-dd71-4439-b700-9c902439199a"
      unitRef="usd">5244000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC01LTEtMS0w_dafd6fc2-de84-4725-8ce3-430e98391154"
      unitRef="usd">7000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNC03LTEtMS0w_d0d1f49d-1870-4f57-9e4d-c92e19a6b89d"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS0xLTEtMS0w_5ebeb4c3-0fc6-4724-b782-19f3d1b631e8"
      unitRef="usd">208326000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS0zLTEtMS0w_81c0530c-22a4-47b3-84dd-b45e700652e9"
      unitRef="usd">232000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS01LTEtMS0w_f290d5c6-084c-4c88-a0fb-26ef84053cb5"
      unitRef="usd">4000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNS03LTEtMS0w_f50548fe-3d4c-4e08-bfc4-3c3449a43d00"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi0xLTEtMS0w_ded18d6b-4bc5-43d6-9a0f-a0ff0bc679d9"
      unitRef="usd">28680000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi0zLTEtMS0w_da15b30f-43e9-42a7-bb80-ffbe0437cb31"
      unitRef="usd">83000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi01LTEtMS0w_46069ec7-bbed-41b4-8e01-9791d8464f07"
      unitRef="usd">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNi03LTEtMS0w_0278336f-73ad-43d7-9b93-9aa478e89dce"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy0xLTEtMS0w_79194393-49ff-40cc-8bae-27a82f9630a0"
      unitRef="usd">1349982000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy0zLTEtMS0w_bc4a8cae-c8c9-4f24-a658-854b618b7393"
      unitRef="usd">5931000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy01LTEtMS0w_fdef1bfa-b923-412d-9bd2-10673f1ba96f"
      unitRef="usd">12000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfNy03LTEtMS0w_85aded54-1843-48bc-bb08-f28c69848896"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i8eec5258de424553baf107e5e554b35a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC0xLTEtMS0w_a40c071a-fba8-46dc-b393-73c20eab4a76"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i8eec5258de424553baf107e5e554b35a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC0zLTEtMS0w_ccecf450-1369-4346-a60c-bcfc0d0f6774"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i8eec5258de424553baf107e5e554b35a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC01LTEtMS0w_c482e138-fae4-49a7-a4b5-f64eb4fb7968"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i8eec5258de424553baf107e5e554b35a_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOC03LTEtMS0w_948e09b7-1df8-4489-967e-416e2f755fe4"
      unitRef="usd">82176000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i56912199faad49c0be4543e8883c2d26_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS0xLTEtMS0w_91b01a63-5991-43a4-bc13-425511941865"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="i56912199faad49c0be4543e8883c2d26_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS0zLTEtMS0w_9acedf7c-ec8e-4bbd-b2c6-2547ca765834"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="i56912199faad49c0be4543e8883c2d26_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS01LTEtMS0w_64c244a7-f7ca-47e3-8b09-4ec753342dbf"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="i56912199faad49c0be4543e8883c2d26_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfOS03LTEtMS0w_2bc9c4a7-af97-4fc8-86a6-067972ae10f4"
      unitRef="usd">40761000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtMS0xLTEtMA_aefac6cf-73f3-4ace-b6a6-d565199953c6"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain
      contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtMy0xLTEtMA_4dee9000-8a8e-49a7-8647-d6a374981c0b"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss
      contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtNS0xLTEtMA_6ba02ce2-8a42-42a7-80a7-6d01f71182c8"
      unitRef="usd">0</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure
      contextRef="iedb4d96362ae4f3ea84cba6dc5edaa3b_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTAtNy0xLTEtMA_a466af2a-961b-4711-b9a1-dd37d6739656"
      unitRef="usd">60004000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtMS0xLTEtMA_398a8ec6-96e4-4ec9-93bc-9ae28d8fb618"
      unitRef="usd">1532923000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtMy0xLTEtMA_ebb62359-b010-4601-97d1-df77b582c413"
      unitRef="usd">5931000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtNS0xLTEtMA_51bbfd73-816d-4455-b775-cf0250714231"
      unitRef="usd">12000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjY4MDNjYmQ3NzMzNDRkYWJhNzYyYjg2ZGZjYWM2NzUwL3RhYmxlcmFuZ2U6NjgwM2NiZDc3MzM0NGRhYmE3NjJiODZkZmNhYzY3NTBfMTEtNy0xLTEtMA_9ca204db-7504-4c64-a347-a62ea4902130"
      unitRef="usd">1538842000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities>
    <us-gaap:InterestReceivable
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTE5NQ_c89acd81-18d7-4640-b4af-c7079b331339"
      unitRef="usd">3300000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTIwMg_7c911998-466b-4ebc-882e-31cab7974d49"
      unitRef="usd">4500000</us-gaap:InterestReceivable>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY1Nw_181d2b2e-f86a-4c76-a67c-8c2f5e6eeed3">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.376%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.692%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,002&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;154,767&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(166)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;38,088&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(13)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,897&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;199,754&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(183)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.227%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.841%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Gross Unrealized Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,445&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21,989&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,865&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(12)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMi05LTEtMS0w_6158ad44-84fb-4610-904f-7d76393b2519"
      unitRef="usd">1002000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i09bcb5c048774ea58a3a925f982a1ee1_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMi0xMS0xLTEtMA_cb763301-4aaa-48bf-b571-01f8bfbfd611"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMy05LTEtMS0w_dfa14272-ce11-4108-ab54-0786cea49648"
      unitRef="usd">154767000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ic65851a71fcb4a37a10e68a564581e81_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfMy0xMS0xLTEtMA_c4cf9bbc-e662-4325-bc87-f115db1e4911"
      unitRef="usd">166000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNC05LTEtMS0w_b5ac856b-a857-4427-ba3f-d8e35e019f9b"
      unitRef="usd">38088000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="ib0a0cc5004514d9f8a6f7faf599b321e_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNC0xMS0xLTEtMA_a0b63407-1c80-4d72-9c03-27cf749d6a30"
      unitRef="usd">13000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNS05LTEtMS0w_c39f007a-fc0c-445b-8b9d-2ca7ce20da23"
      unitRef="usd">5897000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNS0xMS0xLTEtMA_fff6e5f3-35bd-4aa5-869e-9847f5b6a255"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNi05LTEtMS0w_6853b8d2-a843-45ba-b30f-3d0b7f790c34"
      unitRef="usd">199754000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjk5YTY0MGZlYzFkNDRkNWE5YmRhNjIyNTdkM2I5NDY3L3RhYmxlcmFuZ2U6OTlhNjQwZmVjMWQ0NGQ1YTliZGE2MjI1N2QzYjk0NjdfNi0xMS0xLTEtMA_40845f31-6b5d-4a94-92a1-3ec61bb53599"
      unitRef="usd">183000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMi05LTEtMS0w_d2a47a0a-a0dc-41cb-8ed2-de4928fd957a"
      unitRef="usd">28445000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i6fe4968ea10a4a2e846882843c6487fa_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMi0xMS0xLTEtMA_22472bf4-f99c-434f-a930-d1395ef526e9"
      unitRef="usd">7000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMy05LTEtMS0w_356876cb-be1c-4757-8652-4b6b27fe2a46"
      unitRef="usd">21989000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i59ae6b1df6274fec86aaf9ceb876e1b1_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfMy0xMS0xLTEtMA_0b6c7c99-e302-4ba6-9247-3507e48f87f2"
      unitRef="usd">4000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNC05LTEtMS0w_77d00f6c-6668-45f1-a78b-d2a000855d4d"
      unitRef="usd">5865000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i8c46dcfba0fc4cd19a6824880aa5fbae_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNC0xMS0xLTEtMA_8d48e06d-47a6-4250-b70a-93baac214103"
      unitRef="usd">1000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNS05LTEtMS0w_4a15e477-96f9-4e5b-8581-a7fcf73a6bc8"
      unitRef="usd">56299000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOmI2NjVjZGE4NGMxNDQ5OTc5YTA5MDdlOTlkYThlNzg4L3RhYmxlcmFuZ2U6YjY2NWNkYTg0YzE0NDk5NzlhMDkwN2U5OWRhOGU3ODhfNS0xMS0xLTEtMA_4330977c-538c-48e3-9ee7-f3d1ccec0391"
      unitRef="usd">12000</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTkyNg_72f1392c-c8ca-41e9-9ddd-5099542369f6"
      unitRef="investment">53</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMTkzMw_a286dba6-1f8b-4682-89fc-a39628bcc0ac"
      unitRef="investment">14</us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjA0Mg_520fa795-6a7f-42b3-b884-72aed8d60dca"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="ia8f9fa82236043fe887f9ad585c7a6cc_I20200703"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjA0Mg_8b6f7313-8ab0-457e-917c-0570f549d287"
      unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RleHRyZWdpb246OWFhYzM5N2VhMGE5NDIzZDg2ZjU3MGZmN2U5Y2MxZWFfMjY4Mg_9aa6e840-5943-4daf-9c49-176ea097cdb0">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing in one year or less&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,015,650&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,034,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Maturing after one year through five years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;339,913&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;321,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMS0xLTEtMS0w_8dfe1b34-3d6d-4cbb-bdbb-892500a13802"
      unitRef="usd">1015650000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMS0zLTEtMS0w_910200c0-f091-48c8-be2e-1b0228c28b0f"
      unitRef="usd">1034150000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMi0xLTEtMS0w_dac28f7d-69c9-4083-b2f1-5a7f7d0e987d"
      unitRef="usd">339913000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMi0zLTEtMS0w_7d1d9130-b587-4e0e-b04b-0821e8ab000c"
      unitRef="usd">321751000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMy0xLTEtMS0w_24d7bc21-056f-4f66-a478-435705c19afa"
      unitRef="usd">1355563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV80Ni9mcmFnOjlhYWMzOTdlYTBhOTQyM2Q4NmY1NzBmZjdlOWNjMWVhL3RhYmxlOjhmYTE4NDcxNTkxMzQ4NmFhMmJiOTg0M2E5NTM0ODhjL3RhYmxlcmFuZ2U6OGZhMTg0NzE1OTEzNDg2YWEyYmI5ODQzYTk1MzQ4OGNfMy0zLTEtMS0w_1b0b96c5-f433-4522-9e9b-a7266034dc10"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTUzOQ_b87a422c-3a57-436f-9c49-73abca8f9caf">FAIR VALUE MEASUREMENTS&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt"&gt;Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:72pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Forward Foreign Currency Contracts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021, we had one forward contract outstanding to sell &#x20ac;9.3&#160;million. The forward contract has a maturity of three months, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of June 30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June&#160;30, 2021, we recognized $0.3&#160;million net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTU0MQ_3c426857-b32e-435f-883a-356532e98888">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;717,057&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;492,142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;132,066&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,706&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;179,306&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,471,269&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,650,575&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:61.995%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.804%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:10.807%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level&#160;2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Commercial paper&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;569,828&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;548,757&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S. Treasury and government-sponsored enterprises&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;208,554&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Municipal bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,762&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total debt securities available-for-sale&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,355,901&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Money market funds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Certificates of deposit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60,004&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total financial assets carried at fair value&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40,761&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,415,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,456,666&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="icc9727a7b4814f58b8af72b38460bca0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi0xLTEtMS0w_4ebe6a17-f6e7-40df-b3f4-622c77caf1a3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i4e91c1139a56409d95f01dc2177e91d2_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi0zLTEtMS0w_3c89bf87-cf8d-4ea3-9a67-807f50110fa6"
      unitRef="usd">717057000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="id53a0786827d478e814c805cc8cd0afb_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMi01LTEtMS0w_223057d7-fe1b-4ed0-9eed-52a982a29389"
      unitRef="usd">717057000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9dc7c2c162434fe38126e2d6f15ae9bb_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy0xLTEtMS0w_3276386e-1052-435c-a41b-878128a5dcb3"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i950c47d917ec494488175b4cdbe0c129_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy0zLTEtMS0w_e04af92e-f2fc-4d5c-8116-68c011f0c62a"
      unitRef="usd">492142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i550ee82623734ffe9f05bdbde43fba7d_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfMy01LTEtMS0w_b9b2d5a5-371e-436b-8992-897f266fe00a"
      unitRef="usd">492142000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iad4faa5c3b4a426aad73596700ef7140_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC0xLTEtMS0w_cc71a6a4-1575-4ffb-9afe-7c0e344962de"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iffc0af7755c040318682d07ce7adc16d_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC0zLTEtMS0w_a86416a8-efc2-4a04-aa22-a06d9c9ed04d"
      unitRef="usd">132066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i6c48c5faa613472abda97540d85b1a43_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNC01LTEtMS0w_98fa3b20-780d-4f79-afd5-2917c750ad93"
      unitRef="usd">132066000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac6e199ed30442d3aea617ff04d7c031_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS0xLTEtMS0w_c9d3e6ee-6c9e-4155-9a59-c5d1e738fe19"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7bda6107aee140518bf785e603a9f752_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS0zLTEtMS0w_82e6583f-909c-4d01-9687-7ceab5ffd4ff"
      unitRef="usd">14298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i3a06f360ba44412d9bbdf897884ec918_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNS01LTEtMS0w_04c8c780-54a4-4a3e-84da-6cf040e7e14f"
      unitRef="usd">14298000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i68ab09d76ab342579d2258fdbf2c378c_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi0xLTEtMS0w_d874db70-4d79-40f9-81c5-af85f5ce29fa"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i353b0bfaee7d45d3976a470abaef3b27_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi0zLTEtMS0w_7bb62a30-6cff-444f-8285-76cb692d7955"
      unitRef="usd">1355563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i7549b8270e70414ca9988e4dbb8aa47f_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNi01LTEtMS0w_d2dc349c-ce42-4c4d-bfa1-7a3992d72359"
      unitRef="usd">1355563000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i461e78644dac46b59b980d4bf5e337b4_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0xLTEtMS0w_1ca713e6-f214-426f-bb84-179b66baa36c"
      unitRef="usd">179306000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i461e78644dac46b59b980d4bf5e337b4_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0xLTEtMS0w_fd1c3b5f-4569-44ce-bece-4fb03f1e188e"
      unitRef="usd">179306000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i5b52c97911274efa88b507b4b137edec_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy0zLTEtMS0w_b5d7c539-4d28-42c3-aace-dc6e8297579d"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="ic67977ad378747debfe28bbf32306bd3_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfNy01LTEtMS0w_5063f8b5-944c-42f6-88bd-724f5a9450f8"
      unitRef="usd">179306000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i6cfecbfae6504e7dac8dae1b622df61b_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0xLTEtMS0w_474cf517-a7b6-4c19-a833-5341845c3457"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost
      contextRef="i4acd99a8477349aa9356042fc2d2b74a_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0zLTEtMS0w_05147d24-52b7-4f60-a6c4-63134a329f56"
      unitRef="usd">115706000</exel:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i2a7078826e91452db52a24c7cbbe97de_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC0zLTEtMS0w_98982da9-e5b2-4cc5-955d-a9ba552cb5fb"
      unitRef="usd">115706000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iae9f679824f7428da09abd42de1550ae_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOC01LTEtMS0w_edc4bdf5-b644-40ba-afe5-825b015df06a"
      unitRef="usd">115706000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i68ab09d76ab342579d2258fdbf2c378c_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS0xLTEtMS0w_437b9ae6-df13-454f-a751-e2c9b963e39a"
      unitRef="usd">179306000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i353b0bfaee7d45d3976a470abaef3b27_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS0zLTEtMS0w_2efff23e-85e9-4334-880a-08a350564470"
      unitRef="usd">1471269000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i7549b8270e70414ca9988e4dbb8aa47f_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOjE5YWE3NzQzNjNlYjQ3YWU5MjY5NTZmNmE5ZGJiNjc4L3RhYmxlcmFuZ2U6MTlhYTc3NDM2M2ViNDdhZTkyNjk1NmY2YTlkYmI2NzhfOS01LTEtMS0w_00a3c5fd-3302-4be9-96ce-6148a4a1568a"
      unitRef="usd">1650575000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib1444ac4a7464905b1d3c72e3eadd436_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi0xLTEtMS0w_44035070-5eb6-4948-b0cb-14f310f9d62c"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9acdde179aaf4fdc8bbfce84bea41c94_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi0zLTEtMS0w_5c18dc12-13c7-486d-9db6-ef1544dc1c87"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i284bab61e8734898a70c2fcec89c67c2_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMi01LTEtMS0w_2a5d2f62-771f-4c04-97cc-c47cc0cdaf96"
      unitRef="usd">569828000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i5ed62cb99076473f80954b556b50f8c4_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy0xLTEtMS0w_c5faa5e8-2d4a-4c92-90e9-9b4bed2de196"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iac2529e3f7d44eb5a9f3e462363e4bef_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy0zLTEtMS0w_030eb8f2-d431-4b3b-b4a5-13ad742117cc"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i8290d5383c23424f8de0d1411e5defda_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfMy01LTEtMS0w_b10419b4-e96f-4f18-9d9b-07c7d653f4b1"
      unitRef="usd">548757000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iaf572e25486645ec8191ae913a4d5273_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC0xLTEtMS0w_4bcecf20-dba7-46c4-9c4c-2fd26b4e062a"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i9ecbc8770d4f4636ac3bd47cc6e7a318_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC0zLTEtMS0w_075c9215-9669-412c-9867-cd357a903efe"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i60c12cafde1f455185fb18b04e0ee5cf_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNC01LTEtMS0w_7fb6ac2a-d705-4825-98e6-725f7625d5c4"
      unitRef="usd">208554000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="if81d88ee2f624302a41cbb273629023e_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS0xLTEtMS0w_a3adcad3-0af8-41c0-a9db-14f0d0053222"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ib31966a54bf84f61b847e6dc212903cc_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS0zLTEtMS0w_d2e55348-725c-453c-ae09-b4fcb305857f"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="iace3e234989f44a18209f335a3858e67_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNS01LTEtMS0w_7ca58488-0f27-44f6-911f-f689362475c8"
      unitRef="usd">28762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="ibf3b9823001c4ababc937b8119958bcd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi0xLTEtMS0w_f1dc07cd-c650-4844-bc90-3b53af083f81"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i18e4500f722142808c3c50a9a09c4590_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi0zLTEtMS0w_05498bcf-cdfa-472c-807d-cfe491cb0423"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="i10577d8c6f0a44c29a3ded5c80584629_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNi01LTEtMS0w_23be8567-e16e-4b11-bc57-8c9190bd91c5"
      unitRef="usd">1355901000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i10fce4b7140142ae8b453252c5a9aa1f_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy0xLTEtMS0w_7c4177ec-26ff-431e-a964-e2aa9bb3dffe"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaed63e180d5c44929716ad53c8d1a9a3_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy0zLTEtMS0w_cc37beb4-be9d-4811-bead-a12bd63f687e"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i98ada18f5c9f4383a40c65d6ad47b375_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfNy01LTEtMS0w_389c38a3-abf8-45fa-9559-79df90d9da17"
      unitRef="usd">40761000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="iaf994d5e216c490ebc4de2ede7eb66ab_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC0xLTEtMS0w_94c71f58-754d-49d3-af31-1a147df838dd"
      unitRef="usd">0</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i94140ba1405e4bbabc2a2ce63c52a2cf_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC0zLTEtMS0w_50b75ade-66ee-4ea7-a9fb-861a00ecb057"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="i43efb9d920154cdd94ec40616b7279ab_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOC01LTEtMS0w_559e802b-1fa4-47bd-b715-c9bec0576fd0"
      unitRef="usd">60004000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="ibf3b9823001c4ababc937b8119958bcd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS0xLTEtMS0w_11d17575-2ce8-43c8-bbab-1cb686a66e0e"
      unitRef="usd">40761000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i18e4500f722142808c3c50a9a09c4590_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS0zLTEtMS0w_0a4893b2-45c3-4001-8aa9-54d5e14eee08"
      unitRef="usd">1415905000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="i10577d8c6f0a44c29a3ded5c80584629_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RhYmxlOmIyNmEzMGNiZGM2ODRkZjU5OTQxYTQ2MzhiZDMyNGE1L3RhYmxlcmFuZ2U6YjI2YTMwY2JkYzY4NGRmNTk5NDFhNDYzOGJkMzI0YTVfOS01LTEtMS0w_ebea89d4-cc87-427c-be58-e23f813be51c"
      unitRef="usd">1456666000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:DerivativeNumberOfInstrumentsHeld
      contextRef="ic668b647625e4bde9c974a9c70e123ee_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYyOTY0Nw_cc97c475-275c-48cc-a9e7-1dd5cbbbdd0a"
      unitRef="forwardcontract">1</us-gaap:DerivativeNumberOfInstrumentsHeld>
    <us-gaap:DerivativeNotionalAmount
      contextRef="ic668b647625e4bde9c974a9c70e123ee_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYzMDI2NQ_010e298b-34eb-4d05-8e56-77f5e1c47075"
      unitRef="eur">9300000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeTermOfContract
      contextRef="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYyOTc0Ng_f887782b-8472-4934-9674-52fecfbf24ce">P3M</us-gaap:DerivativeTermOfContract>
    <us-gaap:GainOnDerivativeInstrumentsPretax
      contextRef="i02c097b3b64b4bf6a995717bfec329f6_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81Mi9mcmFnOjE4MTkyMDFiMDYyZjQ5NDVhNmE0YmQ4MzRkMmVkNzVmL3RleHRyZWdpb246MTgxOTIwMWIwNjJmNDk0NWE2YTRiZDgzNGQyZWQ3NWZfMTA5OTUxMTYzMDA5NQ_c8ef9f0f-70e5-4ecb-9538-6c665a6748ca"
      unitRef="usd">300000</us-gaap:GainOnDerivativeInstrumentsPretax>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTkx_27dd3665-0964-48b9-b4fb-ecc57a24e7ad">INVENTORY&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Write-downs related to excess and expiring inventory were $2.3 million and $1.3 million for the six months ended June&#160;30, 2021 and 2020, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTg2_7d449ade-8bdd-4513-8c0c-7c5b182eed4c">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Inventory consisted of the following (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:64.673%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.715%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:15.717%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;June 30, 2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;December 31, 2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Raw materials&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,773&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;25,951&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,610&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"&gt;Balance Sheet classification:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Current portion included in inventory&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;24,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;20,973&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Long-term portion included in other long-term assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,461&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,701&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;41,443&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35,674&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterials
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMS0xLTEtMS0w_78cbe570-344f-46e9-9f92-4b28153392a9"
      unitRef="usd">6905000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryRawMaterials
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMS0zLTEtMS0w_1effd33e-c7db-4273-a367-c9fb7002dbf0"
      unitRef="usd">7773000</us-gaap:InventoryRawMaterials>
    <us-gaap:InventoryWorkInProcess
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMi0xLTEtMS0w_38f6d464-918e-4d00-8e07-acea4b1004c0"
      unitRef="usd">25951000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryWorkInProcess
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMi0zLTEtMS0w_39b7735d-9833-4da9-a9fa-89b7b642a075"
      unitRef="usd">20610000</us-gaap:InventoryWorkInProcess>
    <us-gaap:InventoryFinishedGoods
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMy0xLTEtMS0w_c64a90dc-28a6-48fc-8c49-238f99429319"
      unitRef="usd">8587000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryFinishedGoods
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfMy0zLTEtMS0w_adef18bb-72d2-4a28-bac7-5c32c903d1b3"
      unitRef="usd">7291000</us-gaap:InventoryFinishedGoods>
    <us-gaap:InventoryGross
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNC0xLTEtMS0w_83857c20-4024-446f-b306-d6db72e7114c"
      unitRef="usd">41443000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNC0zLTEtMS0w_e9ed5723-a8a7-484d-b82f-f5444f91ec7d"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i38f66ecf6b3d46bfbf2bdb0f567643a6_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNy0xLTEtMS0w_56d64eab-c8a3-4fce-ad36-d597dcef95d9"
      unitRef="usd">24982000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i3a9ad4a65b6e4c889ee3d1e4d70baafd_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfNy0zLTEtMS0w_2484182e-6123-41dd-a856-24a14c6d7fb4"
      unitRef="usd">20973000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i01981fa8e6c344ba974b2f8d40f68058_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOC0xLTEtMS0w_96f4ba4f-3120-482f-8be7-f147487eb2b2"
      unitRef="usd">16461000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="ie6f3c04a508a4cfcada935eafb00cbba_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOC0zLTEtMS0w_cb17408a-2cab-4310-b7e2-b839ac516324"
      unitRef="usd">14701000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOS0xLTEtMS0w_4a0d3b5d-9d51-4d7a-8162-0715d10218b7"
      unitRef="usd">41443000</us-gaap:InventoryGross>
    <us-gaap:InventoryGross
      contextRef="i7d18f1537d8b43a38ece66de91e63886_I20210101"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RhYmxlOjQ5MGRiNjEzNDc3YzQzMzA5NzJlNzBlMGVkYWY4ZjgyL3RhYmxlcmFuZ2U6NDkwZGI2MTM0NzdjNDMzMDk3MmU3MGUwZWRhZjhmODJfOS0zLTEtMS0w_e3c4ba18-3102-482f-9690-3246f3a78729"
      unitRef="usd">35674000</us-gaap:InventoryGross>
    <us-gaap:InventoryWriteDown
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTM2_d6bb2afc-1da6-4750-bd65-eb08fc1ca97b"
      unitRef="usd">2300000</us-gaap:InventoryWriteDown>
    <us-gaap:InventoryWriteDown
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81NS9mcmFnOjE4MTJhZDAwNTEwMjQwZWNhMzdmOTJiMGVlZjM4YzA1L3RleHRyZWdpb246MTgxMmFkMDA1MTAyNDBlY2EzN2Y5MmIwZWVmMzhjMDVfMTQz_7c7e5d7b-b543-4999-9364-84e7e45f61d6"
      unitRef="usd">1300000</us-gaap:InventoryWriteDown>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU0NQ_dca8f231-3b76-4e08-abe7-30a494962f6e">STOCK-BASED COMPENSATION&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of June&#160;30, 2021&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 8,254,455 sh&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, we granted 1,733,554 stock options with a weighted average exercise price of $22.50 per share and a weighted average grant&#160;date fair&#160;value of $9.70&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per s&lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;hare. As of June&#160;30, 2021, there were 15,443,578 stock options outstanding and $32.2 million of related unrecognized compensation expense. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the six months ended June&#160;30, 2021, we granted 3,575,190 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $21.76 per share. As of June&#160;30, 2021, there were 8,314,774 RSUs outstanding and $149.0 million of related unrecognized compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock options and RSUs granted to employees during the six months ended June&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2021, we awarded 1,027,650 (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to employee&#x2019;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#x2019;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of&#160;June&#160;30, 2021, there were&#160;8,709,765 PSUs outstanding and $155.7 million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#x201c;Note 8. Employee Benefit Plans&#x201d; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU4Mg_24f39cd3-bf37-4d8a-93f0-5199066d8d4f">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13,667&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6,112&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;26,063&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,198&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;14,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,042&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36,625&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18,938&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.593%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,902&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,301&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;15,412&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,599&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;27,081&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,396&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Performance stock units&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4,698&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,429&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22,645&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,925&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;ESPP&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,023&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;825&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,366&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1,520&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Total stock-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;28,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62,688&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;30,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ieca864111b874024a399be99230353ae_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi0xLTEtMS0w_dbeae02a-e0a2-405c-8b8d-64dcce1c6720"
      unitRef="usd">13667000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2cd6d6f2194144d995d98bdace4f2a41_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi0zLTEtMS0w_bd83aecb-b3f8-4550-8e00-619bf8653f24"
      unitRef="usd">6112000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2de5b4fa16f7460680d4046f0519a111_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi01LTEtMS0w_131fd686-75bd-40e3-b8c9-b44aa2110250"
      unitRef="usd">26063000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5334bcd0ce864909917f7d16cd9888e7_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMi03LTEtMS0w_e10a4ad5-1d80-47d5-a2e2-cbd81715ceb0"
      unitRef="usd">11198000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i0f9135f913a844cf9141b680dfeb2cea_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy0xLTEtMS0w_4c590d49-88d7-4229-bb58-c23a9b764bc4"
      unitRef="usd">14368000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4941e12d857a41d3ac2f0ff6bbe78328_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy0zLTEtMS0w_9c4a9f9f-c099-4e5a-a421-643bdfaeaf91"
      unitRef="usd">10042000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="idb3a79263fd94414b9fae499fb7a8ed4_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy01LTEtMS0w_0adf698b-fd0b-46c1-a431-7f02d11f4a00"
      unitRef="usd">36625000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4037354e5adc450194ea75e59903a4c2_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfMy03LTEtMS0w_19e6dd2a-ba95-4b3c-bb02-7e6cacf4bf80"
      unitRef="usd">18938000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC0xLTEtMS0w_f206cad9-7d43-4f2e-9a68-05dfde0be2e6"
      unitRef="usd">28035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC0zLTEtMS0w_e54d042f-5f27-4fa9-85b4-437ed7c19d0e"
      unitRef="usd">16154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC01LTEtMS0w_6131e7e5-8fc4-440a-978b-593382ec2be0"
      unitRef="usd">62688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjg0M2ZiMzcwMzcyZTQyOGM4ODZkMzFjZTQ2MDVhM2ZmL3RhYmxlcmFuZ2U6ODQzZmIzNzAzNzJlNDI4Yzg4NmQzMWNlNDYwNWEzZmZfNC03LTEtMS0w_bbfa8beb-3025-4b8e-8c05-b3ca05cdd4f8"
      unitRef="usd">30136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i3bef33e85fa14e96ae49c48c326d27de_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi0xLTEtMS03MjM_1e958a5a-fa85-42eb-97d9-7bd507d34dd0"
      unitRef="usd">5902000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i19afc667658d40998a38958b53efb61e_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi0zLTEtMS03MTk_ce8beb28-c73c-4aac-8814-16847919274b"
      unitRef="usd">5301000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi01LTEtMS0w_15f2d1a3-406a-4d79-a650-de043276e467"
      unitRef="usd">10596000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i75db9e248ada421fb6801122acc77816_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMi03LTEtMS0w_53a8dfc6-1ab9-4205-9820-9587a3f706ec"
      unitRef="usd">10295000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i873e7a2c3edf40ecb5bbd511274cbf4f_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy0xLTEtMS03MjM_69dd9e27-dcb8-4bed-9711-3013b8cd8296"
      unitRef="usd">15412000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="id9124f541cea43cfb250f0c46a24ea95_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy0zLTEtMS03MTk_0d1e2358-d9f5-4d50-8c9b-b52001197a86"
      unitRef="usd">8599000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy01LTEtMS0w_b2f4f895-f694-428a-97c5-72bd33c64d1b"
      unitRef="usd">27081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i6ced14542a07421e8805f7ee34d1747f_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfMy03LTEtMS0w_265f81f0-4b9a-474c-b194-d1db5ed7a02f"
      unitRef="usd">16396000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i10aae8da808c4e4a9bdc5ee3346228a9_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC0xLTEtMS03MjM_03b159d3-d62a-4b2c-8438-1cdc28ada02c"
      unitRef="usd">4698000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i996fd974645e4c3db9f8f6b13e514f51_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC0zLTEtMS03MTk_d935174f-a291-4eb5-8285-d6420c4efdee"
      unitRef="usd">1429000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC01LTEtMS0w_a66b50e0-fabd-4dd4-b4f5-fc2c8769594c"
      unitRef="usd">22645000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i8d55c4bf90594514b0b8f4b81adf037e_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNC03LTEtMS0w_6b2f1df4-fb40-45c9-8af7-13acb5096f84"
      unitRef="usd">1925000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i2457de481e214911a4d49d6872661199_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS0xLTEtMS03MjM_b1feeaba-a6c2-4d9c-a6c9-36975b14d317"
      unitRef="usd">2023000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i17e867cac56f4c6fbee7d87303f4e416_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS0zLTEtMS03MTk_a4142861-9062-4a4c-b4bf-9c0e40a1c1d1"
      unitRef="usd">825000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i5d96596fd611426fba7a4e5d05b69795_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS01LTEtMS0w_5f01d5f2-af57-48d4-8e41-2a679b56464c"
      unitRef="usd">2366000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="ife5de7f12696428c822881cfca50b36d_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNS03LTEtMS0w_52c78030-6bb8-4ced-8ce3-766d2d5d5304"
      unitRef="usd">1520000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi0xLTEtMS0yNzkz_990aa24e-96e1-4dd7-887e-53dbab244c13"
      unitRef="usd">28035000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi0zLTEtMS0yNzkz_fd611719-78f7-4155-8e8e-922aa449cdcc"
      unitRef="usd">16154000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi01LTEtMS0w_61f14d23-1808-4bb4-9b1d-a3c5b5e136e0"
      unitRef="usd">62688000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOmFiNWMyMzhjZjI0ZDQ3N2ZhMDE2OTIyNjRmMTMzNWM4L3RhYmxlcmFuZ2U6YWI1YzIzOGNmMjRkNDc3ZmEwMTY5MjI2NGYxMzM1YzhfNi03LTEtMS0w_0f99774e-4ede-41df-a21d-ab2f1c3e5034"
      unitRef="usd">30136000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i5bd2889c307341ccba8eaee7f5f573c0_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzI5_e8ca0d60-1cf9-46c1-9b12-d70e150882a6"
      unitRef="shares">8254455</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNDkw_970699a4-d6cd-4626-8e96-026207b826d3"
      unitRef="shares">1</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward>
    <exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNTUy_3db96262-c0f9-41a6-8569-de9f096eebbc"
      unitRef="shares">1.5</exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNjY4_78e2597a-d86b-40f1-9301-5d8c2abe60b6"
      unitRef="shares">1733554</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNzI3_8eb6709f-68d2-4361-b540-e47496e9effc"
      unitRef="usdPerShare">22.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i4134486a3c824f2181dcb53797e46891_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfNzg4_72cf4103-aff4-42af-bfa7-f7283fa8cf49"
      unitRef="usdPerShare">9.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i167594f9829443bdb7383a81ca5f83e5_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfODIz_29bd3254-7255-4ab5-a1c5-8c84858624b0"
      unitRef="shares">15443578</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i167594f9829443bdb7383a81ca5f83e5_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfODU2_1f32733f-eb88-4193-bd78-e96bf843fb25"
      unitRef="usd">32200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfOTM1_52d491db-0607-4ec3-bea6-02edbc42f0e2"
      unitRef="shares">3575190</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="ifb9c0e4829a349dfae6b71018f16b8bb_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTAzMQ_a006c3bd-6f86-4f8e-9728-25163c1db4ff"
      unitRef="usdPerShare">21.76</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i32a62386d90e4627a31537ead3413cd9_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTA2Ng_d9fb3449-bbd5-4e57-acbb-1d4ab50bbe69"
      unitRef="shares">8314774</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i32a62386d90e4627a31537ead3413cd9_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTA5MA_ba291f61-c4bc-4824-9563-fad43b98e048"
      unitRef="usd">149000000.0</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTQ3MA_bfc83232-2383-424d-901b-c940086e4828"
      unitRef="shares">1027650</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest
      contextRef="ia7a35af9de3b44d4836118f6e8f85c1c_D20210301-20210331"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMTY4NA_e27867d6-825a-4203-be75-d8d67ac6f7fe"
      unitRef="number">2</exel:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage
      contextRef="i06bb3436aa3243dc82099b2b7e64415a_D20210301-20210331"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjA5MA_6599a3ac-5f5e-424c-9f8d-ee941f4cd043"
      unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="iba0fcc072d1d49eea6319ba9d01188e7_D20210301-20210331"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjI2MA_7410cdf8-2add-46d6-ae1c-76e1c7c00a41">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzU0MQ_2fe32b4e-bf4e-4d10-9d00-ce5c30d3a3c9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:90.120%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:7.680%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Fair value of the Company&#x2019;s common stock on grant date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;21.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Expected volatility&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;49&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;0.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Dividend yield&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMjUyMg_7f4432d1-dd54-4b3e-aba1-d0c7137bbb91"
      unitRef="usdPerShare">24.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharePrice
      contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMC0xLTEtMS0w_51008774-c67e-42bd-b4fa-f40a902b8533"
      unitRef="usdPerShare">21.31</us-gaap:SharePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMS0xLTEtMS0w_3a7d4ab4-f7a9-437e-a1b6-f55e2490253c"
      unitRef="number">0.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"
      decimals="4"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMi0xLTEtMS0w_7cccef68-73f4-4aa4-9953-bbe0cb707ac3"
      unitRef="number">0.0029</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RhYmxlOjVhMzliNjdkMzhjZjQxMWZhODY2MjUwNGQ3ZGY2MGU0L3RhYmxlcmFuZ2U6NWEzOWI2N2QzOGNmNDExZmE4NjYyNTA0ZDdkZjYwZTRfMy0xLTEtMS0w_c003d16a-153a-4fba-a111-4fc90d0c13e9"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702"
      decimals="INF"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzAzMQ_99c62133-712a-4f8c-9502-a26c6397ca6c"
      unitRef="shares">8709765</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="icdc25c9244d74752a7a86d0fc1f9a390_I20210702"
      decimals="-5"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV81OC9mcmFnOmU4ZGNkMzYwMzJjNzQzNGI4MTQ1ZTQ0MDcwODI5ZTIzL3RleHRyZWdpb246ZThkY2QzNjAzMmM3NDM0YjgxNDVlNDQwNzA4MjllMjNfMzA1NQ_d694ca41-9011-4d2d-9fe8-29a8dc4ecbda"
      unitRef="usd">155700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfNTQ3_5a3f81ca-f3f1-454d-90de-6842ece5bb15">PROVISION FOR INCOME TAXESThe effective tax rate for the three and six months ended June&#160;30, 2021 was 23.1% and 20.5%, respectively, as compared to 17.2% and 18.0% for the corresponding periods in 2020. The effective tax rate for the three and six months ended June&#160;30, 2021 and 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ3Nw_c6151505-9d53-46c6-9984-7014c8f21d4b"
      unitRef="number">0.231</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ3MA_054f7427-1156-4e40-a395-009b56b2eca9"
      unitRef="number">0.205</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ1Mg_68ab8a8c-fead-49f6-9832-fecdb7c3e530"
      unitRef="number">0.172</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82MS9mcmFnOjJiYWIyZTY4OWY3ZDQ4Y2ZiNzBmODgzMGExMzE0ZTIxL3RleHRyZWdpb246MmJhYjJlNjg5ZjdkNDhjZmI3MGY4ODMwYTEzMTRlMjFfMTA5OTUxMTYyODQ2MA_b14f4187-14e8-4d38-8b4c-2411ddb4bdf8"
      unitRef="number">0.180</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzMw_2c1c4263-bed9-47cf-9087-b4abf518bafb">NET INCOME PER SHARE&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Dilutive securities included outstanding stock options and Performance Stock Options, unvested RSUs and PSUs and ESPP contributions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;/span&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzI2_6f0ed830-435c-43ce-8077-dfe923ba88c9">&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.417%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Numerator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;96,092&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;66,821&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;97,693&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;115,433&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Denominator:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;314,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;307,807&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;313,295&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;306,598&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Dilutive securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,824&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,819&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,394&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding &#x2014; diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,941&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;318,144&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;322,114&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;316,992&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; basic&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.22&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.31&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"/&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.38&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Net income per share &#x2014; diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.21&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy0xLTEtMS0w_8c59a938-ba77-46f6-bfe2-d1973b4ebadf"
      unitRef="usd">96092000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy0zLTEtMS0w_0ed6bc29-5d72-4285-846f-ae3ed36c72fc"
      unitRef="usd">66821000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy01LTEtMS0w_cc002bf7-78c1-476e-b30a-a6ba0dfbd22e"
      unitRef="usd">97693000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMy03LTEtMS0w_440a50f1-946b-426a-8c74-53c935a85e7f"
      unitRef="usd">115433000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS0xLTEtMS0w_29e2868a-8b38-4875-a887-d7c75f9af8f0"
      unitRef="shares">314117000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS0zLTEtMS0w_4e3f1f2a-e580-44d9-9acf-364bac526287"
      unitRef="shares">307807000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS01LTEtMS0w_0c983555-5ab8-4398-810b-60e29450066d"
      unitRef="shares">313295000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNS03LTEtMS0w_579d327e-e1b5-40c8-b5e1-07460774ef43"
      unitRef="shares">306598000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi0xLTEtMS0w_f44493d5-36b6-492d-bc86-dbfc1fc6f384"
      unitRef="shares">8824000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi0zLTEtMS0w_affa1734-a967-49ba-90ee-036588548552"
      unitRef="shares">10337000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi01LTEtMS0w_e33b2df5-4891-4872-8171-147dcd190375"
      unitRef="shares">8819000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNi03LTEtMS0w_a5079d44-88f7-4d2c-92e2-d72a279fd830"
      unitRef="shares">10394000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy0xLTEtMS0w_45b5ca19-1534-46ab-bcdf-72a8335df827"
      unitRef="shares">322941000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy0zLTEtMS0w_6e9738ab-361c-4682-aade-f523e052cadf"
      unitRef="shares">318144000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy01LTEtMS0w_8db72b6a-fb8d-4d73-a589-67acaa0cb364"
      unitRef="shares">322114000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfNy03LTEtMS0w_4a589885-e699-4bb0-84c0-b3fd0ee5f665"
      unitRef="shares">316992000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS0xLTEtMS0w_db364df9-420c-4664-ba8f-4dba8f3d3d5e"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS0zLTEtMS0w_a8181d0d-a138-44ff-8fb3-35d1836987a7"
      unitRef="usdPerShare">0.22</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS01LTEtMS0w_897385f8-22ab-4504-bf49-eb4a6bd32c5b"
      unitRef="usdPerShare">0.31</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfOS03LTEtMS0w_bbc6ce9a-fefe-412b-8516-d5361bb8b0ce"
      unitRef="usdPerShare">0.38</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtMS0xLTEtMA_beecd631-c0bd-4197-a468-ed60af27687c"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i7e5861bd5eb04345902c0be070dab07f_D20200404-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtMy0xLTEtMA_a372761b-f96f-44e0-afcc-29e5a02bd2fe"
      unitRef="usdPerShare">0.21</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtNS0xLTEtMA_2a732a89-e223-41ba-a0a9-5210dae65758"
      unitRef="usdPerShare">0.30</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="i153a2e8e37e8439394b91e1949a77142_D20200104-20200703"
      decimals="2"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOmUzNTYwNmRlOGFlODQwNGI5OWFiMmQzNmVmMGY3YjZiL3RhYmxlcmFuZ2U6ZTM1NjA2ZGU4YWU4NDA0Yjk5YWIyZDM2ZWYwZjdiNmJfMTAtNy0xLTEtMA_119fc0ce-5935-4989-a55d-0c6842d0a25b"
      unitRef="usdPerShare">0.36</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RleHRyZWdpb246OTAyZDdkOTQ3ZGM4NDY4Yjk4NmIyZGU0N2I0YTBmMjFfNzM3_e1c06b9c-6f3c-4cb0-9b4c-68e305562025">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:40.566%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.544%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.436%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.739%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:0.395%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td style="width:1.0%"/&gt;&lt;td style="width:12.742%"/&gt;&lt;td style="width:0.1%"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Three Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;Six Months Ended June 30,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2021&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%"&gt;2020&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Anti-dilutive securities and contingently issuable shares excluded&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12,285&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,812&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11,146&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"/&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;td colspan="3" style="display:none"/&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi0xLTEtMS0w_e690bd63-c034-4a85-b27c-dd67f4b808c0"
      unitRef="shares">12285000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0c6782e60aa74aa18a2400a167db7d7e_D20200404-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi0zLTEtMS0w_2b83636f-8ce0-4308-8f85-8c283a2fdf03"
      unitRef="shares">8812000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="i0d82c6e6cf824115b296671898dbd282_D20210102-20210702"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi01LTEtMS0w_3cab26b5-a961-4798-9650-98f856a9e4ac"
      unitRef="shares">11146000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="if3e6164d65ce46689c7c42db6169a463_D20200104-20200703"
      decimals="-3"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82NC9mcmFnOjkwMmQ3ZDk0N2RjODQ2OGI5ODZiMmRlNDdiNGEwZjIxL3RhYmxlOjgyODkyMGY5NGNkYzQyZTlhNWU2OWQzZjg3ZDYzMGZjL3RhYmxlcmFuZ2U6ODI4OTIwZjk0Y2RjNDJlOWE1ZTY5ZDNmODdkNjMwZmNfMi03LTEtMS0w_d7039ac6-70db-4f94-981a-f60226d17733"
      unitRef="shares">10413000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702"
      id="id3VybDovL2RvY3MudjEvZG9jOjE2NGQxZmNjMTYwMDRkODY4NDc2MTliMzBjYmRjMGJhL3NlYzoxNjRkMWZjYzE2MDA0ZDg2ODQ3NjE5YjMwY2JkYzBiYV82Ny9mcmFnOjg2NjBiMWM3YTgwNjQxMmFhYjE3ZmM3MmFmMWIzYWMyL3RleHRyZWdpb246ODY2MGIxYzdhODA2NDEyYWFiMTdmYzcyYWYxYjNhYzJfNDMzMw_c46b819f-2167-4398-93bc-fa7a4bbfb82d">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#x2019;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#x2019;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#x2019;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#x2019;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#x2019;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. &lt;div style="margin-top:9pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#x2019;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#x2019;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited, asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#x2019;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#x2019;s ANDA would be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;and Teva Pharmaceutical Industries Limited &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;from infringing these patents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:9pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874685886120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 26, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jul.  02,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-30235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">EXELIXIS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">04-3257395<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1851 Harbor Bay Parkway<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Alameda,<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94502<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">837-7000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock $.001 Par Value per Share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">EXEL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,048,788<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000939767<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681470456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 492,462<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">854,171<span></span>
</td>
<td class="nump">887,319<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesNetCurrent', window );">Trade receivables, net</a></td>
<td class="nump">171,753<span></span>
</td>
<td class="nump">160,875<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventory</a></td>
<td class="nump">24,982<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">49,878<span></span>
</td>
<td class="nump">57,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">1,593,246<span></span>
</td>
<td class="nump">1,445,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">345,613<span></span>
</td>
<td class="nump">330,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">95,133<span></span>
</td>
<td class="nump">67,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxAssetsNet', window );">Deferred tax assets, net</a></td>
<td class="nump">134,667<span></span>
</td>
<td class="nump">156,711<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">63,684<span></span>
</td>
<td class="nump">63,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
<td class="nump">134,928<span></span>
</td>
<td class="nump">73,408<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">2,367,271<span></span>
</td>
<td class="nump">2,137,333<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">20,450<span></span>
</td>
<td class="nump">23,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and benefits</a></td>
<td class="nump">48,324<span></span>
</td>
<td class="nump">51,189<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedClinicalLiabilitiesCurrent', window );">Accrued clinical trial liabilities</a></td>
<td class="nump">67,075<span></span>
</td>
<td class="nump">52,251<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CustomerRefundLiabilityCurrent', window );">Rebates and fees due to customers</a></td>
<td class="nump">31,197<span></span>
</td>
<td class="nump">20,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AccruedCollaborationLiabilityCurrent', window );">Accrued collaboration liabilities</a></td>
<td class="nump">24,428<span></span>
</td>
<td class="nump">12,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">63,852<span></span>
</td>
<td class="nump">44,447<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">255,326<span></span>
</td>
<td class="nump">204,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion of deferred revenues</a></td>
<td class="nump">8,577<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term portion of operating lease liabilities</a></td>
<td class="nump">53,223<span></span>
</td>
<td class="nump">49,086<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">7,068<span></span>
</td>
<td class="nump">721<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">324,194<span></span>
</td>
<td class="nump">258,220<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 314,822 and 311,627 at June&#160;30, 2021 and December&#160;31, 2020, respectively</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1,985<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(349,877)<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#8217; equity</a></td>
<td class="nump">2,043,077<span></span>
</td>
<td class="nump">1,879,113<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#8217; equity</a></td>
<td class="nump">$ 2,367,271<span></span>
</td>
<td class="nump">$ 2,137,333<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedClinicalLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Clinical Liabilities, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedClinicalLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AccruedCollaborationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Collaboration Liability, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AccruedCollaborationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CustomerRefundLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CustomerRefundLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-06(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401414&amp;loc=d3e604059-122996<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874768601368">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Shares authorized (in shares)</a></td>
<td class="nump">400,000,000<span></span>
</td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Shares issued (in shares)</a></td>
<td class="nump">314,822,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Shares outstanding (in shares)</a></td>
<td class="nump">314,822,000<span></span>
</td>
<td class="nump">311,627,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681531000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Income - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of goods sold</a></td>
<td class="nump">14,884<span></span>
</td>
<td class="nump">9,221<span></span>
</td>
<td class="nump">28,082<span></span>
</td>
<td class="nump">18,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">148,790<span></span>
</td>
<td class="nump">114,933<span></span>
</td>
<td class="nump">308,078<span></span>
</td>
<td class="nump">216,810<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">98,495<span></span>
</td>
<td class="nump">59,791<span></span>
</td>
<td class="nump">200,846<span></span>
</td>
<td class="nump">122,731<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">262,169<span></span>
</td>
<td class="nump">183,945<span></span>
</td>
<td class="nump">537,006<span></span>
</td>
<td class="nump">358,051<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income from operations</a></td>
<td class="nump">123,008<span></span>
</td>
<td class="nump">75,534<span></span>
</td>
<td class="nump">118,401<span></span>
</td>
<td class="nump">128,343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeOther', window );">Interest income</a></td>
<td class="nump">1,891<span></span>
</td>
<td class="nump">5,162<span></span>
</td>
<td class="nump">4,573<span></span>
</td>
<td class="nump">12,382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(11)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(101)<span></span>
</td>
<td class="nump">6<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Income before income taxes</a></td>
<td class="nump">124,888<span></span>
</td>
<td class="nump">80,696<span></span>
</td>
<td class="nump">122,873<span></span>
</td>
<td class="nump">140,731<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="nump">28,796<span></span>
</td>
<td class="nump">13,875<span></span>
</td>
<td class="nump">25,180<span></span>
</td>
<td class="nump">25,298<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net income per share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">314,117<span></span>
</td>
<td class="nump">307,807<span></span>
</td>
<td class="nump">313,295<span></span>
</td>
<td class="nump">306,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">322,941<span></span>
</td>
<td class="nump">318,144<span></span>
</td>
<td class="nump">322,114<span></span>
</td>
<td class="nump">316,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 284,248<span></span>
</td>
<td class="nump">$ 178,730<span></span>
</td>
<td class="nump">$ 511,460<span></span>
</td>
<td class="nump">$ 372,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 61,289<span></span>
</td>
<td class="nump">$ 21,515<span></span>
</td>
<td class="nump">$ 76,779<span></span>
</td>
<td class="nump">$ 33,671<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest income earned from interest bearing assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874686763480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of ($257), $2,287, ($756) and $1,346, respectively</a></td>
<td class="num">(755)<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
<td class="num">(2,491)<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income</a></td>
<td class="nump">$ 95,337<span></span>
</td>
<td class="nump">$ 74,883<span></span>
</td>
<td class="nump">$ 95,202<span></span>
</td>
<td class="nump">$ 120,204<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678696536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact</a></td>
<td class="num">$ (257)<span></span>
</td>
<td class="nump">$ 2,287<span></span>
</td>
<td class="num">$ (756)<span></span>
</td>
<td class="nump">$ 1,346<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874770528136">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">304,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 03, 2020</a></td>
<td class="nump">$ 1,685,970<span></span>
</td>
<td class="nump">$ 305<span></span>
</td>
<td class="nump">$ 2,241,947<span></span>
</td>
<td class="nump">$ 3,069<span></span>
</td>
<td class="num">$ (559,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">115,433<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">4,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,771<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,055<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">17,955<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">17,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(20,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(20,941)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">30,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 03, 2020</a></td>
<td class="nump">1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
<td class="num">(443,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">305,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 03, 2020</a></td>
<td class="nump">1,747,652<span></span>
</td>
<td class="nump">$ 306<span></span>
</td>
<td class="nump">2,258,307<span></span>
</td>
<td class="num">(222)<span></span>
</td>
<td class="num">(510,739)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">66,821<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66,821<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">8,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,106<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">13,783<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">13,780<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(19,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(19,148)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">16,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,154<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 03, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">308,886<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 03, 2020</a></td>
<td class="nump">$ 1,833,324<span></span>
</td>
<td class="nump">$ 309<span></span>
</td>
<td class="nump">2,269,093<span></span>
</td>
<td class="nump">7,840<span></span>
</td>
<td class="num">(443,918)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Jan. 01, 2021</a></td>
<td class="nump">311,627<span></span>
</td>
<td class="nump">311,627<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Jan. 01, 2021</a></td>
<td class="nump">$ 1,879,113<span></span>
</td>
<td class="nump">$ 312<span></span>
</td>
<td class="nump">2,321,895<span></span>
</td>
<td class="nump">4,476<span></span>
</td>
<td class="num">(447,570)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">97,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(2,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,491)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">15,484<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(9,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 62,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 02, 2021</a></td>
<td class="nump">314,822<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 02, 2021</a></td>
<td class="nump">$ 2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">2,390,654<span></span>
</td>
<td class="nump">1,985<span></span>
</td>
<td class="num">(349,877)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Apr. 02, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">313,262<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Apr. 02, 2021</a></td>
<td class="nump">1,911,187<span></span>
</td>
<td class="nump">$ 313<span></span>
</td>
<td class="nump">2,354,103<span></span>
</td>
<td class="nump">2,740<span></span>
</td>
<td class="num">(445,969)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">96,092<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,092<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(755)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,560<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive and stock purchase plans</a></td>
<td class="nump">11,285<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">11,283<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Stock transactions associated with taxes withheld on equity awards</a></td>
<td class="num">(2,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,767)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jul. 02, 2021</a></td>
<td class="nump">314,822<span></span>
</td>
<td class="nump">314,822<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jul. 02, 2021</a></td>
<td class="nump">$ 2,043,077<span></span>
</td>
<td class="nump">$ 315<span></span>
</td>
<td class="nump">$ 2,390,654<span></span>
</td>
<td class="nump">$ 1,985<span></span>
</td>
<td class="num">$ (349,877)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874682907640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfCashFlowsAbstract', window );"><strong>Statement of Cash Flows [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 97,693<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation</a></td>
<td class="nump">6,895<span></span>
</td>
<td class="nump">4,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">62,688<span></span>
</td>
<td class="nump">30,136<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NoncashLeaseExpense', window );">Non-cash lease expense</a></td>
<td class="nump">2,586<span></span>
</td>
<td class="nump">2,383<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Deferred taxes</a></td>
<td class="nump">22,800<span></span>
</td>
<td class="nump">22,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other, net</a></td>
<td class="nump">22,831<span></span>
</td>
<td class="nump">726<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade receivables, net</a></td>
<td class="num">(12,313)<span></span>
</td>
<td class="num">(2,014)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventory</a></td>
<td class="num">(8,020)<span></span>
</td>
<td class="num">(7,049)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(12,296)<span></span>
</td>
<td class="num">(18,954)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">9,346<span></span>
</td>
<td class="nump">9,659<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable and other liabilities</a></td>
<td class="nump">28,835<span></span>
</td>
<td class="nump">262<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">221,045<span></span>
</td>
<td class="nump">157,751<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, equipment and other</a></td>
<td class="num">(33,768)<span></span>
</td>
<td class="num">(9,925)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(688,903)<span></span>
</td>
<td class="num">(433,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Proceeds from maturities and sales of investments</a></td>
<td class="nump">714,081<span></span>
</td>
<td class="nump">548,973<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(8,590)<span></span>
</td>
<td class="nump">105,894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from issuance of common stock under equity incentive plans</a></td>
<td class="nump">15,487<span></span>
</td>
<td class="nump">17,938<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(9,413)<span></span>
</td>
<td class="num">(20,941)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">6,074<span></span>
</td>
<td class="num">(3,003)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash equivalents</a></td>
<td class="nump">218,529<span></span>
</td>
<td class="nump">260,642<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at beginning of period</a></td>
<td class="nump">320,772<span></span>
</td>
<td class="nump">268,137<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash equivalents at end of period</a></td>
<td class="nump">539,301<span></span>
</td>
<td class="nump">528,779<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract', window );"><strong>Non-cash operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability', window );">Right-of-use assets obtained in exchange for lease obligations</a></td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">1,824<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract', window );"><strong>Non-cash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Unpaid liabilities incurred for purchases of property and equipment</a></td>
<td class="nump">5,125<span></span>
</td>
<td class="nump">804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAssumed1', window );">Unpaid liabilities incurred in asset acquisition</a></td>
<td class="nump">9,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid', window );">Unpaid liabilities incurred for unsettled investment purchases</a></td>
<td class="nump">$ 7,378<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash Lease Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_RightOfUseAssetObtainedInExchangeForLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-Of-Use Asset Obtained In Exchange For Lease Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_RightOfUseAssetObtainedInExchangeForLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unsettled Investment Purchases Incurred But Not Yet Paid</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAssumed1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of liabilities assumed in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAssumed1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678559752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text">ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Organization</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exelixis, Inc. (Exelixis, we, our or us) is an oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. We have invented and brought to market novel, effective and tolerable therapies using our drug discovery and development resources and capabilities and commercialization platform; we will continue to build on this foundation, working toward providing cancer patients with additional treatment options.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since we were founded in 1994, four products resulting from our discovery efforts&#160;have progressed through clinical development, received regulatory approval and established a commercial presence in various geographies around the world. Our flagship molecule, cabozantinib, is an inhibitor of multiple tyrosine kinases including MET, AXL, VEGF receptors and RET and has been approved by the U.S. Food and Drug Administration (FDA) and foreign regulatory authorities as two products: CABOMETYX&#174; (cabozantinib) tablets approved for advanced renal cell carcinoma (RCC), both alone and in combination with Bristol Myers Squibb Company&#8217;s OPDIVO&#174; (nivolumab), and for previously treated hepatocellular carcinoma (HCC); and COMETRIQ&#174;&#160;(cabozantinib) capsules approved for progressive, metastatic medullary thyroid cancer (MTC). For these types of cancer, cabozantinib has become or is becoming a standard of care.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The other two products resulting from our discovery efforts are: COTELLIC&#174; (cobimetinib), an inhibitor of MEK, approved as part of multiple combination regimens to treat specific forms of advanced melanoma and marketed under a collaboration with Genentech, Inc. (a member of the Roche Group) (Genentech); and MINNEBRO&#174; (esaxerenone), an oral, non-steroidal, selective blocker of the mineralocorticoid receptor, approved for the treatment of hypertension in Japan and licensed to Daiichi Sankyo Company, Limited (Daiichi Sankyo).</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Leveraging the revenue stream derived from our cabozantinib franchise and other marketed products, we are expanding our oncology product pipeline through drug discovery efforts, which encompass both small molecule and biologics programs with multiple modalities and mechanisms of action.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended  July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our long-lived assets are located in the U.S. See &#8220;Note 2. Revenues&#8221; for enterprise-wide disclosures about product sales, revenues from major customers and revenues by geographic region.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reclassifications</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity. </span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Significant Accounting Policies</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Except for the foreign currency forward contracts for non-designated hedges, there have been no material changes to our significant accounting policies during the six months ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">June&#160;30, 2021</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, as compared to the significant accounting policies disclosed in Note 1 &#8211; Significant Accounting Policies included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678799800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">REVENUES</a></td>
<td class="text">REVENUES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.039%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Product Sales Discounts and Allowances</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Contract assets and liabilities were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Contract assets as of June&#160;30, 2021 are primarily related to a $12.5 million development milestone that we deemed probable of achievement and recognized $11.8&#160;million of revenues during the three months ended June 30, 2021. Contract liabilities as of June&#160;30, 2021 are primarily related to deferred revenues from Takeda Pharmaceutical Company Limited (Takeda). </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021 and 2020, we recognized $4.8 million and $3.4 million, respectively, in revenues that were included in the beginning deferred revenues balance for those periods.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the three and six months ended June&#160;30, 2021, we recognized $40.6 million and $67.8 million, respectively, in revenues for performance obligations satisfied in previous periods, as compared to $62.0 million and $82.2 million for the corresponding periods in 2020. Such revenues were primarily related to royalty payments allocated to the license performance obligations for our collaborations with Ipsen Pharma SAS (Ipsen), Takeda, Daiichi Sankyo and Genentech.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$86.9 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of t</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">he combined transaction prices for our Ipsen and Takeda collaborations were allocated to performance obligations that had not yet been satisfied. See &#8220;Note 3. Collaboration Agreements&#8212; Cabozantinib Collaborations - Performance Obligations and Transaction Prices for our Ipsen and Takeda Collaborations&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020 for information about the expected timing to satisfy these performance obligations.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130550-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130558-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130554-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678581208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES</a></td>
<td class="text">COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have established multiple collaborations with leading pharmaceutical companies for the commercialization and further development of our cabozantinib franchise. Additionally, we have entered into several research collaborations and in-licensing arrangements to further enhance our early-stage pipeline and expand our ability to discover, develop and commercialize novel therapies with the goal of providing new treatment options for cancer patients and their physicians. We also entered into other collaborations with leading pharmaceutical companies for other compounds and programs in our portfolio. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Note 3. Collaboration Agreements&#8221; to our Consolidated Financial Statements included in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, or as further described below, for additional information on each of our collaboration agreements and in-licensing arrangements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cabozantinib Collaborations</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ipsen Collaboration </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> In February 2016, we entered into a collaboration agreement with Ipsen for the commercialization and further development of cabozantinib. Under the terms of the collaboration agreement, as amended, Ipsen received exclusive commercialization rights for current and potential future cabozantinib indications outside of the U.S. and Japan. We have </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">also agreed to collaborate with Ipsen on the development of cabozantinib for current and potential future indications. The parties&#8217; efforts are governed through a joint steering committee and appropriate subcommittees established to guide and oversee the collaboration&#8217;s operation and strategic direction; provided, however, that we retain final decision-making authority with respect to cabozantinib&#8217;s ongoing development. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the second quarter of 2021, Ipsen opted into and is now co-funding the development costs for COSMIC-311, our phase 3 pivotal trial evaluating cabozantinib versus placebo in patients with radioactive iodine differentiated thyroid cancer who have progressed after up to two VEGF receptor-targeted therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Agreement, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ipsen is now obligated to reimburse us for their share of the COSMIC-311 global development costs, as well as an additional payment calculated as a percentage of such costs, </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">triggered by the timing of the exercise of its option. </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We determined that the decision to opt into and co-fund the development costs for COSMIC-311 represented a contract modification for additional distinct services at their standalone selling price and therefore was treated as a separate contract under Topic 606. Accordingly, collaboration services revenues for the three and six months ended June 30, 2021, includes a cumulative catch up for Ipsen&#8217;s share of global development costs incurred since the beginning of the study and through the end of the period.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$46.2 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the tr</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ansaction price was allocated to our research and development services performance obligations that has not yet been satisfied.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Takeda Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2017, we entered into a collaboration and license agreement with Takeda for the commercialization and further development of cabozantinib. Pursuant to this collaboration and license agreement, as amended, Takeda has exclusive commercialization rights for current and potential future cabozantinib indications in Japan, and the parties have agreed to collaborate on the clinical development of cabozantinib in Japan. The operation and strategic direction of the parties&#8217; collaboration is governed through a joint executive committee and appropriate subcommittees.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, $40.7 million of the transaction price was allocated to our research and development services performance obligations that has not yet been satisfied. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">GSK and Royalty Pharma</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2002, we established a product development and commercialization collaboration agreement with GSK, that required us to pay a 3% royalty to GSK on the worldwide net sales of any product incorporating cabozantinib by us and our collaboration partners. As disclosed in Note 2, we received notification that, effective January 1, 2021, Royalty Pharma acquired from GSK all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for U.S. market through September 2026, after which time U.S. royalties will revert back to GSK. Royalties earned by GSK and Royalty Pharma in connection with our sales of cabozantinib are included in cost of goods sold and as a reduction of collaboration services revenues for sales by our collaboration partners. Such royalties were $12.1 million and $22.2 million during the three and six months ended June&#160;30, 2021, respectively, as compared to $7.6 million and $15.7 million in the corresponding periods in 2020. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Collaboration</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2006, we out-licensed the development and commercialization of cobimetinib to Genentech under a worldwide collaboration agreement. In&#160;November&#160;2015, the FDA approved cobimetinib, under the brand name COTELLIC, in combination with Genentech&#8217;s ZELBORAF&#174; (vemurafenib) for the treatment of patients with BRAF V600E or V600K mutation-positive advanced melanoma. COTELLIC in combination with ZELBORAF has also been approved in the European Union and multiple additional countries for use in the same indication. In July 2020, the FDA also approved COTELLIC for use in combination with ZELBORAF and TECENTRIQ&#174; (atezolizumab) for the treatment of patients with BRAF V600 mutation-positive advanced melanoma in previously untreated patients. License revenues under the collaboration agreement with Genentech were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research Collaborations, In-Licensing Arrangements and Other Business Development Activities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June 30, 2021, in support of our development pipeline, we entered into additional collaboration and in-licensing arrangements with Adagene, Inc. (Adagene) and WuXi Biologics Ireland Limited (WuXi Bio), and amended our existing collaboration agreement with StemSynergy Therapeutics, Inc. (StemSynergy). In conjunction with each of these arrangements we have made aggregate upfront payments totaling $17.0&#160;million and will make payments for potential future development milestones of up to $58.5&#160;million, regulatory milestones of up to $139.0&#160;million and commercial milestones of up to $377.5&#160;million, each in the aggregate per product, as well as royalties on future net product sales. Additionally, we entered into an asset purchase agreement with GamaMabs Pharma SA (GamaMabs), pursuant to which we made an upfront payment of $5.0&#160;million for the initial technology transfer, and subject to certain conditions, will make a $9.0&#160;million payment upon closing of the transaction. We will also make payments for potential future development milestones of up to $42.0&#160;million and regulatory milestones of up to $22.5&#160;million, per product.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678700680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock', window );">CASH AND INVESTMENTS</a></td>
<td class="text">CASH AND INVESTMENTS<div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents and Restricted Cash Equivalents </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash equivalents are used to collateralize letters of credit and consist of money-market funds and certificates of deposit with original maturities of 90 days or less. The restricted cash equivalents are classified as other long-term assets based upon the remaining term of the underlying restriction. As of June&#160;30, 2021, restricted cash equivalents included $45.3&#160;million of short-term investments, which is collateral under our January 2021 standby letter of credit to guarantee our obligation to fund a portion of the total tenant improvements related to our build-to-suit lease at our corporate campus. As we fund these tenant improvements, our restricted cash becomes available for operations.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash, Cash Equivalents, Restricted Cash Equivalents and Investments</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interest receivable was $3.3 million and $4.5 million as of June&#160;30, 2021 and December&#160;31, 2020, respectively, and is included in prepaid expenses and other current assets in the accompanying Condensed Consolidated Balance Sheets.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Realized gains and losses on the sales of investments were insignificant during the three and six months ended June&#160;30, 2021 and 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We manage credit risk associated with our investment portfolio through our investment policy, which limits purchases to high-quality issuers and limits the amount of our portfolio that can be invested in a single issuer. The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.376%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All securities presented have been in an unrealized loss position for less than 12 months. There were 53 and 14 investments in an unrealized loss position as of June&#160;30, 2021 and December&#160;31, 2020, respectively. During the six months ended June&#160;30, 2021 and 2020, we did not record an allowance for credit losses or other impairment charges on our investment securities. Based upon our quarterly impairment review, we determined that the unrealized losses were not attributed to credit risk but were primarily associated with changes in interest rates and market liquidity. Based on the scheduled maturities of our investments, we determined that it was more likely than not that we will hold these investments for a period of time sufficient for a recovery of our cost basis.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680833352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">FAIR VALUE MEASUREMENTS</a></td>
<td class="text">FAIR VALUE MEASUREMENTS<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Fair value reflects the amounts that would be received upon sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value hierarchy has the following three levels:</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 1 -&#160;quoted prices (unadjusted) in active markets for identical assets and liabilities;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 2 -&#160;inputs other than level 1 that are observable either directly or indirectly, such as quoted prices in active markets for similar instruments or on industry models using data inputs, such as interest rates and prices that can be directly observed or corroborated in active markets;</span></div><div style="margin-top:3pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.02pt">Level 3 -&#160;unobservable inputs that are supported by little or no market activity that are significant to the fair value measurement</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When available, we value investments based on quoted prices for those financial instruments, which is a Level 1 input. Our remaining investments are valued using third-party pricing sources, which use observable market prices, interest rates and yield curves observable at commonly quoted intervals for similar assets as observable inputs for pricing, which is a Level 2 input.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying amount of our remaining financial assets and liabilities, which include cash, receivables and payables, approximate their fair values due to their short-term nature.</span></div><div style="margin-top:9pt;text-indent:72pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Forward Foreign Currency Contracts</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2021, we initiated an operational hedging program and entered into forward contracts to hedge certain operational exposures for the changes in foreign currency exchanges rates associated with assets or liabilities denominated in foreign currencies, primarily the Euro. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021, we had one forward contract outstanding to sell &#8364;9.3&#160;million. The forward contract has a maturity of three months, is recorded at fair value and is included in prepaid expenses and other current assets in the Condensed Consolidated Balance Sheets. The unrealized gain/loss on the settlement of the forward contract is not material as of June 30, 2021. The forward contract is considered a Level 2 in the fair value hierarchy of our fair value measurements. For the six months ended June&#160;30, 2021, we recognized $0.3&#160;million net gains on the maturity of our forward contracts, which is included in other income (expense), net on our Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680032664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">INVENTORY</a></td>
<td class="text">INVENTORY<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Write-downs related to excess and expiring inventory were $2.3 million and $1.3 million for the six months ended June&#160;30, 2021 and 2020, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678785144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">STOCK-BASED COMPENSATION</a></td>
<td class="text">STOCK-BASED COMPENSATION<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of June&#160;30, 2021</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 8,254,455 sh</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ares were available for grant under the Exelixis, Inc. 2017 Equity Incentive Plan (as amended and restated, the 2017 Plan). The share reserve is reduced by 1 share for each share issued pursuant to a stock option and 1.5 shares for full value awards granted in the form of restricted stock units (RSUs).&#160;</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we granted 1,733,554 stock options with a weighted average exercise price of $22.50 per share and a weighted average grant&#160;date fair&#160;value of $9.70</span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per s</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hare. As of June&#160;30, 2021, there were 15,443,578 stock options outstanding and $32.2 million of related unrecognized compensation expense. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the six months ended June&#160;30, 2021, we granted 3,575,190 service-based RSUs with a weighted average grant&#160;date fair&#160;value of $21.76 per share. As of June&#160;30, 2021, there were 8,314,774 RSUs outstanding and $149.0 million of related unrecognized compensation expense.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock options and RSUs granted to employees during the six months ended June&#160;30, 2021 have vesting conditions and contractual lives of a similar nature to those described in &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2021, we awarded 1,027,650 (the target amount) performance-based (PSUs), subject to a performance and a market condition (the 2021 PSUs). Pursuant to the terms of 2021 PSUs, the holders of the awards may earn up to 200% of the target amount of shares, depending on the level of achievement of the performance condition related to certain net product revenues and a total shareholder return (TSR) market condition. The TSR market condition is based on our relative TSR percentile rank compared to companies in the NASDAQ Biotechnology Index during the performance period, which is January 2, 2021 through December 29, 2023. Fifty percent of the shares earned subject to the performance and market conditions will vest at the end of the performance period and the remainder will vest approximately one year later subject to employee&#8217;s continuous service. The 2021 PSUs will be forfeited if the performance condition at or above a threshold level is not achieved by December 29, 2023.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Monte Carlo simulation model also assumed correlations of returns of the stock prices of the Company&#8217;s common stock and the common stock of a peer group of companies and historical stock price volatility of the peer group of companies. The valuation model also used terms based on the length of the performance period and compound annual growth rate goals for total stockholder return based on the provisions of the award.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of&#160;June&#160;30, 2021, there were&#160;8,709,765 PSUs outstanding and $155.7 million of related unrecognized compensation expense. Expense recognition for PSUs commences when it is determined that achievement of the performance target is probable. For more information about our PSUs, see &#8220;Note 8. Employee Benefit Plans&#8221; of the Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678515416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">PROVISION FOR INCOME TAXES</a></td>
<td class="text">PROVISION FOR INCOME TAXESThe effective tax rate for the three and six months ended June&#160;30, 2021 was 23.1% and 20.5%, respectively, as compared to 17.2% and 18.0% for the corresponding periods in 2020. The effective tax rate for the three and six months ended June&#160;30, 2021 and 2020 differed from the U.S. federal statutory tax rate of 21% primarily due to excess tax benefits related to the exercise of certain stock options during the periods and the generation of federal tax credits, partially offset by state taxes.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874682770360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">NET INCOME PER SHARE</a></td>
<td class="text">NET INCOME PER SHARE<div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dilutive securities included outstanding stock options and Performance Stock Options, unvested RSUs and PSUs and ESPP contributions.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain potential common shares were excluded from our calculation of weighted-average common shares outstanding - diluted because either they would have had an anti-dilutive effect on net income per share or they were related to shares from PSUs that were contingently issuable and the contingency had not been satisfied at the end of the reporting period. The weighted-average potential common shares excluded from our calculation were as follows (in thousands):</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680034632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">COMMITMENTS AND CONTINGENCIES</a></td>
<td class="text">COMMITMENTS AND CONTINGENCIESIn September 2019, we received a notice letter regarding an Abbreviated New Drug Application (ANDA) submitted to the FDA by MSN Pharmaceuticals, Inc. (MSN), requesting approval to market a generic version of CABOMETYX tablets. MSN&#8217;s initial notice letter included a Paragraph IV certification with respect to our U.S. Patent Nos. 8,877,776, 9,724,342, 10,034,873 and 10,039,757, which are listed in the Approved Drug Products with Therapeutic Equivalence Evaluations, also referred to as the Orange Book. MSN&#8217;s initial notice letter did not provide a Paragraph IV certification against U.S. Patent No. 7,579,473, the composition of matter patent, or U.S. Patent No. 8,497,284, a method of use patent. On October 29, 2019, we filed a complaint in the United States District Court for the District of Delaware (the Delaware District Court) for patent infringement against MSN asserting U.S. Patent No. 8,877,776 arising from MSN&#8217;s ANDA filing with the FDA. On November 20, 2019, MSN filed its response to the complaint, alleging that U.S. Patent No. 8,877,776 is invalid and not infringed. On May 5, 2020, we received notice from MSN that it had amended its ANDA to assert additional Paragraph IV certifications. The ANDA now requests approval to market a generic version of CABOMETYX tablets prior to expiration of the two previously unasserted CABOMETYX patents: U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284. On May 11, 2020, we filed a complaint in the Delaware District Court for patent infringement against MSN asserting U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 arising from MSN&#8217;s amended ANDA filing with the FDA. Neither of our complaints alleges infringement of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757. On May 22, 2020, MSN filed its response to the complaint, alleging that each of U.S. Patent No. 7,579,473 and U.S. Patent No. 8,497,284 is invalid and not infringed. On March 23, 2021, MSN filed its First Amended Answer and Counterclaims (amending its prior filing from May 22, 2020), seeking, among other things, a declaratory judgment that U.S. Patent No. 9,809,549 is invalid and would not be infringed by MSN if its generic version of CABOMETYX tablets were approved by the FDA. On April 7, 2021, we filed our response to MSN&#8217;s First Amended Answer and Counterclaims, denying, among other things, that U.S. Patent No. 9,809,549 is invalid or would not be infringed. In our complaints, we are seeking, among other relief, an order that the effective date of any FDA approval of MSN&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent No. 7,579,473, U.S. Patent No. <div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8,497,284 and U.S. Patent No. 8,877,776, the latest of which expires on October 8, 2030, and equitable relief enjoining MSN from infringing these patents. These lawsuits against MSN have been consolidated, and a bench trial has been scheduled for May 2022. </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2021, we received notice letters from Teva Pharmaceuticals Development, Inc. and Teva Pharmaceuticals USA, Inc. (individually and collectively referred to as Teva) regarding an ANDA Teva submitted to the FDA, requesting approval to market a generic version of CABOMETYX tablets. Teva&#8217;s notice letters included a Paragraph IV certification with respect to our U.S. Patent Nos. 9,724,342 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment), which are listed in the Orange Book and expire in 2033, 2031 and 2031, respectively. Teva&#8217;s notice letters did not provide a Paragraph IV certification against any additional CABOMETYX patents. On June 17, 2021, we filed a complaint in the Delaware District Court for patent infringement against Teva, along with Teva Pharmaceutical Industries Limited, asserting U.S. Patent Nos. 9,724,324 (formulations), 10,034,873 (methods of treatment) and 10,039,757 (methods of treatment) arising from Teva&#8217;s ANDA filing with the FDA. We are seeking, among other relief, an order that the effective date of any FDA approval of Teva&#8217;s ANDA would be a date no earlier than the expiration of all of U.S. Patent Nos. 9,724,342, 10,034,873 and 10,039,757, the latest of which expires on July 9, 2033, and equitable relief enjoining Teva </span><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and Teva Pharmaceutical Industries Limited </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">from infringing these patents.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The sale of any generic version of CABOMETYX earlier than its patent expiration could significantly decrease our revenues derived from the U.S. sales of CABOMETYX and thereby materially harm our business, financial condition and results of operations. It is not possible at this time to determine the likelihood of an unfavorable outcome or estimate of the amount or range of any potential loss.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also from time to time become a party or subject to various other legal proceedings and claims, either asserted or unasserted, which arise in the ordinary course of business. Some of these proceedings have involved, and may involve in the future, claims that are subject to substantial uncertainties and unascertainable damages.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874773219880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Basis of Consolidation</a></td>
<td class="text">The accompanying Condensed Consolidated Financial Statements include the accounts of Exelixis and those of our wholly-owned subsidiaries. These entities&#8217; functional currency is the U.S. dollar. All intercompany balances and transactions have been eliminated.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The accompanying unaudited Condensed Consolidated Financial Statements have been prepared in accordance with accounting principles generally accepted in the U.S. for interim financial information and pursuant to Form 10-Q and Article 10 of Regulation S-X of the Securities and Exchange Commission (SEC). Accordingly, they do not include all of the information and footnotes required by U.S. generally accepted accounting principles for complete financial statements. In our opinion, all adjustments (consisting only of normal recurring adjustments) considered necessary for a fair presentation of our financial statements for the periods presented have been included. Operating results for the six months ended June&#160;30, 2021 are not necessarily indicative of the results that may be expected for the year ending December&#160;31, 2021 or for any future period. The accompanying Condensed Consolidated Financial Statements and Notes thereto should be read in conjunction with our Consolidated Financial Statements and Notes thereto for the year ended December&#160;31, 2020, included in our Annual Report on Form 10-K submitted to the SEC on February&#160;10, 2021.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiscalPeriod', window );">Fiscal Period</a></td>
<td class="text"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a 52- or 53-week fiscal year policy that generally ends on the Friday closest to December 31</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">st</span>. Fiscal year 2021, which is a 52-week fiscal year, will end on December&#160;31, 2021 and fiscal year 2020, which was a 52-week fiscal year, ended on January&#160;1, 2021. For convenience, references in this report as of and for the fiscal periods ended  July&#160;2, 2021 and July&#160;3, 2020, and as of and for the fiscal year ended January&#160;1, 2021, are indicated as being as of and for the fiscal periods ended June&#160;30, 2021 and June&#160;30, 2020, and the year ended December&#160;31, 2020, respectively.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We operate in one business segment that focuses on the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Our Chief Executive Officer, as the chief operating decision-maker, manages and </span></div>allocates resources to our operations on a total consolidated basis. Consistent with this decision-making process, our Chief Executive Officer uses consolidated, single-segment financial information for purposes of evaluating performance, forecasting future period financial results, allocating resources and setting incentive targets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the accompanying Condensed Consolidated Financial Statements conforms to accounting principles generally accepted in the U.S., which requires management to make judgments, estimates and assumptions that affect the reported amounts of assets, liabilities, equity, revenues and expenses, and related disclosures. On an ongoing basis, we evaluate our significant estimates. We base our estimates on historical experience and on various other market-specific and other relevant assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text">ReclassificationsCertain prior period amounts in the accompanying Condensed Consolidated Financial Statements have been reclassified to conform to the current period presentation. Such reclassifications did not impact previously reported total revenues, income from operations, net income, total assets, total liabilities or total stockholders&#8217; equity.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Foreign Currency Forward Contracts for Non-Designated Hedges</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Foreign Currency Forward Contracts for Non-Designated Hedges</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may use forward foreign currency exchange contracts (forward contracts) to hedge certain operational exposures resulting from potential changes in foreign currency exchange rates. Our strategy is to enter into forward contracts so that increases or decreases in our foreign currency exposures are offset by gains or losses on the foreign currency forward contracts thereby mitigating the risks and volatility associated with our foreign currency transactions. We do not apply hedge accounting treatment to these non-designated hedging instruments. We do not hold or issue derivative instruments for trading or speculative purposes.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our forward contracts are generally short-term in duration. Given the short duration of the forward contracts, amounts recorded generally are not significant. We account for our derivative instruments as either assets or liabilities on our Condensed Consolidated Balance Sheets and measure them at fair value. Derivatives not designated as hedging instruments are adjusted to fair value through earnings in other income (expense), net in the Condensed Consolidated Statements of Income.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted</a></td>
<td class="text"><div style="margin-top:9pt"><span style="background-color:#ffffff;color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 1, 2021, we adopted the Accounting Standards Board&#8217;s (FASB) Accounting Standards Update (ASU) 2019-12,&#160;</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740)-Simplifying the Accounting for Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (ASU 2019-12). ASU 2019-12 simplifies the accounting for income taxes by removing certain exceptions to the general principles in Accounting Standards Codification (ASC) Topic 740, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and clarifying and amending existing guidance. Our adoption of ASU 2019-12 did not have a significant impact on the accompanying Condensed Consolidated Financial Statements.</span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no new accounting pronouncements issued since our filing of the Annual Report on Form 10-K for the year ended December 31, 2020, which could have a significant effect on our condensed consolidated financial statements.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenues</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Total revenues include net product revenues attributed to geographic regions based on the ship-to location and license and collaboration services revenues attributed to geographic regions based on the location of our collaboration partners&#8217; headquarters.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues and license revenues are recorded in accordance with ASC Topic 606, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (Topic 606). License revenues include the recognition of the portion of milestones payments allocated to the transfer of intellectual property licenses for which it had become probable in the current period that the milestone would be achieved and a significant reversal of revenues would not occur, as well as royalty revenues and our share of profits under our collaboration agreement with Genentech. Collaboration services revenues were recorded in accordance with ASU 2018-18, </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic 808 and Topic 606</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and by analogy to Topic 606. Collaboration services revenues include the recognition of deferred revenues for the portion of upfront and milestone payments allocated to our research and development services performance obligations, development cost reimbursements earned under our collaboration agreements, product supply revenues, net of product supply costs, and the royalties we paid on sales of products containing cabozantinib by our collaboration partners. We received notification that, effective January 1, 2021, Royalty Pharma plc (Royalty Pharma) acquired from GlaxoSmithKline (GSK) all rights, title and interest in royalties on net product sales containing cabozantinib for non-U.S. markets for the full term of the royalty and for the U.S. market through September 2026, after which time U.S. royalties will revert back to GSK.</span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The allowance for chargebacks, discounts for prompt payment and other are recorded as a reduction of trade receivables, net and the remaining reserves are recorded as rebates and fees due to customers in the accompanying Condensed Consolidated Balance Sheets. </span></div><div style="margin-top:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contract Assets and Liabilities </span></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We receive payments from our collaboration partners based on billing schedules established in each contract. Amounts are recorded as accounts receivable when our right to consideration is unconditional. We may also recognize revenue in advance of the contractual billing schedule and such amounts are recorded as a contract asset when recognized. We may be required to defer recognition of revenue for upfront and milestone payments until we perform our obligations under these arrangements, and such amounts are recorded as deferred revenue upon receipt or when due. For those contracts that have multiple performance obligations, contract&#160;assets and liabilities are reported on a&#160;net&#160;basis&#160;at the&#160;contract&#160;level.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41638-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=d3e41675-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiscalPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=d3e5291-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiscalPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429488&amp;loc=d3e326-107755<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130561-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130563-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130564-203045<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130566-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874684630040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueTableTextBlock', window );">Schedule of Disaggregation of Revenue</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.715%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Product revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gross product revenues</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">380,204&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">229,898&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">694,409&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482,464&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Discounts and allowances</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95,956)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(51,168)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(182,949)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(109,854)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration revenues:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">39,640&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">59,234&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">67,168&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,113&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">61,289&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,779&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,671&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total collaboration revenues</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100,929&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">80,749&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,947&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">113,784&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,394&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenues by product were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.864%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">CABOMETYX</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">275,614&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">173,610&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">499,209&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">362,826&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">COMETRIQ</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,120&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,251&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product revenues</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">284,248&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">178,730&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">511,460&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372,610&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock', window );">Schedule of Concentration Risks</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of total revenues by customer who individually accounted for&#160;10%&#160;or more of our total revenues were as follows:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.039%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of Optum Specialty Pharmacy</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accredo Health, Incorporated</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The percentage of trade receivables by customer who individually accounted for 10% or more of our trade receivables were as follows: </span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Ipsen Pharma SAS</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of McKesson Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Affiliates of AmerisourceBergen Corporation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Affiliates of CVS Health Corporation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Takeda Pharmaceutical Company Limited</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Schedule of Revenues Disaggregated by Geographic Region</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues by geographic region were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">287,190&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,231&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">517,147&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">377,827&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Japan</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,331&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,533&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,614&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">385,177&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">259,479&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">655,407&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,394&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock', window );">Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The activities and ending reserve balances for each significant category of discounts and allowances, which constitute variable consideration, were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.905%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.590%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Chargebacks, Discounts for Prompt Payment and Other</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Customer Credits/Fees and Co-pay Assistance</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Rebates</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at December&#160;31, 2020</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,853&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,279&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">17,404&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,536&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Provision related to sales made in:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">114,489&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,392&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,355&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">181,236&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prior periods</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(40)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(164)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,917&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,713&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Payments and customer credits issued</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(108,487)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,637)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(46,349)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166,473)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Balance at June&#160;30, 2021</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,815&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,870&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,327&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,012&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Other Assets and Other Liabilities</a></td>
<td class="text">Contract assets and liabilities were as follows (in thousands):<div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9,749&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">948&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,697&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contract liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,314&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,790&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion</span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,577&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total contract liabilities</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,891&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,545&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">____________________</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;Presented in prepaid and other current assets and other long-term assets, respectively, on the accompanying Condensed Consolidated Balance Sheets.</span></div>(2)&#160;&#160;&#160;&#160;Presented in other current liabilities and long-term portion of deferred revenues, respectively, in the accompanying Condensed Consolidated Balance Sheets.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6327-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6442-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678680104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Revenues Under Collaboration Agreement</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Ipsen were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,656&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">33,597&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,107&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51,546&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">57,265&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,320&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">68,620&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,407&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">90,921&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">52,917&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124,727&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81,953&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues under the collaboration agreement with Takeda were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">License revenues</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,097&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,398&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,946&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Collaboration services revenues</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,024&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,195&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,264&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,121&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,141&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,557&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,210&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div>License revenues under the collaboration agreement with Genentech were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.822%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.780%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.846%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.743%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Profits on U.S. commercialization</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,376&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,954&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,783&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty revenues on ex-U.S. sales</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,125&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,733&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,434&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874679922696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Investments (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash</a></td>
<td class="text">A reconciliation of cash, cash equivalents, and restricted cash equivalents reported in the accompanying Condensed Consolidated Balance Sheets to the amount reported within the accompanying Condensed Consolidated Statements of Cash Flows was as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,462&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">319,217&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash equivalents included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46,839&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,555&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">539,301&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">320,772&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock', window );">Schedule of Investments by Security Type</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash, cash equivalents, restricted cash equivalents and investments consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">716,916&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">489,678&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,630&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,036&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,352,891&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">88,511&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,736,414&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,855&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,739,086&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.495%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.808%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Amortized Cost</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Gains</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Debt securities available-for-sale:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,456&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">543,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,244&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,326&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">232&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,680&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">83&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,349,982&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">82,176&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total cash, cash equivalents, restricted cash equivalents and investments</span></div></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,532,923&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,931&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,538,842&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock', window );">Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position</a></td>
<td class="text">The fair value and gross unrealized losses on debt securities available-for-sale in an unrealized loss position were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.376%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.692%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,002&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">154,767&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(166)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38,088&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,897&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">199,754&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(183)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.227%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.841%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Unrealized Losses</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,445&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21,989&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,865&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56,299&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of debt securities available-for-sale by contractual maturity was as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing in one year or less</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,015,650&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,034,150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Maturing after one year through five years</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">339,913&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">321,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrealized gains and losses on investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680000376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The classifications within the fair value hierarchy of our financial assets that were measured and recorded at fair value on a recurring basis were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">717,057&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">492,142&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">132,066&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,298&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,563&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,706&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">179,306&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,471,269&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,650,575&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.804%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.807%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level&#160;2</span></div></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Commercial paper</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">569,828&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Corporate bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">548,757&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S. Treasury and government-sponsored enterprises</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">208,554&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Municipal bonds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,762&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total debt securities available-for-sale</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,355,901&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Money market funds</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Certificates of deposit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60,004&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total financial assets carried at fair value</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40,761&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,415,905&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,456,666&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:3pt double #000000;padding:0 1pt"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681222520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Inventory</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inventory consisted of the following (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:64.673%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.715%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.717%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">June 30, 2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">December 31, 2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Raw materials</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,905&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,773&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25,951&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,610&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,443&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%"><br/></span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">Balance Sheet classification:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current portion included in inventory</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,982&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,973&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Long-term portion included in other long-term assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,461&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,701&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">41,443&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35,674&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678524824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Allocated Employee Stock-Based Compensation Expense</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We allocated the stock-based compensation expense for our equity incentive plans and our Employee Stock Purchase Plan (ESPP) as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13,667&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,112&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,063&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,198&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">14,368&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,042&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18,938&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Stock-based compensation for each type of award under our equity incentive plans and ESPP were as follows (in thousands):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.593%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,902&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,301&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,596&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,295&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted stock units</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,412&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,599&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,081&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,396&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Performance stock units</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,429&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22,645&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,925&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ESPP</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,023&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">825&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,366&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total stock-based compensation expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,154&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62,688&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,136&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A Monte Carlo simulation model was used to determine the grant date fair value of $24.54 for the 2021 PSUs based on the following assumptions:</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:90.120%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.680%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Fair value of the Company&#8217;s common stock on grant date</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">21.31&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Expected volatility</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">49&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk-free interest rate</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">0.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Dividend yield</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:115%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680219576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jul. 02, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share</a></td>
<td class="text"><div style="margin-top:9pt;text-indent:36pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net income per share - basic and diluted, were computed as follows (in thousands, except per share amounts):</span></div><div style="margin-top:9pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.417%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Numerator:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">96,092&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">66,821&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">97,693&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,433&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Denominator:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; basic</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">314,117&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">307,807&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">313,295&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">306,598&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dilutive securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,824&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,337&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,819&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,394&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:5pt;margin-top:5pt;padding-left:11.25pt"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding &#8212; diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,941&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">318,144&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">322,114&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,992&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; basic</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.22&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.31&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.38&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net income per share &#8212; diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.21&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.30&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.36&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share</a></td>
<td class="text">The weighted-average potential common shares excluded from our calculation were as follows (in thousands):<table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.566%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.544%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.436%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.739%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.395%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.742%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Three Months Ended June 30,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Six Months Ended June 30,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2021</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:9pt;font-weight:700;line-height:120%">2020</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Anti-dilutive securities and contingently issuable shares excluded</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12,285&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,812&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,146&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10,413&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874677401160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 02, 2021 </div>
<div>product </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of business segments | segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember', window );">Resulting from discovery efforts</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember', window );">Products derived from other compounds</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems', window );"><strong>Organization And Summary Of Significant Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_NumberofProductsinCommercialMarket', window );">Number of products that entered in the commercial marketplace</a></td>
<td class="nump">2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_NumberofProductsinCommercialMarket">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Products in Commercial Market</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_NumberofProductsinCommercialMarket</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_OrganizationAndSummaryOfSignificantPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization And Summary Of Significant Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_OrganizationAndSummaryOfSignificantPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ResultingFromDiscoveryEffortsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductsDerivedFromOtherCompoundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874683329464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues by Disaggregated Category (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductGrossMember', window );">Gross product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">380,204<span></span>
</td>
<td class="nump">229,898<span></span>
</td>
<td class="nump">694,409<span></span>
</td>
<td class="nump">482,464<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember', window );">Discounts and allowances</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="num">(95,956)<span></span>
</td>
<td class="num">(51,168)<span></span>
</td>
<td class="num">(182,949)<span></span>
</td>
<td class="num">(109,854)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">284,248<span></span>
</td>
<td class="nump">178,730<span></span>
</td>
<td class="nump">511,460<span></span>
</td>
<td class="nump">372,610<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">21,515<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CollaborationMember', window );">Total collaboration revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 100,929<span></span>
</td>
<td class="nump">$ 80,749<span></span>
</td>
<td class="nump">$ 143,947<span></span>
</td>
<td class="nump">$ 113,784<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductGrossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductGrossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_ProductSalesDiscountsAndAllowancesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874770448776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Significant Customer (Details) - Customer Concentration Risk<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">24.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_IpsenMember', window );">Ipsen Pharma SAS | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember', window );">Affiliates of McKesson Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">14.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember', window );">Affiliates of CVS Health Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">13.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember', window );">Affiliates of AmerisourceBergen Corporation | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember', window );">Affiliates of Optum Specialty Pharmacy | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember', window );">Accredo Health, Incorporated | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">9.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_TakedaMember', window );">Takeda Pharmaceutical Company Limited | Accounts Receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems', window );"><strong>Revenue, Initial Application Period Cumulative Effect Transition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percent of total revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13531-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13537-108611<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_IpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_IpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofMcKessonCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofCVSHealthCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesOfAmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AffiliatesofOptumSpecialtyPharmacyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_AccredoHealthIncorporatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_TakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_TakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681008120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Revenues Disaggregated by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">287,190<span></span>
</td>
<td class="nump">181,231<span></span>
</td>
<td class="nump">517,147<span></span>
</td>
<td class="nump">377,827<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">90,921<span></span>
</td>
<td class="nump">52,917<span></span>
</td>
<td class="nump">124,727<span></span>
</td>
<td class="nump">81,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_JP', window );">Japan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 7,066<span></span>
</td>
<td class="nump">$ 25,331<span></span>
</td>
<td class="nump">$ 13,533<span></span>
</td>
<td class="nump">$ 26,614<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681541128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Net Product Revenues Disaggregated by Product (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CabometyxMember', window );">CABOMETYX</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">275,614<span></span>
</td>
<td class="nump">173,610<span></span>
</td>
<td class="nump">499,209<span></span>
</td>
<td class="nump">362,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=exel_CometriqMember', window );">COMETRIQ</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">8,634<span></span>
</td>
<td class="nump">5,120<span></span>
</td>
<td class="nump">12,251<span></span>
</td>
<td class="nump">9,784<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Net product revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisaggregationOfRevenueLineItems', window );"><strong>Disaggregation of Revenue [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenues</a></td>
<td class="nump">$ 284,248<span></span>
</td>
<td class="nump">$ 178,730<span></span>
</td>
<td class="nump">$ 511,460<span></span>
</td>
<td class="nump">$ 372,610<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisaggregationOfRevenueLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisaggregationOfRevenueLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CabometyxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CabometyxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CometriqMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CometriqMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681525288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">$ 30,536<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">181,236<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(166,473)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2021</a></td>
<td class="nump">47,012<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember', window );">Chargebacks, Discounts for Prompt Payment and Other</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">9,853<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">114,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(40)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(108,487)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2021</a></td>
<td class="nump">15,815<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember', window );">Other Customer Credits/Fees and Co-pay Assistance</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">3,279<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">15,392<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="num">(164)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(11,637)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2021</a></td>
<td class="nump">6,870<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember', window );">Rebates</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at December&#160;31, 2020</a></td>
<td class="nump">17,404<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract', window );"><strong>Provision related to sales made in:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod', window );">Current period</a></td>
<td class="nump">51,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod', window );">Prior periods</a></td>
<td class="nump">1,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Payments and customer credits issued</a></td>
<td class="num">(46,349)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at June&#160;30, 2021</a></td>
<td class="nump">$ 24,327<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Current Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions For Sales In Prior Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Valuation Allowances And Reserves, Additions To Provision [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e24092-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_ChargebacksAndDiscountsForPromptPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=exel_AllowanceForProductRebatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681757704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenues - Contract Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetAbstract', window );"><strong>Contract assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetCurrent', window );">Current portion</a></td>
<td class="nump">$ 9,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,749<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNetNoncurrent', window );">Long-term portion</a></td>
<td class="nump">948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Total contract assets</a></td>
<td class="nump">10,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,697<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Contract liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Current portion</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Long-term portion</a></td>
<td class="nump">8,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,577<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,755<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Total contract liabilities</a></td>
<td class="nump">14,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,891<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,545<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized', window );">Contract revenue recognized, including revenue from deferred revenue beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,800<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod', window );">Revenues recognized for performance obligations satisfied in previous periods</a></td>
<td class="nump">40,600<span></span>
</td>
<td class="nump">$ 62,000<span></span>
</td>
<td class="nump">67,800<span></span>
</td>
<td class="nump">$ 82,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">86,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement', window );">Milestone receivable upon achievement of development achievement</a></td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement', window );">Collaborative arrangement, revenue recognized upon development milestone achievement</a></td>
<td class="nump">11,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 46,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Amount Receivable From Collaboration For Development And Regulatory Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Revenue Recognized Upon Development Milestone Achievement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Including New Contract Revenue, Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNetNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130533-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNetNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12A<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL108322424-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681462152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">90,921<span></span>
</td>
<td class="nump">52,917<span></span>
</td>
<td class="nump">124,727<span></span>
</td>
<td class="nump">81,953<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">33,656<span></span>
</td>
<td class="nump">33,597<span></span>
</td>
<td class="nump">56,107<span></span>
</td>
<td class="nump">51,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">21,515<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 57,265<span></span>
</td>
<td class="nump">$ 19,320<span></span>
</td>
<td class="nump">$ 68,620<span></span>
</td>
<td class="nump">$ 30,407<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678516984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember', window );">Collaborative Arrangement with Ipsen</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 46.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithIpsenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681064856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">6,121<span></span>
</td>
<td class="nump">25,141<span></span>
</td>
<td class="nump">11,557<span></span>
</td>
<td class="nump">26,210<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">39,640<span></span>
</td>
<td class="nump">59,234<span></span>
</td>
<td class="nump">67,168<span></span>
</td>
<td class="nump">80,113<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">2,097<span></span>
</td>
<td class="nump">22,946<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">22,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">61,289<span></span>
</td>
<td class="nump">21,515<span></span>
</td>
<td class="nump">76,779<span></span>
</td>
<td class="nump">33,671<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember', window );">Collaboration services revenues | Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenues</a></td>
<td class="nump">$ 4,024<span></span>
</td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 8,159<span></span>
</td>
<td class="nump">$ 3,264<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ServiceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ServiceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874677419096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 86.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember', window );">Collaborative Arrangement with Takeda</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Remaining performance obligation</a></td>
<td class="nump">$ 40.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130556-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithTakedaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874683330488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember', window );">Collaboration Agreement with GlaxoSmithKline</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty expense</a></td>
<td class="nump">$ 12.1<span></span>
</td>
<td class="nump">$ 7.6<span></span>
</td>
<td class="nump">$ 22.2<span></span>
</td>
<td class="nump">$ 15.7<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember', window );">GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale', window );">Percent of royalty on net sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborationAgreementPercentOfRoyaltyOnNetSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration Agreement, Percent Of Royalty On Net Sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborationAgreementPercentOfRoyaltyOnNetSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementswithGlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=exel_GlaxoSmithKlineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874686648488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 385,177<span></span>
</td>
<td class="nump">$ 259,479<span></span>
</td>
<td class="nump">$ 655,407<span></span>
</td>
<td class="nump">$ 486,394<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember', window );">Collaborative Arrangement with Genentech | Cotellic</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementIncomeLossFromAgreement', window );">Profits on U.S. commercialization</a></td>
<td class="nump">2,160<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
<td class="nump">3,954<span></span>
</td>
<td class="nump">2,783<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Royalty revenues on ex-U.S. sales</a></td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 1,125<span></span>
</td>
<td class="nump">$ 1,733<span></span>
</td>
<td class="nump">$ 2,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementIncomeLossFromAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Income (Loss) from Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementIncomeLossFromAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=exel_CollaborativeArrangementwithGenentechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=exel_CotellicMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=exel_CotellicMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874683162152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 17.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments', window );">Collaborative arrangement, maximum aggregate development milestone payments</a></td>
<td class="nump">58.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments', window );">Collaborative arrangement, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">139.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments', window );">Collaborative arrangement, maximum aggregate commercial milestone payments</a></td>
<td class="nump">377.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember', window );">Collaborative Agreement With GamaMabs Pharma SA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetAcquisitionLineItems', window );"><strong>Asset Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to acquire assets</a></td>
<td class="nump">5.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction', window );">Payment upon closing of transaction</a></td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments', window );">Asset acquisition, maximum aggregate development milestone payments</a></td>
<td class="nump">42.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments', window );">Asset acquisition, maximum aggregate regulatory milestone payments</a></td>
<td class="nump">$ 22.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_AssetAcquisitionPaymentUponClosingOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Payment Upon Closing Of Transaction</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_AssetAcquisitionPaymentUponClosingOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9212-128498<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 30<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123362884&amp;loc=d3e9215-128498<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 50<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123385561&amp;loc=d3e9135-128495<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetAcquisitionAxis=exel_CollaborativeAgreementWithGamaMabsPharmaSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874677365640">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 492,462<span></span>
</td>
<td class="nump">$ 319,217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsNoncurrent', window );">Restricted cash equivalents included in other long-term assets</a></td>
<td class="nump">46,839<span></span>
</td>
<td class="nump">1,555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows</a></td>
<td class="nump">$ 539,301<span></span>
</td>
<td class="nump">$ 320,772<span></span>
</td>
<td class="nump">$ 528,779<span></span>
</td>
<td class="nump">$ 268,137<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874682533512">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Narrative (Details)<br></strong></div></th>
<th class="th">
<div>Jul. 02, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jan. 01, 2021 </div>
<div>USD ($) </div>
<div>investment</div>
</th>
<th class="th">
<div>Jul. 03, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalentsCurrent', window );">Restricted cash short-term investments</a></td>
<td class="nump">$ 45,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Interest receivable</a></td>
<td class="nump">$ 3,300,000<span></span>
</td>
<td class="nump">$ 4,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions', window );">Number of investments in an unrealized loss position | investment</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for credit losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalentsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120413209&amp;loc=SL6242269-115581<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL6242262-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalentsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681019848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Investments by Security Type (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 1,352,891<span></span>
</td>
<td class="nump">$ 1,349,982<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,355,563<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,736,414<span></span>
</td>
<td class="nump">1,532,923<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,855<span></span>
</td>
<td class="nump">5,931<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,739,086<span></span>
</td>
<td class="nump">1,538,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">716,916<span></span>
</td>
<td class="nump">569,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">141<span></span>
</td>
<td class="nump">372<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">717,057<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">489,678<span></span>
</td>
<td class="nump">543,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">2,630<span></span>
</td>
<td class="nump">5,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">492,142<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">132,036<span></span>
</td>
<td class="nump">208,326<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">132,066<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesAbstract', window );"><strong>Debt securities available-for-sale:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">14,261<span></span>
</td>
<td class="nump">28,680<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">41<span></span>
</td>
<td class="nump">83<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">14,298<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember', window );">Cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">88,511<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">88,511<span></span>
</td>
<td class="nump">82,176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">179,306<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">179,306<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">115,706<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain', window );">Gross Unrealized Gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure', window );">Fair Value</a></td>
<td class="nump">$ 115,706<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CashMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CashMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874681514184">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">$ 199,754<span></span>
</td>
<td class="nump">$ 56,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(183)<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">1,002<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">154,767<span></span>
</td>
<td class="nump">28,445<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(166)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">38,088<span></span>
</td>
<td class="nump">21,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract', window );"><strong>Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition', window );">Fair Value</a></td>
<td class="nump">5,897<span></span>
</td>
<td class="nump">5,865<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss', window );">Gross Unrealized Losses</a></td>
<td class="num">$ (4)<span></span>
</td>
<td class="num">$ (1)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27290-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922888-210455<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874678652664">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Maturing in one year or less</a></td>
<td class="nump">$ 1,015,650<span></span>
</td>
<td class="nump">$ 1,034,150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Maturing after one year through five years</a></td>
<td class="nump">339,913<span></span>
</td>
<td class="nump">321,751<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,355,563<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874768473688">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">$ 1,355,563<span></span>
</td>
<td class="nump">$ 1,355,901<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,355,563<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,650,575<span></span>
</td>
<td class="nump">1,456,666<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">179,306<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">1,355,563<span></span>
</td>
<td class="nump">1,355,901<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total financial assets carried at fair value</a></td>
<td class="nump">1,471,269<span></span>
</td>
<td class="nump">1,415,905<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">717,057<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">717,057<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial paper | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">717,057<span></span>
</td>
<td class="nump">569,828<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">492,142<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">492,142<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember', window );">Corporate bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">492,142<span></span>
</td>
<td class="nump">548,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">132,066<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">132,066<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember', window );">U.S. Treasury and government-sponsored enterprises | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">132,066<span></span>
</td>
<td class="nump">208,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">14,298<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">14,298<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember', window );">Municipal bonds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total debt securities available-for-sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">179,306<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">179,306<span></span>
</td>
<td class="nump">40,761<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">115,706<span></span>
</td>
<td class="nump">60,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level 1 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember', window );">Certificates of deposit | Level&#160;2 | Recurring</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 115,706<span></span>
</td>
<td class="nump">$ 60,004<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USTreasuryAndGovernmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CertificatesOfDepositMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680185768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Narratives (Details) - 6 months ended Jul. 02, 2021 - Foreign Exchange Forward<br> &#8364; in Millions, $ in Millions</strong></div></th>
<th class="th"><div>USD ($)</div></th>
<th class="th">
<div>EUR (&#8364;) </div>
<div>forwardContract</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNumberOfInstrumentsHeld', window );">Number of contract | forwardContract</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative notional amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 9.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainOnDerivativeInstrumentsPretax', window );">Gain on derivative instruments, pretax | $</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNumberOfInstrumentsHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of derivative instruments of a particular group held by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5579245-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5580258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNumberOfInstrumentsHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainOnDerivativeInstrumentsPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=125515794&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainOnDerivativeInstrumentsPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeForwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874682097624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventory (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterials', window );">Raw materials</a></td>
<td class="nump">$ 6,905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,773<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcess', window );">Work in process</a></td>
<td class="nump">25,951<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,610<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoods', window );">Finished goods</a></td>
<td class="nump">8,587<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,291<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">41,443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,674<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWriteDown', window );">Inventory write-down</a></td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember', window );">Current portion included in inventory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">24,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,973<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember', window );">Long-term portion included in other long-term assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryLineItems', window );"><strong>Inventory [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryGross', window );">Total</a></td>
<td class="nump">$ 16,461<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,701<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWriteDown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4542-108314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWriteDown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_InventoriesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=exel_OtherLongtermAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874686616904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="nump">$ 62,688<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">13,667<span></span>
</td>
<td class="nump">6,112<span></span>
</td>
<td class="nump">26,063<span></span>
</td>
<td class="nump">11,198<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 14,368<span></span>
</td>
<td class="nump">$ 10,042<span></span>
</td>
<td class="nump">$ 36,625<span></span>
</td>
<td class="nump">$ 18,938<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874682949256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="nump">$ 62,688<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">5,301<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
<td class="nump">10,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">15,412<span></span>
</td>
<td class="nump">8,599<span></span>
</td>
<td class="nump">27,081<span></span>
</td>
<td class="nump">16,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,698<span></span>
</td>
<td class="nump">1,429<span></span>
</td>
<td class="nump">22,645<span></span>
</td>
<td class="nump">1,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 2,023<span></span>
</td>
<td class="nump">$ 825<span></span>
</td>
<td class="nump">$ 2,366<span></span>
</td>
<td class="nump">$ 1,520<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874686874040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares available for grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,254,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,254,455<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward', window );">Reduction in share reserve after stock option or stock appreciation award (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards', window );">Reduction in share reserve after all other awards (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28,035<span></span>
</td>
<td class="nump">$ 16,154<span></span>
</td>
<td class="nump">$ 62,688<span></span>
</td>
<td class="nump">$ 30,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted in the period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,733,554<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted in the period (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,443,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,443,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,902<span></span>
</td>
<td class="nump">5,301<span></span>
</td>
<td class="nump">10,596<span></span>
</td>
<td class="nump">10,295<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 149,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,575,190<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,314,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,314,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,412<span></span>
</td>
<td class="nump">8,599<span></span>
</td>
<td class="nump">$ 27,081<span></span>
</td>
<td class="nump">16,396<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of awards granted (in shares)</a></td>
<td class="nump">1,027,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of awards outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,709,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,709,765<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest', window );">Maximum potential to vest</a></td>
<td class="nump">200.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,698<span></span>
</td>
<td class="nump">$ 1,429<span></span>
</td>
<td class="nump">$ 22,645<span></span>
</td>
<td class="nump">$ 1,925<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting award percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance stock units | Share-based Payment Arrangement, Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>exel_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874684546632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details) - Performance stock units<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jul. 02, 2021 </div>
<div>$ / shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value, awarded (in dollars per share)</a></td>
<td class="nump">$ 24.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Fair value of the Company's common stock on grant date (in dollars per share)</a></td>
<td class="nump">$ 21.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">49.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.29%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874680178920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Provision For Income Taxes (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective income tax rate</a></td>
<td class="nump">23.10%<span></span>
</td>
<td class="nump">17.20%<span></span>
</td>
<td class="nump">20.50%<span></span>
</td>
<td class="nump">18.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874686905000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareReconciliationAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income</a></td>
<td class="nump">$ 96,092<span></span>
</td>
<td class="nump">$ 66,821<span></span>
</td>
<td class="nump">$ 97,693<span></span>
</td>
<td class="nump">$ 115,433<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">314,117<span></span>
</td>
<td class="nump">307,807<span></span>
</td>
<td class="nump">313,295<span></span>
</td>
<td class="nump">306,598<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Dilutive securities (in shares)</a></td>
<td class="nump">8,824<span></span>
</td>
<td class="nump">10,337<span></span>
</td>
<td class="nump">8,819<span></span>
</td>
<td class="nump">10,394<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">322,941<span></span>
</td>
<td class="nump">318,144<span></span>
</td>
<td class="nump">322,114<span></span>
</td>
<td class="nump">316,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income per share - basic (in dollars per share)</a></td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.22<span></span>
</td>
<td class="nump">$ 0.31<span></span>
</td>
<td class="nump">$ 0.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income per share - diluted (in dollars per share)</a></td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.21<span></span>
</td>
<td class="nump">$ 0.30<span></span>
</td>
<td class="nump">$ 0.36<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm139874684610408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
<th class="th"><div>Jul. 02, 2021</div></th>
<th class="th"><div>Jul. 03, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember', window );">Share-based Payment Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities and contingently issuable shares excluded (in shares)</a></td>
<td class="nump">12,285<span></span>
</td>
<td class="nump">8,812<span></span>
</td>
<td class="nump">11,146<span></span>
</td>
<td class="nump">10,413<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>72
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M\*VI?&LO/]!RF^V.K:36,LY^!ISY7)D;X/I:2GT\, \H-E@G_P%02P,$%
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M35#*-\DA5P_B^7?>$0IJ?VN1R^8O>NZPW@2M#U*)HC.&'119V7XF+UT@3@S
MC]V = 9$-_!'#&AG0"]=P>\,_$M7"#J#AOJTY=X$;IFH9#ZKQ#.J:C1XJ[\T
MT6^L(5Y961?*HZK@OQG8J?E"E"FDG:<(ODF19VFBX.)1P0?4@Y)(;-#'<BT*
MCMZC;X]+]/;-.R1W2<4ERDKT=2<.,BE3>87>G%W/I@JV5R\R77=;N6NW0D:V
M0M%G4:J=1"O84FJQ7[KM0X?]%,+2QX:\QN:..!U^.N37R"-7B'@$6_:SN,2<
M-N:>C<ZOK;[ZWZN?!8/VA4(;?W3$WP,_\O+ Y8W#E]_[\AM?_HBOKT(E.;29
MUJ.M4EK[L+&O>]UQ3EF HV@V/9XFP(21(/:C^!RV-&%A$/B>YFUEPGP6TMCO
M86=D@YYLX S<ESVO$I656\1?]O6MY@QAV'L-G2%<"*GJ6W,K1"H1W+BV&^:N
M]1&<,,(^8[X611,5D[KDSF)H@@CS&-%":%D0\N;9(QCU7",GUP<N>5*M=PCZ
M"@R!(TRW?=V;;(PC&^,H]C3*%ACV8THUTB:,>LR+F,;:A!$<LC':K*?-G+0?
M87I"V5RA+2^AA/*&?I+"$,BDJDOJR&T18&8VF1\'6@!,5!!'L9YT$P4"A/FA
MQM^$84(BBNW\XYY_?$&7$,;M8R,=FQL-(0=:(UB8,,S@!M>"LS1A 8U >6FT
M31@-F!>,T,;>,)(])_%NW&XJ4;S2A]EL':B>)?(44J3QMN"B(*!:(UC:W&'F
M>UI9K*S+,NK3$>8G8@3_A+GB("P4*(DZ!%;*V))#O7 7%E2 0Z+S-5%^$%&=
MK65%0D]:WSE9,I E3K)?U(Y7'5/TMJON=U>HY-;.UGD[W<9[;/ V09Y.VN;'
M3+&)"D<(#PH"TTOJ^HG#^8:_$E?)B_V6[IR=AQVFEU';)HYY81SJM&WN"#.S
M;<&!5!AK9GC0/-@M>NXK<<R:\Q70_SE[WS)O(YW5P@+#E$5Z0[-Y"S#S=.XV
M&(G9"/5! >' 2?U/[KRC T-WQ:$7$YVJ"0M#9N@4F[<HC(TTFS", Y^.M;!!
ME^'0*?<&K@A:=WM2<@D^/*@@[)9!=XG,UN@M'+)2D>=))8<%WEGCVKICI[W@
MFAH=PX8B1J>\Q-?*CAHKGT$'8;<06F;YH3Z4_@?JS+81G;D-9-;3!:Y6=M!8
MPQP$$(Z=M?2]><S!T_?)$53 EB,HJP(:2'?\%@<E%8A"$$>N"B.#\"!NX3%4
M6+N"-;;$'/X4^QCK9S,;#J2S?NI:6OU1HBO6E=5?&(QU)S*(#N(6':?EY>)M
MR@!*2.SK-Y0-AQGV=;%E]P?'$)VWS5\8QR/Z@PSZ@[CU1]VI]I5(#VLU<A8_
M=SS,>?+KCPK(,#?)KSXL();' ,P'K:!GQL3A"!2 KI LN #R$NKCTH*C$0G'
MSGUDF)?$/2__R-:U%KPH*\-@(N[!=%%6AF%$W,/H@JQ8#L]QZ.LG<0LLB(EQ
M-+' P@@.V7I*3!CS,!Z9ZF080<0]@A;UV'D2[5$,25X=(47RH@0-W9ZXN_TE
M":)#+Z?N7O[S!'4.S@05'./T,[,%1G" =8EI@45AI#^*6UE@E$(FM01-3YYH
M%[S:-J\2),R_0ZG:9Y;]K_WKB@_-0WKM]SM\L\"6WY?X9M6^C!C<M^]&/B?5
M-BLEROD&EO*N(RBFJGW=T%XHL6^>IS\)I431?-WQ).55#8#_;X10KQ?U OU+
MG_F_4$L#!!0    ( %6"!5/&I4-;1P,  &8)   8    >&PO=V]R:W-H965T
M<R]S:&5E=#4N>&ULI59;;]LV%/XKA."'&'"BN^0$MH'$=K$.Z!HT[?8P](&V
MCBVBE.B1E)WNU^^04E1'EKV@?9%X.=]WKN3AY"#D-Y4#:/)<\%)-G5SKW9WK
MJG4.!54W8@<E[FR$+*C&J=RZ:B>!9A94<#?PO,0M*"N=V<2N/<K91%2:LQ(>
M)5%545#Y_0&X.$P=WWE9^,2VN38+[FRRHUMX OUE]RAQYK8L&2N@5$R41,)F
MZMS[=\O4R%N!/QD<U-&8&$]60GPSD_?9U/&,0<!AK0T#Q=\>YL"Y(4(S_FDX
MG5:E 1Z/7]C?6=_1EQ55,!?\+Y;I?.J,'9+!AE9<?Q*'WZ#Q)S9\:\&5_9)#
M(^LY9%TI+8H&C!84K*S_]+F)PQ$ >?H!00,(NH#H#"!L .%;-40-('JKAK@!
M6-?=VG<;N 75=#:1XD"DD48V,[#1MVB,%RM-G3QIB;L,<7HV%V6&68>,X$@)
MSC*J<?*D\8?EH!41&]PJL AS4QU[(._+M2B 7),O3PMR-1B2 6$E^9R+2M$R
M4Q-7HUV&W5TW-CS4-@1G; C)!U'J7)$EVI+UX!>7\<D%O(OQ:(,2O 3E(;A(
M^'O%;X@7C$C@!7Z//?.WP$,+]_K<^37MRY_6_BH885LAH>4+S_"UI7"V$OZ^
M7RDM\<A_O: N:M5%5EUT1MT?>#<RR]M72#4VL5AS!>YGMXEW&TS<_7%Z3J62
M9&QB>2RUZ.%*D]OPM=3R5,KWXRC\(?;*R[CU,KX8U(\Z!TG6KZ)9>TVNN%!J
M>'<AE$FK)/G?4%8E=@_._L4SO<6NH6IZ4$-B;ND]99RN.%QCP[E6E />L2M-
M%*PKR30#-2(EV,1K^DQ8L<,DF]G5((C3X8@,@E$P3D<X3^-D2/#XDX$_"J-D
MA#U$[<!V ?Z]+Y.UZ?%17*_3..XD\E1H["6=;"]ZF(+HMI/MY:E4E*9^?Q;3
M-L#IQ0#/>_+7YVMZ6FEQ&*8=9T^ETF@\[M3CHH\+3WK'VU,IWUP'4<=?]ZAQ
M%""WMF,KK,NJU/4-T:ZVCX)[VPL[ZP_^W=SO65_@(Z+N^3_HZQ?(!RJWIAXY
M;%"5=Y-B:F3=U>N)%CO;ME9"8Q.TPQP?0B"- .YOA- O$Z.@?5K-_@-02P,$
M%     @ 58(%4[V;J:ZT @  !P<  !@   !X;"]W;W)K<VAE971S+W-H965T
M-BYX;6RE55U/VS 4_2M6Q -(E*1)6A!J*]&/:4QBJNC8'J8]N,EM8^'8F>VT
ML%^_:R<-!=(*;2^-/^XY]]R;VY/!5JI'G0$8\I1SH8=>9DQQ[?LZR2"G^D(6
M(/!F)55.#6[5VM>% IHZ4,[], CZ?DZ9\$8#=S97HX$L#6<"YHKH,L^I>AX#
ME]NAU_5V!_=LG1E[X(\&!5W# LQ#,5>X\QN6E.4@-)."*%@-O9ON]2RV\2[@
M.X.MWEL36\E2RD>[N4V'7F % 8?$6 :*CPU,@'-+A#)^UYQ>D]("]]<[]D^N
M=JQE235,)/_!4I,-O2N/I+"B)3?W<OL9ZGIZEB^17+M?LJUC X\DI38RK\&H
M(&>B>M*GN@][ .1I!X0U('P+B \ HAH0?31#7 /BCV;HU0!7NE_5[AHWI8:.
M!DINB;+1R&87KOL.C?UBPL[)PBB\98@SHXD4*;YU2 FNM.0LI08W"X,/' >C
MB5SA58Y#F-GIV "Y%8G,@9S.J<* # Q+*#\C'?*PF)+3DS-R0I@@WS)9:BI2
M/? -ZK39_*36-*XTA0<T1>1.(K$F,]26MN"GQ_'](W@?^],T*=PU:1P>)?Q2
M\@L2A.<D#,)NBY[)1^"1@P=MY?Q?]MD_9W_5C*B9F,CQ10?XFM$X.!D_;Y;:
M*+2 7T?2Q4VZV*6+#Z3[BEY9"K1 SO[@8*[1^C0YY5)KT&?$6LV&,DZ7'#KH
MFAU-.:!1+ W1D)2*&0;ZG AP:@U](BPO4%G;4%8Z^DZ'M=?-J!/V+@?^9O]-
MOP\*PZLW0=,6ILM>_W70['U0-XI?@JIF^7O_[!S4VEFJ)HDLA:E>67/:N/:-
M,ZLWY^/N]:3;<CY%EZ],^86^^D3<4;6VO>:PPE3!Q24:CZILM]H863A?64J#
M+N66&7ZI0-D O%]):78;FZ#Y]HW^ E!+ P04    " !5@@53J@J HD\'  "<
M)P  &    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;+U:VV[;.!#]%<(HL U0
MU^)%MR()T-@)MHN]!$V[^[#8!]5B8J&2Z$IRW/[]4K)J6N20BH/6+['DG!D?
M<C@\A[+/MZ+Z7*\X;]#7(B_KB\FJ:=9O9K-ZN>)%4K\6:U[*_]R+JD@:>5L]
MS.IUQ9.T"RKR&?&\8%8D63FY/._>NZTNS\6FR;.2WU:HWA1%4GV[XKG87DSP
MY/L;[[.'5=.^,;L\7R</_(XW']>WE;R;[;.D6<'+.A,EJOC]Q>0M?G/#_#:@
M0_R=\6U]<(W:H7P2XG-[\RZ]F'@M(Y[S9=.F2.3+(Y_S/&\S21Y?^J23_6>V
M@8?7W[/?=(.7@_F4U'PN\G^RM%E=3*()2OE]LLF;]V+[*^\'U!%<BKSN_J)M
MC_4F:+FI&U'TP9)!D96[U^1K/Q$' 9A: D@?0)X:0/L J@60T!+ ^@"F!;#
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M.284]RN93XX$.!PQ35?),9U$^K$Z0!V3ZL$+C@X/31V%/,7F$4N",!O!UA$
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M*P73(HR#JAPB.D%T>Q@>'QF5VI"X.^/7 X3E'>BF)'^PWW!";CPYJI$0SBM
M&;E)@>4"YX'?<,(<<$<\#RLWK,!QE0+X$^/#2/UJU%+?&66+.YP*&>G<F7<U
MHIZ$0=#<@D,+2) -E)G/#?,-+ZL<B3G+6$ZO2P0/M*=8(E.DOEYTPO.&OOR
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MJ05.3!R.9DQF0B__,&<WS9/4O%ML)+]M:(@C:<VR,0/8.DO>]GN8_=YOE]"
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M<VAE970Q,2YX;6S%6FMSV[@5_2L8K[N3S-"RWK8WCQG945)G'=NUG&RGG7Z
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M4KL4[@XLCW\APQ&?)'*I2.BIB3OB1?7V)6_]I?R[%L?:IA9<WXM31PF8(+E
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M"IOQRY5"A!TMP.<+"^]4;^B YO<\;_\-4$L#!!0    ( %6"!5,4X(HUV0@
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M1C:K7Q!ZV^#'QIO,L3:_ 0$9MN'PB&$+5=K79U:F:@TL,^?/V;NV%BSR'?"
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M;IXBBU3:]EKEU/'AEBS- 7O:CN&'#(D;*6Y$]K-<N[_8;__;3SGOK1Q F#[
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M"E:^XYZ?GUISSRSMAC1:!%?#:1@G-07EUEO\*G'.G__*I65?N6H$NQ'<-58
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M^XGE+QOK9"45I_-@9A/RD<0!=TB$FW;'*E, &M8X0@OP\M;:O2*IO0"_/;,
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M@]S@R1&H?A1J4G\\F2T6R6(Y&ZS05,2N(\JF(6W3U4DR2Y?[8^W[E4 5"BR
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MQ.=A)_0Q!I+?K])].)E&W2(@>A"&,0S*GV;$H,0,@Q;C@R^F$NR7-G2ODZ
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ME*7%X\4M;7K4SH"^KY6RCQ<7H/_O6/P&4$L#!!0    ( %6"!5-H:(!_=@@
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MJ9#@4*8=8:0+QFC,">.947VP)BECL)"#>$P50F3,Q/6W4@,74%*):_PH.5@
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M3]L[A4=0%M"2IC:)N<!(Y3;CQK17LOL>K6W@[/=K.'^P-)2$9+\*X_U8O:.
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M/4W ^,Q@_ZL'<M#\3\+Y_P%02P,$%     @ 58(%4RQ1!'0-#@  _2<  !D
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M8[B>3DY'(AHFU(-=T<I++_D%(<YO$0P[@$,_WSVR_]:&CH;7]>L!\NAX66H
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M83S"EG]2::HL+<!S^N*AO: #TA=_+_\+4$L#!!0    ( %6"!5.XCUW^; <
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M@+(&N%Y(:8X#FV#X+5K_"U!+ P04    " !5@@53^]" S,P"  #1!0  &0
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MIWJER H.*#DOL=)<5J!P._=NHNER8/V=PU\<][HW!YO)1LI':[S+YUYH":'
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M%536@=YO)96G,^P&A[^?Q7]02P,$%     @ 58(%4T1V+BBT @  N0<  !D
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MI=:HV)[0;F\43XL3Q2>N%(^+RS4E(17Y _KW)>=J=Y,'J,[)1_\!4$L#!!0
M   ( %6"!5/$9. =/@,  )L+   9    >&PO=V]R:W-H965T<R]S:&5E=#,P
M+GAM;+5676^;,!3]*Q;:PR9M =M\5DFD-<FV3IM4M>OV,.W!#0Z@ <YLDW3_
M?K8AE )%U:J^!-N<<Z[O/8ZY\R/COT5*J01W15Z*A95*N3^S;;%-:4'$C.UI
MJ=[L&"^(5%.>V&+/*8D-J<AMY#B^79"LM)9SLW;)EW-6R3PKZ24'HBH*PO^>
MTYP=%Q:T3@M769)*O6 OYWN2T&LJ;_:77,WL5B7."EJ*C)6 T]W">@_/-A!K
M@D%\S^A1=,9 IW++V&\]N8@7EJ-W1'.ZE5J"J,>!KFB>:R6UCS^-J-7&U,3N
M^*3^P22ODKDE@JY8_B.+9;JP0@O$=$>J7%ZQXR?:).1IO2W+A?D%QP;K6&!;
M"<F*AJQV4&1E_21W32$Z!*4S3D - ?4)[B,$W!#P4R.X#<%]:@2O(9C4[3IW
M4[@UD60YY^P(N$8K-3TPU3=L5:^LU ?E6G+U-E,\N;RB!UI65(!WH!VN,T&2
MA-.$2!J#V[_@(V4))_LTVRI0HOU]O::29+EXHW@WUVOP^M4;\ ID)?B6LDJ0
M,A9S6ZKMZ2#VMMG*>;T5],A6,/C*2ID*L"EC&H_PU]-\?X)OJ[*TM4&GVIRC
M2<'/53X##GH+D(/@R'Y63Z%C0W?&TGE>],U_1W]0#-P>%&ST\"-ZG4.A#P#;
MG<X+^/E%0<&%I(7X-1'(;0.Y)I#[2*!O3))<W4'U81P[1C7?-WQ]$1Z6./1@
M$,SM0]>=(0QYD1M$#V'K(<SW/-?IJ6V&,#?T<>2VL ?)>FVRWF2R-[/KV43-
M_%;&?UES@C90\$QS:K[7K7H8P,CIF3.$P1 B#'OF#&'*:.CVS1G"<!"$*!@W
M)VR3#2>3W51<?9 GJA:U0M'+V@.=^^O<>:9!C4"W6)$3H5[E5R,P#T6P5_GU
M" PB-T!]AT9P(8P\/.X0['R^X&2^G\F>E%.50_=*Z(5-NK]*(7ZN27APW02.
M[_<]&J*0AP=_HA$8Q K7MVA$S?=A_X:S.\U&07EBNCP!MJPJ9?TY:5?;3O*]
MZ9]ZZ^?P; 5'UM>Z\S3-S;U\W;9^)3S)2@%RNE.AG%F@CA.O.\%Z(MG>M#JW
M3*K&R0Q3U3U3K@'J_8XQ>9KH &T_OOP'4$L#!!0    ( %6"!5/S*W7B0@,
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ME[:2KQO):$!R!+[P4FVD44BSQ_:>3K^K 7JHP35R.OQ<Y>? 1V< ^0A^7=Z
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M<$NBR&PB^!$(@];6S$,1_8*MXY4PDRA/2NC51//43 <X)<]<D$*V^4Y0JM-
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M/?\@*\>P,/ &@X.C,.^P%@P'@X,<+XYA07_HAX<GQFTU0?/$?<=R2[E"C&R
MZ%T/P(ZLGHUJHD5A^^)::.BR=IC!2TND <#^1@C]/C&MMGF[IW\!4$L#!!0
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M<V(A UP4!NXQJ6:7R4-HJ708^7A@"(["A?2!3+,+XW:=;0@XJNQ(E]D>>=B
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MZ5&[ -I?*F5?)ZZ9-/^.T1]02P,$%     @ 58(%4WA;@2>K!@  LS(  !D
M  !X;"]W;W)K<VAE971S+W-H965T-#8N>&ULS5MA;YLX&/XK5FXZ;=+:@,$V
MV;65MDS3=EI/T[KM/ISN@YLX#1K@S#CI)MV//T-2WB08 ZTBL0\K)*]?7ONQ
MG\=Y@(M[J;[G2R$T^IDF67XY6FJ]>C4>Y[.E2'E^+E<B,]\LI$JY-J?J;IRO
ME.#SLE&:C+'GT7'*XVQT=5%^]DE=7<BU3N),?%(H7Z<I5[_>B$3>7X[\T<,'
MG^.[I2X^&%]=K/B=N!'ZZ^J3,F?C*LL\3D66QS)#2BPN1Z_]5].H;%!&?(O%
M?;YWC(JNW$KYO3CY,+\<>45%(A$S7:3@YL]&3$62%)E,'3]V24?5-8N&^\</
MV=^5G3>=N>6YF,KD[WBNEY>C:(3F8L'7B?XL[]^+78=(D6\FD[S\']WO8KT1
MFJUS+=-=8U-!&F?;O_SG;B#V&OAA0P.\:X"[-@AV#8*RH]O*RFZ]Y9I?72AY
MCU01;;(5!^78E*U-;^*L@/%&*_-M;-KIJW<\5N@;3]8"70N>KY4P&.D</7\K
M-(^3_ 4Z0U]OWJ+GSUZ@9RC.T)>E7.<\F^<78VVN7V09SW;7>K.]%FZXUI_K
MY!QY^"7"'O8MS:<MS7EFFONVYF/3ZZKKN.HZ+O,%K5U_B5[GN3"]-OU"'V-^
M&R>QCD7^,"1S9";<9S%;*Q5G=V747S)3U0=O>![GZ)^/Y@+H@Q9I_J^CO* J
M+RC+"QO*^R(U3\R,O-4H+ZZTK8AO#"K\-A%G9@F?Y3P1-ARVF6F9N5C(FRL_
M((30X&*\V1]P>]S$\ZNX@]+#JO3067HU5(YA(%4N,D24:%4>/1E*V\RD%25[
M7"-*K"J==2A]$6<\F\7FB&]'=\;-<)G!Y!HMBK'?%&-O*Y_5RZ+$(XP<E6^)
M"PDU_^SE1U7YD;/\CV(C$N2C_U"7Z3:ILDZ&.-U\#_C:.]F$VZ7>A\([ LL9
M<ECRGL3X)YUHN_0',XA- H\>UUZ/"SU&&Y:)#SKAX_:9]OMO/O7^P!VGFP\L
M[P>#G'# Y;Z;S)\TX<*.%-<0V,AQ/LB'3TX[^8B%OIB/Z>2X"[9 WW2!-'0!
M),9W:\Q4IJE09?4KOA+*!2N0O\\&.>^ WGTWOS]IWD4U+)C/C#8=8U:/(W02
MX:@!,E 1?](+LHZT@4$&L#=$^#"0/NY"^H^##]>)W J?)<X%'][[9>!F? M\
M_;8;&/@?#Y+_,? _/AW_XSJM'V\XG"&')0/G8S?G-\'73\,Q$#2F@\00R!YW
MV>H_$L/Z_MV^&.MQSL4(0H#=0C"5:B45UP+=RIKO<)@3^!D/<IL? +\'I]OF
M!_4]?#C!?HB/?_W7XT@8L3UD#XL'[@_<W'^$6,?U%@ ]!\-T;O:LFQ-Z-T%'
M].IQ3O2 \ ,WX=?1ZZ=] ?!T,$AO)P!B#T[G[@1UV^98^YPAAR4#U0=NJF]
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MIN7A4O"Y4$6 ^7XAI7XX*=Y;J-Y3N?H?4$L#!!0    ( %6"!5,!"#1#Q@(
M *P&   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;(U586_:,!#]*Z>L
MFEJ)D9  :SM :J'=.K551=7MP[0/)CG JF,SVP$F[<?O[*195@$;'XC/OO?R
M[MF^##9*/YLEHH5M+J09!DMK5^=A:-(EYLRTU0HEK<R5SIFE4"]"L]+(,@_*
M11A'43_,&9?!:.#G'O1HH HKN,0'#:;(<Z9_7J)0FV'0"5XFIGRQM&XB' U6
M;(&/:)]6#YJBL&;)>([2<"5!XWP87'3.QWV7[Q.^<-R8QAA<)3.EGEUPDPV#
MR E"@:EU#(P>:QRC$(Z(9/RH.(/ZE0[8'+^P7_O:J989,SA6XBO/['(8G :0
MX9P5PD[5YA-6]?0<7ZJ$\?^PJ7*C -+"6)578%*0<UD^V;;RH0'H)'L <06(
M7P'B?8"D B2^T%*9+VO"+!L-M-J =MG$Y@;>&X^F:KATN_AH-:URPMG1->,:
MOC!1(-PA,X5&VB)KX!W<,ZV9\]C \00MX\*<T'0?<B7MT@#*##/X7(@V1'$+
MXBCNT#)Y2\Y)N-JF2R87Z"8V3&?P]LUITN]^ "[AC@M!6VA:<-0,!Z&E@IRL
M,*W$7Y;BXSWBGQXG<'QTL@,X/@R\>IK"<:7H9%XJ'%-9FD[5WVPA^5F;&M>F
MQIX^^:>I+;@P!LE/)C.XY6S&!;><+*W,SH".\A330FLN%S[K7DE=3UPRPPU\
MNZ47P(W%W'P_("^IY25>7G>/O/LBGZ$&-8>TJAE^P4$72D]+UIYG==UA/>H,
MPO4.(=U:2/>@D EJOO9G#*1RMYH)8+DJI!-4;<\N(25KI]-0<M9.HN9OC[)>
MK:SWO\HLZKSIU:YC>I@LJ:[,@:WKU[KZ!ZD^4E]V1R;[HX]+8W7A;VT+J)-;
MMB7WCG;)++G/&K9%[>2546&CE[@^?L?T@EX! N>$BMKOJ59=]L8RL&KEV\M,
M66I6?KBDSPEJET#K<Z7L2^ Z5OV!&OT&4$L#!!0    ( %6"!5/[:',\/0,
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M_SMM QH9OI4HE?U%^]8V\-"J5EI4+1AV4#'>_),?K1 ] /"X 6$+"(> ^ U
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M]DJ&'?:N;!DI>70IM!,E"^^<4;(,'"5[SQ77A6  ,D$@DPDA_TL 9(I II-
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MV1SR6?>5PN034$L! A0#%     @ 58(%4P=!36*!    L0   !
M     ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    " !5@@53R[IJ
MP.X    K @  $0              @ &O    9&]C4')O<',O8V]R92YX;6Q0
M2P$"% ,4    " !5@@53F5R<(Q &  "<)P  $P              @ ', 0
M>&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( %6"!5.6(VZN/P4  &P5
M   8              " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q0
M2P$"% ,4    " !5@@53<13E#J<&  ![&@  &               @(&"#0
M>&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ 58(%4_6DY;JG
M @  W@@  !@              ("!7Q0  'AL+W=O<FMS:&5E=',O<VAE970S
M+GAM;%!+ 0(4 Q0    ( %6"!5/MJGQB&08    :   8              "
M@3P7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    " !5@@53
MQJ5#6T<#  !F"0  &               @(&+'0  >&PO=V]R:W-H965T<R]S
M:&5E=#4N>&UL4$L! A0#%     @ 58(%4[V;J:ZT @  !P<  !@
M     ("!""$  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (
M %6"!5.J"H"B3P<  )PG   8              " @?(C  !X;"]W;W)K<VAE
M971S+W-H965T-RYX;6Q02P$"% ,4    " !5@@53Z G;[IX&   .&@  &
M            @(%W*P  >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#
M%     @ 58(%4_'";:HN#P  )B<  !@              ("!2S(  'AL+W=O
M<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( %6"!5.A)=&)K@P   ,C
M   9              " @:]!  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL
M4$L! A0#%     @ 58(%4^S$>XX/#0  VR,  !D              ("!E$X
M 'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4    " !5@@53%."*
M-=D(  !E&   &0              @(':6P  >&PO=V]R:W-H965T<R]S:&5E
M=#$R+GAM;%!+ 0(4 Q0    ( %6"!5.0%#8#6P<   02   9
M  " @>ID  !X;"]W;W)K<VAE971S+W-H965T,3,N>&UL4$L! A0#%     @
M58(%4U'R.28$ P  1P8  !D              ("!?&P  'AL+W=O<FMS:&5E
M=',O<VAE970Q-"YX;6Q02P$"% ,4    " !5@@53:&B ?W8(  !_%0  &0
M            @(&W;P  >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4
M Q0    ( %6"!5,QE"8*] (  &@&   9              " @61X  !X;"]W
M;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ 58(%4]?6<"@@!
MSPD  !D              ("!CWL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX
M;6Q02P$"% ,4    " !5@@53.?SIT5P(  !5&   &0              @('F
M?P  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( %6"!5,L
M401T#0X  /TG   9              " @7F(  !X;"]W;W)K<VAE971S+W-H
M965T,3DN>&UL4$L! A0#%     @ 58(%4[B/7?YL!P  %Q0  !D
M     ("!O98  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %6"!5,@LSYR5P0   (*   9              "
M@82O  !X;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ 58(%
M4PB;YM>F P  "0D  !D              ("!$K0  'AL+W=O<FMS:&5E=',O
M<VAE970R-BYX;6Q02P$"% ,4    " !5@@531'8N*+0"  "Y!P  &0
M        @('OMP  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0
M   ( %6"!5/RZGI:"P0  /H0   9              " @=JZ  !X;"]W;W)K
M<VAE971S+W-H965T,C@N>&UL4$L! A0#%     @ 58(%4X%BYU8 !0  ,Q\
M !D              ("!'+\  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q0
M2P$"% ,4    " !5@@53Q&3@'3X#  ";"P  &0              @(%3Q
M>&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( %6"!5/S*W7B
M0@,  ,P+   9              " @<C'  !X;"]W;W)K<VAE971S+W-H965T
M,S$N>&UL4$L! A0#%     @ 58(%4UZ#Q4^8!   51,  !D
M ("!0<L  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    " !5
M@@53A?7[*X<$  "I$0  &0              @($0T   >&PO=V]R:W-H965T
M<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( %6"!5-"S]EW^P,  /00   9
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M970S."YX;6Q02P$"% ,4    " !5@@53O$/:6E8#  !0"@  &0
M    @(&%Y0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    (
M %6"!5.M3<G0.@,   8*   9              " @1+I  !X;"]W;W)K<VAE
M971S+W-H965T-# N>&UL4$L! A0#%     @ 58(%4S7PE$C7 @  QP<  !D
M             ("!@^P  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"
M% ,4    " !5@@53+$:?7ZD"   )!P  &0              @(&1[P  >&PO
M=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( %6"!5- *9;8$08
M .<@   9              " @7'R  !X;"]W;W)K<VAE971S+W-H965T-#,N
M>&UL4$L! A0#%     @ 58(%4Z-BA1V. P  1@X  !D              ("!
MN?@  'AL+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    " !5@@53
M] NH9Y@"  !'!@  &0              @(%^_   >&PO=V]R:W-H965T<R]S
M:&5E=#0U+GAM;%!+ 0(4 Q0    ( %6"!5-X6X$GJP8  +,R   9
M      " @4W_  !X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%
M  @ 58(%4P$(-$/& @  K 8  !D              ("!+P8! 'AL+W=O<FMS
M:&5E=',O<VAE970T-RYX;6Q02P$"% ,4    " !5@@53^VAS/#T#  "6"@
M&0              @($L"0$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+
M 0(4 Q0    ( %6"!5/<(]&N3@,  "0+   9              " @: , 0!X
M;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ 58(%4W\JS?2/
M P  E0X  !D              ("!)1 ! 'AL+W=O<FMS:&5E=',O<VAE970U
M,"YX;6Q02P$"% ,4    " !5@@53.?=']/P%   D'   &0
M@('K$P$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( %6"
M!5/3#YK]YP(  $T'   9              " @1X: 0!X;"]W;W)K<VAE971S
M+W-H965T-3(N>&UL4$L! A0#%     @ 58(%4Q"B<+]8 @  S 8  !D
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M 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " !5@@53EXJ[',     3 @  "P
M            @ $C*@$ 7W)E;',O+G)E;'-02P$"% ,4    " !5@@53L"Z^
M>%4$  #-)   #P              @ $,*P$ >&PO=V]R:V)O;VLN>&UL4$L!
M A0#%     @ 58(%4[P!UL'@ 0  ["   !H              ( !CB\! 'AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L! A0#%     @ 58(%4Q34<>30
M 0  K2   !,              ( !IC$! %M#;VYT96YT7U1Y<&5S72YX;6Q0
52P4&     #\ /P P$0  IS,!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>275</ContextCount>
  <ElementCount>299</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>59</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001002 - Statement - Condensed Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets</Role>
      <ShortName>Condensed Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1003004 - Statement - Condensed Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome</Role>
      <ShortName>Condensed Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1007008 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>2101101 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>2104102 - Disclosure - Revenues</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Revenues</Role>
      <ShortName>Revenues</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2121104 - Disclosure - Cash and Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestments</Role>
      <ShortName>Cash and Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2128105 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2132106 - Disclosure - Inventory</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/Inventory</Role>
      <ShortName>Inventory</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2135107 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2141108 - Disclosure - Provision For Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxes</Role>
      <ShortName>Provision For Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2143109 - Disclosure - Net Income Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShare</Role>
      <ShortName>Net Income Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2147110 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Revenues (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesTables</Role>
      <ShortName>Revenues (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Revenues</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2322303 - Disclosure - Cash and Investments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsTables</Role>
      <ShortName>Cash and Investments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CashandInvestments</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2329304 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurements</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2333305 - Disclosure - Inventory (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryTables</Role>
      <ShortName>Inventory (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/Inventory</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2336306 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/StockBasedCompensation</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2344307 - Disclosure - Net Income Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareTables</Role>
      <ShortName>Net Income Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/NetIncomePerShare</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails</Role>
      <ShortName>Revenues - Revenues by Disaggregated Category (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Significant Customer (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails</Role>
      <ShortName>Revenues - Revenues Disaggregated by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails</Role>
      <ShortName>Revenues - Net Product Revenues Disaggregated by Product (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails</Role>
      <ShortName>Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails</Role>
      <ShortName>Revenues - Contract Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails</Role>
      <ShortName>Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails</Role>
      <ShortName>Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2424416 - Disclosure - Cash and Investments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails</Role>
      <ShortName>Cash and Investments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails</Role>
      <ShortName>Cash and Investments - Investments by Security Type (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails</Role>
      <ShortName>Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails</Role>
      <ShortName>Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2430420 - Disclosure - Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2431421 - Disclosure - Fair Value Measurements - Narratives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails</Role>
      <ShortName>Fair Value Measurements - Narratives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2434422 - Disclosure - Inventory (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/InventoryDetails</Role>
      <ShortName>Inventory (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/InventoryTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails</Role>
      <ShortName>Stock-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails</Role>
      <ShortName>Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2442427 - Disclosure - Provision For Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails</Role>
      <ShortName>Provision For Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.exelixis.com/role/ProvisionForIncomeTaxes</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails</Role>
      <ShortName>Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="exel-20210702.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="exel-20210702.htm">exel-20210702.htm</File>
    <File>exel-20210702.xsd</File>
    <File>exel-20210702_cal.xml</File>
    <File>exel-20210702_def.xml</File>
    <File>exel-20210702_lab.xml</File>
    <File>exel-20210702_pre.xml</File>
    <File>exel20210526ex31restatedce.htm</File>
    <File>exel20210630exhibit311.htm</File>
    <File>exel20210630exhibit312.htm</File>
    <File>exel20210630exhibit321.htm</File>
    <File>exhibit41exel20210630sto.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>exel-20210702_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2021</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2021</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>77
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "exel-20210702.htm": {
   "axisCustom": 0,
   "axisStandard": 18,
   "contextCount": 275,
   "dts": {
    "calculationLink": {
     "local": [
      "exel-20210702_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "exel-20210702_def.xml"
     ]
    },
    "inline": {
     "local": [
      "exel-20210702.htm"
     ]
    },
    "labelLink": {
     "local": [
      "exel-20210702_lab.xml"
     ],
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-doc-2021-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "exel-20210702_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-ref-2021-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "exel-20210702.xsd"
     ],
     "remote": [
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_ref.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-parts-codification-2021-01-31.xsd",
      "https://xbrl.sec.gov/dei/2021/dei-2021_doc.xsd"
     ]
    }
   },
   "elementCount": 396,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021": 5,
    "total": 5
   },
   "keyCustom": 33,
   "keyStandard": 266,
   "memberCustom": 25,
   "memberStandard": 34,
   "nsprefix": "exel",
   "nsuri": "http://www.exelixis.com/20210702",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001001 - Document - Cover Page",
     "role": "http://www.exelixis.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104102 - Disclosure - Revenues",
     "role": "http://www.exelixis.com/role/Revenues",
     "shortName": "Revenues",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112103 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2121104 - Disclosure - Cash and Investments",
     "role": "http://www.exelixis.com/role/CashandInvestments",
     "shortName": "Cash and Investments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2128105 - Disclosure - Fair Value Measurements",
     "role": "http://www.exelixis.com/role/FairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2132106 - Disclosure - Inventory",
     "role": "http://www.exelixis.com/role/Inventory",
     "shortName": "Inventory",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2135107 - Disclosure - Stock-Based Compensation",
     "role": "http://www.exelixis.com/role/StockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2141108 - Disclosure - Provision For Income Taxes",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxes",
     "shortName": "Provision For Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2143109 - Disclosure - Net Income Per Share",
     "role": "http://www.exelixis.com/role/NetIncomePerShare",
     "shortName": "Net Income Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2147110 - Disclosure - Commitments and Contingencies",
     "role": "http://www.exelixis.com/role/CommitmentsandContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2202201 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConsolidationPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001002 - Statement - Condensed Consolidated Balance Sheets",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
     "shortName": "Condensed Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Revenues (Tables)",
     "role": "http://www.exelixis.com/role/RevenuesTables",
     "shortName": "Revenues (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisaggregationOfRevenueTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313302 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2322303 - Disclosure - Cash and Investments (Tables)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsTables",
     "shortName": "Cash and Investments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2329304 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2333305 - Disclosure - Inventory (Tables)",
     "role": "http://www.exelixis.com/role/InventoryTables",
     "shortName": "Inventory (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2336306 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2344307 - Disclosure - Net Income Per Share (Tables)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareTables",
     "shortName": "Net Income Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403401 - Disclosure - Organization and Summary of Significant Accounting Policies (Details)",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
     "shortName": "Organization and Summary of Significant Accounting Policies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "us-gaap:SegmentReportingPolicyPolicyTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "segment",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Revenues - Revenues by Disaggregated Category (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails",
     "shortName": "Revenues - Revenues by Disaggregated Category (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisaggregationOfRevenueTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i947f11dce7724c8a92d7f9d767d30430_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails",
     "shortName": "Revenues - Revenues Disaggregated by Significant Customer (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i2c575340caf04b61ab5e0005aa839d41_D20210403-20210702",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002003 - Statement - Condensed Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408404 - Disclosure - Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "role": "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
     "shortName": "Revenues - Revenues Disaggregated by Geographic Region (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i576124c34cb14293a07e65c0e116b0fd_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409405 - Disclosure - Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "role": "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
     "shortName": "Revenues - Net Product Revenues Disaggregated by Product (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i4abad55b764942b8838caffe168cd460_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i7d18f1537d8b43a38ece66de91e63886_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "role": "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails",
     "shortName": "Revenues - Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i7d18f1537d8b43a38ece66de91e63886_I20210101",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Revenues - Contract Assets and Liabilities (Details)",
     "role": "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails",
     "shortName": "Revenues - Contract Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i7d18f1537d8b43a38ece66de91e63886_I20210101",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetNetCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414408 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Ipsen (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i7e90ca7353d7420d850374043f19414f_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2415409 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Ipsen Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2416410 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Collaboration Revenues under the Collaboration Agreement with Takeda (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i6b587653d3b346778dc4850b1f98eaa1_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417411 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Takeda Collaboration Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i086ec86c38f3430bbc22864119abfbea_I20210702",
      "decimals": "-5",
      "lang": "en-US",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418412 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - GSK (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i14b63de4ffbb4643b8592b5b5d6c76fe_D20210403-20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RoyaltyExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2419413 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - Royalty Revenues under the Collaboration Agreement with Genentech (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i0e7b0c04c90241ae95bd4f97c2976ba6_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementIncomeLossFromAgreement",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003004 - Statement - Condensed Consolidated Statements of Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
     "shortName": "Condensed Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:CostOfGoodsAndServicesSold",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2420414 - Disclosure - Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)",
     "role": "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails",
     "shortName": "Collaboration Agreements, In-Licensing Arrangements And Business Development Activities - In-Licensing Collaborations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "exel:CollaborativeArrangementRightsAndObligationsUpfrontPayment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2423415 - Disclosure - Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
     "shortName": "Cash and Investments - Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2424416 - Disclosure - Cash and Investments - Narrative (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails",
     "shortName": "Cash and Investments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-5",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestrictedCashEquivalentsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2425417 - Disclosure - Cash and Investments - Investments by Security Type (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
     "shortName": "Cash and Investments - Investments by Security Type (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2426418 - Disclosure - Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
     "shortName": "Cash and Investments - Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2427419 - Disclosure - Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "role": "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
     "shortName": "Cash and Investments - Fair Value of Cash Equivalents and Investments by Contractual Maturity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:UnrealizedGainLossOnInvestmentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2430420 - Disclosure - Fair Value Measurements (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i7549b8270e70414ca9988e4dbb8aa47f_I20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ic668b647625e4bde9c974a9c70e123ee_I20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forwardcontract",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2431421 - Disclosure - Fair Value Measurements - Narratives (Details)",
     "role": "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails",
     "shortName": "Fair Value Measurements - Narratives (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ic668b647625e4bde9c974a9c70e123ee_I20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DerivativeNumberOfInstrumentsHeld",
      "reportCount": 1,
      "unique": true,
      "unitRef": "forwardcontract",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2434422 - Disclosure - Inventory (Details)",
     "role": "http://www.exelixis.com/role/InventoryDetails",
     "shortName": "Inventory (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryRawMaterials",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2437423 - Disclosure - Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Allocated Employee Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ieca864111b874024a399be99230353ae_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004005 - Statement - Condensed Consolidated Statements of Comprehensive Income",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2438424 - Disclosure - Stock-Based Compensation - Based Compensation Expense (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i2457de481e214911a4d49d6872661199_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i5bd2889c307341ccba8eaee7f5f573c0_I20210702",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2439425 - Disclosure - Stock-Based Compensation - Narrative (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails",
     "shortName": "Stock-Based Compensation - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "INF",
      "lang": "en-US",
      "name": "exel:ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i9725617d21e743d9b5a61c2ee8825f34_D20210102-20210702",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2440426 - Disclosure - Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "role": "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
     "shortName": "Stock-Based Compensation - Estimate Grant-Date Fair Value (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "exel:ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "icdc25c9244d74752a7a86d0fc1f9a390_I20210702",
      "decimals": "2",
      "lang": "en-US",
      "name": "us-gaap:SharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2442427 - Disclosure - Provision For Income Taxes (Details)",
     "role": "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails",
     "shortName": "Provision For Income Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2445428 - Disclosure - Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails",
     "shortName": "Net Income Per Share - Computation of Basic and Diluted Net Income Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2446429 - Disclosure - Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "role": "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income Per Share - Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ied8f71f534fe4c62b89dd346838cecf9_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005006 - Statement - Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i34c29e2a0ae542cfaded906e9f1a9e88_D20210403-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1006007 - Statement - Condensed Consolidated Statements of Stockholders' Equity",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "ib26e3f7ec84e4b5584cb9688c3d0e8ec_I20200103",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "-3",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1007008 - Statement - Condensed Consolidated Statements of Cash Flows",
     "role": "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
     "shortName": "Condensed Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": "-3",
      "lang": "en-US",
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101101 - Disclosure - Organization and Summary of Significant Accounting Policies",
     "role": "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies",
     "shortName": "Organization and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "baseRef": "exel-20210702.htm",
      "contextRef": "i57263a6fe4d34aa2aba806839c4148bc_D20210102-20210702",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 59,
   "tag": {
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "Japan"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "U.S."
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2021",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r476"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r477"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding (in shares)"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r486"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r478"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r475"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021",
     "presentation": [
      "http://www.exelixis.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "exel_AccredoHealthIncorporatedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accredo Health, Incorporated [Member]",
        "label": "Accredo Health, Incorporated [Member]",
        "terseLabel": "Accredo Health, Incorporated"
       }
      }
     },
     "localname": "AccredoHealthIncorporatedMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AccruedClinicalLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Clinical Liabilities, Current",
        "label": "Accrued Clinical Liabilities, Current",
        "terseLabel": "Accrued clinical trial liabilities"
       }
      }
     },
     "localname": "AccruedClinicalLiabilitiesCurrent",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AccruedCollaborationLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Collaboration Liability, Current",
        "label": "Accrued Collaboration Liability, Current",
        "terseLabel": "Accrued collaboration liabilities"
       }
      }
     },
     "localname": "AccruedCollaborationLiabilityCurrent",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AffiliatesOfAmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "label": "Affiliates Of Amerisource Bergen Corporation [Member]",
        "terseLabel": "Affiliates of AmerisourceBergen Corporation"
       }
      }
     },
     "localname": "AffiliatesOfAmerisourceBergenCorporationMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofCVSHealthCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of CVS Health Corporation [Member]",
        "label": "Affiliates of CVS Health Corporation [Member]",
        "terseLabel": "Affiliates of CVS Health Corporation"
       }
      }
     },
     "localname": "AffiliatesofCVSHealthCorporationMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofMcKessonCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of McKesson Corporation [Member]",
        "label": "Affiliates of McKesson Corporation [Member]",
        "terseLabel": "Affiliates of McKesson Corporation"
       }
      }
     },
     "localname": "AffiliatesofMcKessonCorporationMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AffiliatesofOptumSpecialtyPharmacyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Affiliates of Optum Specialty Pharmacy [Member]",
        "label": "Affiliates of Optum Specialty Pharmacy [Member]",
        "terseLabel": "Affiliates of Optum Specialty Pharmacy"
       }
      }
     },
     "localname": "AffiliatesofOptumSpecialtyPharmacyMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForCustomerCreditsFeesandCoPayAssistanceMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "label": "Allowance For Customer Credits, Fees, and Co-Pay Assistance [Member]",
        "terseLabel": "Other Customer Credits/Fees and Co-pay Assistance"
       }
      }
     },
     "localname": "AllowanceForCustomerCreditsFeesandCoPayAssistanceMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AllowanceForProductRebatesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Allowance For Product Rebates [Member]",
        "label": "Allowance For Product Rebates [Member]",
        "terseLabel": "Rebates"
       }
      }
     },
     "localname": "AllowanceForProductRebatesMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Asset Acquisition, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Asset acquisition, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_AssetAcquisitionPaymentUponClosingOfTransaction": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "label": "Asset Acquisition, Payment Upon Closing Of Transaction",
        "terseLabel": "Payment upon closing of transaction"
       }
      }
     },
     "localname": "AssetAcquisitionPaymentUponClosingOfTransaction",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CabometyxMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cabometyx [Member]",
        "label": "Cabometyx [Member]",
        "terseLabel": "CABOMETYX"
       }
      }
     },
     "localname": "CabometyxMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale, Debt Securities",
        "totalLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale Debt Securities, Accumulated Gross Unrealized Gain, Before Tax",
        "totalLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available For Sale, Debt Securities, Accumulated Gross Unrealized Loss, Before Tax",
        "negatedTotalLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents And Available-For-Sale Debt Securities, Amortized Cost Basis",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsFairValueDisclosure",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Gain",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedGain",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAmortizedCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "label": "Cash, Cash Equivalents, Restricted Cash And Restricted Cash Equivalents, Gross Unrealized Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsGrossUnrealizedLoss",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ChargebacksAndDiscountsForPromptPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Chargebacks And Discounts For Prompt Payment [Member]",
        "label": "Chargebacks And Discounts For Prompt Payment [Member]",
        "terseLabel": "Chargebacks, Discounts for Prompt Payment and Other"
       }
      }
     },
     "localname": "ChargebacksAndDiscountsForPromptPaymentMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborationAgreementPercentOfRoyaltyOnNetSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "label": "Collaboration Agreement, Percent Of Royalty On Net Sale",
        "terseLabel": "Percent of royalty on net sale"
       }
      }
     },
     "localname": "CollaborationAgreementPercentOfRoyaltyOnNetSale",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_CollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration [Member]",
        "label": "Collaboration [Member]",
        "verboseLabel": "Total collaboration revenues"
       }
      }
     },
     "localname": "CollaborationMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeAgreementWithGamaMabsPharmaSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Agreement With GamaMabs Pharma SA",
        "label": "Collaborative Agreement With GamaMabs Pharma SA [Member]",
        "terseLabel": "Collaborative Agreement With GamaMabs Pharma SA"
       }
      }
     },
     "localname": "CollaborativeAgreementWithGamaMabsPharmaSAMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Amount Receivable From Collaboration For Development And Regulatory Milestone Achievement",
        "label": "Collaborative Arrangement, Amount Receivable From Collaboration For Development And Regulatory Milestone Achievement",
        "terseLabel": "Milestone receivable upon achievement of development achievement"
       }
      }
     },
     "localname": "CollaborativeArrangementAmountReceivableFromCollaborationForDevelopmentAndRegulatoryMilestoneAchievement",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementIncomeLossFromAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Income (Loss) from Agreement",
        "label": "Collaborative Arrangement, Income (Loss) From Agreement",
        "terseLabel": "Profits on U.S. commercialization"
       }
      }
     },
     "localname": "CollaborativeArrangementIncomeLossFromAgreement",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Revenue Recognized Upon Development Milestone Achievement",
        "label": "Collaborative Arrangement, Revenue Recognized Upon Development Milestone Achievement",
        "terseLabel": "Collaborative arrangement, revenue recognized upon development milestone achievement"
       }
      }
     },
     "localname": "CollaborativeArrangementRevenueRecognizedUponDevelopmentMilestoneAchievement",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Commerical Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate commercial milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateCommericalMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Development Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate development milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateDevelopmentMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "label": "Collaborative Arrangement, Rights And Obligations, Maximum Aggregate Regulatory Milestone Payments",
        "terseLabel": "Collaborative arrangement, maximum aggregate regulatory milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsMaximumAggregateRegulatoryMilestonePayments",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementRightsAndObligationsUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "label": "Collaborative Arrangement, Rights And Obligations, Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "CollaborativeArrangementRightsAndObligationsUpfrontPayment",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CollaborativeArrangementswithGlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangements with Glaxo Smith Kline",
        "label": "Collaborative Arrangements with Glaxo Smith Kline [Member]",
        "terseLabel": "Collaboration Agreement with GlaxoSmithKline"
       }
      }
     },
     "localname": "CollaborativeArrangementswithGlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithGenentechMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Genentech [Member]",
        "label": "Collaborative Arrangement with Genentech [Member]",
        "terseLabel": "Collaborative Arrangement with Genentech"
       }
      }
     },
     "localname": "CollaborativeArrangementwithGenentechMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithIpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Ipsen [Member]",
        "label": "Collaborative Arrangement with Ipsen [Member]",
        "terseLabel": "Collaborative Arrangement with Ipsen"
       }
      }
     },
     "localname": "CollaborativeArrangementwithIpsenMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CollaborativeArrangementwithTakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative Arrangement with Takeda [Member]",
        "label": "Collaborative Arrangement with Takeda [Member]",
        "terseLabel": "Collaborative Arrangement with Takeda"
       }
      }
     },
     "localname": "CollaborativeArrangementwithTakedaMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_CometriqMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cometriq [Member]",
        "label": "Cometriq [Member]",
        "terseLabel": "COMETRIQ"
       }
      }
     },
     "localname": "CometriqMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "label": "Contract With Customer, Liability, Including New Contract Revenue, Recognized",
        "terseLabel": "Contract revenue recognized, including revenue from deferred revenue beginning balance"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityIncludingNewContractRevenueRecognized",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_CotellicMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cotellic [Member]",
        "label": "Cotellic [Member]",
        "terseLabel": "Cotellic"
       }
      }
     },
     "localname": "CotellicMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_GlaxoSmithKlineMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Smith Kline [Member].",
        "label": "Glaxo Smith Kline [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_IpsenMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ipsen [Member]",
        "label": "Ipsen [Member]",
        "terseLabel": "Ipsen Pharma SAS"
       }
      }
     },
     "localname": "IpsenMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash Lease Expense",
        "label": "Noncash Lease Expense",
        "terseLabel": "Non-cash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_NumberofProductsinCommercialMarket": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of Products in Commercial Market",
        "label": "Number of Products in Commercial Market",
        "terseLabel": "Number of products that entered in the commercial marketplace"
       }
      }
     },
     "localname": "NumberofProductsinCommercialMarket",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Line Items]",
        "label": "Organization And Summary Of Significant Policies [Line Items]",
        "terseLabel": "Organization And Summary Of Significant Policies [Line Items]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesLineItems",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OrganizationAndSummaryOfSignificantPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization And Summary Of Significant Policies [Table]",
        "label": "Organization And Summary Of Significant Policies [Table]",
        "terseLabel": "Organization And Summary Of Significant Policies [Table]"
       }
      }
     },
     "localname": "OrganizationAndSummaryOfSignificantPoliciesTable",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "exel_OtherLongtermAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other Long-term Assets [Member]",
        "label": "Other Long-term Assets [Member]",
        "terseLabel": "Long-term portion included in other long-term assets"
       }
      }
     },
     "localname": "OtherLongtermAssetsMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductGrossMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Gross [Member]",
        "label": "Product, Gross [Member]",
        "terseLabel": "Gross product revenues"
       }
      }
     },
     "localname": "ProductGrossMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductSalesDiscountsAndAllowancesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Product, Sales Discounts And Allowances [Member]",
        "label": "Product, Sales Discounts And Allowances [Member]",
        "terseLabel": "Discounts and allowances"
       }
      }
     },
     "localname": "ProductSalesDiscountsAndAllowancesMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ProductsDerivedFromOtherCompoundsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Products Derived From Other Compounds [Member]",
        "label": "Products Derived From Other Compounds [Member]",
        "terseLabel": "Products derived from other compounds"
       }
      }
     },
     "localname": "ProductsDerivedFromOtherCompoundsMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "label": "Reconciliation Of Sales Discount And Allowances Reserve Balances [Table Text Block]",
        "terseLabel": "Schedule of Activities and Ending Reserve Balances for Significant Categories of Discounts and Allowances"
       }
      }
     },
     "localname": "ReconciliationOfSalesDiscountAndAllowancesReserveBalancesTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ResultingFromDiscoveryEffortsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Resulting From Discovery Efforts [Member]",
        "label": "Resulting From Discovery Efforts [Member]",
        "terseLabel": "Resulting from discovery efforts"
       }
      }
     },
     "localname": "ResultingFromDiscoveryEffortsMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_RightOfUseAssetObtainedInExchangeForLeaseLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "label": "Right-Of-Use Asset Obtained In Exchange For Lease Liability",
        "terseLabel": "Right-of-use assets obtained in exchange for lease obligations"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForLeaseLiability",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions",
        "label": "Schedule Of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-Based Payment Award, Equity Instruments Other Than Options, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Other Awards",
        "terseLabel": "Reduction in share reserve after all other awards (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToOtherAwards",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award,Reduction of Number of Shares in Share Reserve After Stock Option or Stock Appreciation Award",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Reduction In Share Reserve Due To Stock Option Or Stock Appreciation Award",
        "terseLabel": "Reduction in share reserve after stock option or stock appreciation award (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardReductionInShareReserveDueToStockOptionOrStockAppreciationAward",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "exel_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "label": "Share-based Compensation Arrangement By Share-based Payment Award, Equity Instruments Other Than Options, Maximum Potential To Vest",
        "terseLabel": "Maximum potential to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsMaximumPotentialToVest",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "exel_TakedaMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Takeda [Member]",
        "label": "Takeda [Member]",
        "terseLabel": "Takeda Pharmaceutical Company Limited"
       }
      }
     },
     "localname": "TakedaMember",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "exel_UnsettledInvestmentPurchasesIncurredButNotYetPaid": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsettled Investment Purchases Incurred But Not Yet Paid",
        "label": "Unsettled Investment Purchases Incurred But Not Yet Paid",
        "terseLabel": "Unpaid liabilities incurred for unsettled investment purchases"
       }
      }
     },
     "localname": "UnsettledInvestmentPurchasesIncurredButNotYetPaid",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Current Period",
        "terseLabel": "Current period"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInCurrentPeriod",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "label": "Valuation Allowances And Reserves, Additions For Sales In Prior Period",
        "terseLabel": "Prior periods"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsForSalesInPriorPeriod",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "exel_ValuationAllowancesAndReservesAdditionsToProvisionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "label": "Valuation Allowances And Reserves, Additions To Provision [Abstract]",
        "terseLabel": "Provision related to sales made in:"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesAdditionsToProvisionAbstract",
     "nsuri": "http://www.exelixis.com/20210702",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Europe [Member]",
        "terseLabel": "Europe"
       }
      }
     },
     "localname": "EuropeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r167",
      "r259",
      "r264",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Customer [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [
      "r167",
      "r259",
      "r264",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r163",
      "r259",
      "r262",
      "r415",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r163",
      "r259",
      "r262",
      "r415",
      "r445",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r164",
      "r165",
      "r259",
      "r263",
      "r447",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r164",
      "r165",
      "r259",
      "r263",
      "r447",
      "r458",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r470",
      "r471",
      "r472"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]"
       }
      }
     },
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounts Payable and Accrued Liabilities [Abstract]",
        "terseLabel": "Contract liabilities:"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r36",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Accounts Receivable"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccruedEmployeeBenefitsCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Employee Benefits, Current",
        "terseLabel": "Accrued compensation and benefits"
       }
      }
     },
     "localname": "AccruedEmployeeBenefitsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r23",
      "r53",
      "r55",
      "r56",
      "r435",
      "r453",
      "r454"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r52",
      "r56",
      "r63",
      "r64",
      "r65",
      "r101",
      "r102",
      "r103",
      "r339",
      "r449",
      "r450",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalCashFlowElementsInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Investing Activities [Abstract]",
        "terseLabel": "Non-cash investing activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalCashFlowElementsOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Cash Flow Elements, Operating Activities [Abstract]",
        "terseLabel": "Non-cash operating activities:"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r21",
      "r302",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r299",
      "r300",
      "r301",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease to equity for grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Decrease for Tax Withholding Obligation",
        "negatedTerseLabel": "Stock transactions associated with taxes withheld on equity awards"
       }
      }
     },
     "localname": "AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r279",
      "r281",
      "r304",
      "r305"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r281",
      "r295",
      "r303"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "netLabel": "Total stock-based compensation expense",
        "terseLabel": "Stock-based compensation",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Anti-dilutive securities and contingently issuable shares excluded (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionAxis": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by asset acquisition.",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionDomain": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Asset acquisition.",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Asset Acquisition [Line Items]",
        "terseLabel": "Asset Acquisition [Line Items]"
       }
      }
     },
     "localname": "AssetAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetAcquisitionTable": {
     "auth_ref": [
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset acquisition.",
        "label": "Asset Acquisition [Table]",
        "terseLabel": "Asset Acquisition [Table]"
       }
      }
     },
     "localname": "AssetAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r91",
      "r146",
      "r155",
      "r161",
      "r188",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r335",
      "r340",
      "r371",
      "r380",
      "r382",
      "r418",
      "r433"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r48",
      "r91",
      "r188",
      "r218",
      "r219",
      "r220",
      "r221",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r335",
      "r340",
      "r371",
      "r380",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r360"
     ],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "totalLabel": "Total financial assets carried at fair value"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r173"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r174"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r170",
      "r195"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails_1": {
       "order": 2.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale [Abstract]",
        "terseLabel": "Debt securities available-for-sale:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesContinuousUnrealizedLossPositionAccumulatedLossAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r175",
      "r177",
      "r429"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "terseLabel": "Maturing after one year through five years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r175",
      "r176",
      "r428"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "terseLabel": "Maturing in one year or less"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r169",
      "r171",
      "r195",
      "r422"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails": {
       "order": 1.0,
       "parentTag": "exel_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAndAvailableForSaleDebtSecurities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Total debt securities available-for-sale",
        "verboseLabel": "Total debt securities available-for-sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueofCashEquivalentsandInvestmentsbyContractualMaturityDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r283",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r349",
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Unpaid liabilities incurred for purchases of property and equipment"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and Cash Equivalents [Abstract]",
        "terseLabel": "Cash and Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r4",
      "r33",
      "r84"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/FairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r79",
      "r84",
      "r88"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash equivalents at beginning of period",
        "totalLabel": "Cash, cash equivalents, and restricted cash equivalents as reported in the accompanying Condensed Consolidated Statements of Cash Flows"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r79",
      "r372"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashMember": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits.",
        "label": "Cash [Member]",
        "terseLabel": "Cash"
       }
      }
     },
     "localname": "CashMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CertificatesOfDepositMember": {
     "auth_ref": [
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest. Certificates of deposit (CD) are typically Federal Deposit Insurance Corporation (FDIC) insured.",
        "label": "Certificates of Deposit [Member]",
        "terseLabel": "Certificates of deposit",
        "verboseLabel": "Certificates of deposit"
       }
      }
     },
     "localname": "CertificatesOfDepositMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r328",
      "r329",
      "r331"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "COLLABORATION AGREEMENTS, IN-LICENSING ARRANGEMENTS AND BUSINESS DEVELOPMENT ACTIVITIES"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial paper",
        "verboseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r41",
      "r215",
      "r423",
      "r440"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]",
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r212",
      "r213",
      "r214",
      "r216",
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "COMMITMENTS AND CONTINGENCIES"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CommitmentsandContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r101",
      "r102",
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Common stock"
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r19",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "verboseLabel": "Shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r19",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 314,822 and 311,627 at June\u00a030, 2021 and December\u00a031, 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r59",
      "r61",
      "r62",
      "r67",
      "r425",
      "r442"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r368",
      "r369",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r368",
      "r369",
      "r456",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r368",
      "r369",
      "r456",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r368",
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percent of total revenues"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r134",
      "r135",
      "r167",
      "r368",
      "r369",
      "r462"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r89",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Basis of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Schedule of Other Assets and Other Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "auth_ref": [
      "r237",
      "r239",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "totalLabel": "Total contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss [Abstract]",
        "terseLabel": "Contract assets"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r237",
      "r239",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current",
        "verboseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetNoncurrent": {
     "auth_ref": [
      "r237",
      "r239",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerAssetNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as noncurrent.",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Noncurrent",
        "terseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "totalLabel": "Total contract liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r237",
      "r238",
      "r260"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ContractWithCustomerLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Long-term portion of deferred revenues",
        "verboseLabel": "Long-term portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from performance obligation satisfied or partially satisfied in previous reporting periods. Includes, but is not limited to, change in transaction price.",
        "label": "Contract with Customer, Performance Obligation Satisfied in Previous Period",
        "terseLabel": "Revenues recognized for performance obligations satisfied in previous periods"
       }
      }
     },
     "localname": "ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount).",
        "label": "Corporate Bond Securities [Member]",
        "terseLabel": "Corporate bonds",
        "verboseLabel": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateBondSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r70",
      "r415"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "terseLabel": "Cost of goods sold"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostsAndExpenses": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total costs of sales and operating expenses for the period.",
        "label": "Costs and Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "CostsAndExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r133",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CustomerRefundLiabilityCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current regulatory liabilities generally represent obligations to make refunds to customers for various reasons including overpayment.",
        "label": "Customer Refund Liability, Current",
        "terseLabel": "Rebates and fees due to customers"
       }
      }
     },
     "localname": "CustomerRefundLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r172",
      "r195",
      "r201",
      "r202"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Allowance for Credit Loss",
        "terseLabel": "Allowance for credit losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]",
        "terseLabel": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPosition": {
     "auth_ref": [
      "r181",
      "r196",
      "r204"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position without allowance for credit loss.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPosition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss": {
     "auth_ref": [
      "r182",
      "r197"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Accumulated Loss",
        "negatedTerseLabel": "Gross Unrealized Losses"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionAccumulatedLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock": {
     "auth_ref": [
      "r180",
      "r199",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Fair Value and Gross Unrealized Losses of Investments Available-for-Sale in an Unrealized Loss Position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions": {
     "auth_ref": [
      "r183",
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of investments in debt securities measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in unrealized loss position, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-sale, Unrealized Loss Position, Number of Positions",
        "terseLabel": "Number of investments in an unrealized loss position"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DeferredIncomeTaxAssetsNet": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, with jurisdictional netting.",
        "label": "Deferred Income Tax Assets, Net",
        "terseLabel": "Deferred tax assets, net"
       }
      }
     },
     "localname": "DeferredIncomeTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r82",
      "r144"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r49",
      "r350",
      "r351",
      "r353",
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNumberOfInstrumentsHeld": {
     "auth_ref": [
      "r344",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of derivative instruments of a particular group held by the entity.",
        "label": "Derivative, Number of Instruments Held",
        "terseLabel": "Number of contract"
       }
      }
     },
     "localname": "DerivativeNumberOfInstrumentsHeld",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r94",
      "r343",
      "r345",
      "r347",
      "r348",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Forward Contracts for Non-Designated Hedges"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisaggregationOfRevenueLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Disaggregation of Revenue [Line Items]",
        "terseLabel": "Disaggregation of Revenue [Line Items]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTable": {
     "auth_ref": [
      "r259",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table]",
        "terseLabel": "Disaggregation of Revenue [Table]"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisaggregationOfRevenueTableTextBlock": {
     "auth_ref": [
      "r259"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.",
        "label": "Disaggregation of Revenue [Table Text Block]",
        "terseLabel": "Schedule of Disaggregation of Revenue"
       }
      }
     },
     "localname": "DisaggregationOfRevenueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "STOCK-BASED COMPENSATION"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]",
        "terseLabel": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]",
        "terseLabel": "Net income per share:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r68",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r114",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r358",
      "r359",
      "r426",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Basic (in dollars per share)",
        "verboseLabel": "Net income per share - basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r68",
      "r106",
      "r107",
      "r108",
      "r109",
      "r110",
      "r116",
      "r118",
      "r119",
      "r120",
      "r124",
      "r125",
      "r358",
      "r359",
      "r426",
      "r443"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Diluted (in dollars per share)",
        "verboseLabel": "Net income per share - diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share Reconciliation [Abstract]",
        "terseLabel": "Numerator:"
       }
      }
     },
     "localname": "EarningsPerShareReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "NET INCOME PER SHARE"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "terseLabel": "Effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]",
        "terseLabel": "Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r296"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock.",
        "label": "Employee Stock [Member]",
        "terseLabel": "ESPP"
       }
      }
     },
     "localname": "EmployeeStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r293"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Stock options"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r63",
      "r64",
      "r65",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r127",
      "r189",
      "r235",
      "r236",
      "r299",
      "r300",
      "r301",
      "r315",
      "r316",
      "r357",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r449",
      "r450",
      "r451",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r360",
      "r361",
      "r362",
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r360",
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value, Assets Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Classification of Financial Assets Measured and Recorded at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r361",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r360",
      "r361",
      "r363",
      "r364",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]",
        "terseLabel": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r365"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "FAIR VALUE MEASUREMENTS"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r229",
      "r271",
      "r272",
      "r277",
      "r278",
      "r361",
      "r386"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r271",
      "r272",
      "r277",
      "r278",
      "r361",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level\u00a02"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r229",
      "r231",
      "r232",
      "r271",
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r386",
      "r387",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r365",
      "r367"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r185",
      "r186",
      "r187",
      "r190",
      "r191",
      "r192",
      "r193",
      "r194",
      "r199",
      "r200",
      "r203",
      "r204",
      "r230",
      "r234",
      "r356",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiscalPeriod": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining an entity's fiscal year or other fiscal period. This disclosure may include identification of the fiscal period end-date, the length of the fiscal period, any reporting period lag between the entity and its subsidiaries, or equity investees. If a reporting lag exists, the closing date of the entity having a different period end is generally noted, along with an explanation of the necessity for using different closing dates. Any intervening events that materially affect the entity's financial position or results of operations are generally also disclosed.",
        "label": "Fiscal Period, Policy [Policy Text Block]",
        "terseLabel": "Fiscal Period"
       }
      }
     },
     "localname": "FiscalPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeForwardMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Foreign exchange forward traded on an exchange (examples include but are not limited to the International Securities Exchange, Philadelphia Stock Exchange, or the Chicago Mercantile Exchange) for options or future contracts to buy or sell a certain currency, at a specified date, at a fixed exercise exchange rate.",
        "label": "Foreign Exchange Forward [Member]",
        "terseLabel": "Foreign Exchange Forward"
       }
      }
     },
     "localname": "ForeignExchangeForwardMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainOnDerivativeInstrumentsPretax": {
     "auth_ref": [
      "r350"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate gain on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain on Derivative Instruments, Pretax",
        "terseLabel": "Gain on derivative instruments, pretax"
       }
      }
     },
     "localname": "GainOnDerivativeInstrumentsPretax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/FairValueMeasurementsNarrativesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r207",
      "r208",
      "r382",
      "r417"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "totalLabel": "Income before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]",
        "terseLabel": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r210",
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r211"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]",
        "terseLabel": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r92",
      "r312",
      "r313",
      "r314",
      "r317",
      "r319",
      "r321",
      "r322",
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "PROVISION FOR INCOME TAXES"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/ProvisionForIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r93",
      "r112",
      "r113",
      "r145",
      "r310",
      "r318",
      "r320",
      "r444"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedTerseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r81",
      "r413"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "negatedTerseLabel": "Deferred taxes"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventory"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestIncomeOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of interest income earned from interest bearing assets classified as other.",
        "label": "Interest Income, Other",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoriesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property held for sale in the ordinary course of business, or in process of, or to be consumed in, production for sale.",
        "label": "Inventories [Member]",
        "terseLabel": "Current portion included in inventory"
       }
      }
     },
     "localname": "InventoriesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InventoryCurrentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about inventory expected to be sold or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Current [Table]",
        "terseLabel": "Inventory, Current [Table]"
       }
      }
     },
     "localname": "InventoryCurrentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Inventory Disclosure [Abstract]",
        "terseLabel": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "INVENTORY"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Inventory"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoods": {
     "auth_ref": [
      "r43"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of completed merchandise or goods expected to be sold within one year or operating cycle, if longer.",
        "label": "Inventory, Finished Goods, Gross",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoods",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryGross": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross amount, as of the balance sheet date, of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Inventory, Gross",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "InventoryGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Inventory [Line Items]",
        "terseLabel": "Inventory [Line Items]"
       }
      }
     },
     "localname": "InventoryLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r5",
      "r46",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventory"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryRawMaterials": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of raw materials expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Raw Materials, Gross",
        "terseLabel": "Raw materials"
       }
      }
     },
     "localname": "InventoryRawMaterials",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcess": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.exelixis.com/role/InventoryDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before valuation and LIFO reserves of merchandise or goods in the production process expected to be completed within one year or operating cycle, if longer.",
        "label": "Inventory, Work in Process, Gross",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWriteDown": {
     "auth_ref": [
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from reductions in inventory due to subsequent measurement adjustments, including, but not limited to, physical deterioration, obsolescence, or changes in price levels.",
        "label": "Inventory Write-down",
        "terseLabel": "Inventory write-down"
       }
      }
     },
     "localname": "InventoryWriteDown",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Fair Value of Cash Equivalents and Investments by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]",
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for cash, cash equivalents, investments in debt and equity instruments (including cost and equity investees and related income statement amounts), equity and cost method investments, investments in joint ventures and any other investment.",
        "label": "Investments in Debt and Equity Instruments, Cash and Cash Equivalents, Unrealized and Realized Gains (Losses) [Text Block]",
        "terseLabel": "CASH AND INVESTMENTS"
       }
      }
     },
     "localname": "InvestmentsInDebtAndEquityInstrumentsCashAndCashEquivalentsUnrealizedAndRealizedGainsLossesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r37",
      "r91",
      "r156",
      "r188",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r336",
      "r340",
      "r341",
      "r371",
      "r380",
      "r381"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r26",
      "r91",
      "r188",
      "r371",
      "r382",
      "r419",
      "r437"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders\u2019 equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesAssumed1": {
     "auth_ref": [
      "r85",
      "r86",
      "r87"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of liabilities assumed in noncash investing or financing activities.",
        "label": "Liabilities Assumed",
        "terseLabel": "Unpaid liabilities incurred in asset acquisition"
       }
      }
     },
     "localname": "LiabilitiesAssumed1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r39",
      "r91",
      "r188",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r336",
      "r340",
      "r341",
      "r371",
      "r380",
      "r381",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "netLabel": "License revenues",
        "terseLabel": "License revenues",
        "verboseLabel": "License revenues"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds",
        "verboseLabel": "Money market funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]"
       }
      }
     },
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MunicipalBondsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments.",
        "label": "Municipal Bonds [Member]",
        "terseLabel": "Municipal bonds",
        "verboseLabel": "Municipal bonds"
       }
      }
     },
     "localname": "MunicipalBondsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash (used in) provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r79",
      "r80",
      "r83"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r57",
      "r60",
      "r65",
      "r66",
      "r83",
      "r91",
      "r104",
      "r106",
      "r107",
      "r108",
      "r109",
      "r112",
      "r113",
      "r117",
      "r146",
      "r154",
      "r157",
      "r160",
      "r162",
      "r188",
      "r218",
      "r219",
      "r220",
      "r222",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r359",
      "r371",
      "r424",
      "r441"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      },
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "netLabel": "Net income",
        "terseLabel": "Net income",
        "totalLabel": "Net income",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Adopted Accounting Pronouncements and Recent Accounting Pronouncements Not Yet Adopted"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r141"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of business segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r146",
      "r154",
      "r157",
      "r160",
      "r162"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Income from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r379"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Long-term portion of operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r3",
      "r100",
      "r140",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]",
        "terseLabel": "ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r9",
      "r10",
      "r11",
      "r38"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r35"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "verboseLabel": "Other long-term assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r58",
      "r61",
      "r333",
      "r334",
      "r338"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact of ($257), $2,287, ($756) and $1,346, respectively"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r51",
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "terseLabel": "Net unrealized gains (losses) on available-for-sale debt securities, net of tax impact"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r40"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "Payment, Tax Withholding, Share-based Payment Arrangement",
        "negatedTerseLabel": "Taxes paid related to net share settlement of equity awards"
       }
      }
     },
     "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments to Acquire Investments",
        "negatedLabel": "Purchases of investments"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r75",
      "r325",
      "r326",
      "r327"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to acquire assets"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesInLicensingCollaborationsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, equipment and other"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance stock units"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock, Number of Shares, Par Value and Other Disclosures [Abstract]",
        "terseLabel": "Preferred stock"
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r18",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "verboseLabel": "Par value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "verboseLabel": "Shares authorized (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r18",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "verboseLabel": "Shares issued (in shares)"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r18",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r6",
      "r31",
      "r32"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "verboseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "terseLabel": "Reclassifications"
       }
      }
     },
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "auth_ref": [
      "r77",
      "r298"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.",
        "label": "Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised",
        "terseLabel": "Proceeds from issuance of common stock under equity incentive plans"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds from Sale, Maturity and Collection of Investments",
        "terseLabel": "Proceeds from maturities and sales of investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "netLabel": "Net product revenues",
        "terseLabel": "Net product revenues",
        "verboseLabel": "Net product revenues"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r14",
      "r15",
      "r209",
      "r382",
      "r430",
      "r439"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReceivablesNetCurrent": {
     "auth_ref": [
      "r20",
      "r27",
      "r382",
      "r438",
      "r457"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including trade accounts receivable, notes and loans receivable, as well as any other types of receivables, net of allowances established for the purpose of reducing such receivables to an amount that approximates their net realizable value.",
        "label": "Receivables, Net, Current",
        "terseLabel": "Trade receivables, net"
       }
      }
     },
     "localname": "ReceivablesNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r307",
      "r414",
      "r473"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashEquivalentsCurrent": {
     "auth_ref": [
      "r4",
      "r13",
      "r88",
      "r459",
      "r461"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as current. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Current",
        "terseLabel": "Restricted cash short-term investments"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r8",
      "r16",
      "r88",
      "r459",
      "r460",
      "r461"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents, Noncurrent",
        "verboseLabel": "Restricted cash equivalents included in other long-term assets"
       }
      }
     },
     "localname": "RestrictedCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsReconciliationofCashCashEquivalentsandRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r22",
      "r236",
      "r302",
      "r382",
      "r436",
      "r452",
      "r454"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r189",
      "r299",
      "r300",
      "r301",
      "r315",
      "r316",
      "r357",
      "r449",
      "r451"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue from Contract with Customer [Abstract]",
        "terseLabel": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r142",
      "r143",
      "r153",
      "r158",
      "r159",
      "r163",
      "r164",
      "r167",
      "r258",
      "r259",
      "r415"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "netLabel": "Net product revenues",
        "terseLabel": "Total revenues",
        "verboseLabel": "Royalty revenues on ex-U.S. sales"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesNetProductRevenuesDisaggregatedbyProductDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbyGeographicRegionDetails",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r134",
      "r167"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r90",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "auth_ref": [
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r248",
      "r249",
      "r261",
      "r270"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.",
        "label": "Revenue from Contract with Customer [Text Block]",
        "terseLabel": "REVENUES"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/Revenues"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Schedule of Revenues Disaggregated by Geographic Region"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Line Items]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueInitialApplicationPeriodCumulativeEffectTransitionTable": {
     "auth_ref": [
      "r269"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information when using transition method for cumulative effect in initial period of application for revenue from contract with customer.",
        "label": "Revenue, Initial Application Period Cumulative Effect Transition [Table]",
        "terseLabel": "Revenue, Initial Application Period Cumulative Effect Transition [Table]"
       }
      }
     },
     "localname": "RevenueInitialApplicationPeriodCumulativeEffectTransitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesRevenuesDisaggregatedbySignificantCustomerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue.",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "terseLabel": "Remaining performance obligation"
       }
      }
     },
     "localname": "RevenueRemainingPerformanceObligation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RoyaltyExpense": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.",
        "label": "Royalty Expense",
        "verboseLabel": "Royalty expense"
       }
      }
     },
     "localname": "RoyaltyExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potential Shares of Common Stock Not Included in the Computation of Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash and cash equivalents.",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Revenues Under Collaboration Agreement"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Computation of Basic and Diluted Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r281",
      "r294",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]",
        "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r281",
      "r294",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "verboseLabel": "Schedule of Allocated Employee Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r12",
      "r28",
      "r29",
      "r30"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Inventory"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/InventoryTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "auth_ref": [
      "r13",
      "r88",
      "r416",
      "r434"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash"
       }
      }
     },
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r283",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock": {
     "auth_ref": [
      "r132",
      "r134",
      "r135",
      "r136",
      "r368",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Schedules of Concentration of Risk, by Risk Factor [Table Text Block]",
        "terseLabel": "Schedule of Concentration Risks"
       }
      }
     },
     "localname": "SchedulesOfConcentrationOfRiskByRiskFactorTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r164"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segment Information"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_CostsAndExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, general and administrative"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationAllocatedEmployeeStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ServiceMember": {
     "auth_ref": [
      "r262"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Assistance, including, but not limited to, technology, license and maintenance, license and service, maintenance, oil and gas, and financial service.",
        "label": "Service [Member]",
        "netLabel": "Collaboration services revenues",
        "terseLabel": "Collaboration services revenues",
        "verboseLabel": "Collaboration services revenues"
       }
      }
     },
     "localname": "ServiceMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/RevenuesRevenuesbyDisaggregatedCategoryDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r81"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "terseLabel": "Number of awards granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "verboseLabel": "Weighted average grant date fair value, awarded (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r287"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "terseLabel": "Number of awards outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r292"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Number of shares available for grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Options granted in the period (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r286",
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "terseLabel": "Options outstanding (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r280",
      "r285"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationBasedCompensationExpenseDetails",
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails",
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "verboseLabel": "Options granted in the period (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Fair value of the Company's common stock on grant date (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationEstimateGrantDateFairValueDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Vesting award percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r17",
      "r420",
      "r421",
      "r432"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r42",
      "r63",
      "r64",
      "r65",
      "r101",
      "r102",
      "r103",
      "r105",
      "r111",
      "r113",
      "r127",
      "r189",
      "r235",
      "r236",
      "r299",
      "r300",
      "r301",
      "r315",
      "r316",
      "r357",
      "r373",
      "r374",
      "r375",
      "r376",
      "r377",
      "r378",
      "r449",
      "r450",
      "r451",
      "r487"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]",
        "terseLabel": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]",
        "terseLabel": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]",
        "terseLabel": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]",
        "terseLabel": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r101",
      "r102",
      "r103",
      "r127",
      "r415"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockCompensationPlanMember": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement in which award of equity shares are granted. Arrangement includes, but is not limited to, grantor incurring liability for product and service based on price of its shares.",
        "label": "Share-based Payment Arrangement [Member]",
        "terseLabel": "Share-based Payment Arrangement"
       }
      }
     },
     "localname": "StockCompensationPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerSharePotentialSharesofCommonStockNotIncludedintheComputationofDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r235",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r18",
      "r19",
      "r236",
      "r282",
      "r289"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Issuance of common stock under equity incentive and stock purchase plans"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r19",
      "r24",
      "r25",
      "r91",
      "r168",
      "r188",
      "r371",
      "r382"
     ],
     "calculation": {
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total stockholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheets",
      "http://www.exelixis.com/role/CondensedConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow disclosures:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r178",
      "r179",
      "r185",
      "r186",
      "r187",
      "r230",
      "r234",
      "r356",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r479",
      "r480",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithIpsenDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesCollaborationRevenuesundertheCollaborationAgreementwithTakedaDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesGSKDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesIpsenCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesRoyaltyRevenuesundertheCollaborationAgreementwithGenentechDetails",
      "http://www.exelixis.com/role/CollaborationAgreementsInLicensingArrangementsAndBusinessDevelopmentActivitiesTakedaCollaborationNarrativeDetails",
      "http://www.exelixis.com/role/RevenuesContractAssetsandLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasuryAndGovernmentMember": {
     "auth_ref": [
      "r271",
      "r427",
      "r455"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes investments in debt securities issued by the United States Department of the Treasury, US Government Agencies and US Government-sponsored Enterprises. Such securities may include treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years), debt securities issued by the Government National Mortgage Association (Ginnie Mae) and debt securities issued by the Federal National Mortgage Association (Fannie Mae) or the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "US Treasury and Government [Member]",
        "terseLabel": "U.S. Treasury and government-sponsored enterprises",
        "verboseLabel": "U.S. Treasury and government-sponsored enterprises"
       }
      }
     },
     "localname": "USTreasuryAndGovernmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsFairValueandGrossUnrealizedLossesofInvestmentsAvailableforSaleinanUnrealizedLossPositionDetails",
      "http://www.exelixis.com/role/CashandInvestmentsInvestmentsbySecurityTypeDetails",
      "http://www.exelixis.com/role/FairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrealizedGainLossOnInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of unrealized gains and losses on investments.",
        "label": "Unrealized Gain (Loss) on Investments [Table Text Block]",
        "terseLabel": "Schedule of Investments by Security Type"
       }
      }
     },
     "localname": "UnrealizedGainLossOnInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CashandInvestmentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r137",
      "r138",
      "r139"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "verboseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/OrganizationandSummaryofSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "auth_ref": [
      "r95",
      "r99"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "periodEndLabel": "Balance at June\u00a030, 2021",
        "periodStartLabel": "Balance at December\u00a031, 2020"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesBalance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "auth_ref": [
      "r98"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "negatedTerseLabel": "Payments and customer credits issued"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDeductions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "auth_ref": [
      "r95",
      "r96",
      "r97",
      "r98",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by valuation and qualifying accounts and reserves.",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]"
       }
      }
     },
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/RevenuesActivitiesandEndingReserveBalancesforSignificantCategoriesofDiscountsandAllowancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting [Axis]"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting [Domain]"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/StockBasedCompensationNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Dilutive securities (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r115",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Diluted (in shares)",
        "totalLabel": "Weighted-average common shares outstanding - diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r114",
      "r120"
     ],
     "calculation": {
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Basic (in shares)",
        "verboseLabel": "Weighted-average common shares outstanding - basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]",
        "terseLabel": "Weighted-average common shares outstanding:",
        "verboseLabel": "Denominator:"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.exelixis.com/role/CondensedConsolidatedStatementsofIncome",
      "http://www.exelixis.com/role/NetIncomePerShareComputationofBasicandDilutedNetIncomePerShareDetails"
     ],
     "xbrltype": "stringItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=124429488&loc=d3e326-107755"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1505-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9031-108599"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9054-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27198-111563"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27290-111563"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4542-108314"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130533-203044"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130554-203045"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL108322424-203045"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130556-203045"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130558-203045"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130561-203045"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130563-203045"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130564-203045"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130566-203045"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130543-203045"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130545-203045"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130550-203045"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123410239&loc=SL49130690-203046-203046"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123338486&loc=SL49131195-203048"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911878&loc=d3e8732-128492"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123385561&loc=d3e9135-128495"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9212-128498"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "50",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123362884&loc=d3e9215-128498"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=d3e5291-111683"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569643-111683"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579240-113959"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5579245-113959"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5580258-113959"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41620-113959"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41638-113959"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=d3e41675-113959"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13531-108611"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13537-108611"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=SL120269850-112803"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116652737&loc=d3e64164-112818"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(5))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117783719-158441"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=123600520&loc=SL75241803-196195"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.6-06(3))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401414&loc=d3e604059-122996"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL6242262-115580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413209&loc=SL6242269-115581"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=123364037&loc=d3e3115-115594"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r474": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r475": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r476": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r477": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r478": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r479": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r481": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r482": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r483": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r484": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r485": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r486": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e640-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(1)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column C(2)))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e24092-122690"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>78
<FILENAME>0000939767-21-000076-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000939767-21-000076-xbrl.zip
M4$L#!!0    ( %:"!5,*4 )>;8$" '3[&@ 1    97AE;"TR,#(Q,#<P,BYH
M=&WLO6M;4\G6+OQ]_XJ\//M]=O=U.;4.HTYVM_NB!5WT8X("ZH(O?=5A% 1S
M8"5!@5^_1R6 HMBB0I(9TJZE2>:I9MWC<(]15:-^_[\GW4[C/0Z&[7[OCQ7^
MD*TT_N^3W_^_JOKWGULO&FO]>-S%WJCQ=(!^A*GQH3TZ:+Q-.'S7R(-^M_&V
M/WC7?N^K:GS-T_[1Z:"]?S!J"";X9P<'CT,4)K(,E>: %0@9*N==JHQT/D8;
M&-/BP?YCZW5TC-M*2P<58,+*6QXKJYP2#+PRP3Y(C[F&Q'.,7#,&R6H+1G,7
M)(LA11;&CST8T=O1&_:&?ZP<C$9'CQ\]^O#AP\,/\F%_L/^(.^<>G91S5B8G
M/3X)@TYJ7YY;OH[/%-2T1Y.#%Z>V3Z[<\I-3N7S4[G7:/2Q=^.F=VU^[@I4K
MAB/?BWAY^V$?!#?_=,7DC(L+\ 0[5\XN/[1/VL.'L=]]5/!@AHF/K1]=?^N/
M+7\T&OC>,/<'73\BX2@OIBHF*J$O;C(<?+Q)]L,PO@'].'Y:Q7@E^<6IQ\-J
MW_NC+T\_/W#-)2?#]G6@T;OS1_]NOMB.!]CUU1?]=C*JAABO7$G?'^[WWW_S
MW>PG3T_XF1A<W(0.C!M[<2+=\MT_H%0.!S^\;%_L'_=&@]/K[WU^\,K]3[YX
MP!7I+4?'IS[N^-[^'RO8JUYOKY#DHT]/?N_BR#?*I17^Y[C]_H^5I_W>B/2Y
MVCD]HB;%R;<_5D9X,GHT5H1'3_[7__I?OX_:HPX^*1)474C.[X\F/_[^:'+K
MT$^G3WY/[?>-X>BT@W^LI/;PJ.-/'_?Z/:0&M$\>EQ-Q,/G83@E[XX]TO$5&
M9=".D^>?C+8P_['25D9HZ75&2!*\%SYXR[25+@('&^+?:^.F\"*"E]+<\]WR
M:&P_7B4[E8JM>M;Q^RN-=J);)OGF-*SUW[\06^]W9?,X':Z_WWON#C</UT7K
M^:N3O6[KL+FS^Z&YMO5N<VT76FM1-'<Z[>;9GX>[W:W#YO._#E[(5F?WK'_2
M.MQZUWR[=[A[MBZ::ZML;VU?;*Z]DJW#=;5[V/RP*_YZMWOV9WOWC64OQ-[I
M[MNH=\_>=%MOG[VC^W1;W29OK:WR9G?CK+G3_$#?Y>[A5J?9I7/67KU/SY^U
MP_/7>G?G%=\]?'.X^[9YNOEVG;>>-\_VWC[K[NZDP]9S:K>@W]8.VIMOF^?7
MO*%GJ=[>SM%!:^U-N_6V=;![MJ%V=UZSW3-J^]N]@Y9HLMV=75E^VWQ.Q[@]
M?;&S/FINLY,7.ZM_6RV,SP(KD8VNP(*J@F6R2J!\4$YX(PC2[#M#_/W1%0CO
M$M$+Y_.L/8R^LXM^\(Q^&2ZQ_1:V[ JV4EF=)!E79Q(Y7?*\/I)?%5'F@";Q
M9,3*D]+_,X/V)=V_GY;@W@A<_BFX2>:HI?95@*@J(')56:=Y%:C3LTC +(:5
M)Z_$%*%=[Y&?.'U*X Y\9Z.7\.1_\'0)Z[=@%9_"BD+I%#7Q$8G$@#FXBE@O
M5-$0_37<*TRDLXS^<](9;>X<W@E3HJM/1H\3!0)=NN-!\J?8^Q3ZI\>#P15[
MO=Y+:W3V$OUOH2^OH)\8. ><O+%U%00NJA"EJH3ECEOG5+1ZY<D:1NP&'#3D
MEX;[T57&-<",!$S$X35$L1#(Q\,QF28!:8P)Y>,1T<,_5H;M[E&G,-?Q;P>#
M(C]7..'#DV&B6SRZ>H_)\S\^]+P-P_[Q8/QM' H]/A?*B6C\B%!>W C'!N?B
M6SN5[[E-'3-N$%X;"3S=^)^K^O/YQ4\N?KIZ]Z.QI[KX1I''8%0$_,E%]%)H
M\N?'+IN9/CG5?'+JQ9&+[Q</>72EHR[N<]QK3SIM>."I4R^[H8M^>#S )^>/
M'Q^\N,7%L8OOY1Y?P8'B\.(XLI: C'G/B20 &L.B5S;\O3'I?HH!9]_]D]!O
M=-FC0E_>Z/S(=_;H\5B:KW;9>93]^/7VVO?W9DC"6A<E,Q)XC"34Z!%-5ED9
M&=E%;\Z%,'_>FQ_E\_MZ\TH/$+VTF2MID@T@O;1DM+1.Z#AJ::T^[P'Z,W<]
M4/[W\_)$U':[J.+EZU' 3,WZ]-2QU?:C_N '1>^+Z\N/:]CK=]N]ZVY[4P-Q
MY1:/KK;^6Y)O;(9@1)(F9A#6>QE($X($!M9'KL[M.5",.2T5.']MW"]QQ^1K
MHH>=''7:L3UJ3GQI:M/122IT.!@]?CGHI^,XVAQLX^!].^+J29L,[GG*ZN+H
MY-+?'UU[Q\NNNGSP#_@5J)B\<[]R!3\;99".62 ]!<<(2QM0.";(-Y-_SF/\
M&.$'U?B#87*)W_7XL3%^<!/\V!@_>0OX.1XQ:"*+4F1(C%ER1(F04TIRAB'/
M@$_5%;]I\;HK^$GKC!0*R$!J0!4L.(B!C"DWR+U-Y_K'E_IW$_WCT]<_H<K(
MEG%2<M"2V6@%5\QZ24$9"K,0_N\%_=(;XB+ZOT"6$DQ4(F1R?IHY+Z-![77@
M/C&'"^'_IH/?3/R?%YRX)[=*QTB,4Y?H@SD+1CJ=O64+X?^FIG_3]W_&D)I%
MRX.6 93A#B3/DCYG9EE LQ#^;VKZ-WW_)P+77@2MM4?P(EGFE,B*IX@"F9$+
MX?_.?UQ$_\<T>,S96,X]@)/>\6"R-@H=X0JP$/YO.OC-Q/]E%D$*:9"E!$XK
MLI^H=0;E4#J%>B'\W]3T;_K^+TH5C;9616:!(D"KI&9*6PXQ6A/80OB_J>G?
M]/V?A"@<"L\\*A Q^X3),8TN<^_0VAGXOUKX'8/*:AZ2PL! DKEB(A+?H_Y)
M/C SB[QC+>P]5](+M$@6WX*DEX'@.!)M=MX8#F(&]J(6>LIM-A18<"AC[BES
M&X)V6D1I@!GJS?/Q*9@_]WAI1$=E.@9=L_Z?XS+OIM\]ZO?HZ_"JK:7?N_W>
M]J@?W]V^O;TZ< :W,W1H$X7P06EB,1FR9H$YQ\#K**S/F/W"0+.:4KM,0O:=
ME[Z=-GI/_5%[Y#LU@<F;;$1P)J!3("79;9[(YD@@"R0@P.+ %.-Q][A35D%L
MC@YP4,X;X$&YVWO<Z,5^]PZ8S)U YIA2J%S4 !8(/-(GGP1#4B]E^.6TA/I#
MMH4CW^YA6O>#7KNW/ZP)/E$D\DCDI3&7Z4_"ZJ@LLC(+N\S%QNGA,ZL> *"P
ME0Q*!I_I-8DV,V-BDI)XH2'V4H/TT=R)ZNS)O9(!!60P&1U(:QU*KU/RVD1"
MEKO%0W4F/F,.@&::&>FSM5$"0^+4(DAIN8[,7,X>62B@[Y1>SQY0%[P,DOLH
MO *+-GC%1);&H#;:&K]X@$Z-E,\>W.2]MUEC*-.O)=.!:VDUS\XZ)H7DTYNE
M6F<EO9/IL]K)%"%;P[@ 9,&EE PHG8071MJX,-#,* :^)9C(LWF?./=*DW\S
M9"UM,LEY%2.S.<O%@6GV,?!M34P'RSC1$\.#!A.(G#"9, 4OHH6$BV/TIAT#
MWQ(^$13Q1V$T]5TQ>-[*[ ((^I/H8QKC4P8"YF[<:TZ=$KM*+7X&FIA9E@DT
M!$Z^25OG?43ME'%$#J5;&&AFX91N#R:6E90&LG?@P(L0,D;K6?(1(GW2BP/3
MC)W2[4&6 8SV%"IKG2!0I"PE\Q!8]HH;3'EA()NJ4[H]?!SH&"D^4MP!Y!0M
MH@:)7!G"1\8IJM2L>B HB,YX<!0B HIL UF9Z+7/FI,7\#68%S9WHCK[V0-2
M<^URCJBX@I1]*',M#$=G3/3,NL5#=?:)V9D K37Q9X;*<"TAYN S5SYR5$)S
MY0Q?/*"GEYB=S3J'8)1@1J!AI+D)+>>1$:(08Q!9Z<4#=#:)V=DLXD2C?")&
MZ)("P8.G^(K'DJ/@T4#PYW2C_IA.,08VM\.#P$ED  JS 9 N>V]12K1)AN1<
MC@L#S8QBX%N"26GO.0\I!9Y!2>N5=09LF5LJ'1-A<6":?0Q\2Y!)1;$$$RFG
M' &\"2Y$0BLI%T-91+LPD$T[!KXE?+S-9.ZL$%*3%F6TUF3GD[(J&D_A\?3P
MF54/,,N%TA'*E&MP5KJR.L-D(EY<271Y>C5M%L0M_U2QG:O&PS,'S*,6J(#Q
MX*)@,AJFDW4IB\6!9D;CI;<$$U,VR.PD9U(".!5*>;M2O3LD74;C%@>FV8^7
MWA)DF6EK L4> !$TIR]&$KEBWF3O@N + ]FTQTMO"1_,P).QJ%@,X)WT6CC!
MDC<1(V:L0\&?.NC6[%>&9L]+0H"+Q#@DQQQGD T#Q:U.R/GB 3W5N973!Y00
M!.(HJ80]P'FR!KU"95EBV4.6BP?HS.963A_<(#3*;#!:0 A*68C!Z3(O.C&T
M>!$M\=I'LU-,X?';">/&Q8"2RKS4-^3<E+GJRIG2A4(3$5T8:&:4PKLEF)2B
M6!NS H>)N">W41DGM4-I8J28;G%@FGT*[Y8@DTRH $PK[S.4\0IM0Q(N,R%-
M63^P,)!-.X5W2_AD+I/WI9A/<&"9L\X[@DEGX84S.$7+-S/;SZ(M*U[IWP@^
MF1 ]3]%QC-DHD'4H+S9WHCK[8@[,<F<X,(7< $<,/$=3IBJ)6$;%_>*A.OL8
M>"9 !^XS,0&9A4D@D_,60JDX(,GG!)OBX@$]U6DLTP=4<^V#"9C11TB).R>9
MTXX;;D$EIA</T)E-8YD*N)<[(!Q-"H!]L:M&V47F\?G!BWO<>%L-9JP-WA65
MM\"L<)"B4"Y*;X6/ 6J0,?EZ<;1QSVSA\+@S(C_];-#OKK6'L?\>!Z?K.?<'
MHRF4!IA!GH1\-1JA5"DN*5 XE07+8)0J,+M4?TC/#PW7J%/>8RK 7KKL_G$O
M+0JL'[<GFK3T>M4_/_C=JN_ 9%ZJR!HC(%KO1#+9)8(P24;^OP8+T6\F)\\'
M_>%"%@$)/LA(_CT:#9",=Z!3#$)IS,FK4(>YYO.#X$RFI0:N35""(F4T$*6S
MTL;(@B/T?,98AQ&H^4%P-M5E(0DIH[8B);*B:#51JIB]4:24,M0A4)X?!&<2
M,"6;F=;!F#+OGX$+VGA@94Y>U-Y8L3!^<-MW<#AFP,<EANJEU4ZG_Z%L^+Z0
MWI$"F^2#1B<5AZBB+RMUT#'4!H@/UV$]Q[SC.A.?F21'XJD%0@<A9>L$SU'9
M,EO1QF06QF?.5%^G[TF=B]*RR&-*&@)YU)13 $(V12Z]6AQ/.E-]G;Y_M3)"
M*3-2BOE Y-HGF1R4W3BE!A%F4;_]EG%]VN]T?.@/?,E"+J(KU='G(!E'&R)X
M^L=8,"RZP#(7P==AJ?H<03@3KXF<)1L)0JY)]S)Z]%$RRYD+1(A2O7<QF846
MSF C2^DT=T*6U>40,03OLF, 1(0DD5U;?P<Y92V<[OA-[[@T_"M[S!_1Q^_.
MX(JHC)+ R#J7G16Y#PH)+N6]E2X!KXEG;?K#_N#I\7#4[^)@^(DX;!P-\5MB
M\,TG?!SV)8+5&TUD:ZL]?/?GZ9_8BP==/WCW^?R.]]@[QC*L0!?1%7'TMCTZ
MN&CA'39HY_3HLWU]+A[ZQ<F+2#-$2CP:ZVTIK!4,4$@G5&2><Z.29K8F-&,I
MS_,GS[/)[J<R\II]0,:!$4]6@1D% M&7PE=UV3EU*<_S)\\S(:"<2\.);0HO
M/90-$+7062H!)CD;4UTR-$MYGC]YGDEF*K/H#,7 MNQ:EC%88U3T7F-VD).M
M W^^G]+V<VJ^FG.[TR:9&?9S,_X/#H?]WM/^X&B!$WC6)Q: I-P)^L<PSYBW
M+GN1)/THZ[ '\5+2ZR;I,^'<AI4Y-8@)0X)8MM/+D&1F92YDYL;5@',O);UN
MDCX3-JZR41:R*GM% DO!<V-BMF3@':#FO 9L?"GI=9/TV<S02CH*DPP7R8$,
M9?!1H=?!A#+;E>LE3U]X27_Z9OM?Z#OT_HM-U+,,27LA=$0%699IB2HZI;@E
M#0##ED1]*>H+PM0S!A6"EAR#(,D./F27;6*69><TU*G,UE+4:R/JLZE+)16G
M:#0(7FHT0O#"62V3<]&:4CIG2=67HKX@7)V"42%S-C(35[?<6LPDX0G1!HV6
M0PVX^@TQW<RK=*P][!\/(OZ)@WW\CCALJ6^+P]D9*J9X2$$+#SZAEX$'KWGT
M22(SH0:<?2GRM17YV<QL$9*S2/1%1 \B,Y< >2G'F$DF?:I#EGTI\K45^9EP
M>"LX(@!+V9;%#]QIRYAPQ.(E0RGK4"AI*?*U%?F9<'FC)'?*.84*02GMZ9,6
M DK]R124J0&7OY_2=GMAZ^;1Z+B[?82Q3;'KZ<L#/^CZ>+J(+%[EQ#T*)H$"
M5RZ8=>B<S<PFI5%%60,6OQ3V&@K[3/B[,%%J\-D*(C/HT 9O$W@M3!;&A&7N
M?2GLB\/<0V)>2.2@<H:R"3.4B;].\V2#] IJP-R7PEY#89_-7!FG0/@,$"0#
M4S:\C1""$@A&VT7(O\<XP-2?C*64LLR3P!33,BZ]-PEWJ0"-<=Z1] (*Y4.I
M5^T%,\ 3FKJ4HUC*>#UD?"8,/:)1R0L=R\P!QYB5UFN.!KPB]B)%#1CZ4L;K
M(^,S(>8B2X8:@Q6H(1@7A%%"1I_1FAPXJP$Q7\IX?61\-CGT0/8:&'HC+0BT
M/J08O'/*IR11I[KS\1W_#I-?"O2](=\IR("H TB2:RFYIVC31,L"D(@;ENI.
MOI<"?<^8-I?, ?(4K+60K7&9BZ1-\HFK:%A=:K O!7H.!7HV=0)#2I8SEGFV
M$$%ZKQV'7/9^X2;).BP,70KTG KT3#@T!J,H3$Q!: Z:A-L0D4Y.AQ@XEGUK
M:VZA[[KNT!1'9+Y?JRA('M?!WL*([?<^=.YZF\69V&2O$W@)),,H@4.9*^Z"
M==$(@1[D9[OR%5GF2Q%>BO#/6^&)M//;$&$22S2 0D@$ =X9AA*ETBQ996T=
M*DC/AX#=87F'11#NV:2BDV-E5FN&LLUQ5CX)!Y(QR9D.%VFZ^;;/2^&N@7#/
MQG);3,Y)U$@!H<[,@C!"!@7.9>Y5[3,<<[!T8<E/9F["HTPZJLQD,>&2A!M9
MD,JR+)FUQK :F/"EE-=)RF=BRV5 %B%KJX4!2-+R6.;X69^T2U+7H:;X? C8
M759N6 3IGLT><$)@SL&"\A&LUE:%*!)$SU$$#5@#&[Z4[CI(]TQL-P/N##%O
M"C83&++ASA,U5Z@@9L6CK8'MGNW S))_S-Q"8R+CK !R] E0,!<$!972(^.<
M:>=K8*&7,CP_,CP3.ZR,Y@(B!8J!@W#2,X-:18:<Z\!R7>;D;8_H_<OYS[&_
M/_!'!^WH.Q,\QR@.3A^_WKY+ZS/]R6?(LPS,!&ML!M#.DN&QZ'44X*T2=5BD
M/7OD9C++R@GM18HI1*-!)!E \Y2DU]R!CP9JPGUFKG/3]_C&:1&3S60S/:#Q
M9"]Y#%(9ST 869=9^C/7N1GL;V2SL2*1WA%RRC*'4H>@-4D'64VGZN_GRN'U
MXT'_: I<>P;[8<J,7@3&#7K0(A'5]L)'*XB\!.9-_;W=U/";S<QB5%PY4T8?
M!/# O0PA9!U-M,;SVJSAFP?\9C.1%IETS((+-H!5&- *8%Z9Q$JPH.KO^::I
M?]/W?R$+3@%>!$@1,"EKT61PX)16SL("^+\+YO+7R\7R?#8P2#F6V64>K*<P
MP20IB+(HE":R7'_/-P7D9N+S5%!&@516:6(IQ%,R:!\H<)"$)$MU&)^</7(S
M\7:0A0.(T05R>1ZYQ6 ARD ]:TH-F?I[N^GHW/3]')""):6"T>3<1+!6VNAS
M1JYM3' Y)V#>_=S+03\=Q]'F8!L'[]L1/\G*/_6AW\71Z<DBAGD4CWL"S3AF
M)!B,'K)-21B0#%02==CS:4[@FXG'*[Y- 3BI2V%H:X)T$@77VK+@T:B:>+PY
M@&\VTP:=U3P9=#D2YS3&%0"#*YN5$)BL+FYO#N";C>\CEP<E1"#H  12I" I
MVI-,9V"*UZ%&];?@*^ -VO]91-=GE3*,2YD"P25T"L%F$XS3S%EA75TJN<T>
MO9EX/DW6$FV@OLR!E) ,::3P+VNC1<#D<0$\W]1T;_J.+T=?-J1S-C -EIF@
MM8;@D-G(K31B 1S?U'1O!FOBI3+:!:.(HP!+RGLE)$5_20@7K39_;\SK]*N+
MN49O?.=X/"-IM=/I?_"]B,/57MK"(>&(PX_3I"90'OC!/@8?WY63UMK#R3RE
M9_T!X=\]&KWTI^7QMX]TNT=XTKE?3D"Z./(CB6DB*EP("3YRD)YY@,!XTF@\
MDQ2W+QAXE^<\^SCG[ND 4YL 1!SZ7GK:)P!7A\-VZ=)X!X,1=P(CV,2=X4YZ
MZT$%:7WF#,%FE15')Q<8QG.KNT4J.<)A3? R 3,Q3:[!&?)TI>*3! .2>PO1
ML#I$ZO4RGK,G.39;KD.0FF@J6"F]2<P%X&1VLTJV#M/.ZFIR9P\^$+7-3&AG
MR2JC)7T'K;G16M+?*=8A/IE[0SU[E%7.P:<4&08.Z)SCP7C%77 NQ>S2N1=>
M%'#GA E_"MY/N&0I,7/+#5'@,OB8;$)F5,S@E2S+6Q<,O#DPRW<"HV<. 40H
M80W($"TD'UE0#+620K,%AG&Z3/B6\%)D*+6UN20-()CD0V36!&X#>FT%SC]>
M!9'-O#H8^-[^>+C_2MZGT_%AO)CU/7YRRH?VZ. FA<KF!26#CD5OI)+)@"AE
MMI@TP(BZ<@<<<@W&-N84KMF/? B)WB7R<IG"44#OF7<4HPCEO >CZH#MU[.O
M%ZB_H%]ZPV\YL:40_?"BJAP<*E6&/_4DP#&HG;/6QK(5DJOU\-D]%**9C.(A
M$DMSL53RUR"<"BH!PVB,T3G)%&H0)2^%:-9!.$B*W++5B6FB*IH^F1@E8\18
M' B4M1Y,O(="-),QS1AD3B(YX[('YI/W40AG<^+9V*SJL"Y_&MC>@B2?_[B(
MG,@JSU19YJIX!"V=X]$DK03+/GJK8PTXT5*(9LV)- -N<V2\9"6U4<$I#UX*
M0R GG4T-.-%2B&;-B;Q4D#P(B,@ >/;")>FSYE%K#PYKP(F60C1K3N2CM2'D
M;(TJ:\C)GQG#O,N6Q;)&L@XS9&O"=Z?O91*"TL;%D+@$Y,HGDQ)R8,HIASPN
MO4Q]C3\&FYQE@BAH!LGI6R2L):,XF8G ZC"[M@[8SJ:N !@CDU0B. TN9BNR
MRD*7';L#F>7[$*?>3IG$VTJYU#)093['R%Q0GE., 3ZPG'UBFHR&9ZD6:U^6
M4C1S#L&BB,0>M'"18E9MO$;4J"Q36B8A_3W@$(LE1;.INZZE=HZIG+4#ZR"@
MT(E))PT&+[V_!VQEL:1H-FMQT4<LOBSQ !%#X%E[;PUFT)BR7_*BFF4\9L*+
M3 F4M%:9:P$JY1"\US$',DH<?*[#I(:E%,V<%^4$&1W+$&T QH3CQG/-QO-D
M7#1UF-6PE**9\R)I<O02@PY<@V R.'"6(RAGK41AEKRH9E(T$UZD@[)&*YED
MH$C-&)LB6,6('CF+WO,E+ZHQ7;':"I#2.(X&O#&>8 V&S(5/Q&$T+.E*C5F$
MU%EXEW,L"(8</"%-RJLBQHR ]V$>P+0T=P:5O\@4 _VEB0^"482O4($QG1(&
M)F&9]*BSSV568[0Z2ILE2!9"%,)JX-QYTF/TB[O"Z:XPO9,E3D$IG\ KP8 #
M:NG!168"9]9D[T4=AL#_<3NQYQU_TM_N$BS_TVGW%C)&XA"T3 @YAP :9+#*
MB5"6$>AH=,8%9[?#HG-3AWGZ/%=Z[8@$90A>@V'<<^.5Y38IGR&+.E72J _,
MT]?FP+D*(G**4C6P&"T#):32UICL!+<+'L[, .;9;,>F#-KDA$;GP"*,:\:E
MS%UV+"FVZ-QW-C#/@ 6C"2PRB(X)X!Z="@FR,U$0"F3(:^";OUGC<80=NG36
MB[*>8X\^83Q81-^?*&JBR EC(H*NB)A+$87U+/%(Q#WH&CB%I1C-WNDD3W&=
M  K(4P27DLU"2.<TCR@$/U\D.M\4<BE&LZ>H*EM%;-0 I PV92^1B?$NI5&!
MCW79EFTI1C->;6RL--PG1]($F65;7)D2.4N!6D97 VMTN6W[<(BCU?B?X_:P
M/:YA]35X]P<X!O=M ==W?=.'X<L#/^CZ[=5%-!41@TN"&\91 8?H4W+*:J=3
M9DQ%F/\L\)Q">R?)8.9"#(K"%6L,H%=EXS\G5'96>(Z79;'G&*UG[9[OQ;;O
M;% O#(X_FMJ+$Y[VNUT<E#->>NJ9F@ 3M;**>\-S#."E(1Z'VGJE05F.=C&
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M,PG\;@D@Y3SJP%/6PD N,QZ]SRYBL$8C#S7826Q> []; LA&T"GFX%F.$,M
M:EDO8"WS7M&ON   33?PNRU<$*,2RB8$ 4K)4/9N,ZA*.>T@U4)8MBD$?K=E
MQK3C@CN7O4]E!G! 4"#16BM+A*$7 (UI!WZWA RF *F4AQ >(4LL6^4%3R9-
M8?)>A@5 9B:!WX_#0];V')O>>QR.RO,ON[X["0(FXT,?CU_<Z>+PQ?=RJ^L3
M_M$98;PA&LXA*QNLST8$2?R/A>AKL)_/+1/R.0S>IAI:\YI$DH".1\ZE*X-3
MS"6*'QE/47!CZ$A:A#S[W0ON'"1@[ET*)"GIF2F+B4T"8Y'L;K1,Q6AC8CZ'
MI> N9>5R\GZ*II1]TP(D!?W2<J%1))VY\NC"8LC*CV1EYE!FEE[Z.@%6+())
MCAN,I<*^M=RH #$%9)$+MQ3@I;>>:P%6BB%:H84T9($SNLQ42"$AR!R\J<&>
MPW,DP/=$9GR"[+V*,H 'H;U/1BJG#6.8#8=%B*E_+%4_AS*S]-K7"'#.D2(1
M8U29HLLD+\%*8B:B\8G(:!V,WEQYS7NC3?,BP#J"C67YHN82C/ A>6<4E(V5
M _=0@\WFES(S=:\=-7+G,$D&()+T2-)C<F:03"0CN  R\UWCMW,H*DMG?8W<
M2L]TEIH%#P!<)!="RM89:P&CXW8IMS.7VWD1%6U]8"X9[8,$H8Q+0BB;4\@B
M2F-C#41E:6MF:FN4#"QDCV@2J%3@]6"8#QZS#*(.BRCF*C"X=Q:(2+@+5AB&
MAHV7Z3IG+4(*P7J2I%PK ;HGF('F6&J$0?(1=% N.,L2A*Q02A-JL+3ZGGJ-
M6R1@]5S+I((2T1G'N3" V5L;%".)#5P:3%@OOG.?W-6]E]RHC3/&)V+E!DS"
MD%&4W8&ED$R'5(<$UE)8IA;6Q8RQL'*M&! S]]$FCSQH(5+6?"%FB2S&,KRY
MH@?S(KX>729S5^K%&1 DNLSYD$ DY$HQ7X<EK?=$?.=%8@('  I&O $-CJG
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M':DT- ]7Q6['GK;.7D'K+*KF6CQIGL73OTMB ;3#2G"?*@ 9J^"3K+C7,D4
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MET$&DU>>./6 RWD:8U[.":D/;UCJ[ZWJ[U4"@5:KE(*NF-:Z J9-Y9%C%4&
M<)YK1+GR1)L'TL(<Z>\B9QK6,..@[( V\B?GHQ_+Q2:S(@\78&ST8K^+._YD
MD@A=FI[O-CWB"^K@,M=<J2IG!Q7(&"KK;:JX<ZB069608A<NX8'6\[12?IES
MJ ]W6*KO+:KO5>80C4,70ZA"E+P"3LPA1,:JJ(67045,O*BOT@_,(LZBF$OJ
M\+S?3Q_:G<XRSS #JG#1^4O+\GV617Y.#*0EM"#(*CL3*TB9;$S(L4HHDLE:
M>JT$Q23_C[UO;6KK:-;]*RKV/J>2*@V92\_-?@]5Q!"_9$?@"TE>_,4U5R,L
M)+8D?/OU9V9)&'%S$!)B29I*"@LT6IHUW<\SW;UZNEE3U,HG*3&%Y;$+"E8?
MC-5K5@"5' NO$:%,)2M 161E,N(9-DE(1@,GMH987>7XP:B;8.=[OD(YD_%D
M)L%$[O9^K^M*]M1#. >NVP>8\*C!122-A'P*0R,C:$21>$VH(1%C.PH<:%J.
M8:P@<A=@(!3DS@>YUTZD)DL!2QV0C-X@P(8@E>QYE(06B)9,6:XVMB1K JX3
M<.=Y\(+)FIH-HU,7MQL+CYMSO80EB*>^[Z7GW(6=*"DD.QW)\AO/552,$MOL
MC>73;91:9(6RB)#$ARJZ8*C<V*)-)F23SJT(Z+(<)2E4MO94MK#C,H7*IJ:R
M:^FMD6&EK4"**(H@)D]/V:@1,8%I8-1P55$98;+)YI9@5L[)S- .ZX^][5_W
M_M@[W-M]V]C>WVF\/3QX\3__/OAC9_?-V__[7XH2^;RQ^_K/O<.C.;7,8DD(
MOG>>.VS6N&?6?6>YRD\G+YIF==K&MCOM83N4SEE+7Q1HV[FJB6_CS'S-I3U+
MPZP5;5"S" =PK$NO1JI43AL_Q(K:NU&U**B03-W@$4EV+@+%,3)5S1.CE:18
M66-H50<..*Y1U*UTR"H$M&BWK1#0? CHJALG,:?8!X,X%A$!S36JI:-(NYB<
M.^^H=[EP+&L*5J<6?>M2HCII??\\Y'L\S47'3 7$?'C1AFZ([=(=ZZF,H2R5
MW=.S3N]K"+^.95$XZ4&<=*/@$HX&!Q ".<$ 0=I)D":8HD1%%IQWSAF\L06J
MR6B=$I=*DN%261,%P?-$\%6K0BGJP/N(L*C2A+U#ACN)*'74N ".:[VQQ4F3
MJ-(QZPFMBO16GDMCV&^GGQ/!OY*2N$"S(GP)G0M&>C$6R1^7LBBD]"!2NE%(
MB3IC)%81*6UL,BLX0]9BC+#3# N!M?*J.D^-:]6-IZ0FUM^L* A^) 1?-2N$
ML513J9&P@2)@@B,=L48\_53.:HJ#3V8%;=)5K*A4>[/B3;!F..X]$4-ZX<]#
M8]AKN/-!6HW0+\&*IPA6O!BO?OK"M*H7K/2U<-*#..E&E24)P2M,%1*03 L
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M?)=O%;QY"JI+MJ;+BODYN="#T+V/5NX-!N=%(Y]2(VEK^WW:48.1B>*H H[
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MHP^9D<HQXDGB)Z<0$!J0Q;F3B-+*>NY4$#A'7S&P)IZ]W6FI#+Y*D%] .*1
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M*^8\[G72W0S&SE;U]]W_/6\/O]YC(R(PRT:T2J7Y1]TA2S>#:1!]VCOOW@?
M4ZS* H>6=.TU'UD48,U'%@58\Y%% =9\9%& -1]9%&#-1Q8%6/.110'6?&11
M@#4?611@S4<6!5CSD44!UGQD48 U'UD48,U'%@58\Y%% =9\9%& -1]9%&#-
M1Q8%6/.110'6?.2">C>.JH)6!PSS5UQ<WCUR88E?3<=T76B88:-E^NYX5#Z
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M).N1"*#G',=H7"Z&@EN&7\WMJ)%R-^<1FDFH6QRQ_CD \SO_LWR Z^+830Y
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MZX>5ULX:IQC7'&MJ>/!4&,^LIM8[_H,@[W;[]84H"CR4SY%>$$L LW<AE@+
MZ.*@G]Y4 X&EM'&^#';*A7@>/,$OS,*U]_W)I^B2%S1YA$7([9P51QH;@Z23
M! OG7"1D90T$/K@2]R@FPAUFQ0,HR I0-ELO5?5<2T'!^X/1L(J2E,  WSN
MKV3X&AV6N%!X6'(YS#&OSRVXKH^ #+EVVL$8=+6?E?XXJQM\LLQ/'^9 16=X
MF%%F3L'A%ID ^;+1P%<[Z/3'P^(@PFWM\6&)!V5(I@1#6#7=L%KLPJ!3UQX,
M#SO'Q1' $*!;S*7<7/^;S:#0<:T)"'=ZAQW7@=%D;#S*3WZ< >ML -YY+Q8
M#64R?6=::;K8V=IO%>O__:M5_+/UQ^ORL8[AZQ4LO=W:+W\>VF'A8NQ-GK!J
M-)4'^&YU;[5XW>]70+J9,7 ]@$/; 8"O<.R7UYOKOY;OPE2#VO8N3-AX=-@?
M3& 0K,%)_UQPKXJ-]=]W870?_@OB4?RWXI?YY_VU*,- N3[==$@9^VWXFF$N
M2R5C&EB67+ #YKW7/[+%+V\W-GYM%:Z?D:_;[U6XGOL]](\<S$PYX!(7?Q_
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MF7:VV^VMW]^>@UX<VE-@73E(7STXW R(,_R-AJ.8D2;_.02"7_%HE[WUV<T
M.H!)PVO]O)/0+_MX5_:G=1'8\H?G"&HJ#L_R23"8IM)W[!5_V@P9>8C=CJ]"
MX3!_F[;3\8>=8L_VOISUIP#>*O[J'.7(3O'+Q0_\NBR8]1<PD8$]*'D^S Q8
MF9@=@V&>HB/ F$')3,Y7\04,3P-8.N U5,:O0K[SE3/5A>SBE7L.\10>*TR=
MG*F+-_U<<=PYCGEXYV3IDALTT1JXW"',<P&T)XM@.*QL\!"0L'M.:"I?K)-O
MT/'#RI;9HXFC<JXJ1WU84C/'Z2CF8]N=X40O2I6^K10?.0+PNQUVRE'.1\"6
M9,$]<+SP0HRPC.Z=O>#8WK?=]4^Y43M3)B+NG$9<<HF,\ 2D&I7C%!,;]>58
MW96MPSML"TX\@BH&8ZM(:[E8IT&?*@1RV!^6FR<9#$X.P;R<H?Y)KBLT'+MA
M)W3 G8G#U6*_Y))PW5)1)X2Y2..>GP0;RD2!GC_+'/+<CPC97 U6BW4 A;S1
M.9B&C)SM9G,W&0/@U[!2]&$5S"D]$QCE43:A,:Q^/_#X4G6LA)_=="F*?O;B
MM8WL_OW)&JFCR)-G=4"<)(NL8PPE2BQ73C!E?ZQMYQM&=]*[V0H&9Q&(X>1L
M$EQX$&P9V"KC=.=2@X^!JF93F*,&)7T"[S('48]'U7?/]2D3IU*/.D?37M V
M:U;E=&3BE/7I>#P8CH$<9+X$?N!103#ZNWQG/9,R,+D$9Y5_6[GM^6M[Z+]3
M!K<'IGLP,\?3*BJ9:AUUAB4[^V5O*_N8Z^4CP1-T@8#!5\] WW-RPSGR9"XP
MN>KE,:9^?U3E00SRL?]!%8 H'_*:.;A^LO)L9&EU@>C,3<=PEAD!C+AB.<=
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MUJ3A+8Y- U -0-44H#P/E#$O-0T!7+RH)5;:)ZL$4"KF[(1!D89!+05 L7.
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M+VJC^R[I^D^YR=1@PO>#')XY9K#F)$IN,."#=I$:# N'<FM3D_RR5)@PBVV
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MGF78NMG0^AEP8+E;FS+6@-KS2(5UG#.@5UAQ$J*R3?CE"<'AVP5P\-9PP9E
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M:1D""H()$KVV//F5-:IY@W(]WZ#UL]+KO.1N7@VM-;3>$#_SS)6U-4F4W&"
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M!R/&-+1@&2;$NX@$SIDTUC!D8&J1"SI2"E: 9CFTT%#DT9DT<T2,%Z .?YG
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M,';Q O@N;QA/26NM+\LD=$ZS+_BVFW$KDP[#;V5:4<G4^J=MEZ7&/A_$6.Z
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MW/R0OW\';?QW:WMC[SOT]V#W;)<U=_Y,6[/UD;P@4@3L$1'&(:XT1XXHA;C
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MJ_<-+HA:R>^GY#// TBP3UQ@1)@TB#,ND948--TGCP-.4BF^L/ILM9;76OY
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MYEK=G0?7/%K5N*S7U_Q=N$!U3I?'BG'B/1#%:&-4222AF,<_.4>X3US6!;\
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M!KIE ;H0A>/)$ID4EUAJ' #49,*"& M,[[88D1KH7AKHR*Q5 B,I2"V1$BX
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MH$K=2*21E&E3W!](?3R*M5R',M1=]R=&E.S%L%%9-IO@WU7V"#XQBN&'.2*
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M6^#^K3A]XY5-9MYRGA?">>Z9E--RGJ?B/#]+SF.RL.>#O#"Z8=\V7'O0-0;
M?PR/.2QT>D'?QKF\O9X^L._=9Z;E/"WG>23.<\_TT);S/!7GL:KZXL T;3_J
M&_U!8!ENO\<,WS$]P^OYGAE&?FC;8)T-^WIOZ+2<I^4\&\IY[IF2VG*>I^(\
M3LEY7-?TNF9D&4.WYX/.T_.,0=!WC:X3#)VN-^BR/EA;%@ZS=C:?];3NZ%54
M?,#2;!RG]W9(;XJGM%WCSFMLA'-X;2)9S'!2<I"4G"?\4[S#P 7?6!9YGI^8
MSF0/1D-.B99]/O@\#;5H7[2+X6EB]V@QMZZ6M 4JQ?+AQ$_HPVVTT.3]*L1
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MD1R%+O8J'9<^V\6W XRG[&>6Q#\1[3H2,Q LR%:%4Y#3B.63:)PWB:/P(K2
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M)9ZR$7 L+A (R-P))>*KPL6%^_&H/TV#K2M,@;-P4LDH/$'J('=K";[.=3O
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M4ED#B#F":RK=_'7I>E*LRTH'HL(8V2]@B8JJQL-71)[Y$!C1VX*%<I"<DOT
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ML['V@:6HH@:C#<+X:Q'EN+Q>>0.Z !?J#17@?3:]8D#\21.Q\+X"Y/N^4-;
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M!VI%4%,EPS9.82_4"X%W6(<KC'-,3*<D;%GD=)7'4V:$V54]:YO]F,2Y[++
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M P?'3W= #E"Q\>/G7\EDN-%B8GH=/S@\(J@FK(?53CC@?3"^KB(VPA9RZ4U
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M4*BP4LY9I$6+<IH!YKM5,NDR&IU94)]&J?*"H&50.)+J6 B&E3^.*0X)32_
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M0%EKQ;G38GC\'E;M7SBI))]19)-_7;:-.JETG(>C%^RD2]S9^ :^.%]K[#H
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M.GMW^N+T?A+YL<K UJFX2 M)X]>A#S:3%PGFBE*<)1OZK:6VN>D3<U4@,II
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M0S>\8>T;K]G*-3;][#:(*X(E J[V388^C[5Y+5%7Q2P%(HOFYI'1Z^3PFO;
MF/^]V[HR05!JAR2[9-;60_5<G3()QOD+Q1*1>E_?)F!+$:-H&L=&==0GKG6J
MMB2&?S'[-)EWAFGUW.1 YL!C6<44=GCI'0D9GE&WB4/T29''+-:Y6$L!<\ER
M-=<\#=4X$SXKHT'V._ML ?37K5R._58++KZ%SB#3D4,-9-AK&*/J6UD:X*@U
M3#\=,$=);E@5T*TA?('NZ'L^BS,2#^\UR'$*J[OWXOW9^]/[-[BX)EC2V4'4
M$ R'T1VS:#=GETE+8-T31FMK.!!U0$/8L5A>4I7 9"-PGC,"R8IOI=P%6*F3
MAIVE*V0>"Z)/!4 J] &IS-YQ#9.5)GM<HUZ*^^D^Q?U3IKAW,DYT'E>>F4(@
M$/-9W8V[X[^-@RW#;NLFF!'# ;N![%;(85$G.#K!=1^T(J1()3@I4=R[XOS\
M'6RBLOK(]!FD+L9.TH OKNAV-B$28=GW-4K)L*L:[<C+B0_#DC:5; 8N)"=R
MXSOYV%KOCD9E!0.]4-9-@9]T>T(H'SP<IM>9W33)K.?/8^T!Q;!0NX$6*U=.
MQT#K_&;?'"(AAUJGDVI (;(#<7>,URW8FQ:K7"8P>P_*1!AN< .D!BT7_!U:
M/T8+2JU: QKAJ3. -?YTEF=<&>P1W+6JG1=)/"+V7.H+2/U?TT+@8-E)I;KX
MH*)SGLI-R)H2X"1:5XX@$&5&,$YN]HCP]:0"YJ(QM17P2#'5R>!XI.I7X5#R
M=&5&M9)/S!D[91<R5%#Y1_$-RE?&L%IP!5L.**9K1OUP+&7C5> O,IO(V0TM
M:$$F+U=9M[(^2F7(+DG^;'/045F& 8$7Y/=2ZRP(I=< 7Y #./!\?#=829=.
MPQU7*-)H#B2(5!!WTO(<1(:2S9OW80BWA+2WD=B]C"TG=J9F#A %._HY3W.U
MU+\Q=TG%N8^KBY#VPSK'*TK 582DSJL1<18%*X1EJ%YE1/4J]8;X!^.VVUQ2
M@&L7MSS3BAD/-Z)+3/BZ$(5E^1;5>DNNB&&T)4U&G*4X^UD%EYSRLAP@B67E
M4+-IM^6DH1D]//35EZ*0EWQ%%:JP QENS&DPVE(,\R_'82(^. 4LM*P&YNXC
MZ-XEG/AS4P3_(9Y@?FYKZ=]*+?WN& \W--=>H*O(L0=DY<EJ[*H#X)%T\C&>
MK$(A"*_<;9. J=4W20L.Y<RJ%(1-.Y&H@)9'<S7 AGYUG[>OL121L)3-*Q/P
M<!>:9^B\$\-I$8.N!\NMW+)M[E;/.U_&L@+UBOD;H&@5  A"Q.0J# >,3)%^
M4$/K?*ZMK,$67#@E,UY>)KX4-6JQ<$X4?) 83@$V"0@1B1^NZ@:TE;7[UC.
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M9#YKZ(4>R@:PW9SH^L+U]YL,BCN1:3!$A#6G%-+H7-Z!^V</KY$N>SQFKC_
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M9/=PHF^B173EL%/Y"(4>06Y<6[*J*5=P%6FEJV!7\8JFDI8BF$!0"S:M2<^
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M24I9@F\'?SXI,MOC1]%_+23?,^^<6$ >:^;'C9 ?EVAT:RF_6#\$*G=)H1(
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M>P&)A@-:+?/WZ5*U<)H% 7J^"4A,S<4WCE8.](5\:CM&JF"!<L9C Y8<\MF
M/=C>Z6@F4E&_+_O&RO:<1#,"32S\7Z$QNH4*WT-2,4:/W2J+JV7XU+E/<'DI
M=96UC%4XU:P%$A<BWP=3'+U!>/=US[W#GHAG9;Q".3ZUF*"YHZX%,5QN^0G/
MPQ76,+=L73<');>IW%J_8<ZIN](>%P5Q'<SWSA>ZT$&X'LJ)*_8@ OY$7,O%
MGG%Q'"M#NJ71!G$]/,1LA2GMQ<SY 0_%>)*RV>9V"2IYUG5DJMK<$U_$O_K^
MH R+.AC_.E,NJQC.UN3];$95IL*!,Q'[?=ZF@97R?K8&[H[%$N0#MC#DUB*;
MAHPB-<* ]#KY1@:1E&?LJVN-")19*9G9O +_R.F8Y.Z]+<VII$74M!7G(Z;>
MH"NZ(:<^C$'/,1OB5<9=Y;C4(@:M V[.!.9VK"A74.UMB0YZ$\\?/T[$ZB%D
M3T$&;<W*C][5]/6PG[Y899R]+AF;+1:K@^[Q&CP$@S"+>,!]T?)+$%I*5X?:
MK=7AYE=CQ.?#MM.S<P75M6>'^\"3XXCX6$W93>1JXKH.])(F'YTHNI 2^27&
MP=E#&*Y":DJ$>M:2V;:5V=6A8Y4XJE*_XRA%F<GBP2^Q22YO.7^=P?AJ0FJ[
M[' !87@(_MYZ%BE=M-^2!\%@/(DVERP)B-68U,&&HHFVKR!UBFV14LG=?&+S
M%2AOESORL)R\#G7=Y&A5K V_R; X$%37$!+BG]JDS%.[E$O93PGZ.AB0"/?8
MIL'Y4K&T&F1_V%X2&)>1U:%NE3?LWX-V;-.G %),:QLL'JT1MGT']P;Y6U&7
M;I">MPOG_CAX5O)\P)O(KLG9 =7D?YE-<N7IW[0'RNLH.. X1E\^_!]02P,$
M%     @ 5H(%4^/;(U5E&@  @ L! !4   !E>&5L+3(P,C$P-S R7V-A;"YX
M;6SM75ES6S>R?I]?X>MYO1UC7U*33#EVDNNJ)$XYR63N$PM+P^(-17I(RLO\
M^ML@)4<+)5,D0!ZYIBJE:*'/^8#^T!L:C;_]_?WIY-%;G"_&L^E7C_D7[/$C
MG*99'D]??_7XMU^_ _?X[U__Y2]_^R^ ?W[SZH='SV?I[!2GRT?/YAB6F!^]
M&R]/'OV><?''HS*?G3[Z?3;_8_PV 'R]^D?/9F\^S,>O3Y:/!!/\^E_G7\8D
M;&)%@>$*00D9P0>?P4H?4G*1,2/^^_67+ICD&7=@I%>@,",$QQ,X[;5@*F@;
MW>JAD_'TCR_KEQ@6^(@&-UVL?OSJ\<ER^>;+)T_>O7OWQ?LXGWPQF[]^(AB3
M3RX^_?C\X^]O?/Z=7'V:>^^?K/[Z\:.+\:8/TF/YDW_^^,,OZ01/ XRGBV68
MIOJ"Q?C+Q>J7/\Q26*[F_).X'MWZB?H37'P,ZJ^ "Y#\B_>+_/CKOSQZM)Z.
M^6R"K[ \JO__[=6+*Z_$]S@9OQ\OODBSTR?U T^>S:89IPO,],UB-AGG*N9O
MPJ2.X)<3Q.6"QK%Z[O+#&_SJ\6)\^F:"%[\[F6/YZG%]*E2!,\M$1?/7+9[Z
MY$_$*4S2V60U03_0S^?/KO :@\?W2Z1_L9ZMB[=/9NG*AR955K/YQ;^<A(B3
MU6]'9PMX'<*;T0_C$,>3\7*,BV=G\SFMCQ%W!0M'"<D%#2HK <%'XFZ1'DT,
MQB5S==+JP!8TLI6,2UC$E:#/7_&DSN83G"P7%[]9S2\P?B[OO]Z.93VSNX_N
M:4JSL^ER\7/X$.($+T:8DY16T;J++$10*2EPQ6J04:0L;<2<<Y<1;L9S=927
M&/1TGA[-YAGGI-\>/WJ'51N=J[HUN#!/-ZAU=:&=?^+)XNST=/5,&"_Q].+?
M5[W7E _+67,!K&5-XVA AOD9YF]IT<\^('Z#4RSCY<=A"E,0DT7@.0H@Q4SH
ME"E@;-%1,X/2\5ZDN /7-N00#Y8<K02R-TFJ0KX ](S^.*:9WC#<(H(FAB*8
M5!@HB0J\+AS0&9DX+RPI_RF#LMVKMI&[?%AR[S#'S93#L[/%<G:*<_(VSJ;Y
M M6'"TS1.UNDBL!HW*"8RN!154)&G7Q$FY3HHASNQK4-2=3#(DD'@;15#K,)
M_64V/W?QKL&RW$J%QH+565)0@.3H<Y= BQ20U)E+2MY+/]SUMFVDKQ^6]/O,
M=#,M\7)Y@O-S>!M&3)&?S#QP\#D;<FN$!&=(A]F4K2@EA^!L%RUQ-ZYM>&(>
M%D\Z"*0922[A>#K-ORQGZ8^3V81F>?'MO\Z(P2.5 X\E"/)Y26TIAO2=E0:X
M5M8%0U!%Z!U@;436<.0C;90F1PU!&T$*&KD#IRC&]R59$;@0TJ7>@QQH8+4_
M*ZXO@UTGOIW[-#L]'2]K>JV.[MELNAQ/7^,T54!!2,,]DX">O'=EZ3OG2%WK
MG(HOQFB691_?Z790 XVJVC.CE6":,67#^ )%_,9)BO&R\/0E9 B19X@A*O+X
MLXVZCS[\E 8<3-35GA=[BJ%=4F:QP#]#?NV<]9I+$-I0Z)<MAXB%?D26"V/.
M9-%'55R!L3?%3V;SY:\X/WTQ?8N+]>(;%<^M)]4+K-#XE/8(T07ZD7/N([DI
M#%D?DF] ,R3#N#L#;G!ZWWEOQNI7F'#\MF8\%S_A\F)LCG.!0A>()7)0/ <(
M@2=:8%Y*YX-.,7:AP$8X0S*![3BP_\PW(T%EX90^\H& C$16QHD< :,D6\MK
MD*-3 B^XS/2K&'T?S789Q9"L6SN1[SS/S23]\QS?A''^]OV;NH-'QGH=EEX9
MH0^L%$OFU-E$H:A- 2+9;TC,()(=YYGUV57; MR0THCM>-%:*NV"I; XJ<XX
M_:^Z7F_#9.6>+Y^%^?P#N>?_"),S''G.I0NA\C>3SHK:@U<H27%9SD(D+HL^
MA-D*WI!RC^THTUXR/>.FHAQ3@N)[;K(&E0KY_\P0CF1I#HQ4R?1)L;3/'-%:
M+4CR6X<YZVEV-I02G8)D:H%-0 /!\PA96.N9\C4#W$MC7@<S)(=Y3R9L4)-[
M37W3'-)L>@F%D479D@6MY$BCDE%!%(F#]T(SEXQ,7G=+'%U&,B17N;'T]YKT
M=EF G,=U[&'R,UGL%]-GX<UX&2:CQ+Q+R"V!"1Z4\X+ E BN$M3D4ISHH^%N
M 30D![HQ$5J(H&6ISMEIG5I<.VW$TC=S/"$_;OP67TS3[!1_F"UJA/>R_!K>
MCWQFV;O,0 =# [>8R2)+@JN4%R;S:*3K5;MS'Z!#<K1;\Z>CR!KF999A/,7\
M;9A/R9U;7 +]',LXC6MA@0J:)T^2KMLGM;;7*:O !A.-E]DRUBM)\REL0_*Y
M&[.GL6 :IZ='O'H]2*I/V%J2Q"R1E7D.FE X+9E-N9,=6KV_;9*]^.BRU)(B
MW5I7EY6&R%4"[6A(UMDL)78<S "+7G>0\@WUM_,4MZL[F$U?W\A^L\A+BAY$
M%(J\.4=K$B6'XJ)21<ED0Q\7>@.8(7G1#22^[W0WS#[.WN!\^>'G29@NGTYS
M5<=O*IZ:#V4Z89"J@/.Y(C*>/'G2FL();LG66N7ZE+K?A6I(;G0#)C030#-*
M/#\/Z==^%[E;ZU%6/,8:,J*61%9T(CRY5M<2J$RS9X42/C#5A1"W8QJ25]R
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M#,M:;_%A=7WG9()I5?KZLEP&:A-S"8T&2WP&92*#F)P 'HIWS+$<2I_^]SN
M?0#[1LU)UEFD36^FNG;YT2M"-!^G)>;SRY&N_N+2)]<50#<]H/,3H=^^3R=A
M^AI?A25^6PH->I0".DE>%<VDKR<T8@9?FT)E&5B)2ELO.]T,?-!Q=O+<-OFN
M#IUW/D4@YBA0W L(SDD@ ^=4$%HDU6=&=RV[.7*=YW#YOJ',I0<)CA%>D"8U
M6IH,V=2ML2@\A3^%-)V*3@D=K5-]&I[L&EX<N?;SP9-T7Q+T)NEWXVF8IFN+
M*/,0D#LHH:8/N:08/>75;:*:Y1(M8I]#.-MC')(G]?!)NB\)CD%2%7B*VCI
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M-#G];@'OY62<:<B8Z9O9Y&24Z_KZ;DY?ZX([FY17M#"?XOW ZZ.A+K?,,K%
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M=5/M/8EY, [8E-'K4DT?(4%AM."84! M)HD^:A,V<J,.4?=7#N3L1?5=I-O
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M+&<AN$W<B_M4O?7;MUWF%B\\/YH[*:M2\M&X&G4X32/:OL/T#YP?<10Y\.
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M<C:[72>7ZASJCR_J56WDOO9();EE6@@=C=$+#$!>N_+6N%)*&P>Y]Z$<>GU
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M'*?D)YT/4&27A%;@L(9<O$?:'!SM"Y(KKZW-AK>)03<?VO.TV"M9]M'+J\L
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M+LR%.PH.S>M)5C1(0#.IFIEI2[PK##2B)2 :&XZ&N$26:T)JH:&Z\6H-1)E
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MU?+Y!X]CR-K$*\EQD:Z?]_E[[S ]E)A7OF)S[/(I=VTVUD+/-)<E?[/?']Z
MOY#'?V:Y?<R+\KB-;T8^6_^4\A)@S?.O9Q__ZHC-V1>/Q.Y_^RSL3_G;%TUW
M#&_O?^:P^?USYIUYRP/7G&AOGO>HL=V\<<AG-]UP]/,G7%^(W?_L2\\\DZ7>
MU3,7+]8I;/.RA9>=\&5/>,:#_J]7';-E?@Z^:ONF"]]8\>:U*_]TW[ -5V_)
MWM<\PW;&ECGV+7>M_*:%O?3UJ?.?BJ[B5UV=/6;,AFNO7+=RW$??SCQ/F?;^
M=4N/FO:G&\><=?MMAP^)S-MK[N\OG7_"@H?&[S )\S^]Z<0M[UQ[:_'2HP][
MX(HKEYXS64>LZ[8]=GC7A_Z5]64?;-][[;=W/R?YN_SRX4]^M?#-;:\;C:/#
M'X=FO?/41/N2Y+-+U[]ST]Y;5[4]\TZ\^772_M<MQWV5V7;%IAVF5\];TSAC
M[<@I,ZG#IGX!W[SG@L??6_7%80_<U?_P![^[TEO81,]8]MEAD\=?,/Y4\^J]
MKQR\Y.@E2>\WO[F(^WA=!4,NNKX:OW[Z(?:7[FQLWW#50NB/ZX#//&EW_[^A
MWYQ:MV#QO+6)K?MMG'^FY\W7]CBW?N))FZ1S#A:F+#+-V^^I^_/,=8>NL"TL
M?MN?>6"?T;$QV0EM^O/SJ/:=PN8KSKUB0_3MQ?KQK6TW'D\<%+O8>D7O$[7@
M'.(;Y\./^M;=^C9\T:N?W7O"D.80:O;G1X<^]SU[T!)$:AQ^\9GO+CGN_:N7
MK3GK=63IXK\D_O+RYANH)[>^]=8BX=T%2UM[A%V'/)T7[A(^BYZ5N^^3FQ8D
MOSQ1!1G1%\^G?YXC;5F^??B9&]<'1[YC_^W<26^%MY^Q[(AZ<,Z$#1<BIH,2
MDY>-G[#EB'E35O5LA;8M?N" .Q]>^=KB!]L?GO?4.<]G[_2?/NF/YSX:W6%Z
MU][>MGK9^N>'?-'*W99A#SW\'O2V':91*^8OMC^QO?=;2MMJGDV->GC);8\2
M]NWX<<MVF*:]5W[N$[#^MI.VMW[!TC4KY=&O[4-LN^C$L>LG0QL'K[QKQ>2C
M5]QV5Z;\V?###UB\[=J''-OW'O7X2<KU&R\\Z_:59SPP;C7V;.'S2?.H%]<H
MER[]/^R\!U13Z[8VO!05!16EB@I1NE25JI38$! 1 0$!(2H@ D)$05I(% 2D
M"TBQ$0$1D!+IG=";()W02>B=A!(":?]R[V_ON\_>YYQ[[O>-^]W[__\=8[T,
MWA%XUUOF?.;SS#57@F[PBAA$^="?3T8!S2J8!MA0*KFQ%_H($G(6QMCNKCVJ
MXZ%@L0<ZGRS^]H[KFDV53/ASR<FE9@K'(97!V(N^])&/GB,7GZV(3V+YON <
M-R+V(>0Q]6_1*_#C,F(?==R7]F*GXTS))F4#&AP3,XUZWN1P2DJZ!Z;.5-"6
M_*E?^S5:LNODYLE0P5>?Z#HB'Z)T)AXF8<//' DN#L[-,K]A&.U45 9_UKYN
MS>J7_#)QO])1R=.^!L'F(K%!<E?<T"R5'/-HB(;TK-7ASCCEP9&N*I&A$J<)
M:M>U6FK:BWCJ*<PP$_!''W#%^*$/NL+99[_1T;H=2X9]NZ&>S^=;O?/.2.L_
MJ<,UHHE780-&C$-HP))VO7>)/)\@=K6@RQ@7+QT3,'?N.+\E&.3N*PH'*FZ*
MHFYY:-9@!P;@Y# WZB#9L05BBQH:XUJ=6D3MHY]46:'"SC$::UK63V>E.J48
MV4.I[@1+M/)5,/8@RU'J_MP&%W;_3_O_1_. T[ACR;H<_:AQKIHALTSA4"90
MNGE8BJ..RVK*2I@)[!;LFNZ#WH>\>EU3]E%AZL,&5/JIEK K9,2(X8GA",+0
M(T(,Q@9N,8$NLW4:YWAQ"#!35)2"TK?G(ET-EL#@U^@&?P]E17R?%7P4#7LK
M$N8GQ>+[^<E>S*RJ-I;1V^7D7.B)>A@D.O1A:7A' ^HH [&8.=D#/UGDCVA.
M=3DJJ]5:AS_HL[!]L%N:3[<[:^E-GDRY+F?L_*7GYS"S\!U;F+ E*A8[!HU$
MQMR)_<XW2-\<H2;5<QO .AI7_R:M9<@[6**V0Q?& M(J,Y OH2A7'\$U>"@:
M1-1#R\8I2L V'Q.(N-V/:DR*I#W:.^HM][WW/?Q%7;FF?_-ISL;["2%72ELL
MA2I0N]T[MG^PXVGNG-/YJ^5L?>8MEB=YRM%1LZ5EHAEJ< 9;&-6;"=1>H&3K
M[Z(8KKG[YH.WZY(5@L>9EQAMKHUR"T\N-LHU#41$S"9A@_,6UWC>3]B%-ZBV
MP)Y8<B[&T?@R[+:-:\K/O"#0<A-,XQHZ?,<RT68Z&TXKJ]>:17CF43F-BV.>
M5",:HK-<BN.M8(+%DM?G.28@VQ?YV@:>82/$!/(7AA2G8K:7F,"NS_08+ '-
MV)%=\=7"TTJ,E*8[]'QA;7#P^?5#U.-GGLT^P4.*I681Z@3WA <=R8K4-._N
M=9@=8]3+O6#L\B3BSD1*+?_NZWKBU.V$*47Z=$'<9]X*C,VFQOM.!0O]_;.%
M7LYH.$]*.'JGA<7%0S67.26,-06>WP2VC4LE,$M'ZC6?9$6L/3!\\WE*_%E-
ML,17D7\F]_^G_7^K27VDY.%O,\1I,B3Q@.E!8=QZV4>UZ$Y$_UMYBG,[P9*'
MYZ.#089>][O2*/MM];9O&S.7,AT-G[TQMR?;CT#:]>BA@[;K?;C#^<J\JPJ&
MPFY7C7PYBD_T**['T7@NDY'1>-2260;,HL:Z$V%C89;[6,- &+W^BI%DV1;^
M7<BTK8#&\]'6[<FBVYT#\. /[S8*VSNS3*.AO>''VB5F^"WW=W,0>X/CDAV-
M%_A<:1T&FCS3@AU_2ICNF$?GB-<&:4@Q^JQV=!KOCVS.J'5[#/RX]WQK%341
M^8WFN"F$/0?%OX+FT>+.SP1IB,(NU(SV01<MI;\1)ITPJA&;MZY^"N>(G\C!
M=)8ROA'AXK%<(AY?@W_D?XBCF(20RJST(%5,0'M9*.!>W7<6S5&5AQ)8TO?1
MN.$/1HO=(')B[T#1-?_VY.0[RC%B,/H*/5KC\*A'R*V'RW*?6X]:H;&/WODW
MJ!@,2\RW]7M%[9AJM'YX3T*?)R@J]$3VT&S<QIIJ;FL15_S].?SCQT_3#=+J
M9890?1B; B]!. CY0O02 OT-4O" L.8[_G*W\;VW;S>^'AOH^)!>YD8^\9(U
MX*[^R2.FDX*):?H9,'TW-X4B/M.S"MVZPKR>EN%F\0DZ(E$Z\WK.B-N4]"S:
M(TK@5X_D.M,P[PR';OXOR."*F$,H-LGG7U5!>\!,:*A,'-UB0(=4&]XX)PI^
M+V.L+0QI=H [H"9'7#A08V98FW&M0O=\WO*V)NK9^90QLX<COL&2NH[V<K+"
M 4<F8\UNB[@D+=N)/P<$=##!U[8A*4X9&KY,P->!T8(E=J/SU='DL**/!/A^
MIQXWI^_Q,]7TWI)%1./Q\-E<5Q7,P,U$4Y;G4G78N_H#SZ #1F2O;E?O5Z_!
MK6Q(S-(^!WWX&.KV 1VKN$-%141^O[/B4B\]CH!E ZF6[9DP8X=>F5.;ELE,
MP!E3GT<CD*+#F4#?(\;31"G"["@W50%= :7ZS*-7T\;N@AIRG67U9M)_^;/?
M_VG_EQM+-1:?.);KQ>AE L!RYB/KR^,^>PL8H9,3B!>/B5QS0J'/COER56$:
M9"[KHW4J$_KF^9V6LSX__!*L*4DZ_^'L-S7?O2?\.H(9_AD$"$62@\85 '_U
M9 RA0Q1 O\T6\BSMBV&C#;X2<!9BR:SRF80@]D>@3S*!PR3K%Y+6!'K.\[!Y
M37,7BQ:I!V7%Y/G"P?;MIU5RW'.VQM#>Q4%$OH-J=_0@EW=]961TK_H;C(_(
M(*TSZ</5;E^EF/E3!;0:E//?$$8WR!Z-0PLP00VQAPSN#IFVAI3,&T(W#C:9
M9K3,Y KYUFVSX(*;B7$O"_0%/:+:M3H?R1;H&=U\K>GDZ,0?919/!KQMJ("^
M QU4*[[NR!I>=*[<B_>&O7VC*XWFDR?=V%^>[&N07N;M5/YT@D]XY;3 I2R?
MQIW$!\+0AC2SKV?L?UC!6K#EV\_,UZ%G2%IUH>+[IL)3>G+D]8P"W6E=L.^"
M%6.E!>Y6S40I_'(<D94@%D@X((#J<-6]M_=UJ&+=R]@H$\BHNW3C2$9V4C#C
M1RUAKB/EJ()Q,G>4KDU4+DP$];ZXW/B1L>>X"^>3#T-OWH\4+@^MP4&WE;+^
M\&L82RPO#[R>]VY\_&'6TE+GYUBSXY)7GMOD<54!^Z,\ZL66,H[JE0GSC:/J
M1OCP,\\+]+D\@LGJ4*VND_+M4AOK;,F4MT%L7\\].'&P@))'O<OH+<4MN9"<
M9^J.QBY8*HV=MC__^%&*?Z6'X/(PG_/,%VX)P1@0D<7I90_HZ30?>N"G8>T$
MEHX'4!N A]']P>98G, S_.M@KU/BOG4<<0M;NO4'-3P+4(N+W-@!_(;C4K,;
M$V"CJF\NP5>@+.6GS/;PV/%_@ [.9W$Q@;B;/FJI<@4#WMBV)R!5;]*?O8#)
M@>(CQG+3*66D*'T!A\+%;59?&]/"4:SHCT]79ZLV5@-$U&N/E!W=4JVN/-2C
MAAH?4;[<Y32X8M0G:YU7X._5+/S-6' XLOTBK 2:QU&E#B4_I @G4J#ZJY/G
M756SEWD>PV4MIF.-QF+%^2<E#/I-YT>YB!AR@OU&R_QZFEGE#Y@MHE)\-GJ8
M!FG\H<:H;6(">=]R"Q#&XUGE]\A34]ZK&!-<C1=HB;"^QBT&J%B!_[VFYWX[
M\FV\9%JS"'$W<#YX#?(*6AA1 _,/$_':K(.S]@]?KAUB @Z:,C5D)G#+'[V.
M@9#<:;QH,HI8JUTX*MKKUAAQ(BL@PJ69'\]OHJA^WL\OLDW#I-[5QU(3(9P)
M:HHJZ#XGL2%K OP57_"^_2N.]FSH2]BY71_6>O:CI"&45Z;5V/4;-#TF\*(#
MY:]A(FN###" ):!(AS!^J-F/E/=,@.43>'9Y7\"Q:JQVQ*&&U%@G]IX)2[C>
MU[6\\&$J3J "=7!&ZJ -\D4GC',62K0:\RW-^SIBC]3HVMZ).^I4EM8.VWB:
M4[7]H(P)[$-5WX/:M?.JN3"!FB>#-EW6F^[;EL.J3\,Q4_$-^QI'%[V?:DE!
MSFJ\3RK?K,(6I-8P@:#,H$^(2T3G#/F)0Q<SJNQFOEB/E".%"[PXO[DU30H&
M]GV^]_<2U;\WSXC&]B$I0MQB/2O-I%*N:_U]DK)H<-X=JZ:]34)[:W7\&EMO
MR:EK(HHFY"@JK 1DI$?GPTINTI?<M'[Y:['DR&\;=YK:YGI-L:F*+?V6$$\#
M&-I+GW9<&'\*8PPO9YU@]T:->X@5O6U4CWF[8X5V>1N'1>P!826%QD7_A/F4
MTXVP/!B1<>=0^KVLAD<BS]1Y++&NBUY.IN)0@^B8D+>0RR#%$_X/IP>K*7&D
MR[5CK&I\GN-RW YD<\&0U.RYY66T@]PG@8&("U_9S^!W>J1KG*1=Z-+@\3AF
M3!*K\!9$)\\6MKNYNXAK=U[5%VB>!7ZFLA0IIE1/Y$BE"+T0*:'GXZE8'_%R
M?<O,U?((='DI>7*?#4O VT#IX0G5J]QL:0V3+28:&'H:%E_IWCTZ;(_>AX >
MJ/@:Y6?1ESPF74Z?S:K>H<6_YU*=7\LIS.ORGSSN&&6.M',C6ZY2@E(Z\K;(
MJ5ONQCN_V4+&[4:"E<R:M\&:M\G\*?XU^6X4H:#R+*K3G/*6"?CK;3(!@63&
M,8L)<3H/)@A-N36&(@VNR;T?C'@_^/%U=CMHLP%]E&8FH.DX;L?@41ZC/8N@
M.,%#T>LFE6(H@I$/$VAT;*V$.VC ':1]%]?'_OSAP[\.4/Y]FIP\34YJDOV?
MX?][#5\Y#[H4+\*#U%@_%B)XOHAD%THS'0_Q5A?;=R+$I'=9SI!5_FYND(!O
ME$K3#,]6Y)JWZ2R,=JR3"8C&C8O37S@Q@77/M(^9*D5/-QR")3(/^*8OE*HA
M3W;*28O%+A_!W/,0U+4(+$HXW7+QE-"AV5JULZ\O5N\Z;"KQB:-N92AW96)S
MT9A4N5!;-,9;><IRUKTL.U]=F_*.ZK11Z,4U;=UVW=]M\3%RX93&&29P((L4
MS0C&U;73).%8RA)RA#&(SA7SISZ@<582*S.%"WJ$VWY$IBVVOG/K@$AYO8&7
M+HSHW^>.J(X(@;!MC/G"#A>@V#RB&O2@YAW+1P?G>2=MGO#K7[UJR'_[<4M5
M^ &G/6_?9(?G_=DWH']Q'\S9K8JTK8H,72'G__,C<YA^0?6B/2*.; ];($Q(
MM"BYBVY9PY8-*#QGGMR<E=XOGFQ@PV<W!&.!XLN@O!H0RUJ.4!E7N*#]UPNO
MO[/U6TW0W][;":7.BXGCLI AR*8QHH%< +90,W>(XG[+!UJG([B5+Z,MK?P5
M^*YPES,W;>:-R O?ZB>[D:RTT5Z[*S@YA'RF^?Q1MY$V?_J;$,6*^O* <W?=
MSNW/+):\N'PN/4:AX7,G7=8 =@ ,5I)8?/H!JJX6WW.$MPN<(SSK'AA*?,A*
MLMBCIV0BPS+.OXC:PQ+Z>D^7U/*UZHR'3L6@KG[^C],&Y1GD!GJF*T?_!#XV
M<;SM859]55ME7&K@D%BJZ\53A]0('M)M?@475<2!YQXS-!YK!MMAOL4P8A/%
MO=;=H*@.RG7ANWU^@)/@\)3Y4N!FZ:MJ_#>9IDL<DTR IE34H+\M!>."$M,K
MF<!$02O"AE*-H7E1WF90BNIP63Y9CD9O4Z./W%I,\Z,8W-IM+ #PM((;TGGD
M<ZBMV'_H8#-.6B:\_XN!0HB#8_S0V2S$=3 J?Z$R@7#<6\1H#WB9[1Z8P_[E
MT\Z_C. 9U[:DU;:D^?KO#6_>@76,"->0Z%M<'U$>#ZS77;I\\ZU,5A:>)$-M
M5@NO-N:Y\E9:!]C1\VX5A':L,10?"B'>(."=>+O'-\.DH>-NZ9>QM<^,4I64
MEJ$32R^80&S4J2WU0S-1$X]:FN^XE&FDT5\R=E+R\%K5[+?5W,=7.#UJ&\P+
MARIN.)F:)C!4>86G"@-;G[&E'>2/6RG4UTOT^1(L]:'_]WS0!'3H,H-=$0\;
MJ#4H)S*!E_B(Q@3) FON\7VTBO,U%U^;Z#S7L$Z?C_15.5$:&;P*H4A#:=P-
M:[6#L<G$P"J^AE$W??&ZTJPR!DGYX*.D>QUX!BE06%6E-IA6!WK?;:/*S!^&
MLQ%?D-*@75HAU1 FE3%Q]4N$]\KWF^T3+423-!-J]-]94YH<6YG /W1BJUM:
M\NK*_[+3I^6RY_T'(FK(B;+_&?R__>!C3, ..L0Z/EI"O>1QL&5S/*[.\;MJ
M^V%[HOXNADAYU*D)Q_C>R#=-ET_M\MU;O0?KF;'50X_#3DXA!9A ?QM(XN=N
M&=-Y^A0/G/+G-C"+_3<E8@6A(I"#Y_47=8F7X(?N:!T@5Z2?R>]4F/'!.A8W
MZ"J=6TW>)7^8T3+)R^V\IW')@FI/826K$),<-$[W*HU:2AT3D.S9!U]I8DQZ
M'K&J[_^Z\X*X",M6,O4":/)NC%.(*]CB(J)Z]GN\NDA4SOFZN$$_#-7PVI<S
M:,U0GO91E3V5ERD%)/<ZE(":3YH'NMX\JR\GRP%>Z1CT_M-B\'DA"8+Q!;8]
M ,\/Q&AON7U*24BT788CI C>D/5D(UN,DD-B.W<LK0BW[-2=#GVB;+PR1_,W
M^8<4(V/JTG]TXV>9P  ?N922,PX;Q!("WJ<C]"F!:?;;@2&N&8X9%NC#H[H'
M6O4].<N=PTZ:F!A>--Q[XK7CICDV =6?RM 7)LC1P\VAC+C+L(YZ:Z.GVH_
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M\7DF0(3)A6YNJF;EHP+)9W8^2[+'R;HDG#7'KZI_4_]:,9.C,3^\'5<'(U[
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M/OZ#ZDU__D>.!/R=IQ#9UM/D;#0>0XN%[D/U/VAG EHI)Z#)\Q)))3>>_YF
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M2N$RQB&4$^ZO(";T4+>0<R)7S\."LQ/#=FS%*A45O.94'QA;U=@@;US/M[8
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M3H#*_0@SZ"$4  +J*#\4AU4,DC6_ *>B5FB4*\G:D6PUFORZH*50D86,(@&
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M=+(CVK%[95%[R/>^MF3,1=!7;)@^U\151/KLG<?[J#S^P /:,:JOX9;PB]$
M"&= -1HA*R)P"08(W0'XCA?*T-TL5"P#Y!>(G+I"OL$ P>+#Z4^<C01:8UJ^
M#7Q'"BU$CO_NZ=T<BLJ7T3/)3:M#;AR'Q:$42A!QP-,J?57/(K]R,T /N+A4
M#Z=6;%D#%/;\^[]SJN&.>GHO>,41<@B"-^O%K,68TSV W: #_JH]^Z8\*A!%
M.C,/V]*50"H"SW74_OSV3ZK'CCE, 92:I%4/H_ 7(VF2SS')0?3MP"!J4SG\
M&89TWI8!VK)@1:IS^>MUV.'_5*>9_S ^OGU!E !\+H(5LK4$3/3[.:Z4Q=I,
MG)JT#'CV?):X%OH"LMK>%XKP&5CCFL"RS-'/$SXGI]KW%UC.Q:=7#8_>^"A=
MI(G+$=MZBH@F!U-@](Z' ?@L8H\Q(:\KTD$88M>]-(AL^98:]0U#:=A]X_W=
M^ZY/D;'46S@&*&NBW]4_?&D>@Q@5Q78#PA5$ZZ+5K7D1]U.T0&0O/JFQ+R;O
ML,,9(_WL4$*)LW\2#!"."9NU#W]92Z-E5N](2MW8B8*^XJJL7 \):??*DO+
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M^NT^77!A*[2MP3EY@>/3YG#$D/:G0=YS()MW#EM74W*&.?"='Y:?H0AZD%#
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MT\V=VHA:]>6^%&E^#)")#ZJY_].PD $B"V7\6 ^M/M&(/5CBX+L%]K/>?T<
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M:PXF+X'MZ1,(^UF+Y=_I^;$]6N@7;?2J 7<7<+I$U DY]*9@,.UP"9[KH[/
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M+V-OLF_-MH%4NCAJ'7!PS0DT_LH[@S0&Z)'!:( [P)I'S;=&*K9:_. LY(3
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MCHE ?GH>8X7&M"NKKEHVO_Y*)NE4+H&G&_7(*:!SH*5TRTRB?Y^)7?]\BS=
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MSV_I/KJ_>X(!,7MJAI >X%F:(,OG$:4^</GS^\NO6L[L]$';V9<YR9?O0M#
M )0](AQTO.YB.)ZOJ4^B>>L!5\,R8 [66\2R/$^VZR+)TV;<A_RQ2HY5?_)
M_ROQ^Y5=>1FC3;*6(3#4V.)BA]5@X>X-Z%PG),P#@C,>CXXK;8VQX^4M?P@?
MTTB]P4$%C%\%IM-$3V);Q4Y/<9OW^8%L!SN(Q=::_DH.]1NI@X7KJ832#STE
M(OZ\=<:Y;:$.#@]TUMHE0[&1:J[-3Y5*B'<GT43AK>6#V*M#\M&A.V_R'-Z+
M!27EOU)V^V*=HH=5U! :JW)J'N?P,\8;S7;@U<(45"8OT+4X@.\FS&43UCFP
MN-3!S_X?=[5VE6FS:D(Y0F) )G"0U&LN]6(G[/U X9_ N_>FKG_@1<D^)'=#
M$F&E3B36Q$GQ92LG]Y2A,IQ58 &=6M?&]KOT*K#F"QR7\K5:78;G[O<B^MM^
M0'\;+IN34P,_AU"/_V84\%<)'$X20SSA-3G3CQLS_6*JI%?Z@-T:JM8&N"ID
M3R /7>6=.KY)9E0]6<O5S)5S#I"3(\%R_.D1TBS-!]!3VL0^$/7-B(6Y1F_@
M1AVO/L:;J59<<13@19]+V=_C+3Z8NV%;OJ!H[\#Z@19-'OSW[!'ZW[KHW6'?
MZWV#?;78R\ ],(:1>>W6N_<V//9047*7&K$$S^6<^35:O20RL3/!\@Q4WG@M
M*[OP[@A9[Z^J6T5F8,0+\<O+5KNLI+-K&X-GRO$T$#_1F<\]LWMYP[><?NL4
MZ#S('R=+U[K3ORR]J^;E2;A/E,GU0C?$.A1U]S]FF_NBE65RQ:_L''UN(?W@
M?4D>X1C0 9#UZA!C ZB$OI%LW&0F6+8N?>P6.(9?Z&O1<Q>>2X&=+"X+VAI?
M^1.?.V5??A.E8M*WJJ"5;[H@%]33'[^UKMC8V-!AIC'E:ICT8BI&@W\G(?\O
M._S7_F9UWL_ OD#2^Z&@$3T"7D.ANRSJ*E8'S7?JZ8?C&OS/GO6A;&EHY?5>
MQ6P6[#$H&(1[Z176=X48-.G%BF $-&L@KUH4WR.O1)[E80.XGCBU/DMB-J<<
MQERT*"*V8S5YFCG')^PXNU<E6F2^97:GF6U#6WIWW SNQZO\.';MW2^/7:-K
M]7,@7OH _0YC+(EF\$IH=Y+RM]U_-+>)F)AS*X3X^";=:\(9]WE( +QD=@F!
MH#2/<TN+,]B%=:D!=VXF^;';^[S)/7G2@A3ZD"2:)]L$WA S8Z)9MH/D%T\0
MPW:8]T,WDK4RPZ22MN2.IV IBC-G'".C(<+*^SXM72\]K"R<*G+J_ CIY ^
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M7QQCQYUJSZ4"K+&I%#1]"LQ1DQ8?FJV.KCK-HGC\] P/,4]M/Z8"AA;RC:B
M>&=_OTSQHEYQ7[#'KIZ'\WR<\_!P/6MU=86HBRK70?671P_>N0J@>TK/D9V5
M@LJ-T3 $UD:6KNRQ_/T>9^=!AWNW2_LVVL)%6LY6%%6]^)#,>5_*C>]87MZ/
MXPKZ)Y'+V%WA$>A7.*]XL5></HZ0F;C,YK&-'"X"CL:MX-]GKT;F-TU 2G4G
MQI&K2Q_IERUP7%N:R"@04:/8OW^'O_G(#8S;8?-. <CK*<SI"+=B_5DH/RZL
M8ZUI#C'>5?5Q="L:G9E@9K7$RT@,(%K)WVUH(R=4I]XKAL7!"(L^5(![32F(
M]7PV8LFR:S6CI#Q8TS?<TSH]3%487_&>]<P:PYF(^](DYV[M;U3 S5-:IG\Y
M(GN/==^9_!1ENTT%/!Z/UO-);X@!'EWDMG=OT>?W/H"7N-L[Z?3VP>."38X1
M.T)<T\YIG5;N7)O4,F29:MP%O@=?A25:'J@=.''M$"HYARQ#\P"RT/YQW'NB
M,#AH9[IOV;B^D[/8ZE5Y>1']S'.?XALXN:4'] QV6[!#Q/H!/6_>"[M%GAGC
M&N[1Y.H*RN9."\5PYZ:7[V;>Y4F_H_X[-C=S3!]V03\-TCXPLQA<OE>0\@84
M?OW?DGF1+A"O4H<<DR.Z%5A7F)6X3XRJW2],Z!N^5ZJ\;J ^IVMQQS=;=H'I
M(_T!& A4C%I"3ZX.WIN,G TBF3X@;-TIM/--.YA?PE&IQ?AJ_0*I9TKB* .P
M4\ ;OJR[*T@$$;X0;82"2<;F,PQ;&@_]F=K<,V[?5&A)7&M]GPNX?/R0\.7"
MRY'HV<2?/@]A32ZBV2<8%[215\X!U, VLZM2]2HX/G_XXZ[8SB: "D#+*N]V
MQKZ\5FM1#V2G&;V/'/\(6\"_\ *A38Y&69XV)U02-U.(,K<,^8+G2>1;^'NN
M\P1KM<1+RR\9=.GIDEYYM3LKG<0E9V+1IPSF*L0B^S)S;=W$JO/SJRPUK%Y%
M[<LZK8$801$%MY:$S'=/DGC8MB!65?B,JI-8D^H("]VGVPZIBGYE:]X40=&1
M?2PWIA_?-W<;J:+#:(E/A 1(P8_/Q65;I%E[O!HT4D:M=4C=R46[-?.O:?"O
MV3WZGV@7^^>VC/VO":\72)1!3+P>@M2+AYI=3+ABL)ET<U@3:<G14AHYY5K3
M,'(>?3NS$/$->-!+\CXQ''M,\EJG_4R/M,.C:=&EY12@5%?EP3ORQ\'WOO"\
MU]]@W16 HDMAG\>7\!/1!PS?3CGP]OA_=@?B-Y],577Y8%K:(S;NI'[*R]'4
M9#^&5M_CZ?JIB37'C _/&OU<BG%4_WXELGMC] I]>45Y4IVJT\E]WY;  ,!A
MH:&"_FD@B<V7<N0T%<#(;5I!5,,,+P\=CU524/%F)%4$M<J0?/?)-9\"&.]V
M,=TXF'.I\E-B(0:%TX$-5^P2^HA-: N!1F2 @M+JH1>6@Q IJV/NYVC+34/B
M*LC=N=KSU/I?1&7*K"?Q=^8B][)NNK!:,1 &WDT9H )8824EP]ZI1-^)=V\V
MA:9AQ3,<%D4W>=8D3*)TK[:(9E0%$FZ1XTC7=B%^-MU^P _B;V;A<I3MV"=&
M#CFO9FYC([!7=5M&&O7Y9('5\'V4PUZ^!'>B89H7J([P"*W>.<&<X?PX"2TN
M&DG2D;=XNY,L(7'(7<"!V26R(Z6N[IAP$[>QP4-D"3+R43#'2WZ7<Q'".3].
M=3NHI<KZ+.OWJL]QB+V=NKU#\1@7ZT[ZW<(%15$!G$3H.%=DWN'XOOP3[@#_
M^13.X=%8D:_W]Z^=HNG-?!R*#X;Y#,1IXW'&C6Y^=W$.T?$3IWVP%$$"+:Y-
M,RVG @P^^ ]8F'>GE/,];4DU<IW[-LN;6?OSW3[[O]$0M?=GDB(Q,,_O KXI
M?A+,-*Z5L6@D73=J9-( M4Z"76<Z$_CRVIFIDR+</VES&OTJ:HE]U]J:"BA%
MU8KX^_1_+<(?@I?VFW;KEG\N:QZ[X[V65OM8 ?_FJX6]KSM,"588O6Q7 &T:
MY\Y3T$]=*2NR-[:M\/;/SAJ*86SRYS!WE<%].GWS&GF6> WO=(VXC!M6PUL%
M.\7>Z73/=7%Q.C\17\07/>'^0/?U&J?ZLLE:9&2J2)(8RUV=._]O!SV^*-(I
MH8GB<1:0(SJ8X-S0)9B8*U@H>712JKB]28,*\)'>W_/I].)6!4H!A@D<_ZS8
M'.#'GNMGT)=OQ(T^I4I.2A$-#V:[-9&>R!NCGL7^L>'&&H_^G+M;CZ=EYYZ5
M#O@S\?0_DW#Z7W%1@,( :Q7M".'$V@]$2>7G7[/MD-</.J3'C<I]E<02F?=?
M(MQ39^H#$\_*U&OX<>ZRM>>-J)6"V1:1,M\+.<0.V,8M4@'1]1=(=LO"LS4L
M?E)=E&-^4M^K+J0T/>PB@2Q8(S^9QPF'L;OQ+@V(@ETU"H++$RO+OQ?3P++.
M/XM[MQI!.=R,ZW*BH3@D?;WIY:M#ZLLE6>X:%).LL!YR^I9'+;/#U@B]CDCC
M7KN!)@T$'J.TK'M!ZGV0C>VVO:EPDQ?%U0<?FT&_\7#.[B>7,]\%TS.C[M1E
MZ'P6EBO:L T[7V#^X+_J_K:;*4?L=G5A]5)0M+[$/%*,*4S!$*7=U7JE'VG"
M)(?QY&9^>N")I\I ?V+BS.O+(ZRW/02&6+J=-C3;*P5FT.8A:PIZ;N_NMN)L
M-X6_JGI[.K4*+V\+[N7E#VKOD6ZD@*PO%"==QG[#H0(9!PR7[-._;?/Z4;8M
M&*I>E4K<E.':C@H3(5K)M>?.>"V\)6EN9:S.#XKSY\7'@'JTN5LDR@4-U81K
M<Z^_UC%SRH._3QI>MZ=I\!K:622%> ^'-"9VX^DU<>@0^Z%=O=Z,$_4<$_KE
M'J"ZL,O?FI_228<\?*B4[7^LI%C2Q-1$O5"51=U,PS2*55>-/T89X*H%K8;5
MRL >JH,L0"'CPW)3S)I8](GK&9ME3DLMVAQ&J3X;%]4./@6\S $/X4#T^I-'
M?5(*LF]VN"Y5BJ\JP66^D_H;J !FB1&!-PJW\X77*S*/K^;Z>YM7KJ94V&\@
M!KD)AIV@QZCG'C6GNWHOBJ<U[&1\+#IIR\Y1:SYR9B[W.Y-KP\X;%GV"(_U^
M%?KK'"92]Q\>B-%,@?2CW4CCW]9%]1Z&94<U:76DWYR^H#@,ZPM_7&Q$BUY,
MU1C^NV:G[6C:_$>27Z(F#N'38"Q2(J85X-#T$XL7N/ .WM%QYG.?GWVE[,1X
MNT".]:_.-H*"$\!-XB$^J*#-85B)C5QOD;&)T$W &B?84H_N-4'X&)27T@FG
MDT8,9DX2\B?$7&76\_C%')SOY'D2IN 7GU !%D\WKYY]O9:FOX8,?P\DPZ,H
M/?5J6[K)I4.2BVMQBQT4M2W/SJT&Z<1I^(#7()0*.!XOMI6D&-\!9%R;'AV9
MH$4W)&=*V%\J*.>4V/TT>VN.^UWO)-W]..(?K]OIJ#<SNI/-%Y GGWM!N+[L
MD7P_2-7F9O&\EF[&\OGB;N.,$BV.28F-Q:XW7)TZ$;%:BO? -Q.6.G>_[LK[
MN='B>*; (9GP8K?2\?O/.3^(E2_-FO$'1?/D[I-\]BK@ZKG*,-)>E8CV7@3W
MD2(!J^/+-_6&LN)?MW'8 )D'QIT+V]!TD% : "G3H!/93$"5>)T*^Y@\[=*
MFE0;35@6Z.\R1B3,P1)J+C@+:+.BA0+#H$W03:&Q8TOC7BCWK<Y-FM'0'X0G
M!OU3&S06QS\)U<O67(0.HHYM&)BOORH9]AT.:KH6,%K3>06V_!Z\O35OIK+7
M'[-*.F%%N%G>Y2#M%#XTBGA=\1R<1O121TDVE_FG8'S9[G*]0K>)/Y(\Z:&J
MI@=]_:M.[H<D=:+-!Q($9[H5X@=.&UPT$DP'QKO9/$E\U7Q'S?V!L\J%HVG[
M&,YPD>#D*A@F?(R?*"0P^Z*&4\U_$GVXP")1J_E=]KS=^!'Z52QOCLRS7O6#
MBYMK85E?/UX=H5B^\W@/?!W%H+AG,+<8"=]_8J^3)^?7].89JU(!#+!(P3:8
MG<'UHYY.5 !88DH4OKH/T2VJW C5@_;"<&#PB_'/IS>ZO&)58M:OZ348K21P
M3=8I^SC:[S_%F_CXB$;'95GYFS;OKA9[_3Q\T%/_WTIFI&*H /H%^ F%N^8I
M<S[^8[FTR(U!S$',_+*F?/*S^VX4@/Y':!NH$!Z-LF=BHP(LB2!U[_R'SLB$
M](Y'GSX!-[IN Q,/G CC1%OP\4.;H?4PG#;L(*5A#'C*X$._PD-WWK9ECYDS
MGT_X-.];GVI>.FQ)$;0'G--1SVHL>D:;W,>P6@E1T&-%-A"KUV=Y+?"DXL8-
M1QW^$)7(X*-WDH.O7_6F?Z0+-6VDU*6$U58F[FG"F?_3$NG?+Y/>X=N]3W.D
M7$KB?I;D-#^7R?9SL[6+Z<1PPW)4"3M71/;Y* W&B]/,)[CI,[2<0;@)=.3X
M^A8&0N*B^<,FNX\:'&M%D^B?7&I--Q40<MS/D0J H_91 9@N"$52C735#>M)
M(A/W,D@Q5  ^P:]%UA!O]9,.0&RH@/H0)1D8>OP9#&<C3H/IJ10>67PE!4IB
MI ("-6#$=I[_W/YO>'MV'@@3 .)"" T*9N,HO2Y):PN>!Z%PL4I@5_SEXWI^
M6NN^NJN,1&,=/#+402J)MV[]?J_TX0-7^N(*I8JT9U-R"C2D=\1QN91C"SWI
ME<$0;M+US\AGZI>'YCP<1%KD@Q(</D(S!'?T1R!%]$OBN&["C6X"4;X>WYC]
M%1CODCLF,R3-^&J$$SQR[]GKB',GZ883M%.,CUU+IJ<"#A30UA@$5B\ZE!E5
MY<+"S@NJ>9Y>\D&$W^>HML07F9M)P2H25^_<BIA^L6L;)L*VLF*WU^_\]'Q*
M8<T94[LX*$,O/ZXW/W(KE&V4"BB:J'Y;;[^./3QS.>#Z_@#GPV=<E(%G:>O%
M#(3YF$JPP9WR8J_S'/;SGM0TGP4S^NT(I#H_1N.^8<_*9[7AGZ.QOE>PL5\5
M8GS[1\=/PC 1D&*UQG%>VQI!/%L)IAILU%? -;,RHZ5GVB6[1!_[],,#X8B#
M=P!? 'I"OUHW8Q<O<-Y:(A;]V'DKI@(FZN'<J-G5+RBB5#P5$-%)<_0\1-H[
M@Z ':2^8AB)9YKYC? -G^Q&&$>"_>B+HET_X%OB/W-Z;CAFGMX6?J-+/G/,1
MB&Q*S[7M/VQG8[=O)<:;8^(^5!&]OT9D"4ATGFU:W=[%B5.."5 !6.G-5=))
M*H!RV$)HZ44.A%C9M&9CE!F9-FJ7R:AFD[]1Z2K1D=>:UB:H+@04CMB_+BUT
ME_^(Z":<*(18 J53&E '/W:#.E<5#/,.E/>7L'"N6S:?:%)'Q_*JFV#YBQZP
M?=EJ/5_@_ZMS?_YJ9'G!Z[E@D0JR_JD+?<ZV7&:9^X=&C;4K4Y.%#AH:^)Q0
MS]VX0X^%DU@D*8</3P('Q^_4X/7KAXU73WJ=B)4J_?H.47RW)V3_3,S9#G[
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M6K U-H'S==JKBF!]'8EK] $,2[:WSN_'T@)=7PH#$I>*K319X#T=# E)V&A
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MRMI :&PY,8G/'U_ _!AX8F3625G+-,RP8K\LW,4:L>WJ_N3!#0
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MD)68'4Q.G0Q#T:/Z%79PO'4E+._N1T75"J%>,:Q#,F=AA"F))(,>"W0ZM9]
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M;.U5D1DF&/)XFL"4LT17#,>*I*-0)TP+@CR9,FI4-7C_XR='KW=WE[;%Z=X
M9L:%_6$8FL6:^@<#%,C9;[/;3-YM$>.FY.XU;R>W=O]5??M^M8U@=,&R3_/\
M]\MY31LWST+O?>CBNFKM67N'[1L:>4%"H\"#48@#7?2 02JD!U$:4(I2W0K
MJCY8+RVF]N5?YPM8M?S.6YT!72G]9]L^77V&Q9 XA@9[:'Y9Z5^7B=06@-:$
M,[ R JRM&(:,3L'1<8.L/IJ,W/7J!+!V6UF=\K"^^5_?Q.)%K:750^G\_/EY
MKCNN*"7J5?+%RY/>#U:K[;J?];WRO\I*R2I1>(8%\0,O$6J1JH80<4F5.T0\
M&*-4\L1+.(J-JG*Y46=JU-E8H]O@5?: #8.:V$>P-@G4-H&U44U:O>5"]L0A
M-6/;\09J8-H=?(QZI*ZY@-9Q5MM)*HV<\.8"OMU<."=/=1@Z]%4'>9:Z=6XZ
MSQXJ7<HO]'OV]/)T_O!0"/4CL><XKUDJES/B82%"AF!047?H!9 D%$$/(^RQ
M(&)$FI=>&$C)J1'Z=@  W0P >*JM K0U"Q3KD_VGU<G^<V.9@R"04U^ ;J*?
MRK .3/\=(1VUD560QH:99Z Q%*PLW1_#<3N=D780W3/BB+]_,,_0(^\F=,?1
MD/2*U#E5]OL'YCA"SR@.QY6LD]O!7,QI668R$_S#ZT6^J!:0+W3^A2[U0>FK
M3A)Y4]!,I"B- E]W>)&A6N!Y$J8X0I!QS#$-F.]C(R_!A3)3\P8V:Z*ML]3T
MO][V^:@"7S8[AJ2O8,-DT-K<N_F+_<":+?/&&JZ!9_E-Z-=V'!J%.N]PR))V
M+F =JJ&*O4+OU2BE-W0=#5#Z/W/:2?HSBB+BQY+ ) P11(R$$,<BA5%,$I)*
M/T:Q=!I3XDCQJ9'^]8O.!=(D7R70EW5Z_2DUG4=[!1P%H[S#P X\/;Q?ZOL?
M+Z7]?6)C7"D_K7@9QT/R7OGF)TZ!%QI-/=/J1W_-RK^KI^H?T ?AS^(XDF$H
M*<1I+"&*F0>Q%T>0,B^,)(YQXEO5'NP2-K6IIE&MBJ[/E\I!+>I-:,OTZ$Y\
MS>8$5Z@-OIFWH2;0>IZ!M:;NN-8$#J?\V"EP5$XS,?TM#QG=TX\[;A7*HB@$
MOULJ7[PN <0CR9#.!I+"BR'R4JQC\A2L7A0@A&7""+.AC#TR)L<4K8J@U#J>
M@7_T?O(\'SS35;DGWSOS/*_M1$)?EH]YL6H[NLC;7^B6)>*P6V(\"&:\<B*T
M ]/)&M6[&M6_UE!>=6-D32<=*#AED7UR1B6/#D/?<D;7I7VI(F="\%(G0>H1
MU(7W;F3E )6_+M1SKBJ6TCNW"[[?==+AQ,KKT=T^LL5#I5GC$,U$E/@I00CZ
MD> 0A11#$J 4<A8D0M&13'VK0)A!M9T>?=7&UAUXLL9<[?>P_.E)3>45JX$7
M;3<0]4HK:^T'S]I.6\8:\ETPY;Z)C/#@+%K;6?-F.["UG6?[E]2;9W$K\YI%
M-+C\KKR'K'1+P",,A6,J'U+CD2>%$<#?G5[&$#KREG C_N9E62Z55Z>TJC<K
M9UC@)$()@H1%#"(>2$@\SJ"'8T9ER!.)K3QBYQI.;4)J] 3Y6M%WV-\].)X#
M;^2Z&*7I[]BN]F0W[#P#M:43V)8]-@C3V'\]J.4?8Z/U&,C.=E2/"K*;*KC(
M9I=J>EJ^GG.NOJOR0OWUIKC/?U_,1.P'-, $^DFD*\!Q K&?"BB0^GO"(Q8%
M1BN1#AE3H^M:3=#H>0:TI@I'H'4UX^HN0+O9UA%, _-E+X2,R<X @SUT50KV
MTT/^[6=U=\U4ZB\50574U/7,4<C%P*B6'DPN[9N>LZ390O"VDVA3W#0-112E
MD?JR18QTE4<":8)2R!)?<H][H7+V[-)N]HF9VF=^SE@=9B]T%R&9L<RZ_])>
M-,W<J=,Q&O@;;Q5<]RP>HJU2%PB.<T[VBAHYEZ3+W-T<D<ZK^T9OLD(H=^*C
MJ/][M;@MQ#/-^,=F@[3IQZ2C2_4I;9U&/8M]SC!*4\@E"2#26<R8,@Y)2#AC
MS(L)\F:+*O*4FW%$/T6,O@]2?Q^;Z@RZJZ^U!J)6MX[-S*M8#5JI;!N$V6M\
MS#AG0,S'"KRL%0<_M";\6 6_-&/0]G_30U"'RYQW#T&/2,M3$'0<8]E+E9&C
M*T^!:S>N\J2G]2S]T%:I^Y07ND;=1A6P5>D60E'$: 09\1*(6*AXD5(/DA@S
MC!,I<6AU6'-<Y-1<J8_;51SW%'JTK>QP''4SRG.+Y<#T=J1$8E4P<Y :#<8@
MN2W(<%SLN-47C&'8*;5@?F??H+:GIZP.*5?LIB/)E4<H%DQ)^)B5;)Z7+\5&
M-D8@J(Q90F&$D@@BJO?J YE"2G#*8BS#2%A5GK$3/S5VNKCY\N7J_LOE]?T=
M.+_^""YNKN^OKG^YO+ZXNK2L064Y#F8<-1RZ _/5AN*5S[6E.ECK#GX;).VE
M'VZ.(^FL5!@YMJX//+O1=KV><EIE@GS1[*7X(1&$BQ#ZB"DB0P&'F",._5C]
M57+J2YF8-3 Z),+F<QJG>=%]%9S+MDK]VX7J'H2SFX]<0#0XXVRBTJ,K[SY4
M^N6S]T%G_%QT$Y1ZYX^_A< T]WMUW[OD;;_5^E#.]<YU/>,OFK3>&WFNN)-G
M\Q<=![+V$"^_ZY@/P>MN"D_/+_7;<2/;?;];452G@'4]I2B4B"5^"!F3""*)
M0DA2SF'LQ9)*$GF$6650NU5O:J[?9D[UIGT;JRS06EB'"V[8J&]:;7XK,^OC
M_WY5M!R_!6:.Y?N-[<#3P'L,JWVLQB#HNPW4<*OBN%$:@\"[$Z(QC)1^4XG>
M']K86GBSZ;!N7:#[%=SF=<&P59?6-P4;, Y2+KT$!@'6"=Q8U^O"0LTH'DXI
M]XB'K,Y\'>HVY4EDHS"'7O'^4BAS-KN6?*ZZW>@K-XM$[+8ZT<<6=/'V3M B
M8S>YN'POS&:6=QKM]]]_/3LX9&>;[\:0U3X&P-[II.)2OU%GE & ?3N=#"&B
M?QFGA:X/=?%2%.IOM5\9!CY5TT(*0]WE%=$T@&DH)?0X%[Y/ HD\J]#NO5*F
MQN\K)<] HV8_'W\_I&:$>C)0 U-C#XQZE3$ZB('S^D2[DD8O/'30V'T5A0Y?
M["H2Z)PQW>"Q7'=XG*5,BE"F$622$AW]&T/LQP@R(GCB1X(*Y+=Q/_<VM'!<
M=H]0G_L1R.*^H'RSD7/=LO#4()\]T)ORAB,DWS6 I]5YH^'MD#$[AR$:.$)G
MC^!WCL<Y#,7QZ)N.>WN><M/G;$GG51@/SY8OZLU34C7E\0\OR^M\^1]B>4LS
M/B/(1S)1?HD@80 1IRDD?J"\=(Q2I%@A# .KCG:F@J?FN?RZJ.+>YAE-LWF]
M[94U>@.U8@'/2M C;1:DSX5NN;)\K1:N.NVYZM)K>?YM.D)F[#4$[D.?0-4J
M@TV=0:LT2%^60*D-7L42:,4='G9;0N7VF-M4^+@'W):0[!QMV]Y_0@)N>CS+
M*]W;>NZOHM0G[G7-WW6EFQGQ?"82IBA0)IYNZDDA13Z&H?1P0I*8^[%5):M!
MM)P:7S9JUK46P?/Q6DXC#JCAD<Y[#]/0)SNG9^+6_4';H:YM':9PUZ"#X3XC
MU[FFXV?E#@7VWLS<P80-& .Z;C[(4YIBDL(P8 @B3X9J?@@(3"A#+)5QA /W
M(:!3C4\W#U0\'EWM8&P,G>.A$!_:0W8(]C QH8-&M=MI,+V(T&.Q[OT>TK<@
MP=5"\4/5(%1\I$O:['_.$ ICA@(*"8YCB +E_9(P"J#DE./$YY1X1J?7QP1-
MC<B:Q/L-975W =KNR=M6)SB ;C<_N<1L8"KJ"U>/4@7=6)Q0K^# @T<N6M!M
MWF[E@B/7]P@/K[+YSME_O63UL6CC=?WZG"\N%.DH$KJ159\\+35?S'R?T)!%
M,9124T2J_L!QB""604!C)B0R:S731_C4:*-=(;TH?0&K%:[J0*]5MHBAMAV)
M;CH9&M^!*:;2'&RH?K9:CVKM0:,^N)'@?A2T+:+9!T1]I$AWQ^C;1<+WA*\S
M2M[VF>-%T/>T=BNZON\S^BV8ZYI8-W+5[OI./-0=#(7/HI3KNO\)]2!B/H:I
M#!/(:9+&@B"?DLAF<7Q0TM0F@G6[F?1%P2W*$I2-JG8+WL/8FBUNG2 V,+6O
MP5II">Z.H66]8CV*A-/5Z6%IHZY$CQK]=M5Y_(9^'''Y]#S/7X6X$\6WC(D#
M%?GFU3!6<=U?!<L?%CI&KVG5G)?+\K/ZE*Z6XJF<R8CZ@E %?:@+Y2"!( U#
M JD.HT$^%U)8A54[UF]J?-2:!QK[P*']_S.P-E)_D6LS5UW5M:'@-VTJJ&RU
MW,)S_2:8\> [CN^()SE[2W$WU5KJEA'-6:RV2PWUDXXK,1M+:[X="'&G+.U:
MQU&Y?2" W\X(0XGI.8^\2?=1FF1LEC(:$N)QR"*F9@-/A)!ZA$*$&4HP1DQ$
MOM5LL$_*U#B]4JJJ;\UU,FU1ZH/VNM:U9:GK_: F%,<>32D,XBB""D<?$IFD
M$%'EOM,@"/TP,JL)X S6<0H#7*NE;K9@^9-8(PH@2 ?&VW B.Q7#H;>"=S(^
MST"EH\.9I0L"M_/#7DGCLGR7L3M<W7EQ/\;]]>Y>QZ&^%*_G"_Y+KC[!A?8K
MVIH.22Q9$H<P)9BI%3Y3+GB@F$(P)H,T#GD86H5'=4J;&@/_^M/=3Z#5MW*O
M'E8:P_(Y7Y2Y#E84>H_^N<A*VQ: W="G@20^"0(8I1[6.0-JTL,DAB02$?*]
M..&I9\?/SL ?AZ??%WXSNG8&Z<"T_>O=-I)K50<H1VP$BE,B[Y8X*J$;&?^6
MV,UNZENLO*IY5&?6UZW3_Y8M'R]>RJ5R@8IURC)3;A]C<0!]3*E.6E3+SE"Y
MAB+P(\Z)2+%GM9MK*GAJM/_U\J^7U[_:EK0SAMF,6(8 ;V".:51N"X742H/?
ME=:@57N@"G:V8#FNB&XH?.0:Z7:0[%9-M[S_)'*Z6F3+C,[/GY_G6;W/T.PM
MU)T%LF_B4DK!EM6A5G7DM=X@9*&/99PB&$@<ZD.H!&(:*NZ*(D[\*,8XL4IB
M.EVER1%:;9'NVE?9!#:,6FW[KLP"M5U@;=@)N\$.QM>*+T<:M7&8=. !ZTNS
M#C >@H!/4>L]J-D!C =(V\631VZ2>%FUC[U:E,NBBG<IJ\KS]X]TT?3HNLZK
M.D""-\WV:!SX,N61SE65$,5)#%-*N.ZE&*4^3D(BY2C-$VTUG]KDL#Z=K[*Y
MWKN[HO6+8#8]3')X1SPY[)D#5EL/-LQO&H(L%0#K7HTK#";4J;'OP$VC@Z.U
M]G^,SHY]!\59Q\?>"M@G7GQL0C?OU:TS09F?1@A![%,]7<6^^N#\$/(T\6B:
MQ)R;15&_??#49I-6-Z"5,T^CV,*JF]%/06!@PC4SWBHI8I^EO9(@MAXT6M+#
M/O4WDQSV_KZ?ZZE+NZUB%7[7G<-U7M5748I"?=!:P/GWK%12N9<RY2UZ,HHA
M2F+E-\9) ED48(&CD$N:V/B-9F*G]IG>75Z MASG&? #Z)$SL#(%K&VI#@M:
M:ZKW&ORF#;+<!C <'#-?SCWD0SMBPZ%M[4_9@>?4&3(4/:HG8P?'6S?$\NZ>
MU8JSDCX\%+HT6Q-_52WRW]2;)=SGE$4<)BAE$(4<0YI*#\HX#E@4QB@25KN@
M1E(G1VL;%8:W#:AC72L3+&L"&Z%O1ES.,1W:GSD$X;!U>6U0<EMQUTCRN+5T
M;<#8J9)K=?.)]6^_TM^_4/619W1>SF@@!/64@\52K+PL)E-(1*J31FG (XIY
M0$2O^K>;4J;&/DHW\-0JU[/D[1:*9JQR,C8#L\A&R5N-T$K%L[KJ^P!U;_<!
M,4S=VRU)[U/W=I^Q!^O>[KVX;TV))AG]JWC.BRJ5:$F7+^5,,I[@"(50Y_!
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M@5"_BH0'(#BM.N';AXY?J?" 67NK%AZZMF\I'9V=<$^_KY==J]DT8$FD_E=
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M3)<\E0C2!!&81((0Z7F"8*N2IX=%38U/6DUU51A *RW/P$(<_A!LH36C$#>
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MA1]C[$G(_41"Y D."?-2*$.9>&$41NI'QN'3KK6;&CV-7QYQWY!UL]>[#\3
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M L)]+Y0"<JZ6V,A32^P410KL6#>C3;Q8AE:>[ $Y4_-&5VJ>VI_D$*YFY.(
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M5NVA#R.<,A9'G'K8[BS/2.S4.&2C3_!*V6K[^/K\K_V.^,S0-SSQ<X[IT >
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M>%S-DXQ3B'E*81 D)&*1%W$:&\>7G:#(U.:[.B.1KFTY T^U-6#5;@T4*WO
M4VL0>&XLL@AV.F4 NZ>O,8=EX&FH'I'SS1%I# $K2\#:%+"RI4W_&FM$+*+0
M1AJ9D8+1!APANX@T![!V!J:=\OSQXM,<H+ 5IN;B>7VCU?8':*_GV;4[[[$8
MTX1QR+E'(**A#ZD?(<A%@EF8!'$LL%T<F['LJ<UA%S>?/Y]_N/G:+-I^^7IY
M^>7R^O[N#%Q=0[4VN[R^T^NT\Z]?SZ]_J7]5+>T^_*I^?GEW!SY>_O7R\\VM
M_HU:V-U?_?7JWGH]9S-V9DNQ@49DX.GK< K(QM)HF&5/#\ <A^69RQ\Y8,\:
MF-U0/OM']"/!JP73[4+%1U'_]ZH.('S,Y^H9Y:6BY>7K5Z7-I[SXG19\%@F)
M6(@(## .(8I1 %,O$#".PBCR,4G3P*HP@J7\J9%AJS[XH37@1UUK9].&_QO4
M5H#?M!V@,<0R$,AVF,PX;T#P!^:] 7"W)L">Z#DE05L=1B7"G@"])<.^C^D9
M"ZDK?'S0!3YT0PNQ*.L%%THY2EF (0J1!U$2>#"5(8$>3Z@0F*'0-VJ=VBUF
M:O16 =V4.V$;>EI&,>Z'U(RC3@=J8"HZ6A+F6GTMM'QTWS&Y&QJW 8C[18T;
M:=AI[DY(8??5CFLM7#V7HJUV)$42,A%':H6H@$2>)R%.?1^F@L=1&L9"(*.<
M)QNA4R..(ZGIE>:.TO\WH3?8MAP T'=;XZVQ=%U381-41_44>H([C5H*AB"[
MJZ.P!ZW>-10VGS6-^@E[K#.NG;#OWIZ!?YQ76XYT?DLS?K6XH,_9DLZ;UUX@
MQ=\ZR\UCN@2@ST-( Y'"!*$X0%CP*+&J/]\I;6K\O586:&VA6ELU^EK&Z75"
M;.8!.@-NZ*.D@Y@-D/IJ!(K; +A.B>,&MID8OQ.P9G13SZ,$Y=^?+[C^CUZ/
M?J-S?3YQOKR@1?&:+1[J) ,6T13)@$#),%$+21HKQS 6$/&$(\(3R8G=(8*)
MU*DQB]:V"M:IUD1BK;?E 8 1X@DC?N)1"B/"E"L>2@2)"!21QRC$'DT]'B&[
MW@G.,1^G6\*HJ!L>N+A&<F@WO(6P^LN&RF> +D&K=9TEX_"4Q08EM^<K1I+'
M/5FQ 6/G3,7JYC[[ ^K);Y[^593+(F-+P1OIVS_8U.,I+Y8Z/OHB+Y<S'\L(
M,P]#[F$*49 *2%B40"$%%1[GA/N)29D%QWI9S24CE&98*0>T=C9+7W=#9;+E
M\"X#, (=GNWAPK4A]2]U^:BW/]NZ80J#:+/%\2Z#.=8NR,B#:KE?XASZ[BT5
M=^)&W'5QCM'VQHS[QSM=<:5EU:EHYF&>L)1A&*2I+L2>"$@][L,4$9(@@L,X
M3ATLM1IQDUUCO?TPP6^MRI;Q!T?@/LGC[P'B>[GZ)OBY<O'?P#*&;]^*G()3
M_\9\0V_^[5V]COF>A.*O_VKV*,,D)D'("$Q)PB!* PG3%*<P8F%,/)P*)(VV
M@?<\>W*T<?/E\O[KU;];G2%M@65T_M87@L&/V6K%^AVE;<%@=6+6%X[1#L9,
M8;$]_-IG^)$SKJU;QCS*VJ?KFQ.KO9>X"LK\J%;^1:%[8>F2;_?TNRAGPDLC
MSF,"8TH\Y>.@"!*D.2KT41(2BAG";<6)^U,B,O<(-WI1M\M*W(_ 8*VF8*F5
M/#7$<A_H9IZ..PS?-9QR!6=3W?&^$U4' 90=* T<-KE/\CL'2W: <3Q$LNOF
ML?<V]U2 F!$2^;X71U#ZNI L(QBJ19K0S5L5;PDN%;-9D-<@2DZ4Y$XJH#/,
M: Z]"=IW</Y@6Z%[1_8]QW6L?=$3Q_>/MCMJ-\XC;I)VC,-P6Z7[A/Y!-DP[
M\'*W;=HEI&?@VSJBKE22K_,%7?_D7OVMI*RJ<MYV<1 LQ($,(?>B ")/S=,X
ME1X4F* @XFJ=0:S*'EG*G]P^R<%84;UGN/GOF^6CT&5.Z0)LW_3;Q_R)9@O+
M75C;<3-;K PX&H-OV0P_$/:1>?W@=!NK9ZG#N-%[_0#:B>?K^9@>JQ]%S2]S
M76#GDS)&Y^#FWT3Q>BEE7BS;;XU*%D>4(>C'/-'U/Q.H7M\84AXG$6&)QR+S
MDC<& J=&BBN5ZTX9O%4:B%IK"S?6!&Z#%8=C$ ?FLC5^6EVPTA<T"O?9EC8!
MTL+%=PSH2%[[Z<#:.> 6*'7ZU";/&<]-MK!JR_.UN:^?,_M1%,I3UI/Y=5['
M=Y\_Z7IHLPB',8D1@7&H@^@8(3 5OH !H=(G""?,K-_Q,4%38^*UGF#1* IH
MI:F=MWD06#.WT@5< W/N6D6=I=M ==X-E;4_> P'IX[?06&C>GC'3'[KRAV]
MOF=Y8.WT*[\PWVZ8U.1AST(<48DH@3[B.D]7Z"WH4$*1QA$/ K7@C815,=].
M<5-CB7I%E#5MNT2MY(]G8"$L:>((RF9DX0Z[@2FCAFU3TU7KLT99E]W/C%!Q
M6P>V6^2X55N-S-^IL6IV5S]*:4O/W>=5R;I"W!9:SO+U=JXKL2ZXWK=[UI?,
M1,A2YH<IC&2$U8*0Z>Y BFCBE 6!^HL?4FK7$,)<>(^3JX'IYE8]Z)&6HM2U
MG)\;O<^J3*3GU8Y-KH?.CGTL!L2,B1R#/ XKM4J#90X:M<'M"N1*\[,*X97R
M[DC*'C"GA&4A?E3RLH?E+9'U>$+/%=2JJMR-W"R6\E54#1QTM'99E5.IBMRT
M:JV"?T,<<C\2%/J!6ETA(CBD@2<AHAZ)(H_0F%FEM9ZFSM3\K"/E@7I'9)\X
M:(9KN-&&8F""=# *]@L_)^"Y71Z>IM*XBT@G\.TL-=T\]=0^NX<*G#0G&>S
MKS>/->YU\YUUE=LX"41 _0C&B0ZH\M5"EA),()8!8U1Z/*!6A3D'U'5R%-V8
MJEW3[=/!K^*;6+P(':NA1GGSE_D"G#\40G3Z4J._!&:L/I&A_0,<#E?&@4'*
M)X\P" .U(':O[SLU+!X,^,/MC8<3V6]&^IS1-)M7+=MTE$_LTSB&)-8;%C@(
M(<&804$2+%+D^\*3)D4']CS;BO%'*!QPKV6 ^5I!.PK?1,V,<GMB,3!%?C8
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MS6SQUZJ*M3*-Z(!O9/^W,'N[P[CXF<W]HMTSN5KAJ^C]1GQGZ?[B-+!&[-_
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M77BEJ\G2Q!27??P^GZY77QY^K[]P7#!A*..0:%Y C 6UNQ'$(=4*(4XRE+-
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M"<1IFD)N"(,J)[1P-6&YR8-.AL)E&!N#-RJX*W"W L^E7:=YD[?K'%V<H(?
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MRA+&(:7,0,SR' J9Y=8 9,P4"".)P[*<>G0Z-LK?5BA?&+"1&C1B=XX[]!H
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M!+:_,E05WFO8R2[&MCC]^O ? 3QV&C6/5>-J+'I>#DKY0"D@*"6\7/[4%YT
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MA.2H@EOH^UV362VDUFKUP2K@NOF-KUW#+R[MW6(VT[*,K;\SNU=SB.%4D$S
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M6*I4,&LKRMR==0L#J2 ,"L%U46A24.IUS!U=LK'1^YYN@.]&SM15L^Q_&_W
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M./\R:.#*N9IY:(=YG84VKH6(_JA35SW>WER^42^XL^'VYB]02P,$%     @
M5H(%4R/& V@M=   F'L% !4   !E>&5L+3(P,C$P-S R7W!R92YX;6SLO=F6
MF[>2)GK?3^&S^_;$-N:A5E7WDF5[M[IL2RW)5=WGA@M#0&*;2:I(IFS5TY\
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MC?^O\["D3YQ]>HT?%LOUQ!05HR3JT40&RAD/,7,+VI*$N%).IN,P^\#".^%
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MUZD89[Q&.Y@<+.$.T/%JB1_"-/_PQX<:V=)9^W+]'I<W9#1)/-G ZYT5D4^
M#P5\0 6H&%E,Q7QPC\U=.!PT.Q WSI".=E@:6A\'0^PC+N.B13 V(:-:O%(%
MDF1T\!I?[T$L_9%*YC['C.ZQ7LF!@K!QYGJT \[A,C[<"BW6838(0'Y:S-_=
M]L^\2B*HB""\<Z $&5)G90!O/2M<EXCJL13RX3"YAY@>'.)!(O5C!=W%B;7X
M@,OUIU>S0%MGGFM@^*%R4D]?%ITP6280LM;QD3C &]H!4F@40=8MU2;!\QA5
M/;C%@Z!G,-%W */OM\O6B3=G^#;\<2&GRHF1T;F@/%@TIE[=.!*13V2+A2\J
M*IYXFP/J89IZ<)D'@=! 8N\ 0/]8+/+OT]ELPF,VVFH'*7DZM4-!B"P'2%$I
MY:SU1K:)P2\IZ,$''@0<!XFT RA<\]%_6<S3E0\FB 4B/00I:PV8AR@"!XS6
M:^E*%H]V^QZ.BWO)Z<'?'00DQPN[HYAH$G7*TMLJ"8F@L@\0M<,Z39X):9/1
MP34!R<7ZXTRM:W8%M9<X>XA[IB%.9]/U%%?D3FTJB-\O9B3T576MUI^N1&.8
MH>B>?'27O:ZO#"@(6460:#TG1SV[\EB!U1'!T(X4CALA-;\,;Z*H#DZN:WS=
M3D8$8Z5&8\$S1IR@K EO0YP0%W0\A\RQS8W4PS2->[W9!@,/ ^T8A70 K6<I
MU=&AJU?A4[U!N<Q,^921F6Q!EMIQZ>@/'[2%A%P&KKW$V,:2W4]/-Y Z2MNW
M#\/C1=\'@);GF'\X^S!;?$+\#N=8II]3G$*6XB3I.2LD;R%H 8[$! Z--D)P
M%EV;2HS'Z1KW(&P'J*%4,2*P:D7G)2O/Z8?31&[<'8%-C%8J9E<?:)*BCAAR
M$+U.H.F3;!',FW K_7.W)'6WI<9-# Z,E0;2[< (/3]?K1=GN'R-Y7R>+_FY
MG#PR43%HSH2!;#SYE!1L4@ :/21!_/#(BQ5M8OS'Z1HW7=C(" VHBEZ,T&)&
M/]E.6[_#D,W>J!(ST.%LZS6O):LJ,RCIR;L4(26>][)#CZTV;@ZQI2D:3,8=
M6*.+W-<%8_?8UI)]#%X7,+XF4+1@$/RF,BDD3VQ%D]I4]SQ.U[BIQT;6:$!5
M= "L>SC0S/- \*?P(!$'K,[<TTI#8-PDQ9V6^K%'-8:,_\?-4C8"T)$B[R![
M^7PQWXCAWZ?K]Y>'\Y6%O9:;CYPQ9XL'1Y]!1I;7S$A@Q&4V$E5,Y!*V<9)V
M([";D*U=6JF%JCHP6R\_8#W8Y^]^PD ?>0]#OEXJ2$'QA4$ZU@U99%^KYD1F
M29;,&/=M+F>_2%HWP5\[U VKGBZN[3;'_C7A7>/%V")YHM@CV=JWC4X3+Z$.
MH)3:)Z3XPSTV,.-([^M>FKJ) QMB;!B%=&#,KC$Q$<9X$X, %ZMC$;P$CX8L
ML@I"BB"+#,V=KVY"PI/<MNPE\BZ<K[.SZ44%9^V0H_.=["S.4V4E:4'G-0K@
M2410ED3B4\K@=>(IYN+5HZ]+'.-P/4A4-T%@2R=K&)5T8(L>D9!/''.B($<Q
M(>KHW B;JKWBLLHHDC&VS3%W9/'!*>+#=M@:2"$=0.O5Y;H;EBXZ>)WVP<HD
MH1@CZQM/ H@#\@J%*T)GH0U_;!CZ41U&MXD9>ZS#,'J^VU9TE- [P,VU*8L7
M]&O/R&H6"ZG4W*W"!"'15T4;^H8/F&R;MK3;E(Q=^]0$,4>)NP.X/,MY4_X5
M9J_"-+^8/P\?IN1[32+/TC/MP08FZX2U I$EA,)TL@)U?3F@3=G _02-FP9H
M!)XAA-\#AE(Z/SN?U3%/FS"S#@)>XGN<KZ8?\:*#X:?%JC8OO"QOPQ^3E+6/
M(BE 5Q*H6FH3@\\0.(DPH=*AT1"'/0D=-RW0"G,-E=4!%E_C.DSGF'\(RSF%
M%:MK['Z/99JFZTD)TON(&K1$61\S<!"%(8,MI(VVJ%)\F^N_+],V;BZA$>(&
M5DD'(+LKJ(D,]4)<9XI9:W=H9@C120Y">,]U<H:G-O6:=VD9-X70"$1'BKR#
M3-27XM^)0%^L+JS6XS!BRB $5L@)X,[RY)C1C683?HFRG0 U^/S8L3*<QRMG
M,+"=?*SHJXU&WN.Z5B7>9&>H&:,WESC1P-%'^#KE]-%$SI+5WH';/,U9J_ \
MQP#($AFK'(/S;8*J4TP?W7F?TG8I3#@+7-97*E56$#F=^,@ERU)3Z&,>>U&C
MDR:M<2>6[H.D@YNT]E%4EU[9YYXV9#(RDP%M?0R[PL/7+E@"2M$.A>:AT=C
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M5*Q2;=!Y0B;'GL\UL,'L$QQ='-Q;EK?[?OL<Z$2S@HK9^O@Z>:ETBECP(6I
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MW;N5WV/--U1F)\Z5FGT24)*IQ9!U:*#6$H2M7@I7D:4V5^*[4CAN$J@OY_)
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M"P*/.8"RS(+/WH#2F$UPV7%O=CS,KG_NZ"H_5DN+8436@7L]:$J8)SK90RC
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M*?F,(O[$\SOZ1/7^"AZ.:G^%ZOF:R#<W#EZ_W8"SQ$QP(2C@FBF@2*M =$Q
MEH8SY;A2ZCC!PS8))Q[(<5QTCJ*F#MSJ04\5;W?6F6S0IP").<H+@F#@C"I@
MDXJ%95UXH_1J%/&G#1:.EX$=7]=3D^,?MN+[F<"9UD9HEC*(S MMO/$0Z[BS
M[*5D=0YW>9B[;1N'-)I,TS-*'!E-B^E5.V%^=_BR-^0#="@F+7FTY$:*HS1
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M&+0 9%*4&"*E<6UJXMLDZ@1$^RM[T6#G.T70];6L-4%;+0(P$T2=8FZA%AX
M%1;'R,2*;]/>O5VF:5$TCLYW -(>"N@ 2C=&=D<.B8A9188@X_HY>N!UC#$'
MB@2-8Z$(VXC7\Y$H_0%G'QUO.<+VV_ )$5.#R[-W%Y]P^68Q_TB?]_EF?L=Z
M%8$[S6(M:=(A#I0Z.(@IE]IA+C(S-IF'$P@>Q\!/?\6TMV(CPV'$W>S(BWR]
MJW@;$Z(VA&6)VH"*)D'0I@ZZ"SZEPA13;081/I9E^M&8XX8Q!^YV3WAY'_[\
M)=#GSL+YZHR5XH5E#H3*9$?):@A6)N"N&&>+%B*U>2>P49Q.@M\]=;P-,GMO
M>$^H^?=B^?O/\U^7BX2KU9DTB-PZ18&<8W5?*)!SKH!(B:=HLA:ES27Z9GDZ
M\38CXV;_+>\).#_.YK/5)\P_+19Y=69]5#('!,<*^6"LPU>MY,!E$04ET[3(
MML#Y1I[I)^.V ,[^6]X3<'Y:+@CVWDC.7-T0R2EE-$*!5TX"$Q3!H\Y&-.H1
M_U:.:1LC6@%E^!:/]IITC"-I.;O [Q=_SL^B8\B581"R496^-T 0PM3073JF
M?4F-!@<]EJ63HZA5$7B_/>_U$NFWBT7Z_7588?YN\?D+SE?K3]SG*FG+)XUR
MH;2+E"-=*]W!IO;?W7W9>SRG"):^?W6Q^NT303%6<7X-7]<M47<C2I5B1E-0
M$JSBH)C.! <OP1 \<D2K"1AM>BL/DOO@7M-=O_WU_6^_NX]E*<F<E8"84P#E
MLH7 7*UHH,<H)3)LDX0=*/C$3Z6.A]5'K:I'5/AI^<[]VX">_+R&?K1A@]"!
M"&7)>9]- .,=(30Q3R&\T>"#EH$'0<=VF\;$:;WI71O+#X2;Q5?$JT$/>&=1
M]X5Z=7Y^71I^5]YC6GR<S_Z7A,+E;'$EZ?VAUM:Y4 U=UTS(6@E!DMDE&RH?
MH43GVUSV-EO227O@(?C>WNLT)4@FY2%;7V?<[<.C\^95?>!;6:PNOMYK7U_?
M?WSX%.;OOM3M6-5^^ZLM6JTN/U_]W8-V,:L0D^89T&4-JAA;IS@EL(H.JA04
MI^1SIVNF(P@[;?HU@4%TB8+3BEFNG0/F6U>R\<=^^*O^%@_H-QSSZQM&1"/L
M1Q\!E,\RZ6QBG06FZQ!Y!\%K!R;X:)E"B:5-(^0+"Z#6MZ<Y>6XM=\!9KIW)
M6H KLH L%I,UDLMP(L'3]+V:1\1U\\!I,#BZN&,@%TANC3:[[NRW/6HAB>A4
M?>(<(B@=Z9R+QH!(I6B6"B^YU0W55J&F16L'D'E4CAY'?_U"\;K-B3OI,Q:"
MBZV7OACKW9TOX$MAP4O%=+-[]B?$FKI-8R3E[P:J/331 :S>DTY(@$IF_'T=
M4+3X4M=T';+=#"O"E,D*!8@@:,=8H)PW!UW'@1AO&8J4VKR>V$&X+B&V#Q06
M;?72 =1^PW/ZIX\_X1R7X9P6]BI_K@T(%U<<N-=KN^FR5*8PYK@&86A=JKZ@
M]U&0[P_11R]2EK[-5>T@,:>^Q6T%OW:ZZH*2?YSXY,UMDX7TC&P.$Q0A'&UU
M'29M'8(MPDDM3;:-)CF.O)!IX=Q?_#@E3CKPV+<%GLT+O_8"9T)ZZ92U0#9/
M.RPJY0XG1Z.3YB8R8W)L$Q_L)M^T(<*D$'HX*&!\?8[HSH]2PSU:M7;"NNP)
M5F"C23$FH<':*"B 50&<J#/9I*TT2<FZW(BXO),*[!:_L%Q6$M[U=[[^NOG.
MYNJ42]8JA12"H:"S3;FPYGM$X"98EA+&%-OT (RVA).NM [![_9*ZS%!T$-X
ML9:<?OAJA+SQDE*3!$9&"2H91KLG*&<1 04JEXUOXP*^$:.7"NI1H? P3-A;
M+QV :O^-NUOV//]Z'N9OP^<;0O54> C",Q"ZSFE$VD@GG:>4@N><3/(FMKD@
M;+&::2%^ +@>^LVI-=T!VK^Y>;_JT;BIR63-LEU'[9'RA*PUA"04^0.==4'Z
M<VKC3K>*-+%KG1PMVVH+!ZFN PR^1PJ"9JFFE74I_YK/+E;O?_O7]6*<D2PD
MI"V2+H*JOT3C-<C@1$@I>\HU6UT>;!=KXD)7;U@<3X4=X/%77);%\O,5(P1M
MXBV7AZ5MX!Z!*:Y U1I@$#H!2YQ;XUSAC098;A%HVC>EW6%P#+5U@+YOW/KU
M$GQ2H;@B(*&K#KT@1!4L:/3<!BURB8VO!^Z$F?:!:G>H.U1='2#NV3W=MJ5W
M1>6B<S#"*V#%TXJ=8A +)HC)V,AI;VVK!P\'R][+E=64"?N1$= !YG>\R9#*
MRTJ2399<.R2BL.!XUF"%%D$'*8-N@^M3N)DZ-FKVNXP:HL+AP/17P)SCQ;$O
MHFYG/X]^\_3HDQM>-3V]BD[NEJ263$<)A6<&2O$(+E).S7WFWH=BC6W32?12
M[I:L$(53C 61U:,IQ 0^"0-9"#J<.*= O UOZ3]W2T/QV^YN:0@(>@@0OBDS
MZY -YW1.V< 2*"MK%YQ/D%7BRF?IF&K#-_$B[Y8&0>')NZ4A>ND 5$VR5\I=
M=;3:@N6, IP4$@4X-E#V&B1'%[V2;;JG7OK=TB!P'>-N:8BF.T#[]@L*FP7S
MVA806L6KX:*._@,I"_IK17#S;9X^_9WNE@:A9>>[I2&JZP"#3U],*,8R<\Y"
ME*R^@R?,1(T(9-S>H&%1AS:<?W^WNZ5#L#B>"CO X[9+"A,K95Y4$$.A9:"F
M&#VX!,AYQ'4%NM$+\K_/W=(A&!Q#;1V@[[_)E.HXTQK=,%$4*\9!M-: $J:
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MSC+F6-"U>54W3,YIW6([G#WT?0VUU][)7?]#_:6../@___'_ 5!+ P04
M" !6@@538>JFN543  "6?0  '@   &5X96PR,#(Q,#4R-F5X,S%R97-T871E
M9&-E+FAT;>T]VW+;.++OYRNPSIF,4T7+DGQ)8F=2Y3C.C*H2.Q5[D]VG+8B$
M)$PH@@."DK5?O]T-@!>)LI6K98U=%<>D2*"[T?=N0"_^\?KB].K?[\_8R(QC
M]OZ?K][V3MG6SN[NI[W3W=W75Z_9'U?OWK+]5KO#KC1/,FFD2GB\NWMVOL6V
M1L:D1[N[T^FT-=UK*3W<O?JPBT/M[\9*9:(5F6CKY0N\ [\%CU[^WXM_[.RP
MURK,QR(Q+-2"&Q&Q/)/)D'V*1/:9[>RXITY5.M-R.#*LV^YVV">E/\L)MY\;
M:6+QTH_S8M=>O]BE25[T531[^2*2$R:CW[9DA^_UV]&S]J ;'>P_&X3/#Y\>
M=J,^WW_^-(JB_MY_.@#D+CQNW\G,+!:_;8UELC,2./_1TVYJCJ<R,J.C3KO]
MRU;M.2.NS0Z/Y3 Y(FCATX$"W-S'H8J5/GK4II]C_&1GP,<RGAW]>JIR+85F
MYV+Z:S!6B<I2'@K[3";_*V RF)<NIPX0&"*6B?" =;H(S=GU2/:E87NMSHM=
M?-QCLX@3UT- JZ^,4>.C0QB] GT(E!1Z=?"OY%AD"#S[H,8\^37(@$%V,J'E
MH(I#]S8<B*(?SBZO3J[.7K/3LP]7O3>]4[A@%V]8[_STXL/[BP\G5[V+\SIV
M]P*OBS<K MW=7R.HS_YU]K;WK]YE@/1OK8@!C9WR* )9WB%1.&JWGM:Q^C//
MC!S,["V91(#DT1ZLUP_'<[\9SVL1RVN9 9Y)V H89Z]%S*=<"Q8JG2K-4=\%
M;"2TZ,]8*#1 +V%^,^+F\:.#9\>;2YM.Z_&CSF'[>/'WU4BP5(L,-7C"QX*I
M 1"D1C(F,U8G+KN:>V+*,R83?P>- *"L:2 :]/&CO?UC/P9[/^)Z#-HQ-S+D
ML1OS\:-GW6[GF,'2#&2,)D2:C"F@KP0CQ4[M<H4P.H+82VK32S.BR2X%6"'#
M]0R?N33N8?K$7Q1, >^=JXD8]P'0SD' .L^?[[?8YO) =RD/G!C#PQ&L&HJ&
M40P6TY/AYP-JR16)T"WN$;$2/E4:1V*G$_I]=X!NO43!0-[Z(#)#7'\CDRX*
M5L"F(QF.@!/C&=-VD(SQ) )9,F*HB\M(P1^),FR0:QA#,Y IN-V$>Y^'GX=:
M =%V'!D&]'/LKO;HYP<295M<AR(UR$2IT&-I2G6 W/;TN+O?W>9/MCM/"+7R
M7I_N.2H54OJ[2(1&^:]0\BV?/KG3=3>D--5$9@!.YF&^??6!7ZKWD$1:3*3*
M,V  6E.@E=(LR],T%N@-BZC%4-L")22R (MD!BHNY4DX8WUAID(D/Q4<6K2F
M"6&PE>2 \%GU838"H/J(8Y0C3)%*\16P$7.B]&O&7BFN(]+P4HO0*(TFB?$0
MGHJ 7,):"; 0-'!W_V!57K,K\*7"C>OE7(U"FBWUM,<<5"W$3"CM9.N O@"Y
MF>%"9 *$78&PXX=>[9U\D?>VEI:(8IS>.?O4NSH_N[QDG_XX^W!V\29@&9<1
MFU_YD.<9TFEU?@&2]@7+ &G+)DA7RSJY&8$S\5_DZ &\#>H('\>1NX= YHB3
MS_".SP(*47\0J2&>U2^_QL>(Q< <=0^*V=S0.W3KCCR*9?[$S]'-2Z*=FJ/Z
MHRC]0Y?QBP9_UCCX'3'$JQG%46OJ/3Y^M/_T.*/?[!WX75S$[%V+O5-:RRP3
MLZ7L7%F..W$W[$\3R B:^_@]F!6)S$0VYG0DQ0"CMA""K(E@%T[G+66K:G8L
M538W>*3!,N+K2_-EC@O;Y2N\GZDX-XNOO'PAQT/&8_/;EASSH?A/F[?^3(=;
M+-/APJT:3-W#]/JXSO8' .4$[0#$CT[QTL+;C]W<W<-GZ?56/7]6XKU:-G&_
M>'^D/5@I@+K3!\O]>8</C-!'/)[R6;:U+.-X\+1UN)$YQT7-!C%P8V \9R3O
M.!_V1^]5[ZHIB-Q(?-FWI6/G\3UHPO=@C?!=.4M+X[E;1J64:KY/J]O]MNSN
M;1C<EDGXX:CUOAR=Y;'-3\2F.>BY\KE0'Y[?F&#=QD<H)=H^KCSIDJ1/-FRA
M-V^E066 /U;D8K08R@PH7T2?C5R0+,E4R\RZU:Q[T&%OI3&Q8&]X'&?LM0;O
M+/!OGDI#0>PG&8/[,328800?(;%W$;M3GL'+F.M^UGZV<42OBE>%XN"N : -
M!.< ?AZ.BL4",:Q^?"GT!)?J5(U3GLPV3>8V3^C2'!8O6Z9AC6(B&0(S4%HP
MF3&0KD$>,QX:3'+"?W*" C2 "YN7KR26,C;FF'"%)X<\H3126>):DC=<6GK:
M,$[Z>$\9J1F=TYA#9)W9 J(*/[>6Y[36@.GG5!9<5A*=P/$RRW+!S%2QL,0K
M0[Q<JC02F"S%Q&J B>D4T^,3$<^"TOL8CU$9XCN^1FL+-_3Q>RT&0J.:]=2R
MCZ \&F5 *I*<2JPX[PB8/W/"95:$'6X/(,YE(R"S]O4'D3 @9XRO;>]WV@&0
M&?\]L6MEYVFQ-]7WRN?;S<\C>'&,-*FB'##! =H1GV!)FK.4:S;A<4X"K6!!
M !8S<A<,)91M_W^[U6YWGK38517.)6"6T\Z1\EMFWB2!7.2P-9;'A57T=H.8
M.6(#K<;,P)S(X/0_&"-</S Z8P6^'LZ,O(M#-56TBJ)2*2M!I6>"^[X6*H]L
M\R5B"J;(BGTEID#SF>4<R(F@K5 78]MN\->_G[[UHP3X]D!>DTF-P5PUH(R#
M1R4  4O55&@(?5*"4B2A@ LJE2%Q"R_:"0Q<D620[V;I550E_\K!5!+V:+0#
M%LNQ-,Z" T18>M,R-+YLB6[ =*3B> ;FW"V1&Q$^71!(F@7<B,SP?BRST1+<
M%C1>"-,9:7)#2P1S5D%'0B4SA^,8//WGQWXBF6!394;<$0GW=^,,#A<W9);W
M,_%7+LJU1-RH"%I[!3N?W#O 1+FA'H.^B-5TZ2Q5R.$98-[< #D2S)"T('9E
MX:HP>K7G$8N:RK4X$#AD8JB0=-BEA-P15-FA1EP"KR"5G0,>RMW*8 DQMQU?
M>#T#[1H!UTF@+_:]8'FY4LV%%S&737=<'U*,DG:-,ZU H,WR\S;+S2MKZ6ME
M0;ZDI'KG-%RT3VM)TQ8#3]!&:C 6!(#C2CZ@C^WJ&/Q["P+J),K#XG,^&'"I
MLX:8,G"=6D535B0&,I'VH]+NN):/81[7.D6LR?-7MY7E7 GIAQ3F&NI0/RFC
MW;Q<G05BW%067Z>RXD.)L-$6K%NJJ";#((#4(U1XV"BN[B;%R> =1B2IUDVC
M,!IE5@LU"+!5BY0&>AO6TP_@50I:G5:@/KF(NIB^HLU\W<UHY\&,?GN 2Z9@
M+>GH6A^_I]DL'?\)Q%&BZ'Y<="8VRM_L/@C*-]/PO BWUMWAO*H%AZ5QL:E/
M*P%%W&I#4TQ#-*9\"GF!P!/$15R',0@?YF@Q[U/-'97Q:C;?*OUCI>MGM7;L
M-0K1W[K=-7;][+6E70L9;B;B9=[_$Z#T>:EZ@J_PM6J9HL5,'"7A$',LW;IM
MS!4ILY4YK&7@!K^(A5*'^1BS5&$E5:C%F$.\E@R;MC)DCJQ[ 8QF9#QOQ3#=
MV7EZG&&O>!N&3'* 8"P$):%\B<6A8[-5T:) @\R19R@3HH86HJC2E&49=#&I
M)L5Z@?^C9WL\W46O7KEI^4U=-DMZ,VQL).*(#50<JZG/:H6QRMRCE#K$F!9&
M2/-^+$/L7X!E0:I5TL4\80+N$P2N].ZM/18_R7,HZZ67(H2HQ.#:GEB7H?-\
M;X^<:;?K) #M.+'3X LT)^&<\9ARF-42C><E!R"USO0<T._MO0L'M-US5"3\
MT*<W-RQMY_FM2TLT]FM+^R"),3'5CZ.[99T)#A,*/887KE-)B+F9@=UT=-LJ
ME0N$S D#8V0AG.RWV)T+E65Q1+#(SA<TH2PQ5CELXXOE?J*"N)GZ*PA6H@RF
MB7T"VB6T\^KT&)6-.+ E;2.:6QP$F-X!^V:W._7%3#D%$;FRO>T1J4'B9&P-
MZ!Z"((@DK##45Q.SOFR>4IZ@_C44(+Z:;J$HF?(?B".,$@J*@[%'H^H3X34N
MA:LH.-XHU&3#FLT+40+KM[H,P1NR(CY?X BM42J#K.GY O]7RR7+[=K\8EM:
M Q @)];>5?0,+5R6P95TFZD*W@!><!4WNU-PX=U(<#,B^^2K?;8,-U83'K?8
MN2J+-:Z)K<EMKI5XFMU9C\)(:>.V1'IUA-(GDQ#'A:7SHVY4=+F_GM$ENU?A
MY0?+E?<AOOQ.AF>N?AO0\X52<#43NRVU2>1<:P-)<QEJ5J>'1_Y4VK6E5FJV
M5L\G=-(/5;HGRI WP)-"+]=4P$9)ZT'KJ[;N/R2#:N5H'H(+!)R]EJ3<*'[E
MZVE=EK'K=U&.5A=./)/9S>*-6A#;2V+R3*@;:-'C"?#0AEIC4N ](-2QBLI$
MM-7=)B=PXD1,P<_R1ZH5:G DTX4)G7MSFQ,56 \)\QFQL"6L)FPB@6X3YO91
MGU<Z8"A,*GJ7*H31-P);R5[&<6DDYB*/XL@0(L949J*LF_6I4SNHC$'GI;B!
M.$25>DS%<&M$&LU.Z4K6HU&8>D+>HLJ'(^;H C:(@UNK=#[V[R\2RE;_J5]J
M$:,6.ZD:4N\N+^EO2N$Q$57[FQS5<#0?-@^<-;99J\@N+KG[.3SI7=TJKI5&
M=KQM5VQ&*0J_5,A]89AKWU=KW?=:_%R$D&44X(!;B*EKT<!R!?@W;&GH/K0T
M;%9+P]J;[/[],MF]09$.E78/%ZIZWRWK59=KP5AN;N8S[8VIQTK=K:KPYTV&
MK<?U2?%O\TH. A7Y> P*&Z8'.,KN46\;O3%^$M3;J)%Q*=M].D(#H&<80($]
M3K%)+$UCYQP4KDEI4.@0IEK6'OYWZ:\8IC*T(R(5VNX"Z+1_<5L,'"[S&S$J
MD5B-[&4HZ+<=% Y4$:0-Z$"HBH5 SR(?@XP NP"@$67JRRC.;C.A,@-UAL,*
M?+$7$3!+8BW2&&1];I5#3" FW@XO6_V,R@N8',.CAOS1:P68A9\RQ,*#.SW(
M'19E:=GM=(H3HWX_?7L_TH9+&C<W*CQYZ$'Z#APQ R7%3K#ZAL6Z-0VJ637Q
ME7+-AYJG([8]*M5=363W]PH''O%S92K[M\]>T285ZPM7CKP#9>2?F^ND: PX
MO!K.Y+69 4[7MLH\53M4WLM*W7QXN-.E(XCV?BD..X1A*%V/?6 T7!S[CU"'
M[53U<G7S1O&FW=#7< ;=?(IMZ;XBJ_YXG"GKV!<MRL6^B,"2)[#Y^U2 0;$$
MVBA=\M"F]1V.)&GJ24'Q^:3Q--"$O0)>4V8M">T:'DLGHD&H$JQBVIU21>P+
MV$T==GW"KI9FL8H$9,LE-39*9)J;LNY\)>^5R)Q8@:G(R"F$&Y5^V\N*][^6
MY ;!.5=TB$+5F3;\<^F9U]OI&XR5RP)2%<@5\Y5K?;BAKA]R2@HN2:XYV8-Q
M*B(:EL2M#77S&$6DU] DM:3?B-R &[NKEKV8? DQ%U&[IQJFF;?VEYY<OI;"
M? Y.F=UI^\ZR[-I*[$DT(4Y/"HBK28=$C67B]D[[]'-C<=;OF2DV!=B8OZ\Q
MJTX)\CJW"HS"*0M0D>E5-$09I,N)* Y, DHDU8TV[K:7_(5A-FQ;[GT]Q^=>
M[<N]7YTL/5C?<5*4&]>2HJA^*KTFR_8).3\;XN=,V?WWL>3]6'@[7'T#.]3F
MM^T-:'-$8K\4).)8/+$W4?U@.2,<V71SE(.7@<_D]@1V7@!7U"?Q-9Q=QI@G
MWI8NZ[ X6C4/6130:&#X,%8S'L.?JR$0P#RUB4+Z5A0&NCFSK7U((5!Y0Z7
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M>3 !7H+&0@H[P^*R:5N$MHN["ZE'Y8.I*RV)(\[[TJ"\T#E RKABF"1*,Z>
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M:S\R6.:!(ZS&<@F-(1D*NWW)MM><6W^Q4'[Z'T^XGW&<_0E02P,$%     @
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MB >XI9D:HPQ9Y>>M34A%((SA>D93QOQ>8-\5F0;W0BB#+1/7%6 /FA!(C2X
MTU(LAR8A #F-91 SD]/'<OU4:%$((0/&TB1H%ZCSF$H;PT"3B< I2'(SJ*9"
MF#G!LI -9ZMN>-V1;GXETH)%,H4O*2Q+WY5=+5"6LGTY+M,(R<"I)\3W(,E#
MR$1\5AQ51FRE3F8L@WL)&828)%F&OO"Z>;(UT!6Z9K-,,_($$Q!OA:"X[8S3
M)^ F9E&BIF8.!BU&8"5TJI9QNNGUAI;EE9B:N3)KVK[NL+:J;/#(!V_?'.TW
M#D],$;B"FPGP*HHD+O>,+_)]QK5PH8!KY3 1Y#(F$/]A(DU,*VC:&/E..4_7
MH31!HDR.=<0$6B4^)IE6@0AQV[ ]A" 4B*GW<^\AB'DZ$JR#)+O-$\QPK<;!
MGEAI->C*7TJJS:G' LEGE(DK$/$A(UUVWBAZM%&$C<C.I\#!#.+]G<O7P5,P
M--\_!0/!XYG1@);M[9O&^_K)^N>Y,.A^X"S'D-^.9)G(.^"YV7T)L>A0("K%
M3IZ75:XA %DXD<;E-F:)U,FAAF')"JO,HD7"79@+8EZ&JERP#@U*, 1T,2J1
MH3M3FGQH9"BYEF2 ].7#<5U*DG)#E.X2PSC^=TR 0RL4PFG2+<HX\!7D"2<"
M@UE.B65IP I?:%;K([X-!4T$QV"]"'?FE!<*H^&.,-HY7=?0M'NB[PPJ '$B
M0\(*-RKEQ&C< &?4)!" N [GP02\)!_*1-H959%-VQ*T7=Q=2#TJ'TU=:3(<
M<3X4!F6YS@ IXZI>$"@=.@5<NS$2:)A1"F<T(C*"+$U!*^71 VC+#-SUVO$3
M;,5/;\*3W.4J.5=$$?H .8%;S(9ZOJAE.W"/O]Q<XAU<L!"\87PC,52YW:[!
M+NS(%[,%=4G1M_M'-ISW7RX#A/<$]''1I@U><<3#[8SAG;D>%#I$%$7;C6R,
M_'?P!!43%02Y)M>O,/<&J6-E+.[3HP#(,@$$_9J#^"%Z;\N2"!A"!C^972B.
MIE2X\P\=C=)\H=<[KU7,S:+,4>X[S(G0D:+S1T%8,YQR[D52'(:>S"__;A=]
M%\Y>9+=[4-V&LO^Y"7:G_7".T?(R28DS5G&RS%>*]'=4OK469J$=1QMCE3:+
M8N-N0.08AV8KQ%<8<:A0SF@\E-#/"=D#FD! A@@.?ZF9FJ> ^#674-_!/4\#
M=YIZ]]?M=3LX;%*[(!%KZN[IG!!(@<@4A6+1<TX%OR?F]^7:<;]K--R3B_G!
M\[OB7;2'_FRU(:]YB(5&+-)Z*S:*]@1+$&!T$65??@QJC\G'" ]\Y8PIZ'3C
M$?VO4%JV-Z,=5)!((VG*\+IPJ8ZXN><\18#+GH!E.E')1! +IWQ4/*[2!3N(
M<9:HF<#H-%:>#_@C^"#<?TB)JJX%X0_RY/%.CO0^VQ4(&UY@6==3%].'@*30
M%>B<\,R(]OS+";@T2_BL+5.G@EMT4@@?*FO5V,F?$">CE!9[N.W\</'6K=6L
MOJ\WZ,6;U?@?SC<NWLE5W3NYF@W7QXZ/JL?U[</U:F,Q5G.RO7Q88#*>?B@U
M2_,%13:T][,'UMCTBNRI&=Z"Y\N0N@]L"SATGYL?T2]BOH/)15P)!K"8N;,U
MF^O^)_OCZ%OO6IP[?K<+OF(ET>*+B'GO000YG5O8O]'/L!N<2211M*L(W5B*
MB%TL&.C:-SWTVGKOQA\R<7=M_-VZDVHN?;_.%JUG+PGG8'?7O;!./LJ-]<QV
M4/8_&MC*<*MO]G%$=X^:V_Y)TT2LO>M?)H3CK/IR"1\B*W*[?<FVMXU;?SA0
M?/K?,+A?4YS]!E!+ P04    " !6@@53@Y]QIHH%   ]&@  &@   &5X96PR
M,#(Q,#8S,&5X:&EB:70S,C$N:'1M[5EM<]HX$/Y^OV)+YMID!K_QDA>@F:'&
MF=)) @72M)]NA"UC38WEDT0(]^MO)4/>2%J:FS3-]/C@P5[MZMG=9U>2W7K5
MZ?FC+_T $C5-H7_V[KCK0\ERG/.J[SB=40?>CTZ.H6:['HP$R213C&<D=9S@
MM 2E1*F\X3CS^=R>5VTN)LYHX&A3-2?E7%([4E'IL*6?X)62Z/"/UBO+@@X/
M9U.:*0@%)8I&,),LF\!Y1.57L*SE*)_G"\$FB8**6_'@G(NO[((4<L542@]7
M=EI.<=]RS"2M,8\6AZV(70"+WI:85X\K]<BM5*O$K7F[X['G'L34W=VKC3U:
MW1W_Y2%(!X<7.E(M4OJV-&69E5 ]?Z-V8-=SU9RS2"4-SW7_+)F1AZV89PJG
M$ZA>_"VLK-E2]%)9)&63K&$\*A6J*W'(4RX:6Z[Y-;7$BLF4I8O&&Q^UQH*]
M*4N,OB6I8'$Q0+)_*&)!6.9V7B#=0_V4972%W*MHL,%EPL9,0;5B>[>1WO27
MB FZK'C>.$"K-R"'&&(J?C)F/QB,ND==OSWJ]DZ'T#N"_J![ZG?[[6,(/@?^
MV:C[*<#'."080/NT<T-^U#UMXU_\MY0_Z/1S>]D_&PS/VJ<C&/5^68S>/IS9
M0]NW81CX.AO@5>MN^9?%VQY"N]/KCP*DQ L([RJH!^ZN9OGH?0##]N!=^S08
M6KW/Q\$7:/LC+:FX;N6'JI=E$3K4J.[F3]=P:O?3>B;DC.!\BL,-^M!0+Q\%
M?8!((!'/=?O/;PQ?#=+AX#&HA,*0B#')J+1ZERE=0#M46J+#4883%B:$IG!B
MPPD7@DE)%V7H)W;'+AOEOJ"2Z3@ R2+P$T9C""YI.%/L@D(OCEE(A;:'#U-V
MR609NEEHP[96?KVU7ZFX39]/<Y(MS)W7W"DO3>%L&.\$U3]HY[*,BF+.:_N?
MT/J]$(Y81K*0D?0F!*V[G*L,E(0)H'$Z7@#*%8L9E3B$J+*.DQX[IM*$(F$2
MOF9\GM)H0E]OU?>;F_!$+VDYB2)<>JV4QJI1K]UACN7M_W3J (!GO][R=MWF
M^G5T'2"=#&^O*>'CC BLVG0! YIS@0')X(B+*7BN]1%B+DRH<D3#(Z#H6 0?
M9NFB,(@,TIL+$]%Y@ES"P1A,OXAW2 P5\0%1"M.!JLC:FZOI+9H4\U^S))ZE
MB"I$O*E.W9RIQ& 1].\9$U3O7*1.WY+R!2*ONDUV %'??EK?CG:NZ@'9)7 G
M1C46I'\VH:NB\ ZJM:*TIL95),-!4]/N11.B8L.W&,$RS/*TR%6(]@C:B/"I
M"=:2%#%AFB(YEJ(.>UF+29H"JB$L+$,4Y!AQ651P?%6>:# RNUY3O#AJEA99
MXT@I,Z>\4[KV"VG2W0S.F<*^*N%<]QD>%[[/$)&0N!YB$!."34Q2I05,X&T6
M2=.4L%[(E>-U)'9$%OJV/9O,9+%C?S@.3^7XP49^%\39L" 0FB+CE*ZD8RXP
M.A9"3$DN:6/UIQDQF:=DT6"9F=$H-9>VQEPI/C7U=:$[2TC2Y8[#1*(07Q\O
M;+<X8B@\5ZAH-?-2;!N1HZ)U6:UJU[R'Q:[M/4I6L7>]_4=I?A.L7:D]#L\S
M8-6!K6YDUC%)*Q*'W)#8$-Z6JJ65PK*]-BKY)7CWG;+N$J3@QL_K#&Y1(35<
M6<WU6QNLJQ):!N7'_-4KS--ZN[^AL[?:P?=]<;4GI=_.[9=#V7MWYK<\_4Z5
M+IN\7@+08Y \91&LL#]S/.YF=^U0:<+Q?]7^YE7[\BG\GZOX6=.Y8=O:Z.V$
M?L&\W1<,#R0YGDC6Y#M/4P9/,_17SL9CWMO<2<Z:?&>=LHXY'-QS]%B",<?N
MG!<?6QJ"ID1C6OO\<%WJYG3A7JN0,=;[3#VL\M [SP>_92ROQ8<5\XGG\%]0
M2P,$%     @ 5H(%4[K*;(%,"@  ZB4  !P   !E>&AI8FET-#%E>&5L,C R
M,3 V,S!S=&\N:'1M[5KK<]K&%O^>O^)<M].Q/8 !)VEC.YZ10=AJ0:*2<.)\
MN;.(!3866JH'Q'?RQ]_?60G\2)HVO7UX[E@DF'V=/>\]>XY.+L)!__39R85M
M=4]/_E6O4U='Q4(F.<UD(E.1RPF-;^B-3J_52I"31%2O8T'HA'W[5'Z8J['*
MG[?D!QFWF^U6\^5A,\OUR4$Y_NSDP$!^=G+F=:]H/(MTK-/7.^NYRN4.NKO.
M)8E8S9+7.Q$VE>FF,\MO8OEZ9R'2F4KJL9SF1RVY.%ZK23X_:AV^?'&\4^+[
M:R@TFZW&^^6LQ/8.Q*683%0RJ^=Z>=0&1-[0&9Q3ED:O=WX#V [E*F<@6:PF
MLK5#!IW7.XS/#LVEFLWSUSL_M%]55)R>]#PWI$S]!VLPO4)AJI.\SIU'K65^
M;%AR5'$DO' "ZMA^Z/0<.Z#PP@I)993/)>DUY$%Z2IU1X RI:X5VEZCCC=S0
M]@/GW$73<KODV^=.@"Z[>X31P7#$PQ>6;U/HCX+0]%GN58W<AM5 G^4&/=O_
M[IL?VLWFL75N V& J=HE,-_R:]0;]?M7-+2<<AO7<ZT@L(/ .NO;9#8(R.LQ
M^('G4A!ZG9]J]&T#K,,BGRZM_LBN\0RRW]I]YZT3U,AQ.PW*4Y%D4^C:. :5
MB2%VK/5UQL1RHZ/3I88J*@Q"%[EKKN,)N#&7J<0DE=!2IAF&=<HS)D5\0Z+(
MYSH%ER<D\ERGB;RA8HDY69&F,IF4S,SG8&\DTUQ-501MIV6J 0OK,46GF9R
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M*ENI.)8U^NF*GC?;AX=U'BI3<P=.UW9- L\G>FL>XG]T42:MG&[5:T:<)"M
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M,#(Q,#<P,BYH=&U02P$"% ,4    " !6@@534]/GK#(1   ?NP  $0
M        @ &<@0( 97AE;"TR,#(Q,#<P,BYX<V102P$"% ,4    " !6@@53
MX]LC564:  " "P$ %0              @ ']D@( 97AE;"TR,#(Q,#<P,E]C
M86PN>&UL4$L! A0#%     @ 5H(%4^(H\(!C2   CU(# !4
M ( !E:T" &5X96PM,C R,3 W,#)?9&5F+GAM;%!+ 0(4 Q0    ( %:"!5-A
MT2J161$! ,+& 0 4              "  2OV @!E>&5L+3(P,C$P-S R7V<Q
M+FIP9U!+ 0(4 Q0    ( %:"!5.W5@<1CKT  *[L!P 5              "
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?,S!S=&\N:'1M4$L%!@     ,  P .@,  &=N!0    $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
